7352670
D009599_D006973 NONE nitroprusside_4\NN (r_advmod) hypertensive_1\JJ
D009599_D006973 NONE SNP_2\NNP (r_compound) infusion_3\NN (r_pobj) During_0\IN (r_prep) demonstrated_7\VBD (l_dobj) increase_10\NN (l_prep) in_11\IN (l_pobj) pressure_13\NN
D009599_D007022 CID nitroprusside_19\NN (l_parataxis) evaluated_24\VBN (l_nsubjpass) hypotension_22\NN
D009599_D007022 CID SNP)-induced_21\VBN (r_amod) hypotension_22\NN
D009599_D007022 CID SNP_19\NNP (r_conj) halothane_17\NN (r_pobj) of_16\IN (r_prep) effects_15\NNS (l_amod) hypotensive_14\JJ
D012504_D006973 NONE saralasin_7\NN (r_pobj) by_6\IN (r_agent) prevented_5\VBN (r_acl) hypertensive_1\JJ
D012504_D006973 NONE saralasin_20\NN (r_npadvmod) treated_22\VBN (r_amod) animals_23\NNS (r_nsubj) showed_24\VBD (r_advcl) demonstrated_7\VBD (l_dobj) increase_10\NN (l_prep) in_11\IN (l_pobj) pressure_13\NN
D006221_D007022 CID halothane_15\NN (r_compound) anesthesia_16\NN (l_conj) nitroprusside_19\NN (l_parataxis) evaluated_24\VBN (l_nsubjpass) hypotension_22\NN
D006221_D007022 CID halothane_17\NN (r_pobj) of_16\IN (r_prep) effects_15\NNS (l_amod) hypotensive_14\JJ
D000809_D007022 NONE angiotensin_6\NN (r_compound) system_7\NN (l_prep) in_8\IN (l_pobj) maintenance_10\NN (l_prep) during_14\IN (l_pobj) anesthesia_16\NN (l_conj) nitroprusside_19\NN (l_parataxis) evaluated_24\VBN (l_nsubjpass) hypotension_22\NN
D000809_D007022 NONE angiotensin_8\NN (r_compound) system_9\NN (l_prep) in_10\IN (l_pcomp) antagonizing_11\VBG (l_dobj) effects_15\NNS (l_amod) hypotensive_14\JJ
15145918
D008750_D007022 CID methyldopa_10\NN (r_conj) rilmenidine_6\NN (r_amod) rats_4\NNS (r_pobj) In_0\IN (r_prep) elicited_11\VBD (l_dobj) hypotension_13\NN
D008750_D007022 CID methyldopa_9\NN (r_pobj) to_6\IN (r_prep) response_5\NN (l_amod) hypotensive_4\JJ
D008750_D007022 CID methyldopa_9\NN (r_pobj) to_6\IN (r_prep) response_5\NN (r_dobj) enhanced_2\VBD (l_prep) in_11\IN (l_pobj) contrast_12\NN (l_prep) to_13\IN (l_pobj) effect_15\NN (l_prep) on_16\IN (l_pobj) hypotension_18\NN
D008750_D007022 CID methyldopa_4\NN (r_compound) hypotension_5\NN
D008750_D007022 CID methyldopa_25\NN (r_compound) estrogen_27\NN (r_compound) interaction_28\NN (r_pobj) in_22\IN (r_prep) control_21\NN (r_pobj) for_17\IN (r_prep) role_16\NN (r_dobj) highlight_14\VB (r_conj) downregulates_5\VBZ (l_conj) hypotension_12\NN
D003000_D007022 NONE clonidine_12\NN (r_pobj) of_11\IN (r_prep) effect_10\NN (l_amod) hypotensive_9\JJ
C032302_D007022 CID rilmenidine_6\NN (r_amod) rats_4\NNS (r_pobj) In_0\IN (r_prep) elicited_11\VBD (l_dobj) hypotension_13\NN
C032302_D007022 CID rilmenidine_17\JJ (r_amod) hypotension_18\NN (r_pobj) on_16\IN (r_prep) effect_15\NN (r_pobj) to_13\IN (r_prep) contrast_12\NN (r_pobj) in_11\IN (r_prep) enhanced_2\VBD (l_dobj) response_5\NN (l_amod) hypotensive_4\JJ
C032302_D007022 CID rilmenidine_17\JJ (r_amod) hypotension_18\NN
D048288_D007022 NONE I1-imidazoline_7\NNP (r_punct) mediated_10\VBN (r_conj) alpha2-adrenergic_5\JJ (r_amod) hypotension_11\NN
D004967_D007022 NONE estrogen_3\NN (l_prep) of_4\IN (l_pobj) hypotension_11\NN
D004967_D007022 NONE estrogen_5\NN (r_nsubj) modulates_7\VBZ (l_dobj) effect_10\NN (l_amod) hypotensive_9\JJ
D004967_D007022 NONE estrogen_4\NN (r_nsubj) downregulates_5\VBZ (l_conj) hypotension_12\NN
D004967_D007022 NONE estrogen_27\NN (r_compound) interaction_28\NN (r_pobj) in_22\IN (r_prep) control_21\NN (r_pobj) for_17\IN (r_prep) role_16\NN (r_dobj) highlight_14\VB (r_conj) downregulates_5\VBZ (l_conj) hypotension_12\NN
D008750_D001523 NONE methyldopa_4\NN (r_compound) hypotension_5\NN (r_nsubjpass) paralleled_10\VBN (l_prep) with_11\IN (l_pobj) reduction_13\NN (l_conj) activity_20\NN
11672959
D012460_D056486 CID sulphasalazine_27\NN (r_pobj) of_25\IN (r_prep) course_24\NN (r_pobj) of_22\IN (r_prep) day_21\NN (r_pobj) on_18\IN (r_prep) beginning_17\VBG (r_advcl) developed_5\VBD (l_dobj) constellation_7\NN (l_prep) of_8\IN (l_pobj) dermatitis_9\NN (l_conj) fever_11\NN (l_conj) lymphadenopathy_13\NN (l_conj) hepatitis_15\NN
D012460_D003872 CID sulphasalazine_27\NN (r_pobj) of_25\IN (r_prep) course_24\NN (r_pobj) of_22\IN (r_prep) day_21\NN (r_pobj) on_18\IN (r_prep) beginning_17\VBG (r_advcl) developed_5\VBD (l_dobj) constellation_7\NN (l_prep) of_8\IN (l_pobj) dermatitis_9\NN
D012460_D008206 CID sulphasalazine_27\NN (r_pobj) of_25\IN (r_prep) course_24\NN (r_pobj) of_22\IN (r_prep) day_21\NN (r_pobj) on_18\IN (r_prep) beginning_17\VBG (r_advcl) developed_5\VBD (l_dobj) constellation_7\NN (l_prep) of_8\IN (l_pobj) dermatitis_9\NN (l_conj) fever_11\NN (l_conj) lymphadenopathy_13\NN
D012460_D005334 CID sulphasalazine_27\NN (r_pobj) of_25\IN (r_prep) course_24\NN (r_pobj) of_22\IN (r_prep) day_21\NN (r_pobj) on_18\IN (r_prep) beginning_17\VBG (r_advcl) developed_5\VBD (l_dobj) constellation_7\NN (l_prep) of_8\IN (l_pobj) dermatitis_9\NN (l_conj) fever_11\NN
D012460_D001172 NONE sulphasalazine_27\NN (l_prep) for_28\IN (l_pobj) arthritis_33\NN
1664218
C042315_D002289 NONE CI-921_7\NNP (r_punct) (_8\-LRB- (r_punct) NSC_9\NNP (r_appos) study_2\NN (l_prep) in_12\IN (l_pobj) cancer_18\NN
C042315_D002289 NONE 343499_10\CD (r_nummod) NSC_9\NNP (r_appos) study_2\NN (l_prep) in_12\IN (l_pobj) cancer_18\NN
D000677_D002289 NONE amsacrine_5\NN (r_compound) analogue_6\NN (r_pobj) of_3\IN (r_prep) study_2\NN (l_prep) in_12\IN (l_pobj) cancer_18\NN
6103707
D005445_D010146 CID flunitrazepam_7\NN (r_pobj) of_6\IN (r_prep) injection_5\NN (r_pobj) on_3\IN (r_prep) pain_2\NN
16787750
D014635_D003244 CID VPA_4\NNP (r_npadvmod) induced_6\VBN (r_amod) encephalopathy_7\NN (r_pobj) of_3\IN (r_prep) signs_2\NNS (r_nsubj) are_8\VBP (l_attr) consciousness_10\NN
D014635_D001855 CID VPA_17\NNP (r_npadvmod) induced_19\VBN (r_amod) hepatotoxicity_20\NN (r_npadvmod) occur_4\VB (l_prep) in_5\IN (l_pobj) patients_7\NNS (l_prep) including_9\VBG (l_pobj) pancreatitis_11\NN (l_conj) suppression_15\NN
D014635_D001855 CID VPA_22\NNP (r_npadvmod) induced_24\VBN (r_compound) encephalopathy_25\NN (r_conj) hepatotoxicity_20\NN (r_npadvmod) occur_4\VB (l_prep) in_5\IN (l_pobj) patients_7\NNS (l_prep) including_9\VBG (l_pobj) pancreatitis_11\NN (l_conj) suppression_15\NN
D014635_D012640 NONE VPA_4\NNP (r_npadvmod) induced_6\VBN (r_amod) encephalopathy_7\NN (r_pobj) of_3\IN (r_prep) signs_2\NNS (r_nsubj) are_8\VBP (l_advcl) marked_13\VBD (l_ccomp) slowing_16\VBG (l_dobj) frequency_20\NN (l_compound) seizure_19\NN
D014635_D056486 CID VPA_17\NNP (r_npadvmod) induced_19\VBN (r_amod) hepatotoxicity_20\NN
D014635_D056486 CID VPA_22\NNP (r_npadvmod) induced_24\VBN (r_compound) encephalopathy_25\NN (r_conj) hepatotoxicity_20\NN
D014635_D001927 CID acid_1\NN (r_nsubj) induced_2\VBD (l_advmod) encephalopathy--19_3\NNP
D014635_D001927 CID VPA_18\NNP (r_compound) therapy_20\NN (r_pobj) to_17\IN (r_prep) associated_16\VBN (r_acl) effect_15\NN (r_pobj) to_10\IN (r_prep) induced_2\VBD (l_advmod) encephalopathy--19_3\NNP
D014635_D001927 CID VPA_17\NNP (r_npadvmod) induced_19\VBN (r_amod) hepatotoxicity_20\NN (l_conj) encephalopathy_25\NN
D014635_D001927 CID VPA_22\NNP (r_npadvmod) induced_24\VBN (r_compound) encephalopathy_25\NN
D014635_D001927 CID VPA_4\NNP (r_npadvmod) induced_6\VBN (r_amod) encephalopathy_7\NN
D014635_D001927 CID VPA_9\NNP (r_pobj) of_8\IN (r_prep) effect_7\NN (l_prep) in_10\IN (l_pobj) patients_11\NNS (l_prep) with_12\IN (l_pobj) encephalopathy_13\JJ
D014635_D001927 CID VPA_5\NNP (r_npadvmod) associated_7\VBN (r_amod) encephalopathy_8\NN
D014635_D022124 NONE VPA_4\NNP (r_npadvmod) induced_6\VBN (r_amod) encephalopathy_7\NN (r_pobj) of_3\IN (r_prep) signs_2\NNS (r_nsubj) are_8\VBP (l_advcl) marked_13\VBD (l_ccomp) slowing_16\VBG (l_dobj) frequency_20\NN (l_prep) with_22\IN (l_conj) without_24\IN (l_pobj) hyperammonemia_25\NN
D014635_D010195 CID VPA_17\NNP (r_npadvmod) induced_19\VBN (r_amod) hepatotoxicity_20\NN (r_npadvmod) occur_4\VB (l_prep) in_5\IN (l_pobj) patients_7\NNS (l_prep) including_9\VBG (l_pobj) pancreatitis_11\NN
D014635_D010195 CID VPA_22\NNP (r_npadvmod) induced_24\VBN (r_compound) encephalopathy_25\NN (r_conj) hepatotoxicity_20\NN (r_npadvmod) occur_4\VB (l_prep) in_5\IN (l_pobj) patients_7\NNS (l_prep) including_9\VBG (l_pobj) pancreatitis_11\NN
9931093
C079574_D006973 NONE 139317_14\CD (r_nummod) FR_13\NNP (l_prep) on_15\IN (l_pobj) hypertension_18\NN
D016559_D007674 NONE 506_5\CD (r_nummod) FK_4\NNP (r_pobj) of_3\IN (r_prep) utility_2\NN (r_nsubjpass) complicated_7\VBN (l_agent) by_8\IN (l_pobj) hypertension_10\NN (l_conj) nephrotoxicity_12\NN
D009569_D006973 NONE oxide_44\NN (r_compound) synthase_45\NN (r_conj) expression_27\NN (r_dobj) studied_10\VBD (l_advcl) clarify_1\VB (l_dobj) mechanisms_3\NNS (l_prep) of_4\IN (l_pobj) hypertension_7\NN
D016559_D006973 CID 506-induced_3\JJ (r_nummod) hypertension_4\NN
D016559_D006973 CID 506_5\CD (r_nummod) FK_4\NNP (r_pobj) of_3\IN (r_prep) utility_2\NN (r_nsubjpass) complicated_7\VBN (l_agent) by_8\IN (l_pobj) hypertension_10\NN
D016559_D006973 CID 506-induced_6\JJ (r_compound) hypertension_7\NN
D016559_D006973 CID 506_16\CD (r_nummod) FK_15\NNP (r_pobj) of_14\IN (r_prep) effects_13\NNS (r_dobj) studied_10\VBD (l_advcl) clarify_1\VB (l_dobj) mechanisms_3\NNS (l_prep) of_4\IN (l_pobj) hypertension_7\NN
D016559_D006973 CID 506-induced_17\JJ (r_nummod) FK_16\NNP (r_poss) hypertension_18\NN
D016559_D006973 CID 506-induced_4\JJ (r_nummod) hypertension_5\NN
230316
D007464_D001927 CID clioquinol_25\NN (r_pobj) of_24\IN (r_prep) dose_23\NN (r_pobj) of_20\IN (r_prep) ingestion_19\NN (r_pobj) to_17\IN (r_prep) related_16\VBN (r_acl) encephalopathy_14\NN
D006912_D020258 NONE hydroxyquinolines_3\NNS (r_pobj) of_1\IN (r_prep) Neurotoxicity_0\NN
D006912_D020258 NONE hydroxyquinolines_13\NNS (r_pobj) to_11\IN (r_prep) reactions_10\NNS (l_amod) neurotoxic_9\JJ
D007464_C538178 NONE clioquinol_13\NN (l_prep) as_14\IN (l_pobj) treatment_15\NN (l_prep) for_16\IN (l_pobj) enteropathica_18\NN
D007464_D009422 NONE clioquinol_25\NN (r_pobj) of_24\IN (r_prep) dose_23\NN (r_pobj) of_20\IN (r_prep) ingestion_19\NN (r_pobj) to_17\IN (r_prep) related_16\VBN (r_acl) encephalopathy_14\NN (r_pobj) of_10\IN (r_prep) consisted_9\VBD (l_nsubj) disturbance_8\NN
9727773
D001067_D006976 CID suppressants_9\NNS (r_pobj) with_7\IN (r_prep) associated_6\VBN (r_acl) incidence_1\NN (l_prep) of_2\IN (l_pobj) hypertension_5\NN
D001067_D006976 CID suppressant_21\NN (r_compound) drugs_22\NNS (r_pobj) of_19\IN (r_prep) intake_18\NN (r_pobj) with_16\IN (r_prep) associated_15\VBN (r_relcl) disease_10\NN (r_attr) is_3\VBZ (l_nsubj) hypertension_2\NN
D001067_D006976 CID suppressants_18\NNS (r_dobj) taken_16\VBN (l_ccomp) was_9\VBD (l_nsubj) diagnosis_4\NN (l_prep) of_5\IN (l_pobj) hypertension_8\NN
D001067_D006976 CID suppressants_7\NNS (r_pobj) of_5\IN (r_prep) prescription_4\NN (r_pobj) of_2\IN (r_prep) policy_1\NN (r_nsubj) lead_9\VB (l_prep) to_10\IN (l_pobj) incidence_13\NN (l_prep) of_14\IN (l_pobj) hypertension_18\NN
8302922
D000527_D007022 CID E1_5\NNP (r_pobj) during_3\IN (r_prep) flow_2\NN (r_nsubj) induced_8\VBD (l_dobj) hypotension_9\NN
D000527_D007022 CID E1_6\NNP (r_nmod) PGE1_8\NNP (r_pobj) of_4\IN (r_prep) effect_3\NN (r_dobj) evaluate_1\VB (r_csubj) induced_15\VBN (l_dobj) hypotension_16\NN
D000527_D007022 CID PGE1_8\NNP (r_pobj) of_4\IN (r_prep) effect_3\NN (r_dobj) evaluate_1\VB (r_csubj) induced_15\VBN (l_dobj) hypotension_16\NN
D000527_D007022 CID PGE1_2\NNP (r_dobj) starting_1\VBG (r_pcomp) After_0\IN (r_prep) decreased_14\VBD (l_conj) remained_34\VBD (l_nsubj) degree_28\NN (l_prep) of_29\IN (l_pobj) hypotension_30\NN
D000527_D007022 CID PGE1_33\NNP (r_pobj) to_32\IN (r_pcomp) due_31\IN (r_prep) degree_28\NN (l_prep) of_29\IN (l_pobj) hypotension_30\NN
D000527_D007022 CID PGE1_4\NNP (r_nsubj) be_6\VB (l_acomp) preferable_7\JJ (l_xcomp) TMP_9\VB (l_prep) for_10\IN (l_pobj) anaesthesia_12\NN (l_amod) hypotensive_11\JJ
D007530_D007022 NONE isoflurane_47\JJ (r_amod) anaesthesia_48\NN (r_pobj) under_46\IN (r_prep) fusion_45\NN (r_dobj) underwent_40\VBD (r_relcl) patients_38\NNS (r_pobj) in_36\IN (r_prep) using_31\VBG (r_advcl) measured_30\VBN (l_advcl) induced_15\VBN (l_dobj) hypotension_16\NN
D014294_D007022 CID trimethaphan_7\RB (r_conj) E1_5\NNP (r_pobj) during_3\IN (r_prep) flow_2\NN (r_nsubj) induced_8\VBD (l_dobj) hypotension_9\NN
D014294_D007022 CID trimethaphan_11\NN (r_conj) PGE1_8\NNP (r_pobj) of_4\IN (r_prep) effect_3\NN (r_dobj) evaluate_1\VB (r_csubj) induced_15\VBN (l_dobj) hypotension_16\NN
D014294_D007022 CID TMP_13\NNP (r_appos) trimethaphan_11\NN (r_conj) PGE1_8\NNP (r_pobj) of_4\IN (r_prep) effect_3\NN (r_dobj) evaluate_1\VB (r_csubj) induced_15\VBN (l_dobj) hypotension_16\NN
D014294_D007022 CID TMP_4\NNP (r_conj) PGE1_2\NNP (r_dobj) starting_1\VBG (r_pcomp) After_0\IN (r_prep) decreased_14\VBD (l_conj) remained_34\VBD (l_nsubj) degree_28\NN (l_prep) of_29\IN (l_pobj) hypotension_30\NN
D014294_D007022 CID TMP_9\VB (l_prep) for_10\IN (l_pobj) anaesthesia_12\NN (l_amod) hypotensive_11\JJ
D014294_D007022 CID TMP_17\NNP (r_nsubj) decreased_18\VBD (r_advcl) be_6\VB (l_acomp) preferable_7\JJ (l_xcomp) TMP_9\VB (l_prep) for_10\IN (l_pobj) anaesthesia_12\NN (l_amod) hypotensive_11\JJ
3437726
D003647_D064420 NONE debrisoquine_13\JJ (r_compound) polymorphism_14\NN (r_pobj) of_10\IN (r_prep) phenotype_9\NN (r_pobj) to_4\IN (r_prep) belonging_3\VBG (r_acl) patients_2\NNS (r_nsubj) experience_29\VB (l_dobj) reactions_32\NNS
D013034_D064420 NONE sparteine_11\NN (r_nmod) debrisoquine_13\JJ (r_compound) polymorphism_14\NN (r_pobj) of_10\IN (r_prep) phenotype_9\NN (r_pobj) to_4\IN (r_prep) belonging_3\VBG (r_acl) patients_2\NNS (r_nsubj) experience_29\VB (l_dobj) reactions_32\NNS
12789195
D008914_D004194 NONE minoxidil_9\NN (r_pobj) of_8\IN (r_prep) use_7\NN (r_pobj) by_2\IN (r_agent) induced_1\VBN (l_nsubj) Pseudoacromegaly_0\NNS
D008914_D004194 NONE minoxidil_15\NN (r_pobj) of_14\IN (r_prep) use_13\NN (r_pobj) from_8\IN (r_prep) resulted_7\VBD (r_relcl) patient_3\NN (l_prep) with_4\IN (l_pobj) pseudoacromegaly_5\NNS
D008914_D004194 NONE minoxidil_13\JJ (r_amod) use_14\NN (r_pobj) of_12\IN (r_prep) effect_11\NN (r_pobj) as_8\IN (r_prep) report_5\NN (l_prep) of_6\IN (l_pobj) pseudoacromegaly_7\NNS
12198388
D009388_D012640 CID neostigmine_12\NN (r_conj) Sensitivity_0\NN (l_prep) to_1\IN (l_pobj) endpoints_4\NNS (l_compound) convulsion_3\NN
D009538_D012640 CID nicotine_7\NN (r_pobj) by_6\IN (r_agent) induced_5\VBN (r_acl) endpoints_4\NNS (l_compound) convulsion_3\NN
D009538_D014202 NONE nicotine_3\NN (r_dobj) administered_2\VBN (l_conj) recorded_25\VBN (l_nsubjpass) latencies_17\NNS (l_relcl) onset_19\VB (l_prep) of_20\IN (l_pobj) tremor_21\NN
D009388_D014202 NONE neostigmine_8\JJ (r_conj) carbachol_5\NN (r_conj) nicotine_3\NN (r_dobj) administered_2\VBN (l_conj) recorded_25\VBN (l_nsubjpass) latencies_17\NNS (l_relcl) onset_19\VB (l_prep) of_20\IN (l_pobj) tremor_21\NN
D000431_D012640 NONE alcohol_6\NN (r_compound) na_8\TO (r_aux) ve_9\VB (l_dobj) mice_23\NNS (l_nmod) Prone_13\NNP (l_compound) Seizure_11\NN
D000431_D012640 NONE ethanol_18\NN (r_compound) withdrawal_19\NN (r_compound) severity_20\NN (r_pobj) with_17\IN (r_prep) associated_16\VBN (l_nsubjpass) differences_4\NNS (l_prep) in_5\IN (l_pobj) activity_7\NN (l_conj) sensitivity_10\NN (l_prep) to_11\IN (l_pobj) convulsants_13\NNS
D000431_D012640 NONE alcohol_26\NN (r_compound) withdrawal_27\NN (r_pobj) in_25\IN (r_prep) mechanisms_24\NNS (r_dobj) implicate_22\VB (r_conj) associated_16\VBN (l_nsubjpass) differences_4\NNS (l_prep) in_5\IN (l_pobj) activity_7\NN (l_conj) sensitivity_10\NN (l_prep) to_11\IN (l_pobj) convulsants_13\NNS
D000109_D012640 NONE acetylcholine_4\NN (r_compound) release_5\NN (l_conj) sensitivity_9\NN (l_prep) in_10\IN (l_pobj) lines_22\NNS (l_amod) prone_14\JJ (l_npadvmod) seizure_12\NN
D000109_D012640 NONE acetylcholine_4\NN (r_compound) release_5\NN (l_conj) sensitivity_9\NN (l_prep) in_10\IN (l_pobj) lines_22\NNS (l_amod) resistant_19\JJ (l_npadvmod) seizure_17\NN
D000109_D012640 NONE ACh_1\NNS (r_nsubjpass) measured_4\VBN (l_prep) during_5\IN (l_pobj) testing_6\VBG (l_prep) for_7\IN (l_pobj) convulsions_11\NNS
D000109_D012640 NONE ACh_2\NNS (r_nsubjpass) measured_4\VBN (l_prep) during_5\IN (l_pobj) testing_6\VBG (l_prep) for_7\IN (l_pobj) convulsions_11\NNS
D000109_D012640 NONE ACh_14\NNS (r_nsubjpass) elevated_17\JJ (l_advcl) measured_4\VBN (l_prep) during_5\IN (l_pobj) testing_6\VBG (l_prep) for_7\IN (l_pobj) convulsions_11\NNS
D002217_D014202 NONE carbachol_5\NN (r_conj) nicotine_3\NN (r_dobj) administered_2\VBN (l_conj) recorded_25\VBN (l_nsubjpass) latencies_17\NNS (l_relcl) onset_19\VB (l_prep) of_20\IN (l_pobj) tremor_21\NN
D002217_D012640 CID carbachol_9\NN (r_conj) nicotine_7\NN (r_pobj) by_6\IN (r_agent) induced_5\VBN (r_acl) endpoints_4\NNS (l_compound) convulsion_3\NN
6518066
D008094_D006331 NONE lithium_9\NN (r_pobj) to_8\IN (r_prep) exposed_7\VBN (r_csubj) provide_13\VB (l_dobj) assessment_18\NN (l_prep) of_19\IN (l_pobj) presence_21\NN (l_prep) of_24\IN (l_pobj) malformations_29\NNS
D008094_D006331 NONE lithium_25\NN (r_npadvmod) induced_27\VBN (r_amod) malformations_29\NNS
D008094_D004437 CID lithium_1\NN (l_conj) anomaly_6\NN
10520387
D004809_D013610 CID ephedrine_9\NN (r_pobj) of_8\IN (r_prep) use_7\NN (r_pobj) with_5\IN (r_prep) associated_4\VBN (r_acl) tachycardia_3\NNS
D004809_D013610 CID ephedrine_24\NN (r_nmod) mixtures_28\NNS (r_pobj) of_22\IN (r_prep) any_21\DT (r_pobj) of_20\IN (r_prep) patients_19\NNS (r_pobj) in_17\IN (r_prep) use_16\NN (r_dobj) recommend_14\VB (l_prep) Due_0\IN (l_pobj) risk_3\NN (l_prep) of_4\IN (l_pobj) tachycardia_6\NN
D015742_D007022 CID propofol_13\NN (l_prep) in_14\IN (l_pobj) order_15\NN (l_acl) obtund_17\VB (l_dobj) response_20\NN (l_amod) hypotensive_19\JJ
D015742_D007022 CID propofol_5\NN (r_acl) addition_1\NN (r_nsubj) appears_6\VBZ (l_xcomp) be_8\VB (l_attr) method_11\NN (l_prep) of_12\IN (l_pcomp) obtunding_13\VBG (l_dobj) response_16\NN (l_amod) hypotensive_15\JJ
D015742_D007022 CID propofol_18\NN (r_advcl) obtunding_13\VBG (l_dobj) response_16\NN (l_amod) hypotensive_15\JJ
D004809_D017202 NONE ephedrine_24\NN (r_nmod) mixtures_28\NNS (r_pobj) of_22\IN (r_prep) any_21\DT (r_pobj) of_20\IN (r_prep) patients_19\NNS (r_pobj) in_17\IN (r_prep) use_16\NN (r_dobj) recommend_14\VB (l_prep) Due_0\IN (l_pobj) risk_3\NN (l_prep) of_4\IN (l_pobj) tachycardia_6\NN (l_acl) inducing_7\VBG (l_dobj) ischemia_9\NN
D004809_D007022 NONE ephedrine_11\NN (r_pobj) of_10\IN (r_prep) doses_9\NNS (r_dobj) adding_7\VBG (l_xcomp) propofol_13\NN (l_prep) in_14\IN (l_pobj) order_15\NN (l_acl) obtund_17\VB (l_dobj) response_20\NN (l_amod) hypotensive_19\JJ
D004809_D007022 NONE ephedrine_3\NN (r_pobj) of_2\IN (r_prep) addition_1\NN (r_nsubj) appears_6\VBZ (l_xcomp) be_8\VB (l_attr) method_11\NN (l_prep) of_12\IN (l_pcomp) obtunding_13\VBG (l_dobj) response_16\NN (l_amod) hypotensive_15\JJ
D015742_D013610 CID propofol_13\NN (r_pobj) with_12\IN (r_prep) combination_11\NN (r_pobj) in_10\IN (r_prep) use_7\NN (r_pobj) with_5\IN (r_prep) associated_4\VBN (r_acl) tachycardia_3\NNS
D015742_D013610 CID propofol_26\NN (r_nmod) mixtures_28\NNS (r_pobj) of_22\IN (r_prep) any_21\DT (r_pobj) of_20\IN (r_prep) patients_19\NNS (r_pobj) in_17\IN (r_prep) use_16\NN (r_dobj) recommend_14\VB (l_prep) Due_0\IN (l_pobj) risk_3\NN (l_prep) of_4\IN (l_pobj) tachycardia_6\NN
D015742_D017202 NONE propofol_26\NN (r_nmod) mixtures_28\NNS (r_pobj) of_22\IN (r_prep) any_21\DT (r_pobj) of_20\IN (r_prep) patients_19\NNS (r_pobj) in_17\IN (r_prep) use_16\NN (r_dobj) recommend_14\VB (l_prep) Due_0\IN (l_pobj) risk_3\NN (l_prep) of_4\IN (l_pobj) tachycardia_6\NN (l_acl) inducing_7\VBG (l_dobj) ischemia_9\NN
6888657
D004054_D009369 NONE DES_12\NNP (r_npadvmod) induced_14\VBN (r_amod) tumor_15\NN
D004054_D010911 CID diethylstilbestrol_12\NN (r_pobj) with_11\IN (r_prep) treatment_10\NN (r_pobj) by_8\IN (r_agent) induced_3\VBN (l_nsubjpass) tumors_1\NNS
D004054_D010911 CID DES_14\NNP (r_npadvmod) implanted_21\VBN (r_parataxis) induced_3\VBN (l_nsubjpass) tumors_1\NNS
D004967_D010911 NONE estrogen_2\NN (r_npadvmod) induced_4\VBN (r_amod) tumors_6\NNS
15036754
D010755_D012640 NONE Organophosphate_0\NNP (r_npadvmod) induced_2\VBN (r_amod) convulsions_3\NNS
D003975_D011041 NONE diazepam_3\NN (r_nsubjpass) given_7\VBN (r_advcl) prevented_16\VBD (l_conj) delayed_18\VBN (l_conj) shortened_20\VBN (l_dobj) occurrence_22\NN (l_prep) of_23\IN (l_pobj) signs_25\NNS (l_prep) of_26\IN (l_pobj) poisoning_27\NN
D003975_D011041 NONE diazepam_5\NN (r_conj) CPA_3\NN (r_nsubj) prevented_12\VBD (l_dobj) occurrence_14\NN (l_prep) of_15\IN (l_pobj) signs_17\NNS (l_prep) of_18\IN (l_pobj) poisoning_19\NN
D007531_D064420 NONE DFP_4\NNP (r_compound) atropine_6\NN (r_pobj) with_3\IN (r_prep) treated_2\VBD (l_conj) showed_7\VBD (l_dobj) signs_14\NNS (l_compound) toxicity_13\NN
D007531_D064420 NONE DFP_10\NNP (r_compound) toxicity_11\NN
D007531_D064420 NONE DFP_26\NNP (r_pobj) of_25\IN (r_prep) toxicity_24\NN
D000109_D064420 NONE acetylcholine_25\NN (r_nmod) levels_29\NNS (r_dobj) elevates_24\VBZ (r_relcl) system_18\NN (r_pobj) in_14\IN (r_prep) AChEs_13\NNP (r_pobj) with_12\IN (r_prep) binding_11\NN (r_pobj) of_8\IN (r_prep) result_7\NN (r_attr) is_5\VBZ (l_nsubj) toxicity_2\NN
D000109_D064420 NONE ACh_27\NNS (r_nmod) levels_29\NNS (r_dobj) elevates_24\VBZ (r_relcl) system_18\NN (r_pobj) in_14\IN (r_prep) AChEs_13\NNP (r_pobj) with_12\IN (r_prep) binding_11\NN (r_pobj) of_8\IN (r_prep) result_7\NN (r_attr) is_5\VBZ (l_nsubj) toxicity_2\NN
D010755_D064420 NONE OPs_4\NNS (r_pobj) of_3\IN (r_prep) toxicity_2\NN
D010755_D064420 NONE OP_10\NN (r_npadvmod) induced_12\VBN (r_amod) signs_14\NNS (l_compound) toxicity_13\NN
D011220_D064420 NONE 2PAM_7\CD (r_conj) diazepam_5\NN (r_conj) CPA_3\NN (r_nsubj) prevented_12\VBD (l_conj) reduced_22\VBD (l_dobj) toxicity_24\NN
D007531_D011041 NONE DFP_10\NNP (r_compound) atropine_12\NN (r_pobj) after_9\IN (r_prep) given_7\VBN (r_advcl) prevented_16\VBD (l_conj) delayed_18\VBN (l_conj) shortened_20\VBN (l_dobj) occurrence_22\NN (l_prep) of_23\IN (l_pobj) signs_25\NNS (l_prep) of_26\IN (l_pobj) poisoning_27\NN
D007531_D011041 NONE DFP_26\NNP (r_pobj) of_25\IN (r_prep) toxicity_24\NN (r_dobj) reduced_22\VBD (r_conj) prevented_12\VBD (l_dobj) occurrence_14\NN (l_prep) of_15\IN (l_pobj) signs_17\NNS (l_prep) of_18\IN (l_pobj) poisoning_19\NN
D003975_D064420 NONE diazepam_5\NN (r_conj) CPA_3\NN (r_nsubj) prevented_12\VBD (l_conj) reduced_22\VBD (l_dobj) toxicity_24\NN
C048599_D064420 NONE CPA_3\NN (r_nsubj) prevented_12\VBD (l_conj) reduced_22\VBD (l_dobj) toxicity_24\NN
D016291_D064420 NONE MK801_2\NNP (r_nsubj) offer_5\VB (l_dobj) protection_8\NN (l_prep) against_9\IN (l_pobj) toxicity_11\NN
D010755_D004194 NONE Organophosphate_0\NNP (r_npadvmod) induced_2\VBN (r_amod) convulsions_3\NNS (l_prep) of_6\IN (l_pobj) damages_8\NNS
D001285_D011041 NONE atropine_12\NN (r_pobj) after_9\IN (r_prep) given_7\VBN (r_advcl) prevented_16\VBD (l_conj) delayed_18\VBN (l_conj) shortened_20\VBN (l_dobj) occurrence_22\NN (l_prep) of_23\IN (l_pobj) signs_25\NNS (l_prep) of_26\IN (l_pobj) poisoning_27\NN
D001285_D011041 NONE atropine_11\NN (r_pobj) with_10\IN (r_prep) combination_9\NN (r_pobj) in_8\IN (r_prep) diazepam_5\NN (r_conj) CPA_3\NN (r_nsubj) prevented_12\VBD (l_dobj) occurrence_14\NN (l_prep) of_15\IN (l_pobj) signs_17\NNS (l_prep) of_18\IN (l_pobj) poisoning_19\NN
D011220_D011041 NONE 2PAM_5\CD (r_conj) diazepam_3\NN (r_nsubjpass) given_7\VBN (r_advcl) prevented_16\VBD (l_conj) delayed_18\VBN (l_conj) shortened_20\VBN (l_dobj) occurrence_22\NN (l_prep) of_23\IN (l_pobj) signs_25\NNS (l_prep) of_26\IN (l_pobj) poisoning_27\NN
D011220_D011041 NONE 2PAM_7\CD (r_conj) diazepam_5\NN (r_conj) CPA_3\NN (r_nsubj) prevented_12\VBD (l_dobj) occurrence_14\NN (l_prep) of_15\IN (l_pobj) signs_17\NNS (l_prep) of_18\IN (l_pobj) poisoning_19\NN
D001285_D064420 NONE atropine_6\NN (r_pobj) with_3\IN (r_prep) treated_2\VBD (l_conj) showed_7\VBD (l_dobj) signs_14\NNS (l_compound) toxicity_13\NN
D001285_D064420 NONE Atropine_0\NNP (r_compound) MK801_2\NNP (r_nsubj) offer_5\VB (l_dobj) protection_8\NN (l_prep) against_9\IN (l_pobj) toxicity_11\NN
D001285_D064420 NONE atropine_11\NN (r_pobj) with_10\IN (r_prep) combination_9\NN (r_pobj) in_8\IN (r_prep) diazepam_5\NN (r_conj) CPA_3\NN (r_nsubj) prevented_12\VBD (l_conj) reduced_22\VBD (l_dobj) toxicity_24\NN
C048599_D011041 NONE CPA_1\NN (r_nsubjpass) given_7\VBN (r_advcl) prevented_16\VBD (l_conj) delayed_18\VBN (l_conj) shortened_20\VBN (l_dobj) occurrence_22\NN (l_prep) of_23\IN (l_pobj) signs_25\NNS (l_prep) of_26\IN (l_pobj) poisoning_27\NN
C048599_D011041 NONE CPA_3\NN (r_nsubj) prevented_12\VBD (l_dobj) occurrence_14\NN (l_prep) of_15\IN (l_pobj) signs_17\NNS (l_prep) of_18\IN (l_pobj) poisoning_19\NN
2887062
D001971_D000236 NONE bromocriptine_15\JJ (r_amod) treatment_16\NN (l_prep) of_17\IN (l_pobj) cells_20\NNS (l_compound) adenoma_19\NN
D004967_D015175 CID estrogen_8\NN (r_npadvmod) induced_10\VBN (r_amod) prolactinomas_12\NNS
D004967_D015175 CID estrogen_21\NN (r_npadvmod) induced_23\VBN (r_amod) cells_26\NNS (r_pobj) to_20\IN (r_prep) applied_19\VBN (l_advcl) clarify_1\VB (l_dobj) effects_3\NNS (l_prep) on_6\IN (l_pobj) cells_8\NNS (l_compound) prolactinoma_7\NN
D004967_D015175 CID estrogen_21\NN (r_npadvmod) induced_23\VBN (r_amod) cells_26\NNS (l_compound) prolactinoma_25\NN
D001971_D015175 NONE bromocriptine_14\NN (r_amod) treatment_15\NN (r_pobj) after_13\IN (r_prep) prolactinomas_12\NNS
D001971_D015175 NONE bromocriptine_5\NN (r_pobj) of_4\IN (r_prep) effects_3\NNS (l_prep) on_6\IN (l_pobj) cells_8\NNS (l_compound) prolactinoma_7\NN
D001971_D015175 NONE bromocriptine_5\NN (r_pobj) of_4\IN (r_prep) effects_3\NNS (r_dobj) clarify_1\VB (r_advcl) applied_19\VBN (l_prep) to_20\IN (l_pobj) cells_26\NNS (l_compound) prolactinoma_25\NN
D001971_D015175 NONE bromocriptine_35\NN (r_pobj) of_34\IN (r_prep) injection_33\NN (r_pobj) after_32\IN (r_prep) h_31\NN (r_conj) applied_19\VBN (l_advcl) clarify_1\VB (l_dobj) effects_3\NNS (l_prep) on_6\IN (l_pobj) cells_8\NNS (l_compound) prolactinoma_7\NN
D001971_D015175 NONE bromocriptine_35\NN (r_pobj) of_34\IN (r_prep) injection_33\NN (r_pobj) after_32\IN (r_prep) h_31\NN (r_conj) applied_19\VBN (l_prep) to_20\IN (l_pobj) cells_26\NNS (l_compound) prolactinoma_25\NN
10669626
D014807_D002114 NONE D_8\JJ (r_conj) growth_5\NN (r_nmod) treatment_9\NN (r_nsubj) enhance_10\VB (l_prep) given_18\VBN (l_advcl) inhibit_24\VB (l_dobj) carboxylation_27\NN (l_prep) of_28\IN (l_pobj) protein_31\NN (l_appos) inhibitor_35\NN (l_compound) calcification_34\NN
D014807_D002114 NONE D_30\NN (r_npadvmod) treated_32\VBN (r_amod) rats_33\NNS (r_pobj) of_28\IN (r_prep) media_27\NNS (r_pobj) in_25\IN (r_prep) calcification_24\NN
D014807_D002114 NONE D_15\NN (r_pobj) by_13\IN (r_agent) produced_12\VBN (r_acl) calcium_11\NN (r_pobj) in_9\IN (r_prep) elevation_8\NN (r_pobj) on_6\IN (r_prep) effect_5\NN (r_dobj) had_3\VBD (r_advcl) explained_27\VBN (l_agent) by_28\IN (l_pobj) hypothesis_30\NN (l_acl) inhibits_33\VBZ (l_prep) as_40\IN (l_pobj) inhibitor_43\NN (l_compound) calcification_42\NN
D014807_D002114 NONE D_23\NN (r_pobj) between_19\IN (r_prep) synergy_18\NN (r_appos) D_15\NN (r_pobj) by_13\IN (r_agent) produced_12\VBN (r_acl) calcium_11\NN (r_pobj) in_9\IN (r_prep) elevation_8\NN (r_pobj) on_6\IN (r_prep) effect_5\NN (r_dobj) had_3\VBD (r_advcl) explained_27\VBN (l_agent) by_28\IN (l_pobj) hypothesis_30\NN (l_acl) inhibits_33\VBZ (l_prep) as_40\IN (l_pobj) inhibitor_43\NN (l_compound) calcification_42\NN
D015055_D002114 NONE carboxyglutamate_8\NN (r_compound) residues_9\NNS (r_nsubjpass) required_16\VBN (l_prep) as_20\IN (l_pobj) inhibitor_23\NN (l_compound) calcification_22\NN
D015055_D002114 NONE carboxyglutamate_8\NN (r_compound) residues_9\NNS (r_nsubjpass) required_16\VBN (r_advcl) required_28\VBN (l_prep) for_29\IN (l_pobj) accumulation_31\NN (l_prep) at_32\IN (l_pobj) sites_34\NNS (l_compound) calcification_33\NN
D014859_D061205 CID Warfarin_0\NNP (r_npadvmod) induced_2\VBN (r_amod) calcification_4\NN
D014859_D061205 CID Warfarin_22\NNP (r_pobj) of_21\IN (r_prep) doses_20\NNS (r_dobj) given_18\VBN (r_prep) enhance_10\VB (l_dobj) extent_12\NN (l_prep) of_13\IN (l_pobj) calcification_15\NN
D014859_D061205 CID Warfarin_17\NNP (r_npadvmod) treated_19\VBN (r_amod) rats_20\NNS (r_pobj) in_16\IN (r_prep) calcification_15\NN
D014859_D061205 CID Warfarin_5\NNP (r_pobj) with_4\IN (r_prep) Treatment_0\NN (r_nsubj) caused_6\VBD (l_dobj) calcification_9\NN (l_prep) of_10\IN (l_pobj) media_13\NNS (l_compound) artery_12\NN
D014859_D061205 CID Warfarin_20\NNP (r_compound) treatment_21\NN (r_pobj) of_19\IN (r_prep) weeks_18\NNS (r_pobj) after_16\IN (r_prep) detected_8\VBN (l_nsubjpass) calcification_5\NN
D014859_D061205 CID Warfarin_8\NNP (r_npadvmod) induced_10\VBN (r_amod) calcification_12\NN
D014859_D061205 CID Warfarin_7\NNP (r_pobj) with_6\IN (r_prep) groups_5\NNS (r_pobj) of_2\IN (r_prep) treatment_1\NN (r_nsubj) produced_8\VBD (l_dobj) calcification_11\NN (l_prep) of_12\IN (l_pobj) media_15\NNS (l_compound) artery_14\NN
D014859_D061205 CID Warfarin_7\NNP (r_pobj) with_6\IN (r_prep) groups_5\NNS (r_pobj) of_2\IN (r_prep) treatment_1\NN (r_nsubj) produced_8\VBD (l_dobj) calcification_11\NN (l_conj) calcification_27\NN
D014859_D061205 CID Warfarin_61\NNP (r_npadvmod) induced_63\VBN (r_amod) calcification_65\NN (r_pobj) to_60\IN (r_prep) resistant_59\JJ (r_acomp) was_58\VBD (r_relcl) groups_56\NNS (r_pobj) of_54\IN (r_prep) either_53\DT (r_pobj) with_52\IN (r_prep) compared_51\VBN (r_prep) rats_50\NNS (r_appos) relationship_24\NN (r_attr) was_22\VBD (l_advcl) determined_15\VBN (l_nsubjpass) explanation_2\NN (l_prep) for_3\IN (l_pobj) association_5\NN (l_prep) between_6\IN (l_pobj) calcification_8\NN
D014859_D061205 CID Warfarin_61\NNP (r_npadvmod) induced_63\VBN (r_amod) calcification_65\NN (r_pobj) to_60\IN (r_prep) resistant_59\JJ (r_acomp) was_58\VBD (r_relcl) groups_56\NNS (r_pobj) of_54\IN (r_prep) either_53\DT (r_pobj) with_52\IN (r_prep) compared_51\VBN (r_prep) rats_50\NNS (r_appos) relationship_24\NN (l_prep) between_25\IN (l_pobj) phosphate_28\NN (l_conj) susceptibility_30\NN (l_prep) to_31\IN (l_pobj) calcification_33\NN
D014859_D061205 CID Warfarin_61\NNP (r_npadvmod) induced_63\VBN (r_amod) calcification_65\NN
D014859_D061205 CID Warfarin_7\NNP (r_npadvmod) induced_9\VBN (r_amod) calcification_11\NN
D014859_D061205 CID Warfarin_13\NNP (r_conj) D_11\NN (r_pobj) between_9\IN (r_prep) synergy_8\NN (l_prep) in_14\IN (l_pobj) calcification_16\NN
D014859_D061205 CID Warfarin_0\NNP (r_nsubjpass) known_3\VBN (l_xcomp) cause_5\VB (l_dobj) calcification_6\NN (l_prep) of_7\IN (l_pobj) media_10\NNS (l_compound) artery_9\NN
D014859_D061205 CID Warfarin_20\NNP (r_conj) D_18\NNP (r_pobj) with_16\IN (r_prep) treated_15\VBN (r_acl) rats_14\NNS (r_pobj) in_13\IN (r_prep) calcification_12\NN
D010710_D061205 NONE phosphate_28\NN (r_pobj) between_25\IN (r_prep) relationship_24\NN (r_attr) was_22\VBD (l_advcl) determined_15\VBN (l_nsubjpass) explanation_2\NN (l_prep) for_3\IN (l_pobj) association_5\NN (l_prep) between_6\IN (l_pobj) calcification_8\NN
D010710_D061205 NONE phosphate_28\NN (l_conj) susceptibility_30\NN (l_prep) to_31\IN (l_pobj) calcification_33\NN
D010710_D061205 NONE phosphate_28\NN (r_pobj) between_25\IN (r_prep) relationship_24\NN (l_appos) rats_50\NNS (l_prep) compared_51\VBN (l_prep) with_52\IN (l_pobj) either_53\DT (l_prep) of_54\IN (l_pobj) groups_56\NNS (l_relcl) was_58\VBD (l_acomp) resistant_59\JJ (l_prep) to_60\IN (l_pobj) calcification_65\NN
D010710_D061205 NONE phosphate_42\NN (r_pobj) of_40\IN (r_prep) levels_39\NNS (r_pobj) with_35\IN (r_prep) relationship_24\NN (r_attr) was_22\VBD (l_advcl) determined_15\VBN (l_nsubjpass) explanation_2\NN (l_prep) for_3\IN (l_pobj) association_5\NN (l_prep) between_6\IN (l_pobj) calcification_8\NN
D010710_D061205 NONE phosphate_42\NN (r_pobj) of_40\IN (r_prep) levels_39\NNS (r_pobj) with_35\IN (r_prep) relationship_24\NN (l_prep) between_25\IN (l_pobj) phosphate_28\NN (l_conj) susceptibility_30\NN (l_prep) to_31\IN (l_pobj) calcification_33\NN
D010710_D061205 NONE phosphate_42\NN (r_pobj) of_40\IN (r_prep) levels_39\NNS (r_pobj) with_35\IN (r_prep) relationship_24\NN (l_appos) rats_50\NNS (l_prep) compared_51\VBN (l_prep) with_52\IN (l_pobj) either_53\DT (l_prep) of_54\IN (l_pobj) groups_56\NNS (l_relcl) was_58\VBD (l_acomp) resistant_59\JJ (l_prep) to_60\IN (l_pobj) calcification_65\NN
D010710_D061205 NONE phosphate_18\NN (r_compound) levels_19\NNS (r_pobj) to_15\IN (r_prep) related_14\VBN (l_nsubjpass) susceptibility_5\NN (l_prep) to_6\IN (l_pobj) calcification_11\NN
D002118_D002114 NONE calcium_11\NN (r_pobj) in_9\IN (r_prep) elevation_8\NN (r_pobj) on_6\IN (r_prep) effect_5\NN (r_dobj) had_3\VBD (r_advcl) explained_27\VBN (l_agent) by_28\IN (l_pobj) hypothesis_30\NN (l_acl) inhibits_33\VBZ (l_prep) as_40\IN (l_pobj) inhibitor_43\NN (l_compound) calcification_42\NN
D014807_D061205 NONE D._11\NNP (r_conj) growth_8\NN (r_pobj) by_7\IN (r_agent) accelerated_6\VBN (l_nsubjpass) calcification_4\NN
D014807_D061205 NONE D_8\JJ (r_conj) growth_5\NN (r_nmod) treatment_9\NN (r_nsubj) enhance_10\VB (l_dobj) extent_12\NN (l_prep) of_13\IN (l_pobj) calcification_15\NN
D014807_D061205 NONE D_11\NN (r_pobj) between_9\IN (r_prep) synergy_8\NN (l_prep) in_14\IN (l_pobj) calcification_16\NN
D014807_D061205 NONE D_4\NNP (r_pobj) of_2\IN (r_prep) doses_1\NNS (r_nsubjpass) known_6\VBN (l_xcomp) cause_8\VB (l_dobj) calcification_9\NN (l_prep) of_10\IN (l_pobj) media_13\NNS (l_compound) artery_12\NN
D014807_D061205 NONE D_10\NN (r_compound) dose_11\NN (l_prep) on_12\IN (l_pobj) calcification_14\NN
D014807_D061205 NONE D_10\NN (r_compound) dose_11\NN (r_pobj) of_8\IN (r_prep) effect_7\NN (l_conj) effect_17\NN (l_prep) of_18\IN (l_pobj) dose_21\NN (l_prep) on_22\IN (l_pobj) elevation_24\NN (l_relcl) suggests_30\VBZ (l_ccomp) induce_35\VB (l_dobj) calcification_37\NN
D014807_D061205 NONE D_20\NNP (r_compound) dose_21\NN (r_pobj) of_18\IN (r_prep) effect_17\NN (r_conj) effect_7\NN (l_prep) of_8\IN (l_pobj) dose_11\NN (l_prep) on_12\IN (l_pobj) calcification_14\NN
D014807_D061205 NONE D_20\NNP (r_compound) dose_21\NN (l_prep) on_22\IN (l_pobj) elevation_24\NN (l_relcl) suggests_30\VBZ (l_ccomp) induce_35\VB (l_dobj) calcification_37\NN
D014807_D061205 NONE D_33\NN (r_nsubj) induce_35\VB (r_ccomp) suggests_30\VBZ (r_relcl) elevation_24\NN (r_pobj) on_22\IN (r_prep) dose_21\NN (r_pobj) of_18\IN (r_prep) effect_17\NN (r_conj) effect_7\NN (l_prep) of_8\IN (l_pobj) dose_11\NN (l_prep) on_12\IN (l_pobj) calcification_14\NN
D014807_D061205 NONE D_33\NN (r_nsubj) induce_35\VB (l_dobj) calcification_37\NN
D014807_D061205 NONE D_18\NNP (r_pobj) with_16\IN (r_prep) treated_15\VBN (r_acl) rats_14\NNS (r_pobj) in_13\IN (r_prep) calcification_12\NN
D014859_D002114 NONE Warfarin_22\NNP (r_pobj) of_21\IN (r_prep) doses_20\NNS (r_dobj) given_18\VBN (l_advcl) inhibit_24\VB (l_dobj) carboxylation_27\NN (l_prep) of_28\IN (l_pobj) protein_31\NN (l_appos) inhibitor_35\NN (l_compound) calcification_34\NN
D014859_D002114 NONE Warfarin_5\NNP (r_pobj) with_4\IN (r_prep) Treatment_0\NN (r_nsubj) caused_6\VBD (l_dobj) calcification_9\NN (l_conj) calcification_23\NN
D014859_D002114 NONE Warfarin_17\NNP (r_compound) administration_18\NN (r_nsubj) increased_20\VBD (l_dobj) extent_22\NN (l_prep) of_23\IN (l_pobj) calcification_24\NN
D014859_D002114 NONE Warfarin_1\NNP (r_compound) treatment_2\NN (r_nsubj) had_3\VBD (r_advcl) explained_27\VBN (l_agent) by_28\IN (l_pobj) hypothesis_30\NN (l_acl) inhibits_33\VBZ (l_prep) as_40\IN (l_pobj) inhibitor_43\NN (l_compound) calcification_42\NN
D014859_D002114 NONE Warfarin_20\NNP (r_nmod) D_23\NN (r_pobj) between_19\IN (r_prep) synergy_18\NN (r_appos) D_15\NN (r_pobj) by_13\IN (r_agent) produced_12\VBN (r_acl) calcium_11\NN (r_pobj) in_9\IN (r_prep) elevation_8\NN (r_pobj) on_6\IN (r_prep) effect_5\NN (r_dobj) had_3\VBD (r_advcl) explained_27\VBN (l_agent) by_28\IN (l_pobj) hypothesis_30\NN (l_acl) inhibits_33\VBZ (l_prep) as_40\IN (l_pobj) inhibitor_43\NN (l_compound) calcification_42\NN
D014859_D002114 NONE Warfarin_32\NNP (r_nsubj) inhibits_33\VBZ (l_prep) as_40\IN (l_pobj) inhibitor_43\NN (l_compound) calcification_42\NN
D002118_D061205 NONE calcium_27\NN (r_pobj) of_25\IN (r_prep) elevation_24\NN (r_pobj) on_22\IN (r_prep) dose_21\NN (r_pobj) of_18\IN (r_prep) effect_17\NN (r_conj) effect_7\NN (l_prep) of_8\IN (l_pobj) dose_11\NN (l_prep) on_12\IN (l_pobj) calcification_14\NN
D002118_D061205 NONE calcium_27\NN (r_pobj) of_25\IN (r_prep) elevation_24\NN (l_relcl) suggests_30\VBZ (l_ccomp) induce_35\VB (l_dobj) calcification_37\NN
D002118_D061205 NONE calcium_43\NN (r_pobj) on_41\IN (r_prep) effect_40\NN (r_pobj) through_38\IN (r_prep) induce_35\VB (r_ccomp) suggests_30\VBZ (r_relcl) elevation_24\NN (r_pobj) on_22\IN (r_prep) dose_21\NN (r_pobj) of_18\IN (r_prep) effect_17\NN (r_conj) effect_7\NN (l_prep) of_8\IN (l_pobj) dose_11\NN (l_prep) on_12\IN (l_pobj) calcification_14\NN
D002118_D061205 NONE calcium_43\NN (r_pobj) on_41\IN (r_prep) effect_40\NN (r_pobj) through_38\IN (r_prep) induce_35\VB (l_dobj) calcification_37\NN
D015055_D061205 NONE carboxylated_36\JJ (r_acomp) was_31\VBD (r_ccomp) showed_25\VBD (r_conj) found_7\VBN (l_prep) at_8\IN (l_pobj) sites_9\NNS (l_prep) of_10\IN (l_pobj) calcification_12\NN
18004067
D000082_D056486 CID paracetamol_15\JJ (r_pobj) of_14\IN (r_prep) doses_13\NNS (r_pobj) with_11\IN (r_prep) associated_10\VBN (r_acl) hepatotoxicity_9\NN
D000082_D056486 CID acetaminophen_17\NN (r_appos) paracetamol_15\JJ (r_pobj) of_14\IN (r_prep) doses_13\NNS (r_pobj) with_11\IN (r_prep) associated_10\VBN (r_acl) hepatotoxicity_9\NN
D000082_D056486 CID paracetamol_15\NN (r_pobj) of_14\IN (r_prep) doses_13\NNS (r_pobj) with_11\IN (r_prep) treated_10\VBN (r_acl) patients_9\NNS (r_pobj) in_8\IN (r_prep) development_5\NN (l_prep) of_6\IN (l_pobj) hepatotoxicity_7\NN
D000082_D017114 NONE paracetamol_11\NN (r_dobj) ingesting_10\VBG (r_acl) consumption_9\NN (r_pobj) with_6\IN (r_prep) patients_5\NNS (r_pobj) in_3\IN (r_prep) failure_2\NN
D000431_D017114 NONE alcohol_8\NN (r_compound) consumption_9\NN (r_pobj) with_6\IN (r_prep) patients_5\NNS (r_pobj) in_3\IN (r_prep) failure_2\NN
D000431_D056486 NONE alcohol_4\NN (r_pobj) of_3\IN (r_prep) role_2\NN (l_prep) in_5\IN (l_pobj) development_7\NN (l_prep) of_8\IN (l_pobj) hepatotoxicity_9\NN
D000082_D017093 CID paracetamol_32\JJ (r_advmod) 4_30\CD (r_nummod) day_34\NN (r_pobj) with_29\IN (r_prep) treated_28\VBN (r_advcl) stopping_23\VBG (r_conj) developed_12\VBD (l_dobj) failure_14\NN
D000431_D017093 NONE alcohol_9\NN (r_pobj) of_8\IN (r_prep) consumers_7\NNS (r_attr) were_5\VBD (l_conj) developed_12\VBD (l_dobj) failure_14\NN
D000431_D017093 NONE alcohol_24\NN (r_compound) consumption_25\NN (r_dobj) stopping_23\VBG (r_conj) developed_12\VBD (l_dobj) failure_14\NN
D000431_D017093 NONE alcohol_10\NN (r_pobj) of_9\IN (r_prep) consumption_8\NN (r_appos) factors_4\NNS (r_pobj) with_2\IN (r_prep) patients_1\NNS (r_pobj) In_0\IN (r_prep) is_14\VBZ (l_nsubj) failure_13\NN
17439425
D003907_D015431 CID Dex_0\NNP (r_nsubj) increased_1\VBD (l_dep) P_13\NN (l_conj) decreased_18\VBN (l_dobj) thymus_19\NN (l_conj) bodyweights_26\NNS
D019820_D006973 NONE xanthine_2\NN (r_compound) oxidase_3\NN (r_pobj) of_1\IN (r_prep) Role_0\NN (l_prep) in_4\IN (l_pobj) hypertension_8\NN
D019820_D006973 NONE xanthine_5\NN (r_compound) oxidase_6\NN (r_pobj) of_4\IN (r_prep) role_3\NN (l_prep) in_22\IN (l_pobj) hypertension_26\NN
D019820_D006973 NONE xanthine_5\NN (r_compound) oxidase_6\NN (r_pobj) of_4\IN (r_prep) role_3\NN (l_prep) in_22\IN (l_pobj) hypertension_26\NN (l_appos) HT_30\NNP
D000493_D006973 NONE Allopurinol_0\NNP (r_nsubj) prevent_3\VB (l_dobj) HT_6\NNP
D000493_D006973 NONE allopurinol_8\NN (r_nsubj) failed_9\VBD (r_acl) findings_6\NNS (r_pobj) with_3\IN (r_prep) induced_14\VBN (l_dobj) hypertension_15\NN
D000493_D006973 NONE allopurinol_8\NN (r_nsubj) failed_9\VBD (r_acl) findings_6\NNS (r_pobj) with_3\IN (r_prep) induced_14\VBN (r_ccomp) suggests_17\VBZ (l_ccomp) is_21\VBZ (l_attr) determinant_25\NN (l_prep) of_26\IN (l_pobj) HT_29\NNP
D003907_D006973 CID dexamethasone_5\NN (r_npadvmod) induced_7\VBN (r_amod) hypertension_8\NN
D003907_D006973 CID dexamethasone_23\NN (r_npadvmod) induced_25\VBN (r_amod) hypertension_26\NN
D003907_D006973 CID dexamethasone_23\NN (r_npadvmod) induced_25\VBN (r_amod) hypertension_26\NN (l_appos) HT_30\NNP
D003907_D006973 CID dex_28\NN (r_compound) HT_30\NNP (r_appos) hypertension_26\NN
D003907_D006973 CID dex_28\NN (r_compound) HT_30\NNP
D003907_D006973 CID Dex_0\NNP (r_nsubj) increased_1\VBD (l_dobj) SBP_2\NNP
D003907_D006973 CID dex_4\NN (r_compound) HT_6\NNP
D009569_D006973 NONE oxide_16\NN (r_compound) redox_18\NN (r_compound) imbalance_19\NN (r_pobj) with_14\IN (r_prep) associated_13\VBN (l_nsubjpass) hypertension_3\NN
D009569_D006973 NONE oxide_16\NN (r_compound) redox_18\NN (r_compound) imbalance_19\NN (r_pobj) with_14\IN (r_prep) associated_13\VBN (l_nsubjpass) hypertension_3\NN (l_appos) HT_7\NNP
18996674
D003042_D011317 CID cocaine_9\NN (r_compound) user_10\NN (r_appos) man_4\NN (r_nsubj) presented_12\VBN (l_prep) on_20\IN (l_pobj) occasions_23\NNS (l_prep) with_24\IN (l_pobj) history_26\NN (l_prep) of_27\IN (l_pobj) priapism_28\NN
D003042_D011317 CID cocaine_30\NN (r_compound) use_31\NN (r_pobj) after_29\IN (r_prep) history_26\NN (l_prep) of_27\IN (l_pobj) priapism_28\NN
D004837_D011317 NONE epinephrine_1\NN (l_appos) treatment_6\NN (l_prep) for_7\IN (l_pobj) priapism_8\NN
9653867
D013974_D013971 CID Thyroxine_0\NNP (r_compound) abuse_1\NN (l_appos) case_5\NN (l_prep) of_6\IN (l_pobj) thyrotoxicosis_7\NN
D013974_D013971 CID thyroxine_28\NN (r_compound) abuse_29\NN (r_nsubjpass) considered_32\VBN (l_advcl) remains_25\VBZ (l_nsubj) cause_22\NN (l_prep) for_23\IN (l_pobj) thyrotoxicosis_24\NN
D013974_D001068 NONE thyroxine_28\NN (r_compound) abuse_29\NN (r_nsubjpass) considered_32\VBN (r_ccomp) reminds_17\VBZ (r_conj) illustrates_3\VBZ (l_dobj) derangements_5\NNS (l_prep) of_6\IN (l_pobj) function_8\NN (l_acl) seen_9\VBN (l_prep) with_13\IN (l_pcomp) eating_14\VBG (l_dobj) disorders_15\NNS
2348231
D010431_D006940 NONE Pentoxifylline_0\NNP (r_nsubj) inhibit_6\VB (l_dobj) hyperemia_11\NN
D010431_D006940 NONE Trental_2\NNP (r_appos) Pentoxifylline_0\NNP (r_nsubj) inhibit_6\VB (l_dobj) hyperemia_11\NN
D010431_D006940 NONE pentoxifylline_1\NN (r_nsubj) inhibits_2\VBZ (l_dobj) hyperemia_7\NN
D010431_D006940 NONE pentoxifylline_3\NN (r_pobj) of_2\IN (r_prep) dose_1\NN (r_nsubj) decreased_5\VBD (l_dobj) hyperemia_10\NN
D010431_D006940 NONE pentoxyifylline_3\NN (r_nsubj) inhibit_6\VB (l_dobj) hyperemia_11\NN
D013793_D006940 NONE thallium-201_17\NN (r_nmod) imaging_19\NN (r_pobj) for_14\IN (r_prep) implications_13\NNS (r_appos) hyperemia_11\NN
D013793_D006940 NONE thallium-201_22\NN (r_compound) imaging_23\NN (r_pobj) to_19\IN (r_prep) prior_18\RB (r_advmod) stopped_17\VBN (r_conj) inhibits_2\VBZ (l_dobj) hyperemia_7\NN
C008514_D007383 NONE methylxanthine_12\NN (r_compound) derivative_13\NN (l_relcl) improve_16\VB (l_dobj) claudication_18\NN
D004176_D006940 CID dipyridamole_7\NN (r_npadvmod) induced_9\VBN (r_amod) hyperemia_11\NN
D004176_D006940 CID dipyridamole_15\JJ (r_npadvmod) thallium-201_17\NN (r_nmod) imaging_19\NN (r_pobj) for_14\IN (r_prep) implications_13\NNS (r_appos) hyperemia_11\NN
D004176_D006940 CID dipyridamole_3\NN (r_dep) induced_5\VBN (r_amod) hyperemia_7\NN
D004176_D006940 CID dipyridamole_20\NN (r_compound) thallium-201_22\NN (r_compound) imaging_23\NN (r_pobj) to_19\IN (r_prep) prior_18\RB (r_advmod) stopped_17\VBN (r_conj) inhibits_2\VBZ (l_dobj) hyperemia_7\NN
D004176_D006940 CID dipyridamole_7\NN (r_npadvmod) induced_9\VBN (r_amod) hyperemia_10\NN
D013806_D006940 NONE theophylline_13\NN (r_pobj) as_12\IN (r_prep) methylxanthines_10\NNS (r_pobj) like_8\IN (r_prep) hyperemia_7\NN
D013806_D006940 NONE theophylline_21\NN (r_pobj) after_20\IN (r_prep) was_17\VBD (r_ccomp) peak_13\JJ (r_advcl) decreased_5\VBD (l_dobj) hyperemia_10\NN
C008514_D006940 NONE methylxanthines_10\NNS (r_pobj) like_8\IN (r_prep) hyperemia_7\NN
D010431_D007383 CID pentoxifylline_6\NN (r_dobj) taking_5\VBG (l_conj) derivative_13\NN (l_relcl) improve_16\VB (l_dobj) claudication_18\NN
D010431_D007383 CID Trental_8\NNP (r_npadvmod) taking_5\VBG (l_conj) derivative_13\NN (l_relcl) improve_16\VB (l_dobj) claudication_18\NN
10807237
D003042_D017542 CID Cocaine_0\NN (r_compound) use_1\NN (r_nsubj) predisposed_2\VBN (l_dobj) rupture_4\NN
D003042_D000783 NONE cocaine_12\NN (r_npadvmod) related_14\VBN (r_amod) aneurysms_15\NNS
D003042_D000783 NONE cocaine_25\NN (r_npadvmod) related_27\VBN (r_amod) aneurysms_28\NNS
D003042_D000783 NONE Cocaine_0\NN (r_compound) use_1\NN (r_nsubj) predisposed_2\VBN (l_prep) at_5\IN (l_conj) in_11\IN (l_pobj) aneurysms_14\NNS
3865016
D005047_D017254 NONE etoposide_4\NN (r_nmod) A_7\NNP (r_pobj) of_3\IN (r_prep) administration_2\NN (r_nsubj) resulted_8\VBD (l_prep) in_9\IN (l_pobj) eradication_10\NN (l_prep) of_11\IN (l_pobj) infiltration_15\NN
D016572_D054218 NONE A_7\NNP (r_pobj) of_3\IN (r_prep) effect_2\NN (r_nsubjpass) observed_9\VBN (l_prep) in_10\IN (l_pobj) patient_12\NN (l_prep) with_13\IN (l_pobj) leukemia_18\NN
D016572_D017254 NONE A_7\NNP (r_pobj) of_3\IN (r_prep) administration_2\NN (r_nsubj) resulted_8\VBD (l_prep) in_9\IN (l_pobj) eradication_10\NN (l_prep) of_11\IN (l_pobj) infiltration_15\NN
D005047_D054218 NONE etoposide_4\NN (r_nmod) A_7\NNP (r_pobj) of_3\IN (r_prep) effect_2\NN (r_nsubjpass) observed_9\VBN (l_prep) in_10\IN (l_pobj) patient_12\NN (l_prep) with_13\IN (l_pobj) leukemia_18\NN
10791295
D001058_D010554 CID apomorphine_2\NN (r_pobj) of_1\IN (r_prep) Development_0\NN (r_nsubj) induced_4\VBN (l_dobj) behavior_6\NN
D001058_D010554 CID apomorphine_3\NN (r_pobj) of_2\IN (r_prep) development_1\NN (r_nsubj) induced_5\VBN (l_dobj) behavior_14\NN
D001058_D010554 CID apomorphine_5\NN (r_compound) treatment_6\NN (r_nsubj) induced_7\VBD (l_dobj) development_10\NN (l_prep) of_11\IN (l_pobj) behavior_13\NN
D001058_D010554 CID apomorphine_5\NN (r_compound) treatment_6\NN (r_nsubj) induced_7\VBD (l_advcl) evidenced_15\VBN (l_agent) by_16\IN (l_pobj) intensity_19\NN (l_prep) of_20\IN (l_pobj) aggressiveness_21\NN
D001058_D010554 CID apomorphine_14\NN (r_preconj) the_13\DT (r_det) behavior_18\NN
1992636
D009853_D000743 CID omeprazole_7\NN (r_pobj) of_6\IN (r_prep) use_5\NN (r_pobj) with_3\IN (r_prep) associated_2\VBN (r_acl) anemia_1\NN
D009853_D000743 CID omeprazole_17\NN (r_pobj) of_16\IN (r_prep) use_15\NN (r_pobj) with_13\IN (r_prep) reaction_12\NN (r_pobj) of_5\IN (r_prep) case_4\NN (l_appos) anemia_20\NN
D009853_D000743 CID omeprazole_4\NN (r_nsubj) caused_5\VBD (l_ccomp) is_11\VBZ (l_nsubj) anemia_10\NN
D009853_D053609 CID omeprazole_17\NN (r_pobj) with_16\IN (r_prep) starting_14\VBG (r_pcomp) after_13\IN (r_prep) weakness_3\NN (l_conj) lethargy_5\NN
D009853_D004417 CID omeprazole_17\NN (r_pobj) with_16\IN (r_prep) starting_14\VBG (r_pcomp) after_13\IN (r_prep) weakness_3\NN (l_conj) lethargy_5\NN (l_conj) shortness_8\NN (l_prep) of_9\IN (l_pobj) breath_10\NN
9660111
D006916_D007035 NONE 5-hydroxytryptophan_22\JJ (r_poss) head_23\NN (r_compound) twitches_24\NNS (r_dobj) potentiate_20\VB (r_conj) antagonize_11\VB (l_dobj) hypothermia_14\VBN
D003000_D010554 NONE clonidine_28\NN (r_pobj) by_27\IN (r_agent) evoked_26\VBN (r_acl) aggressiveness_25\NN
D014299_D006948 CID TRI_0\NNP (r_nsubj) increases_5\VBZ (l_dobj) hyperactivity_8\NN
D003913_D006948 CID amphetamine_13\NN (r_pobj) by_10\IN (r_agent) induced_9\VBN (r_acl) hyperactivity_8\NN
D012110_D007035 CID reserpine_13\NN (r_compound) hypothermia_14\VBN
D010656_D010554 NONE phenylephrine_7\NN (l_acl) evaluated_15\VBN (l_conj) aggressiveness_25\NN
D019257_D006948 CID quinpirole_15\NN (r_conj) amphetamine_13\NN (r_pobj) by_10\IN (r_agent) induced_9\VBN (r_acl) hyperactivity_8\NN
D004298_D006948 NONE dopamine_24\NN (r_compound) D2_25\NN (r_appos) dipropyloaminotetralin_22\NN (r_conj) quinpirole_15\NN (r_conj) amphetamine_13\NN (r_pobj) by_10\IN (r_agent) induced_9\VBN (r_acl) hyperactivity_8\NN
D014299_D007035 NONE TRI_4\NNP (r_nsubj) antagonize_11\VB (l_dobj) hypothermia_14\VBN
19211690
D017673_D006973 NONE salt_11\NN (r_npadvmod) sensitive_13\JJ (r_amod) rats_14\NNS (r_pobj) in_9\IN (r_prep) upregulation_5\NN (r_conj) hypertension_3\NN
D000809_D006973 NONE angiotensin_25\NN (r_compound) system_26\NN (r_pobj) of_20\IN (r_prep) upregulation_19\NN (r_pobj) through_18\IN (r_prep) contributes_1\VBZ (l_prep) to_2\IN (l_pobj) development_4\NN (l_prep) of_5\IN (l_pobj) hypertension_6\NN
D013739_D006973 NONE Testosterone_0\NN (r_npadvmod) dependent_2\JJ (r_amod) hypertension_3\NN
D013739_D006973 NONE Testosterone_0\NN (r_nsubj) contributes_1\VBZ (l_prep) to_2\IN (l_pobj) development_4\NN (l_prep) of_5\IN (l_pobj) hypertension_6\NN
D000809_D007674 NONE angiotensin_25\NN (r_compound) system_26\NN (r_pobj) of_20\IN (r_prep) upregulation_19\NN (r_pobj) through_18\IN (r_prep) contributes_1\VBZ (l_prep) to_2\IN (l_pobj) development_4\NN (l_prep) of_5\IN (l_pobj) hypertension_6\NN (l_conj) injury_9\NN
D013739_D007674 NONE testosterone_24\NN (r_pobj) by_23\IN (r_agent) mediated_22\VBN (r_acl) angiotensinogen_21\NN (r_pobj) of_19\IN (r_prep) upregulation_18\NN (r_pobj) in_14\IN (r_prep) dimorphism_13\NN (l_relcl) causes_27\VBZ (l_dobj) increases_28\NNS (l_prep) in_29\IN (l_pobj) BP_30\NNP (l_conj) injury_33\NN
D013739_D007674 NONE Testosterone_0\NN (r_compound) replacement_1\NN (r_nsubj) increased_6\VBD (l_npadvmod) BP_7\NNP (l_appos) injury_10\NN
D013739_D007674 NONE Testosterone_0\NN (r_nsubj) contributes_1\VBZ (l_prep) to_2\IN (l_pobj) development_4\NN (l_prep) of_5\IN (l_pobj) hypertension_6\NN (l_conj) injury_9\NN
18410508
D015632_D009422 CID MPTP_17\NNP (r_npadvmod) induced_19\VBN (r_amod) neurodegeneration_20\NN
D015632_D009422 CID MPTP_8\NNP (r_conj) METH_6\NNP (r_pobj) by_5\IN (r_agent) caused_4\VBN (r_acl) damage_3\NN
D008694_D020258 NONE Methamphetamine_0\NN (r_npadvmod) induced_2\VBN (r_amod) activation_6\NN (l_nmod) neurotoxicity_3\NN
D008694_D020258 NONE METH_6\NNP (r_pobj) by_5\IN (r_agent) caused_4\VBN (r_acl) damage_3\NN (r_nsubj) is_9\VBZ (l_prep) for_12\IN (l_pobj) system_16\NN (l_prep) in_17\IN (l_pobj) models_19\NNS (l_prep) of_20\IN (l_pobj) neurotoxicity_21\NN
D008694_D020258 NONE METH_6\NNP (r_pobj) by_5\IN (r_agent) caused_4\VBN (r_acl) damage_3\NN (r_nsubj) is_9\VBZ (r_advcl) hypothesized_24\VBD (l_ccomp) plays_28\VBZ (l_dobj) role_30\NN (l_prep) in_31\IN (l_pobj) neurotoxicity_35\NN
D008694_D020258 NONE METH_32\NNP (r_npadvmod) induced_34\VBN (r_amod) neurotoxicity_35\NN (r_pobj) in_31\IN (r_prep) role_30\NN (r_dobj) plays_28\VBZ (r_ccomp) hypothesized_24\VBD (l_advcl) is_9\VBZ (l_prep) for_12\IN (l_pobj) system_16\NN (l_prep) in_17\IN (l_pobj) models_19\NNS (l_prep) of_20\IN (l_pobj) neurotoxicity_21\NN
D008694_D020258 NONE METH_32\NNP (r_npadvmod) induced_34\VBN (r_amod) neurotoxicity_35\NN
D008694_D020258 NONE METH_25\NNP (r_pobj) with_24\IN (r_prep) treated_23\VBN (l_conj) examined_27\VBN (l_prep) for_28\IN (l_pobj) neurotoxicity_30\NN
D008694_D020258 NONE METH_11\NNP (r_compound) neurotoxicity_12\NN
D004298_D009422 NONE DA_22\NNP (r_compound) neurons_23\NNS (r_pobj) of_21\IN (r_prep) neurodegeneration_20\NN
D004298_D009422 NONE DA_14\NNP (r_compound) system_16\NN (r_pobj) for_12\IN (r_prep) is_9\VBZ (l_nsubj) damage_3\NN
D004298_D020258 NONE DA_14\NNP (r_compound) system_16\NN (l_prep) in_17\IN (l_pobj) models_19\NNS (l_prep) of_20\IN (l_pobj) neurotoxicity_21\NN
D004298_D020258 NONE DA_14\NNP (r_compound) system_16\NN (r_pobj) for_12\IN (r_prep) is_9\VBZ (r_advcl) hypothesized_24\VBD (l_ccomp) plays_28\VBZ (l_dobj) role_30\NN (l_prep) in_31\IN (l_pobj) neurotoxicity_35\NN
D008694_D009422 CID METH_6\NNP (r_pobj) by_5\IN (r_agent) caused_4\VBN (r_acl) damage_3\NN
D008694_D009422 CID METH_32\NNP (r_npadvmod) induced_34\VBN (r_amod) neurotoxicity_35\NN (r_pobj) in_31\IN (r_prep) role_30\NN (r_dobj) plays_28\VBZ (r_ccomp) hypothesized_24\VBD (l_advcl) is_9\VBZ (l_nsubj) damage_3\NN
D015632_D020258 NONE MPTP_8\NNP (r_conj) METH_6\NNP (r_pobj) by_5\IN (r_agent) caused_4\VBN (r_acl) damage_3\NN (r_nsubj) is_9\VBZ (l_prep) for_12\IN (l_pobj) system_16\NN (l_prep) in_17\IN (l_pobj) models_19\NNS (l_prep) of_20\IN (l_pobj) neurotoxicity_21\NN
D015632_D020258 NONE MPTP_8\NNP (r_conj) METH_6\NNP (r_pobj) by_5\IN (r_agent) caused_4\VBN (r_acl) damage_3\NN (r_nsubj) is_9\VBZ (r_advcl) hypothesized_24\VBD (l_ccomp) plays_28\VBZ (l_dobj) role_30\NN (l_prep) in_31\IN (l_pobj) neurotoxicity_35\NN
10743446
D002211_D006930 CID capsaicin_16\NN (r_pobj) by_14\IN (r_agent) induced_13\VBN (r_acl) effects_1\NNS (l_prep) of_2\IN (l_pobj) ketamine_5\NN (l_prep) on_8\IN (l_pobj) hyperalgesia_12\NN
D002211_D006930 CID capsaicin_30\NN (r_pobj) by_29\IN (r_agent) induced_28\VBN (r_acl) effect_4\NN (l_prep) of_5\IN (l_pobj) administration_7\NN (l_prep) on_12\IN (l_pobj) hyperalgesia_27\NN
D008012_D010146 NONE lidocaine_11\NN (r_conj) ketamine_9\NN (r_pobj) of_8\IN (r_prep) administration_7\NN (l_prep) on_12\IN (l_pobj) hyperalgesia_27\NN (l_nmod) pain_19\NN
D007649_D006930 NONE ketamine_5\NN (l_prep) on_8\IN (l_pobj) hyperalgesia_12\NN
D007649_D006930 NONE ketamine_9\NN (r_pobj) of_8\IN (r_prep) administration_7\NN (l_prep) on_12\IN (l_pobj) hyperalgesia_27\NN
D007649_D006930 NONE Ketamine_0\NN (r_nsubj) reduced_1\VBD (l_dobj) area_4\NN (l_prep) of_5\IN (l_pobj) hyperalgesia_13\NN
D007649_D006930 NONE ketamine_4\NN (r_pobj) of_3\IN (r_prep) effects_2\NNS (l_prep) on_7\IN (l_pobj) hyperalgesia_11\NN
D007649_D006930 NONE ketamine_4\NN (r_pobj) of_3\IN (r_prep) effects_2\NNS (r_nsubj) suggest_12\VBP (l_ccomp) mediated_20\VBN (l_nsubjpass) types_16\NNS (l_prep) of_17\IN (l_pobj) hyperalgesia_18\NN
D008012_D006930 NONE lidocaine_7\NN (r_conj) ketamine_5\NN (l_prep) on_8\IN (l_pobj) hyperalgesia_12\NN
D008012_D006930 NONE lidocaine_11\NN (r_conj) ketamine_9\NN (r_pobj) of_8\IN (r_prep) administration_7\NN (l_prep) on_12\IN (l_pobj) hyperalgesia_27\NN
D008012_D006930 NONE Lidocaine_0\NN (r_nsubj) reduced_1\VBD (l_dobj) area_3\NN (l_prep) of_4\IN (l_pobj) hyperalgesia_8\NN
D008012_D006930 NONE lidocaine_6\NN (r_conj) ketamine_4\NN (r_pobj) of_3\IN (r_prep) effects_2\NNS (l_prep) on_7\IN (l_pobj) hyperalgesia_11\NN
D008012_D006930 NONE lidocaine_6\NN (r_conj) ketamine_4\NN (r_pobj) of_3\IN (r_prep) effects_2\NNS (r_nsubj) suggest_12\VBP (l_ccomp) mediated_20\VBN (l_nsubjpass) types_16\NNS (l_prep) of_17\IN (l_pobj) hyperalgesia_18\NN
D002211_D010146 CID capsaicin_30\NN (r_pobj) by_29\IN (r_agent) induced_28\VBN (r_acl) effect_4\NN (l_prep) of_5\IN (l_pobj) administration_7\NN (l_prep) on_12\IN (l_pobj) hyperalgesia_27\NN (l_nmod) pain_19\NN
D007649_D010146 NONE ketamine_9\NN (r_pobj) of_8\IN (r_prep) administration_7\NN (l_prep) on_12\IN (l_pobj) hyperalgesia_27\NN (l_nmod) pain_19\NN
D007649_D010146 NONE Ketamine_0\NN (r_nsubj) reduced_1\VBD (l_conj) tended_17\VBD (l_xcomp) reduce_19\VB (l_dobj) pain_23\NN
18442015
D004872_D014456 CID D2_47\NN (r_pobj) of_45\IN (r_prep) coadministration_44\NN (r_pobj) by_43\IN (r_prep) induced_42\VBN (l_nsubj) release_20\NN (l_conj) peroxide_23\NN (l_appos) permeability_31\NN (l_prep) in_32\IN (l_pcomp) modulating_33\VBG (l_dobj) hemorrhage_35\NN (l_conj) ulcer_37\NN
D002784_D050197 CID cholesterol_49\NN (r_conj) D2_47\NN (r_pobj) of_45\IN (r_prep) coadministration_44\NN (r_pobj) by_43\IN (r_prep) induced_42\VBN (l_nsubj) release_20\NN (l_conj) peroxide_23\NN (l_appos) permeability_31\NN (l_prep) in_32\IN (l_pcomp) modulating_33\VBG (l_dobj) hemorrhage_35\NN (l_prep) in_38\IN (l_pobj) rats_39\NNS (l_prep) with_40\IN (l_pobj) atherosclerosis_41\NN
D002784_D050197 CID cholesterol_23\NN (r_conj) D2_21\NN (r_dobj) containing_19\VBG (l_advcl) induce_25\VB (l_dobj) atherosclerosis_26\NN
D002784_D050197 CID cholesterol_10\NN (r_conj) calcium_7\NN (r_pobj) as_5\IN (r_prep) parameters_2\NNS (l_amod) atherosclerotic_1\JJ
D002784_D050197 CID cholesterol_10\NN (r_conj) calcium_7\NN (r_pobj) as_5\IN (r_prep) parameters_2\NNS (r_nsubjpass) obtained_18\VBN (l_prep) in_19\IN (l_pobj) rats_21\NNS (l_amod) atherosclerotic_20\JJ
D002118_D050197 NONE calcium_7\NN (r_pobj) as_5\IN (r_prep) parameters_2\NNS (l_amod) atherosclerotic_1\JJ
D002118_D050197 NONE calcium_7\NN (r_pobj) as_5\IN (r_prep) parameters_2\NNS (r_nsubjpass) obtained_18\VBN (l_prep) in_19\IN (l_pobj) rats_21\NNS (l_amod) atherosclerotic_20\JJ
D006632_D050197 NONE histamine_19\NN (r_compound) release_20\NN (l_conj) peroxide_23\NN (l_appos) permeability_31\NN (l_prep) in_32\IN (l_pcomp) modulating_33\VBG (l_dobj) hemorrhage_35\NN (l_prep) in_38\IN (l_pobj) rats_39\NNS (l_prep) with_40\IN (l_pobj) atherosclerosis_41\NN
D006632_D050197 NONE histamine_6\NN (r_pobj) of_5\IN (r_prep) correlation_4\NN (r_nsubjpass) found_14\VBN (l_prep) in_15\IN (l_pobj) rats_18\NNS (l_amod) atherosclerotic_17\JJ
D006632_D050197 NONE histamine_18\NN (r_compound) release_19\NN (r_conj) generation_16\NN (l_ccomp) produce_2\VB (l_nsubj) Atherosclerosis_0\NN
D010634_D014456 NONE luminal_16\JJ (r_amod) content_18\NN (l_conj) areas_21\NNS (l_compound) ulcer_20\NN
D010634_D014456 NONE luminal_22\JJ (r_amod) content_24\NN (r_conj) generation_20\NN (r_conj) release_17\NN (r_conj) diffusion_14\NN (r_pobj) including_9\VBG (r_prep) factors_7\NNS (r_pobj) with_4\IN (r_prep) accompanied_3\VBN (l_nsubj) ulcers_2\NNS
D006632_D014456 NONE histamine_19\NN (r_compound) release_20\NN (l_conj) peroxide_23\NN (l_appos) permeability_31\NN (l_prep) in_32\IN (l_pcomp) modulating_33\VBG (l_dobj) hemorrhage_35\NN (l_conj) ulcer_37\NN
D006632_D014456 NONE histamine_10\NN (r_compound) concentration_11\NN (l_conj) permeability_14\NN (l_conj) content_18\NN (l_conj) areas_21\NNS (l_compound) ulcer_20\NN
D006632_D014456 NONE histamine_16\NN (r_compound) release_17\NN (r_conj) diffusion_14\NN (r_pobj) including_9\VBG (r_prep) factors_7\NNS (r_pobj) with_4\IN (r_prep) accompanied_3\VBN (l_nsubj) ulcers_2\NNS
D006632_D014456 NONE histamine_6\NN (r_pobj) of_5\IN (r_prep) correlation_4\NN (l_prep) to_7\IN (l_conj) to_11\IN (l_pobj) ulcer_12\NN
D006632_D014456 NONE histamine_18\NN (r_compound) release_19\NN (r_conj) generation_16\NN (l_ccomp) produce_2\VB (l_dobj) ulcer_5\NN
D002784_D014456 CID cholesterol_49\NN (r_conj) D2_47\NN (r_pobj) of_45\IN (r_prep) coadministration_44\NN (r_pobj) by_43\IN (r_prep) induced_42\VBN (l_nsubj) release_20\NN (l_conj) peroxide_23\NN (l_appos) permeability_31\NN (l_prep) in_32\IN (l_pcomp) modulating_33\VBG (l_dobj) hemorrhage_35\NN (l_conj) ulcer_37\NN
D004872_D006471 CID D2_47\NN (r_pobj) of_45\IN (r_prep) coadministration_44\NN (r_pobj) by_43\IN (r_prep) induced_42\VBN (l_nsubj) release_20\NN (l_conj) peroxide_23\NN (l_appos) permeability_31\NN (l_prep) in_32\IN (l_pcomp) modulating_33\VBG (l_dobj) hemorrhage_35\NN
D014700_D050197 NONE verapamil_3\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (l_prep) on_4\IN (l_pobj) ulcers_7\NNS (l_prep) in_8\IN (l_pobj) rats_11\NNS (l_amod) atherosclerotic_10\JJ
D014700_D050197 NONE verapamil_28\NN (r_pobj) by_27\IN (r_agent) ameliorated_26\VBN (r_relcl) generation_16\NN (l_ccomp) produce_2\VB (l_nsubj) Atherosclerosis_0\NN
D002784_D006471 CID cholesterol_49\NN (r_conj) D2_47\NN (r_pobj) of_45\IN (r_prep) coadministration_44\NN (r_pobj) by_43\IN (r_prep) induced_42\VBN (l_nsubj) release_20\NN (l_conj) peroxide_23\NN (l_appos) permeability_31\NN (l_prep) in_32\IN (l_pcomp) modulating_33\VBG (l_dobj) hemorrhage_35\NN
D014700_D006471 NONE verapamil_3\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (l_prep) on_4\IN (l_pobj) ulcers_7\NNS (l_amod) hemorrhagic_6\JJ
D014700_D006471 NONE verapamil_15\NN (r_pobj) by_12\IN (r_agent) ameliorated_11\VBN (r_acomp) were_7\VBD (l_nsubj) ulcer_2\NN (l_amod) hemorrhagic_1\JJ
D014700_D006471 NONE verapamil_28\NN (r_pobj) by_27\IN (r_agent) ameliorated_26\VBN (r_relcl) generation_16\NN (l_ccomp) produce_2\VB (l_dobj) ulcer_5\NN (l_amod) hemorrhagic_4\JJ
D004872_D050197 CID D2_47\NN (r_pobj) of_45\IN (r_prep) coadministration_44\NN (r_pobj) by_43\IN (r_prep) induced_42\VBN (l_nsubj) release_20\NN (l_conj) peroxide_23\NN (l_appos) permeability_31\NN (l_prep) in_32\IN (l_pcomp) modulating_33\VBG (l_dobj) hemorrhage_35\NN (l_prep) in_38\IN (l_pobj) rats_39\NNS (l_prep) with_40\IN (l_pobj) atherosclerosis_41\NN
D004872_D050197 CID D2_21\NN (r_dobj) containing_19\VBG (l_advcl) induce_25\VB (l_dobj) atherosclerosis_26\NN
D006632_D006471 NONE histamine_19\NN (r_compound) release_20\NN (l_conj) peroxide_23\NN (l_appos) permeability_31\NN (l_prep) in_32\IN (l_pcomp) modulating_33\VBG (l_dobj) hemorrhage_35\NN
D006632_D006471 NONE histamine_6\NN (r_pobj) of_5\IN (r_prep) correlation_4\NN (l_prep) to_7\IN (l_pobj) hemorrhage_9\NN
D006632_D006471 NONE histamine_18\NN (r_compound) release_19\NN (r_conj) generation_16\NN (l_ccomp) produce_2\VB (l_dobj) ulcer_5\NN (l_amod) hemorrhagic_4\JJ
D014700_D014456 NONE verapamil_3\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (l_prep) on_4\IN (l_pobj) ulcers_7\NNS
D014700_D014456 NONE verapamil_6\NN (r_pobj) of_5\IN (r_prep) effect_4\NN (l_prep) on_7\IN (l_pobj) model_10\NN (l_compound) ulcer_9\NN
D014700_D014456 NONE verapamil_15\NN (r_pobj) by_12\IN (r_agent) ameliorated_11\VBN (r_acomp) were_7\VBD (l_nsubj) ulcer_2\NN
D014700_D014456 NONE verapamil_28\NN (r_pobj) by_27\IN (r_agent) ameliorated_26\VBN (r_relcl) generation_16\NN (l_ccomp) produce_2\VB (l_dobj) ulcer_5\NN
6286738
D002762_D054559 CID D3_5\NNP (r_pobj) of_3\IN (r_prep) doses_2\NNS (r_nsubjpass) associated_18\VBN (l_prep) with_19\IN (l_pobj) hypercalcemia_21\NN (l_conj) hyperphosphatemia_23\NN
D002762_D054559 CID D3_15\NNP (r_appos) doses_2\NNS (r_nsubjpass) associated_18\VBN (l_prep) with_19\IN (l_pobj) hypercalcemia_21\NN (l_conj) hyperphosphatemia_23\NN
D002762_D054559 CID D3_30\NNP (r_pobj) of_28\IN (r_prep) increases_27\NNS (r_conj) hyperphosphatemia_23\NN
D002762_D064420 NONE D3_1\NN (r_compound) toxicity_2\NN
D002762_D064420 NONE D3_3\NNP (r_compound) toxicity_4\NN
D002762_D064420 NONE D3_3\NNP (r_compound) toxicity_4\NN (r_pobj) of_1\IN (r_prep) Signs_0\NNS (r_nsubjpass) observed_7\VBN (r_ccomp) developed_18\VBN (l_dobj) signs_20\NNS (l_prep) of_21\IN (l_pobj) toxicity_24\NN
D002762_D064420 NONE D3_23\NNP (r_compound) toxicity_24\NN (r_pobj) of_21\IN (r_prep) signs_20\NNS (r_dobj) developed_18\VBN (l_ccomp) observed_7\VBN (l_nsubjpass) Signs_0\NNS (l_prep) of_1\IN (l_pobj) toxicity_4\NN
D002762_D064420 NONE D3_23\NNP (r_compound) toxicity_24\NN
D002762_D064420 NONE D3_7\NN (r_pobj) of_5\IN (r_prep) toxicity_4\NN
D002762_D064420 NONE D3_22\NNP (r_pobj) of_20\IN (r_prep) doses_19\NNS (r_pobj) between_18\IN (r_prep) safety_17\NN (r_pobj) of_16\IN (r_prep) margin_15\NN (r_conj) toxicity_4\NN
D002762_D064420 NONE D3_38\NNP (r_nsubjpass) used_42\VBN (r_ccomp) concluded_35\VBD (l_prep) Because_0\IN (l_pobj) toxicity_4\NN
D002762_D010319 NONE D3_7\NNP (r_pobj) with_5\IN (r_prep) treated_4\VBN (r_acl) cows_3\NNS (r_pobj) of_1\IN (r_prep) None_0\NN (r_nsubj) showed_8\VBD (l_dobj) signs_9\NNS (l_prep) of_10\IN (l_pobj) fever_12\NN
D002762_D010319 NONE D3_7\NNP (r_pobj) with_5\IN (r_prep) treated_4\VBN (r_acl) cows_3\NNS (r_pobj) of_1\IN (r_prep) None_0\NN (r_nsubj) showed_8\VBD (r_ccomp) developed_26\VBD (l_dobj) signs_28\NNS (l_prep) of_29\IN (l_pobj) fever_31\NN
D002762_D010319 NONE D3_7\NN (r_pobj) of_5\IN (r_prep) toxicity_4\NN (l_conj) margin_15\NN (l_prep) of_16\IN (l_pobj) safety_17\NN (l_prep) between_18\IN (l_pobj) doses_19\NNS (l_prep) of_20\IN (l_pobj) D3_22\NNP (l_relcl) prevent_24\VBP (l_dobj) fever_26\NN
D002762_D010319 NONE D3_7\NN (r_pobj) of_5\IN (r_prep) toxicity_4\NN (l_conj) margin_15\NN (l_prep) of_16\IN (l_pobj) safety_17\NN (l_prep) between_18\IN (l_pobj) doses_19\NNS (l_prep) of_20\IN (l_pobj) D3_22\NNP (l_relcl) prevent_24\VBP (l_dobj) fever_26\NN (l_relcl) induce_30\VBP (l_dobj) fever_32\NN
D002762_D010319 NONE D3_7\NN (r_pobj) of_5\IN (r_prep) toxicity_4\NN (r_pobj) Because_0\IN (r_prep) concluded_35\VBD (l_ccomp) used_42\VBN (l_xcomp) prevent_45\VB (l_dobj) fever_47\NN
D002762_D010319 NONE D3_22\NNP (l_relcl) prevent_24\VBP (l_dobj) fever_26\NN
D002762_D010319 NONE D3_22\NNP (l_relcl) prevent_24\VBP (l_dobj) fever_26\NN (l_relcl) induce_30\VBP (l_dobj) fever_32\NN
D002762_D010319 NONE D3_22\NNP (r_pobj) of_20\IN (r_prep) doses_19\NNS (r_pobj) between_18\IN (r_prep) safety_17\NN (r_pobj) of_16\IN (r_prep) margin_15\NN (r_conj) toxicity_4\NN (r_pobj) Because_0\IN (r_prep) concluded_35\VBD (l_ccomp) used_42\VBN (l_xcomp) prevent_45\VB (l_dobj) fever_47\NN
D002762_D010319 NONE D3_38\NNP (r_nsubjpass) used_42\VBN (r_ccomp) concluded_35\VBD (l_prep) Because_0\IN (l_pobj) toxicity_4\NN (l_conj) margin_15\NN (l_prep) of_16\IN (l_pobj) safety_17\NN (l_prep) between_18\IN (l_pobj) doses_19\NNS (l_prep) of_20\IN (l_pobj) D3_22\NNP (l_relcl) prevent_24\VBP (l_dobj) fever_26\NN
D002762_D010319 NONE D3_38\NNP (r_nsubjpass) used_42\VBN (r_ccomp) concluded_35\VBD (l_prep) Because_0\IN (l_pobj) toxicity_4\NN (l_conj) margin_15\NN (l_prep) of_16\IN (l_pobj) safety_17\NN (l_prep) between_18\IN (l_pobj) doses_19\NNS (l_prep) of_20\IN (l_pobj) D3_22\NNP (l_relcl) prevent_24\VBP (l_dobj) fever_26\NN (l_relcl) induce_30\VBP (l_dobj) fever_32\NN
D002762_D010319 NONE D3_38\NNP (r_nsubjpass) used_42\VBN (l_xcomp) prevent_45\VB (l_dobj) fever_47\NN
D002762_D006934 CID D3_5\NNP (r_pobj) of_3\IN (r_prep) doses_2\NNS (r_nsubjpass) associated_18\VBN (l_prep) with_19\IN (l_pobj) hypercalcemia_21\NN
D002762_D006934 CID D3_15\NNP (r_appos) doses_2\NNS (r_nsubjpass) associated_18\VBN (l_prep) with_19\IN (l_pobj) hypercalcemia_21\NN
D002762_D006934 CID D3_30\NNP (r_pobj) of_28\IN (r_prep) increases_27\NNS (r_conj) hyperphosphatemia_23\NN (r_conj) hypercalcemia_21\NN
603022
D005702_D062787 NONE hydrobromide_1\RB (r_nsubjpass) used_16\VBN (l_prep) in_17\IN (l_pobj) patient_19\JJ (l_acl) demonstrating_20\NN (l_dobj) effects_22\NNS (l_prep) of_23\IN (l_pobj) overdosage_28\NN
D012601_D062787 CID scopolamine_24\NN (r_nmod) overdosage_28\NN
D012601_D062787 CID hyoscine_26\NN (r_nmod) overdosage_28\NN
1601297
D003042_D009203 CID cocaine_3\NN (r_compound) abusers_4\NNS (r_pobj) of_1\IN (r_prep) Eleven_0\CD (r_nsubj) had_10\VBD (l_dobj) evidence_12\NN (l_prep) of_13\IN (l_pobj) injury_16\NN (l_acl) defined_17\VBN (l_prep) as_18\IN (l_pobj) infarction_20\NN
D003042_D007511 NONE cocaine_3\NN (r_compound) abusers_4\NNS (r_pobj) of_1\IN (r_prep) Eleven_0\CD (r_nsubj) had_10\VBD (l_dobj) evidence_12\NN (l_prep) of_13\IN (l_pobj) injury_16\NN (l_acl) defined_17\VBN (l_prep) as_18\IN (l_pobj) infarction_20\NN (l_conj) ischemia_22\NN
D003042_D012559 NONE cocaine_7\NN (r_npadvmod) abusing_9\VBG (r_amod) patients_10\NNS (r_pobj) of_5\IN (r_prep) ECG_3\NNP (r_appos) electrocardiograms_1\NNS (r_nsubjpass) compared_12\VBN (l_prep) with_13\IN (l_pobj) ECGs_15\NNS (l_prep) of_16\IN (l_pobj) controls_19\NNS (l_amod) schizophrenic_18\JJ
D003042_D009202 NONE cocaine_8\NN (r_compound) abusers_9\NNS (r_pobj) in_5\IN (r_prep) injury_4\NN
D003042_D009202 NONE cocaine_3\NN (r_compound) abusers_4\NNS (r_pobj) of_1\IN (r_prep) Eleven_0\CD (r_nsubj) had_10\VBD (l_dobj) evidence_12\NN (l_prep) of_13\IN (l_pobj) injury_16\NN
D003042_D002037 CID cocaine_3\NN (r_compound) abusers_4\NNS (r_pobj) of_1\IN (r_prep) Eleven_0\CD (r_nsubj) had_10\VBD (l_dobj) evidence_12\NN (l_prep) of_13\IN (l_pobj) injury_16\NN (l_acl) defined_17\VBN (l_prep) as_18\IN (l_pobj) infarction_20\NN (l_conj) ischemia_22\NN (l_conj) block_27\NN
8643971
D017239_D064420 NONE paclitaxel_16\NN (r_compound) doses_17\NNS (r_pobj) of_14\IN (r_prep) response_11\NN (l_conj) toxicity_13\NN
D017239_D064420 NONE paclitaxel_5\NN (r_compound) doses_6\NNS (r_dobj) incorporate_3\VBP (l_conj) permitted_17\VBN (l_advcl) permits_20\VBZ (l_nsubj) toxicity_19\NN
D002945_D064420 NONE cisplatin_23\NN (r_pobj) with_19\IN (r_prep) combined_18\VBN (r_acl) doses_17\NNS (r_pobj) of_14\IN (r_prep) response_11\NN (l_conj) toxicity_13\NN
D017239_D006258 NONE paclitaxel_7\NN (r_pobj) of_6\IN (r_prep) study_5\NN (r_dobj) phase_1\NN (l_conj) cisplatin_9\NN (l_prep) as_10\IN (l_pobj) therapy_14\NN (l_prep) for_15\IN (l_pobj) cancers_19\NNS
D017239_D006258 NONE paclitaxel_13\NN (r_pobj) of_9\IN (r_prep) study_8\NN (r_pobj) of_2\IN (r_prep) results_1\NNS (r_nsubj) reported_27\VBD (l_dobj) rate_32\NN (l_prep) in_33\IN (l_pobj) patients_34\NNS (l_prep) with_35\IN (l_pobj) cancer_39\NN
D017239_D006258 NONE Taxol_15\NNP (r_appos) paclitaxel_13\NN (r_pobj) of_9\IN (r_prep) study_8\NN (r_pobj) of_2\IN (r_prep) results_1\NNS (r_nsubj) reported_27\VBD (l_dobj) rate_32\NN (l_prep) in_33\IN (l_pobj) patients_34\NNS (l_prep) with_35\IN (l_pobj) cancer_39\NN
D017239_D006258 NONE paclitaxel_43\NN (r_nmod) combination_46\NN (r_nsubjpass) used_49\VBN (r_conj) reported_27\VBD (l_dobj) rate_32\NN (l_prep) in_33\IN (l_pobj) patients_34\NNS (l_prep) with_35\IN (l_pobj) cancer_39\NN
D017239_D006258 NONE paclitaxel_16\NN (r_compound) doses_17\NNS (l_acl) combined_18\VBN (l_prep) with_24\IN (l_pobj) support_30\NN (l_prep) in_31\IN (l_pobj) patients_32\NNS (l_prep) with_33\IN (l_pobj) head_38\NN (l_conj) carcinoma_41\NN
D017239_D006258 NONE Paclitaxel_0\NNP (r_nsubj) is_3\VBZ (l_attr) regimen_9\NN (l_prep) for_10\IN (l_pobj) head_13\NN (l_conj) cancer_16\NN
D017239_D010051 NONE paclitaxel_13\NN (r_pobj) of_9\IN (r_prep) study_8\NN (r_pobj) of_2\IN (r_prep) results_1\NNS (r_nsubj) reported_27\VBD (l_conj) used_49\VBN (l_conj) improved_54\VBN (l_dobj) duration_57\NN (l_prep) in_58\IN (l_pobj) patients_61\NNS (l_compound) cancer_60\NN
D017239_D010051 NONE Taxol_15\NNP (r_appos) paclitaxel_13\NN (r_pobj) of_9\IN (r_prep) study_8\NN (r_pobj) of_2\IN (r_prep) results_1\NNS (r_nsubj) reported_27\VBD (l_conj) used_49\VBN (l_conj) improved_54\VBN (l_dobj) duration_57\NN (l_prep) in_58\IN (l_pobj) patients_61\NNS (l_compound) cancer_60\NN
D017239_D010051 NONE paclitaxel_43\NN (r_nmod) combination_46\NN (r_nsubjpass) used_49\VBN (l_conj) improved_54\VBN (l_dobj) duration_57\NN (l_prep) in_58\IN (l_pobj) patients_61\NNS (l_compound) cancer_60\NN
D002945_D010051 NONE cisplatin_45\NN (r_compound) combination_46\NN (r_nsubjpass) used_49\VBN (l_conj) improved_54\VBN (l_dobj) duration_57\NN (l_prep) in_58\IN (l_pobj) patients_61\NNS (l_compound) cancer_60\NN
D002945_D006258 NONE cisplatin_9\NN (l_prep) as_10\IN (l_pobj) therapy_14\NN (l_prep) for_15\IN (l_pobj) cancers_19\NNS
D002945_D006258 NONE cisplatin_45\NN (r_compound) combination_46\NN (r_nsubjpass) used_49\VBN (r_conj) reported_27\VBD (l_dobj) rate_32\NN (l_prep) in_33\IN (l_pobj) patients_34\NNS (l_prep) with_35\IN (l_pobj) cancer_39\NN
D002945_D006258 NONE cisplatin_23\NN (r_pobj) with_19\IN (r_prep) combined_18\VBN (l_prep) with_24\IN (l_pobj) support_30\NN (l_prep) in_31\IN (l_pobj) patients_32\NNS (l_prep) with_33\IN (l_pobj) head_38\NN (l_conj) carcinoma_41\NN
D002945_D006258 NONE cisplatin_2\NN (r_advmod) is_3\VBZ (l_attr) regimen_9\NN (l_prep) for_10\IN (l_pobj) head_13\NN (l_conj) cancer_16\NN
9523805
D008012_D009422 CID lidocaine_16\NN (r_pobj) with_15\IN (r_prep) than_14\IN (r_prep) incidence_9\NN (r_appos) symptoms_2\NNS
D008012_D009422 CID lidocaine_12\NN (r_amod) anesthesia_14\NN (r_dobj) follow_11\VBP (l_nsubj) symptoms_6\NNS
D008012_D009422 CID lidocaine_12\NN (r_amod) anesthesia_14\NN (r_dobj) follow_11\VBP (l_nsubj) symptoms_6\NNS (l_appos) TNSs_8\NNS
D008012_D009422 CID lidocaine_13\NN (l_conj) bupivacaine_15\NN (l_prep) with_16\IN (l_pobj) respect_17\NN (l_prep) to_18\IN (l_pobj) duration_19\NN (l_prep) of_20\IN (l_pobj) action_21\NN (l_conj) risk_24\NN (l_prep) of_25\IN (l_pobj) TNSs_26\NNS
D008012_D009422 CID lidocaine_6\NN (r_dobj) receiving_5\VBG (l_dobj) TNSs_8\NNS
D008012_D009422 CID lidocaine_6\NN (r_dobj) receiving_5\VBG (r_acl) patients_4\NNS (r_nsubj) had_21\VBD (l_conj) had_31\VBD (l_dobj) TNSs_32\NNS
D008012_D009422 CID lidocaine_5\NN (r_xcomp) preferable_3\JJ (r_acomp) be_2\VB (l_advcl) has_12\VBZ (l_dobj) duration_15\NN (l_conj) incidence_21\NN (l_prep) of_22\IN (l_pobj) TNSs_23\NNS
D011318_D009422 CID prilocaine_11\NN (r_pobj) with_10\IN (r_prep) incidence_9\NN (r_appos) symptoms_2\NNS
D011318_D009422 CID prilocaine_11\JJ (l_prep) with_12\IN (l_pobj) lidocaine_13\NN (l_conj) bupivacaine_15\NN (l_prep) with_16\IN (l_pobj) respect_17\NN (l_prep) to_18\IN (l_pobj) duration_19\NN (l_prep) of_20\IN (l_pobj) action_21\NN (l_conj) risk_24\NN (l_prep) of_25\IN (l_pobj) TNSs_26\NNS
D011318_D009422 CID prilocaine_15\NN (r_dobj) receiving_14\VBG (r_acl) patients_13\NNS (r_nsubj) had_21\VBD (l_nsubj) patients_4\NNS (l_acl) receiving_5\VBG (l_dobj) TNSs_8\NNS
D011318_D009422 CID prilocaine_15\NN (r_dobj) receiving_14\VBG (r_acl) patients_13\NNS (r_nsubj) had_21\VBD (l_conj) had_31\VBD (l_dobj) TNSs_32\NNS
D011318_D009422 CID Prilocaine_0\NNP (r_nsubj) be_2\VB (l_advcl) has_12\VBZ (l_dobj) duration_15\NN (l_conj) incidence_21\NN (l_prep) of_22\IN (l_pobj) TNSs_23\NNS
D002045_D009422 NONE bupivacaine_13\NN (r_conj) prilocaine_11\NN (r_pobj) with_10\IN (r_prep) incidence_9\NN (r_appos) symptoms_2\NNS
D002045_D009422 NONE bupivacaine_19\NN (r_pobj) with_18\IN (r_prep) infrequent_17\JJ (r_acomp) are_16\VBP (r_conj) follow_11\VBP (l_nsubj) symptoms_6\NNS
D002045_D009422 NONE bupivacaine_19\NN (r_pobj) with_18\IN (r_prep) infrequent_17\JJ (r_acomp) are_16\VBP (r_conj) follow_11\VBP (l_nsubj) symptoms_6\NNS (l_appos) TNSs_8\NNS
D002045_D009422 NONE bupivacaine_15\NN (l_prep) with_16\IN (l_pobj) respect_17\NN (l_prep) to_18\IN (l_pobj) duration_19\NN (l_prep) of_20\IN (l_pobj) action_21\NN (l_conj) risk_24\NN (l_prep) of_25\IN (l_pobj) TNSs_26\NNS
D002045_D009422 NONE bupivacaine_30\NN (r_dobj) receiving_29\VBG (r_acl) patients_28\NNS (r_pobj) of_26\IN (r_prep) none_25\NN (r_nsubj) had_31\VBD (r_conj) had_21\VBD (l_nsubj) patients_4\NNS (l_acl) receiving_5\VBG (l_dobj) TNSs_8\NNS
D002045_D009422 NONE bupivacaine_30\NN (r_dobj) receiving_29\VBG (r_acl) patients_28\NNS (r_pobj) of_26\IN (r_prep) none_25\NN (r_nsubj) had_31\VBD (l_dobj) TNSs_32\NNS
16167916
D020849_D054556 CID raloxifene_11\NN (r_compound) treatment_12\NN (r_pobj) to_10\IN (r_pcomp) due_9\IN (r_amod) thromboembolism_8\NN
8092427
-1_D007645 NONE BPO_8\NNP (r_pobj) to_7\IN (r_prep) negative_6\JJ (r_amod) test_5\NN (r_attr) were_3\VBD (r_ccomp) were_17\VBD (l_acomp) negative_19\JJ (l_prep) to_20\IN (l_pobj) MDM_21\NNP
D047090_D004342 NONE lactam_12\NN (r_amod) antibiotics_13\NNS (r_pobj) to_9\IN (r_prep) reactions_8\NNS
D047090_D004342 NONE lactam_31\NN (r_amod) antibiotics_32\NNS (r_pobj) to_28\IN (r_prep) allergic_27\JJ
D047090_D004342 NONE lactam_31\NN (r_amod) antibiotics_32\NNS (r_pobj) to_28\IN (r_prep) allergic_27\JJ (r_ccomp) establish_24\VB (r_xcomp) used_22\VBN (l_conj) had_33\VBD (l_dobj) responses_37\NNS (l_amod) allergic_36\JJ
D047090_D004342 NONE lactam_12\NN (r_amod) antibiotics_13\NNS (r_pobj) to_9\IN (r_prep) allergic_8\JJ
D010400_D004342 NONE PG_17\NNP (r_pobj) of_16\IN (r_prep) tolerance_15\NN (r_pobj) with_13\IN (r_prep) allergy_12\NN
D010400_D004342 NONE PG_13\NNP (r_dobj) tolerated_12\VBN (r_relcl) patients_9\NNS (l_amod) allergic_8\JJ
D000658_D004342 CID amoxicillin_4\NNP (r_pobj) to_3\IN (r_prep) reactions_2\NNS
D000658_D004342 CID amoxicillin_39\NNP (r_pobj) to_38\IN (r_prep) responses_37\NNS (r_dobj) had_33\VBD (r_conj) used_22\VBN (l_xcomp) establish_24\VB (l_ccomp) allergic_27\JJ
D000658_D004342 CID amoxicillin_39\NNP (r_pobj) to_38\IN (r_prep) responses_37\NNS (l_amod) allergic_36\JJ
D000658_D004342 CID AX_41\NN (r_appos) amoxicillin_39\NNP (r_pobj) to_38\IN (r_prep) responses_37\NNS (r_dobj) had_33\VBD (r_conj) used_22\VBN (l_xcomp) establish_24\VB (l_ccomp) allergic_27\JJ
D000658_D004342 CID AX_41\NN (r_appos) amoxicillin_39\NNP (r_pobj) to_38\IN (r_prep) responses_37\NNS (l_amod) allergic_36\JJ
D000658_D004342 CID AX_11\NNP (r_compound) allergy_12\NN
D000658_D004342 CID AX_3\NN (r_pobj) with_2\IN (r_prep) tests_1\NNS (r_nsubjpass) performed_5\VBN (l_advcl) establish_14\VB (l_dobj) diagnosis_16\NN (l_prep) of_17\IN (l_pobj) reaction_20\NN
D000658_D004342 CID AX_22\NN (r_pobj) to_21\IN (r_prep) reaction_20\NN
D000658_D004342 CID AX_38\NN (r_pobj) for_37\IN (r_prep) RAST_36\NNP (r_conj) test_34\NN (r_appos) %_30\NN (r_nsubj) were_39\VBD (r_conj) performed_5\VBN (l_advcl) establish_14\VB (l_dobj) diagnosis_16\NN (l_prep) of_17\IN (l_pobj) reaction_20\NN
D000658_D004342 CID AX_6\NN (r_npadvmod) allergic_8\JJ
D010406_D004342 NONE penicillin_50\NN (r_compound) derivatives_51\NNS (r_pobj) with_48\IN (r_prep) reacting_47\VBG (r_acomp) were_44\VBD (r_conj) had_33\VBD (r_conj) used_22\VBN (l_xcomp) establish_24\VB (l_ccomp) allergic_27\JJ
D010406_D004342 NONE penicillin_50\NN (r_compound) derivatives_51\NNS (r_pobj) with_48\IN (r_prep) reacting_47\VBG (r_acomp) were_44\VBD (r_conj) had_33\VBD (l_dobj) responses_37\NNS (l_amod) allergic_36\JJ
D010400_D007645 NONE PG_32\NNP (r_pobj) to_31\IN (r_prep) 44_24\CD (r_conj) were_17\VBD (l_acomp) negative_19\JJ (l_prep) to_20\IN (l_pobj) MDM_21\NNP
11807648
D014148_D012640 CID tAMCA_5\NN (r_nsubj) retains_6\VBZ (l_dobj) action_9\NN (l_amod) convulsive_8\JJ
D014148_D012640 CID tAMCA_4\NN (r_appos) FINDINGS_0\NNS (r_nsubj) caused_5\VBD (l_dobj) activity_8\NN (l_relcl) associated_11\VBN (l_prep) with_12\IN (l_pobj) behaviours_15\NNS (l_amod) convulsive_14\JJ
D014148_D012640 CID tAMCA_10\CD (r_pobj) of_9\IN (r_prep) concentration_8\NN (r_pobj) with_6\IN (r_prep) increased_5\VBD (l_nsubj) degree_1\NN (l_prep) of_2\IN (l_pobj) seizures_4\NNS
D014148_D012640 CID tAMCA_0\NN (r_advmod) evoked_1\VBD (l_dobj) seizures_3\NNS
D014148_D012640 CID tAMCA_0\NN (r_advmod) evoked_1\VBD (l_advcl) evoked_24\VBD (l_dobj) episodes_26\NNS (l_prep) of_27\IN (l_pobj) potentials_32\NNS (l_amod) convulsive_31\JJ
D014148_D012640 CID tAMCA_16\NN (r_nmod) ml_21\NNS (r_pobj) of_15\IN (r_prep) concentration_14\NN (r_nsubj) evoked_24\VBD (r_advcl) evoked_1\VBD (l_dobj) seizures_3\NNS
D014148_D012640 CID tAMCA_16\NN (r_nmod) ml_21\NNS (r_pobj) of_15\IN (r_prep) concentration_14\NN (r_nsubj) evoked_24\VBD (l_dobj) episodes_26\NNS (l_prep) of_27\IN (l_pobj) potentials_32\NNS (l_amod) convulsive_31\JJ
D014148_D012640 CID acid_1\NN (r_nsubj) retains_2\VBZ (l_dobj) action_5\NN (l_amod) convulsive_4\JJ
D014148_D004827 NONE acid_10\NN (r_dobj) containing_8\VBG (r_acl) sealants_7\NNS (r_pobj) of_5\IN (r_prep) application_4\NN (r_dobj) following_2\VBG (r_prep) seizures_1\NNS
D014148_D004827 NONE tAMCA_2\NN (r_nsubjpass) shown_5\VBN (l_xcomp) cause_7\VB (l_dobj) seizures_9\NNS
3101906
D007654_D003643 NONE ketoconazole_9\JJ (r_compound) treatment_10\NN (r_pobj) with_8\IN (r_prep) associated_7\VBN (r_acl) deaths_5\NNS
D007654_D056486 CID ketoconazole_9\JJ (r_compound) treatment_10\NN (r_pobj) with_8\IN (r_prep) associated_7\VBN (r_acl) deaths_5\NNS (r_pobj) of_2\IN (r_prep) two_1\CD (r_pobj) In_0\IN (r_prep) continued_15\VBN (l_prep) after_16\IN (l_pobj) onset_18\NN (l_prep) of_19\IN (l_pobj) jaundice_20\NN (l_conj) symptoms_23\NNS (l_prep) of_24\IN (l_pobj) hepatitis_25\NN
D007654_D056486 CID ketoconazole_18\NN (r_pobj) with_17\IN (r_prep) treatment_16\NN (r_pobj) during_13\IN (r_prep) advised_12\VBN (l_nsubjpass) monitoring_3\NN (l_prep) for_7\IN (l_pobj) evidence_8\NN (l_prep) of_9\IN (l_pobj) hepatitis_10\NN
D007654_D056486 CID ketoconazole_18\NN (r_pobj) with_17\IN (r_prep) treatment_16\NN (r_pobj) during_13\IN (r_prep) advised_12\VBN (l_advcl) prevent_20\VB (l_dobj) injury_24\NN
D007654_D007565 CID ketoconazole_9\JJ (r_compound) treatment_10\NN (r_pobj) with_8\IN (r_prep) associated_7\VBN (r_acl) deaths_5\NNS (r_pobj) of_2\IN (r_prep) two_1\CD (r_pobj) In_0\IN (r_prep) continued_15\VBN (l_prep) after_16\IN (l_pobj) onset_18\NN (l_prep) of_19\IN (l_pobj) jaundice_20\NN
17244258
D003520_D003556 CID cyclophosphamide_9\NN (r_npadvmod) induced_11\VBN (r_amod) cystitis_12\NN
D003520_D003556 CID cyclophosphamide_1\NN (r_npadvmod) induced_3\VBN (r_amod) cystitis_4\NN
26094
D008750_D001523 NONE dopa_13\NN (r_pobj) in_11\IN (r_prep) occurring_10\VBG (r_acl) depressions_9\NNS (r_pobj) of_8\IN (r_prep) number_7\NN (l_acl) treated_14\VBD (l_dobj) patients_15\NNS (l_prep) with_16\IN (l_pobj) histories_18\NNS (l_amod) psychiatric_17\JJ
D008750_D003866 CID dopa_13\NN (r_pobj) in_11\IN (r_prep) occurring_10\VBG (r_acl) depressions_9\NNS
1428568
D015784_D003866 NONE betaxolol_4\NN (r_nsubj) be_6\VB (l_attr) less_7\JJR (l_prep) of_8\IN (l_pobj) inducer_12\NN (l_compound) depression_10\NN
D013999_D003866 CID timolol_6\NN (r_compound) 0.5%/12h_7\CD (r_pobj) with_5\IN (r_prep) treated_4\VBN (l_advcl) suffering_9\VBG (l_prep) from_10\IN (l_pobj) depression_11\NN
D013999_D003866 CID timolol_15\NN (r_compound) treatment_16\NN (r_pobj) under_14\IN (r_prep) patients_13\NNS (r_nsubj) presented_17\VBD (l_dobj) values_20\NNS (l_compound) depression_19\NN
D013999_D003866 CID timolol_14\NN (r_pobj) than_13\IN (r_prep) less_7\JJR (l_prep) of_8\IN (l_pobj) inducer_12\NN (l_compound) depression_10\NN
D013999_D005901 NONE timolol_6\NN (r_compound) 0.5%/12h_7\CD (r_pobj) with_5\IN (r_prep) treated_4\VBN (l_nsubj) patients_2\NNS (l_amod) glaucomatous_1\JJ
20722491
D005472_D009369 NONE 5-FU_1\CD (r_nsubj) been_5\VBN (l_attr) mainstay_7\NN (l_prep) of_8\IN (l_pobj) treatment_9\NN (l_prep) for_10\IN (l_pobj) tumors_13\NNS
C110904_D007674 NONE capecitabine_10\NN (r_pobj) of_9\IN (r_prep) safety_8\NN (l_prep) in_11\IN (l_pobj) populations_13\NNS (l_prep) as_15\IN (l_pobj) patients_16\NNS (l_prep) with_17\IN (l_pobj) disease_24\NN
C110904_D007674 NONE Capecitabine_0\NNP (r_nsubj) has_1\VBZ (l_conj) given_11\VBN (l_prep) to_13\IN (l_pobj) patients_14\NNS (l_prep) with_15\IN (l_pobj) dysfunctions_22\NNS
D005472_D001943 NONE 5-FU_1\CD (r_nsubj) been_5\VBN (l_attr) mainstay_7\NN (l_prep) of_8\IN (l_pobj) treatment_9\NN (l_prep) for_10\IN (l_pobj) tumors_13\NNS (l_prep) including_15\VBG (l_pobj) colorectal_16\NN (l_conj) breast_18\NN (l_conj) cancers_23\NNS
C110904_D014839 CID capecitabine_7\NN (r_pobj) of_6\IN (r_prep) effects_5\NNS (r_nsubj) are_8\VBP (l_attr) diarrhea_9\NN (l_appos) nausea_11\NN (l_conj) vomiting_13\NN
C110904_D013280 CID capecitabine_7\NN (r_pobj) of_6\IN (r_prep) effects_5\NNS (r_nsubj) are_8\VBP (l_attr) diarrhea_9\NN (l_appos) nausea_11\NN (l_conj) vomiting_13\NN (l_conj) stomatitis_15\JJ
C110904_D003967 CID capecitabine_7\NN (r_pobj) of_6\IN (r_prep) effects_5\NNS (r_nsubj) are_8\VBP (l_attr) diarrhea_9\NN
C110904_D009325 CID capecitabine_7\NN (r_pobj) of_6\IN (r_prep) effects_5\NNS (r_nsubj) are_8\VBP (l_attr) diarrhea_9\NN (l_appos) nausea_11\NN
C110904_D008107 NONE Capecitabine_0\NNP (r_nsubj) has_1\VBZ (l_conj) given_11\VBN (l_prep) to_13\IN (l_pobj) patients_14\NNS (l_prep) with_15\IN (l_pobj) dysfunctions_22\NNS
D005472_D015179 NONE 5-FU_1\CD (r_nsubj) been_5\VBN (l_attr) mainstay_7\NN (l_prep) of_8\IN (l_pobj) treatment_9\NN (l_prep) for_10\IN (l_pobj) tumors_13\NNS (l_prep) including_15\VBG (l_pobj) colorectal_16\NN (l_conj) breast_18\NN (l_conj) cancers_23\NNS
C110904_D060831 CID capecitabine_7\NN (r_pobj) of_6\IN (r_prep) effects_5\NNS (r_nsubj) are_8\VBP (l_attr) diarrhea_9\NN (l_appos) nausea_11\NN (l_conj) vomiting_13\NN (l_conj) stomatitis_15\JJ (l_conj) syndrome_20\NN
D005472_D006258 NONE 5-FU_1\CD (r_nsubj) been_5\VBN (l_attr) mainstay_7\NN (l_prep) of_8\IN (l_pobj) treatment_9\NN (l_prep) for_10\IN (l_pobj) tumors_13\NNS (l_prep) including_15\VBG (l_pobj) colorectal_16\NN (l_conj) breast_18\NN (l_conj) cancers_23\NNS
9855119
D016559_D007674 NONE FK506_28\NN (r_compound) nephropathy_29\NN
D016559_D007674 NONE FK506_28\NN (r_compound) nephropathy_29\NN (l_conj) nephropathy_41\NN
D016559_D007674 NONE FK506_40\NN (r_compound) nephropathy_41\NN (r_conj) nephropathy_29\NN
D016559_D007674 NONE FK506_40\NN (r_compound) nephropathy_41\NN
D016559_D007674 NONE FK506_18\NN (r_compound) nephropathy_19\NN
D016559_D007674 NONE FK506_1\NNP (r_compound) nephropathy_2\NN
D016559_D007674 NONE FK506_12\NN (r_compound) nephropathy_13\NN
D016559_D007674 NONE FK506_12\NN (r_compound) nephropathy_13\NN (r_compound) group_14\NN (r_pobj) in_6\IN (r_prep) patients_5\NNS (r_pobj) of_4\IN (r_prep) levels_3\NNS (r_nsubj) were_22\VBD (l_acomp) higher_24\JJR (l_prep) than_25\IN (l_pobj) those_26\DT (l_prep) in_27\IN (l_pobj) group_34\NN (l_compound) FK506-nephropathy_33\NNP
D016559_D007674 NONE FK506-nephropathy_33\NNP (r_compound) group_34\NN (r_pobj) in_27\IN (r_prep) those_26\DT (r_pobj) than_25\IN (r_prep) higher_24\JJR (r_acomp) were_22\VBD (l_nsubj) levels_3\NNS (l_prep) of_4\IN (l_pobj) patients_5\NNS (l_prep) in_6\IN (l_pobj) group_14\NN (l_compound) nephropathy_13\NN
D016559_D007674 NONE FK506-nephropathy_33\NNP
D016559_D007674 NONE FK506_5\NNP (r_compound) nephropathy_6\NN
D016559_D007674 NONE FK506_5\NNP (r_compound) nephropathy_6\NN (r_nsubj) consists_7\VBZ (r_ccomp) demonstrates_2\VBZ (l_conj) suggests_21\VBZ (l_ccomp) is_29\VBZ (l_nsubj) nephropathy_28\NN
D016559_D007674 NONE FK506_27\NN (r_compound) nephropathy_28\NN (r_nsubj) is_29\VBZ (r_ccomp) suggests_21\VBZ (r_conj) demonstrates_2\VBZ (l_ccomp) consists_7\VBZ (l_nsubj) nephropathy_6\NN
D016559_D007674 NONE FK506_27\NN (r_compound) nephropathy_28\NN
D003404_D007674 NONE creatinine_2\NN (r_compound) levels_3\NNS (l_prep) of_4\IN (l_pobj) patients_5\NNS (l_prep) in_6\IN (l_pobj) group_14\NN (l_compound) nephropathy_13\NN
D003404_D007674 NONE creatinine_2\NN (r_compound) levels_3\NNS (r_nsubj) were_22\VBD (l_acomp) higher_24\JJR (l_prep) than_25\IN (l_pobj) those_26\DT (l_prep) in_27\IN (l_pobj) group_34\NN (l_compound) FK506-nephropathy_33\NNP
D016559_D005923 CID FK506_1\NNP (r_compound) nephropathy_2\NN (r_nsubj) consisted_3\VBD (r_ccomp) angiodegeneration_17\NN (l_appos) biopsies_24\NNS (l_conj) glomerulosclerosis_29\NN
D016559_D005355 NONE FK506_1\NNP (r_compound) nephropathy_2\NN (r_nsubj) consisted_3\VBD (r_ccomp) angiodegeneration_17\NN (l_appos) biopsies_24\NNS (l_conj) glomerulosclerosis_29\NN (l_conj) form_37\NN (l_prep) of_38\IN (l_pobj) fibrosis_40\NN
D016559_D005922 NONE FK506_28\NN (r_compound) nephropathy_29\NN (r_conj) findings_17\NNS (r_conj) nephropathy_9\NN
D016559_D005922 NONE FK506_40\NN (r_compound) nephropathy_41\NN (r_conj) nephropathy_29\NN (r_conj) findings_17\NNS (r_conj) nephropathy_9\NN
16755009
D003975_D000647 CID Diazepam-_0\NN (l_appos) amnesia_7\NN
D003975_D000647 CID diazepam_16\NN (r_conj) scopolamine_8\NN (r_pobj) by_7\IN (r_agent) induced_6\VBN (r_acl) amnesia_5\NN
D012601_D000647 CID scopolamine-_2\NN (r_nmod) amnesia_7\NN
D012601_D000647 CID scopolamine_8\NN (r_pobj) by_7\IN (r_agent) induced_6\VBN (r_acl) amnesia_5\NN
D002784_D003072 NONE cholesterol_30\NN (r_nsubj) lowering_31\VBG (r_conj) property_28\NN (r_dobj) improving_27\VBG (r_acl) remedy_9\NN (l_prep) for_10\IN (l_pobj) management_12\NN (l_prep) of_13\IN (l_pobj) dysfunctions_15\NNS
D010936_D000647 NONE DCE_2\NNP (r_nsubj) reversed_3\VBD (l_dobj) amnesia_5\NN
D010936_D003072 NONE DCE_2\NNP (r_nsubj) prove_4\VB (l_xcomp) be_6\VB (l_attr) remedy_9\NN (l_prep) for_10\IN (l_pobj) management_12\NN (l_prep) of_13\IN (l_pobj) dysfunctions_15\NNS
19843802
D004837_D006973 CID epinephrine_5\NN (r_pobj) of_4\IN (r_prep) bolus_3\NN (r_nsubj) provoked_11\VBD (l_dobj) crisis_14\NN (l_amod) hypertensive_13\JJ
6534871
D007545_D009203 CID isoproterenol_8\NN (r_npadvmod) induced_10\VBN (r_amod) infarction_12\NN
7449470
D004317_D066126 NONE doxorubicin_3\NN (r_compound) cardiotoxicity_4\NN
D004317_D066126 NONE adriamycin_11\NNS (r_pobj) of_10\IN (r_prep) use_9\NN (r_dobj) limits_7\VBZ (r_relcl) complication_5\NN (r_attr) is_2\VBZ (l_nsubj) toxicity_1\NN
11419773
D002110_D008945 NONE caffeine_34\NN (r_pobj) of_33\IN (r_prep) concentration_32\NN (r_dobj) containing_29\VBG (r_acl) drink_28\NN (r_dobj) consuming_20\VBG (r_pcomp) after_19\IN (r_prep) developed_15\VBD (r_relcl) woman_6\NN (l_prep) with_7\IN (l_pobj) prolapse_13\NN
D002110_D014693 CID caffeine_34\NN (r_pobj) of_33\IN (r_prep) concentration_32\NN (r_dobj) containing_29\VBG (r_acl) drink_28\NN (r_dobj) consuming_20\VBG (r_pcomp) after_19\IN (r_prep) developed_15\VBD (l_dobj) fibrillation_18\NN
D002110_D001145 NONE Caffeine_0\NN (r_nsubj) induced_2\VBN (r_amod) arrhythmia_4\NN
6287825
D007538_D009422 NONE Isoniazid_0\NNP (r_nsubj) was_1\VBD (l_attr) agent_5\NN (l_prep) in_6\IN (l_pobj) neuropathy_10\NN
D013831_D044342 NONE thiamine_7\NN (r_pobj) of_6\IN (r_prep) deficiency_5\NN
D013831_D010523 CID thiamine_7\NN (r_pobj) of_6\IN (r_prep) deficiency_5\NN (r_pobj) due_2\IN (r_prep) neuropathy_1\NNS
D013831_D010523 CID thiamine_7\NN (r_pobj) of_6\IN (r_prep) deficiency_5\NN (r_pobj) due_2\IN (r_prep) neuropathy_1\NNS (r_nsubj) was_10\VBD (l_conj) presented_17\VBN (l_prep) as_19\IN (l_pobj) neuropathy_25\NN
D012256_D044342 NONE riboflavin_9\NN (r_conj) thiamine_7\NN (r_pobj) of_6\IN (r_prep) deficiency_5\NN
D012256_D010523 CID riboflavin_9\NN (r_conj) thiamine_7\NN (r_pobj) of_6\IN (r_prep) deficiency_5\NN (r_pobj) due_2\IN (r_prep) neuropathy_1\NNS
D012256_D010523 CID riboflavin_9\NN (r_conj) thiamine_7\NN (r_pobj) of_6\IN (r_prep) deficiency_5\NN (r_pobj) due_2\IN (r_prep) neuropathy_1\NNS (r_nsubj) was_10\VBD (l_conj) presented_17\VBN (l_prep) as_19\IN (l_pobj) neuropathy_25\NN
19820426
C558899_D066126 NONE ritonavir_10\NNS (r_compound) therapy_11\NN (r_appos) lopinavir_8\NNS (r_pobj) to_7\IN (r_prep) related_6\VBN (r_acl) toxicity_5\NN
C558899_D001919 CID ritonavir_15\NNS (r_compound) therapy_16\NN (r_appos) lopinavir_13\NNS (r_pobj) to_12\IN (r_prep) related_11\VBN (r_acl) cardiomyopathy_10\NN (r_conj) block_7\NN (r_dobj) developed_4\VBD (l_advcl) developed_29\VBD (l_dobj) bradycardia_31\NNS
C558899_D002311 CID ritonavir_15\NNS (r_compound) therapy_16\NN (r_appos) lopinavir_13\NNS (r_pobj) to_12\IN (r_prep) related_11\VBN (r_acl) cardiomyopathy_10\NN
C558899_D006327 CID ritonavir_15\NNS (r_compound) therapy_16\NN (r_appos) lopinavir_13\NNS (r_pobj) to_12\IN (r_prep) related_11\VBN (r_acl) cardiomyopathy_10\NN (r_conj) block_7\NN
9766615
D003024_D015430 NONE clozapine_40\NN (r_appos) threshold_37\NN (r_dobj) lowered_35\VBD (l_nsubj) effects_21\NNS (l_conj) effects_24\NNS (l_conj) gain_27\NN
D003024_D015430 NONE clozapine_46\NN (r_appos) agranulocytosis_44\NN (r_conj) lowered_35\VBD (l_nsubj) effects_21\NNS (l_conj) effects_24\NNS (l_conj) gain_27\NN
D003024_D012640 NONE clozapine_40\NN (r_appos) threshold_37\NN (l_compound) seizure_36\NN
D003024_D012640 NONE clozapine_46\NN (r_appos) agranulocytosis_44\NN (r_conj) lowered_35\VBD (l_dobj) threshold_37\NN (l_compound) seizure_36\NN
D003024_D001480 NONE clozapine_40\NN (r_appos) threshold_37\NN (r_dobj) lowered_35\VBD (r_conj) associated_13\VBN (r_conj) have_4\VBP (l_dobj) risk_7\NN (l_prep) of_8\IN (l_pobj) EPS_9\NNP
D003024_D001480 NONE clozapine_46\NN (r_appos) agranulocytosis_44\NN (r_conj) lowered_35\VBD (r_conj) associated_13\VBN (r_conj) have_4\VBP (l_dobj) risk_7\NN (l_prep) of_8\IN (l_pobj) EPS_9\NNP
D003024_D000380 CID clozapine_40\NN (r_appos) threshold_37\NN (r_dobj) lowered_35\VBD (l_conj) agranulocytosis_44\NN
D003024_D000380 CID clozapine_46\NN (r_appos) agranulocytosis_44\NN
D003024_D012735 NONE clozapine_40\NN (r_appos) threshold_37\NN (r_dobj) lowered_35\VBD (l_nsubj) effects_21\NNS (l_conj) effects_24\NNS (l_conj) gain_27\NN (l_conj) dysfunction_30\NN
D003024_D012735 NONE clozapine_46\NN (r_appos) agranulocytosis_44\NN (r_conj) lowered_35\VBD (l_nsubj) effects_21\NNS (l_conj) effects_24\NNS (l_conj) gain_27\NN (l_conj) dysfunction_30\NN
16330766
C040029_D009437 NONE gabapentin_11\NN (l_appos) drug_14\NN (l_amod) effective_15\JJ (l_prep) in_16\IN (l_pobj) patients_19\NNS (l_compound) pain_18\NN
D002211_D006930 CID capsaicin_32\NN (r_npadvmod) induced_34\VBN (r_amod) hyperalgesia_36\NN
C040029_D006930 NONE gabapentin_15\NN (r_npadvmod) induced_17\VBN (r_amod) modulation_18\NN (l_prep) in_22\IN (l_pobj) response_23\NN (l_prep) to_24\IN (l_pobj) stimulation_27\NN (l_prep) of_28\IN (l_pobj) skin_30\NN (l_conj) hyperalgesia_36\NN
6640832
D004317_D002277 NONE adriamycin_2\NNS (l_prep) in_3\IN (l_pobj) carcinoma_6\NN
D004317_D001749 NONE adriamycin_2\NNS (l_prep) in_3\IN (l_pobj) carcinoma_6\NN
D004317_D001749 NONE Adriamycin_0\NNP (r_nsubjpass) administered_7\VBN (l_prep) after_12\IN (l_pobj) resection_14\NN (l_prep) of_15\IN (l_pobj) tumors_25\NNS
8421099
D015282_D002764 NONE octreotide_25\NN (r_compound) therapy_26\NN (r_pobj) during_24\IN (r_prep) formation_15\NN (l_prep) of_16\IN (l_pobj) sludge_18\NN (l_conj) gallstones_20\NNS (l_conj) cholecystitis_23\NN
D015282_D000172 NONE octreotide_12\NN (r_appos) analog_10\NN (r_pobj) of_8\IN (r_prep) effects_7\NNS (l_prep) on_14\IN (l_pobj) function_16\NN (l_prep) in_20\IN (l_pobj) patients_23\NNS (l_compound) acromegalic_22\JJ
D015282_D000172 NONE octreotide_26\NN (r_appos) analog_25\NN (r_pobj) of_22\IN (r_prep) injection_21\NN (r_pobj) with_19\IN (r_prep) treated_18\VBN (r_acl) patients_14\NNS (l_prep) with_15\IN (l_pobj) acromegaly_17\NNS
D015282_D000172 NONE octreotide_25\NN (r_compound) therapy_26\NN (l_prep) in_27\IN (l_pobj) patients_30\NNS (l_compound) acromegalic_29\JJ
D015282_D000172 NONE octreotide_16\NN (r_compound) therapy_17\NN (l_prep) of_18\IN (l_pobj) patients_20\NNS (l_compound) acromegalic_19\JJ
D015282_D042882 CID octreotide_12\NN (r_appos) analog_10\NN (r_pobj) of_8\IN (r_prep) effects_7\NNS (l_prep) on_14\IN (l_pobj) function_16\NN (l_conj) formation_19\NN (l_compound) gallstone_18\NN
D015282_D042882 CID octreotide_3\NN (r_pobj) with_2\IN (r_prep) treatment_1\NN (r_pobj) During_0\IN (r_prep) developed_7\VBD (l_conj) had_11\VBD (l_dobj) gallstones_12\NNS
D015282_D042882 CID octreotide_3\NN (r_pobj) of_2\IN (r_prep) withdrawal_1\NN (l_prep) in_4\IN (l_pobj) patients_6\NNS (l_prep) without_7\IN (l_pobj) gallstones_8\NNS
D015282_D042882 CID octreotide_25\NN (r_compound) therapy_26\NN (r_pobj) during_24\IN (r_prep) formation_15\NN (l_prep) of_16\IN (l_pobj) sludge_18\NN (l_conj) gallstones_20\NNS
D015282_D041881 CID octreotide_3\NN (r_pobj) with_2\IN (r_prep) treatment_1\NN (r_pobj) During_0\IN (r_prep) developed_7\VBD (l_conj) had_11\VBD (l_conj) developed_16\VBD (l_dobj) cholecystitis_18\NN
7453952
D011188_D003919 NONE potassium_48\NN (r_compound) level_49\NN (r_pobj) in_45\IN (r_prep) elevation_44\NN (r_conj) concentration_31\NN (r_pobj) between_28\IN (r_prep) ratio_27\NN (r_pobj) of_25\IN (r_prep) reduction_24\NN (r_pobj) by_22\IN (r_agent) accompanied_21\VBN (l_nsubjpass) attenuation_6\NN (l_prep) of_7\IN (l_pobj) syndrome_17\NN
D000584_D011141 NONE amiloride_3\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (l_prep) on_4\IN (l_pobj) polydipsia_8\NN (l_conj) polyuria_10\NN
D000584_D011141 NONE amiloride_5\NN (r_compound) administration_6\NN (l_prep) to_7\IN (l_pobj) patients_11\NNS (l_acl) suffering_12\VBG (l_prep) from_13\IN (l_pobj) polydipsia_14\NN (l_conj) polyuria_16\NN
D000584_D011141 NONE amiloride_23\JJ (r_compound) supplementation_24\NN (r_nsubj) result_26\VB (r_conj) relieve_18\VB (l_nsubj) administration_6\NN (l_prep) to_7\IN (l_pobj) patients_11\NNS (l_acl) suffering_12\VBG (l_prep) from_13\IN (l_pobj) polydipsia_14\NN (l_conj) polyuria_16\NN
D008094_D011141 NONE lithium_5\NN (r_npadvmod) induced_7\VBN (r_amod) polydipsia_8\NN (l_conj) polyuria_10\NN
D008094_D011141 NONE lithium_14\NN (r_compound) concentration_15\NN (r_pobj) on_12\IN (r_conj) on_4\IN (l_pobj) polydipsia_8\NN (l_conj) polyuria_10\NN
D008094_D011141 NONE lithium_8\NN (r_npadvmod) treated_10\VBN (r_amod) patients_11\NNS (l_acl) suffering_12\VBG (l_prep) from_13\IN (l_pobj) polydipsia_14\NN (l_conj) polyuria_16\NN
D008094_D011141 NONE lithium_29\NN (r_compound) levels_30\NNS (r_pobj) in_27\IN (r_prep) result_26\VB (r_conj) relieve_18\VB (l_nsubj) administration_6\NN (l_prep) to_7\IN (l_pobj) patients_11\NNS (l_acl) suffering_12\VBG (l_prep) from_13\IN (l_pobj) polydipsia_14\NN (l_conj) polyuria_16\NN
D000584_D059606 NONE amiloride_3\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (l_prep) on_4\IN (l_pobj) polydipsia_8\NN
D000584_D059606 NONE amiloride_5\NN (r_compound) administration_6\NN (l_prep) to_7\IN (l_pobj) patients_11\NNS (l_acl) suffering_12\VBG (l_prep) from_13\IN (l_pobj) polydipsia_14\NN
D000584_D059606 NONE amiloride_23\JJ (r_compound) supplementation_24\NN (r_nsubj) result_26\VB (r_conj) relieve_18\VB (l_nsubj) administration_6\NN (l_prep) to_7\IN (l_pobj) patients_11\NNS (l_acl) suffering_12\VBG (l_prep) from_13\IN (l_pobj) polydipsia_14\NN
D008094_D059606 NONE lithium_5\NN (r_npadvmod) induced_7\VBN (r_amod) polydipsia_8\NN
D008094_D059606 NONE lithium_14\NN (r_compound) concentration_15\NN (r_pobj) on_12\IN (r_conj) on_4\IN (l_pobj) polydipsia_8\NN
D008094_D059606 NONE lithium_8\NN (r_npadvmod) treated_10\VBN (r_amod) patients_11\NNS (l_acl) suffering_12\VBG (l_prep) from_13\IN (l_pobj) polydipsia_14\NN
D008094_D059606 NONE lithium_29\NN (r_compound) levels_30\NNS (r_pobj) in_27\IN (r_prep) result_26\VB (r_conj) relieve_18\VB (l_nsubj) administration_6\NN (l_prep) to_7\IN (l_pobj) patients_11\NNS (l_acl) suffering_12\VBG (l_prep) from_13\IN (l_pobj) polydipsia_14\NN
D000584_D003919 NONE amiloride_13\NN (r_pobj) by_12\IN (r_prep) syndrome_11\NN
D000584_D003919 NONE amiloride_19\NN (r_pobj) by_18\IN (r_prep) syndrome_17\NN
D008094_D003919 CID lithium_3\NN (r_npadvmod) induced_5\VBN (r_amod) syndrome_11\NN
D008094_D003919 CID lithium_9\NN (r_npadvmod) induced_11\VBN (r_amod) syndrome_17\NN
D008094_D003919 CID lithium_30\NN (r_compound) concentration_31\NN (r_pobj) between_28\IN (r_prep) ratio_27\NN (r_pobj) of_25\IN (r_prep) reduction_24\NN (r_pobj) by_22\IN (r_agent) accompanied_21\VBN (l_nsubjpass) attenuation_6\NN (l_prep) of_7\IN (l_pobj) syndrome_17\NN
D018021_D011141 NONE LiCl_37\NNP (r_pobj) with_36\IN (r_prep) treated_35\VBN (r_conj) investigated_30\VBN (l_nsubjpass) effect_1\NN (l_prep) on_4\IN (l_pobj) polydipsia_8\NN (l_conj) polyuria_10\NN
D018021_D059606 NONE LiCl_37\NNP (r_pobj) with_36\IN (r_prep) treated_35\VBN (r_conj) investigated_30\VBN (l_nsubjpass) effect_1\NN (l_prep) on_4\IN (l_pobj) polydipsia_8\NN
3564823
D008012_D020301 NONE lidocaine_11\NN (r_nsubjpass) given_13\VBN (l_advcl) counteract_24\VB (l_dobj) vasospasm_26\NN
D008012_D013035 NONE lidocaine_7\NN (r_pobj) by_6\IN (r_prep) relieved_5\VBN (l_nsubj) spasm_4\NN
D013874_D002545 NONE pentothal_12\NNS (r_nsubjpass) infused_15\VBN (l_advcl) minimize_17\VB (l_dobj) ischaemia_19\NN
2304736
D011224_D014550 CID Prazosin_0\NN (r_npadvmod) induced_2\VBN (r_amod) incontinence_4\NN
D011224_D014550 CID prazosin_8\NN (r_pobj) due_6\IN (r_amod) case_1\NN (l_prep) of_2\IN (l_pobj) incontinence_5\NN
D011224_D014550 CID prazosin_8\NN (r_dobj) taking_7\VBG (r_advcl) present_2\VBP (l_prep) with_3\IN (l_pobj) incontinence_5\NN
D011224_D014549 NONE prazosin_8\NN (r_dobj) taking_7\VBG (r_advcl) present_2\VBP (r_relcl) Patients_0\NNS (r_nsubj) change_10\VB (l_advcl) resolve_22\VB (l_nsubj) incontinence_20\NN
4071154
D007213_D001201 CID indomethacin_24\NN (r_advcl) reported_2\VBN (l_dobj) case_4\NN (l_prep) in_12\IN (l_pobj) patient_14\NN (l_prep) with_15\IN (l_pobj) cirrhosis_16\NN (l_conj) ascites_18\NNS
D007213_D006947 CID indomethacin_24\NN (r_advcl) reported_2\VBN (l_dobj) case_4\NN (l_prep) of_5\IN (l_pobj) failure_9\NN (l_prep) with_10\IN (l_pobj) hyperkalemia_11\NN
D007213_D051437 NONE Indomethacin_0\NNP (r_npadvmod) induced_2\VBN (r_amod) insufficiency_4\NN
D007213_D051437 NONE indomethacin_24\NN (r_advcl) reported_2\VBN (l_dobj) case_4\NN (l_prep) of_5\IN (l_pobj) failure_9\NN
D007213_D011660 CID indomethacin_24\NN (r_advcl) reported_2\VBN (l_dobj) case_4\NN (l_prep) in_12\IN (l_pobj) patient_14\NN (l_prep) with_15\IN (l_pobj) cirrhosis_16\NN (l_conj) ascites_18\NNS (l_conj) pulmonale_22\NN
D007213_D005355 CID indomethacin_24\NN (r_advcl) reported_2\VBN (l_dobj) case_4\NN (l_prep) in_12\IN (l_pobj) patient_14\NN (l_prep) with_15\IN (l_pobj) cirrhosis_16\NN
D007213_D009846 CID indomethacin_18\NN (r_pobj) of_17\IN (r_prep) dose_16\NN (r_pobj) to_13\IN (r_punct) caused_19\VBD (l_dobj) recurrence_20\NN (l_prep) of_21\IN (l_pobj) oliguria_24\NN
3800626
D010423_D020425 CID pentazocine_8\NN (r_advmod) induced_10\VBN (r_amod) myopathy_12\NNS (r_pobj) due_6\IN (r_prep) neuropathy_1\NN (l_prep) of_2\IN (l_pobj) nerve_5\NN
D010423_D005355 CID pentazocine_8\NN (r_advmod) induced_10\VBN (r_amod) myopathy_12\NNS
D010423_D005355 CID pentazocine_13\NN (r_compound) injection_14\NN (r_pobj) of_11\IN (r_prep) effect_10\NN (r_attr) is_2\VBZ (l_nsubj) myopathy_1\NN
D010423_D005355 CID pentazocine_8\NN (r_advmod) induced_10\VBN (r_amod) myopathy_12\NNS (r_pobj) with_6\IN (r_prep) woman_5\NN (r_pobj) In_0\IN (r_prep) showed_32\VBD (l_prep) in_51\IN (l_pobj) addition_52\NN (l_prep) to_53\IN (l_pobj) myopathy_56\NN
D010423_D009135 CID pentazocine_8\NN (r_advmod) induced_10\VBN (r_amod) myopathy_12\NNS
D010423_D009135 CID pentazocine_13\NN (r_compound) injection_14\NN (r_pobj) of_11\IN (r_prep) effect_10\NN (r_attr) is_2\VBZ (l_nsubj) myopathy_1\NN
D010423_D009135 CID pentazocine_10\NN (r_npadvmod) induced_12\VBN (r_compound) myopathy_13\NN
D010423_D009135 CID pentazocine_8\NN (r_advmod) induced_10\VBN (r_amod) myopathy_12\NNS (r_pobj) with_6\IN (r_prep) woman_5\NN (r_pobj) In_0\IN (r_prep) showed_32\VBD (l_prep) in_51\IN (l_pobj) addition_52\NN (l_prep) to_53\IN (l_pobj) myopathy_56\NN
D010423_D009408 CID pentazocine_8\NN (r_advmod) induced_10\VBN (r_amod) myopathy_12\NNS (r_pobj) due_6\IN (r_prep) neuropathy_1\NN (l_prep) of_2\IN (l_pobj) nerve_5\NN
D010423_D009408 CID pentazocine_10\NN (r_npadvmod) induced_12\VBN (r_compound) myopathy_13\NN (r_pobj) by_9\IN (r_agent) affected_8\VBN (r_acl) muscle_7\NN (r_pobj) due_4\IN (r_amod) neuropathy_3\NN
15804801
D017239_D003323 CID paclitaxel_6\NN (r_compound) eluting_8\VBG (r_amod) stent_9\NN (r_pobj) of_4\IN (r_prep) implantation_3\NN (r_pobj) after_2\IN (r_prep) aneurysm_1\NN
D017239_D003323 CID paclitaxel_22\NN (r_compound) eluting_24\VBG (r_amod) stent_25\NN (r_dobj) receiving_20\VBG (r_pcomp) after_19\IN (r_prep) developed_8\VBD (l_dobj) aneurysm_11\NN
11773892
D016559_D007674 CID tacrolimus_5\NN (r_conj) cyclosporine_3\VBP (r_appos) inhibitors_2\NNS (r_nsubjpass) known_8\VBN (l_xcomp) be_10\VB (l_acomp) nephrotoxic_11\JJ
D003404_D006530 NONE creatinine_13\NN (r_compound) levels_14\NNS (l_appos) percentage_18\NN (l_prep) of_19\IN (l_pobj) patients_20\NNS (l_prep) with_21\IN (l_pobj) syndrome_23\NN
D003404_D006530 NONE creatinine_42\NN (r_conj) requirement_27\NN (r_appos) levels_14\NNS (l_appos) percentage_18\NN (l_prep) of_19\IN (l_pobj) patients_20\NNS (l_prep) with_21\IN (l_pobj) syndrome_23\NN
D003404_D006530 NONE creatinine_11\NN (r_dobj) have_4\VBP (l_conj) are_13\VBP (l_acomp) likely_15\JJ (l_xcomp) have_17\VB (l_dobj) syndrome_19\NN
D016572_D007674 CID cyclosporine_3\VBP (r_appos) inhibitors_2\NNS (r_nsubjpass) known_8\VBN (l_xcomp) be_10\VB (l_acomp) nephrotoxic_11\JJ
D003404_D007676 NONE creatinine_20\NN (r_conj) CRF_16\NNP (r_conj) Controls_7\NNS (l_conj) CRF_10\NNP
D003404_D007676 NONE creatinine_20\NN (r_conj) CRF_16\NNP (r_conj) Controls_7\NNS (l_conj) CRF_10\NNP (l_conj) ESRD_12\NNP
D003404_D007676 NONE creatinine_20\NN (r_conj) CRF_16\NNP
D003404_D007676 NONE creatinine_20\NN (r_conj) CRF_16\NNP (r_conj) Controls_7\NNS (r_appos) groups_5\NNS (l_conj) n=45_32\JJ (l_nmod) ESRD_30\NNS
D003404_D007676 NONE creatinine_13\NN (r_compound) levels_14\NNS (r_dobj) had_9\VBD (l_nsubj) patients_8\NNS (l_nmod) CRF_5\NNP
D003404_D007676 NONE creatinine_13\NN (r_compound) levels_14\NNS (r_dobj) had_9\VBD (l_nsubj) patients_8\NNS (l_compound) ESRD_7\NNP
D003404_D007676 NONE creatinine_42\NN (r_conj) requirement_27\NN (r_appos) levels_14\NNS (r_dobj) had_9\VBD (l_nsubj) patients_8\NNS (l_nmod) CRF_5\NNP
D003404_D007676 NONE creatinine_42\NN (r_conj) requirement_27\NN (r_appos) levels_14\NNS (r_dobj) had_9\VBD (l_nsubj) patients_8\NNS (l_compound) ESRD_7\NNP
D003404_D007676 NONE creatinine_16\NN (r_pobj) of_14\IN (r_prep) increase_13\NN (r_nsubj) were_31\VBD (l_attr) factors_34\NNS (l_prep) for_35\IN (l_pobj) development_37\NN (l_prep) of_38\IN (l_pobj) CRF_39\NNP
D003404_D007676 NONE creatinine_16\NN (r_pobj) of_14\IN (r_prep) increase_13\NN (r_nsubj) were_31\VBD (l_attr) factors_34\NNS (l_prep) for_35\IN (l_pobj) development_37\NN (l_prep) of_38\IN (l_pobj) CRF_39\NNP (l_conj) ESRD_41\NNP
D003404_D007676 NONE creatinine_11\NN (r_dobj) have_4\VBP (l_nsubj) Patients_0\NNS (l_relcl) develop_2\VBP (l_dobj) ESRD_3\NNS
D003404_D007676 NONE creatinine_6\NN (r_pobj) of_4\IN (r_prep) increase_3\NN (r_nsubj) is_11\VBZ (l_acomp) predictive_13\JJ (l_prep) of_14\IN (l_pobj) development_16\NN (l_prep) of_17\IN (l_pobj) CRF_18\NNP
D003404_D007676 NONE creatinine_6\NN (r_pobj) of_4\IN (r_prep) increase_3\NN (r_nsubj) is_11\VBZ (l_acomp) predictive_13\JJ (l_prep) of_14\IN (l_pobj) development_16\NN (l_prep) of_17\IN (l_pobj) CRF_18\NNP (l_conj) ESRD_20\NNP
17466854
D008775_D006261 CID methylprednisolone_3\NN (r_pobj) of_2\IN (r_prep) administration_1\NN (r_nsubjpass) related_15\VBN (l_prep) to_16\IN (l_pobj) incidence_19\NN (l_prep) of_20\IN (l_pobj) effects_22\NNS (l_prep) including_23\VBG (l_pobj) nausea_24\NN (l_conj) vomiting_26\NN (l_conj) headache_29\NN
D008775_D020250 CID methylprednisolone_3\NN (r_pobj) of_2\IN (r_prep) administration_1\NN (r_nsubjpass) related_15\VBN (l_prep) to_16\IN (l_pobj) incidence_19\NN (l_prep) of_20\IN (l_pobj) effects_22\NNS (l_prep) including_23\VBG (l_pobj) nausea_24\NN (l_conj) vomiting_26\NN
D005839_D006261 CID gentamicin_5\NN (r_conj) administration_1\NN (r_nsubjpass) related_15\VBN (l_prep) to_16\IN (l_pobj) incidence_19\NN (l_prep) of_20\IN (l_pobj) effects_22\NNS (l_prep) including_23\VBG (l_pobj) nausea_24\NN (l_conj) vomiting_26\NN (l_conj) headache_29\NN
D008775_D002386 NONE methylprednisolone_13\NN (r_pobj) of_12\IN (r_prep) administration_11\NN (r_pobj) after_9\IN (r_prep) incidence_3\NN (r_dobj) assess_1\VB (l_conj) gentamicin_15\NN (l_prep) at_24\IN (l_pobj) end_26\NN (l_prep) of_27\IN (l_pobj) surgery_30\NN (l_compound) cataract_29\NN
D005839_D020250 CID gentamicin_5\NN (r_conj) administration_1\NN (r_nsubjpass) related_15\VBN (l_prep) to_16\IN (l_pobj) incidence_19\NN (l_prep) of_20\IN (l_pobj) effects_22\NNS (l_prep) including_23\VBG (l_pobj) nausea_24\NN (l_conj) vomiting_26\NN
D005839_D002386 NONE gentamicin_15\NN (l_prep) at_24\IN (l_pobj) end_26\NN (l_prep) of_27\IN (l_pobj) surgery_30\NN (l_compound) cataract_29\NN
8590259
C016986_D015814 CID apraclonidine_8\NN (r_npadvmod) treated_10\VBN (r_amod) eyes_11\NNS (r_pobj) for_7\IN (r_prep) significant_6\JJ (r_acomp) were_4\VBD (l_nsubj) effects_3\NNS (l_amod) hypotensive_2\JJ
C016986_D015814 CID apraclonidine_31\NN (r_pobj) of_28\IN (r_prep) administration_27\NN (r_pobj) after_25\IN (r_prep) hours_24\NNS (r_pobj) from_22\IN (r_prep) significant_18\JJ (r_conj) significant_6\JJ (r_acomp) were_4\VBD (l_nsubj) effects_3\NNS (l_amod) hypotensive_2\JJ
14568327
D015632_D004409 NONE MPTP_7\NNP (r_npadvmod) induced_9\VBN (r_amod) parkinsonism_10\NN (r_pobj) of_6\IN (r_prep) types_5\NNS (r_pobj) with_3\IN (r_prep) Using_0\VBG (r_advcl) evaluated_15\VBD (l_dobj) degree_17\NN (l_relcl) involved_38\VBN (l_prep) in_39\IN (l_pobj) development_41\NN (l_prep) of_42\IN (l_pobj) LIDs_43\NNS
D015632_D004409 NONE MPTP_8\NNP (r_compound) exposure_9\NN (r_pobj) with_1\IN (r_prep) Monkeys_0\NNS (r_nsubj) developed_24\VBD (l_dobj) dyskinesia_25\RB
D015632_D004409 NONE MPTP_8\NNP (r_compound) exposure_9\NN (r_pobj) with_4\IN (r_prep) monkeys_3\NNS (r_nsubj) progression_13\NN (r_nsubj) were_24\VBD (l_acomp) resistant_26\JJ (l_prep) to_27\IN (l_pcomp) developing_28\VBG (l_dobj) LIDs_29\NNS
D015632_D004409 NONE MPTP_8\NNP (r_compound) exposure_9\NN (r_pobj) with_4\IN (r_prep) monkeys_3\NNS (r_nsubj) progression_13\NN (r_nsubj) were_24\VBD (l_parataxis) developed_34\VBD (l_nsubj) dyskinesia_33\NN
D007980_D010302 NONE levodopa_34\NN (r_compound) therapy_35\NN (r_pobj) of_33\IN (r_prep) duration_32\NN (r_conj) response_29\NN (r_conj) severity_26\NN (r_nsubjpass) involved_38\VBN (r_relcl) degree_17\NN (r_dobj) evaluated_15\VBD (l_advcl) Using_0\VBG (l_prep) with_3\IN (l_pobj) types_5\NNS (l_prep) of_6\IN (l_pobj) parkinsonism_10\NN
D007980_D004409 CID levodopa_2\NN (r_npadvmod) induced_4\VBN (r_amod) dyskinesias_5\NNS
D007980_D004409 CID Levodopa_0\NNP (r_npadvmod) induced_2\VBN (r_amod) dyskinesias_3\NNS
D007980_D004409 CID Levodopa_0\NNP (r_npadvmod) induced_2\VBN (r_amod) dyskinesias_3\NNS (l_appos) LIDs_5\NNPS
D007980_D004409 CID levodopa_34\NN (r_compound) therapy_35\NN (r_pobj) of_33\IN (r_prep) duration_32\NN (r_conj) response_29\NN (r_conj) severity_26\NN (r_nsubjpass) involved_38\VBN (l_prep) in_39\IN (l_pobj) development_41\NN (l_prep) of_42\IN (l_pobj) LIDs_43\NNS
D007980_D004409 CID levodopa_22\NN (r_compound) therapy_23\NN (r_pobj) of_21\IN (r_prep) initiation_20\NN (r_pobj) to_19\IN (r_prep) prior_18\RB (r_advmod) developed_24\VBD (l_dobj) dyskinesia_25\RB
D007980_D004409 CID levodopa_33\JJ (r_compound) administration_34\NN (r_pobj) of_31\IN (r_prep) days_30\NNS (r_npadvmod) developed_24\VBD (l_dobj) dyskinesia_25\RB
D007980_D004409 CID levodopa_22\NN (r_compound) therapy_23\NN (r_pobj) of_21\IN (r_prep) initiation_20\NN (r_pobj) to_19\IN (r_prep) prior_18\RB (r_advmod) progression_13\NN (r_nsubj) were_24\VBD (l_acomp) resistant_26\JJ (l_prep) to_27\IN (l_pcomp) developing_28\VBG (l_dobj) LIDs_29\NNS
D007980_D004409 CID levodopa_22\NN (r_compound) therapy_23\NN (r_pobj) of_21\IN (r_prep) initiation_20\NN (r_pobj) to_19\IN (r_prep) prior_18\RB (r_advmod) progression_13\NN (r_nsubj) were_24\VBD (l_parataxis) developed_34\VBD (l_nsubj) dyskinesia_33\NN
D007980_D004409 CID levodopa_42\JJ (r_compound) administration_43\NN (r_pobj) of_40\IN (r_prep) days_39\NNS (r_pobj) than_37\IN (r_prep) sooner_36\RBR (r_advmod) developed_34\VBD (r_parataxis) were_24\VBD (l_acomp) resistant_26\JJ (l_prep) to_27\IN (l_pcomp) developing_28\VBG (l_dobj) LIDs_29\NNS
D007980_D004409 CID levodopa_42\JJ (r_compound) administration_43\NN (r_pobj) of_40\IN (r_prep) days_39\NNS (r_pobj) than_37\IN (r_prep) sooner_36\RBR (r_advmod) developed_34\VBD (l_nsubj) dyskinesia_33\NN
D007980_D004409 CID levodopa_24\VB (r_pobj) to_23\IN (r_prep) prior_22\RB (r_advmod) develop_9\VB (l_dobj) LIDs_10\NNS
D007980_D004409 CID levodopa_24\VB (r_pobj) to_23\IN (r_prep) prior_22\RB (r_advmod) develop_9\VB (r_acl) propensity_7\NN (r_pobj) in_5\IN (r_prep) differences_4\NNS (r_dobj) suggest_2\VBP (l_conj) demonstrate_26\VB (l_dobj) value_28\NN (l_prep) for_32\IN (l_pcomp) studying_34\VBG (l_dobj) pathophysiology_36\NN (l_prep) of_37\IN (l_pobj) LIDs_38\NNS
D007980_D010300 NONE levodopa_2\NN (r_npadvmod) induced_4\VBN (r_amod) dyskinesias_5\NNS (l_prep) in_6\IN (l_pobj) monkeys_8\NNS (l_amod) parkinsonian_7\JJ
D007980_D010300 NONE Levodopa_0\NNP (r_npadvmod) induced_2\VBN (r_amod) dyskinesias_3\NNS (r_nsubj) present_7\VBP (l_dobj) problem_10\NN (l_prep) for_11\IN (l_pobj) management_16\NN (l_prep) of_17\IN (l_pobj) patients_24\NNS (l_nmod) disease_20\NN
D007980_D010300 NONE Levodopa_0\NNP (r_npadvmod) induced_2\VBN (r_amod) dyskinesias_3\NNS (r_nsubj) present_7\VBP (l_dobj) problem_10\NN (l_prep) for_11\IN (l_pobj) management_16\NN (l_prep) of_17\IN (l_pobj) patients_24\NNS (l_nmod) PD_22\NNP
D015632_D010302 CID MPTP_7\NNP (r_npadvmod) induced_9\VBN (r_amod) parkinsonism_10\NN
9522143
D011318_D034381 CID prilocaine_2\NN (r_dobj) given_1\VBN (r_acl) Patients_0\NNS (r_nsubj) were_3\VBD (l_acomp) likely_5\JJ (l_xcomp) develop_7\VB (l_xcomp) hearing_8\VBG (l_dobj) loss_9\NN
D011318_D034381 CID prilocaine_12\NN (r_pobj) after_11\IN (r_prep) was_7\VBD (l_nsubj) loss_3\NN
D002045_D034381 CID bupivacaine_19\NN (r_pobj) than_16\IN (r_prep) loss_9\NN
D002045_D034381 CID bupivacaine_17\NN (r_pobj) after_16\IN (r_prep) dB_15\NN (r_conj) prilocaine_12\NN (r_pobj) after_11\IN (r_prep) was_7\VBD (l_nsubj) loss_3\NN
15233872
D007545_D009203 CID isoproterenol_7\NN (r_npadvmod) induced_9\VBN (r_amod) infarction_11\NN
C007145_D009203 NONE Crataegus_5\NNP (r_pobj) of_4\IN (r_prep) tincture_3\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (l_prep) on_6\IN (l_pobj) infarction_11\NN
C007145_D009203 NONE TCR_11\NNP (r_pobj) of_10\IN (r_prep) effect_9\NN (l_prep) on_12\IN (l_pobj) infarction_16\NN
1378968
D008094_D007676 CID lithium_8\NN (r_npadvmod) induced_10\VBN (r_amod) failure_13\NN
D008094_D051437 NONE lithium_2\NN (r_npadvmod) induced_4\VBN (r_amod) nephropathy_5\NN (r_pobj) with_1\IN (r_prep) Rats_0\NNS (r_nsubjpass) subjected_7\VBN (l_prep) in_26\IN (l_pobj) attempt_28\NN (l_acl) induce_30\VB (l_dobj) hyperfiltration_32\NN (l_conj) progression_35\NN (l_prep) of_36\IN (l_pobj) failure_38\NN
D008094_D051437 NONE lithium_21\NN (r_nmod) rats_23\NNS (r_pobj) in_20\IN (r_prep) levels_19\NNS (r_dobj) decrease_16\NN (r_conj) increase_13\VB (r_xcomp) tended_11\VBD (r_conj) failed_1\VBD (l_xcomp) accentuante_3\NN (l_dobj) progression_4\NN (l_prep) of_5\IN (l_pobj) failure_7\NN
D008094_D007674 NONE lithium_2\NN (r_npadvmod) induced_4\VBN (r_amod) nephropathy_5\NN
D008094_D007674 NONE Li_4\NNP (r_npadvmod) induced_6\VBN (r_amod) nephropathy_7\NN
D008094_D005921 NONE Lithium_0\NN (r_nsubj) caused_2\VBD (l_prep) in_7\IN (l_pobj) absence_8\NN (l_prep) of_9\IN (l_pobj) glomerulosclerosis_10\NN
D003404_D051437 NONE creatinine_18\NN (r_compound) levels_19\NNS (r_dobj) decrease_16\NN (r_conj) increase_13\VB (r_xcomp) tended_11\VBD (r_conj) failed_1\VBD (l_xcomp) accentuante_3\NN (l_dobj) progression_4\NN (l_prep) of_5\IN (l_pobj) failure_7\NN
D008094_D006973 CID Lithium_0\NN (r_nsubj) caused_2\VBD (l_dobj) proteinuria_3\NN (l_conj) hypertension_6\NN
D008094_D006973 CID Li_4\NNP (r_npadvmod) induced_6\VBN (r_amod) nephropathy_7\NN (r_nsubjpass) associated_19\VBN (l_prep) with_20\IN (l_pobj) proteinuria_21\NN (l_conj) hypertension_25\NN
D008094_D011507 CID Lithium_0\NN (r_nsubj) caused_2\VBD (l_dobj) proteinuria_3\NN
D008094_D011507 CID Li_4\NNP (r_npadvmod) induced_6\VBN (r_amod) nephropathy_7\NN (r_nsubjpass) associated_19\VBN (l_prep) with_20\IN (l_pobj) proteinuria_21\NN
3503576
D003676_D014786 NONE deferoxamine_26\NN (r_pobj) with_23\IN (r_prep) receiving_19\VBG (r_relcl) anemia_16\NN (r_pobj) with_12\IN (r_prep) patients_11\NNS (r_pobj) in_7\IN (r_prep) documented_6\VBN (l_nsubjpass) neurotoxicity_3\NN
D003676_D000740 NONE deferoxamine_26\NN (r_pobj) with_23\IN (r_prep) receiving_19\VBG (r_relcl) anemia_16\NN
D007501_D006311 NONE iron_20\NN (r_compound) therapy_22\NN (r_dobj) receiving_19\VBG (r_relcl) anemia_16\NN (r_pobj) with_12\IN (r_prep) patients_11\NNS (r_pobj) in_7\IN (r_prep) documented_6\VBN (l_nsubjpass) neurotoxicity_3\NN
D003676_D064420 NONE deferoxamine_9\NN (r_compound) doses_10\NNS (r_dobj) receiving_8\VBG (r_advcl) restarted_24\VBN (l_conj) demonstrated_55\VBN (l_nsubjpass) toxicity_53\NN
D007501_D014786 NONE iron_20\NN (r_compound) therapy_22\NN (r_dobj) receiving_19\VBG (r_relcl) anemia_16\NN (r_pobj) with_12\IN (r_prep) patients_11\NNS (r_pobj) in_7\IN (r_prep) documented_6\VBN (l_nsubjpass) neurotoxicity_3\NN
D003676_D006311 NONE deferoxamine_8\NN (r_compound) therapy_9\NN (r_dobj) receiving_7\VBG (r_acl) patients_6\NNS (r_pobj) in_5\IN (r_prep) studies_1\NNS (l_prep) of_2\IN (l_pobj) neurotoxicity_4\NN
D003676_D006311 NONE deferoxamine_26\NN (r_pobj) with_23\IN (r_prep) receiving_19\VBG (r_relcl) anemia_16\NN (r_pobj) with_12\IN (r_prep) patients_11\NNS (r_pobj) in_7\IN (r_prep) documented_6\VBN (l_nsubjpass) neurotoxicity_3\NN
D003676_D006311 NONE deferoxamine_9\NN (r_compound) doses_10\NNS (r_dobj) receiving_8\VBG (r_advcl) restarted_24\VBN (l_prep) with_25\IN (l_pobj) doses_27\NNS (l_prep) depending_36\VBG (l_prep) on_37\IN (l_pobj) degree_39\NN (l_prep) of_40\IN (l_pobj) abnormality_42\NN
D003676_D006311 NONE deferoxamine_14\NN (r_dobj) receiving_13\VBG (r_conj) receiving_10\VBG (r_acl) patients_9\NNS (r_pobj) in_7\IN (r_prep) demonstrated_5\VBD (l_prep) provided_18\VBD (l_pcomp) convincing_19\JJ (l_dobj) evidence_20\NN (l_prep) for_21\IN (l_pobj) relation_28\NN (l_prep) between_29\IN (l_pobj) administration_31\NN (l_conj) ototoxicity_33\NN
D003676_D006311 NONE deferoxamine_30\NN (r_compound) administration_31\NN (l_conj) ototoxicity_33\NN
D007501_D000740 NONE iron_20\NN (r_compound) therapy_22\NN (r_dobj) receiving_19\VBG (r_relcl) anemia_16\NN
7628595
D002955_D064420 NONE acid_9\NN (r_compound) supplementation_10\NN (l_prep) in_11\IN (l_pcomp) preventing_12\VBG (l_dobj) toxicity_14\NN
D015215_D001855 CID zidovudine_20\NNP (r_nmod) suppression_25\NN
D015215_D001855 CID ZDV)-induced_22\VBN (r_amod) suppression_25\NN
D015215_D001855 CID ZDV_7\NNP (r_compound) therapy_8\NN (r_pobj) of_6\IN (r_prep) supplementation_5\NN (r_conj) B12_1\NN (r_nsubj) seem_11\VB (l_oprd) useful_12\JJ (l_prep) in_13\IN (l_pcomp) preventing_14\VBG (l_conj) reducing_16\VBG (l_dobj) myelotoxicity_20\NN
D015215_D001855 CID ZDV_17\NNP (r_npadvmod) induced_19\VBN (r_amod) myelotoxicity_20\NN
D015215_D015658 NONE ZDV_21\NNP (r_dobj) receive_19\VB (r_xcomp) randomized_17\VBN (l_nsubjpass) virus_5\NN (l_appos) patients_8\NNS (l_amod) HIV)-infected_7\VBN
D005492_D001855 NONE folate_8\JJ (r_compound) levels_9\NNS (l_conj) development_11\NN (l_prep) of_12\IN (l_pobj) myelosuppression_13\NN
D015215_D064420 NONE zidovudine_16\NN (r_pobj) of_15\IN (r_prep) toxicity_14\NN
D014805_D001855 NONE B12_13\NN (l_conj) supplementation_17\NN (l_prep) in_18\IN (l_pcomp) preventing_19\VBG (l_dobj) suppression_25\NN
D014805_D001855 NONE B12_6\NN (l_conj) levels_9\NNS (l_conj) development_11\NN (l_prep) of_12\IN (l_pobj) myelosuppression_13\NN
D014805_D001855 NONE B12_1\NN (r_nsubj) seem_11\VB (l_oprd) useful_12\JJ (l_prep) in_13\IN (l_pcomp) preventing_14\VBG (l_conj) reducing_16\VBG (l_dobj) myelotoxicity_20\NN
D014805_D064420 NONE B12_6\NN (l_conj) supplementation_10\NN (l_prep) in_11\IN (l_pcomp) preventing_12\VBG (l_dobj) toxicity_14\NN
D002955_D001855 NONE acid_16\NN (r_compound) supplementation_17\NN (l_prep) in_18\IN (l_pcomp) preventing_19\VBG (l_dobj) suppression_25\NN
D002955_D001855 NONE acid_4\NN (r_compound) supplementation_5\NN (r_conj) B12_1\NN (r_nsubj) seem_11\VB (l_oprd) useful_12\JJ (l_prep) in_13\IN (l_pcomp) preventing_14\VBG (l_conj) reducing_16\VBG (l_dobj) myelotoxicity_20\NN
16298782
D019331_D034381 NONE NAME_2\NN (r_nsubj) reduced_3\VBN (l_dobj) loss_8\NN
D009569_D006319 NONE NO_17\DT (r_pobj) of_16\IN (r_prep) production_15\NN (r_dobj) involves_13\VBZ (r_conj) is_2\VBZ (r_ccomp) need_20\VBP (l_xcomp) assess_22\VB (l_dobj) use_24\NN (l_prep) for_28\IN (l_pobj) prevention_30\NN (l_prep) of_31\IN (l_pobj) loss_37\NN
D009569_D006319 NONE NO_26\DT (r_det) inhibitors_27\NNS (r_pobj) of_25\IN (r_prep) use_24\NN (l_prep) for_28\IN (l_pobj) prevention_30\NN (l_prep) of_31\IN (l_pobj) loss_37\NN
D019331_D006311 NONE ester_6\NN (l_appos) protector_10\NN (l_prep) against_11\IN (l_pobj) ototoxicity_13\NN
D019331_D006316 NONE ester_13\NN (r_appos) oxide_2\NN (r_nsubj) act_20\VB (l_prep) as_21\IN (l_pobj) otoprotectant_23\NN (l_prep) against_24\IN (l_pobj) loss_29\NN
D019331_D006316 NONE NAME_17\NN (r_appos) ester_13\NN (r_appos) oxide_2\NN (r_nsubj) act_20\VB (l_prep) as_21\IN (l_pobj) otoprotectant_23\NN (l_prep) against_24\IN (l_pobj) loss_29\NN
D005839_D006316 NONE gentamicin_32\NN (r_pobj) by_31\IN (r_agent) caused_30\VBN (r_acl) loss_29\NN
D005839_D006311 NONE gentamicin_12\NN (r_compound) ototoxicity_13\NN
D000617_D006319 NONE aminoglycoside_32\NN (r_npadvmod) induced_34\VBN (r_amod) loss_37\NN
D009569_D006311 NONE NO_17\DT (r_pobj) of_16\IN (r_prep) production_15\NN (r_dobj) involves_13\VBZ (r_conj) is_2\VBZ (l_nsubj) ototoxicity_1\NN
D009569_D006311 NONE NO_17\DT (r_pobj) of_16\IN (r_prep) production_15\NN (r_dobj) involves_13\VBZ (l_nsubj) mechanism_12\NN (l_compound) ototoxic_11\JJ
D009569_D006311 NONE NO_26\DT (r_det) inhibitors_27\NNS (r_pobj) of_25\IN (r_prep) use_24\NN (r_dobj) assess_22\VB (r_xcomp) need_20\VBP (l_ccomp) is_2\VBZ (l_nsubj) ototoxicity_1\NN
D009569_D006311 NONE NO_26\DT (r_det) inhibitors_27\NNS (r_pobj) of_25\IN (r_prep) use_24\NN (r_dobj) assess_22\VB (r_xcomp) need_20\VBP (l_ccomp) is_2\VBZ (l_conj) involves_13\VBZ (l_nsubj) mechanism_12\NN (l_compound) ototoxic_11\JJ
D005839_D034381 CID gentamicin_4\NN (r_npadvmod) induced_6\VBN (r_amod) loss_8\NN
D009569_D006316 NONE oxide_2\NN (r_nsubj) act_20\VB (l_prep) as_21\IN (l_pobj) otoprotectant_23\NN (l_prep) against_24\IN (l_pobj) loss_29\NN
D009569_D006316 NONE NO_4\NNP (r_intj) ester_13\NN (r_appos) oxide_2\NN (r_nsubj) act_20\VB (l_prep) as_21\IN (l_pobj) otoprotectant_23\NN (l_prep) against_24\IN (l_pobj) loss_29\NN
D000617_D006311 NONE aminoglycoside_32\NN (r_npadvmod) induced_34\VBN (r_amod) loss_37\NN (r_pobj) of_31\IN (r_prep) prevention_30\NN (r_pobj) for_28\IN (r_prep) use_24\NN (r_dobj) assess_22\VB (r_xcomp) need_20\VBP (l_ccomp) is_2\VBZ (l_nsubj) ototoxicity_1\NN
D000617_D006311 NONE aminoglycoside_32\NN (r_npadvmod) induced_34\VBN (r_amod) loss_37\NN (r_pobj) of_31\IN (r_prep) prevention_30\NN (r_pobj) for_28\IN (r_prep) use_24\NN (r_dobj) assess_22\VB (r_xcomp) need_20\VBP (l_ccomp) is_2\VBZ (l_conj) involves_13\VBZ (l_nsubj) mechanism_12\NN (l_compound) ototoxic_11\JJ
6538499
D004317_D009202 CID ADR_8\NNP (r_npadvmod) induced_10\VBN (r_amod) alterations_13\NNS
D004317_D002286 NONE ADR_6\NNP (r_compound) activity_8\NN (l_relcl) tumor_16\NN
D004317_D064420 NONE adriamycin_6\JJ (l_dobj) toxicity_7\NN
D011092_D064420 NONE 400_4\CD (r_nummod) glycol_3\NN (l_advcl) adriamycin_6\JJ (l_dobj) toxicity_7\NN
D004317_D007939 NONE ADR_6\NNP (r_compound) activity_8\NN (l_prep) in_9\IN (l_pobj) leukemia_11\NN
12653683
D000450_D009404 NONE aldosterone_38\NN (r_pobj) by_37\IN (r_prep) regulation_36\NN (r_pobj) from_34\IN (r_prep) escape_33\VB (r_xcomp) appears_31\VBZ (r_conj) increased_11\VBN (l_prep) in_12\IN (l_pobj) phase_16\NN (l_prep) of_17\IN (l_pobj) model_20\NN (l_prep) of_21\IN (l_pobj) syndrome_26\NN
D012964_D009404 NONE sodium_1\NN (r_compound) channel_2\NN (l_appos) subunit_6\NN (l_appos) mRNA_7\NN (l_conj) expression_10\NN (l_prep) in_11\IN (l_pobj) rats_12\NNS (l_prep) with_13\IN (l_pobj) syndrome_19\NN
D012964_D009404 NONE sodium_6\NN (r_compound) excretion_7\NN (r_nsubjpass) decreased_9\VBN (l_prep) In_0\IN (l_pobj) syndrome_3\NN
D000450_D011507 NONE aldosterone_9\NN (r_compound) concentration_10\NN (l_conj) proteinuria_12\NN
D011692_D009404 CID aminonucleoside_15\RB (r_advmod) induced_17\VBN (r_amod) syndrome_19\NN
D011692_D009404 CID aminonucleoside_12\NN (l_pobj) syndrome_16\NN
D011692_D009404 CID PAN)-induced_14\VBN (r_amod) syndrome_16\NN
D011692_D009404 CID PAN_22\NNP (r_npadvmod) induced_24\VBN (r_amod) syndrome_26\NN
D011692_D011507 CID PAN_28\NNP (r_pobj) of_26\IN (r_prep) dose_25\NN (r_pobj) with_22\IN (r_prep) treated_21\VBN (r_acl) rats_20\NNS (r_pobj) in_15\IN (r_prep) studied_14\VBN (l_nsubjpass) courses_2\NNS (l_prep) of_3\IN (l_pobj) excretion_6\NN (l_conj) concentration_10\NN (l_conj) proteinuria_12\NN
D012964_D011507 NONE sodium_5\NN (r_compound) excretion_6\NN (l_conj) concentration_10\NN (l_conj) proteinuria_12\NN
D012964_D011507 NONE sodium_4\NN (r_compound) excretion_5\NN (r_pobj) of_2\IN (r_prep) kinetics_1\NNS (l_conj) appearance_8\NN (l_prep) of_9\IN (l_pobj) proteinuria_10\NN
3615541
D000661_D006948 CID amphetamine_6\NN (r_npadvmod) induced_8\VBN (r_amod) hyperactivity_9\NN
D002116_D006948 NONE calcitonin_12\NN (r_compound) injections_13\NNS (r_pobj) by_10\IN (r_prep) antagonism_4\NN (l_prep) of_5\IN (l_pobj) hyperactivity_9\NN
20084309
D008874_D000402 NONE MZ_42\NNP (r_compound) use_43\NN (r_pobj) by_41\IN (r_agent) caused_40\VBN (r_acl) hypoxia_39\NN (r_pobj) due_37\JJ (r_prep) presented_20\VBD (l_prep) due_23\IN (l_pobj) obstruction_27\NN
D008874_D009202 NONE MZ_38\NNP (r_compound) dose_39\NN (r_conj) MR_34\NNP (r_appos) regurgitation_32\NN (r_conj) duration_26\NN (r_dobj) test_7\VB (l_dobj) influence_9\NN (l_prep) of_10\IN (l_pobj) variables_13\NNS (l_appos) age_15\NN (l_conj) sex_17\NN (l_conj) stroke_19\UH (l_conj) MP_23\NNP (l_amod) myocardiopathy_21\NN
D008874_D009202 NONE MZ_38\NNP (r_compound) dose_39\NN (r_conj) MR_34\NNP (r_appos) regurgitation_32\NN (r_conj) duration_26\NN (r_dobj) test_7\VB (l_dobj) influence_9\NN (l_prep) of_10\IN (l_pobj) variables_13\NNS (l_appos) age_15\NN (l_conj) sex_17\NN (l_conj) stroke_19\UH (l_conj) MP_23\NNP
D008874_D009202 NONE MZ_17\NNP (r_pobj) of_16\IN (r_prep) doses_15\NNS (r_appos) MP_8\NNP
D008874_D020521 NONE MZ_38\NNP (r_compound) dose_39\NN (r_conj) MR_34\NNP (r_appos) regurgitation_32\NN (r_conj) duration_26\NN (r_dobj) test_7\VB (l_dobj) influence_9\NN (l_prep) of_10\IN (l_pobj) variables_13\NNS (l_appos) age_15\NN (l_conj) sex_17\NN (l_conj) stroke_19\UH
D008874_D000860 CID MZ_42\NNP (r_compound) use_43\NN (r_pobj) by_41\IN (r_agent) caused_40\VBN (r_acl) hypoxia_39\NN (r_pobj) due_37\JJ (r_prep) presented_20\VBD (l_dobj) hypoxia_22\NN
D008874_D000860 CID MZ_42\NNP (r_compound) use_43\NN (r_pobj) by_41\IN (r_agent) caused_40\VBN (r_acl) hypoxia_39\NN
D008874_D008944 NONE MZ_38\NNP (r_compound) dose_39\NN (r_conj) MR_34\NNP (r_appos) regurgitation_32\NN
D008874_D008944 NONE MZ_38\NNP (r_compound) dose_39\NN (r_conj) MR_34\NNP
D008874_D008944 NONE MZ_17\NNP (r_pobj) of_16\IN (r_prep) doses_15\NNS (r_appos) MP_8\NNP (l_nmod) MR_6\NNP
1786266
D000928_D001480 NONE antidepressant_3\NN (r_compound) use_4\NN (r_conj) syndrome_1\NN
15325671
D017239_D001943 NONE paclitaxel_2\NN (l_conj) melphalan_4\NN (l_conj) cyclophosphamide_9\NN (l_conj) thiotepa_11\NNS (l_conj) carboplatin_14\VB (l_dobj) regimen_22\NN (l_prep) for_23\IN (l_pobj) patients_24\NNS (l_prep) with_25\IN (l_pobj) cancer_28\NN
D003520_D001943 NONE cyclophosphamide_9\NN (r_npadvmod) based_11\VBN (r_amod) chemotherapy_12\NN (l_prep) for_13\IN (l_pobj) cancer_16\NN
D003520_D001943 NONE cyclophosphamide_9\NN (l_conj) thiotepa_11\NNS (l_conj) carboplatin_14\VB (l_dobj) regimen_22\NN (l_prep) for_23\IN (l_pobj) patients_24\NNS (l_prep) with_25\IN (l_pobj) cancer_28\NN
D003520_D001943 NONE cyclophosphamide_16\NN (r_dobj) receiving_13\VBG (r_acl) cancer_12\NN
D008558_D001943 NONE melphalan_4\NN (l_conj) cyclophosphamide_9\NN (l_conj) thiotepa_11\NNS (l_conj) carboplatin_14\VB (l_dobj) regimen_22\NN (l_prep) for_23\IN (l_pobj) patients_24\NNS (l_prep) with_25\IN (l_pobj) cancer_28\NN
D003520_D066126 NONE cyclophosphamide_9\NN (r_npadvmod) based_11\VBN (r_amod) chemotherapy_12\NN (r_pobj) with_5\IN (r_prep) association_4\NN (r_pobj) in_3\IN (r_prep) observed_2\VBD (l_nsubj) toxicity_1\NN
D003520_D066126 NONE cyclophosphamide_3\NN (r_npadvmod) related_5\VBN (r_amod) toxicity_7\NN
D003520_D003920 NONE cyclophosphamide_16\NN (r_dobj) receiving_13\VBG (r_acl) cancer_12\NN (l_conj) characteristics_44\NNS (l_appos) presence_46\NN (l_appos) history_60\NN (l_conj) smoking_62\NN (l_conj) mellitus_65\NN
D016190_D001943 NONE carboplatin_14\VB (l_dobj) regimen_22\NN (l_prep) for_23\IN (l_pobj) patients_24\NNS (l_prep) with_25\IN (l_pobj) cancer_28\NN
D018943_D006973 NONE anthracyclines_70\NNS (r_pobj) of_69\IN (r_prep) use_68\NN (r_conj) mellitus_65\NN (r_conj) smoking_62\NN (r_conj) history_60\NN (r_appos) presence_46\NN (l_prep) of_47\IN (l_pobj) electrocardiogram_48\NN (l_appos) abnormalities_52\NNS (l_appos) hypertension_56\NN
D003520_D006973 NONE cyclophosphamide_16\NN (r_dobj) receiving_13\VBG (r_acl) cancer_12\NN (l_conj) characteristics_44\NNS (l_appos) presence_46\NN (l_prep) of_47\IN (l_pobj) electrocardiogram_48\NN (l_appos) abnormalities_52\NNS (l_appos) hypertension_56\NN
D013852_D001943 NONE thiotepa_11\NNS (l_conj) carboplatin_14\VB (l_dobj) regimen_22\NN (l_prep) for_23\IN (l_pobj) patients_24\NNS (l_prep) with_25\IN (l_pobj) cancer_28\NN
D018943_D001943 NONE anthracyclines_70\NNS (r_pobj) of_69\IN (r_prep) use_68\NN (r_conj) mellitus_65\NN (r_conj) smoking_62\NN (r_conj) history_60\NN (r_appos) presence_46\NN (r_appos) characteristics_44\NNS (r_conj) cancer_12\NN
D018943_D006333 NONE anthracyclines_70\NNS (r_pobj) of_69\IN (r_prep) use_68\NN (r_conj) mellitus_65\NN (r_conj) smoking_62\NN (r_conj) history_60\NN (r_appos) presence_46\NN (r_appos) characteristics_44\NNS (r_conj) cancer_12\NN (l_acl) receiving_13\VBG (l_prep) as_17\IN (l_pobj) part_18\NN (l_prep) of_19\IN (l_pobj) regimen_26\NN (l_acl) assess_28\VB (l_dobj) association_29\NN (l_prep) between_30\IN (l_pobj) presence_31\NN (l_prep) of_32\IN (l_pobj) failure_36\NN
D018943_D006333 NONE anthracyclines_70\NNS (r_pobj) of_69\IN (r_prep) use_68\NN (r_conj) mellitus_65\NN (r_conj) smoking_62\NN (r_conj) history_60\NN (r_appos) presence_46\NN (r_appos) characteristics_44\NNS (r_conj) cancer_12\NN (l_acl) receiving_13\VBG (l_prep) as_17\IN (l_pobj) part_18\NN (l_prep) of_19\IN (l_pobj) regimen_26\NN (l_acl) assess_28\VB (l_dobj) association_29\NN (l_prep) between_30\IN (l_pobj) presence_31\NN (l_prep) of_32\IN (l_pobj) failure_36\NN (l_appos) CHF_38\NNP
D003520_D006333 CID cyclophosphamide_16\NN (r_dobj) receiving_13\VBG (l_prep) as_17\IN (l_pobj) part_18\NN (l_prep) of_19\IN (l_pobj) regimen_26\NN (l_acl) assess_28\VB (l_dobj) association_29\NN (l_prep) between_30\IN (l_pobj) presence_31\NN (l_prep) of_32\IN (l_pobj) failure_36\NN
D003520_D006333 CID cyclophosphamide_16\NN (r_dobj) receiving_13\VBG (l_prep) as_17\IN (l_pobj) part_18\NN (l_prep) of_19\IN (l_pobj) regimen_26\NN (l_acl) assess_28\VB (l_dobj) association_29\NN (l_prep) between_30\IN (l_pobj) presence_31\NN (l_prep) of_32\IN (l_pobj) failure_36\NN (l_appos) CHF_38\NNP
D003520_D006333 CID cyclophosphamide_16\NN (r_dobj) following_14\VBG (r_prep) developed_8\VBD (l_dobj) grade_11\NN (l_appos) CHF_13\NNP
D003520_D006333 CID cyclophosphamide_5\NN (r_pobj) during_3\IN (r_prep) monitoring_2\NN (r_nsubj) predict_8\VB (l_dobj) development_10\NN (l_compound) CHF_9\NNP
D018943_D003920 NONE anthracyclines_70\NNS (r_pobj) of_69\IN (r_prep) use_68\NN (r_conj) mellitus_65\NN
2802551
D000666_D007674 CID B_5\NN (r_compound) nephrotoxicity_6\NN
D000666_D007674 CID B_5\NNP (r_pobj) of_3\IN (r_prep) potential_2\NN (l_amod) nephrotoxic_1\JJ
D012964_D007674 NONE Sodium_0\NN (r_compound) status_1\NN (r_nsubj) influences_2\VBZ (l_dobj) nephrotoxicity_6\NN
2505783
C004656_D006470 CID chloroacetaldehyde_7\NN (r_nsubj) is_11\VBZ (l_attr) metabolite_14\NN (l_relcl) carried_23\VBN (l_prep) in_25\IN (l_pobj) order_26\NN (l_acl) elucidate_28\VB (l_prep) in_33\IN (l_pobj) development_35\NN (l_prep) of_36\IN (l_pobj) cystitis_38\NN
C004656_D006470 CID CAA_9\NNP (r_appos) chloroacetaldehyde_7\NN (r_nsubj) is_11\VBZ (l_attr) metabolite_14\NN (l_relcl) carried_23\VBN (l_prep) in_25\IN (l_pobj) order_26\NN (l_acl) elucidate_28\VB (l_prep) in_33\IN (l_pobj) development_35\NN (l_prep) of_36\IN (l_pobj) cystitis_38\NN
C004656_D006470 CID CAA_32\NNP (r_pobj) of_31\IN (r_prep) role_30\NN (r_dobj) elucidate_28\VB (l_prep) in_33\IN (l_pobj) development_35\NN (l_prep) of_36\IN (l_pobj) cystitis_38\NN
C004656_D001745 NONE CAA_4\NNP (r_nsubj) contribute_10\VB (l_prep) to_11\IN (l_pobj) damage_13\NN
C004656_D003556 CID chloroacetaldehyde_7\NN (r_nsubj) is_11\VBZ (l_attr) metabolite_14\NN (l_relcl) carried_23\VBN (l_prep) in_25\IN (l_pobj) order_26\NN (l_acl) elucidate_28\VB (l_prep) in_33\IN (l_pobj) development_35\NN (l_prep) of_36\IN (l_pobj) cystitis_38\NN
C004656_D003556 CID CAA_9\NNP (r_appos) chloroacetaldehyde_7\NN (r_nsubj) is_11\VBZ (l_attr) metabolite_14\NN (l_relcl) carried_23\VBN (l_prep) in_25\IN (l_pobj) order_26\NN (l_acl) elucidate_28\VB (l_prep) in_33\IN (l_pobj) development_35\NN (l_prep) of_36\IN (l_pobj) cystitis_38\NN
C004656_D003556 CID CAA_32\NNP (r_pobj) of_31\IN (r_prep) role_30\NN (r_dobj) elucidate_28\VB (l_prep) in_33\IN (l_pobj) development_35\NN (l_prep) of_36\IN (l_pobj) cystitis_38\NN
11532387
D004298_D001480 NONE dopamine_26\NN (r_compound) antagonist_27\NN (r_appos) risperidone_21\NN (r_pobj) of_20\IN (r_prep) profile_19\NN (r_pobj) to_16\IN (r_prep) related_15\VBN (l_nsubjpass) mechanism_2\NN (l_prep) of_3\IN (l_pobj) RS_7\NN
D004298_D001480 NONE dopamine_26\NN (r_compound) antagonist_27\NN (r_appos) risperidone_21\NN (r_pobj) of_20\IN (r_prep) profile_19\NN (r_pobj) to_16\IN (r_prep) related_15\VBN (l_advcl) suggesting_29\VBG (l_dobj) influence_32\NN (l_prep) in_37\IN (l_pobj) development_39\NN (l_prep) of_40\IN (l_pobj) RS_41\NN
D012701_D001480 NONE serotonin_24\NN (r_compound) dopamine_26\NN (r_compound) antagonist_27\NN (r_appos) risperidone_21\NN (r_pobj) of_20\IN (r_prep) profile_19\NN (r_pobj) to_16\IN (r_prep) related_15\VBN (l_nsubjpass) mechanism_2\NN (l_prep) of_3\IN (l_pobj) RS_7\NN
D012701_D001480 NONE serotonin_24\NN (r_compound) dopamine_26\NN (r_compound) antagonist_27\NN (r_appos) risperidone_21\NN (r_pobj) of_20\IN (r_prep) profile_19\NN (r_pobj) to_16\IN (r_prep) related_15\VBN (l_advcl) suggesting_29\VBG (l_dobj) influence_32\NN (l_prep) in_37\IN (l_pobj) development_39\NN (l_prep) of_40\IN (l_pobj) RS_41\NN
D012701_D001480 NONE serotonin_35\NN (r_compound) system_36\NN (r_pobj) of_33\IN (r_prep) influence_32\NN (r_dobj) suggesting_29\VBG (r_advcl) related_15\VBN (l_nsubjpass) mechanism_2\NN (l_prep) of_3\IN (l_pobj) RS_7\NN
D012701_D001480 NONE serotonin_35\NN (r_compound) system_36\NN (r_pobj) of_33\IN (r_prep) influence_32\NN (l_prep) in_37\IN (l_pobj) development_39\NN (l_prep) of_40\IN (l_pobj) RS_41\NN
D018967_D013375 CID risperidone_9\NN (r_pobj) of_8\IN (r_prep) reduction_7\NN (r_pobj) during_5\IN (r_prep) syndrome_4\NN
D018967_D013375 CID risperidone_21\NN (r_pobj) of_20\IN (r_prep) profile_19\NN (r_pobj) to_16\IN (r_prep) related_15\VBN (l_nsubjpass) mechanism_2\NN (l_prep) of_3\IN (l_pobj) RS_7\NN
D004298_D013375 NONE dopamine_26\NN (r_compound) antagonist_27\NN (r_appos) risperidone_21\NN (r_pobj) of_20\IN (r_prep) profile_19\NN (r_pobj) to_16\IN (r_prep) related_15\VBN (l_nsubjpass) mechanism_2\NN (l_prep) of_3\IN (l_pobj) RS_7\NN
D012701_D013375 NONE serotonin_24\NN (r_compound) dopamine_26\NN (r_compound) antagonist_27\NN (r_appos) risperidone_21\NN (r_pobj) of_20\IN (r_prep) profile_19\NN (r_pobj) to_16\IN (r_prep) related_15\VBN (l_nsubjpass) mechanism_2\NN (l_prep) of_3\IN (l_pobj) RS_7\NN
D012701_D013375 NONE serotonin_35\NN (r_compound) system_36\NN (r_pobj) of_33\IN (r_prep) influence_32\NN (r_dobj) suggesting_29\VBG (r_advcl) related_15\VBN (l_nsubjpass) mechanism_2\NN (l_prep) of_3\IN (l_pobj) RS_7\NN
D018967_D001480 CID risperidone_9\NN (r_pobj) of_8\IN (r_prep) reduction_7\NN (r_pobj) during_5\IN (r_prep) syndrome_4\NN
D018967_D001480 CID risperidone_8\NN (r_pobj) of_7\IN (r_prep) reduction_6\NN (r_pobj) during_4\IN (r_prep) developed_2\VBN (l_dobj) RS_3\NN
D018967_D001480 CID risperidone_21\NN (r_pobj) of_20\IN (r_prep) profile_19\NN (r_pobj) to_16\IN (r_prep) related_15\VBN (l_nsubjpass) mechanism_2\NN (l_prep) of_3\IN (l_pobj) RS_7\NN
D018967_D001480 CID risperidone_21\NN (r_pobj) of_20\IN (r_prep) profile_19\NN (r_pobj) to_16\IN (r_prep) related_15\VBN (l_advcl) suggesting_29\VBG (l_dobj) influence_32\NN (l_prep) in_37\IN (l_pobj) development_39\NN (l_prep) of_40\IN (l_pobj) RS_41\NN
7420681
D005839_D051437 CID sulfate_25\NN (r_pobj) of_23\IN (r_prep) day_22\NN (r_appos) kg_20\NNS (r_pobj) with_14\IN (r_prep) treated_13\VBN (r_conj) patients_5\NNS (r_nsubjpass) followed_36\VBN (l_prep) for_39\IN (l_pobj) development_41\NN (l_prep) of_42\IN (l_pobj) failure_47\NN
D005839_D051437 CID gentamicin_23\NN (r_npadvmod) treated_25\VBN (r_amod) patients_26\NNS (r_pobj) of_21\IN (r_prep) 16_14\CD (r_nsubj) had_27\VBD (l_dobj) failure_29\NN
D005839_D051437 CID gentamicin_2\NN (r_nsubjpass) associated_4\VBN (l_prep) with_5\IN (l_pobj) failure_7\NN
D014031_D007674 NONE tobramycin_3\JJ (r_pobj) of_2\IN (r_prep) nephrotoxicity_1\NN
D014031_D007674 NONE sulfate_4\NN (r_conj) sulfate_1\NN (r_nsubj) continue_5\VBP (l_xcomp) demonstrate_7\VB (l_dobj) ototoxicity_8\NN (l_conj) nephrotoxicity_10\NN
D005839_D007674 NONE gentamicin_5\NN (r_conj) nephrotoxicity_1\NN
D005839_D007674 NONE sulfate_1\NN (r_nsubj) continue_5\VBP (l_xcomp) demonstrate_7\VB (l_dobj) ototoxicity_8\NN (l_conj) nephrotoxicity_10\NN
D014031_D006311 NONE sulfate_4\NN (r_conj) sulfate_1\NN (r_nsubj) continue_5\VBP (l_xcomp) demonstrate_7\VB (l_dobj) ototoxicity_8\NN
D005839_D006311 NONE sulfate_1\NN (r_nsubj) continue_5\VBP (l_xcomp) demonstrate_7\VB (l_dobj) ototoxicity_8\NN
D000617_D051437 NONE aminoglycoside_43\NN (r_npadvmod) related_45\VBN (r_amod) failure_47\NN
D014031_D051437 CID sulfate_28\NN (r_conj) sulfate_25\NN (r_pobj) of_23\IN (r_prep) day_22\NN (r_appos) kg_20\NNS (r_pobj) with_14\IN (r_prep) treated_13\VBN (r_conj) patients_5\NNS (r_nsubjpass) followed_36\VBN (l_prep) for_39\IN (l_pobj) development_41\NN (l_prep) of_42\IN (l_pobj) failure_47\NN
D014031_D051437 CID tobramycin_9\RB (r_npadvmod) treated_11\VBN (r_amod) patients_12\NNS (r_pobj) of_7\IN (r_prep) %_5\NN (r_pobj) of_1\IN (r_prep) Five_0\CD (r_nsubj) had_27\VBD (l_dobj) failure_29\NN
D014031_D051437 CID tobramycin_16\JJ (r_acomp) was_15\VBD (r_advcl) associated_4\VBN (l_prep) with_5\IN (l_pobj) failure_7\NN
12905102
D003024_D003693 CID clozapine_2\NN (r_amod) treatment_3\NN (r_pobj) during_1\IN (r_prep) Delirium_0\NN
D003024_D003693 CID clozapine_7\NN (r_compound) treatment_8\NN (r_pobj) during_6\IN (r_prep) factors_3\NNS (l_prep) for_4\IN (l_pobj) delirium_5\NN
D003024_D003693 CID clozapine_13\NN (r_pobj) with_12\IN (r_prep) treated_11\VBN (r_acl) inpatients_10\NNS (r_dobj) identify_6\VB (r_xcomp) used_1\VBD (l_conj) reviewed_20\VBD (l_advcl) score_25\VB (l_dobj) incidence_26\NN (l_prep) of_29\IN (l_pobj) delirium_30\NN
D003024_D003693 CID clozapine_7\NN (r_npadvmod) treated_9\VBN (r_amod) inpatients_10\NNS (r_pobj) of_6\IN (r_prep) %_5\NN (r_pobj) in_3\IN (r_prep) found_2\VBN (l_nsubjpass) Delirium_0\NNP
D003024_D001523 NONE clozapine_13\NN (r_pobj) with_12\IN (r_prep) treated_11\VBN (r_acl) inpatients_10\NNS (l_amod) psychiatric_9\JJ
8864707
D010672_D004827 NONE phenytoin_10\NNP (r_compound) overdosages_11\NNS (r_pobj) after_9\IN (r_prep) volumetry_2\NN (l_prep) in_6\IN (l_pobj) patients_8\NNS (l_amod) epileptic_7\JJ
D010672_D062787 CID phenytoin_10\NNP (r_compound) overdosages_11\NNS
D010672_D062787 CID phenytoin_3\JJ (r_compound) overdosage_4\NN
D010672_D062787 CID phenytoin_17\JJ (r_compound) medication_18\NN (r_nsubj) was_19\VBD (r_ccomp) is_14\VBZ (r_conj) result_8\VB (l_nsubj) overdosage_4\NN
D010672_D012640 NONE phenytoin_15\JJ (r_compound) levels_17\NNS (r_pobj) of_14\IN (r_prep) elevation_13\NN (r_conj) duration_11\NN (l_compound) seizure_10\NN
D010672_D002526 NONE phenytoin_11\JJ (r_compound) medication_12\NN (l_conj) atrophy_15\NN
D010672_D002526 NONE phenytoin_3\JJ (r_compound) overdosage_4\NN (r_nsubj) result_8\VB (l_prep) in_9\IN (l_pobj) atrophy_11\NN
D010672_D002526 NONE phenytoin_3\JJ (r_compound) overdosage_4\NN (r_nsubj) result_8\VB (l_conj) is_14\VBZ (l_ccomp) was_19\VBD (l_attr) cause_22\NN (l_prep) of_23\IN (l_pobj) atrophy_25\NN
D010672_D002526 NONE phenytoin_17\JJ (r_compound) medication_18\NN (r_nsubj) was_19\VBD (r_ccomp) is_14\VBZ (r_conj) result_8\VB (l_prep) in_9\IN (l_pobj) atrophy_11\NN
D010672_D002526 NONE phenytoin_17\JJ (r_compound) medication_18\NN (r_nsubj) was_19\VBD (l_attr) cause_22\NN (l_prep) of_23\IN (l_pobj) atrophy_25\NN
20003049
C031942_D013921 NONE argatroban_4\NN (l_prep) in_5\IN (l_pobj) patient_9\NN (l_prep) with_10\IN (l_pobj) history_13\NN (l_prep) of_14\IN (l_pobj) thrombocytopenia_18\NN
C031942_D013921 NONE argatroban_20\NN (r_oprd) administered_19\VBN (l_nsubjpass) patient_11\JJ (l_prep) with_12\IN (l_pobj) history_15\NN (l_prep) of_16\IN (l_pobj) HITT_17\NNP
C031942_D013927 NONE argatroban_4\NN (l_prep) in_5\IN (l_pobj) patient_9\NN (l_prep) with_10\IN (l_pobj) history_13\NN (l_prep) of_14\IN (l_pobj) thrombocytopenia_18\NN (l_prep) with_19\IN (l_pobj) thrombosis_20\NN
C031942_D013927 NONE argatroban_20\NN (r_oprd) administered_19\VBN (l_nsubjpass) patient_11\JJ (l_prep) with_12\IN (l_pobj) history_15\NN (l_prep) of_16\IN (l_pobj) HITT_17\NNP
C031942_D008107 NONE argatroban_4\NN (r_pobj) of_3\IN (r_prep) concentrations_2\NNS (r_nsubjpass) measured_6\VBN (l_conj) is_42\VBZ (l_attr) minutes_46\NNS (l_appos) minutes_52\NNS (l_prep) with_53\IN (l_pobj) impairment_55\NN
C031942_D008107 NONE argatroban_25\JJ (r_amod) life_27\NN (r_npadvmod) plasma_24\NN (r_nsubjpass) observed_36\VBN (r_conj) measured_6\VBN (l_conj) is_42\VBZ (l_attr) minutes_46\NNS (l_appos) minutes_52\NNS (l_prep) with_53\IN (l_pobj) impairment_55\NN
C031942_D001778 NONE argatroban_3\JJ (r_amod) concentration_4\NN (r_nsubj) suggest_14\VBP (l_ccomp) contributed_24\VBN (l_prep) to_25\IN (l_pobj) coagulopathy_30\NN
C031942_D001778 NONE argatroban_21\NN (r_amod) levels_18\NNS (r_nsubj) contributed_24\VBN (l_prep) to_25\IN (l_pobj) coagulopathy_30\NN
C031942_D001778 NONE argatroban_8\JJ (r_amod) concentration_9\NN (r_dobj) measure_6\VB (l_conj) extended_16\VBN (l_dobj) coagulopathy_17\NN
C031942_D016638 NONE argatroban_20\NN (r_oprd) administered_19\VBN (l_nsubjpass) patient_11\JJ (l_amod) ill_10\JJ
D006493_D013927 NONE heparin_15\NN (r_npadvmod) induced_17\VBN (r_amod) thrombocytopenia_18\NN (l_prep) with_19\IN (l_pobj) thrombosis_20\NN
D006493_D013927 NONE heparin_18\NN (r_npadvmod) induced_20\VBN (r_amod) thrombocytopenia_21\NN (r_pobj) of_17\IN (r_prep) history_16\NN (r_pobj) with_14\IN (r_prep) patients_13\NNS (r_pobj) for_12\IN (r_prep) anticoagulation_11\NN (r_pobj) of_10\IN (r_prep) method_9\NN (r_dobj) provide_6\VBP (l_conj) HIT_26\VB (l_prep) with_27\IN (l_pobj) thrombosis_28\NN
D006493_D013927 NONE heparin_18\NN (r_npadvmod) induced_20\VBN (r_amod) thrombocytopenia_21\NN (r_pobj) of_17\IN (r_prep) history_16\NN (r_pobj) with_14\IN (r_prep) patients_13\NNS (r_pobj) for_12\IN (r_prep) anticoagulation_11\NN (r_pobj) of_10\IN (r_prep) method_9\NN (r_dobj) provide_6\VBP (l_conj) HIT_26\VB (l_prep) with_27\IN (l_pobj) thrombosis_28\NN (l_appos) HITT_30\NNP
D006493_D013921 NONE heparin_15\NN (r_npadvmod) induced_17\VBN (r_amod) thrombocytopenia_18\NN
D006493_D013921 NONE heparin_18\NN (r_npadvmod) induced_20\VBN (r_amod) thrombocytopenia_21\NN
D006493_D013921 NONE heparin_18\NN (r_npadvmod) induced_20\VBN (r_amod) thrombocytopenia_21\NN (l_appos) HIT_23\NNP
D006493_D013921 NONE heparin_18\NN (r_npadvmod) induced_20\VBN (r_amod) thrombocytopenia_21\NN (r_pobj) of_17\IN (r_prep) history_16\NN (r_pobj) with_14\IN (r_prep) patients_13\NNS (r_pobj) for_12\IN (r_prep) anticoagulation_11\NN (r_pobj) of_10\IN (r_prep) method_9\NN (r_dobj) provide_6\VBP (l_conj) HIT_26\VB
D006493_D013921 NONE heparin_18\NN (r_npadvmod) induced_20\VBN (r_amod) thrombocytopenia_21\NN (r_pobj) of_17\IN (r_prep) history_16\NN (r_pobj) with_14\IN (r_prep) patients_13\NNS (r_pobj) for_12\IN (r_prep) anticoagulation_11\NN (r_pobj) of_10\IN (r_prep) method_9\NN (r_dobj) provide_6\VBP (l_conj) HIT_26\VB (l_prep) with_27\IN (l_pobj) thrombosis_28\NN (l_appos) HITT_30\NNP
17111419
D002125_C536214 NONE gluconate_5\NN (r_pobj) with_2\IN (r_prep) treatment_1\NN (r_nsubjpass) initiated_7\VBN (l_conj) subsided_13\VBD (l_nsubj) contractions_11\NNS
D002034_D006996 NONE bumetanide_9\NN (r_nsubj) is_10\VBZ (l_attr) loop_12\NN (l_relcl) cause_16\VB (l_dobj) hypocalcemia_18\NN
D002118_D006996 NONE calcium_9\NN (r_compound) chelation_10\NN (r_pobj) to_8\IN (r_prep) reaction_7\NN (l_acl) resulting_15\VBG (l_prep) in_16\IN (l_pobj) hypocalcemia_19\NN
D049994_D006996 NONE diuretic_13\NN (r_amod) loop_12\NN (l_relcl) cause_16\VB (l_dobj) hypocalcemia_18\NN
C102006_D064420 NONE citrate_1\JJ (r_compound) toxicity_2\NN
C102006_D064420 NONE citrate_6\JJ (r_compound) toxicity_7\NN
C102006_D064420 NONE citrate_22\JJ (r_compound) toxicity_23\NN
C102006_D006996 CID citrate_13\NN (r_compound) anticoagulant_14\NN (r_pobj) by_11\IN (r_prep) reaction_7\NN (l_acl) resulting_15\VBG (l_prep) in_16\IN (l_pobj) hypocalcemia_19\NN
C102006_D006996 CID citrate_22\JJ (r_compound) toxicity_23\NN (r_pobj) to_21\IN (r_pcomp) due_20\IN (r_amod) reactions_19\NNS (r_dobj) prevent_17\VB (r_xcomp) help_16\VB (r_xcomp) recommended_14\VBN (l_nsubjpass) screening_4\NN (l_prep) for_5\IN (l_pobj) medications_6\NNS (l_conj) conditions_9\NNS (l_acl) predisposing_10\VBG (l_prep) to_11\IN (l_pobj) hypocalcemia_12\NN
2070391
D008012_D010146 CID lidocaine_6\NN (r_dobj) using_4\VBG (r_acl) Reduction_0\NN (l_prep) in_1\IN (l_pobj) pain_3\NN
D008012_D010146 CID lidocaine_11\NN (r_pobj) of_10\IN (r_prep) injection_9\NN (r_pobj) with_7\IN (r_prep) associated_6\VBN (r_acl) pain_5\NN
D008012_D010146 CID lidocaine_14\NN (r_pobj) of_13\IN (r_prep) pH_12\NN (r_dobj) adjust_10\VB (r_relcl) solution_8\NN (r_pobj) of_5\IN (r_prep) addition_4\NN (r_nsubj) reduce_20\VB (l_dobj) pain_21\NN
D008012_D010146 CID lidocaine_13\NN (r_dobj) receiving_11\VBG (r_pcomp) after_10\IN (r_prep) quantify_5\VB (l_dobj) severity_7\NN (l_prep) of_8\IN (l_pobj) pain_9\NN
D008012_D010146 CID lidocaine_20\NN (r_conj) receiving_11\VBG (r_pcomp) after_10\IN (r_prep) quantify_5\VB (l_dobj) severity_7\NN (l_prep) of_8\IN (l_pobj) pain_9\NN
D008012_D010146 CID lidocaine_6\NN (r_pobj) for_4\IN (r_prep) score_3\NN (l_compound) pain_2\NN
D008012_D010146 CID lidocaine_16\NN (r_pobj) for_14\IN (r_prep) score_13\NN (r_pobj) than_10\IN (r_prep) lower_9\JJR (r_acomp) was_7\VBD (l_nsubj) score_3\NN (l_compound) pain_2\NN
D008012_D010146 CID lidocaine_5\NN (r_pobj) of_3\IN (r_prep) adjustment_2\NN (r_nsubjpass) accomplished_8\VBN (l_prep) in_10\IN (l_pobj) laboratory_13\NN (l_prep) before_14\IN (l_pobj) injection_15\NN (l_prep) in_18\IN (l_pobj) reduction_20\NN (l_prep) of_21\IN (l_pobj) pain_23\NN
2611118
D004008_D056486 CID diclofenac_23\NNP (r_pobj) by_22\IN (r_agent) induced_21\VBN (r_conj) recorded_13\VBN (l_nsubjpass) abnormalities_7\NNS (l_prep) of_8\IN (l_pobj) function_10\NN
D004008_D056486 CID diclofenac_23\NNP (r_pobj) by_22\IN (r_agent) induced_21\VBN (l_nsubj) hepatitis_20\NN
D004008_D006521 NONE sodium_6\NN (r_compound) therapy_7\NN (r_pobj) with_4\IN (r_prep) associated_3\VBN (r_acl) hepatitis_2\NN
D004008_D006521 NONE sodium_13\NN (r_pobj) with_11\IN (r_prep) therapy_10\NN (r_pobj) after_7\IN (r_prep) developed_3\VBD (l_dobj) hepatitis_6\NN
2484011
D002395_D011596 NONE catecholamine_18\NN (r_compound) rate_20\NN (r_pobj) of_17\IN (r_prep) decrease_16\NN (l_conj) increase_29\NN (l_relcl) account_38\VB (l_prep) for_39\IN (l_pobj) depression_42\NN
D000547_D011596 CID amantadine_2\NN (r_pobj) of_1\IN (r_prep) Readministration_0\NN (r_nsubj) increased_12\VBN (l_prep) with_21\IN (l_pobj) exception_22\NN (l_prep) of_23\IN (l_pobj) mice_28\NNS (l_relcl) occurred_33\VBD (l_nsubj) suppression_30\NN (l_prep) of_31\IN (l_pobj) motility_32\NN
D000547_D011596 CID amantadine_45\NN (r_pobj) by_44\IN (r_agent) caused_43\VBN (r_acl) depression_42\NN
D000588_D011596 NONE amines_6\NNS (r_pobj) of_3\IN (r_prep) results_2\NNS (r_nsubj) suggest_13\VBP (l_dobj) decrease_16\NN (l_conj) increase_29\NN (l_relcl) account_38\VB (l_prep) for_39\IN (l_pobj) depression_42\NN
D009638_D011596 NONE norepinephrine_35\NN (r_pobj) of_34\IN (r_prep) methylation_33\NN (r_pobj) in_30\IN (r_prep) increase_29\NN (l_relcl) account_38\VB (l_prep) for_39\IN (l_pobj) depression_42\NN
D000547_D003866 NONE amantadine_4\JJ (r_nmod) activity_7\NN (l_amod) depressed_5\JJ
9754849
D003932_D002819 NONE heroine_30\NN (r_dobj) abusing_29\VBG (r_acl) inpatient_27\NN (r_pobj) in_25\IN (r_prep) adjustment_15\NN (r_pobj) by_13\IN (r_agent) induced_12\VBN (r_xcomp) choreoathetoid_8\JJ (l_dobj) movements_9\NNS
D003042_D002819 CID cocaine_12\NN (r_pobj) with_11\IN (r_prep) intoxications_10\NNS (r_pobj) during_9\IN (r_prep) be_5\VB (r_xcomp) known_3\VBN (l_nsubjpass) hyperkinesias_1\NNS
D003042_D002819 CID cocaine_32\NN (r_conj) heroine_30\NN (r_dobj) abusing_29\VBG (r_acl) inpatient_27\NN (r_pobj) in_25\IN (r_prep) adjustment_15\NN (r_pobj) by_13\IN (r_agent) induced_12\VBN (r_xcomp) choreoathetoid_8\JJ (l_dobj) movements_9\NNS
D008691_D002819 CID methadone_7\NN (r_pobj) to_6\IN (r_prep) adjustment_5\NN (r_pobj) with_3\IN (r_prep) associated_2\VBN (r_acl) movements_1\NNS
D008691_D002819 CID methadone_24\NN (r_pobj) to_16\IN (r_prep) adjustment_15\NN (r_pobj) by_13\IN (r_agent) induced_12\VBN (r_xcomp) choreoathetoid_8\JJ (l_dobj) movements_9\NNS
D003042_D020820 NONE cocaine_12\NN (r_pobj) with_11\IN (r_prep) intoxications_10\NNS (r_pobj) during_9\IN (r_prep) be_5\VB (l_attr) abnormalities_8\NNS
D003042_D006948 CID cocaine_12\NN (r_pobj) with_11\IN (r_prep) intoxications_10\NNS (r_pobj) during_9\IN (r_prep) be_5\VB (r_xcomp) known_3\VBN (l_nsubjpass) hyperkinesias_1\NNS
354896
D008012_D003866 NONE lidocaine_8\NN (r_pobj) of_7\IN (r_prep) bolus_6\NN (r_pobj) of_2\IN (r_prep) administration_1\NN (r_nsubj) resulted_15\VBD (l_prep) in_16\IN (l_pobj) depression_18\NN
D008012_D006323 CID Lidocaine_0\NN (r_npadvmod) induced_2\VBN (r_amod) asystole_4\NN
D008012_D001919 NONE lidocaine_29\NN (r_pobj) to_28\IN (r_prep) idiosyncrasy_27\NN (r_dobj) represented_24\VBD (r_conj) had_2\VBD (l_dobj) conditions_6\NNS (l_relcl) predisposed_10\VBN (l_prep) to_12\IN (l_pobj) development_14\NN (l_prep) of_15\IN (l_pobj) bradyarrhythmias_16\NNS
20619828
D002997_-1 NONE Clomipramine_0\NNP (r_compound) exposure_1\NN (r_nsubj) produced_5\VBD (l_npadvmod) inflexibility_25\NN
D002997_-1 NONE Clomipramine_0\NNP (r_compound) exposure_1\NN (r_nsubj) produced_5\VBD (l_npadvmod) inflexibility_25\NN (l_appos) impairment_41\NN (l_conj) hoarding_51\NN (l_conj) dysfunction_55\NN
D002997_D060845 CID Clomipramine_0\NNP (r_compound) exposure_1\NN (r_nsubj) produced_5\VBD (l_npadvmod) inflexibility_25\NN (l_appos) impairment_41\NN (l_conj) hoarding_51\NN
D002997_D008569 CID Clomipramine_0\NNP (r_compound) exposure_1\NN (r_nsubj) produced_5\VBD (l_npadvmod) inflexibility_25\NN (l_appos) impairment_41\NN
D002997_D001008 CID Clomipramine_0\NNP (r_compound) exposure_1\NN (r_nsubj) produced_5\VBD (l_dobj) changes_10\NNS (l_relcl) include_12\VBP (l_dobj) anxiety_14\NN
18329269
D006220_D002375 CID haloperidol_36\NN (r_npadvmod) induced_38\VBN (r_amod) model_40\NN (l_compound) catalepsy_39\NN
D006220_D010300 NONE haloperidol_36\NN (r_npadvmod) induced_38\VBN (r_amod) model_40\NN (l_prep) for_41\IN (l_pobj) disease_44\NN
18752389
D019821_D017114 NONE simvastatin_21\NN (r_nmod) day_25\NN (r_pobj) from_20\IN (r_prep) conversion_19\NN (r_pobj) after_18\IN (r_prep) necessitating_13\VBG (r_acl) failure_12\NN
C492458_D017093 NONE ezetimibe_2\NN (r_npadvmod) induced_4\VBN (r_amod) failure_6\NN
C492458_D017093 NONE ezetimibe_13\NN (r_npadvmod) induced_15\VBN (r_amod) failure_17\NN
C532833_D056486 NONE acid_25\NN (r_pobj) of_22\IN (r_prep) glucuronidation_21\NN (r_dobj) inhibited_19\VBN (l_advcl) resulting_27\VBG (l_prep) in_28\IN (l_pobj) exposure_31\NN (l_conj) hepatotoxicity_34\NN
D015283_D003866 NONE escitalopram_2\NNP (r_conj) Simvastatinezetimibe_0\NNP (l_relcl) taking_7\VBG (l_prep) for_8\IN (l_pobj) depression_9\NN
C492458_D056486 CID ezetimibe_17\NN (r_appos) agent_14\NN (r_conj) ezetimibe_10\NN (r_pobj) with_9\IN (r_prep) published_8\VBN (l_nsubjpass) events_3\NNS (l_amod) hepatotoxic_2\JJ
C492458_D056486 CID Simvastatinezetimibe_0\NNP (r_nsubjpass) discontinued_12\VBN (l_conj) excluded_21\VBN (l_nsubjpass) causes_17\NNS (l_prep) of_18\IN (l_pobj) hepatotoxicity_19\NN
C492458_D056486 CID simvastatinezetimibe_7\NN (r_npadvmod) induced_9\VBN (r_amod) hepatotoxicity_10\NN
C492458_D056486 CID ezetimibe_10\NN (r_pobj) with_7\IN (r_prep) hepatotoxicity_6\NN
C492458_D003866 NONE Simvastatinezetimibe_0\NNP (l_relcl) taking_7\VBG (l_prep) for_8\IN (l_pobj) depression_9\NN
C108606_D056486 NONE ezetimibe_10\NN (r_pobj) with_9\IN (r_prep) published_8\VBN (l_nsubjpass) events_3\NNS (l_amod) hepatotoxic_2\JJ
C108606_D056486 NONE Ezetimibe_0\NNP (r_nsubj) undergoes_1\VBZ (l_conj) inhibited_19\VBN (l_advcl) resulting_27\VBG (l_prep) in_28\IN (l_pobj) exposure_31\NN (l_conj) hepatotoxicity_34\NN
C108606_D056486 NONE ezetimibe_17\NN (r_compound) inhibition_18\NN (r_pobj) by_16\IN (r_prep) exposure_15\NN (r_attr) is_11\VBZ (l_nsubj) mechanism_4\NN (l_prep) of_5\IN (l_pobj) hepatotoxicity_10\NN
D014530_D056486 NONE diphosphate_6\NN (r_compound) glucoronosyltransferases_7\NNS (r_pobj) by_4\IN (r_prep) glucuronidation_3\NN (r_dobj) undergoes_1\VBZ (l_conj) inhibited_19\VBN (l_advcl) resulting_27\VBG (l_prep) in_28\IN (l_pobj) exposure_31\NN (l_conj) hepatotoxicity_34\NN
D019821_D056486 NONE simvastatin_9\NN (r_pobj) with_8\IN (r_prep) maintained_7\VBN (l_prep) for_10\IN (l_pobj) months_12\NNS (l_prep) before_13\IN (l_pobj) conversion_15\NN (l_prep) without_16\IN (l_pobj) evidence_17\NN (l_prep) of_18\IN (l_pobj) hepatotoxicity_19\NN
D019821_D056486 NONE simvastatin_30\NN (r_amod) exposure_31\NN (l_conj) hepatotoxicity_34\NN
D019821_D056486 NONE simvastatin_14\NN (r_amod) exposure_15\NN (r_attr) is_11\VBZ (l_nsubj) mechanism_4\NN (l_prep) of_5\IN (l_pobj) hepatotoxicity_10\NN
D015283_D056486 NONE escitalopram_2\NNP (r_conj) Simvastatinezetimibe_0\NNP (r_nsubjpass) discontinued_12\VBN (l_conj) excluded_21\VBN (l_nsubjpass) causes_17\NNS (l_prep) of_18\IN (l_pobj) hepatotoxicity_19\NN
C492458_D017114 CID mg_33\NN (r_nummod) day_35\NN (r_npadvmod) ezetimibe_31\NN (r_dobj) simvastatin_27\NN (r_advcl) necessitating_13\VBG (r_acl) failure_12\NN
8996652
D005665_D006311 NONE furosemide_19\NN (r_conj) aminoglycosides_17\NNS (r_appos) administration_7\NN (r_pobj) to_4\IN (r_prep) related_3\JJ (r_oprd) appeared_1\VBD (l_nsubj) Ototoxicity_0\NN
D005665_D006311 NONE furosemide_19\NN (r_conj) aminoglycosides_17\NNS (r_appos) administration_7\NN (l_conj) dose_11\NN (l_prep) of_12\IN (l_pobj) drugs_14\NNS (l_compound) ototoxic_13\JJ
D000617_D006311 NONE aminoglycosides_17\NNS (r_appos) administration_7\NN (r_pobj) to_4\IN (r_prep) related_3\JJ (r_oprd) appeared_1\VBD (l_nsubj) Ototoxicity_0\NN
D000617_D006311 NONE aminoglycosides_17\NNS (r_appos) administration_7\NN (l_conj) dose_11\NN (l_prep) of_12\IN (l_pobj) drugs_14\NNS (l_compound) ototoxic_13\JJ
19759529
D006220_D006948 NONE haloperidol_5\NN (r_nmod) antipsychotics_16\NNS (r_nsubj) were_17\VBD (l_acomp) effective_18\JJ (l_prep) in_19\IN (l_pobj) models_22\NNS (l_prep) of_23\IN (l_pobj) hyperactivity_24\NN
-1_D006948 NONE SSR103800_12\NNP (r_pobj) of_11\IN (r_prep) properties_10\NNS (r_dobj) investigating_4\VBG (l_prep) with_14\IN (l_pobj) focus_17\NN (l_prep) on_18\IN (l_pobj) models_19\NNS (l_prep) of_20\IN (l_pobj) hyperactivity_21\NN
-1_D006948 NONE SSR103800_3\NNP (r_nmod) hyperactivity_12\NN
-1_D006948 NONE SSR103800_3\NNP (r_nmod) hyperactivity_12\NN (r_punct) that_2\IN (r_dobj) showed_1\VBD (l_conj) reversed_26\VBD (l_dobj) hyperactivity_28\NN
-1_D006948 NONE SSR103800_3\NNP (r_nsubj) failed_4\VBD (l_xcomp) affect_6\VB (l_dobj) hyperactivity_7\NN
-1_D002375 NONE SSR103800_6\NNP (r_nsubj) produce_9\VB (l_dobj) catalepsy_10\NN
D016202_D012559 NONE aspartate_15\NNP (r_appos) methyl_11\NN (r_nmod) receptor_19\NN (r_pobj) of_6\IN (r_prep) antagonists_5\NNS (r_nsubj) produce_20\VBP (l_dobj) symptoms_24\NNS (l_amod) like_23\JJ (l_npadvmod) schizophrenic_21\JJ
D016202_D012559 NONE NMDA_17\NNP (r_nmod) receptor_19\NN (r_pobj) of_6\IN (r_prep) antagonists_5\NNS (r_nsubj) produce_20\VBP (l_dobj) symptoms_24\NNS (l_amod) like_23\JJ (l_npadvmod) schizophrenic_21\JJ
D016202_D012559 NONE NMDA_41\NNP (r_compound) receptor_42\NN (r_pobj) via_39\IN (r_prep) dysfunctioning_34\NN (r_pobj) of_32\IN (r_prep) idea_31\NN (r_pobj) to_29\IN (r_prep) led_28\VBN (l_nsubj) observation_3\NN (l_relcl) produce_20\VBP (l_dobj) symptoms_24\NNS (l_amod) like_23\JJ (l_npadvmod) schizophrenic_21\JJ
D004298_D006948 NONE dopamine_15\NN (r_compound) transporter_16\NN (r_pobj) in_14\IN (r_prep) observed_13\VBN (r_conj) failed_4\VBD (l_xcomp) affect_6\VB (l_dobj) hyperactivity_7\NN
D000661_D006948 CID amphetamine_30\NN (r_appos) challenge_26\NN (r_dobj) involving_23\VBG (r_prep) properties_10\NNS (r_dobj) investigating_4\VBG (l_prep) with_14\IN (l_pobj) focus_17\NN (l_prep) on_18\IN (l_pobj) models_19\NNS (l_prep) of_20\IN (l_pobj) hyperactivity_21\NN
D000661_D006948 CID amphetamine_10\NN (r_pobj) by_9\IN (r_agent) induced_8\VBN (r_acl) hyperactivity_7\NN
D003024_D006948 NONE clozapine_12\NN (r_nmod) antipsychotics_16\NNS (r_nsubj) were_17\VBD (l_acomp) effective_18\JJ (l_prep) in_19\IN (l_pobj) models_22\NNS (l_prep) of_23\IN (l_pobj) hyperactivity_24\NN
D016291_D006948 CID MK-801_32\NNP (r_punct) )_33\-RRB- (r_punct) amphetamine_30\NN (r_appos) challenge_26\NN (r_dobj) involving_23\VBG (r_prep) properties_10\NNS (r_dobj) investigating_4\VBG (l_prep) with_14\IN (l_pobj) focus_17\NN (l_prep) on_18\IN (l_pobj) models_19\NNS (l_prep) of_20\IN (l_pobj) hyperactivity_21\NN
D016291_D006948 CID MK-801_23\NNP (r_punct) and_24\CC (r_cc) showed_1\VBD (l_dobj) that_2\IN (l_punct) hyperactivity_12\NN
D016291_D006948 CID MK-801_23\NNP (r_punct) and_24\CC (r_cc) showed_1\VBD (l_conj) reversed_26\VBD (l_dobj) hyperactivity_28\NN
C094645_D006948 NONE aripiprazole_14\NN (r_conj) clozapine_12\NN (r_nmod) antipsychotics_16\NNS (r_nsubj) were_17\VBD (l_acomp) effective_18\JJ (l_prep) in_19\IN (l_pobj) models_22\NNS (l_prep) of_23\IN (l_pobj) hyperactivity_24\NN
D004298_D012559 NONE dopamine_8\NN (r_compound) neurotransmission_9\NN (r_pobj) in_7\IN (r_prep) dysfunction_6\NN (r_pobj) with_5\IN (r_prep) associated_4\VBN (l_nsubjpass) Schizophrenia_0\NNP
D018698_D012559 NONE glutamate_8\NN (r_nmod) receptor_19\NN (r_pobj) of_6\IN (r_prep) antagonists_5\NNS (r_nsubj) produce_20\VBP (l_dobj) symptoms_24\NNS (l_amod) like_23\JJ (l_npadvmod) schizophrenic_21\JJ
D016202_D006948 NONE NMDA_40\NNP (r_compound) Nr1(neo-/-_41\NNP (r_appos) mice_36\NNS (r_conj) challenge_26\NN (r_dobj) involving_23\VBG (r_prep) properties_10\NNS (r_dobj) investigating_4\VBG (l_prep) with_14\IN (l_pobj) focus_17\NN (l_prep) on_18\IN (l_pobj) models_19\NNS (l_prep) of_20\IN (l_pobj) hyperactivity_21\NN
D016202_D006948 NONE NMDA_19\NNP (r_compound) antagonist_21\NN (r_pobj) by_14\IN (r_agent) induced_13\VBN (r_acl) hyperactivity_12\NN
D016202_D006948 NONE NMDA_19\NNP (r_compound) antagonist_21\NN (r_pobj) by_14\IN (r_agent) induced_13\VBN (r_acl) hyperactivity_12\NN (r_punct) that_2\IN (r_dobj) showed_1\VBD (l_conj) reversed_26\VBD (l_dobj) hyperactivity_28\NN
D016202_D006948 NONE NMDA_30\NNP (r_nmod) mice_33\NNS (r_pobj) of_29\IN (r_prep) hyperactivity_28\NN (r_dobj) reversed_26\VBD (r_conj) showed_1\VBD (l_dobj) that_2\IN (l_punct) hyperactivity_12\NN
D016202_D006948 NONE NMDA_30\NNP (r_nmod) mice_33\NNS (r_pobj) of_29\IN (r_prep) hyperactivity_28\NN
C076029_D006948 NONE olanzapine_10\NN (r_nmod) clozapine_12\NN (r_nmod) antipsychotics_16\NNS (r_nsubj) were_17\VBD (l_acomp) effective_18\JJ (l_prep) in_19\IN (l_pobj) models_22\NNS (l_prep) of_23\IN (l_pobj) hyperactivity_24\NN
8170551
D000086_D053040 NONE Acetazolamide_0\RB (r_npadvmod) induced_2\VBN (r_amod) nephrolithiasis_3\NN
D000086_D053040 NONE acetazolamide_5\NN (r_pobj) of_4\IN (r_prep) complication_3\NN (r_attr) is_1\VBZ (l_nsubj) Nephrolithiasis_0\NNP
D000086_D007669 CID acetazolamide_3\NN (r_pobj) on_2\IN (r_prep) patients_1\NNS (r_nsubj) developed_8\VBN (l_dobj) calculi_10\NNS
D000086_D009468 NONE Acetazolamide_0\RB (r_npadvmod) induced_2\VBN (r_amod) nephrolithiasis_3\NN (l_appos) implications_5\NNS (l_prep) for_6\IN (l_pobj) treatment_7\NN (l_prep) of_8\IN (l_pobj) disorders_10\NNS
10342929
D000806_D000799 CID inhibitors_4\NNS (r_pobj) to_2\IN (r_pcomp) due_1\IN (r_prep) Angioedema_0\NNP
D000806_D000799 CID inhibitor_13\NN (r_compound) treatment_14\NN (r_nsubj) is_15\VBZ (l_nsubj) incidence_2\NN (l_prep) of_3\IN (l_pobj) angioedema_4\NN
15275829
D009538_D012640 CID nicotine_11\NN (r_npadvmod) induced_13\VBN (r_amod) seizures_14\NNS
D009538_D012640 CID nicotine_2\NN (r_pobj) of_1\IN (r_prep) Binding_0\NN (r_nsubj) elicits_10\VBZ (l_dobj) series_12\NN (l_prep) of_13\IN (l_pobj) behaviors_17\NNS (l_relcl) go_19\VBP (l_prep) to_29\IN (l_pobj) seizures_30\NNS
D009538_D012640 CID nicotine_9\NN (r_npadvmod) induced_11\VBN (r_amod) seizures_12\NNS
D009538_D012640 CID nicotine_10\NN (r_pobj) of_9\IN (r_prep) effects_8\NNS (r_pobj) to_6\IN (r_prep) sensitive_5\JJ (r_acomp) were_3\VBD (l_advcl) measured_16\VBN (l_conj) measured_30\VBN (l_prep) as_31\IN (l_pobj) sensitivity_32\NN (l_prep) to_33\IN (l_pobj) seizures_37\NNS
D009538_D012640 CID nicotine_34\NN (r_npadvmod) induced_36\VBN (r_amod) seizures_37\NNS
D009538_D012640 CID nicotine_7\NN (r_npadvmod) induced_9\VBN (r_amod) seizures_10\NNS
D009538_D012640 CID nicotine_15\NN (r_npadvmod) induced_17\VBN (r_amod) seizures_18\NNS
D009538_D014202 NONE nicotine_2\NN (r_pobj) of_1\IN (r_prep) Binding_0\NN (r_nsubj) elicits_10\VBZ (l_dobj) series_12\NN (l_prep) of_13\IN (l_pobj) behaviors_17\NNS (l_relcl) go_19\VBP (l_prep) from_20\IN (l_pobj) exploration_22\NN (l_conj) sedation_24\NN (l_conj) tremors_27\NNS
D000109_D006948 NONE acetylcholine_5\NN (r_compound) subunits_7\NNS (r_nsubj) are_8\VBP (l_prep) for_10\IN (l_pobj) seizures_14\NNS (l_conj) hypolocomotion_16\NN
D009538_D006948 NONE nicotine_11\NN (r_npadvmod) induced_13\VBN (r_amod) seizures_14\NNS (l_conj) hypolocomotion_16\NN
D009538_D006948 NONE nicotine_9\NN (r_npadvmod) induced_11\VBN (r_amod) seizures_12\NNS (r_pobj) in_8\IN (r_prep) subunits_7\NNS (l_conj) hypolocomotion_14\NN
D009538_D006948 NONE nicotine_15\NN (r_npadvmod) induced_17\VBN (r_amod) seizures_18\NNS (l_conj) hypolocomotion_20\NN
D000109_D003643 NONE acetylcholine_5\NN (r_compound) receptors_6\NNS (r_pobj) to_3\IN (r_prep) Binding_0\NN (r_nsubj) elicits_10\VBZ (l_dobj) series_12\NN (l_prep) of_13\IN (l_pobj) behaviors_17\NNS (l_relcl) go_19\VBP (l_prep) to_29\IN (l_pobj) seizures_30\NNS (l_conj) death_32\NN
D000109_D012640 NONE acetylcholine_5\NN (r_compound) subunits_7\NNS (r_nsubj) are_8\VBP (l_prep) for_10\IN (l_pobj) seizures_14\NNS
D000109_D012640 NONE acetylcholine_5\NN (r_compound) receptors_6\NNS (r_pobj) to_3\IN (r_prep) Binding_0\NN (r_nsubj) elicits_10\VBZ (l_dobj) series_12\NN (l_prep) of_13\IN (l_pobj) behaviors_17\NNS (l_relcl) go_19\VBP (l_prep) to_29\IN (l_pobj) seizures_30\NNS
D000109_D014202 NONE acetylcholine_5\NN (r_compound) receptors_6\NNS (r_pobj) to_3\IN (r_prep) Binding_0\NN (r_nsubj) elicits_10\VBZ (l_dobj) series_12\NN (l_prep) of_13\IN (l_pobj) behaviors_17\NNS (l_relcl) go_19\VBP (l_prep) from_20\IN (l_pobj) exploration_22\NN (l_conj) sedation_24\NN (l_conj) tremors_27\NNS
D009538_D003643 NONE nicotine_2\NN (r_pobj) of_1\IN (r_prep) Binding_0\NN (r_nsubj) elicits_10\VBZ (l_dobj) series_12\NN (l_prep) of_13\IN (l_pobj) behaviors_17\NNS (l_relcl) go_19\VBP (l_prep) to_29\IN (l_pobj) seizures_30\NNS (l_conj) death_32\NN
9812111
D006220_D011595 NONE haloperidol_12\NN (r_appos) A_7\NNP (r_dobj) completed_5\VBD (r_relcl) patients_3\NNS (r_pobj) For_0\IN (r_prep) was_13\VBD (l_acomp) efficacious_14\JJ (l_prep) to_17\IN (l_pobj) haloperidol_22\NN (l_prep) for_25\IN (l_pobj) scores_26\NNS (l_prep) on_27\IN (l_conj) on_36\IN (l_pobj) agitation_38\NN
D006220_D011595 NONE haloperidol_22\NN (l_prep) for_25\IN (l_pobj) scores_26\NNS (l_prep) on_27\IN (l_conj) on_36\IN (l_pobj) agitation_38\NN
D006220_D000544 NONE haloperidol_11\NN (l_prep) for_12\IN (l_pobj) psychosis_13\NN (l_prep) in_17\IN (l_pobj) disease_20\NN
D006220_D000544 NONE haloperidol_17\NN (r_pobj) of_16\IN (r_prep) doses_15\NNS (r_pobj) of_13\IN (r_prep) efficacy_9\NN (r_dobj) compare_7\VB (l_prep) in_20\IN (l_pobj) treatment_22\NN (l_prep) in_28\IN (l_pobj) patients_29\NNS (l_prep) with_30\IN (l_pobj) disease_33\NN
D006220_D000544 NONE haloperidol_20\NN (r_appos) phase_16\NN (r_preconj) In_0\IN (r_prep) compared_48\VBN (l_prep) in_49\IN (l_pobj) outpatients_51\NNS (l_prep) with_52\IN (l_pobj) disease_55\NN
D006220_D000544 NONE haloperidol_34\NN (r_conj) phase_16\NN (r_preconj) In_0\IN (r_prep) compared_48\VBN (l_prep) in_49\IN (l_pobj) outpatients_51\NNS (l_prep) with_52\IN (l_pobj) disease_55\NN
D006220_D000544 NONE haloperidol_6\NN (r_pobj) with_5\IN (r_prep) observed_4\VBN (r_nsubj) apply_9\VB (l_prep) to_10\IN (l_pobj) neuroleptics_12\NNS (l_acl) used_13\VBN (l_prep) in_14\IN (l_pobj) patients_18\NNS (l_compound) disease_17\NN
D006220_D019958 NONE haloperidol_11\NN (l_prep) for_12\IN (l_pobj) psychosis_13\NN (l_conj) behaviors_16\NNS
D006220_D019958 NONE haloperidol_17\NN (r_pobj) of_16\IN (r_prep) doses_15\NNS (r_pobj) of_13\IN (r_prep) efficacy_9\NN (r_dobj) compare_7\VB (l_prep) in_20\IN (l_pobj) treatment_22\NN (l_prep) of_23\IN (l_pobj) psychosis_24\NN (l_conj) behaviors_27\NNS
D006220_D019958 NONE haloperidol_6\NN (r_pobj) with_5\IN (r_prep) observed_4\VBN (r_nsubj) apply_9\VB (l_prep) to_10\IN (l_pobj) neuroleptics_12\NNS (l_acl) used_13\VBN (l_prep) in_14\IN (l_pobj) patients_18\NNS (l_prep) with_19\IN (l_pobj) psychosis_20\NN (l_conj) behaviors_23\NNS
D006220_D011618 NONE haloperidol_11\NN (l_prep) for_12\IN (l_pobj) psychosis_13\NN
D006220_D011618 NONE haloperidol_17\NN (r_pobj) of_16\IN (r_prep) doses_15\NNS (r_pobj) of_13\IN (r_prep) efficacy_9\NN (r_dobj) compare_7\VB (l_prep) in_20\IN (l_pobj) treatment_22\NN (l_prep) of_23\IN (l_pobj) psychosis_24\NN
D006220_D011618 NONE haloperidol_12\NN (r_appos) A_7\NNP (r_dobj) completed_5\VBD (r_relcl) patients_3\NNS (r_pobj) For_0\IN (r_prep) was_13\VBD (l_acomp) efficacious_14\JJ (l_prep) to_17\IN (l_pobj) haloperidol_22\NN (l_prep) for_25\IN (l_pobj) scores_26\NNS (l_prep) on_27\IN (l_pobj) factor_34\NN (l_compound) psychosis_33\NN
D006220_D011618 NONE haloperidol_22\NN (l_prep) for_25\IN (l_pobj) scores_26\NNS (l_prep) on_27\IN (l_pobj) factor_34\NN (l_compound) psychosis_33\NN
D006220_D011618 NONE haloperidol_6\NN (r_pobj) with_5\IN (r_prep) observed_4\VBN (r_nsubj) apply_9\VB (l_prep) to_10\IN (l_pobj) neuroleptics_12\NNS (l_acl) used_13\VBN (l_prep) in_14\IN (l_pobj) patients_18\NNS (l_prep) with_19\IN (l_pobj) psychosis_20\NN
D006220_D001480 CID haloperidol_8\NN (r_pobj) for_7\IN (r_prep) profile_6\NN (r_dobj) indicated_2\VBD (l_advcl) developed_22\VBD (l_acomp) moderate_23\JJ (l_prep) to_24\TO (l_pobj) signs_27\NNS
9351491
D018967_D010302 CID risperidone_10\NN (r_pobj) with_9\IN (r_prep) treated_8\VBN (r_acl) subjects_7\NNS (r_pobj) in_6\IN (r_prep) observed_5\VBN (l_nsubjpass) parkinsonism_3\NN
D006220_D010302 CID haloperidol_16\NN (r_conj) risperidone_10\NN (r_pobj) with_9\IN (r_prep) treated_8\VBN (r_acl) subjects_7\NNS (r_pobj) in_6\IN (r_prep) observed_5\VBN (l_nsubjpass) parkinsonism_3\NN
D018967_D011618 NONE risperidone_6\NN (r_poss) profile_9\NN (r_nsubj) produce_11\VB (l_dobj) efficacy_13\NN (l_prep) for_14\IN (l_pobj) symptoms_17\NNS
8829025
D016559_D007674 NONE tacrolimus_12\NN (r_pobj) with_11\IN (r_prep) associated_10\VBN (r_acl) nephrotoxicity_9\NN
D009543_D006973 NONE nifedipine_23\NN (r_dobj) receiving_22\VBG (r_relcl) patients_19\NNS (l_amod) hypertensive_18\JJ
D009543_D006973 NONE nifedipine_33\NN (r_dobj) receiving_32\VBG (r_acl) patients_30\NNS (r_dobj) comprising_28\VBG (r_acl) other_27\JJ (r_conj) group_16\NN (l_acl) comprising_17\VBG (l_dobj) patients_19\NNS (l_amod) hypertensive_18\JJ
D009543_D006973 NONE nifedipine_5\NN (r_pobj) of_4\IN (r_prep) impact_3\NN (r_nsubj) be_18\VB (l_attr) factor_21\NN (l_prep) in_22\IN (l_pcomp) selecting_23\VBG (l_xcomp) treat_27\VB (l_dobj) hypertension_28\NN
D009543_D007674 NONE nifedipine_5\NN (r_pobj) of_4\IN (r_prep) impact_3\NN (l_prep) on_6\IN (l_pcomp) reducing_7\VBG (l_dobj) nephrotoxicity_9\NN
D016559_D006973 CID tacrolimus_5\NNS (r_dobj) receiving_4\VBG (r_acl) patients_3\NNS (r_pobj) of_2\IN (r_prep) groups_1\NNS (r_nsubjpass) compared_7\VBN (l_appos) group_16\NN (l_acl) comprising_17\VBG (l_dobj) patients_19\NNS (l_amod) hypertensive_18\JJ
D016559_D006973 CID tacrolimus_12\NN (r_pobj) with_11\IN (r_prep) associated_10\VBN (r_acl) nephrotoxicity_9\NN (r_dobj) reducing_7\VBG (r_pcomp) on_6\IN (r_prep) impact_3\NN (r_nsubj) be_18\VB (l_attr) factor_21\NN (l_prep) in_22\IN (l_pcomp) selecting_23\VBG (l_xcomp) treat_27\VB (l_dobj) hypertension_28\NN
2670794
D002216_D011665 NONE Captopril_9\NNP (r_appos) enzyme_7\NN (r_dobj) converting_6\VBG (l_prep) on_11\IN (l_pobj) insufficiency_15\NN
D002216_D011665 NONE Captopril_2\NNP (r_pobj) of_1\IN (r_prep) Injection_0\NN (r_nsubj) reduced_18\VBD (l_dobj) insufficiency_23\NN
D014148_D004211 CID acid_14\NN (r_conj) thrombin_11\NN (r_pobj) of_10\IN (r_prep) injection_9\NN (r_pobj) by_8\IN (r_prep) Induction_0\NN (l_prep) of_1\IN (l_pobj) coagulation_3\NN
D014148_D004211 CID AMCA_16\NNP (r_appos) acid_14\NN (r_conj) thrombin_11\NN (r_pobj) of_10\IN (r_prep) injection_9\NN (r_pobj) by_8\IN (r_prep) Induction_0\NN (l_prep) of_1\IN (l_pobj) coagulation_3\NN
D000809_D051437 NONE angiotensin_5\NN (l_acl) converting_6\VBG (l_prep) on_11\IN (l_pobj) insufficiency_15\NN
D000809_D051437 NONE angiotensin_11\NN (r_pobj) of_10\IN (r_prep) inhibitor_9\NN (r_appos) Injection_0\NN (r_nsubj) reduced_18\VBD (l_dobj) insufficiency_23\NN
D002216_D007674 NONE Captopril_17\NNP (r_pobj) by_16\IN (r_agent) prevented_15\VBN (l_nsubjpass) damage_1\NN
D002216_D007674 NONE Captopril_0\NNP (r_nsubj) reduce_8\VB (l_advcl) diminishing_26\VBG (l_prep) with_36\IN (l_pobj) result_38\NN (l_acl) deposited_44\VBN (l_conj) produced_52\VBN (l_nsubjpass) damage_49\NN
D002216_D051437 NONE Captopril_9\NNP (r_appos) enzyme_7\NN (r_dobj) converting_6\VBG (l_prep) on_11\IN (l_pobj) insufficiency_15\NN
D002216_D051437 NONE Captopril_2\NNP (r_pobj) of_1\IN (r_prep) Injection_0\NN (r_nsubj) reduced_18\VBD (l_dobj) insufficiency_23\NN
D002216_D004211 NONE Captopril_9\NNP (r_appos) enzyme_7\NN (r_dobj) converting_6\VBG (r_acl) angiotensin_5\NN (r_pobj) of_4\IN (r_prep) inhibitor_3\NN (r_pobj) of_1\IN (r_prep) Effects_0\NNS (l_amod) due_16\IN (l_pobj) coagulation_19\NN
D014148_D051437 NONE acid_14\NN (r_conj) thrombin_11\NN (r_pobj) of_10\IN (r_prep) injection_9\NN (r_pobj) by_8\IN (r_prep) Induction_0\NN (r_nsubj) gives_21\VBZ (l_dobj) rise_22\NN (l_prep) to_23\IN (l_pobj) insufficiency_27\NN
D014148_D051437 NONE AMCA_16\NNP (r_appos) acid_14\NN (r_conj) thrombin_11\NN (r_pobj) of_10\IN (r_prep) injection_9\NN (r_pobj) by_8\IN (r_prep) Induction_0\NN (r_nsubj) gives_21\VBZ (l_dobj) rise_22\NN (l_prep) to_23\IN (l_pobj) insufficiency_27\NN
D000809_D004211 NONE angiotensin_5\NN (r_pobj) of_4\IN (r_prep) inhibitor_3\NN (r_pobj) of_1\IN (r_prep) Effects_0\NNS (l_amod) due_16\IN (l_pobj) coagulation_19\NN
D014508_D007674 NONE urea_9\NN (r_pobj) in_7\IN (r_prep) increase_6\NN (r_pobj) by_4\IN (r_agent) reflected_3\VBN (r_advcl) damage_1\NN
D014148_D014947 NONE acid_14\NN (r_conj) thrombin_11\NN (r_pobj) of_10\IN (r_prep) injection_9\NN (r_pobj) by_8\IN (r_prep) Induction_0\NN (r_nsubj) gives_21\VBZ (l_advcl) resembling_28\VBG (l_ccomp) occurring_30\VBG (l_prep) after_31\IN (l_pobj) trauma_32\NN
D014148_D014947 NONE AMCA_16\NNP (r_appos) acid_14\NN (r_conj) thrombin_11\NN (r_pobj) of_10\IN (r_prep) injection_9\NN (r_pobj) by_8\IN (r_prep) Induction_0\NN (r_nsubj) gives_21\VBZ (l_advcl) resembling_28\VBG (l_ccomp) occurring_30\VBG (l_prep) after_31\IN (l_pobj) trauma_32\NN
D000809_D011665 NONE angiotensin_5\NN (l_acl) converting_6\VBG (l_prep) on_11\IN (l_pobj) insufficiency_15\NN
D000809_D011665 NONE angiotensin_11\NN (r_pobj) of_10\IN (r_prep) inhibitor_9\NN (r_appos) Injection_0\NN (r_nsubj) reduced_18\VBD (l_dobj) insufficiency_23\NN
D014148_D018805 NONE acid_14\NN (r_conj) thrombin_11\NN (r_pobj) of_10\IN (r_prep) injection_9\NN (r_pobj) by_8\IN (r_prep) Induction_0\NN (r_nsubj) gives_21\VBZ (l_advcl) resembling_28\VBG (l_ccomp) occurring_30\VBG (l_prep) after_31\IN (l_pobj) trauma_32\NN (l_conj) sepsis_34\NN
D014148_D018805 NONE AMCA_16\NNP (r_appos) acid_14\NN (r_conj) thrombin_11\NN (r_pobj) of_10\IN (r_prep) injection_9\NN (r_pobj) by_8\IN (r_prep) Induction_0\NN (r_nsubj) gives_21\VBZ (l_advcl) resembling_28\VBG (l_ccomp) occurring_30\VBG (l_prep) after_31\IN (l_pobj) trauma_32\NN (l_conj) sepsis_34\NN
D014148_D011665 NONE acid_14\NN (r_conj) thrombin_11\NN (r_pobj) of_10\IN (r_prep) injection_9\NN (r_pobj) by_8\IN (r_prep) Induction_0\NN (r_nsubj) gives_21\VBZ (l_dobj) rise_22\NN (l_prep) to_23\IN (l_pobj) insufficiency_27\NN
D014148_D011665 NONE AMCA_16\NNP (r_appos) acid_14\NN (r_conj) thrombin_11\NN (r_pobj) of_10\IN (r_prep) injection_9\NN (r_pobj) by_8\IN (r_prep) Induction_0\NN (r_nsubj) gives_21\VBZ (l_dobj) rise_22\NN (l_prep) to_23\IN (l_pobj) insufficiency_27\NN
1728522
D019980_D056486 CID acid_9\NN (r_pobj) of_5\IN (r_prep) combination_4\NN (r_pobj) due_2\JJ (r_prep) hepatitis_1\NN
D019980_D056486 CID acid_11\NN (r_npadvmod) induced_13\VBN (r_amod) hepatitis_14\NN
D019980_D006099 CID acid_9\NN (r_pobj) of_5\IN (r_prep) combination_4\NN (r_pobj) due_2\JJ (r_prep) hepatitis_1\NN
D019980_D006099 CID acid_11\NN (r_npadvmod) induced_13\VBN (r_amod) hepatitis_14\NN (r_pobj) with_7\IN (r_prep) patient_6\NN (r_pobj) of_4\IN (r_prep) case_3\NN (l_prep) with_15\IN (l_pobj) granulomas_18\NNS
7890216
D014580_D042882 NONE acid_13\NN (r_pobj) to_10\IN (r_prep) response_9\NN (r_appos) Composition_0\NN (l_prep) of_1\IN (l_pobj) stones_4\NNS
D015282_D000172 NONE Octreotide_0\NNP (l_appos) treatment_4\NN (l_prep) for_5\IN (l_pobj) acromegaly_6\NNS
D015282_D000172 NONE octreotide_28\NN (r_pobj) in_26\IN (r_prep) methods_25\NNS (r_pobj) by_21\IN (r_agent) investigated_20\VBN (l_conj) treated_29\VBD (l_dobj) patients_31\NNS (l_compound) acromegalic_30\JJ
D002118_D042882 NONE calcium_41\NN (r_dobj) containing_40\VBG (r_acl) stones_39\NNS (r_conj) duct_35\NN (r_dobj) have_31\VB (r_conj) induced_4\VBN (l_dobj) stones_6\NNS
D002118_D042882 NONE calcium_41\NN (r_dobj) containing_40\VBG (r_acl) stones_39\NNS (r_conj) duct_35\NN (r_dobj) have_31\VB (r_conj) induced_4\VBN (l_ccomp) are_7\VBP (l_prep) in_18\IN (l_pobj) common_19\JJ (l_prep) with_20\IN (l_pobj) disease_24\NN
D002118_D042882 NONE calcium_41\NN (r_dobj) containing_40\VBG (r_acl) stones_39\NNS
D015282_D042882 CID octreotide_7\NN (r_pobj) with_6\IN (r_prep) associated_5\VBN (r_acl) stones_4\NNS
D015282_D042882 CID Octreotide_0\NNP (r_nsubj) induces_8\VBZ (l_dobj) stones_11\NNS
D015282_D042882 CID octreotide_28\NN (r_pobj) in_26\IN (r_prep) methods_25\NNS (r_pobj) by_21\IN (r_agent) investigated_20\VBN (l_conj) treated_29\VBD (l_prep) with_32\IN (l_pobj) stones_34\NNS
D015282_D042882 CID octreotide_3\NN (r_advmod) induced_4\VBN (l_dobj) stones_6\NNS
D015282_D042882 CID octreotide_3\NN (r_advmod) induced_4\VBN (l_ccomp) are_7\VBP (l_prep) in_18\IN (l_pobj) common_19\JJ (l_prep) with_20\IN (l_pobj) disease_24\NN
D015282_D042882 CID octreotide_3\NN (r_advmod) induced_4\VBN (l_conj) have_31\VB (l_dobj) duct_35\NN (l_conj) stones_39\NNS
D002784_D042882 NONE cholesterol_21\NN (r_conj) %_17\NN (r_dobj) contained_15\VBD (r_ccomp) showed_12\VBD (l_nsubj) analysis_1\NN (l_prep) of_2\IN (l_pobj) stones_4\NNS
D002784_D042882 NONE cholesterol_36\NN (r_nsubj) rich_37\JJ (r_acomp) were_35\VBD (r_ccomp) suggesting_31\VBG (r_advcl) showed_12\VBD (l_dobj) dissolution_29\NN (l_compound) stone_28\NN
D002784_D042882 NONE cholesterol_14\NN (r_conj) multiple_11\JJ (r_conj) small_9\JJ (r_acomp) are_7\VBP (r_ccomp) induced_4\VBN (l_dobj) stones_6\NNS
D002784_D042882 NONE cholesterol_14\NN (r_conj) multiple_11\JJ (r_conj) small_9\JJ (r_acomp) are_7\VBP (l_prep) in_18\IN (l_pobj) common_19\JJ (l_prep) with_20\IN (l_pobj) disease_24\NN
D002784_D042882 NONE cholesterol_14\NN (r_conj) multiple_11\JJ (r_conj) small_9\JJ (r_acomp) are_7\VBP (r_ccomp) induced_4\VBN (l_conj) have_31\VB (l_dobj) duct_35\NN (l_conj) stones_39\NNS
9390208
D002955_D064420 NONE leucovorin_19\NN (r_conj) 5-FU_17\CD (l_conj) benefit_26\NN (l_conj) toxicity_32\NN
D005472_D001943 NONE 5-FU_17\CD (r_pobj) of_13\IN (r_prep) infusion_12\NN (r_conj) Treatment_0\NN (l_prep) of_1\IN (l_pobj) cancer_6\NN
D005472_D001943 NONE 5-FU_34\CD (r_pobj) of_33\IN (r_prep) infusion_32\NN (r_conj) day_28\NN (r_pobj) on_27\IN (r_prep) treated_8\VBD (l_dobj) patients_10\NNS (l_prep) with_11\IN (l_pobj) cancer_18\NN
D002955_D001943 NONE leucovorin_19\NN (r_conj) 5-FU_17\CD (r_pobj) of_13\IN (r_prep) infusion_12\NN (r_conj) Treatment_0\NN (l_prep) of_1\IN (l_pobj) cancer_6\NN
D002955_D001943 NONE leucovorin_43\NN (r_pobj) with_42\IN (r_prep) treated_8\VBD (l_dobj) patients_10\NNS (l_prep) with_11\IN (l_pobj) cancer_18\NN
D008942_D064420 NONE mitoxantrone_8\NN (r_pobj) by_7\IN (r_prep) cancer_6\NN (r_pobj) of_1\IN (r_prep) Treatment_0\NN (l_conj) infusion_12\NN (l_prep) of_13\IN (l_pobj) 5-FU_17\CD (l_conj) benefit_26\NN (l_conj) toxicity_32\NN
C085788_D064420 NONE MFL_21\NNP (r_appos) 5-FU_17\CD (l_conj) benefit_26\NN (l_conj) toxicity_32\NN
C085788_D064420 NONE regimen_2\NN (r_nsubj) achieves_3\VBZ (l_conj) induces_8\VBZ (l_dobj) toxicity_10\NN
D008942_D001943 NONE mitoxantrone_8\NN (r_pobj) by_7\IN (r_prep) cancer_6\NN
D008942_D001943 NONE mitoxantrone_20\NN (r_pobj) by_19\IN (r_prep) treated_8\VBD (l_dobj) patients_10\NNS (l_prep) with_11\IN (l_pobj) cancer_18\NN
C085788_D001943 NONE MFL_21\NNP (r_appos) 5-FU_17\CD (r_pobj) of_13\IN (r_prep) infusion_12\NN (r_conj) Treatment_0\NN (l_prep) of_1\IN (l_pobj) cancer_6\NN
D005472_D064420 NONE 5-FU_17\CD (l_conj) benefit_26\NN (l_conj) toxicity_32\NN
7088431
D004054_D014625 CID diethylstilbestrol_21\NN (r_pobj) to_20\IN (r_prep) exposed_17\VBN (r_acl) women_16\NNS (r_pobj) in_14\IN (r_prep) up_13\NN (r_pobj) at_10\IN (r_prep) detected_9\VBD (l_nsubj) cases_1\NNS (l_prep) of_2\IN (l_pobj) adenocarcinoma_5\NN (l_prep) of_6\IN (l_pobj) vagina_8\NN
D004054_D018262 CID DES_6\NNP (r_npadvmod) exposed_8\VBN (r_amod) offspring_9\NN (r_pobj) in_5\IN (r_prep) Development_0\NN (l_prep) of_1\IN (l_pobj) adenocarcinoma_4\NN
D004054_D018262 CID diethylstilbestrol_21\NN (r_pobj) to_20\IN (r_prep) exposed_17\VBN (r_acl) women_16\NNS (r_pobj) in_14\IN (r_prep) up_13\NN (r_pobj) at_10\IN (r_prep) detected_9\VBD (l_nsubj) cases_1\NNS (l_prep) of_2\IN (l_pobj) adenocarcinoma_5\NN (l_prep) of_6\IN (l_pobj) vagina_8\NN
18417364
D009538_D009759 CID Nicotine_0\NN (r_npadvmod) induced_2\VBN (r_amod) nystagmus_3\NN
D009538_D009759 CID nicotine_3\NN (r_npadvmod) induced_5\VBN (r_amod) nystagmus_6\NN
D009538_D009759 CID nicotine_3\NN (r_npadvmod) induced_5\VBN (r_amod) nystagmus_6\NN (l_appos) NIN_8\NNP
D010100_D009759 NONE oxygen_4\NN (r_nmod) levels_12\NNS (r_pobj) with_2\IN (r_prep) correlated_1\VBD (l_nsubj) NIN_0\NNP
9869257
D012601_D000647 CID scopolamine_36\NN (r_pobj) by_29\IN (r_agent) induced_28\VBN (r_acl) amnesia_27\NN
C098725_D000647 CID S-(-)-ET-126_41\NNP (r_appos) antagonist_40\NN (r_conj) scopolamine_36\NN (r_pobj) by_29\IN (r_agent) induced_28\VBN (r_acl) amnesia_27\NN
C087567_D000647 NONE PG-9_8\NNP (r_nsubj) administered_18\VBN (l_conj) prevented_26\VBN (l_dobj) amnesia_27\NN
C087567_D000647 NONE PG-9_6\NNP (r_nmod) microg_11\NN (r_nsubj) was_17\VBD (l_acomp) able_19\JJ (l_xcomp) prevent_21\VB (l_dobj) amnesia_25\NN
3015567
D009599_D007022 CID Nitroprusside_0\NNP (r_npadvmod) induced_2\VBN (r_amod) hypotension_3\NN
D009599_D007022 CID nitroprusside_7\RB (r_advmod) induced_9\VBN (r_amod) hypotension_10\NN
D003345_D007022 NONE corticosterone_18\NN (r_compound) level_19\NN (r_pobj) at_15\IN (r_prep) occurs_14\VBZ (r_conj) observed_12\VBN (l_nsubjpass) Suppression_0\NN (l_appos) secretion_3\NN (l_prep) in_4\IN (l_pobj) response_5\NN (l_prep) to_6\IN (l_pobj) hypotension_10\NN
8739323
D008466_D007674 NONE nitrogranulogen_8\NN (r_pobj) as_7\IN (r_prep) drugs_5\NNS (r_pobj) of_3\IN (r_prep) action_2\NN (l_amod) nephrotoxic_1\JJ
D008466_D007674 NONE NG_10\NNP (r_appos) nitrogranulogen_8\NN (r_pobj) as_7\IN (r_prep) drugs_5\NNS (r_pobj) of_3\IN (r_prep) action_2\NN (l_amod) nephrotoxic_1\JJ
D005472_D003556 NONE 5-FU_20\CD (r_pobj) with_19\IN (r_prep) combined_18\VBN (r_advcl) cause_14\VB (r_conj) caused_1\VBD (l_dobj) cystitis_3\NN
D008727_D007674 NONE methotrexate_13\NNP (r_conj) nitrogranulogen_8\NN (r_pobj) as_7\IN (r_prep) drugs_5\NNS (r_pobj) of_3\IN (r_prep) action_2\NN (l_amod) nephrotoxic_1\JJ
D008727_D007674 NONE MTX_15\NNP (r_appos) methotrexate_13\NNP (r_conj) nitrogranulogen_8\NN (r_pobj) as_7\IN (r_prep) drugs_5\NNS (r_pobj) of_3\IN (r_prep) action_2\NN (l_amod) nephrotoxic_1\JJ
D008727_D007674 NONE MTX_33\NNP (r_appos) action_2\NN (l_amod) nephrotoxic_1\JJ
D008727_D007674 NONE MTX_6\NNP (r_pobj) of_5\IN (r_prep) nephrotoxicity_4\NN
D003520_D006470 CID CY_0\NNP (r_nsubj) caused_1\VBD (l_dobj) cystitis_3\NN
D005472_D007674 NONE 5-fluorouracil_18\CD (r_punct) 5-FU_20\CD (r_appos) action_2\NN (l_amod) nephrotoxic_1\JJ
D005472_D007674 NONE 5-FU_20\CD (r_appos) action_2\NN (l_amod) nephrotoxic_1\JJ
D005472_D007674 NONE 5-FU_35\CD (r_conj) MTX_33\NNP (r_appos) action_2\NN (l_amod) nephrotoxic_1\JJ
D005472_D007674 NONE 5-FU_8\CD (r_nsubj) is_13\VBZ (r_ccomp) indicate_2\VBP (l_dobj) nephrotoxicity_4\NN
D003520_D007674 NONE cyclophosphamide_23\NN (r_conj) 5-FU_20\CD (r_appos) action_2\NN (l_amod) nephrotoxic_1\JJ
D003520_D007674 NONE CY_25\NNP (r_appos) cyclophosphamide_23\NN (r_conj) 5-FU_20\CD (r_appos) action_2\NN (l_amod) nephrotoxic_1\JJ
D003520_D007674 NONE CY_37\NNP (r_conj) 5-FU_35\CD (r_conj) MTX_33\NNP (r_appos) action_2\NN (l_amod) nephrotoxic_1\JJ
D003520_D007674 NONE CY_10\NNP (r_conj) 5-FU_8\CD (r_nsubj) is_13\VBZ (r_ccomp) indicate_2\VBP (l_dobj) nephrotoxicity_4\NN
D005472_D006470 NONE 5-FU_20\CD (r_pobj) with_19\IN (r_prep) combined_18\VBN (r_advcl) cause_14\VB (r_conj) caused_1\VBD (l_dobj) cystitis_3\NN
D003520_D003556 CID CY_0\NNP (r_nsubj) caused_1\VBD (l_dobj) cystitis_3\NN
D008727_D006470 NONE MTX_22\NNP (r_conj) 5-FU_20\CD (r_pobj) with_19\IN (r_prep) combined_18\VBN (r_advcl) cause_14\VB (r_conj) caused_1\VBD (l_dobj) cystitis_3\NN
D008727_D003556 NONE MTX_22\NNP (r_conj) 5-FU_20\CD (r_pobj) with_19\IN (r_prep) combined_18\VBN (r_advcl) cause_14\VB (r_conj) caused_1\VBD (l_dobj) cystitis_3\NN
20880751
D018698_D004409 NONE glutamate_28\NN (r_compound) receptors_29\NNS (l_conj) systems_36\NNS (l_prep) in_37\IN (l_pobj) pathophysiology_39\NN (l_prep) of_40\IN (l_pobj) dyskinesias_44\NNS
D004298_D004409 NONE dopamine_9\NN (r_compound) precursor_10\NN (r_pobj) of_7\IN (r_prep) use_6\NN (r_nsubjpass) complicated_12\VBN (l_agent) by_13\IN (l_pobj) fluctuations_16\NNS (l_conj) dyskinesias_18\NNS
D004298_D004409 NONE dopamine_21\NN (r_compound) subtypes_23\NNS (l_conj) receptors_29\NNS (l_conj) systems_36\NNS (l_prep) in_37\IN (l_pobj) pathophysiology_39\NN (l_prep) of_40\IN (l_pobj) dyskinesias_44\NNS
D007980_D004409 CID Levodopa_0\NNP (r_npadvmod) induced_2\VBN (l_dobj) dyskinesias_3\NNS
D007980_D004409 CID levodopa_17\NN (r_npadvmod) induced_19\VBN (r_amod) dyskinesias_20\NNS
D007980_D004409 CID levodopa_41\NN (r_npadvmod) induced_43\VBN (r_amod) dyskinesias_44\NNS
D007980_D010300 NONE Levodopa_0\NNP (r_npadvmod) induced_2\VBN (l_dobj) dyskinesias_3\NNS (l_prep) in_4\IN (l_pobj) patients_5\NNS (l_prep) with_6\IN (l_pobj) disease_9\NN
D007980_D010300 NONE Levodopa_0\NNP (r_nsubj) is_1\VBZ (l_attr) drug_5\NN (l_prep) for_6\IN (l_pobj) treatment_8\NN (l_prep) of_9\IN (l_pobj) disease_12\NN
20098969
D008694_D006212 NONE Methamphetamine_0\NN (r_nsubj) is_1\VBZ (l_attr) stimulant_7\NN (l_relcl) increases_9\VBZ (l_conj) produce_16\VB (l_dobj) effects_18\NNS (l_prep) as_20\IN (l_pobj) dysrhythmias_22\NNS (l_conj) hypertension_24\NN (l_conj) hallucinations_26\NNS
D008694_D001523 NONE Methamphetamine_0\NN (r_nsubj) is_1\VBZ (l_attr) stimulant_7\NN (l_relcl) increases_9\VBZ (l_conj) produce_16\VB (l_dobj) effects_18\NNS (l_prep) as_20\IN (l_pobj) dysrhythmias_22\NNS (l_conj) hypertension_24\NN (l_conj) hallucinations_26\NNS (l_conj) behavior_30\NN
D008694_-1 NONE methamphetamine_3\NN (r_dobj) abusing_2\VBG (r_acl) patients_1\NNS (r_nsubj) present_5\VB (l_prep) with_6\IN (l_pobj) hygiene_9\NN (l_conj) xerostomia_11\NN (l_conj) caries_14\NNS (l_appos) mouth_18\NN
D008694_-1 NONE methamphetamines_23\NNS (r_dobj) abusing_22\VBG (r_relcl) patients_18\NNS (r_dobj) manage_17\VBP (r_conj) recognize_15\VBP (r_ccomp) help_12\VB (r_advcl) presented_10\VBN (l_nsubjpass) case_2\NN (l_acl) showing_3\VBG (l_dobj) manifestations_5\NNS (l_prep) of_6\IN (l_pobj) mouth_8\NN
D008694_D003731 CID methamphetamine_3\NN (r_dobj) abusing_2\VBG (r_acl) patients_1\NNS (r_nsubj) present_5\VB (l_prep) with_6\IN (l_pobj) hygiene_9\NN (l_conj) xerostomia_11\NN (l_conj) caries_14\NNS
D008694_D003731 CID methamphetamine_5\NN (r_pobj) of_4\IN (r_prep) use_3\NN (r_dobj) reported_1\VBD (l_conj) experienced_12\VBN (l_dobj) episodes_16\NNS
D008694_D001145 NONE Methamphetamine_0\NN (r_nsubj) is_1\VBZ (l_attr) stimulant_7\NN (l_relcl) increases_9\VBZ (l_conj) produce_16\VB (l_dobj) effects_18\NNS (l_prep) as_20\IN (l_pobj) dysrhythmias_22\NNS
D008694_D006973 NONE Methamphetamine_0\NN (r_nsubj) is_1\VBZ (l_attr) stimulant_7\NN (l_relcl) increases_9\VBZ (l_conj) produce_16\VB (l_dobj) effects_18\NNS (l_prep) as_20\IN (l_pobj) dysrhythmias_22\NNS (l_conj) hypertension_24\NN
D008694_D014987 NONE methamphetamine_3\NN (r_dobj) abusing_2\VBG (r_acl) patients_1\NNS (r_nsubj) present_5\VB (l_prep) with_6\IN (l_pobj) hygiene_9\NN (l_conj) xerostomia_11\NN
D008694_D057085 NONE methamphetamine_3\NN (r_dobj) abusing_2\VBG (r_acl) patients_1\NNS (r_nsubj) present_5\VB (l_prep) with_6\IN (l_pobj) hygiene_9\NN (l_conj) xerostomia_11\NN (l_conj) caries_14\NNS (l_conj) wear_25\NN
16428221
D008774_D019969 NONE methylphenidate_20\NN (r_compound) intake_21\NN (r_pobj) after_19\IN (r_prep) reported_18\VBN (r_conj) documented_8\VBN (l_nsubjpass) vasculitis_1\NN (l_acl) associated_2\VBN (l_prep) with_3\IN (l_pobj) abuse_5\NN
D008774_D002544 NONE methylphenidate_20\NN (r_compound) intake_21\NN (r_pobj) after_19\IN (r_prep) reported_18\VBN (l_nsubjpass) stroke_15\NN
D008774_D002544 NONE methylphenidate_14\NN (r_pobj) with_13\IN (r_prep) treated_12\VBN (l_conj) suffered_19\VBD (l_prep) from_20\IN (l_pobj) strokes_23\NNS
D008774_D020293 CID methylphenidate_4\NN (r_compound) intake_5\NN (r_dobj) following_2\VBG (r_prep) vasculitis_1\NNS
D008774_D020293 CID methylphenidate_20\NN (r_compound) intake_21\NN (r_pobj) after_19\IN (r_prep) reported_18\VBN (r_conj) documented_8\VBN (l_nsubjpass) vasculitis_1\NN
D008774_D014657 NONE methylphenidate_3\NN (l_dobj) vasculitis_5\NN
D008774_D014657 NONE methylphenidate_18\NN (r_compound) therapy_19\NN (r_pobj) of_17\IN (r_prep) history_16\NN (r_conj) symptoms_13\NNS (r_pobj) with_11\IN (r_prep) patients_10\NNS (r_pobj) in_9\IN (r_prep) considered_8\VBN (l_nsubjpass) methylphenidate_3\NN (l_dobj) vasculitis_5\NN
D008774_D006948 NONE methylphenidate_14\NN (r_pobj) with_13\IN (r_prep) treated_12\VBN (l_prep) due_15\IN (l_pobj) hyperactivity_17\NN
220563
C023470_D010523 CID maleate_1\NN (l_conj) neuropathy_4\NN
C023470_D010523 CID maleate_12\NN (r_pobj) with_10\IN (r_prep) complication_7\NN (r_pobj) as_5\IN (r_prep) noted_4\VBN (l_nsubjpass) neuropathy_1\NN
C023470_D000787 NONE maleate_12\NN (r_pobj) with_10\IN (r_prep) complication_7\NN (l_prep) for_30\IN (l_pobj) treatment_33\NN (l_prep) of_34\IN (l_pobj) pectoris_36\NN
9721172
D011241_D002779 NONE prednisone_6\NN (l_conj) tacrolimus_10\VB (l_conj) disease_14\NN
D007052_D001649 NONE ibuprofen_30\JJ (r_compound) use_31\NN (r_pobj) with_29\IN (r_prep) associated_28\VBN (l_nsubjpass) child_3\NN (l_relcl) developed_5\VBD (l_dobj) syndrome_15\NN
D016559_D002779 NONE tacrolimus_10\VB (l_conj) disease_14\NN
D011241_D005355 NONE prednisone_6\NN (r_conj) acid_4\NN (r_pobj) with_2\IN (r_prep) therapy_1\NN (r_pobj) Despite_0\IN (r_prep) was_15\VBD (l_prep) with_18\IN (l_pobj) cirrhosis_19\NN
D014580_D005355 NONE acid_4\NN (r_pobj) with_2\IN (r_prep) therapy_1\NN (r_pobj) Despite_0\IN (r_prep) was_15\VBD (l_prep) with_18\IN (l_pobj) cirrhosis_19\NN
D007052_D013262 CID ibuprofen_30\JJ (r_compound) use_31\NN (r_pobj) with_29\IN (r_prep) associated_28\VBN (l_nsubjpass) child_3\NN (l_relcl) described_23\VBN (l_nsubjpass) syndrome_21\NN
D016559_D005355 NONE tacrolimus_10\VB (r_conj) prednisone_6\NN (r_conj) acid_4\NN (r_pobj) with_2\IN (r_prep) therapy_1\NN (r_pobj) Despite_0\IN (r_prep) was_15\VBD (l_prep) with_18\IN (l_pobj) cirrhosis_19\NN
D014580_D002779 NONE acid_4\NN (l_conj) prednisone_6\NN (l_conj) tacrolimus_10\VB (l_conj) disease_14\NN
7919560
D000667_D009205 CID ampicillin_7\NN (r_pobj) by_6\IN (r_agent) caused_5\VBN (l_nsubj) multiforme_1\NN (l_conj) myocarditis_4\NN
D000667_D009205 CID ampicillin_12\NN (r_pobj) by_11\IN (r_agent) caused_10\VBN (r_acl) case_3\NN (l_prep) of_4\IN (l_pobj) multiforme_6\NNS (l_conj) myocarditis_9\NN
D000667_D004892 CID ampicillin_7\NN (r_pobj) by_6\IN (r_agent) caused_5\VBN (l_nsubj) multiforme_1\NN
D000667_D004892 CID ampicillin_12\NN (r_pobj) by_11\IN (r_agent) caused_10\VBN (r_acl) case_3\NN (l_prep) of_4\IN (l_pobj) multiforme_6\NNS
D010406_D004342 NONE penicillins_11\NNS (r_pobj) to_10\IN (r_prep) is_2\VBZ (l_attr) manifestation_7\NN (l_prep) of_8\IN (l_pobj) allergy_9\NN
D010406_D009205 NONE penicillins_11\NNS (r_pobj) to_10\IN (r_prep) is_2\VBZ (l_nsubj) myocarditis_1\NN
D000667_D018805 NONE ampicillin_8\NN (r_pobj) with_7\IN (r_prep) treated_6\VBN (l_conj) gentamicin_10\NN (l_prep) because_11\IN (l_pobj) septicemia_14\NN
D005839_D018805 NONE gentamicin_10\NN (l_prep) because_11\IN (l_pobj) septicemia_14\NN
2425813
D011239_D009133 CID prednisolone_14\NN (r_pobj) of_13\IN (r_prep) administration_12\NN (r_pobj) following_9\VBG (r_prep) occurred_5\VBD (l_nsubj) enlargement_1\NN (l_conj) wastage_4\NN
D011239_D006529 CID prednisolone_14\NN (r_pobj) of_13\IN (r_prep) administration_12\NN (r_pobj) following_9\VBG (r_prep) occurred_5\VBD (l_nsubj) enlargement_1\NN
12695819
D016559_D009422 NONE tacrolimus_17\NNS (l_relcl) developed_19\VBD (l_dobj) complications_21\NNS
D016559_D020258 NONE tacrolimus_7\NN (r_npadvmod) induced_9\VBN (r_amod) neurotoxicity_10\NN
D016559_D020258 NONE tacrolimus_15\NN (r_npadvmod) induced_17\VBN (r_amod) neurotoxicity_18\NN
6133211
D012460_D000013 NONE sulphasalazine_15\NN (r_pobj) with_14\IN (r_prep) treatment_13\NN (r_dobj) received_12\VBD (r_relcl) disease_10\NN (r_pobj) with_7\IN (r_prep) mothers_6\NNS (r_pobj) of_4\IN (r_prep) born_3\VBN (r_acl) infants_1\NNS (r_nsubjpass) found_20\VBN (l_xcomp) have_22\VB (l_dobj) anomalies_25\NNS
D012460_D015212 NONE sulphasalazine_15\NN (r_pobj) with_14\IN (r_prep) treatment_13\NN (r_dobj) received_12\VBD (r_relcl) disease_10\NN
2355241
D007980_D002543 NONE levodopa_23\NN (r_pobj) of_22\IN (r_prep) effect_21\NN (r_dobj) reflect_18\VB (l_nsubj) incidence_2\NN (l_prep) of_3\IN (l_pobj) haemorrhage_5\NN
D009638_D003643 NONE noradrenaline_31\NN (r_amod) levels_32\NNS (r_pobj) due_28\IN (r_amod) mechanism_27\NN (r_conj) effect_21\NN (r_dobj) reflect_18\VB (l_nsubj) incidence_2\NN (l_prep) as_6\IN (l_pobj) cause_8\NN (l_prep) of_9\IN (l_pobj) death_10\NN
D007980_D007022 CID levodopa_23\NN (r_pobj) of_22\IN (r_prep) effect_21\NN (l_amod) hypotensive_20\JJ
D007980_D007022 CID levodopa_23\NN (r_pobj) of_22\IN (r_prep) effect_21\NN (l_conj) mechanism_27\NN (l_amod) hypotensive_26\JJ
D007980_D010300 NONE levodopa_23\NN (r_pobj) of_22\IN (r_prep) effect_21\NN (r_dobj) reflect_18\VB (l_nsubj) incidence_2\NN (l_prep) as_6\IN (l_pobj) cause_8\NN (l_prep) in_11\IN (l_pobj) patients_12\NNS (l_prep) with_13\IN (l_pobj) disease_16\NN
D007980_D010300 NONE levodopa_23\NN (r_pobj) of_22\IN (r_prep) effect_21\NN (l_conj) mechanism_27\NN (l_amod) due_28\IN (l_pobj) levels_32\NNS (l_prep) in_33\IN (l_pobj) brain_36\NN (l_amod) parkinsonian_35\JJ
D009638_D002543 NONE noradrenaline_31\NN (r_amod) levels_32\NNS (r_pobj) due_28\IN (r_amod) mechanism_27\NN (r_conj) effect_21\NN (r_dobj) reflect_18\VB (l_nsubj) incidence_2\NN (l_prep) of_3\IN (l_pobj) haemorrhage_5\NN
D009638_D010300 NONE noradrenaline_31\NN (r_amod) levels_32\NNS (r_pobj) due_28\IN (r_amod) mechanism_27\NN (r_conj) effect_21\NN (r_dobj) reflect_18\VB (l_nsubj) incidence_2\NN (l_prep) as_6\IN (l_pobj) cause_8\NN (l_prep) in_11\IN (l_pobj) patients_12\NNS (l_prep) with_13\IN (l_pobj) disease_16\NN
D009638_D010300 NONE noradrenaline_31\NN (r_amod) levels_32\NNS (l_prep) in_33\IN (l_pobj) brain_36\NN (l_amod) parkinsonian_35\JJ
D009638_D007022 NONE noradrenaline_31\NN (r_amod) levels_32\NNS (r_pobj) due_28\IN (r_amod) mechanism_27\NN (r_conj) effect_21\NN (l_amod) hypotensive_20\JJ
D009638_D007022 NONE noradrenaline_31\NN (r_amod) levels_32\NNS (r_pobj) due_28\IN (r_amod) mechanism_27\NN (l_amod) hypotensive_26\JJ
D007980_D003643 NONE levodopa_23\NN (r_pobj) of_22\IN (r_prep) effect_21\NN (r_dobj) reflect_18\VB (l_nsubj) incidence_2\NN (l_prep) as_6\IN (l_pobj) cause_8\NN (l_prep) of_9\IN (l_pobj) death_10\NN
17608141
D008070_D005334 NONE Lipopolysaccharide_0\JJ (r_compound) pretreatment_1\NN (r_nsubj) affect_4\VB (l_dobj) temperature_8\NN (l_conj) hyperthermia_13\NN
D008070_D020258 NONE lipopolysaccharide_11\NN (r_compound) pretreatment_12\NN (r_pobj) by_10\IN (r_prep) neurotoxicity_7\NN
D008070_D020258 NONE lipopolysaccharide_9\NN (r_pobj) of_8\IN (r_prep) roles_7\NNS (l_appos) factor_17\NN (l_conj) treatment_19\NN (l_prep) in_20\IN (l_pcomp) modulating_21\VBG (l_dobj) neurotoxicity_28\NN
D008070_D020258 NONE lipopolysaccharide_8\NN (r_compound) pretreatment_9\NN (l_prep) in_10\IN (l_pcomp) exerting_11\VBG (l_dobj) protection_13\NN (l_prep) against_14\IN (l_pobj) neurotoxicity_20\NN
D008694_D020258 NONE methamphetamine_2\NN (r_npadvmod) induced_4\VBN (l_dobj) neurotoxicity_7\NN
D008694_D020258 NONE methamphetamine_23\NN (r_npadvmod) induced_25\VBN (r_amod) neurotoxicity_28\NN
D008694_D020258 NONE methamphetamine_15\NN (r_npadvmod) induced_17\VBN (r_amod) neurotoxicity_20\NN
D004298_D020258 NONE dopamine_27\NN (r_compound) neurotoxicity_28\NN
D004298_D020258 NONE dopamine_19\NN (r_compound) neurotoxicity_20\NN
D008694_D009422 NONE methamphetamine_10\NN (r_npadvmod) induced_12\VBN (r_amod) damage_15\NN
D008694_D005334 CID methamphetamine_10\NN (r_npadvmod) elicited_12\VBN (r_amod) hyperthermia_13\NN
1130930
D002512_D007683 CID sodium_23\NN (r_pobj) of_21\IN (r_prep) combination_20\NN (r_dobj) receiving_18\VBG (r_advcl) developed_2\VBD (l_dobj) necrosis_5\NN
D005839_D007683 CID sulfate_26\NN (r_compound) therapy_27\NN (r_dobj) gentamicin_25\NN (r_conj) receiving_18\VBG (r_advcl) developed_2\VBD (l_dobj) necrosis_5\NN
D005839_D007674 NONE gentamicin_5\NN (r_compound) regimen_6\NN (r_pobj) of_1\IN (r_prep) Nephrotoxicity_0\NN
D002512_D051437 NONE sodium_23\NN (r_pobj) of_21\IN (r_prep) combination_20\NN (r_dobj) receiving_18\VBG (r_advcl) developed_2\VBD (l_dobj) necrosis_5\NN (l_acl) characterized_7\VBN (l_agent) by_9\IN (l_pobj) failure_13\NN
D005839_D009846 NONE sulfate_26\NN (r_compound) therapy_27\NN (r_dobj) gentamicin_25\NN (r_conj) receiving_18\VBG (r_advcl) developed_2\VBD (l_dobj) necrosis_5\NN (l_acl) characterized_7\VBN (l_agent) by_9\IN (l_pobj) failure_13\NN
D005839_D051437 NONE sulfate_26\NN (r_compound) therapy_27\NN (r_dobj) gentamicin_25\NN (r_conj) receiving_18\VBG (r_advcl) developed_2\VBD (l_dobj) necrosis_5\NN (l_acl) characterized_7\VBN (l_agent) by_9\IN (l_pobj) failure_13\NN
D002512_D009846 NONE sodium_23\NN (r_pobj) of_21\IN (r_prep) combination_20\NN (r_dobj) receiving_18\VBG (r_advcl) developed_2\VBD (l_dobj) necrosis_5\NN (l_acl) characterized_7\VBN (l_agent) by_9\IN (l_pobj) failure_13\NN
D002512_D007674 NONE cephalothin_3\NN (r_compound) gentamicin_5\NN (r_compound) regimen_6\NN (r_pobj) of_1\IN (r_prep) Nephrotoxicity_0\NN
8649546
D007980_D004409 CID levodopa_2\NN (r_npadvmod) induced_4\VBN (r_amod) dyskinesia_5\NN
D007980_D004409 CID levodopa_14\RB (r_npadvmod) induced_16\VBN (r_amod) dyskinesia_20\NN
D011433_D004409 NONE propranolol_7\NN (r_pcomp) by_6\IN (r_prep) Improvement_0\NN (l_prep) of_1\IN (l_pobj) dyskinesia_5\NN
D011433_D004409 NONE propranolol_18\NN (r_dobj) received_14\VBN (l_nsubj) patients_1\NNS (l_acl) suffering_2\VBG (l_prep) with_10\IN (l_pobj) dyskinesia_13\NN
D011433_D010300 NONE propranolol_7\NN (l_prep) in_8\IN (l_pobj) disease_11\NN
D011433_D010300 NONE propranolol_18\NN (r_dobj) received_14\VBN (l_nsubj) patients_1\NNS (l_acl) suffering_2\VBG (l_prep) from_3\IN (l_pobj) disease_6\NN
D011433_D010300 NONE propranolol_18\NN (r_dobj) received_14\VBN (l_nsubj) patients_1\NNS (l_acl) suffering_2\VBG (l_prep) from_3\IN (l_pobj) disease_6\NN (l_appos) PD_8\NNP
D007980_D010300 NONE levodopa_2\NN (r_npadvmod) induced_4\VBN (r_amod) dyskinesia_5\NN (r_pobj) of_1\IN (r_prep) Improvement_0\NN (l_prep) by_6\IN (l_pcomp) propranolol_7\NN (l_prep) in_8\IN (l_pobj) disease_11\NN
D007980_D010300 NONE levodopa_14\RB (r_npadvmod) induced_16\VBN (r_amod) dyskinesia_20\NN (l_prep) in_21\IN (l_pobj) PD_22\NNP
9406968
D001127_D011141 NONE vasopressin_4\NN (r_pobj) of_2\IN (r_prep) expression_1\NN (r_nsubjpass) investigated_22\VBN (l_parataxis) polyuria_29\NN
D001127_D011141 NONE AVP_6\NNP (r_nmod) gene_8\NN (r_nsubjpass) investigated_22\VBN (l_parataxis) polyuria_29\NN
D014667_D003919 NONE vasopressin_5\NN (r_compound) gene_6\NN (l_prep) in_7\IN (l_pobj) nuclei_12\NNS (l_prep) of_13\IN (l_pobj) rat_20\NN (l_compound) insipidus_19\NN
D008094_D003919 NONE lithium_15\NN (r_npadvmod) induced_17\VBN (r_amod) diabetes_18\NN (r_compound) rat_20\NN (l_compound) insipidus_19\NN
D008094_D003919 NONE Li_35\NNP (r_npadvmod) induced_37\VBN (r_amod) diabetes_38\NN (r_compound) rat_40\NN (l_compound) insipidus_39\NN
D001127_D003681 NONE AVP_19\NNP (r_pobj) of_17\IN (r_prep) elevation_16\NN (r_pobj) to_14\IN (r_prep) contribute_13\VB (l_nsubj) dehydration_4\NN
D001127_D003681 NONE AVP_24\NNP (r_compound) expression_26\NN (r_pobj) of_23\IN (r_prep) upregulation_22\NN (r_conj) elevation_16\NN (r_pobj) to_14\IN (r_prep) contribute_13\VB (l_nsubj) dehydration_4\NN
D008094_D003681 NONE Li_35\NNP (r_npadvmod) induced_37\VBN (r_amod) diabetes_38\NN (r_compound) rat_40\NN (r_pobj) of_33\IN (r_prep) SON_32\NN (r_conj) PVN_29\NN (r_pobj) in_27\IN (r_prep) expression_26\NN (r_pobj) of_23\IN (r_prep) upregulation_22\NN (r_conj) elevation_16\NN (r_pobj) to_14\IN (r_prep) contribute_13\VB (l_nsubj) dehydration_4\NN
D008094_D011141 NONE lithium_26\NN (r_pobj) with_25\IN (r_prep) rats_24\NNS (r_pobj) in_23\IN (r_prep) investigated_22\VBN (l_parataxis) polyuria_29\NN
D008094_D011141 NONE Li)-induced_28\JJ (r_amod) polyuria_29\NN
D018021_D011141 CID LiCl_9\NNP (r_dobj) contained_8\VBD (r_relcl) diet_6\NN (r_dobj) consuming_4\VBG (r_acl) rats_3\NNS (r_nsubj) developed_19\VBN (l_dobj) polyuria_21\NN
D001127_D003919 NONE AVP_19\NNP (r_pobj) of_17\IN (r_prep) elevation_16\NN (l_conj) upregulation_22\NN (l_prep) of_23\IN (l_pobj) expression_26\NN (l_prep) in_27\IN (l_pobj) PVN_29\NN (l_conj) SON_32\NN (l_prep) of_33\IN (l_pobj) rat_40\NN (l_compound) insipidus_39\NN
D001127_D003919 NONE AVP_24\NNP (r_compound) expression_26\NN (l_prep) in_27\IN (l_pobj) PVN_29\NN (l_conj) SON_32\NN (l_prep) of_33\IN (l_pobj) rat_40\NN (l_compound) insipidus_39\NN
3187073
D005472_D002637 CID 5-FU_6\CD (r_compound) treatment_7\NN (r_pobj) on_5\IN (r_prep) patients_4\NNS (r_nsubj) be_9\VB (l_conj) discontinued_19\VBN (l_advcl) observed_26\VBN (l_nsubjpass) pain_22\NN
D005472_D013610 NONE 5-FU_6\CD (r_compound) treatment_7\NN (r_pobj) on_5\IN (r_prep) patients_4\NNS (r_nsubj) be_9\VB (l_conj) discontinued_19\VBN (l_advcl) observed_26\VBN (l_nsubjpass) pain_22\NN (l_conj) tachyarrhythmia_24\NN
17400887
D013726_D020078 NONE terbutaline_6\JJ (r_compound) treatment_7\NN (r_pobj) after_4\IN (r_prep) abnormalities_3\NNS (l_nmod) Neuroinflammation_0\NN
D013726_D001523 NONE terbutaline_6\JJ (r_compound) treatment_7\NN (r_pobj) after_4\IN (r_prep) abnormalities_3\NNS
D013726_D001321 CID terbutaline_6\JJ (r_compound) treatment_7\NN (r_pobj) after_4\IN (r_prep) abnormalities_3\NNS (l_appos) implications_11\NNS (l_prep) for_12\IN (l_pobj) autism_13\NN
D013726_D001321 CID Terbutaline_0\NNP (r_nsubjpass) associated_13\VBN (l_prep) with_14\IN (l_pobj) concordance_16\NN (l_prep) for_17\IN (l_pobj) autism_18\NN
D013726_D007752 NONE Terbutaline_0\NNP (l_appos) agonist_4\NN (l_acl) used_5\VBN (l_xcomp) arrest_7\VB (l_dobj) labor_9\NN
9522152
D002045_D009461 NONE bupivacaine_11\NN (r_pobj) of_7\IN (r_prep) injection_6\NN (r_dobj) following_4\VBG (r_acl) deficit_3\NN
D002045_D009461 NONE bupivacaine_21\NN (r_pobj) with_14\IN (r_prep) anaesthesia_13\NN (r_pobj) after_10\IN (r_prep) occurred_9\VBD (r_relcl) deficit_7\NN
17562951
C044834_D003920 NONE iodixanol_35\NN (r_pobj) with_34\IN (r_prep) with_23\IN (r_prep) were_14\VBD (r_conj) increases_6\VBZ (l_prep) In_0\IN (l_pobj) patients_1\NNS (l_prep) with_2\IN (l_pobj) diabetes_3\NNS
C044834_D003920 NONE iodixanol_25\NN (r_conj) iopamidol_23\NN (r_pobj) of_22\IN (r_prep) administration_21\NN (r_pobj) after_18\IN (r_prep) is_14\VBZ (l_prep) with_32\IN (l_conj) without_34\IN (l_pobj) mellitus_36\NN
D000111_D003920 NONE acetylcysteine_16\NN (r_pobj) of_13\IN (r_prep) use_12\NN (r_appos) volume_5\NN (l_appos) presence_7\NN (l_prep) of_8\IN (l_pobj) mellitus_10\NN
D007479_D007674 CID iopamidol_23\NN (r_pobj) of_22\IN (r_prep) administration_21\NN (r_pobj) after_18\IN (r_prep) is_14\VBZ (l_nsubj) rate_1\NN (l_prep) of_2\IN (l_pobj) nephropathy_6\NN
C044834_D007674 CID iodixanol_25\NN (r_conj) iopamidol_23\NN (r_pobj) of_22\IN (r_prep) administration_21\NN (r_pobj) after_18\IN (r_prep) is_14\VBZ (l_nsubj) rate_1\NN (l_prep) of_2\IN (l_pobj) nephropathy_6\NN
D007479_D051436 NONE iopamidol_14\NN (r_pobj) of_13\IN (r_prep) comparison_12\NN (l_prep) in_17\IN (l_pobj) patients_18\NNS (l_prep) with_19\IN (l_pobj) disease_22\NN
C044834_D051436 NONE iodixanol_16\NN (r_conj) iopamidol_14\NN (r_pobj) of_13\IN (r_prep) comparison_12\NN (l_prep) in_17\IN (l_pobj) patients_18\NNS (l_prep) with_19\IN (l_pobj) disease_22\NN
D007479_D003920 NONE iopamidol_24\NN (r_pobj) with_23\IN (r_prep) were_14\VBD (r_conj) increases_6\VBZ (l_prep) In_0\IN (l_pobj) patients_1\NNS (l_prep) with_2\IN (l_pobj) diabetes_3\NNS
D007479_D003920 NONE iopamidol_23\NN (r_pobj) of_22\IN (r_prep) administration_21\NN (r_pobj) after_18\IN (r_prep) is_14\VBZ (l_prep) with_32\IN (l_conj) without_34\IN (l_pobj) mellitus_36\NN
12574103
D003907_D006973 CID dexamethasone_1\NN (r_compound) programs_2\NNS (r_compound) hypertension_3\NN
D003907_D006973 CID dexamethasone_11\NN (r_nsubj) programmed_12\VBD (l_dobj) increase_15\NN (l_prep) in_16\IN (l_pobj) pressure_18\NN
D003907_D006973 CID dexamethasone_5\NN (r_dobj) received_3\VBD (r_relcl) rats_1\NNS (r_nsubj) elevated_23\VBN (l_dobj) pressures_25\NNS
D003907_D006973 CID dexamethasone_5\NN (r_nsubj) results_8\VBZ (l_prep) in_9\IN (l_pobj) reduction_11\NN (l_prep) in_12\IN (l_pobj) number_14\NN (l_conj) glomerulosclerosis_16\NN (l_conj) hypertension_19\NN
D003907_D005921 NONE dexamethasone_3\NN (r_dobj) given_2\VBN (l_advcl) had_11\VBD (l_dobj) glomeruli_13\NNS (l_prep) with_14\IN (l_pobj) glomerulosclerosis_15\NN
D003907_D005921 NONE dexamethasone_5\NN (r_nsubj) results_8\VBZ (l_prep) in_9\IN (l_pobj) reduction_11\NN (l_prep) in_12\IN (l_pobj) number_14\NN (l_conj) glomerulosclerosis_16\NN
D003907_D007674 CID dexamethasone_1\NN (r_compound) programs_2\NNS (r_compound) hypertension_3\NN (l_conj) injury_6\NN
D003907_D007674 CID dexamethasone_11\NN (r_nsubj) programmed_12\VBD (l_dobj) increase_15\NN (l_prep) in_16\IN (l_pobj) pressure_18\NN (l_conj) injury_21\NN
D003907_D007674 CID dexamethasone_4\NN (r_dobj) administered_3\VBN (r_csubj) had_11\VBD (l_dobj) reduction_15\NN (l_prep) in_16\IN (l_pobj) number_18\NN
D003907_D007674 CID dexamethasone_5\NN (r_dobj) received_3\VBD (r_relcl) rats_1\NNS (r_nsubj) elevated_23\VBN (r_ccomp) have_37\VB (l_dobj) reduction_39\NN (l_prep) in_40\IN (l_pobj) number_42\NN
D003907_D007674 CID dexamethasone_5\NN (r_nsubj) results_8\VBZ (l_prep) in_9\IN (l_pobj) reduction_11\NN (l_prep) in_12\IN (l_pobj) number_14\NN
18023325
D004221_D010243 NONE disulfiram_24\NN (r_compound) intoxication_25\NN (r_pobj) by_20\IN (r_agent) caused_19\VBN (r_acl) polyneuropathy_18\NN (r_dobj) superimposed_13\VBN (r_conj) was_1\VBD (l_attr) case_3\NN (l_prep) of_4\IN (l_pobj) palsy_6\JJ
D004221_D014826 CID disulfiram_6\NN (r_compound) intoxication_7\NN (r_pobj) after_4\IN (r_prep) palsy_3\JJ
D004221_D014826 CID disulfiram_6\NN (r_compound) overdose_7\NN (r_pobj) by_4\IN (r_agent) caused_3\VBN (r_acl) neuropathy_2\NN (r_nsubj) is_8\VBZ (l_conj) is_13\VBZ (l_attr) report_15\NN (l_acl) leading_18\VBG (l_prep) to_19\IN (l_pobj) palsy_22\JJ
D004221_D010523 CID disulfiram_6\NN (r_compound) overdose_7\NN (r_pobj) by_4\IN (r_agent) caused_3\VBN (r_acl) neuropathy_2\NN
D004221_D062787 NONE disulfiram_6\NN (r_compound) overdose_7\NN
D004221_D011115 NONE disulfiram_24\NN (r_compound) intoxication_25\NN (r_pobj) by_20\IN (r_agent) caused_19\VBN (r_acl) polyneuropathy_18\NN
12369736
C103477_D009069 NONE 55562_1\CD (r_nummod) GR_0\NNP (r_nsubj) administered_11\VBN (l_conj) attenuated_23\VBD (l_dobj) hyperactivity_29\NN
C103477_D009069 NONE 55562_38\CD (r_nummod) GR_37\NNP (r_appos) antagonist_35\NN (r_pobj) of_31\IN (r_prep) effects_30\NNS (r_pobj) in_26\IN (r_prep) consisting_25\VBG (r_acl) modification_24\NN (r_conj) shell_17\NN (r_pobj) into_14\IN (r_prep) microinjected_13\VBN (r_acl) ligands_12\NNS (r_pobj) by_9\IN (r_agent) modified_8\VBN (l_nsubjpass) hyperlocomotion_6\NN
D003042_D009069 CID cocaine_14\NN (r_npadvmod) induced_16\VBN (r_amod) hyperactivity_18\NN
D003042_D009069 CID cocaine_34\NN (r_pobj) by_33\IN (r_agent) induced_32\VBN (r_acl) hyperactivity_31\NN
D003042_D009069 CID cocaine_18\NN (r_pobj) to_17\IN (r_prep) prior_16\RB (r_advmod) administered_11\VBN (l_conj) attenuated_23\VBD (l_dobj) hyperactivity_29\NN
D003042_D009069 CID cocaine_4\NN (r_nsubj) induced_5\VBN (r_ccomp) indicate_2\VBP (l_ccomp) modified_8\VBN (l_nsubjpass) hyperlocomotion_6\NN
C065046_D009069 CID 93129_44\CD (r_nummod) CP_43\NNP (r_appos) agonist_41\NN (r_conj) modification_24\NN (r_conj) shell_17\NN (r_pobj) into_14\IN (r_prep) microinjected_13\VBN (r_acl) ligands_12\NNS (r_pobj) by_9\IN (r_agent) modified_8\VBN (l_nsubjpass) hyperlocomotion_6\NN
8953972
D004837_D006323 CID Epinephrine_0\NN (r_nsubj) has_1\VBZ (l_dobj) role_4\NN (l_prep) in_5\IN (l_pobj) arrest_7\NN
D004837_D013345 CID epinephrine_8\NN (r_pobj) of_7\IN (r_prep) use_6\NN (r_pobj) with_4\IN (r_prep) associated_3\VBN (r_acl) bleeding_2\NN
D004837_D012128 NONE epinephrine_26\NN (r_dobj) administer_24\VB (r_xcomp) led_16\VBD (l_nsubj) onset_2\NN (l_prep) of_3\IN (l_pobj) distress_5\NN
D004837_D005076 NONE epinephrine_26\NN (r_dobj) administer_24\VB (r_xcomp) led_16\VBD (l_nsubj) onset_2\NN (l_prep) of_3\IN (l_pobj) distress_5\NN (l_conj) rash_7\JJ
D004837_D004342 NONE Epinephrine_0\NN (r_nsubj) has_1\VBZ (r_ccomp) use_14\NN (l_prep) by_15\IN (l_pobj) paramedics_16\NNS (l_prep) in_17\IN (l_pobj) patients_18\NNS (l_prep) with_19\IN (l_pobj) reaction_22\NN
D004837_D006973 NONE Epinephrine_0\NN (r_nsubj) has_1\VBZ (r_ccomp) use_14\NN (l_prep) by_15\IN (l_pobj) paramedics_16\NNS (l_prep) in_17\IN (l_pobj) patients_18\NNS (l_prep) with_19\IN (l_pobj) reaction_22\NN (l_conj) hypertension_25\NN
20588063
D011692_D009401 CID aminonucleoside_17\JJ (r_amod) nephrosis_18\NN
D011692_D009401 CID aminonucleoside_2\JJ (r_amod) nephrosis_3\NN
9293063
D003613_D006222 CID danazol_12\NN (r_pobj) with_11\IN (r_prep) treatment_10\NN (r_pobj) with_6\IN (r_prep) association_5\NN (r_pobj) in_4\IN (r_prep) occurring_3\VBG (r_acl) hamartoma_2\NN
D003613_D006222 CID danazol_20\NN (r_compound) treatment_21\NN (r_pobj) on_16\IN (r_prep) been_15\VBN (r_relcl) patient_12\NN (r_pobj) in_10\IN (r_prep) developed_9\VBD (r_relcl) hamartoma_7\NN
D003613_D001650 CID danazol_12\NN (r_pobj) with_11\IN (r_prep) treatment_10\NN (r_pobj) with_6\IN (r_prep) association_5\NN (r_pobj) in_4\IN (r_prep) occurring_3\VBG (r_acl) hamartoma_2\NN
D003613_D001650 CID danazol_20\NN (r_compound) treatment_21\NN (r_pobj) on_16\IN (r_prep) been_15\VBN (r_relcl) patient_12\NN (r_pobj) in_10\IN (r_prep) developed_9\VBD (r_relcl) hamartoma_7\NN
6634932
D010042_D017180 CID ouabain_20\RB (r_npadvmod) induced_22\VBN (r_amod) tachycardias_24\NNS
C002616_D017180 NONE UM-272_0\NNP (r_punct) dimethylpropranolol_6\NNP (r_nsubjpass) administered_15\VBN (l_prep) to_17\IN (l_pobj) dogs_18\NNS (l_prep) with_19\IN (l_pobj) tachycardias_24\NNS
C002616_D017180 NONE dimethylpropranolol_6\NNP (r_nsubjpass) administered_15\VBN (l_prep) to_17\IN (l_pobj) dogs_18\NNS (l_prep) with_19\IN (l_pobj) tachycardias_24\NNS
C002616_D017180 NONE UM-272_1\NNP (r_punct) converted_2\VBD (l_dobj) tachycardia_4\NN
15602202
D017963_D009395 CID azithromycin_6\PRP (r_pobj) by_5\IN (r_prep) induced_4\VBN (l_nsubj) nephritis_3\NN
D017963_D009395 CID azithromycin_10\RB (r_advmod) induced_12\VBN (r_amod) nephritis_16\NN
8638206
D001279_D010243 CID atracurium_6\NN (r_pobj) of_5\IN (r_prep) use_4\NN (r_pobj) after_2\IN (r_prep) paralysis_1\NN
D001279_D010243 CID besylate_1\NN (r_nsubjpass) associated_22\VBN (l_prep) with_23\IN (l_pobj) paralysis_25\NN
D001279_D010243 CID atracurium_5\NN (r_npadvmod) related_7\VBN (r_amod) paralysis_8\NN
D014673_D010243 CID bromide_21\NN (r_pobj) as_19\IN (r_prep) NMBAs_17\NNS (r_dobj) involved_13\VBN (l_nsubj) Reports_0\NNS (l_prep) of_1\IN (l_pobj) paralysis_3\NN
-1_D010243 NONE benzylisoquinolinium_7\NN (r_amod) NMBA_8\NNP (r_appos) besylate_1\NN (r_nsubjpass) associated_22\VBN (l_prep) with_23\IN (l_pobj) paralysis_25\NN
15632880
D011188_D006947 NONE K(+_7\NNP (r_appos) hyperkalemia_5\NN
D011188_D006947 NONE potassium_17\NN (r_compound) levels_18\NNS (r_dobj) had_13\VBD (r_conj) were_4\VBD (l_nsubj) Patients_0\NNS (l_relcl) developed_2\VBD (l_dobj) hyperkalemia_3\NN
D011188_D006947 NONE potassium_22\NN (r_compound) supplement_23\NN (r_compound) doses_24\NNS (r_conj) levels_18\NNS (r_dobj) had_13\VBD (r_conj) were_4\VBD (l_nsubj) Patients_0\NNS (l_relcl) developed_2\VBD (l_dobj) hyperkalemia_3\NN
D013148_D051437 CID Spironolactone_0\NNP (r_npadvmod) induced_2\VBN (l_dobj) insufficiency_4\NN
D013148_D051437 CID spironolactone_9\NN (r_pobj) of_8\IN (r_prep) use_7\NN (r_dobj) evaluating_5\VBG (r_acl) trial_4\NN (r_nsubj) reported_14\VBD (l_dobj) risk_17\NN (l_prep) of_18\IN (l_pobj) hyperkalemia_19\NN (l_conj) insufficiency_26\NN
D013148_D051437 CID spironolactone_21\NN (r_pobj) with_20\IN (r_prep) treated_19\VBN (r_acl) patients_18\NNS (r_pobj) in_15\IN (r_prep) insufficiency_14\NN
D013148_D051437 CID spironolactone_13\NN (r_pobj) of_12\IN (r_prep) discontinuation_11\NN (r_dobj) required_10\VBD (l_prep) due_14\IN (l_pobj) hyperkalemia_16\NN (l_conj) failure_24\NN
D013148_D051437 CID Spironolactone_0\NNP (r_npadvmod) induced_2\VBN (r_amod) hyperkalemia_3\NN (r_nmod) insufficiency_6\NN
D011188_D003920 NONE potassium_17\NN (r_compound) levels_18\NNS (r_dobj) had_13\VBD (r_conj) were_4\VBD (l_acomp) older_5\JJR (l_conj) likely_8\JJ (l_xcomp) have_10\VB (l_dobj) diabetes_11\NNS
D011188_D003920 NONE potassium_22\NN (r_compound) supplement_23\NN (r_compound) doses_24\NNS (r_conj) levels_18\NNS (r_dobj) had_13\VBD (r_conj) were_4\VBD (l_acomp) older_5\JJR (l_conj) likely_8\JJ (l_xcomp) have_10\VB (l_dobj) diabetes_11\NNS
D013148_D006333 NONE Spironolactone_0\NNP (r_npadvmod) induced_2\VBN (l_dobj) insufficiency_4\NN (l_prep) in_7\IN (l_pobj) patients_8\NNS (l_prep) with_9\IN (l_pobj) failure_11\NN
D013148_D006333 NONE spironolactone_9\NN (l_prep) in_10\IN (l_pobj) patients_13\NNS (l_compound) failure_12\NN
D013148_D006333 NONE spironolactone_11\NN (r_pobj) of_10\IN (r_prep) benefits_9\NNS (r_nsubjpass) reported_13\VBN (r_advcl) changed_6\VBN (l_nsubj) treatments_1\NNS (l_prep) for_2\IN (l_pobj) failure_4\NN
D013148_D006333 NONE spironolactone_21\NN (r_pobj) with_20\IN (r_prep) treated_19\VBN (r_acl) patients_18\NNS (l_compound) failure_17\NN
D013148_D006333 NONE spironolactone_12\NN (r_pobj) with_11\IN (r_prep) treated_10\VBN (r_acl) patients_9\NNS (l_compound) failure_8\NN
D049971_D051437 NONE thiazide_31\NN (r_amod) diuretics_32\NNS (r_pobj) with_30\IN (r_prep) treated_29\VBN (r_xcomp) likely_26\JJ (r_acomp) were_24\VBD (r_conj) required_16\VBD (r_conj) had_5\VBD (l_nsubj) Patients_0\NNS (l_relcl) developed_2\VBD (l_dobj) insufficiency_4\NN
D013148_D006947 CID Spironolactone_0\NNP (r_npadvmod) induced_2\VBN (l_dobj) insufficiency_4\NN (l_conj) hyperkalemia_6\NN
D013148_D006947 CID spironolactone_9\NN (r_pobj) of_8\IN (r_prep) use_7\NN (r_dobj) evaluating_5\VBG (r_acl) trial_4\NN (r_nsubj) reported_14\VBD (l_dobj) risk_17\NN (l_prep) of_18\IN (l_pobj) hyperkalemia_19\NN
D013148_D006947 CID spironolactone_21\NN (r_pobj) with_20\IN (r_prep) treated_19\VBN (r_acl) patients_18\NNS (r_pobj) in_15\IN (r_prep) insufficiency_14\NN (r_conj) hyperkalemia_11\NN
D013148_D006947 CID spironolactone_13\NN (r_pobj) of_12\IN (r_prep) discontinuation_11\NN (r_dobj) required_10\VBD (l_prep) due_14\IN (l_pobj) hyperkalemia_16\NN
D013148_D006947 CID Spironolactone_0\NNP (r_npadvmod) induced_2\VBN (r_amod) hyperkalemia_3\NN
D003404_D051437 NONE creatinine_14\NN (r_conj) weight_9\NN (r_dobj) had_5\VBD (l_nsubj) Patients_0\NNS (l_relcl) developed_2\VBD (l_dobj) insufficiency_4\NN
D011188_D051437 NONE K(+_7\NNP (r_appos) hyperkalemia_5\NN (r_dobj) developed_4\VBD (r_relcl) patients_2\NNS (r_attr) were_1\VBD (l_nsubj) Cases_0\NNS (l_appos) L_13\NN (l_conj) insufficiency_17\NN
6386793
D000639_D014786 CID amitriptyline_27\NN (r_pobj) with_26\IN (r_prep) than_25\IN (r_prep) less_22\JJR (r_acomp) were_20\VBD (l_nsubj) incidence_2\NN (l_prep) of_3\IN (l_pobj) effects_5\NNS (l_conj) frequency_8\NN (l_prep) of_11\IN (l_pobj) vision_13\NN
D004308_D014987 NONE dothiepin_24\JJ (r_pobj) with_23\IN (r_prep) less_22\JJR (r_acomp) were_20\VBD (l_nsubj) incidence_2\NN (l_prep) of_3\IN (l_pobj) effects_5\NNS (l_conj) frequency_8\NN (l_prep) of_11\IN (l_pobj) vision_13\NN (l_conj) mouth_16\NN
D000928_D003866 NONE antidepressant_8\NN (r_amod) drug_9\NN (l_acl) associated_10\VBN (l_prep) with_11\IN (l_pobj) effects_14\NNS (l_prep) than_15\IN (l_pobj) amitriptyline_16\NN (l_prep) in_17\IN (l_pobj) treatment_19\NN (l_prep) of_20\IN (l_pobj) outpatients_22\NNS (l_amod) depressed_21\JJ
D000639_D014987 CID amitriptyline_27\NN (r_pobj) with_26\IN (r_prep) than_25\IN (r_prep) less_22\JJR (r_acomp) were_20\VBD (l_nsubj) incidence_2\NN (l_prep) of_3\IN (l_pobj) effects_5\NNS (l_conj) frequency_8\NN (l_prep) of_11\IN (l_pobj) vision_13\NN (l_conj) mouth_16\NN
D004308_D003866 NONE hydrochloride_12\NN (r_pobj) of_10\IN (r_prep) efficacy_7\NN (r_pobj) of_5\IN (r_prep) study_4\NN (l_prep) in_13\IN (l_pobj) treatment_15\NN (l_prep) of_16\IN (l_pobj) disorder_19\NN
D004308_D003866 NONE dothiepin_10\JJ (r_nsubjpass) compared_14\VBN (l_prep) to_15\IN (l_pobj) placebo_16\NN (l_prep) in_17\IN (l_pobj) treatment_19\NN (l_prep) of_20\IN (l_pobj) outpatients_23\NNS (l_amod) depressed_22\JJ
D004308_D003866 NONE Dothiepin_0\JJ (r_nsubj) were_3\VBD (l_acomp) effective_5\JJ (l_prep) in_6\IN (l_pcomp) alleviating_7\VBG (l_dobj) symptoms_9\NNS (l_prep) of_10\IN (l_pobj) illness_12\NN
D004308_D003866 NONE Dothiepin_0\NNP (r_nsubjpass) found_3\VBN (l_xcomp) be_5\VB (l_attr) drug_9\NN (l_acl) associated_10\VBN (l_prep) with_11\IN (l_pobj) effects_14\NNS (l_prep) than_15\IN (l_pobj) amitriptyline_16\NN (l_prep) in_17\IN (l_pobj) treatment_19\NN (l_prep) of_20\IN (l_pobj) outpatients_22\NNS (l_amod) depressed_21\JJ
D004308_D014786 NONE dothiepin_24\JJ (r_pobj) with_23\IN (r_prep) less_22\JJR (r_acomp) were_20\VBD (l_nsubj) incidence_2\NN (l_prep) of_3\IN (l_pobj) effects_5\NNS (l_conj) frequency_8\NN (l_prep) of_11\IN (l_pobj) vision_13\NN
D000639_D003866 NONE amitriptyline_12\NN (r_conj) dothiepin_10\JJ (r_nsubjpass) compared_14\VBN (l_prep) to_15\IN (l_pobj) placebo_16\NN (l_prep) in_17\IN (l_pobj) treatment_19\NN (l_prep) of_20\IN (l_pobj) outpatients_23\NNS (l_amod) depressed_22\JJ
D000639_D003866 NONE amitriptyline_2\NN (r_conj) Dothiepin_0\JJ (r_nsubj) were_3\VBD (l_acomp) effective_5\JJ (l_prep) in_6\IN (l_pcomp) alleviating_7\VBG (l_dobj) symptoms_9\NNS (l_prep) of_10\IN (l_pobj) illness_12\NN
D000639_D003866 NONE amitriptyline_16\NN (l_prep) in_17\IN (l_pobj) treatment_19\NN (l_prep) of_20\IN (l_pobj) outpatients_22\NNS (l_amod) depressed_21\JJ
2673163
D003042_D002532 NONE cocaine_14\NN (r_compound) use_15\NN (r_pobj) to_13\IN (r_prep) related_12\VBN (r_acl) stroke_11\NN (r_pobj) of_10\IN (r_prep) incidence_9\NN (r_nsubj) increasing_17\VBG (r_ccomp) indicate_2\VBP (r_ccomp) occurs_26\VBZ (r_ccomp) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_nsubj) frequency_72\NN (l_nmod) stroke_47\NN (l_advcl) associated_53\VBN (l_prep) with_54\IN (l_pobj) aneurysms_56\NNS
D003042_D002532 NONE cocaine_22\NN (r_npadvmod) associated_24\VBN (r_amod) stroke_25\NN (r_nsubj) occurs_26\VBZ (r_ccomp) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_nsubj) frequency_72\NN (l_nmod) stroke_47\NN (l_advcl) associated_53\VBN (l_prep) with_54\IN (l_pobj) aneurysms_56\NNS
D003042_D002532 NONE cocaine_41\NN (r_compound) administration_42\NN (r_pobj) of_40\IN (r_prep) route_39\NN (r_dobj) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_nsubj) frequency_72\NN (l_nmod) stroke_47\NN (l_advcl) associated_53\VBN (l_prep) with_54\IN (l_pobj) aneurysms_56\NNS
D003042_D002532 NONE cocaine_49\NN (r_compound) use_50\NN (r_nsubjpass) associated_53\VBN (l_prep) with_54\IN (l_pobj) aneurysms_56\NNS
D003042_D002532 NONE cocaine_66\NN (r_npadvmod) associated_68\VBN (r_amod) stroke_69\NN (r_pobj) in_65\IN (r_prep) 5_63\CD (r_conj) stroke_47\NN (l_advcl) associated_53\VBN (l_prep) with_54\IN (l_pobj) aneurysms_56\NNS
D003042_D020521 NONE cocaine_3\NN (r_compound) use_4\NN (r_pobj) with_2\IN (r_prep) associated_1\VBN (r_acl) Stroke_0\NN
D003042_D020521 NONE cocaine_6\NN (r_compound) use_7\NN (r_nsubjpass) related_9\VBN (l_prep) to_10\IN (l_pobj) stroke_11\NN
D003042_D020521 NONE cocaine_2\NN (r_compound) use_3\NN (r_dobj) followed_1\VBD (l_nsubj) Stroke_0\NN
D003042_D020521 NONE cocaine_14\NN (r_compound) use_15\NN (r_pobj) to_13\IN (r_prep) related_12\VBN (r_acl) stroke_11\NN
D003042_D020521 NONE cocaine_14\NN (r_compound) use_15\NN (r_pobj) to_13\IN (r_prep) related_12\VBN (r_acl) stroke_11\NN (r_pobj) of_10\IN (r_prep) incidence_9\NN (r_nsubj) increasing_17\VBG (r_ccomp) indicate_2\VBP (r_ccomp) occurs_26\VBZ (l_nsubj) stroke_25\NN
D003042_D020521 NONE cocaine_14\NN (r_compound) use_15\NN (r_pobj) to_13\IN (r_prep) related_12\VBN (r_acl) stroke_11\NN (r_pobj) of_10\IN (r_prep) incidence_9\NN (r_nsubj) increasing_17\VBG (r_ccomp) indicate_2\VBP (r_ccomp) occurs_26\VBZ (r_ccomp) follow_37\VB (l_nsubj) stroke_35\NN
D003042_D020521 NONE cocaine_14\NN (r_compound) use_15\NN (r_pobj) to_13\IN (r_prep) related_12\VBN (r_acl) stroke_11\NN (r_pobj) of_10\IN (r_prep) incidence_9\NN (r_nsubj) increasing_17\VBG (r_ccomp) indicate_2\VBP (r_ccomp) occurs_26\VBZ (r_ccomp) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_nsubj) frequency_72\NN (l_nmod) stroke_47\NN
D003042_D020521 NONE cocaine_14\NN (r_compound) use_15\NN (r_pobj) to_13\IN (r_prep) related_12\VBN (r_acl) stroke_11\NN (r_pobj) of_10\IN (r_prep) incidence_9\NN (r_nsubj) increasing_17\VBG (r_ccomp) indicate_2\VBP (r_ccomp) occurs_26\VBZ (r_ccomp) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_nsubj) frequency_72\NN (l_nmod) stroke_47\NN (l_conj) 5_63\CD (l_prep) in_65\IN (l_pobj) stroke_69\NN
D003042_D020521 NONE cocaine_22\NN (r_npadvmod) associated_24\VBN (r_amod) stroke_25\NN (r_nsubj) occurs_26\VBZ (l_ccomp) indicate_2\VBP (l_ccomp) increasing_17\VBG (l_nsubj) incidence_9\NN (l_prep) of_10\IN (l_pobj) stroke_11\NN
D003042_D020521 NONE cocaine_22\NN (r_npadvmod) associated_24\VBN (r_amod) stroke_25\NN
D003042_D020521 NONE cocaine_22\NN (r_npadvmod) associated_24\VBN (r_amod) stroke_25\NN (r_nsubj) occurs_26\VBZ (r_ccomp) follow_37\VB (l_nsubj) stroke_35\NN
D003042_D020521 NONE cocaine_22\NN (r_npadvmod) associated_24\VBN (r_amod) stroke_25\NN (r_nsubj) occurs_26\VBZ (r_ccomp) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_nsubj) frequency_72\NN (l_nmod) stroke_47\NN
D003042_D020521 NONE cocaine_22\NN (r_npadvmod) associated_24\VBN (r_amod) stroke_25\NN (r_nsubj) occurs_26\VBZ (r_ccomp) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_nsubj) frequency_72\NN (l_nmod) stroke_47\NN (l_conj) 5_63\CD (l_prep) in_65\IN (l_pobj) stroke_69\NN
D003042_D020521 NONE cocaine_41\NN (r_compound) administration_42\NN (r_pobj) of_40\IN (r_prep) route_39\NN (r_dobj) follow_37\VB (l_ccomp) occurs_26\VBZ (l_ccomp) indicate_2\VBP (l_ccomp) increasing_17\VBG (l_nsubj) incidence_9\NN (l_prep) of_10\IN (l_pobj) stroke_11\NN
D003042_D020521 NONE cocaine_41\NN (r_compound) administration_42\NN (r_pobj) of_40\IN (r_prep) route_39\NN (r_dobj) follow_37\VB (l_ccomp) occurs_26\VBZ (l_nsubj) stroke_25\NN
D003042_D020521 NONE cocaine_41\NN (r_compound) administration_42\NN (r_pobj) of_40\IN (r_prep) route_39\NN (r_dobj) follow_37\VB (l_nsubj) stroke_35\NN
D003042_D020521 NONE cocaine_41\NN (r_compound) administration_42\NN (r_pobj) of_40\IN (r_prep) route_39\NN (r_dobj) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_nsubj) frequency_72\NN (l_nmod) stroke_47\NN
D003042_D020521 NONE cocaine_41\NN (r_compound) administration_42\NN (r_pobj) of_40\IN (r_prep) route_39\NN (r_dobj) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_nsubj) frequency_72\NN (l_nmod) stroke_47\NN (l_conj) 5_63\CD (l_prep) in_65\IN (l_pobj) stroke_69\NN
D003042_D020521 NONE cocaine_49\NN (r_compound) use_50\NN (r_nsubjpass) associated_53\VBN (r_advcl) stroke_47\NN (r_nmod) frequency_72\NN (r_nsubj) exceeds_76\VBZ (l_ccomp) follow_37\VB (l_ccomp) occurs_26\VBZ (l_ccomp) indicate_2\VBP (l_ccomp) increasing_17\VBG (l_nsubj) incidence_9\NN (l_prep) of_10\IN (l_pobj) stroke_11\NN
D003042_D020521 NONE cocaine_49\NN (r_compound) use_50\NN (r_nsubjpass) associated_53\VBN (r_advcl) stroke_47\NN (r_nmod) frequency_72\NN (r_nsubj) exceeds_76\VBZ (l_ccomp) follow_37\VB (l_ccomp) occurs_26\VBZ (l_nsubj) stroke_25\NN
D003042_D020521 NONE cocaine_49\NN (r_compound) use_50\NN (r_nsubjpass) associated_53\VBN (r_advcl) stroke_47\NN (r_nmod) frequency_72\NN (r_nsubj) exceeds_76\VBZ (l_ccomp) follow_37\VB (l_nsubj) stroke_35\NN
D003042_D020521 NONE cocaine_49\NN (r_compound) use_50\NN (r_nsubjpass) associated_53\VBN (r_advcl) stroke_47\NN
D003042_D020521 NONE cocaine_49\NN (r_compound) use_50\NN (r_nsubjpass) associated_53\VBN (r_advcl) stroke_47\NN (l_conj) 5_63\CD (l_prep) in_65\IN (l_pobj) stroke_69\NN
D003042_D020521 NONE cocaine_66\NN (r_npadvmod) associated_68\VBN (r_amod) stroke_69\NN (r_pobj) in_65\IN (r_prep) 5_63\CD (r_conj) stroke_47\NN (r_nmod) frequency_72\NN (r_nsubj) exceeds_76\VBZ (l_ccomp) follow_37\VB (l_ccomp) occurs_26\VBZ (l_ccomp) indicate_2\VBP (l_ccomp) increasing_17\VBG (l_nsubj) incidence_9\NN (l_prep) of_10\IN (l_pobj) stroke_11\NN
D003042_D020521 NONE cocaine_66\NN (r_npadvmod) associated_68\VBN (r_amod) stroke_69\NN (r_pobj) in_65\IN (r_prep) 5_63\CD (r_conj) stroke_47\NN (r_nmod) frequency_72\NN (r_nsubj) exceeds_76\VBZ (l_ccomp) follow_37\VB (l_ccomp) occurs_26\VBZ (l_nsubj) stroke_25\NN
D003042_D020521 NONE cocaine_66\NN (r_npadvmod) associated_68\VBN (r_amod) stroke_69\NN (r_pobj) in_65\IN (r_prep) 5_63\CD (r_conj) stroke_47\NN (r_nmod) frequency_72\NN (r_nsubj) exceeds_76\VBZ (l_ccomp) follow_37\VB (l_nsubj) stroke_35\NN
D003042_D020521 NONE cocaine_66\NN (r_npadvmod) associated_68\VBN (r_amod) stroke_69\NN (r_pobj) in_65\IN (r_prep) 5_63\CD (r_conj) stroke_47\NN
D003042_D020521 NONE cocaine_66\NN (r_npadvmod) associated_68\VBN (r_amod) stroke_69\NN
D003042_D002544 CID cocaine_14\NN (r_compound) use_15\NN (r_pobj) to_13\IN (r_prep) related_12\VBN (r_acl) stroke_11\NN (r_pobj) of_10\IN (r_prep) incidence_9\NN (r_nsubj) increasing_17\VBG (r_ccomp) indicate_2\VBP (r_ccomp) occurs_26\VBZ (r_ccomp) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_dobj) that_77\DT (l_prep) of_78\IN (l_pobj) infarction_80\NN
D003042_D002544 CID cocaine_22\NN (r_npadvmod) associated_24\VBN (r_amod) stroke_25\NN (r_nsubj) occurs_26\VBZ (r_ccomp) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_dobj) that_77\DT (l_prep) of_78\IN (l_pobj) infarction_80\NN
D003042_D002544 CID cocaine_41\NN (r_compound) administration_42\NN (r_pobj) of_40\IN (r_prep) route_39\NN (r_dobj) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_dobj) that_77\DT (l_prep) of_78\IN (l_pobj) infarction_80\NN
D003042_D002544 CID cocaine_49\NN (r_compound) use_50\NN (r_nsubjpass) associated_53\VBN (r_advcl) stroke_47\NN (r_nmod) frequency_72\NN (r_nsubj) exceeds_76\VBZ (l_dobj) that_77\DT (l_prep) of_78\IN (l_pobj) infarction_80\NN
D003042_D002544 CID cocaine_66\NN (r_npadvmod) associated_68\VBN (r_amod) stroke_69\NN (r_pobj) in_65\IN (r_prep) 5_63\CD (r_conj) stroke_47\NN (r_nmod) frequency_72\NN (r_nsubj) exceeds_76\VBZ (l_dobj) that_77\DT (l_prep) of_78\IN (l_pobj) infarction_80\NN
D003042_D001165 NONE cocaine_14\NN (r_compound) use_15\NN (r_pobj) to_13\IN (r_prep) related_12\VBN (r_acl) stroke_11\NN (r_pobj) of_10\IN (r_prep) incidence_9\NN (r_nsubj) increasing_17\VBG (r_ccomp) indicate_2\VBP (r_ccomp) occurs_26\VBZ (r_ccomp) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_nsubj) frequency_72\NN (l_nmod) stroke_47\NN (l_advcl) associated_53\VBN (l_prep) with_54\IN (l_pobj) aneurysms_56\NNS (l_conj) malformations_59\NNS
D003042_D001165 NONE cocaine_22\NN (r_npadvmod) associated_24\VBN (r_amod) stroke_25\NN (r_nsubj) occurs_26\VBZ (r_ccomp) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_nsubj) frequency_72\NN (l_nmod) stroke_47\NN (l_advcl) associated_53\VBN (l_prep) with_54\IN (l_pobj) aneurysms_56\NNS (l_conj) malformations_59\NNS
D003042_D001165 NONE cocaine_41\NN (r_compound) administration_42\NN (r_pobj) of_40\IN (r_prep) route_39\NN (r_dobj) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_nsubj) frequency_72\NN (l_nmod) stroke_47\NN (l_advcl) associated_53\VBN (l_prep) with_54\IN (l_pobj) aneurysms_56\NNS (l_conj) malformations_59\NNS
D003042_D001165 NONE cocaine_49\NN (r_compound) use_50\NN (r_nsubjpass) associated_53\VBN (l_prep) with_54\IN (l_pobj) aneurysms_56\NNS (l_conj) malformations_59\NNS
D003042_D001165 NONE cocaine_66\NN (r_npadvmod) associated_68\VBN (r_amod) stroke_69\NN (r_pobj) in_65\IN (r_prep) 5_63\CD (r_conj) stroke_47\NN (l_advcl) associated_53\VBN (l_prep) with_54\IN (l_pobj) aneurysms_56\NNS (l_conj) malformations_59\NNS
D003042_D020300 NONE cocaine_14\NN (r_compound) use_15\NN (r_pobj) to_13\IN (r_prep) related_12\VBN (r_acl) stroke_11\NN (r_pobj) of_10\IN (r_prep) incidence_9\NN (r_nsubj) increasing_17\VBG (r_ccomp) indicate_2\VBP (r_ccomp) occurs_26\VBZ (r_ccomp) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_nsubj) frequency_72\NN (l_prep) of_73\IN (l_pobj) hemorrhage_75\NN
D003042_D020300 NONE cocaine_22\NN (r_npadvmod) associated_24\VBN (r_amod) stroke_25\NN (r_nsubj) occurs_26\VBZ (r_ccomp) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_nsubj) frequency_72\NN (l_prep) of_73\IN (l_pobj) hemorrhage_75\NN
D003042_D020300 NONE cocaine_41\NN (r_compound) administration_42\NN (r_pobj) of_40\IN (r_prep) route_39\NN (r_dobj) follow_37\VB (r_ccomp) exceeds_76\VBZ (l_nsubj) frequency_72\NN (l_prep) of_73\IN (l_pobj) hemorrhage_75\NN
D003042_D020300 NONE cocaine_49\NN (r_compound) use_50\NN (r_nsubjpass) associated_53\VBN (r_advcl) stroke_47\NN (r_nmod) frequency_72\NN (l_prep) of_73\IN (l_pobj) hemorrhage_75\NN
D003042_D020300 NONE cocaine_66\NN (r_npadvmod) associated_68\VBN (r_amod) stroke_69\NN (r_pobj) in_65\IN (r_prep) 5_63\CD (r_conj) stroke_47\NN (r_nmod) frequency_72\NN (l_prep) of_73\IN (l_pobj) hemorrhage_75\NN
19803309
D013390_D009224 NONE suxamethonium_29\NN (r_pobj) of_27\IN (r_prep) dose_26\NN (r_pobj) following_23\VBG (r_prep) threatening_20\VBG (r_ccomp) developed_18\VBD (r_relcl) primigravida_15\NN (r_pobj) in_8\IN (r_prep) case_4\NN (l_prep) of_5\IN (l_pobj) congenita_7\NN
D013390_D014313 CID suxamethonium_29\NN (r_pobj) of_27\IN (r_prep) dose_26\NN (r_pobj) following_23\VBG (r_prep) threatening_20\VBG (l_dobj) spasm_22\NN
234669
D002245_D014693 NONE dioxide_32\NN (r_conj) PO2_28\NNP (r_appos) oxygen_26\NN (r_pobj) of_25\IN (r_prep) pressures_24\NNS (r_nsubjpass) kept_37\VBN (r_advcl) reduced_11\VBN (l_nsubjpass) threshold_9\NN (l_compound) fibrillation_8\NN
D002245_D014693 NONE CO2_34\NNP (r_appos) dioxide_32\NN (r_conj) PO2_28\NNP (r_appos) oxygen_26\NN (r_pobj) of_25\IN (r_prep) pressures_24\NNS (r_nsubjpass) kept_37\VBN (r_advcl) reduced_11\VBN (l_nsubjpass) threshold_9\NN (l_compound) fibrillation_8\NN
C093415_D014693 NONE PO2_28\NNP (r_appos) oxygen_26\NN (r_pobj) of_25\IN (r_prep) pressures_24\NNS (r_nsubjpass) kept_37\VBN (r_advcl) reduced_11\VBN (l_nsubjpass) threshold_9\NN (l_compound) fibrillation_8\NN
D000628_D012131 NONE aminophylline_2\NN (r_pobj) of_1\IN (r_prep) Effects_0\NNS (l_prep) for_6\IN (l_pcomp) initiating_7\VBG (l_prep) during_10\IN (l_pobj) failure_12\NN
D000628_D012131 NONE aminophylline_3\NN (r_pobj) of_2\IN (r_prep) effects_1\NNS (l_conj) during_16\IN (l_pobj) failure_18\NN
D000628_D012131 NONE aminophylline_30\NN (r_pobj) of_29\IN (r_prep) infusion_28\NN (r_nsubj) resulted_31\VBD (l_advcl) produced_4\VBN (l_nsubjpass) failure_2\NN
D000628_D012131 NONE aminophylline_24\NN (r_appos) agents_21\NNS (r_nsubj) play_27\VB (l_advcl) contribute_8\VB (l_prep) to_9\IN (l_pobj) incidence_12\NN (l_prep) of_13\IN (l_pobj) arrhythmias_15\NNS (l_prep) in_16\IN (l_pobj) failure_18\NN
D010100_D014693 NONE oxygen_26\NN (r_pobj) of_25\IN (r_prep) pressures_24\NNS (r_nsubjpass) kept_37\VBN (r_advcl) reduced_11\VBN (l_nsubjpass) threshold_9\NN (l_compound) fibrillation_8\NN
D000628_D014693 CID aminophylline_2\NN (r_pobj) of_1\IN (r_prep) Effects_0\NNS (l_prep) for_6\IN (l_pcomp) initiating_7\VBG (l_dobj) fibrillation_9\NN
D000628_D014693 CID aminophylline_3\NN (l_prep) on_4\IN (l_pobj) threshold_8\NN (l_compound) fibrillation_7\NN
D000628_D014693 CID aminophylline_4\NN (r_pobj) of_3\IN (r_prep) infusion_2\NN (r_pobj) During_0\IN (r_prep) reduced_11\VBN (l_nsubjpass) threshold_9\NN (l_compound) fibrillation_8\NN
D000628_D014693 CID aminophylline_30\NN (r_pobj) of_29\IN (r_prep) infusion_28\NN (r_nsubj) resulted_31\VBD (l_prep) in_32\IN (l_pobj) decrease_36\NN (l_prep) in_37\IN (l_pobj) threshold_40\NN (l_compound) fibrillation_39\NN
D000628_D007040 NONE aminophylline_30\NN (r_pobj) of_29\IN (r_prep) infusion_28\NN (r_nsubj) resulted_31\VBD (l_advcl) produced_4\VBN (l_agent) by_5\IN (l_pobj) hypoventilation_6\NN
D000628_D001145 NONE aminophylline_24\NN (r_appos) agents_21\NNS (r_nsubj) play_27\VB (l_advcl) contribute_8\VB (l_prep) to_9\IN (l_pobj) incidence_12\NN (l_prep) of_13\IN (l_pobj) arrhythmias_15\NNS
3985451
D014859_D003286 NONE warfarin_12\NN (r_compound) therapy_13\NN (r_pobj) on_10\IN (r_prep) man_9\NN (l_relcl) sustained_15\VBD (l_conj) developed_21\VBD (l_dobj) pain_23\NN (l_conj) contracture_27\NN
D014859_D003286 NONE warfarin_12\RB (r_npadvmod) induced_14\VBN (r_amod) neuropathy_16\NN (r_pobj) of_11\IN (r_prep) form_10\NN (r_dobj) represents_6\VBZ (r_ccomp) characterized_20\VBN (l_agent) by_21\IN (l_pobj) pain_23\NN (l_conj) degrees_30\NNS (l_conj) contracture_39\NN
D014859_D010523 NONE warfarin_12\RB (r_npadvmod) induced_14\VBN (r_amod) neuropathy_16\NN
D014859_D020428 CID Warfarin_0\NNP (r_npadvmod) induced_2\VBN (r_amod) hemorrhage_4\NN (l_prep) with_5\IN (l_pobj) palsy_9\JJ
D014859_D020428 CID warfarin_12\RB (r_npadvmod) induced_14\VBN (r_amod) neuropathy_16\NN (r_pobj) of_11\IN (r_prep) form_10\NN (r_dobj) represents_6\VBZ (l_nsubj) palsy_5\JJ
D014859_D006470 NONE Warfarin_0\NNP (r_npadvmod) induced_2\VBN (r_amod) hemorrhage_4\NN
D014859_D009135 CID warfarin_12\NN (r_compound) therapy_13\NN (r_pobj) on_10\IN (r_prep) man_9\NN (l_relcl) sustained_15\VBD (l_dobj) tear_19\NN
D014859_D010146 NONE warfarin_12\NN (r_compound) therapy_13\NN (r_pobj) on_10\IN (r_prep) man_9\NN (l_relcl) sustained_15\VBD (l_conj) developed_21\VBD (l_dobj) pain_23\NN
D014859_D010146 NONE warfarin_12\RB (r_npadvmod) induced_14\VBN (r_amod) neuropathy_16\NN (r_pobj) of_11\IN (r_prep) form_10\NN (r_dobj) represents_6\VBZ (r_ccomp) characterized_20\VBN (l_agent) by_21\IN (l_pobj) pain_23\NN
D014859_D015417 NONE warfarin_12\RB (r_npadvmod) induced_14\VBN (r_amod) neuropathy_16\NN (r_pobj) of_11\IN (r_prep) form_10\NN (r_dobj) represents_6\VBZ (r_ccomp) characterized_20\VBN (l_agent) by_21\IN (l_pobj) pain_23\NN (l_conj) degrees_30\NNS (l_prep) of_31\IN (l_pobj) impairment_35\NN
19356053
D020123_D009404 NONE sirolimus_16\NN (r_pobj) of_15\IN (r_prep) initiation_14\NN (l_conj) development_19\NN (l_prep) of_20\IN (l_pobj) proteinuria_24\NN (l_compound) range_23\NN (l_amod) nephrotic_21\JJ
D003404_D011507 NONE creatinine_22\NN (r_compound) ratios_23\NNS (r_conj) measurement_16\NN (r_pobj) by_14\IN (r_agent) assessed_9\VBN (l_nsubjpass) magnitude_5\NN (l_prep) of_6\IN (l_pobj) proteinuria_7\NN
D003404_D011507 NONE creatinine_22\NN (r_compound) ratios_23\NNS (l_appos) estimate_26\NN (l_prep) of_27\IN (l_pobj) grams_28\NNS (l_prep) of_29\IN (l_pobj) proteinuria_30\NN
D020123_D011507 CID sirolimus_7\NN (r_pobj) of_6\IN (r_prep) administration_5\NN (r_pobj) following_3\VBG (r_prep) proteinuria_2\NN
D020123_D011507 CID sirolimus_16\NN (r_pobj) of_15\IN (r_prep) use_14\NN (r_pobj) with_12\IN (r_prep) linked_11\VBN (r_acl) proteinuria_10\NN
D020123_D011507 CID sirolimus_11\NN (r_compound) use_12\NN (r_pobj) with_10\IN (r_prep) associated_9\VBN (r_acl) proteinuria_8\NN
D020123_D011507 CID sirolimus_12\NN (r_compound) therapy_13\NN (l_conj) proteinuria_15\NN
D020123_D011507 CID sirolimus_12\NN (r_compound) therapy_13\NN (r_pobj) of_11\IN (r_prep) commencement_10\NN (r_pobj) between_8\IN (r_prep) association_7\NN (r_nsubj) implicated_16\VBN (l_prep) as_18\IN (l_pobj) etiology_22\NN (l_prep) of_23\IN (l_pobj) proteinuria_25\NN
D020123_D011507 CID sirolimus_17\NN (r_dobj) implicated_16\VBN (l_nsubj) association_7\NN (l_prep) between_8\IN (l_pobj) commencement_10\NN (l_prep) of_11\IN (l_pobj) therapy_13\NN (l_conj) proteinuria_15\NN
D020123_D011507 CID sirolimus_17\NN (r_dobj) implicated_16\VBN (l_prep) as_18\IN (l_pobj) etiology_22\NN (l_prep) of_23\IN (l_pobj) proteinuria_25\NN
D020123_D011507 CID sirolimus_16\NN (r_pobj) of_15\IN (r_prep) initiation_14\NN (l_conj) development_19\NN (l_prep) of_20\IN (l_pobj) proteinuria_24\NN
D020123_D011507 CID sirolimus_5\NN (r_compound) therapy_6\NN (r_pobj) with_4\IN (r_prep) correlated_1\VBD (l_nsubj) Proteinuria_0\NNP
D020123_D011507 CID sirolimus_6\NN (r_pobj) of_5\IN (r_prep) discontinuation_4\NN (r_nsubj) resulted_7\VBD (l_conj) resolution_14\NN (l_prep) of_16\IN (l_pobj) proteinuria_17\NN
D020123_D011507 CID Sirolimus_0\NNP (r_nsubj) induces_1\VBZ (l_conj) aggravates_3\VBZ (l_dobj) proteinuria_7\NN
D020123_D011507 CID sirolimus_10\NN (r_nsubjpass) withdrawn_12\VBN (r_advcl) resolve_7\VB (r_conj) improve_2\VB (l_nsubj) Proteinuria_0\NNP
D020123_D007674 NONE Sirolimus_0\NNP (r_nsubj) is_1\VBZ (l_conj) have_13\VB (l_dobj) nephrotoxicity_15\NN
7802851
D000525_D003866 CID alprazolam_5\NN (r_compound) patients_6\NNS (r_nsubj) developed_7\VBD (l_dobj) reactions_10\NNS (l_prep) of_18\IN (l_pobj) depression_19\NN
D000525_D008569 CID alprazolam_5\NN (r_compound) patients_6\NNS (r_nsubj) developed_7\VBD (l_dobj) reactions_10\NNS (l_conj) effects_31\NNS (l_appos) sedation_34\NN (l_conj) irritability_36\NN (l_conj) memory_39\NN
D000525_D016584 NONE alprazolam_3\NN (r_pobj) of_2\IN (r_prep) efficacy_1\NN (l_prep) in_6\IN (l_pobj) disorder_8\NN
D000525_D016584 NONE alprazolam_20\NN (r_xcomp) randomised_18\VBN (l_prep) In_0\IN (l_pobj) London_1\NNP (l_conj) patients_5\NNS (l_relcl) met_7\VBD (l_dobj) criteria_11\NNS (l_prep) for_12\IN (l_pobj) disorder_14\NN
D000525_D001259 CID alprazolam_5\NN (r_compound) patients_6\NNS (r_nsubj) developed_7\VBD (l_dobj) reactions_10\NNS (l_conj) effects_31\NNS (l_appos) sedation_34\NN (l_conj) irritability_36\NN (l_conj) memory_39\NN (l_conj) loss_42\NN (l_conj) ataxia_44\NN
D000525_D001523 NONE alprazolam_5\NN (r_compound) patients_6\NNS (r_nsubj) developed_7\VBD (l_dobj) reactions_10\NNS (l_prep) of_18\IN (l_pobj) depression_19\NN (l_conj) enuresis_21\NN (l_conj) disinhibition_23\NN (l_conj) aggression_25\NN
D000525_D001523 NONE alprazolam_5\NN (r_compound) patients_6\NNS (r_nsubj) developed_7\VBD (l_dobj) reactions_10\NNS (l_conj) effects_31\NNS (l_appos) sedation_34\NN (l_conj) irritability_36\NN
D000525_D015431 CID alprazolam_5\NN (r_compound) patients_6\NNS (r_nsubj) developed_7\VBD (l_dobj) reactions_10\NNS (l_conj) effects_31\NNS (l_appos) sedation_34\NN (l_conj) irritability_36\NN (l_conj) memory_39\NN (l_conj) loss_42\NN
D000525_D000379 NONE alprazolam_3\NN (r_pobj) of_2\IN (r_prep) efficacy_1\NN (l_prep) in_6\IN (l_pobj) disorder_8\NN (l_prep) with_9\IN (l_pobj) agoraphobia_10\NNP
D000525_D000379 NONE alprazolam_20\NN (r_xcomp) randomised_18\VBN (l_prep) In_0\IN (l_pobj) London_1\NNP (l_conj) patients_5\NNS (l_relcl) met_7\VBD (l_dobj) criteria_11\NNS (l_prep) for_12\IN (l_pobj) disorder_14\NN (l_prep) with_15\IN (l_pobj) agoraphobia_16\NNP
D000525_D004775 CID alprazolam_5\NN (r_compound) patients_6\NNS (r_nsubj) developed_7\VBD (l_dobj) reactions_10\NNS (l_prep) of_18\IN (l_pobj) depression_19\NN (l_conj) enuresis_21\NN
6503301
D003606_D008545 NONE dacarbazine_6\NN (r_compound) therapy_7\NN (l_prep) for_11\IN (l_pobj) melanoma_12\NN
D003606_D008545 NONE DTIC_9\NNP (r_appos) therapy_7\NN (l_prep) for_11\IN (l_pobj) melanoma_12\NN
D003606_D008545 NONE dacarbazine_14\NN (r_nmod) therapy_18\NN (l_prep) for_19\IN (l_pobj) melanoma_20\NN
D003606_D008545 NONE DTIC_16\NNP (r_nmod) therapy_18\NN (l_prep) for_19\IN (l_pobj) melanoma_20\NN
D003606_D006504 CID dacarbazine_6\NN (r_compound) therapy_7\NN (r_pobj) after_5\IN (r_prep) disease_4\NN
D003606_D006504 CID DTIC_9\NNP (r_appos) therapy_7\NN (r_pobj) after_5\IN (r_prep) disease_4\NN
D003606_D006504 CID dacarbazine_14\NN (r_nmod) therapy_18\NN (r_nsubjpass) reported_22\VBN (l_nsubjpass) case_1\NN (l_prep) of_2\IN (l_pobj) disease_6\NN (l_prep) of_7\IN (l_pobj) liver_9\NN
D003606_D006504 CID DTIC_16\NNP (r_nmod) therapy_18\NN (r_nsubjpass) reported_22\VBN (l_nsubjpass) case_1\NN (l_prep) of_2\IN (l_pobj) disease_6\NN (l_prep) of_7\IN (l_pobj) liver_9\NN
3714122
D010755_D020258 NONE organophosphate_33\NN (r_appos) Mipafox_24\NNP (r_pobj) to_23\IN (r_prep) exposed_22\VBN (r_acl) rats_20\NNS (r_pobj) in_19\IN (r_prep) examined_18\VBN (l_nsubjpass) correlation_1\NN (l_prep) between_2\IN (l_pobj) damage_4\NN (l_prep) of_7\IN (l_pobj) esterase_9\NN (l_amod) neurotoxic_8\JJ
D010755_D020258 NONE organophosphate_33\NN (l_amod) neurotoxic_32\JJ
C005238_D013118 CID Mipafox_5\NNP (r_pobj) of_4\IN (r_prep) dosages_3\NNS (r_nsubj) produced_39\VBN (l_dobj) degree_41\NN (l_prep) of_42\IN (l_pobj) damage_44\NN
C005238_D009422 NONE mipafox_7\NN (r_npadvmod) induced_9\VBN (r_amod) damage_11\NN
C005238_D009422 NONE Mipafox_24\NNP (r_pobj) to_23\IN (r_prep) exposed_22\VBN (r_acl) rats_20\NNS (r_pobj) in_19\IN (r_prep) examined_18\VBN (l_nsubjpass) correlation_1\NN (l_prep) between_2\IN (l_pobj) damage_4\NN
C005238_D009422 NONE Mipafox_24\NNP (r_pobj) to_23\IN (r_prep) exposed_22\VBN (r_acl) rats_20\NNS (r_pobj) in_19\IN (r_prep) examined_18\VBN (l_nsubjpass) correlation_1\NN (l_prep) between_2\IN (l_pobj) damage_4\NN (l_prep) of_7\IN (l_pobj) esterase_9\NN (l_conj) enzyme_13\NN (l_compound) target_12\NN (l_compound) neuropathy_11\NN
C005238_D009422 NONE N'-diisopropylphosphorodiamidofluoridate_28\NNP (r_appos) Mipafox_24\NNP (r_pobj) to_23\IN (r_prep) exposed_22\VBN (r_acl) rats_20\NNS (r_pobj) in_19\IN (r_prep) examined_18\VBN (l_nsubjpass) correlation_1\NN (l_prep) between_2\IN (l_pobj) damage_4\NN
C005238_D009422 NONE N'-diisopropylphosphorodiamidofluoridate_28\NNP (r_appos) Mipafox_24\NNP (r_pobj) to_23\IN (r_prep) exposed_22\VBN (r_acl) rats_20\NNS (r_pobj) in_19\IN (r_prep) examined_18\VBN (l_nsubjpass) correlation_1\NN (l_prep) between_2\IN (l_pobj) damage_4\NN (l_prep) of_7\IN (l_pobj) esterase_9\NN (l_conj) enzyme_13\NN (l_compound) target_12\NN (l_compound) neuropathy_11\NN
C005238_D009422 NONE Mipafox_18\NNP (r_compound) exposure_19\NN (r_nsubj) predict_21\VB (l_dobj) damage_23\NN
D010755_D009422 NONE organophosphate_33\NN (r_appos) Mipafox_24\NNP (r_pobj) to_23\IN (r_prep) exposed_22\VBN (r_acl) rats_20\NNS (r_pobj) in_19\IN (r_prep) examined_18\VBN (l_nsubjpass) correlation_1\NN (l_prep) between_2\IN (l_pobj) damage_4\NN
D010755_D009422 NONE organophosphate_33\NN (r_appos) Mipafox_24\NNP (r_pobj) to_23\IN (r_prep) exposed_22\VBN (r_acl) rats_20\NNS (r_pobj) in_19\IN (r_prep) examined_18\VBN (l_nsubjpass) correlation_1\NN (l_prep) between_2\IN (l_pobj) damage_4\NN (l_prep) of_7\IN (l_pobj) esterase_9\NN (l_conj) enzyme_13\NN (l_compound) target_12\NN (l_compound) neuropathy_11\NN
C005238_D020258 NONE mipafox_7\NN (r_npadvmod) induced_9\VBN (r_amod) damage_11\NN (r_conj) inhibition_5\NN (l_amod) neurotoxic_3\JJ
C005238_D020258 NONE Mipafox_24\NNP (r_pobj) to_23\IN (r_prep) exposed_22\VBN (r_acl) rats_20\NNS (r_pobj) in_19\IN (r_prep) examined_18\VBN (l_nsubjpass) correlation_1\NN (l_prep) between_2\IN (l_pobj) damage_4\NN (l_prep) of_7\IN (l_pobj) esterase_9\NN (l_amod) neurotoxic_8\JJ
C005238_D020258 NONE Mipafox_24\NNP (l_appos) organophosphate_33\NN (l_amod) neurotoxic_32\JJ
C005238_D020258 NONE N'-diisopropylphosphorodiamidofluoridate_28\NNP (r_appos) Mipafox_24\NNP (r_pobj) to_23\IN (r_prep) exposed_22\VBN (r_acl) rats_20\NNS (r_pobj) in_19\IN (r_prep) examined_18\VBN (l_nsubjpass) correlation_1\NN (l_prep) between_2\IN (l_pobj) damage_4\NN (l_prep) of_7\IN (l_pobj) esterase_9\NN (l_amod) neurotoxic_8\JJ
C005238_D020258 NONE N'-diisopropylphosphorodiamidofluoridate_28\NNP (r_appos) Mipafox_24\NNP (l_appos) organophosphate_33\NN (l_amod) neurotoxic_32\JJ
2559236
D004317_D000419 CID adriamycin_7\NNS (r_pobj) of_6\IN (r_prep) dose_5\NN (r_dobj) given_2\VBN (l_advcl) divided_12\VBD (l_prep) into_13\IN (l_pobj) groups_15\NNS (l_acl) matched_16\VBN (l_prep) for_17\IN (l_pobj) albuminuria_18\NN
D004656_D009401 NONE enalapril_10\NN (r_appos) inhibitor_6\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (r_nsubjpass) assessed_12\VBN (l_prep) with_18\IN (l_pobj) nephrosis_21\NN
D004656_D009401 NONE enalapril_17\NN (r_pobj) of_16\IN (r_prep) effect_15\NN (l_prep) on_18\IN (l_pobj) progression_19\NN (l_prep) of_20\IN (l_pobj) injury_22\NN (l_prep) in_23\IN (l_pobj) nephrosis_25\NN
D004656_D007674 NONE enalapril_17\NN (r_pobj) of_16\IN (r_prep) effect_15\NN (l_prep) on_18\IN (l_pobj) progression_19\NN (l_prep) of_20\IN (l_pobj) injury_22\NN
D004317_D009401 CID adriamycin_20\NNS (r_amod) nephrosis_21\NN
D004317_D009401 CID adriamycin_24\JJ (r_amod) nephrosis_25\NN
D004656_D000419 NONE enalapril_7\DT (r_nsubj) reduced_8\JJ (l_prep) vs._16\IN (l_pobj) Hg_21\NNP (l_conj) pressure_36\NN (l_appos) +/-_39\SYM (l_prep) without_53\IN (l_pcomp) reducing_54\VBG (l_dobj) albuminuria_55\NN
D004656_D000419 NONE enalapril_1\NN (r_compound) treatment_2\NN (r_nsubj) reduced_3\VBN (r_amod) pressure_5\NN (l_prep) without_6\IN (l_pcomp) reducing_7\VBG (l_dobj) albuminuria_8\NN
D004317_D007674 NONE adriamycin_9\NNS (r_npadvmod) induced_11\VBN (r_amod) nephropathy_12\NN
D004317_D007674 NONE adriamycin_24\JJ (r_amod) nephrosis_25\NN (r_pobj) in_23\IN (r_prep) injury_22\NN
10739826
D003276_D054556 CID contraceptives_5\NNS (l_conj) risk_8\NN (l_prep) of_9\IN (l_pobj) thromboembolism_11\NN
D003276_D054556 CID contraceptives_17\NNS (r_pobj) with_14\IN (r_prep) associated_13\VBN (r_acl) thromboembolism_9\NN
D003276_D054556 CID contraceptives_17\NNS (r_pobj) with_14\IN (r_prep) associated_13\VBN (r_acl) thromboembolism_9\NN (l_appos) VTE_11\NNP
D003276_D054556 CID OC_19\NNP (r_appos) contraceptives_17\NNS (r_pobj) with_14\IN (r_prep) associated_13\VBN (r_acl) thromboembolism_9\NN
D003276_D054556 CID OC_19\NNP (r_appos) contraceptives_17\NNS (r_pobj) with_14\IN (r_prep) associated_13\VBN (r_acl) thromboembolism_9\NN (l_appos) VTE_11\NNP
D003276_D054556 CID OC_27\NNP (r_compound) use_28\NN (r_pobj) of_26\IN (r_prep) patterns_25\NNS (r_pobj) between_24\IN (r_prep) distinguish_23\VB (l_nsubj) studies_2\NNS (l_relcl) assessed_4\VBD (l_dobj) risk_6\NN (l_prep) of_7\IN (l_pobj) thromboembolism_9\NN
D003276_D054556 CID OC_27\NNP (r_compound) use_28\NN (r_pobj) of_26\IN (r_prep) patterns_25\NNS (r_pobj) between_24\IN (r_prep) distinguish_23\VB (l_nsubj) studies_2\NNS (l_relcl) assessed_4\VBD (l_dobj) risk_6\NN (l_prep) of_7\IN (l_pobj) thromboembolism_9\NN (l_appos) VTE_11\NNP
D003276_D054556 CID OC_12\NNP (r_pobj) of_9\IN (r_prep) users_8\NNS (r_pobj) for_6\IN (r_prep) ratio_3\NN (l_prep) of_4\IN (l_pobj) VTE_5\NN
12627929
C067311_D054556 CID docetaxel_9\NNS (r_pobj) of_8\IN (r_prep) combination_7\NN (r_pobj) with_5\IN (r_prep) thromboembolism_4\NN
C067311_D054556 CID docetaxel_26\NNS (r_pobj) with_25\IN (r_prep) treated_24\VBN (r_relcl) cancer_21\NN (r_pobj) with_15\IN (r_prep) patients_14\NNS (r_pobj) in_13\IN (r_prep) frequency_6\NN (l_prep) of_7\IN (l_pobj) thromboembolism_9\NN
C067311_D054556 CID docetaxel_26\NNS (r_pobj) with_25\IN (r_prep) treated_24\VBN (r_relcl) cancer_21\NN (r_pobj) with_15\IN (r_prep) patients_14\NNS (r_pobj) in_13\IN (r_prep) frequency_6\NN (l_prep) of_7\IN (l_pobj) thromboembolism_9\NN (l_appos) VTE_11\NNP
C067311_D054556 CID docetaxel_6\NNS (r_dobj) received_5\VBD (r_relcl) patients_3\NNS (r_pobj) of_1\IN (r_prep) None_0\NN (r_nsubj) developed_8\VBN (l_dobj) VTE_9\NNP
C067311_D054556 CID docetaxel_6\NNS (r_dobj) received_5\VBD (r_relcl) patients_3\NNS (r_pobj) of_1\IN (r_prep) None_0\NN (r_nsubj) developed_8\VBN (l_advcl) developed_25\VBD (l_dobj) VTE_26\NNP
C067311_D054556 CID docetaxel_22\NNS (r_dobj) received_21\VBD (r_relcl) patients_15\NNS (r_pobj) of_13\IN (r_prep) 9_12\CD (r_nsubj) developed_25\VBD (r_advcl) developed_8\VBN (l_dobj) VTE_9\NNP
C067311_D054556 CID docetaxel_22\NNS (r_dobj) received_21\VBD (r_relcl) patients_15\NNS (r_pobj) of_13\IN (r_prep) 9_12\CD (r_nsubj) developed_25\VBD (l_dobj) VTE_26\NNP
C067311_D054556 CID docetaxel_5\NNS (r_relcl) addition_1\NN (r_nsubj) increases_13\VBZ (l_dobj) frequency_15\NN (l_prep) of_16\IN (l_pobj) VTE_17\NNP
D013792_D011471 NONE thalidomide_11\NN (r_conj) docetaxel_9\NNS (r_pobj) of_8\IN (r_prep) combination_7\NN (l_prep) in_12\IN (l_pobj) patients_13\NNS (l_prep) with_14\IN (l_pobj) cancer_20\NN
D013792_D011471 NONE thalidomide_32\NN (r_pobj) with_31\IN (r_prep) combination_30\NN (r_pobj) in_29\IN (r_conj) alone_27\RB (r_advmod) treated_24\VBN (r_relcl) cancer_21\NN
D013792_D011471 NONE thalidomide_3\NN (r_pobj) of_2\IN (r_prep) addition_1\NN (l_relcl) docetaxel_5\NNS (l_prep) in_6\IN (l_pobj) treatment_8\NN (l_prep) of_9\IN (l_pobj) cancer_11\NN
D013792_D054556 CID thalidomide_11\NN (r_conj) docetaxel_9\NNS (r_pobj) of_8\IN (r_prep) combination_7\NN (r_pobj) with_5\IN (r_prep) thromboembolism_4\NN
D013792_D054556 CID thalidomide_32\NN (r_pobj) with_31\IN (r_prep) combination_30\NN (r_pobj) in_29\IN (r_conj) alone_27\RB (r_advmod) treated_24\VBN (r_relcl) cancer_21\NN (r_pobj) with_15\IN (r_prep) patients_14\NNS (r_pobj) in_13\IN (r_prep) frequency_6\NN (l_prep) of_7\IN (l_pobj) thromboembolism_9\NN
D013792_D054556 CID thalidomide_32\NN (r_pobj) with_31\IN (r_prep) combination_30\NN (r_pobj) in_29\IN (r_conj) alone_27\RB (r_advmod) treated_24\VBN (r_relcl) cancer_21\NN (r_pobj) with_15\IN (r_prep) patients_14\NNS (r_pobj) in_13\IN (r_prep) frequency_6\NN (l_prep) of_7\IN (l_pobj) thromboembolism_9\NN (l_appos) VTE_11\NNP
D013792_D054556 CID thalidomide_24\NN (r_conj) 9_12\CD (r_nsubj) developed_25\VBD (r_advcl) developed_8\VBN (l_dobj) VTE_9\NNP
D013792_D054556 CID thalidomide_24\NN (r_conj) 9_12\CD (r_nsubj) developed_25\VBD (l_dobj) VTE_26\NNP
D013792_D054556 CID thalidomide_3\NN (r_pobj) of_2\IN (r_prep) addition_1\NN (r_nsubj) increases_13\VBZ (l_dobj) frequency_15\NN (l_prep) of_16\IN (l_pobj) VTE_17\NNP
C067311_D011471 NONE docetaxel_9\NNS (r_pobj) of_8\IN (r_prep) combination_7\NN (l_prep) in_12\IN (l_pobj) patients_13\NNS (l_prep) with_14\IN (l_pobj) cancer_20\NN
C067311_D011471 NONE docetaxel_26\NNS (r_pobj) with_25\IN (r_prep) treated_24\VBN (r_relcl) cancer_21\NN
C067311_D011471 NONE docetaxel_5\NNS (l_prep) in_6\IN (l_pobj) treatment_8\NN (l_prep) of_9\IN (l_pobj) cancer_11\NN
8919272
D014635_D009422 NONE valproate_10\NN (l_dobj) disorders_43\NNS
D014635_D009422 NONE valproate_49\NNP (r_amod) encephalopathy_50\JJ (r_appos) damage_46\NN (r_dobj) indicating_44\VBG (r_acl) disorders_43\NNS
D014635_D056486 NONE valproate_15\NNP (r_amod) encephalopathy_16\NNP (r_pobj) of_14\IN (r_prep) development_13\NN (r_pobj) upon_11\IN (r_prep) hyperammonemia_9\NN (l_nsubj) influence_2\NN (l_prep) of_3\IN (l_pobj) damage_6\NN
D014635_D001927 CID valproate_11\NN (l_nsubj) features_1\NNS (l_prep) of_2\IN (l_pobj) encephalopathy_3\NN
D014635_D001927 CID valproate_10\NN (l_dobj) disorders_43\NNS (l_acl) indicating_44\VBG (l_dobj) damage_46\NN (l_appos) encephalopathy_50\JJ
D014635_D001927 CID valproate_49\NNP (r_amod) encephalopathy_50\JJ
D014635_D001927 CID valproate_15\NNP (r_amod) encephalopathy_16\NNP
D014635_D002526 NONE valproate_10\NN (l_dobj) disorders_43\NNS (l_acl) indicating_44\VBG (l_dobj) damage_46\NN
D014635_D002526 NONE valproate_49\NNP (r_amod) encephalopathy_50\JJ (r_appos) damage_46\NN
D014635_D022124 NONE valproate_15\NNP (r_amod) encephalopathy_16\NNP (r_pobj) of_14\IN (r_prep) development_13\NN (r_pobj) upon_11\IN (r_prep) hyperammonemia_9\NN
18439803
D010862_D012640 CID pilocarpine_10\NN (r_npadvmod) induced_12\VBN (r_amod) seizure_13\NN
D010862_D012640 CID pilocarpine_23\NN (r_npadvmod) induced_25\VBN (r_amod) seizure_26\NN
D010862_D012640 CID pilocarpine_13\NN (r_npadvmod) induced_15\VBN (r_amod) seizure_16\NN
D010862_D012640 CID pilocarpine_12\NN (r_npadvmod) induced_14\VBN (r_amod) increases_15\NNS (r_dobj) reduce_11\VB (r_relcl) finding_6\NN (r_appos) VPA_3\NNP (r_pobj) like_2\IN (r_prep) account_21\VB (l_prep) for_27\IN (l_pobj) activity_30\NN (l_acl) observed_31\VBN (l_prep) in_32\IN (l_pobj) seizure_36\NN
D010862_D012640 CID pilocarpine_33\NN (r_npadvmod) induced_35\VBN (r_amod) seizure_36\NN
D000596_D012640 NONE acid_7\NN (r_compound) neurotransmitters_8\NNS (r_pobj) on_4\IN (r_prep) effects_1\NNS (l_prep) in_9\IN (l_pobj) seizure_13\NN
D000596_D012640 NONE acid_26\NN (r_compound) neurotransmitters_27\NNS (r_pobj) of_23\IN (r_prep) reduction_22\NN (r_nsubj) was_28\VBD (r_ccomp) suggested_19\VBN (l_prep) Based_0\VBN (l_prep) on_1\IN (l_pobj) finding_3\NN (l_acl) protect_9\VB (l_dobj) animals_11\NNS (l_prep) against_12\IN (l_pobj) seizure_16\NN
C108761_D012640 NONE N-(2-propylpentanoyl)urea_3\NNP (r_pobj) of_2\IN (r_prep) effects_1\NNS (l_prep) in_9\IN (l_pobj) seizure_13\NN
C108761_D012640 NONE VPU_0\NNS (r_nsubj) was_1\VBD (l_advcl) exhibiting_7\VBG (l_dobj) dose_11\NN (l_prep) of_16\IN (l_pobj) mg/kg_18\NNS (l_prep) in_19\IN (l_pcomp) protecting_20\VBG (l_prep) against_22\IN (l_pobj) seizure_26\NN
C108761_D012640 NONE VPU_5\NNPS (r_nsubj) protect_9\VB (l_dobj) animals_11\NNS (l_prep) against_12\IN (l_pobj) seizure_16\NN
C108761_D012640 NONE VPU_8\NNP (r_nsubj) reduce_11\VB (r_relcl) finding_6\NN (r_appos) VPA_3\NNP (r_pobj) like_2\IN (r_prep) account_21\VB (l_prep) for_27\IN (l_pobj) activity_30\NN (l_acl) observed_31\VBN (l_prep) in_32\IN (l_pobj) seizure_36\NN
D001224_D012640 NONE aspartate_40\NN (r_conj) glutamate_38\NN (r_pobj) of_37\IN (r_prep) reduction_36\NN (r_pobj) by_33\IN (r_agent) offset_32\VBN (r_conj) was_28\VBD (r_ccomp) suggested_19\VBN (l_prep) Based_0\VBN (l_prep) on_1\IN (l_pobj) finding_3\NN (l_acl) protect_9\VB (l_dobj) animals_11\NNS (l_prep) against_12\IN (l_pobj) seizure_16\NN
D001224_D012640 NONE aspartate_19\NN (r_conj) glutamate_17\NN (r_pobj) in_16\IN (r_prep) increases_15\NNS (r_dobj) reduce_11\VB (r_relcl) finding_6\NN (r_appos) VPA_3\NNP (r_pobj) like_2\IN (r_prep) account_21\VB (l_prep) for_27\IN (l_pobj) activity_30\NN (l_acl) observed_31\VBN (l_prep) in_32\IN (l_pobj) seizure_36\NN
D014635_D012640 NONE VPA_5\NNP (r_pobj) than_4\IN (r_prep) potent_3\JJ (r_acomp) was_1\VBD (l_advcl) exhibiting_7\VBG (l_dobj) dose_11\NN (l_prep) of_16\IN (l_pobj) mg/kg_18\NNS (l_prep) in_19\IN (l_pcomp) protecting_20\VBG (l_prep) against_22\IN (l_pobj) seizure_26\NN
D014635_D012640 NONE VPA_32\NNP (r_pobj) for_31\IN (r_prep) value_30\NN (r_nsubj) was_33\VBD (r_advcl) exhibiting_7\VBG (l_dobj) dose_11\NN (l_prep) of_16\IN (l_pobj) mg/kg_18\NNS (l_prep) in_19\IN (l_pcomp) protecting_20\VBG (l_prep) against_22\IN (l_pobj) seizure_26\NN
D014635_D012640 NONE VPA_7\NNP (r_conj) VPU_5\NNPS (r_nsubj) protect_9\VB (l_dobj) animals_11\NNS (l_prep) against_12\IN (l_pobj) seizure_16\NN
D014635_D012640 NONE VPA_3\NNP (r_pobj) like_2\IN (r_prep) account_21\VB (l_prep) for_27\IN (l_pobj) activity_30\NN (l_acl) observed_31\VBN (l_prep) in_32\IN (l_pobj) seizure_36\NN
D018698_D012640 NONE glutamate_38\NN (r_pobj) of_37\IN (r_prep) reduction_36\NN (r_pobj) by_33\IN (r_agent) offset_32\VBN (r_conj) was_28\VBD (r_ccomp) suggested_19\VBN (l_prep) Based_0\VBN (l_prep) on_1\IN (l_pobj) finding_3\NN (l_acl) protect_9\VB (l_dobj) animals_11\NNS (l_prep) against_12\IN (l_pobj) seizure_16\NN
D018698_D012640 NONE glutamate_17\NN (r_pobj) in_16\IN (r_prep) increases_15\NNS (r_dobj) reduce_11\VB (r_relcl) finding_6\NN (r_appos) VPA_3\NNP (r_pobj) like_2\IN (r_prep) account_21\VB (l_prep) for_27\IN (l_pobj) activity_30\NN (l_acl) observed_31\VBN (l_prep) in_32\IN (l_pobj) seizure_36\NN
1720453
D007069_D064420 NONE ifosfamide_15\NN (r_pobj) of_14\IN (r_prep) m2_13\NN (r_pobj) of_9\IN (r_prep) dose_8\NN (r_pobj) with_4\IN (r_prep) correlated_3\VBN (l_nsubjpass) toxicity_1\NN
D007069_C535700 NONE ifosfamide_7\JJ (r_amod) toxicity_9\NN (r_pobj) of_6\IN (r_prep) up_5\NN (r_nsubj) treated_12\VBN (l_prep) for_13\IN (l_pobj) tumors_16\NNS
D007069_C535700 NONE ifosfamide_19\JJ (r_compound) protocol_21\NN (r_dobj) received_16\VBN (r_relcl) function_2\NN (l_prep) with_6\IN (l_pobj) tumors_9\NNS
D007069_C535700 NONE ifosfamide_19\JJ (r_compound) protocol_21\NN (l_appos) Society_24\NNP (l_prep) of_25\IN (l_pobj) Study_31\NNP (l_compound) Tumor_30\NNP
D007069_C535700 NONE ifosfamide_18\NN (r_pobj) of_17\IN (r_prep) efficacy_16\NN (l_prep) in_19\IN (l_pobj) treatment_21\NN (l_prep) of_22\IN (l_pobj) tumors_24\NNS
D010710_D011507 NONE phosphate_25\NN (r_nmod) reabsorption_27\NN (r_conj) clearance_23\NN (r_conj) osmolarity_20\NN (r_conj) pH_18\NN (r_conj) aminoaciduria_15\JJ (r_conj) proteinuria_13\NN
D010710_D064420 NONE phosphate_51\NN (r_compound) reabsorption_52\NN (r_conj) microglobulinuria_48\NN (r_pobj) with_44\IN (r_prep) patients_43\NNS (r_dobj) included_41\VBD (r_conj) included_13\VBD (l_dobj) patients_15\NNS (l_relcl) developed_25\VBD (l_dobj) toxicity_27\NN
D007069_D009369 NONE ifosfamide_15\NN (r_pobj) of_14\IN (r_prep) m2_13\NN (r_pobj) of_9\IN (r_prep) dose_8\NN (l_conj) predominance_31\NN (l_prep) of_32\IN (l_pobj) involvement_35\NN (l_compound) tumor_34\NN
D003404_D011507 NONE creatinine_22\NN (r_compound) clearance_23\NN (r_conj) osmolarity_20\NN (r_conj) pH_18\NN (r_conj) aminoaciduria_15\JJ (r_conj) proteinuria_13\NN
D003404_D000608 NONE creatinine_22\NN (r_compound) clearance_23\NN (r_conj) osmolarity_20\NN (r_conj) pH_18\NN (r_conj) aminoaciduria_15\JJ
D003404_D006030 NONE creatinine_22\NN (r_compound) clearance_23\NN (r_conj) osmolarity_20\NN (r_conj) pH_18\NN (r_conj) aminoaciduria_15\JJ (r_conj) proteinuria_13\NN (r_conj) glucosuria_11\NN
D010710_D006030 NONE phosphate_25\NN (r_nmod) reabsorption_27\NN (r_conj) clearance_23\NN (r_conj) osmolarity_20\NN (r_conj) pH_18\NN (r_conj) aminoaciduria_15\JJ (r_conj) proteinuria_13\NN (r_conj) glucosuria_11\NN
D007069_D007674 CID ifosfamide_7\JJ (r_amod) toxicity_9\NN
D010710_D000608 NONE phosphate_25\NN (r_nmod) reabsorption_27\NN (r_conj) clearance_23\NN (r_conj) osmolarity_20\NN (r_conj) pH_18\NN (r_conj) aminoaciduria_15\JJ
D010710_D005198 NONE phosphate_51\NN (r_compound) reabsorption_52\NN (r_conj) microglobulinuria_48\NN (r_pobj) with_44\IN (r_prep) patients_43\NNS (r_dobj) included_41\VBD (r_conj) included_13\VBD (l_dobj) patients_15\NNS (l_relcl) developed_25\VBD (l_dobj) toxicity_27\NN (l_acl) resulting_28\VBG (l_prep) in_29\IN (l_pobj) syndrome_32\NN
D010710_D005198 NONE phosphate_51\NN (r_compound) reabsorption_52\NN (r_conj) microglobulinuria_48\NN (r_pobj) with_44\IN (r_prep) patients_43\NNS (r_dobj) included_41\VBD (r_conj) included_13\VBD (l_dobj) patients_15\NNS (l_relcl) developed_25\VBD (l_dobj) toxicity_27\NN (l_acl) resulting_28\VBG (l_prep) in_29\IN (l_pobj) syndrome_32\NN (l_appos) TDFS_34\NNP
9245658
D009538_D013927 NONE Nicotine_0\NN (r_nsubj) appear_3\VB (l_xcomp) enhance_5\VB (l_dobj) thrombosis_6\NN
D009538_D050197 CID nicotine_7\NN (r_nsubj) play_9\VB (l_dobj) role_11\NN (l_prep) in_12\IN (l_pcomp) accelerating_13\VBG (l_dobj) atherosclerosis_14\NN
D009538_D002318 CID nicotine_3\NN (r_pobj) of_2\IN (r_prep) role_1\NN (l_prep) in_4\IN (l_pobj) disease_9\NN
D009538_D002318 CID Nicotine_0\NNP (r_nsubj) activates_1\VBZ (l_conj) contribute_11\VB (l_prep) to_12\IN (l_pobj) disease_14\NN
9746003
D002220_D009207 CID carbamazepine_9\NN (l_conj) two_11\CD (l_prep) of_12\IN (l_pobj) jerks_16\NNS
D002220_D009207 CID carbamazepine_23\NN (r_pobj) of_22\IN (r_prep) withdrawal_21\NN (r_pobj) on_20\IN (r_prep) resolved_19\VBD (r_relcl) jerks_16\NNS
D020888_D004832 CID vigabatrin_5\VBP (l_prep) in_6\IN (l_pobj) seizures_9\NNS
D020888_D004832 CID vigabatrin_2\NN (r_conj) Carbamazepine_0\NNP (r_nsubjpass) contraindicated_4\VBN (l_prep) in_5\IN (l_pobj) seizures_8\NNS
D002220_D004832 CID carbamazepine_3\NN (l_conj) vigabatrin_5\VBP (l_prep) in_6\IN (l_pobj) seizures_9\NNS
D002220_D004832 CID Carbamazepine_0\NNP (r_nsubjpass) contraindicated_4\VBN (l_prep) in_5\IN (l_pobj) seizures_8\NNS
18081909
C026098_D001927 CID levetiracetam_3\NN (r_pcomp) by_2\IN (r_prep) induced_1\VBN (l_nsubj) Encephalopathy_0\JJ
C026098_D001927 CID levetiracetam_7\FW (r_amod) encephalopathy_10\JJ
C026098_D001927 CID LEV)-induced_9\VBN (r_amod) encephalopathy_10\JJ
C026098_C562694 NONE LEV_15\NNP (r_pobj) with_14\IN (r_prep) treated_13\VBN (l_nsubjpass) man_4\NN (l_acl) suffering_5\VBG (l_prep) from_6\IN (l_pobj) epilepsy_8\NN
C026098_D012640 NONE LEV_15\NNP (r_pobj) with_14\IN (r_prep) treated_13\VBN (l_nsubjpass) man_4\NN (l_acl) suffering_5\VBG (l_prep) with_9\IN (l_pobj) seizures_11\NNS
C026098_D012640 NONE LEV_3\NNP (r_pobj) of_2\IN (r_prep) discontinuation_1\NN (r_pobj) Following_0\VBG (l_preconj) improved_9\VBN (l_conj) decreased_13\VBD (l_nsubj) frequency_12\NN (l_compound) seizure_11\NN
D014635_C562694 NONE valproate_22\VB (r_xcomp) added_20\VBN (r_conj) treated_13\VBN (l_nsubjpass) man_4\NN (l_acl) suffering_5\VBG (l_prep) from_6\IN (l_pobj) epilepsy_8\NN
D014635_C562694 NONE VPA_24\NNP (r_dobj) valproate_22\VB (r_xcomp) added_20\VBN (r_conj) treated_13\VBN (l_nsubjpass) man_4\NN (l_acl) suffering_5\VBG (l_prep) from_6\IN (l_pobj) epilepsy_8\NN
D014635_D001927 CID valproate_6\VB (r_xcomp) added_4\VBN (r_conj) induced_1\VBN (l_nsubj) Encephalopathy_0\JJ
D014635_D012640 NONE valproate_22\VB (r_xcomp) added_20\VBN (r_conj) treated_13\VBN (l_nsubjpass) man_4\NN (l_acl) suffering_5\VBG (l_prep) with_9\IN (l_pobj) seizures_11\NNS
D014635_D012640 NONE VPA_24\NNP (r_dobj) valproate_22\VB (r_xcomp) added_20\VBN (r_conj) treated_13\VBN (l_nsubjpass) man_4\NN (l_acl) suffering_5\VBG (l_prep) with_9\IN (l_pobj) seizures_11\NNS
20520283
C522667_D001480 CID asenapine_21\NN (r_pobj) of_19\IN (r_prep) %_18\NN (r_conj) %_14\NN (r_appos) %_8\NN (r_pobj) in_6\IN (r_prep) occurred_5\VBD (r_advcl) reported_2\VBD (l_nsubj) symptoms_1\NNS
C522667_D001480 CID asenapine_9\NN (r_pobj) with_8\IN (r_prep) similar_7\JJ (r_acomp) was_6\VBD (r_ccomp) indicated_3\VBD (r_ccomp) seen_16\VBN (l_prep) in_17\IN (l_pobj) AEs_18\NNS (l_appos) symptoms_22\NNS
C522667_D001714 NONE Asenapine_0\NNP (r_nsubjpass) approved_2\VBN (l_prep) in_9\IN (l_pobj) adults_10\NNS (l_prep) for_11\IN (l_conj) of_17\IN (l_pobj) episodes_21\NNS (l_amod) manic_18\JJ
C522667_D001714 NONE Asenapine_0\NNP (r_nsubjpass) approved_2\VBN (l_prep) in_9\IN (l_pobj) adults_10\NNS (l_prep) for_11\IN (l_conj) of_17\IN (l_pobj) episodes_21\NNS (l_acl) associated_22\VBN (l_prep) with_23\IN (l_pobj) disorder_26\NN
C522667_D011618 NONE Asenapine_0\NNP (r_nsubjpass) approved_2\VBN (l_prep) in_9\IN (l_pobj) adults_10\NNS (l_prep) for_11\IN (l_conj) of_17\IN (l_pobj) episodes_21\NNS (l_acl) associated_22\VBN (l_prep) with_23\IN (l_pobj) disorder_26\NN (l_prep) with_27\IN (l_conj) without_29\IN (l_pobj) features_31\NNS (l_amod) psychotic_30\JJ
D006220_D001480 CID haloperidol_29\NN (r_conj) BID_27\NN (r_pobj) at_22\IN (r_prep) %_18\NN (r_conj) %_14\NN (r_appos) %_8\NN (r_pobj) in_6\IN (r_prep) occurred_5\VBD (r_advcl) reported_2\VBD (l_nsubj) symptoms_1\NNS
D006220_D001480 CID haloperidol_11\NN (r_conj) asenapine_9\NN (r_pobj) with_8\IN (r_prep) similar_7\JJ (r_acomp) was_6\VBD (r_ccomp) indicated_3\VBD (r_ccomp) seen_16\VBN (l_prep) in_17\IN (l_pobj) AEs_18\NNS (l_appos) symptoms_22\NNS
C522667_D012559 NONE asenapine_4\NN (r_pobj) of_3\IN (r_prep) Efficacy_0\NN (l_prep) in_5\IN (l_pobj) trial_12\NN (l_prep) in_13\IN (l_pobj) patients_14\NNS (l_prep) with_15\IN (l_pobj) exacerbation_17\NN (l_prep) of_18\IN (l_pobj) schizophrenia_19\NN
C522667_D012559 NONE Asenapine_0\NNP (r_nsubjpass) approved_2\VBN (l_prep) in_9\IN (l_pobj) adults_10\NNS (l_prep) for_11\IN (l_pobj) treatment_13\NN (l_prep) of_14\IN (l_pobj) schizophrenia_15\NN
C522667_D012559 NONE asenapine_22\NN (r_pobj) with_21\IN (r_prep) treatment_20\NN (r_pobj) to_16\IN (r_prep) assigned_15\VBN (l_nsubjpass) patients_9\NNS (l_prep) with_10\IN (l_pobj) schizophrenia_12\NN
C522667_D012559 NONE asenapine_32\NN (r_dep) assigned_15\VBN (l_nsubjpass) patients_9\NNS (l_prep) with_10\IN (l_pobj) schizophrenia_12\NN
D006220_D012559 NONE haloperidol_9\NN (r_npadvmod) controlled_11\VBN (r_amod) trial_12\NN (l_prep) in_13\IN (l_pobj) patients_14\NNS (l_prep) with_15\IN (l_pobj) exacerbation_17\NN (l_prep) of_18\IN (l_pobj) schizophrenia_19\NN
D006220_D012559 NONE haloperidol_41\NN (r_conj) placebo_38\NN (r_conj) BID_36\NN (r_pobj) at_33\IN (r_prep) asenapine_32\NN (r_dep) assigned_15\VBN (l_nsubjpass) patients_9\NNS (l_prep) with_10\IN (l_pobj) schizophrenia_12\NN
7504976
D002231_D002779 CID carbimazole_8\NN (r_pobj) by_7\IN (r_agent) induced_6\VBN (l_nsubj) hepatitis_5\NN
D002231_D002779 CID omercazole_11\NN (r_appos) carbimazole_8\NN (r_pobj) by_7\IN (r_agent) induced_6\VBN (l_nsubj) hepatitis_5\NN
D002231_D002779 CID carbimazole_12\NN (l_amod) mixed_4\JJ (l_conj) cholestatic_6\JJ
D002231_D056486 CID carbimazole_16\NN (r_pobj) between_15\IN (r_prep) reactivity_14\NN (r_pobj) with_11\IN (r_prep) one_10\CD (r_pobj) including_9\VBG (r_prep) cases_8\NNS (r_appos) induced_2\VBN (l_nsubj) hepatitis_1\NN
D002231_D056486 CID carbimazole_8\NN (r_pobj) by_7\IN (r_agent) induced_6\VBN (l_nsubj) hepatitis_5\NN
D002231_D056486 CID omercazole_11\NN (r_appos) carbimazole_8\NN (r_pobj) by_7\IN (r_agent) induced_6\VBN (l_nsubj) hepatitis_5\NN
D002231_D056486 CID carbimazole_12\NN (l_amod) following_11\VBG (l_compound) hepatitis_10\NN
D002231_D056486 CID carbimazole_21\NN (r_dobj) replaced_20\VBN (l_nsubj) experienced_7\VBD (l_dobj) hepatitis_10\NN
C019269_D056486 NONE benzylthiouracil_18\NN (r_conj) carbimazole_16\NN (r_pobj) between_15\IN (r_prep) reactivity_14\NN (r_pobj) with_11\IN (r_prep) one_10\CD (r_pobj) including_9\VBG (r_prep) cases_8\NNS (r_appos) induced_2\VBN (l_nsubj) hepatitis_1\NN
C019269_D056486 NONE Benzylthiouracil_14\NNP (r_pobj) after_13\IN (r_prep) appeared_12\VBD (r_relcl) hepatitis_10\NN
C019269_D056486 NONE ne_17\NNP (r_appos) Benzylthiouracil_14\NNP (r_pobj) after_13\IN (r_prep) appeared_12\VBD (r_relcl) hepatitis_10\NN
11007689
D016559_D057049 CID tacrolimus_2\NN (r_npadvmod) associated_4\VBN (r_amod) microangiopathy_6\NN
D016559_D057049 CID tacrolimus_6\NN (r_pobj) to_5\IN (r_prep) switching_4\VBG (r_nsubjpass) reported_9\VBN (l_xcomp) be_11\VB (l_attr) option_15\NN (l_prep) in_16\IN (l_pobj) setting_18\NN (l_prep) of_19\IN (l_pobj) TMA_23\NNP
D016559_D057049 CID tacrolimus_6\NN (r_pobj) of_5\IN (r_prep) application_4\NN (r_pobj) With_0\IN (r_prep) recognized_18\VBN (l_nsubjpass) TMA_14\NNP
D016559_D057049 CID tacrolimus_11\NN (r_npadvmod) associated_13\VBN (r_amod) TMA_14\NNP
D016559_D057049 CID tacrolimus_18\NN (r_conj) cyclosporine_16\NN (r_pobj) to_15\IN (r_prep) exposed_13\VBN (r_acl) patients_12\NNS (r_pobj) in_11\IN (r_prep) recurrence_8\NN (l_prep) of_9\IN (l_pobj) TMA_10\NNP
D016559_D057049 CID tacrolimus_2\NN (r_pobj) of_1\IN (r_prep) Introduction_0\NN (r_nsubj) resulted_8\VBD (l_prep) in_9\IN (l_pobj) recurrence_11\NN (l_prep) of_12\IN (l_pobj) TMA_13\NNP
D016559_D057049 CID tacrolimus_7\NN (r_pobj) to_6\IN (r_prep) switched_3\VBN (r_relcl) Patients_0\NNS (r_nsubjpass) monitored_14\VBN (l_prep) for_15\IN (l_pobj) signs_17\NNS (l_prep) of_20\IN (l_pobj) TMA_22\NNP
D016572_D057049 CID Cyclosporine_0\NN (l_conj) microangiopathy_6\NN
D016572_D057049 CID cyclosporine_13\NN (r_pobj) of_12\IN (r_prep) use_11\NN (r_pobj) with_9\IN (r_prep) associated_8\VBN (r_acl) microangiopathy_4\NN
D016572_D057049 CID cyclosporine_13\NN (r_pobj) of_12\IN (r_prep) use_11\NN (r_pobj) with_9\IN (r_prep) associated_8\VBN (r_acl) microangiopathy_4\NN (l_appos) TMA_6\NNP
D016572_D057049 CID cyclosporine_20\NN (r_npadvmod) induced_22\VBN (r_amod) TMA_23\NNP
D016572_D057049 CID cyclosporine_16\NN (r_pobj) to_15\IN (r_prep) exposed_13\VBN (r_acl) patients_12\NNS (r_pobj) in_11\IN (r_prep) recurrence_8\NN (l_prep) of_9\IN (l_pobj) TMA_10\NNP
D016572_D057049 CID cyclosporine_13\NN (r_npadvmod) induced_15\VBN (r_amod) TMA_16\NNP
D016572_D057049 CID cyclosporine_23\NN (r_pobj) of_22\IN (r_prep) withdrawal_21\NN (r_pobj) to_19\IN (r_prep) responded_18\VBD (r_relcl) TMA_16\NNP
D016572_D057049 CID cyclosporine_5\NN (r_pobj) from_4\IN (r_prep) switched_3\VBN (r_relcl) Patients_0\NNS (r_nsubjpass) monitored_14\VBN (l_prep) for_15\IN (l_pobj) signs_17\NNS (l_prep) of_20\IN (l_pobj) TMA_22\NNP
8682684
D000082_D007022 CID Acetaminophen_0\NNP (r_npadvmod) induced_2\VBN (r_amod) hypotension_3\NN
D000082_D007022 CID acetaminophen_2\RB (r_nsubjpass) demonstrated_5\VBN (l_xcomp) produce_7\VB (l_dobj) symptoms_8\NNS (l_prep) including_12\VBG (l_pobj) hypotension_13\NN
D000082_D007022 CID acetaminophen_18\NN (r_pobj) of_17\IN (r_prep) administration_16\NN (r_pobj) after_15\IN (r_prep) developed_14\VBN (l_nsubj) episodes_10\NNS (l_prep) of_11\IN (l_pobj) hypotension_12\NN
D000082_D007022 CID acetaminophen_9\NN (r_dobj) consider_8\VB (l_prep) in_10\IN (l_pobj) patients_11\NNS (l_prep) with_12\IN (l_pobj) hypotension_13\NN
D000082_D002318 NONE acetaminophen_3\NN (r_pobj) for_2\IN (r_prep) potential_1\NN (l_acl) produce_5\VB (l_dobj) toxicities_7\NNS
D000082_D000707 NONE acetaminophen_2\RB (r_nsubjpass) demonstrated_5\VBN (l_xcomp) produce_7\VB (l_dobj) symptoms_8\NNS (l_prep) of_9\IN (l_pobj) anaphylaxis_10\NN
D000082_D016638 NONE acetaminophen_18\NN (r_pobj) of_17\IN (r_prep) administration_16\NN (r_pobj) after_15\IN (r_prep) developed_14\VBN (r_relcl) patients_6\NNS (l_amod) ill_5\JJ
15737522
D002443_D001660 CID Ceftriaxone_0\NN (r_npadvmod) associated_2\VBN (r_amod) pseudolithiasis_4\NN
D002443_D001660 CID ceftriaxone_5\NN (r_nsubj) leads_6\VBZ (l_xcomp) pseudolithiasis_8\NN
D002443_D001660 CID ceftriaxone_19\CD (r_compound) treatment_20\NN (r_dobj) receiving_18\VBG (r_acl) patients_17\NNS (r_pobj) in_14\IN (r_prep) pseudolithiasis_13\NN
19767176
D010100_D009410 NONE oxygen_5\NN (r_compound) species_6\NNS (r_pobj) of_3\IN (r_prep) production_2\NN (r_nsubjpass) implicated_17\VBN (l_prep) in_18\IN (l_pobj) damage_21\NN
D010100_D009410 NONE oxygen_9\NN (r_compound) species_10\NNS (r_pobj) of_7\IN (r_prep) generation_6\NN (r_nsubj) plays_17\VBZ (l_dobj) role_21\NN (l_prep) in_22\IN (l_pobj) damage_27\NN
C020972_D013226 NONE dithiocarbamate_1\NN (r_nsubj) protects_2\VBZ (l_dobj) cortex_5\NN (l_prep) in_6\IN (l_pobj) model_11\NN (l_amod) epilepticus_10\NN
C020972_D013226 NONE PDTC_3\NNP (r_pobj) of_2\IN (r_prep) effect_1\NN (l_prep) on_4\IN (l_pobj) loss_10\NN (l_amod) associated_8\VBN (l_npadvmod) epilepticus_6\NN
C020972_D013226 NONE PDTC_4\NNP (r_pobj) with_1\IN (r_prep) Treatment_0\NN (r_nsubj) increased_11\VBD (l_advmod) epilepticus_9\NN
C020972_D013226 NONE PDTC_4\NNP (r_nmod) dose_8\NN (r_pobj) of_1\IN (r_prep) Administration_0\NN (r_nsubj) exert_12\VB (l_dobj) effects_14\NNS (l_prep) on_15\IN (l_pobj) development_17\NN (l_prep) of_18\IN (l_pobj) epilepticus_21\NN
C020972_D013226 NONE PDTC_16\NNP (r_npadvmod) treated_18\VBN (r_amod) rats_19\NNS (r_conj) vehicle-_14\NN (r_pobj) in_13\IN (r_prep) identified_12\VBN (l_prep) following_20\VBG (l_pobj) epilepticus_22\NN
D010862_D013226 CID pilocarpine_8\NN (r_amod) model_11\NN (l_amod) epilepticus_10\NN
D010862_D013226 CID pilocarpine_23\NN (r_compound) model_24\NN (r_pobj) in_19\IN (r_prep) evaluated_18\VBN (l_nsubjpass) effect_1\NN (l_prep) on_4\IN (l_pobj) loss_10\NN (l_amod) associated_8\VBN (l_npadvmod) epilepticus_6\NN
D010100_D012640 NONE oxygen_9\NN (r_compound) species_10\NNS (r_pobj) of_7\IN (r_prep) generation_6\NN (r_nsubj) plays_17\VBZ (l_dobj) role_21\NN (l_prep) in_22\IN (l_pobj) damage_27\NN (l_amod) associated_25\VBN (l_npadvmod) seizure_23\NN
C020972_D009410 NONE PDTC_10\NNP (r_conj) inhibitor_7\NN (r_nsubj) protected_11\VBD (l_advcl) affect_20\VB (l_dobj) loss_23\NN
10193204
D001241_D013927 NONE acid_36\NN (r_dobj) acetylsalicylic_35\JJ (r_advcl) showed_20\VBD (l_dobj) inhibition_22\NN (l_prep) of_23\IN (l_pobj) thrombosis_24\NN
D001241_D013927 NONE ASA_38\NNP (r_appos) acid_36\NN (r_dobj) acetylsalicylic_35\JJ (r_advcl) showed_20\VBD (l_dobj) inhibition_22\NN (l_prep) of_23\IN (l_pobj) thrombosis_24\NN
D004837_D001791 NONE epinephrine_21\NN (r_conj) collagen_19\NN (r_pobj) by_18\IN (r_agent) induced_17\VBN (r_acl) thrombosis_16\NN (r_pobj) on_13\IN (r_prep) effects_8\NNS (r_dobj) investigate_6\VB (r_advcl) undertaken_4\VBN (l_conj) in_34\IN (l_nsubj) aggregation_30\NN
D004837_D001791 NONE EP_23\NN (r_appos) epinephrine_21\NN (r_conj) collagen_19\NN (r_pobj) by_18\IN (r_agent) induced_17\VBN (r_acl) thrombosis_16\NN (r_pobj) on_13\IN (r_prep) effects_8\NNS (r_dobj) investigate_6\VB (r_advcl) undertaken_4\VBN (l_conj) in_34\IN (l_nsubj) aggregation_30\NN
C009438_D001791 NONE tetrandrine_2\NN (r_pobj) of_1\IN (r_prep) Effects_0\NNS (l_prep) on_5\IN (l_pobj) thrombosis_7\NN (l_prep) in_8\IN (l_pobj) mice_9\NNS (l_conj) aggregation_13\NN
C009438_D001791 NONE TET_10\NNP (r_pobj) of_9\IN (r_prep) effects_8\NNS (r_dobj) investigate_6\VB (r_advcl) undertaken_4\VBN (l_conj) in_34\IN (l_nsubj) aggregation_30\NN
C009438_D001791 NONE TET_14\NNP (r_nsubj) showed_17\VBD (l_prep) In_0\IN (l_pobj) aggregations_5\NNS
C060802_D001778 NONE FAN_12\NNP (r_conj) TET_10\NNP (r_pobj) of_9\IN (r_prep) effects_8\NNS (r_dobj) investigate_6\VB (r_advcl) undertaken_4\VBN (l_conj) in_34\IN (l_nsubj) aggregation_30\NN (l_conj) coagulation_33\NN
C009438_D001778 NONE TET_10\NNP (r_pobj) of_9\IN (r_prep) effects_8\NNS (r_dobj) investigate_6\VB (r_advcl) undertaken_4\VBN (l_conj) in_34\IN (l_nsubj) aggregation_30\NN (l_conj) coagulation_33\NN
D004837_D001778 NONE epinephrine_21\NN (r_conj) collagen_19\NN (r_pobj) by_18\IN (r_agent) induced_17\VBN (r_acl) thrombosis_16\NN (r_pobj) on_13\IN (r_prep) effects_8\NNS (r_dobj) investigate_6\VB (r_advcl) undertaken_4\VBN (l_conj) in_34\IN (l_nsubj) aggregation_30\NN (l_conj) coagulation_33\NN
D004837_D001778 NONE EP_23\NN (r_appos) epinephrine_21\NN (r_conj) collagen_19\NN (r_pobj) by_18\IN (r_agent) induced_17\VBN (r_acl) thrombosis_16\NN (r_pobj) on_13\IN (r_prep) effects_8\NNS (r_dobj) investigate_6\VB (r_advcl) undertaken_4\VBN (l_conj) in_34\IN (l_nsubj) aggregation_30\NN (l_conj) coagulation_33\NN
C060802_D001791 NONE fangchinoline_4\NN (r_conj) tetrandrine_2\NN (r_pobj) of_1\IN (r_prep) Effects_0\NNS (l_prep) on_5\IN (l_pobj) thrombosis_7\NN (l_prep) in_8\IN (l_pobj) mice_9\NNS (l_conj) aggregation_13\NN
C060802_D001791 NONE FAN_12\NNP (r_conj) TET_10\NNP (r_pobj) of_9\IN (r_prep) effects_8\NNS (r_dobj) investigate_6\VB (r_advcl) undertaken_4\VBN (l_conj) in_34\IN (l_nsubj) aggregation_30\NN
C060802_D001791 NONE FAN_16\NNP (r_conj) TET_14\NNP (r_nsubj) showed_17\VBD (l_prep) In_0\IN (l_pobj) aggregations_5\NNS
C060802_D013927 NONE fangchinoline_4\NN (r_conj) tetrandrine_2\NN (r_pobj) of_1\IN (r_prep) Effects_0\NNS (l_prep) on_5\IN (l_pobj) thrombosis_7\NN
C060802_D013927 NONE FAN_12\NNP (r_conj) TET_10\NNP (r_pobj) of_9\IN (r_prep) effects_8\NNS (l_prep) on_13\IN (l_pobj) thrombosis_16\NN
C060802_D013927 NONE FAN_17\NNP (r_conj) TET_15\NNP (r_pobj) of_14\IN (r_prep) administration_7\NN (r_nsubj) showed_20\VBD (l_dobj) inhibition_22\NN (l_prep) of_23\IN (l_pobj) thrombosis_24\NN
C009438_D013927 NONE tetrandrine_2\NN (r_pobj) of_1\IN (r_prep) Effects_0\NNS (l_prep) on_5\IN (l_pobj) thrombosis_7\NN
C009438_D013927 NONE TET_10\NNP (r_pobj) of_9\IN (r_prep) effects_8\NNS (l_prep) on_13\IN (l_pobj) thrombosis_16\NN
C009438_D013927 NONE TET_15\NNP (r_pobj) of_14\IN (r_prep) administration_7\NN (r_nsubj) showed_20\VBD (l_dobj) inhibition_22\NN (l_prep) of_23\IN (l_pobj) thrombosis_24\NN
D004837_D013927 CID epinephrine_21\NN (r_conj) collagen_19\NN (r_pobj) by_18\IN (r_agent) induced_17\VBN (r_acl) thrombosis_16\NN
D004837_D013927 CID EP_23\NN (r_appos) epinephrine_21\NN (r_conj) collagen_19\NN (r_pobj) by_18\IN (r_agent) induced_17\VBN (r_acl) thrombosis_16\NN
7083920
D000638_D013617 NONE amiodarone_13\NN (r_compound) treatment_14\NN (l_prep) for_15\IN (l_pobj) tachycardia_17\NNS
D000638_D006345 NONE amiodarone_13\NN (r_compound) treatment_14\NN (r_pobj) under_12\IN (r_prep) occurring_11\VBG (l_prep) without_21\IN (l_pobj) abnormalities_25\NNS
D000638_D006327 CID amiodarone_13\NN (r_compound) treatment_14\NN (r_pobj) under_12\IN (r_prep) occurring_11\VBG (r_acl) block_10\NN
D000638_D001282 NONE amiodarone_3\NN (r_compound) discontinuation_4\NN (r_pobj) after_2\IN (r_prep) showed_9\VBD (l_dobj) flutter_11\NN
8558192
D002945_D064420 NONE cisplatin_9\NN (r_npadvmod) based_11\VBN (r_amod) chemotherapy_12\NN (r_pobj) with_8\IN (r_prep) pretreated_7\VBN (r_csubj) were_13\VBD (l_acomp) assessable_14\JJ (l_prep) for_15\IN (l_pobj) toxicity_16\NN
C030852_D064420 NONE VNB_0\NNP (r_nsubjpass) tolerated_3\VBN (l_conj) occurred_13\VBD (l_nsubj) toxicity_12\NN
C030852_D064420 NONE VNB_12\NNP (r_pobj) of_11\IN (r_prep) evaluation_10\NN (r_nsubjpass) warranted_17\VBN (l_prep) Given_0\VBN (l_pobj) profile_4\NN (l_conj) toxicity_7\NN
C030852_C562729 NONE vinorelbine_4\NN (r_pobj) of_3\IN (r_prep) trial_2\NN (l_prep) in_5\IN (l_pobj) carcinoma_10\NN
C030852_C562729 NONE vinorelbine_9\NN (r_pobj) of_8\IN (r_prep) effects_7\NNS (r_conj) rate_4\NN (l_acl) administered_13\VBN (l_prep) as_14\IN (l_pobj) agent_17\NN (l_prep) in_18\IN (l_pobj) carcinoma_23\NN
C030852_C562729 NONE VNB_11\NNP (r_appos) vinorelbine_9\NN (r_pobj) of_8\IN (r_prep) effects_7\NNS (r_conj) rate_4\NN (l_acl) administered_13\VBN (l_prep) as_14\IN (l_pobj) agent_17\NN (l_prep) in_18\IN (l_pobj) carcinoma_23\NN
C030852_C562729 NONE VNB_4\NNP (r_nsubj) is_5\VBZ (l_attr) agent_8\NN (l_prep) in_9\IN (l_pobj) carcinoma_14\NN
19299179
D015662_D008100 NONE trimoxazole_35\NN (r_amod) treatment_36\NN (r_dobj) report_3\VBP (l_dobj) cases_5\NNS (l_conj) in_20\IN (l_pobj) lesions_23\NNS (l_acl) mimicking_24\VBG (l_dobj) formation_27\NN (l_compound) abscess_26\NN
D015662_D009894 NONE trimoxazole_25\NN (r_punct) ._26\. (r_punct) treated_18\VBN (l_nsubjpass) pneumonia_1\NN (l_appos) infection_9\NN
D015662_D015658 NONE trimoxazole_11\NN (r_amod) treatment_12\NN (l_prep) for_13\IN (l_pobj) pneumonia_15\NN (l_prep) in_16\IN (l_pobj) patients_20\NNS (l_amod) infected_19\VBN
D015662_D015658 NONE trimoxazole_25\NN (r_punct) ._26\. (r_punct) treated_18\VBN (l_nsubjpass) pneumonia_1\NN (l_appos) infection_9\NN (l_prep) in_10\IN (l_pobj) individuals_14\NNS (l_amod) infected_13\VBN
D015662_D015658 NONE trimoxazole_35\NN (r_amod) treatment_36\NN (r_dobj) report_3\VBP (l_dobj) cases_5\NNS (l_prep) of_6\IN (l_pobj) patients_12\NNS (l_amod) infected_11\VBN
D015662_D011020 NONE trimoxazole_11\NN (r_amod) treatment_12\NN (l_prep) for_13\IN (l_pobj) pneumonia_15\NN
D015662_D011020 NONE trimoxazole_25\NN (r_punct) ._26\. (r_punct) treated_18\VBN (l_nsubjpass) pneumonia_1\NN
D015662_D011020 NONE trimoxazole_25\NN (r_punct) ._26\. (r_punct) treated_18\VBN (l_nsubjpass) pneumonia_1\NN (l_appos) PCP_3\NNP
D015662_D011020 NONE trimoxazole_35\NN (r_amod) treatment_36\NN (l_prep) for_37\IN (l_pobj) PCP_38\NNP
D015662_D002779 NONE trimoxazole_11\NN (r_amod) treatment_12\NN (r_pobj) after_5\IN (r_prep) cholestasis_4\NN
D015662_D002780 CID trimoxazole_35\NN (r_amod) treatment_36\NN (r_dobj) report_3\VBP (l_dobj) cases_5\NNS (l_prep) of_6\IN (l_pobj) patients_12\NNS (l_relcl) developed_14\VBD (l_dobj) cholestasis_17\NN
12639165
D013988_D007565 CID ticlopidine_7\NN (r_pobj) with_6\IN (r_prep) treatment_5\NN (r_pobj) following_4\VBG (r_prep) developed_2\VBD (l_dobj) jaundice_3\NN
D013988_D056486 CID Ticlopidine_0\NNP (r_npadvmod) induced_2\VBN (r_amod) hepatitis_4\NN
D013988_D056486 CID ticlopidine_5\NN (r_npadvmod) induced_7\VBN (r_amod) hepatitis_9\NN
D013988_D056486 CID ticlopidine_8\NN (r_advmod) receiving_7\VBG (r_pcomp) after_6\IN (r_prep) developed_2\VBD (l_dobj) hepatitis_5\NN
D013988_D056486 CID ticlopidine_10\NN (r_advmod) complication_5\NN (r_attr) is_2\VBZ (l_nsubj) hepatitis_1\NN
D013988_D056486 CID ticlopidine_7\NN (r_pobj) with_6\IN (r_prep) treatment_5\NN (r_pobj) following_4\VBG (r_prep) developed_2\VBD (l_conj) showed_9\VBD (l_dobj) characteristics_14\NNS (l_prep) of_15\IN (l_pobj) hepatitis_17\NN
D013988_D056486 CID ticlopidine_8\NN (r_pobj) of_7\IN (r_prep) effect_6\NN (r_attr) is_2\VBZ (l_nsubj) hepatitis_1\NN
D013988_D002779 CID Ticlopidine_0\NNP (r_npadvmod) induced_2\VBN (r_amod) hepatitis_4\NN
D013988_D002779 CID ticlopidine_5\NN (r_npadvmod) induced_7\VBN (r_amod) hepatitis_9\NN
D013988_D002779 CID ticlopidine_8\NN (r_advmod) receiving_7\VBG (r_pcomp) after_6\IN (r_prep) developed_2\VBD (l_dobj) hepatitis_5\NN
D013988_D002779 CID ticlopidine_10\NN (r_advmod) complication_5\NN (r_attr) is_2\VBZ (l_nsubj) hepatitis_1\NN
D013988_D002779 CID ticlopidine_7\NN (r_pobj) with_6\IN (r_prep) treatment_5\NN (r_pobj) following_4\VBG (r_prep) developed_2\VBD (l_conj) showed_9\VBD (l_dobj) characteristics_14\NNS (l_prep) of_15\IN (l_pobj) hepatitis_17\NN
D013988_D002779 CID ticlopidine_4\NN (r_npadvmod) induced_6\VBN (r_amod) cholestasis_7\NN
D013988_D002779 CID ticlopidine_8\NN (r_pobj) of_7\IN (r_prep) effect_6\NN (r_attr) is_2\VBZ (l_nsubj) hepatitis_1\NN
12063090
D004177_D059350 NONE metamizol_9\NN (r_conj) morphine_7\NN (r_pobj) between_6\IN (r_prep) interaction_5\NN (r_dobj) show_2\VBP (l_advcl) suggesting_15\VBG (l_ccomp) be_20\VB (l_acomp) useful_21\JJ (l_prep) for_22\IN (l_pobj) treatment_24\NN (l_prep) of_25\IN (l_pobj) pain_27\NN
D009020_D059350 NONE morphine_7\NN (r_pobj) between_6\IN (r_prep) interaction_5\NN (r_dobj) show_2\VBP (l_advcl) suggesting_15\VBG (l_ccomp) be_20\VB (l_acomp) useful_21\JJ (l_prep) for_22\IN (l_pobj) treatment_24\NN (l_prep) of_25\IN (l_pobj) pain_27\NN
D004177_D003248 NONE Metamizol_0\NNP (r_nsubj) potentiates_1\VBZ (l_dobj) antinociception_3\NN (l_conj) constipation_6\NN
D004177_D003248 NONE metamizol_20\NN (r_pobj) with_16\IN (r_prep) effects_7\NNS (l_amod) antinociceptive_4\NN (l_conj) constipating_6\JJ
D004177_D003248 NONE metamizol_20\NN (r_nsubj) potentiate_23\VB (l_dobj) constipation_27\NN
D002606_D010146 NONE charcoal_25\NN (r_compound) meal_26\NN (r_compound) test_27\NN (r_nsubjpass) used_29\VBN (r_conj) assessed_8\VBN (l_conj) model_21\NN (l_amod) induced_18\VBN (l_npadvmod) pain_16\NN
D009020_D003248 CID morphine_2\NN (r_compound) antinociception_3\NN (l_conj) constipation_6\NN
D009020_D003248 CID morphine_15\NN (r_pobj) of_11\IN (r_prep) combination_10\NN (r_pobj) of_8\IN (r_prep) effects_7\NNS (l_amod) antinociceptive_4\NN (l_conj) constipating_6\JJ
D009020_D003248 CID morphine_4\NN (r_nsubj) inhibited_5\VBD (l_advcl) suggesting_23\VBG (l_ccomp) develop_28\VB (l_prep) to_29\IN (l_pobj) effects_32\NNS (l_amod) constipating_31\JJ
D009020_D003248 CID morphine_10\NN (r_pobj) by_9\IN (r_agent) produced_8\VBN (r_acl) that_7\DT (r_pobj) to_6\IN (r_prep) similar_5\JJ (r_amod) transit_4\NN (r_dobj) inhibited_2\VBD (l_advcl) suggesting_18\VBG (l_ccomp) potentiate_23\VB (l_dobj) constipation_27\NN
D009020_D003248 CID morphine_24\NN (r_npadvmod) induced_26\VBN (r_amod) constipation_27\NN
9672936
D008614_D010149 NONE Pethidine_0\NNP (r_npadvmod) associated_2\VBN (r_amod) seizure_3\NN (l_prep) in_4\IN (l_pobj) adolescent_7\JJ (l_acl) receiving_8\VBG (l_prep) for_10\IN (l_pobj) control_13\NN (l_compound) pain_12\NN
D008614_D010149 NONE pethidine_9\NN (r_dobj) receiving_8\VBG (l_prep) for_10\IN (l_pobj) control_13\NN (l_compound) pain_12\NN
D008614_D010149 NONE pethidine_11\NN (r_pobj) of_10\IN (r_prep) doses_9\NNS (r_nsubj) pump_21\NN (l_prep) for_22\IN (l_pobj) management_23\NN (l_prep) of_24\IN (l_pobj) control_27\NN (l_compound) pain_26\NN
D008614_D012640 CID Pethidine_0\NNP (r_npadvmod) associated_2\VBN (r_amod) seizure_3\NN
D008614_D012640 CID pethidine_9\NN (r_dobj) receiving_8\VBG (r_acl) adolescent_7\JJ (r_pobj) in_4\IN (r_prep) seizure_3\NN
1749407
D003042_D009203 CID Cocaine_0\NN (r_npadvmod) induced_2\VBN (r_amod) infarction_4\NN
D003042_D009203 CID cocaine_13\NN (r_nsubj) result_15\VB (l_prep) in_16\IN (l_pobj) infarction_19\NN
D003042_D009203 CID cocaine_26\NN (r_npadvmod) induced_28\VBN (r_amod) increase_29\NN (r_pobj) with_25\IN (r_prep) associated_24\VBN (r_acl) demand_23\NN (r_pobj) in_20\IN (r_prep) increase_19\NN (r_pobj) from_17\IN (r_prep) result_16\VB (l_nsubj) infarction_14\NN
D003042_D013035 NONE cocaine_16\NN (r_npadvmod) induced_18\VBN (r_amod) vasoconstriction_19\NN (r_pobj) of_15\IN (r_prep) locus_14\NN (r_nsubj) remains_20\VBZ (r_conj) are_8\VBP (l_prep) With_0\IN (l_pobj) regard_1\NN (l_prep) to_2\IN (l_pobj) spasm_3\NN
D010100_D009203 NONE oxygen_22\NN (r_compound) demand_23\NN (r_pobj) in_20\IN (r_prep) increase_19\NN (r_pobj) from_17\IN (r_prep) result_16\VB (l_nsubj) infarction_14\NN
D003042_D013927 NONE cocaine_11\NN (r_pobj) of_10\IN (r_prep) effect_9\NN (l_amod) thrombotic_8\JJ
4812392
D001379_D011565 NONE azathioprine_4\NN (r_pobj) with_3\IN (r_prep) psoriasis_2\NN
D001379_D011565 NONE Azathioprine_0\JJ (r_det) treatment_1\NN (r_nsubj) benefited_2\VBD (l_prep) out_8\IN (l_prep) of_9\IN (l_pobj) patients_11\NNS (l_acl) suffering_12\VBG (l_prep) from_13\IN (l_pobj) psoriasis_15\NN
D001379_D056486 NONE azathioprine_9\JJ (r_amod) therapy_10\NN (r_nsubjpass) continued_12\VBN (l_advcl) detected_20\VBN (l_nsubjpass) damage_17\NN
18343374
D002996_D012170 CID clomiphene_6\NN (r_npadvmod) induced_8\VBN (r_amod) ovulation_9\NN (r_pobj) with_5\IN (r_prep) associated_4\VBN (r_acl) occlusion_3\NN
D002996_D012170 CID citrate_12\NN (r_pobj) with_10\IN (r_prep) associated_9\VBN (r_acl) occlusion_8\NN
D002996_D012170 CID CC_14\NN (r_appos) citrate_12\NN (r_pobj) with_10\IN (r_prep) associated_9\VBN (r_acl) occlusion_8\NN
D002996_D012170 CID CC_13\NN (r_pobj) with_12\IN (r_prep) induction_11\NN (r_pobj) after_9\IN (r_prep) occlusion_8\NN
D002996_D012170 CID CC_18\NN (r_pobj) of_17\IN (r_prep) courses_16\NNS (r_pobj) after_14\IN (r_prep) developed_9\VBD (l_dobj) occlusion_13\NN
D002996_D012170 CID CC_15\NN (r_pobj) with_14\IN (r_prep) treatment_13\NN (r_pobj) after_12\IN (r_prep) occlusion_11\NN
D002996_D014786 CID CC_10\NN (r_pobj) of_9\IN (r_prep) complications_8\NNS (r_pobj) on_5\IN (r_prep) search_1\NN (r_nsubj) include_13\VB (l_advcl) is_26\VBZ (l_nsubj) disturbance_22\NN
D002996_D014786 CID CC_24\NN (r_compound) intake_25\NN (r_pobj) after_23\IN (r_prep) disturbance_22\NN
D002996_D007247 NONE CC_9\NN (r_pobj) with_8\IN (r_prep) treating_5\VBG (l_dobj) patients_7\NNS (l_compound) infertility_6\NN
D002996_D013923 NONE CC_10\NN (r_pobj) of_9\IN (r_prep) complications_8\NNS (l_compound) thromboembolic_7\JJ
D002996_D013923 NONE CC_24\NN (r_compound) intake_25\NN (r_pobj) after_23\IN (r_prep) disturbance_22\NN (r_nsubj) is_26\VBZ (r_advcl) include_13\VB (l_nsubj) search_1\NN (l_prep) on_5\IN (l_pobj) complications_8\NNS (l_compound) thromboembolic_7\JJ
6203452
D001761_D002277 NONE bleomycin_26\NNS (r_conj) treatment_22\NN (r_pobj) after_21\IN (r_prep) developed_4\VBD (l_nsubj) patients_1\NNS (l_prep) with_2\IN (l_pobj) carcinoma_3\NN
D002945_D013921 NONE cisplatin_24\NN (r_pobj) with_23\IN (r_prep) treatment_22\NN (r_pobj) after_21\IN (r_prep) developed_4\VBD (l_dobj) microangiopathy_6\NN (l_acl) characterized_8\VBN (l_conj) anemia_15\NN (l_conj) thrombocytopenia_19\JJ
D002945_D013921 NONE cisplatin_30\VB (r_amod) nephrotoxicity_31\NN (l_conj) thrombocytopenia_36\NN
D002945_D051437 NONE cisplatin_24\NN (r_pobj) with_23\IN (r_prep) treatment_22\NN (r_pobj) after_21\IN (r_prep) developed_4\VBD (l_dobj) microangiopathy_6\NN (l_acl) characterized_8\VBN (l_agent) by_9\IN (l_pobj) insufficiency_11\NN
D002945_D051437 NONE cisplatin_30\VB (r_amod) nephrotoxicity_31\NN (r_pobj) to_29\IN (r_prep) ascribed_28\VBN (l_nsubjpass) failure_25\NN
D001761_D000743 NONE bleomycin_26\NNS (r_conj) treatment_22\NN (r_pobj) after_21\IN (r_prep) developed_4\VBD (l_dobj) microangiopathy_6\NN (l_acl) characterized_8\VBN (l_conj) anemia_15\NN
D014748_D057049 NONE alkaloid_31\NN (r_amod) vinca_30\JJ (r_conj) bleomycin_26\NNS (r_conj) treatment_22\NN (r_pobj) after_21\IN (r_prep) developed_4\VBD (l_dobj) microangiopathy_6\NN
D002945_D007674 CID cisplatin_30\VB (r_amod) nephrotoxicity_31\NN
D002945_D002277 NONE cisplatin_24\NN (r_pobj) with_23\IN (r_prep) treatment_22\NN (r_pobj) after_21\IN (r_prep) developed_4\VBD (l_nsubj) patients_1\NNS (l_prep) with_2\IN (l_pobj) carcinoma_3\NN
D014748_D051437 NONE alkaloid_31\NN (r_amod) vinca_30\JJ (r_conj) bleomycin_26\NNS (r_conj) treatment_22\NN (r_pobj) after_21\IN (r_prep) developed_4\VBD (l_dobj) microangiopathy_6\NN (l_acl) characterized_8\VBN (l_agent) by_9\IN (l_pobj) insufficiency_11\NN
D001761_D013921 NONE bleomycin_26\NNS (r_conj) treatment_22\NN (r_pobj) after_21\IN (r_prep) developed_4\VBD (l_dobj) microangiopathy_6\NN (l_acl) characterized_8\VBN (l_conj) anemia_15\NN (l_conj) thrombocytopenia_19\JJ
D002945_D000743 NONE cisplatin_24\NN (r_pobj) with_23\IN (r_prep) treatment_22\NN (r_pobj) after_21\IN (r_prep) developed_4\VBD (l_dobj) microangiopathy_6\NN (l_acl) characterized_8\VBN (l_conj) anemia_15\NN
D014748_D002277 NONE alkaloid_31\NN (r_amod) vinca_30\JJ (r_conj) bleomycin_26\NNS (r_conj) treatment_22\NN (r_pobj) after_21\IN (r_prep) developed_4\VBD (l_nsubj) patients_1\NNS (l_prep) with_2\IN (l_pobj) carcinoma_3\NN
D002945_D001855 NONE cisplatin_30\VB (r_amod) nephrotoxicity_31\NN (l_conj) thrombocytopenia_36\NN (l_prep) to_37\IN (l_pobj) suppression_43\NN
D014748_D000743 NONE alkaloid_31\NN (r_amod) vinca_30\JJ (r_conj) bleomycin_26\NNS (r_conj) treatment_22\NN (r_pobj) after_21\IN (r_prep) developed_4\VBD (l_dobj) microangiopathy_6\NN (l_acl) characterized_8\VBN (l_conj) anemia_15\NN
D014748_D013921 NONE alkaloid_31\NN (r_amod) vinca_30\JJ (r_conj) bleomycin_26\NNS (r_conj) treatment_22\NN (r_pobj) after_21\IN (r_prep) developed_4\VBD (l_dobj) microangiopathy_6\NN (l_acl) characterized_8\VBN (l_conj) anemia_15\NN (l_conj) thrombocytopenia_19\JJ
D001761_D051437 NONE bleomycin_26\NNS (r_conj) treatment_22\NN (r_pobj) after_21\IN (r_prep) developed_4\VBD (l_dobj) microangiopathy_6\NN (l_acl) characterized_8\VBN (l_agent) by_9\IN (l_pobj) insufficiency_11\NN
D001761_D057049 NONE bleomycin_26\NNS (r_conj) treatment_22\NN (r_pobj) after_21\IN (r_prep) developed_4\VBD (l_dobj) microangiopathy_6\NN
D002945_D057049 NONE cisplatin_24\NN (r_pobj) with_23\IN (r_prep) treatment_22\NN (r_pobj) after_21\IN (r_prep) developed_4\VBD (l_dobj) microangiopathy_6\NN
D002945_D000740 NONE cisplatin_30\VB (r_amod) nephrotoxicity_31\NN (l_conj) anemia_34\NN
11279304
D003630_D006333 CID DNR_16\NNP (r_pobj) given_15\VBN (r_acl) failure_14\NN
D003630_D066126 NONE daunorubicin_36\NN (r_pobj) with_34\IN (r_prep) treated_33\VBN (r_acl) leukemia_32\NN (r_pobj) with_30\IN (r_prep) patients_29\NNS (r_pobj) in_28\IN (r_prep) cardiotoxicity_27\NN
D003630_D066126 NONE DNR)-containing_38\NN (r_compound) regimen_39\NNS (r_appos) daunorubicin_36\NN (r_pobj) with_34\IN (r_prep) treated_33\VBN (r_acl) leukemia_32\NN (r_pobj) with_30\IN (r_prep) patients_29\NNS (r_pobj) in_28\IN (r_prep) cardiotoxicity_27\NN
D018943_D015470 NONE anthracycline_24\NN (r_advmod) induced_26\VBN (r_amod) cardiotoxicity_27\NN (l_prep) in_28\IN (l_pobj) patients_29\NNS (l_prep) with_30\IN (l_pobj) leukemia_32\NN
D018943_D006331 NONE anthracycline_4\NN (r_amod) therapy_5\NN (r_pobj) of_2\IN (r_prep) cardiotoxicity_1\NN (r_nsubj) highlights_6\VBZ (l_dobj) need_8\NN (l_acl) search_10\VB (l_prep) for_11\IN (l_pobj) methods_12\NNS (l_relcl) are_14\VBP (l_acomp) sensitive_16\JJ (l_conj) capable_18\JJ (l_prep) of_19\IN (l_pcomp) predicting_20\VBG (l_dobj) dysfunction_22\NN
D003630_D015470 NONE daunorubicin_36\NN (r_pobj) with_34\IN (r_prep) treated_33\VBN (r_acl) leukemia_32\NN
D003630_D015470 NONE DNR)-containing_38\NN (r_compound) regimen_39\NNS (r_appos) daunorubicin_36\NN (r_pobj) with_34\IN (r_prep) treated_33\VBN (r_acl) leukemia_32\NN
D003630_D015470 NONE DNR_9\NNP (r_npadvmod) containing_11\VBG (r_amod) regimen_12\NN (r_pobj) with_7\IN (r_prep) treated_6\VBN (l_nsubjpass) patients_1\NNS (l_prep) with_2\IN (l_pobj) leukemia_4\NN
D018943_D066126 NONE anthracycline_7\NN (r_advmod) induced_9\VBN (r_amod) cardiotoxicity_10\NN
D018943_D066126 NONE Anthracyclines_0\NNS (r_nsubj) are_1\VBP (l_conj) cause_9\VBP (l_dobj) cardiotoxicity_13\NN
D018943_D066126 NONE anthracycline_4\NN (r_amod) therapy_5\NN (r_pobj) of_2\IN (r_prep) cardiotoxicity_1\NN
D018943_D066126 NONE anthracycline_24\NN (r_advmod) induced_26\VBN (r_amod) cardiotoxicity_27\NN
D018943_D066126 NONE anthracycline_16\NN (r_advmod) induced_18\VBN (r_compound) cardiotoxicity_19\NN
20067456
D017367_D012735 NONE inhibitor_16\NN (r_pobj) by_11\IN (r_agent) induced_10\VBN (r_acl) dysfunction_9\NN
D017367_D012735 NONE inhibitor_28\NN (r_pobj) by_23\IN (r_agent) induced_22\VBN (l_csubj) determine_1\VB (l_dobj) safety_3\NN (l_prep) of_6\IN (l_pobj) bupropion_8\NN (l_prep) on_15\IN (l_pobj) dysfunction_18\NN
D017367_D012735 NONE inhibitor_28\NN (r_pobj) by_23\IN (r_agent) induced_22\VBN (l_csubj) determine_1\VB (l_dobj) safety_3\NN (l_prep) of_6\IN (l_pobj) bupropion_8\NN (l_prep) on_15\IN (l_pobj) dysfunction_18\NN (l_appos) SD_20\NN
D017367_D012735 NONE inhibitor_28\NN (r_pobj) by_23\IN (r_agent) induced_22\VBN (l_advcl) is_35\VBZ (l_nsubj) SD_34\NN
D017367_D012735 NONE SSRI_30\NNP (r_appos) inhibitor_28\NN (r_pobj) by_23\IN (r_agent) induced_22\VBN (l_csubj) determine_1\VB (l_dobj) safety_3\NN (l_prep) of_6\IN (l_pobj) bupropion_8\NN (l_prep) on_15\IN (l_pobj) dysfunction_18\NN
D017367_D012735 NONE SSRI_30\NNP (r_appos) inhibitor_28\NN (r_pobj) by_23\IN (r_agent) induced_22\VBN (l_csubj) determine_1\VB (l_dobj) safety_3\NN (l_prep) of_6\IN (l_pobj) bupropion_8\NN (l_prep) on_15\IN (l_pobj) dysfunction_18\NN (l_appos) SD_20\NN
D017367_D012735 NONE SSRI_30\NNP (r_appos) inhibitor_28\NN (r_pobj) by_23\IN (r_agent) induced_22\VBN (l_advcl) is_35\VBZ (l_nsubj) SD_34\NN
D017367_D012735 NONE SSRIs_42\NNS (r_pobj) of_41\IN (r_prep) effect_40\NN (r_attr) is_35\VBZ (r_advcl) induced_22\VBN (l_csubj) determine_1\VB (l_dobj) safety_3\NN (l_prep) of_6\IN (l_pobj) bupropion_8\NN (l_prep) on_15\IN (l_pobj) dysfunction_18\NN
D017367_D012735 NONE SSRIs_42\NNS (r_pobj) of_41\IN (r_prep) effect_40\NN (r_attr) is_35\VBZ (r_advcl) induced_22\VBN (l_csubj) determine_1\VB (l_dobj) safety_3\NN (l_prep) of_6\IN (l_pobj) bupropion_8\NN (l_prep) on_15\IN (l_pobj) dysfunction_18\NN (l_appos) SD_20\NN
D017367_D012735 NONE SSRIs_42\NNS (r_pobj) of_41\IN (r_prep) effect_40\NN (r_attr) is_35\VBZ (l_nsubj) SD_34\NN
D017367_D012735 NONE SSRI_21\NNP (r_pobj) of_20\IN (r_prep) type_19\NN (r_appos) SD_17\NN
D017367_D012735 NONE SSRIs_10\NNS (r_pobj) by_9\IN (r_agent) induced_8\VBN (r_acl) treatment_4\NN (l_prep) for_5\IN (l_pobj) SD_7\NN
D016642_D012735 NONE bupropion_5\NN (l_prep) on_6\IN (l_pobj) dysfunction_9\NN
D016642_D012735 NONE bupropion_8\NN (l_prep) on_15\IN (l_pobj) dysfunction_18\NN
D016642_D012735 NONE bupropion_8\NN (l_prep) on_15\IN (l_pobj) dysfunction_18\NN (l_appos) SD_20\NN
D016642_D012735 NONE bupropion_8\NN (r_pobj) of_6\IN (r_prep) safety_3\NN (r_dobj) determine_1\VB (r_csubj) induced_22\VBN (l_advcl) is_35\VBZ (l_nsubj) SD_34\NN
D016642_D012735 NONE Bupropion_0\NN (r_nsubj) is_1\VBZ (l_attr) treatment_4\NN (l_prep) for_5\IN (l_pobj) SD_7\NN
8231633
D015764_D012640 NONE bepridil_31\NN (r_pcomp) with_30\IN (r_prep) pronounced_29\VBN (r_acomp) was_27\VBD (l_ccomp) modified_8\VBN (l_conj) decreased_13\VBD (l_dobj) time_15\NN (l_relcl) obtain_19\VB (l_dobj) convulsions_23\NNS
D002045_D064420 NONE bupivacaine_6\NN (r_npadvmod) induced_8\VBN (r_amod) toxicity_9\NN
D002045_D064420 NONE bupivacaine_15\NN (r_npadvmod) induced_17\VBN (r_amod) toxicity_19\NN
D002045_D012640 CID bupivacaine_4\NN (r_pobj) of_3\IN (r_prep) activity_2\NN (r_nsubj) was_5\VBD (r_auxpass) modified_8\VBN (l_conj) decreased_13\VBD (l_dobj) time_15\NN (l_relcl) obtain_19\VB (l_dobj) convulsions_23\NNS
D002045_D012640 CID bupivacaine_20\NN (r_npadvmod) induced_22\VBN (r_amod) convulsions_23\NNS
D002118_D012640 NONE calcium_10\NN (r_compound) channel_11\NN (r_compound) blockers_12\NNS (r_nsubj) decreased_13\VBD (l_dobj) time_15\NN (l_relcl) obtain_19\VB (l_dobj) convulsions_23\NNS
D002118_D064420 NONE calcium_2\NN (r_compound) channel_3\NN (r_compound) blockers_4\NNS (l_prep) on_5\IN (l_pobj) toxicity_9\NN
D002118_D064420 NONE calcium_11\NN (r_compound) channel_12\NN (r_compound) blockers_13\NNS (l_prep) on_14\IN (l_pobj) toxicity_19\NN
2549018
D005473_D009771 NONE fluoxetine_3\NN (r_dobj) receiving_2\VBG (l_prep) for_4\IN (l_pobj) treatment_6\NN (l_prep) of_7\IN (l_pobj) disorder_10\NN
D005473_D017109 CID Fluoxetine_0\NNP (r_npadvmod) induced_2\VBN (r_amod) akathisia_3\NN
D005473_D017109 CID fluoxetine_3\NN (r_dobj) receiving_2\VBG (r_acl) patients_1\NNS (r_nsubj) developed_14\VBD (l_dobj) akathisia_15\NN
D005473_D017109 CID fluoxetine_2\NN (r_npadvmod) induced_4\VBN (r_amod) symptoms_5\NNS (r_nsubj) were_23\VBD (l_acomp) indistinguishable_24\JJ (l_prep) from_25\IN (l_pobj) those_26\DT (l_prep) of_27\IN (l_pobj) akathisia_31\NN
D005473_D017109 CID fluoxetine_17\NN (r_advmod) induced_19\VBN (r_amod) akathisia_20\NN (r_pobj) of_16\IN (r_prep) symptoms_15\NNS (r_nsubj) were_21\VBD (r_ccomp) reported_12\VBD (l_nsubj) patients_1\NNS (l_relcl) experienced_4\VBN (l_dobj) akathisia_8\NN
D005473_D017109 CID fluoxetine_17\NN (r_advmod) induced_19\VBN (r_amod) akathisia_20\NN
D005473_D017109 CID fluoxetine_9\NN (r_pobj) of_8\IN (r_prep) effect_7\NN (r_attr) be_3\VB (r_xcomp) appeared_1\VBD (l_nsubj) Akathisia_0\NNP
D005473_D017109 CID fluoxetine_4\NN (r_advmod) induced_6\VBN (r_amod) akathisia_7\NN
D005473_D017109 CID fluoxetine_4\NN (r_advmod) induced_6\VBN (r_amod) akathisia_7\NN (r_nsubjpass) caused_10\VBN (l_conj) be_36\VB (l_nsubj) pathophysiology_21\NN (l_prep) of_22\IN (l_pobj) akathisia_26\NN
D005473_D017109 CID fluoxetine_23\NN (r_advmod) induced_25\VBN (r_amod) akathisia_26\NN (r_pobj) of_22\IN (r_prep) pathophysiology_21\NN (r_nsubj) be_36\VB (r_conj) caused_10\VBN (l_nsubjpass) akathisia_7\NN
D005473_D017109 CID fluoxetine_23\NN (r_advmod) induced_25\VBN (r_amod) akathisia_26\NN
D000928_D017109 NONE antidepressant_29\NN (r_npadvmod) induced_31\VBN (r_amod) jitteriness_33\NN (r_conj) akathisia_26\NN (r_pobj) of_22\IN (r_prep) pathophysiology_21\NN (r_nsubj) be_36\VB (r_conj) caused_10\VBN (l_nsubjpass) akathisia_7\NN
D000928_D017109 NONE antidepressant_29\NN (r_npadvmod) induced_31\VBN (r_amod) jitteriness_33\NN (r_conj) akathisia_26\NN
D011433_D017109 NONE propranolol_22\NN (r_acl) antagonist_21\NN (r_pobj) with_16\IN (r_prep) treatment_15\NN (r_pobj) to_14\IN (r_prep) responded_12\VBD (r_conj) appeared_1\VBD (l_nsubj) Akathisia_0\NNP
D005473_D001008 NONE fluoxetine_2\NN (r_npadvmod) induced_4\VBN (r_amod) symptoms_5\NNS (l_prep) of_6\IN (l_pobj) restlessness_7\NN (l_conj) pacing_10\NN (l_conj) movements_13\NNS (l_conj) anxiety_22\NN
D005473_D003865 NONE fluoxetine_3\NN (r_dobj) receiving_2\VBG (l_prep) for_4\IN (l_pobj) treatment_6\NN (l_prep) of_7\IN (l_pobj) disorder_10\NN (l_conj) depression_13\NN
3997294
D000638_D013617 NONE amiodarone_11\NN (l_prep) for_28\IN (l_pobj) control_29\NN (l_prep) of_30\IN (l_pobj) tachyarrhythmias_32\NNS
D000638_D010490 CID amiodarone_9\NN (r_compound) therapy_10\NN (r_pobj) during_8\IN (r_prep) effusion_5\NN
D000638_D011014 CID amiodarone_14\NN (r_compound) pneumonitis_15\NN
D000638_D011014 CID amiodarone_20\NN (r_pobj) of_19\IN (r_prep) withdrawal_18\NN (r_dobj) indicates_7\VBZ (l_dobj) need_9\NN (l_prep) for_10\IN (l_pobj) diagnosis_12\NN (l_prep) of_13\IN (l_pobj) pneumonitis_15\NN
D000638_D010996 CID amiodarone_9\NN (r_compound) therapy_10\NN (r_pobj) during_8\IN (r_prep) effusion_5\NN
D000638_D009422 NONE amiodarone_9\NN (r_compound) therapy_10\NN (r_pobj) during_8\IN (r_prep) effusion_5\NN (l_conj) neuropathy_7\NN
D013256_D011014 NONE steroid_26\NN (r_compound) therapy_27\NN (r_conj) prompt_23\JJ (r_conj) withdrawal_18\NN (r_dobj) indicates_7\VBZ (l_dobj) need_9\NN (l_prep) for_10\IN (l_pobj) diagnosis_12\NN (l_prep) of_13\IN (l_pobj) pneumonitis_15\NN
D000638_D002318 NONE amiodarone_11\NN (r_pobj) with_10\IN (r_prep) treated_9\VBN (l_nsubjpass) patient_1\NN (l_prep) with_2\IN (l_pobj) disease_4\NN
2265898
C009265_D012640 NONE levodopa_38\JJ (r_compound) preparation_39\NN (r_dobj) receiving_34\VBG (l_conj) had_43\VBD (l_dobj) onset_45\NN (l_prep) of_46\IN (l_pobj) seizures_50\NNS
C009265_D001523 NONE levodopa_38\JJ (r_compound) preparation_39\NN (r_dobj) receiving_34\VBG (l_conj) had_43\VBD (l_dobj) onset_45\NN (l_prep) of_46\IN (l_pobj) seizures_50\NNS (l_nmod) hallucinosis_47\NN
C009265_D004827 CID carbidopa_6\NN (l_nsubj) epilepsy_1\NN
C009265_D007676 NONE levodopa_38\JJ (r_compound) preparation_39\NN (r_dobj) receiving_34\VBG (l_ccomp) had_11\VBD (l_dobj) failure_14\NN
1147734
D011441_D006521 CID propylthiouracil_29\NN (r_pobj) of_28\IN (r_prep) administration_27\NN (r_pobj) by_25\IN (r_agent) caused_24\VBN (r_acl) hepatitis_23\NN
D011441_D008107 NONE propylthiouracil_4\NN (r_pobj) by_3\IN (r_agent) caused_2\VBN (r_acl) disease_1\NN
14659530
D012701_D008881 NONE serotonin_24\NN (r_compound) release_25\NN (r_pobj) with_22\IN (r_prep) correlation_21\NN (r_conj) concentration_18\NN (r_appos) peptide_14\NN (r_pobj) in_8\IN (r_prep) increase_7\NN (r_appos) attack_4\NN (l_compound) migraine_3\JJ
D012701_D008881 NONE serotonin_24\NN (r_nmod) content_30\NN (r_pobj) in_10\IN (r_prep) changes_9\NNS (r_dobj) investigate_8\VB (l_conj) attack_40\NN (l_compound) migraine_39\JJ
D012701_D008881 NONE 5-hydroxytriptamine_26\NN (r_punct) ,_27\, (r_punct) 5-HT_28\CD (r_nmod) content_30\NN (r_pobj) in_10\IN (r_prep) changes_9\NNS (r_dobj) investigate_8\VB (l_conj) attack_40\NN (l_compound) migraine_39\JJ
D012701_D008881 NONE 5-HT_28\CD (r_nmod) content_30\NN (r_pobj) in_10\IN (r_prep) changes_9\NNS (r_dobj) investigate_8\VB (l_conj) attack_40\NN (l_compound) migraine_39\JJ
D012701_D008881 NONE 5-HT_8\CD (r_nummod) content_9\NN (r_nsubj) tended_10\VBD (l_xcomp) be_12\VB (l_prep) in_14\IN (l_pobj) subjects_15\NNS (l_relcl) experienced_17\VBD (l_dobj) attack_20\NN (l_compound) migraine_19\JJ
D012701_D008881 NONE serotonin_1\NN (r_compound) content_2\NN (r_nsubj) decreased_3\VBD (l_prep) after_8\IN (l_pobj) nitroglycerin_9\NN (l_prep) in_10\IN (l_pobj) subjects_11\NNS (l_prep) with_12\IN (l_pobj) attack_15\NN (l_compound) migraine_14\JJ
D012701_D008881 NONE serotonin_1\NN (r_compound) content_2\NN (r_nsubj) decreased_3\VBD (l_conj) observed_21\VBN (l_prep) in_22\IN (l_pobj) patients_23\NNS (l_prep) with_24\IN (l_pobj) attack_26\NN (l_compound) migraine_25\JJ
D012701_D008881 NONE serotonin_3\NN (r_compound) release_4\NN (r_nsubj) provoke_9\VB (l_dobj) migraine_10\NN
D009569_D008881 NONE NO_0\RB (r_intj) induced_2\VBN (r_amod) attack_4\NN (l_compound) migraine_3\JJ
D015740_D008881 NONE peptide_14\NN (r_pobj) in_8\IN (r_prep) increase_7\NN (r_appos) attack_4\NN (l_compound) migraine_3\JJ
D015740_D008881 NONE CGRP_16\NN (r_nmod) concentration_18\NN (r_appos) peptide_14\NN (r_pobj) in_8\IN (r_prep) increase_7\NN (r_appos) attack_4\NN (l_compound) migraine_3\JJ
D015740_D008881 NONE peptide_17\NN (r_nmod) content_30\NN (r_pobj) in_10\IN (r_prep) changes_9\NNS (r_dobj) investigate_8\VB (l_conj) attack_40\NN (l_compound) migraine_39\JJ
D015740_D008881 NONE CGRP_19\NN (r_nmod) concentration_21\NN (r_nmod) content_30\NN (r_pobj) in_10\IN (r_prep) changes_9\NNS (r_dobj) investigate_8\VB (l_conj) attack_40\NN (l_compound) migraine_39\JJ
D015740_D008881 NONE CGRP_1\NN (r_compound) concentration_2\NN (r_nsubj) increased_3\VBD (l_prep) during_8\IN (l_pobj) attack_11\NN (l_compound) migraine_10\JJ
D015740_D008881 NONE CGRP_1\NN (r_compound) concentration_2\NN (r_nsubj) increased_3\VBD (l_conj) returned_13\VBD (l_prep) after_16\IN (l_pobj) cessation_18\NN (l_prep) of_19\IN (l_pobj) migraine_21\NN
D015740_D008881 NONE CGRP_3\NNP (r_compound) concentrations_4\NNS (r_nsubj) failed_5\VBD (l_xcomp) change_7\VB (l_prep) during_8\IN (l_conj) in_12\IN (l_pobj) subjects_14\NNS (l_prep) with_15\IN (l_pobj) attack_18\NN (l_compound) migraine_17\JJ
D015740_D008881 NONE CGRP_1\NNP (r_compound) concentration_2\NN (r_nsubj) was_3\VBD (l_conj) platelet_7\NN (l_ccomp) tended_10\VBD (l_xcomp) be_12\VB (l_prep) in_14\IN (l_pobj) subjects_15\NNS (l_relcl) experienced_17\VBD (l_dobj) attack_20\NN (l_compound) migraine_19\JJ
D015740_D008881 NONE CGRP_7\NN (r_compound) concentration_8\NN (r_nsubj) correlates_9\VBZ (l_prep) with_10\IN (l_pobj) timing_12\NN (l_prep) of_15\IN (l_pobj) headache_18\NN (l_compound) migraine_17\JJ
D015740_D008881 NONE CGRP_7\NN (r_compound) concentration_8\NN (r_nsubj) correlates_9\VBZ (r_acl) fact_4\NN (r_nsubj) suggests_19\VBZ (l_dobj) relationship_22\NN (l_prep) between_23\IN (l_pobj) CGRP_24\NN (l_conj) migraine_26\NN
D015740_D008881 NONE CGRP_24\NN (r_pobj) between_23\IN (r_prep) relationship_22\NN (r_dobj) suggests_19\VBZ (l_nsubj) fact_4\NN (l_acl) correlates_9\VBZ (l_prep) with_10\IN (l_pobj) timing_12\NN (l_prep) of_15\IN (l_pobj) headache_18\NN (l_compound) migraine_17\JJ
D015740_D008881 NONE CGRP_24\NN (l_conj) migraine_26\NN
D015740_D008881 NONE CGRP_21\NN (r_compound) release_22\NN (r_conj) headache_17\NN (r_dobj) counteract_15\VB (l_ccomp) provoke_9\VB (l_dobj) migraine_10\NN
D005996_D008881 NONE nitroglycerin_43\NN (r_pobj) by_42\IN (r_agent) provoked_41\VBN (r_acl) attack_40\NN (l_compound) migraine_39\JJ
D005996_D008881 NONE nitroglycerin_16\NN (r_compound) application_17\NN (r_pobj) after_14\IN (r_conj) before_12\RB (r_advmod) collected_2\VBN (l_conj) min_23\NN (l_prep) after_24\IN (l_pobj) beginning_26\NN (l_prep) of_27\IN (l_pobj) attack_30\NN (l_compound) migraine_29\JJ
D005996_D008881 NONE nitroglycerin_9\NN (l_prep) in_10\IN (l_pobj) subjects_11\NNS (l_prep) with_12\IN (l_pobj) attack_15\NN (l_compound) migraine_14\JJ
D005996_D008881 NONE nitroglycerin_9\NN (r_pobj) after_8\IN (r_prep) decreased_3\VBD (l_conj) observed_21\VBN (l_prep) in_22\IN (l_pobj) patients_23\NNS (l_prep) with_24\IN (l_pobj) attack_26\NN (l_compound) migraine_25\JJ
D015740_D006261 NONE peptide_17\NN (r_nmod) content_30\NN (r_pobj) in_10\IN (r_prep) changes_9\NNS (l_prep) during_31\IN (l_pobj) headache_34\NN
D015740_D006261 NONE CGRP_19\NN (r_nmod) concentration_21\NN (r_nmod) content_30\NN (r_pobj) in_10\IN (r_prep) changes_9\NNS (l_prep) during_31\IN (l_pobj) headache_34\NN
D015740_D006261 NONE CGRP_3\NNP (r_compound) concentrations_4\NNS (r_nsubj) failed_5\VBD (l_xcomp) change_7\VB (l_prep) during_8\IN (l_pobj) headache_10\NN
D015740_D006261 NONE CGRP_7\NN (r_compound) concentration_8\NN (r_nsubj) correlates_9\VBZ (l_prep) with_10\IN (l_pobj) timing_12\NN (l_prep) of_15\IN (l_pobj) headache_18\NN
D015740_D006261 NONE CGRP_24\NN (r_pobj) between_23\IN (r_prep) relationship_22\NN (r_dobj) suggests_19\VBZ (l_nsubj) fact_4\NN (l_acl) correlates_9\VBZ (l_prep) with_10\IN (l_pobj) timing_12\NN (l_prep) of_15\IN (l_pobj) headache_18\NN
D015740_D006261 NONE CGRP_21\NN (r_compound) release_22\NN (r_conj) headache_17\NN
D012701_D006261 NONE serotonin_24\NN (r_nmod) content_30\NN (r_pobj) in_10\IN (r_prep) changes_9\NNS (l_prep) during_31\IN (l_pobj) headache_34\NN
D012701_D006261 NONE 5-hydroxytriptamine_26\NN (r_punct) ,_27\, (r_punct) 5-HT_28\CD (r_nmod) content_30\NN (r_pobj) in_10\IN (r_prep) changes_9\NNS (l_prep) during_31\IN (l_pobj) headache_34\NN
D012701_D006261 NONE 5-HT_28\CD (r_nmod) content_30\NN (r_pobj) in_10\IN (r_prep) changes_9\NNS (l_prep) during_31\IN (l_pobj) headache_34\NN
D012701_D006261 NONE serotonin_3\NN (r_compound) release_4\NN (r_nsubj) provoke_9\VB (r_ccomp) counteract_15\VB (l_dobj) headache_17\NN
D005996_D006261 NONE nitroglycerin_43\NN (r_pobj) by_42\IN (r_agent) provoked_41\VBN (r_acl) attack_40\NN (r_conj) investigate_8\VB (l_dobj) changes_9\NNS (l_prep) during_31\IN (l_pobj) headache_34\NN
9034419
C047426_D003865 NONE venlafaxine_12\NN (r_pobj) of_11\IN (r_prep) overdose_10\NN (r_dobj) took_8\VBD (l_nsubj) woman_4\NN (l_prep) with_5\IN (l_pobj) depression_7\NN
C047426_D012640 CID venlafaxine_4\NNP (r_amod) overdose_5\NN (r_pobj) from_2\IN (r_prep) resulting_1\VBG (r_acl) Seizure_0\NN
C047426_D012640 CID venlafaxine_5\NNP (r_pobj) of_3\IN (r_prep) ingestion_2\NN (r_pobj) After_0\IN (r_prep) experienced_11\VBD (l_dobj) seizure_15\NN
C047426_D012640 CID venlafaxine_11\NNP (r_amod) overdose_12\NN (r_pobj) of_10\IN (r_prep) case_9\NN (l_relcl) resulted_14\VBD (l_prep) in_15\IN (l_pobj) seizure_18\NN
C047426_D012640 CID venlafaxine_1\NNP (r_amod) overdose_2\NN (r_nsubj) resulted_6\VBD (l_prep) in_7\IN (l_pobj) episode_10\NN (l_prep) of_11\IN (l_pobj) seizure_13\NN
C047426_D062787 CID venlafaxine_4\NNP (r_amod) overdose_5\NN
C047426_D062787 CID venlafaxine_5\NNP (r_amod) overdose_6\NN
C047426_D062787 CID venlafaxine_12\NN (r_pobj) of_11\IN (r_prep) overdose_10\NN
C047426_D062787 CID venlafaxine_11\NNP (r_amod) overdose_12\NN
C047426_D062787 CID venlafaxine_1\NNP (r_amod) overdose_2\NN
18560792
D004298_D006349 NONE dopamine_33\NN (r_compound) agonists_34\NNS (r_pobj) to_29\IN (r_prep) converted_28\VBN (r_advcl) is_22\VBZ (r_ccomp) reveals_17\VBZ (r_conj) treated_13\VBN (r_acl) frequency_5\NN (l_prep) of_6\IN (l_pobj) regurgitation_9\NN
D010479_D006349 NONE pergolide_11\NN (r_pobj) with_10\IN (r_prep) treated_9\VBN (l_nsubj) disease_2\NN
D010479_D006349 NONE pergolide_17\NN (r_pobj) with_16\IN (r_prep) treated_15\VBN (r_acl) patients_7\NNS (r_pobj) in_6\IN (r_prep) reported_5\VBN (l_nsubjpass) abnormalities_2\NNS
D010479_D006349 NONE pergolide_12\NN (r_pobj) of_11\IN (r_prep) role_10\NN (r_pobj) of_8\IN (r_prep) suggestive_7\JJ (r_amod) pattern_2\NN (l_prep) of_3\IN (l_pobj) regurgitation_5\NN
D010479_D006349 NONE Pergolide_0\NNP (r_nsubjpass) discontinued_2\VBN (l_prep) in_3\IN (l_pobj) patients_5\NNS (l_prep) with_6\IN (l_pobj) disease_9\NN
D010479_D006349 NONE pergolide_15\NN (r_pobj) with_14\IN (r_prep) treated_13\VBN (r_acl) frequency_5\NN (l_prep) of_6\IN (l_pobj) regurgitation_9\NN
D004298_D010300 NONE dopamine_33\NN (r_compound) agonists_34\NNS (r_pobj) to_29\IN (r_prep) converted_28\VBN (r_advcl) is_22\VBZ (r_ccomp) reveals_17\VBZ (r_conj) treated_13\VBN (r_acl) frequency_5\NN (l_prep) of_6\IN (l_pobj) regurgitation_9\NN (l_prep) in_10\IN (l_pobj) patients_12\NNS (l_compound) PD_11\NNP
D010479_D010300 NONE pergolide_11\NN (r_pobj) with_10\IN (r_prep) treated_9\VBN (l_nsubj) disease_2\NN (l_prep) in_3\IN (l_pobj) patients_4\NNS (l_prep) with_5\IN (l_pobj) disease_8\NN
D010479_D010300 NONE pergolide_17\NN (r_pobj) with_16\IN (r_prep) treated_15\VBN (r_acl) patients_7\NNS (l_prep) with_8\IN (l_pobj) disease_11\NN
D010479_D010300 NONE pergolide_17\NN (r_pobj) with_16\IN (r_prep) treated_15\VBN (r_acl) patients_7\NNS (l_prep) with_8\IN (l_pobj) disease_11\NN (l_appos) PD_13\NNP
D010479_D010300 NONE pergolide_9\NN (r_pobj) with_8\IN (r_prep) treated_7\VBN (l_nsubj) patients_2\NNS (l_compound) PD_1\NNP
D010479_D010300 NONE pergolide_15\NN (r_pobj) with_14\IN (r_prep) treated_13\VBN (r_acl) frequency_5\NN (l_prep) of_6\IN (l_pobj) regurgitation_9\NN (l_prep) in_10\IN (l_pobj) patients_12\NNS (l_compound) PD_11\NNP
D010479_D006333 NONE pergolide_12\NN (r_pobj) of_11\IN (r_prep) role_10\NN (r_pobj) of_8\IN (r_prep) suggestive_7\JJ (r_amod) pattern_2\NN (r_nsubjpass) observed_15\VBN (l_dobj) patients_22\NNS (l_prep) including_23\VBG (l_pobj) two_24\CD (l_prep) with_25\IN (l_pobj) failure_27\NN
D010479_D006333 NONE Pergolide_0\NNP (r_nsubjpass) discontinued_2\VBN (l_advcl) resulting_11\VBG (l_prep) in_12\IN (l_pobj) grade_16\NN (l_prep) at_20\IN (l_pobj) transthoracic_23\NN (l_conj) patients_28\NNS (l_prep) with_29\IN (l_pobj) failure_31\NN
16181582
D014635_D004827 NONE Valproate_0\NNP (r_npadvmod) induced_2\VBN (r_amod) encephalopathy_3\NN (r_nsubj) is_4\VBZ (l_attr) syndrome_7\NN (l_relcl) manifest_10\VB (l_prep) in_11\RP (l_pobj) individuals_15\NNS (l_amod) epileptic_14\JJ
D014635_D001927 CID Valproate_0\NNP (r_npadvmod) induced_2\VBN (r_amod) encephalopathy_3\NN
D014635_D001927 CID valproate_3\NN (r_npadvmod) induced_5\VBN (r_amod) encephalopathy_6\NN
869641
D015103_D001919 NONE dihydroxyphenylserine_21\NN (r_conj) dopa_15\NNP (r_pobj) by_12\IN (r_agent) enhanced_11\VBN (l_nsubjpass) bradycardia_4\NN
D004298_D007022 NONE dopamine_3\NN (r_compound) oxidase_7\NN (r_compound) inhibitor_8\NN (r_nsubj) have_12\VB (l_dobj) effect_14\NN (l_prep) on_15\IN (l_pobj) hypotension_17\NN
D005406_D001919 NONE FLA-63_0\NN (r_mark) have_12\VB (l_dobj) effect_14\NN (l_prep) on_15\IN (l_pobj) hypotension_17\NN (l_appos) effect_24\NN (l_amod) bradycardia_19\NN
D007980_D001919 NONE dopa_9\NN (r_pobj) by_6\IN (r_prep) Mediation_0\NN (l_prep) of_1\IN (l_pobj) bradycardia_5\NNP
D007980_D001919 NONE dopa_15\NNP (r_pobj) by_12\IN (r_agent) enhanced_11\VBN (l_nsubjpass) bradycardia_4\NN
D007980_D001919 NONE dopa_28\NNP (r_pobj) of_25\IN (r_prep) effect_24\NN (l_amod) bradycardia_19\NN
D007980_D001919 NONE dopa_4\NNP (r_nsubj) restored_5\VBD (l_dobj) bradycardia_7\NN
D007980_D001919 NONE dopa_6\NNP (r_nsubj) enhances_7\VBZ (l_dobj) bradycardia_9\NN
D004298_D001919 NONE dopamine_12\NN (r_compound) formation_13\NN (r_pobj) via_10\IN (r_prep) Mediation_0\NN (l_prep) of_1\IN (l_pobj) bradycardia_5\NNP
D004298_D001919 NONE dopamine_3\NN (r_compound) oxidase_7\NN (r_compound) inhibitor_8\NN (r_nsubj) have_12\VB (l_dobj) effect_14\NN (l_prep) on_15\IN (l_pobj) hypotension_17\NN (l_appos) effect_24\NN (l_amod) bradycardia_19\NN
D005406_D007022 NONE FLA-63_0\NN (r_mark) have_12\VB (l_dobj) effect_14\NN (l_prep) on_15\IN (l_pobj) hypotension_17\NN
D009638_D001919 CID norepinephrine_8\NN (r_pobj) by_6\IN (r_agent) caused_5\VBN (r_acl) bradycardia_4\NN
D009638_D001919 CID norepinephrine_35\NN (r_pobj) to_34\IN (r_prep) responses_33\NNS (r_conj) rate_30\NN (r_conj) pressure_27\NN (r_pobj) on_25\IN (r_prep) effect_24\NN (r_dobj) had_22\VBD (r_conj) enhanced_11\VBN (l_nsubjpass) bradycardia_4\NN
D009638_D001919 CID norepinephrine_10\NN (r_pobj) by_9\IN (r_agent) caused_8\VBN (r_acl) bradycardia_7\NN
D009638_D001919 CID norepinephrine_18\NN (r_pobj) to_17\IN (r_prep) bradycardia_16\NN
D007980_D007022 NONE dopa_28\NNP (r_pobj) of_25\IN (r_prep) effect_24\NN (r_appos) hypotension_17\NN
D006916_D001919 NONE 5-HTP_0\NNP (r_nsubj) decreased_6\VBD (l_conj) decreased_13\VBD (l_dobj) bradycardia_16\NN
7423039
D004317_D066126 CID adriamycin_3\JJ (r_amod) cardiotoxicity_4\NN
D004317_D066126 CID adriamycin_4\NNS (r_pobj) of_3\IN (r_prep) effects_2\NNS (l_amod) cardiotoxic_1\JJ
8386779
D010208_D007172 NONE papaverine_25\NN (r_appos) drugs_21\NNS (r_pobj) of_19\IN (r_prep) combination_18\NN (r_pobj) of_16\IN (r_prep) ml._15\NN (r_dobj) received_13\VBD (l_nsubj) total_1\NN (l_prep) of_2\IN (l_pobj) patients_5\NNS (l_relcl) presented_7\VBD (l_prep) with_11\IN (l_pobj) impotence_12\NN
D017693_D007172 NONE bicarbonate_1\NN (r_nsubj) alleviates_2\VBZ (l_advcl) induced_5\VBN (l_agent) by_6\IN (l_pobj) injections_8\NNS (l_prep) for_9\IN (l_pobj) dysfunction_11\NN
D017693_D004414 NONE bicarbonate_1\NN (r_nsubj) alleviates_2\VBZ (l_dobj) pain_4\NN
D017693_D004414 NONE bicarbonate_43\NN (r_pobj) of_41\IN (r_prep) addition_40\NN (r_pobj) without_38\IN (r_conj) with_36\IN (r_prep) injections_35\NNS (r_pobj) following_33\VBG (r_prep) comparing_27\VBG (r_acl) study_26\NN (r_dobj) performed_23\VBD (l_prep) In_0\IN (l_pobj) attempt_2\NN (l_acl) determine_4\VB (l_ccomp) be_13\VB (l_nsubj) pain_7\NN
D017693_D004414 NONE bicarbonate_43\NN (r_pobj) of_41\IN (r_prep) addition_40\NN (r_pobj) without_38\IN (r_conj) with_36\IN (r_prep) injections_35\NNS (r_pobj) following_33\VBG (r_prep) comparing_27\VBG (l_dobj) incidence_29\NN (l_prep) of_30\IN (l_pobj) pain_32\NN
D017693_D004414 NONE bicarbonate_6\NN (r_pobj) without_4\IN (r_prep) patients_3\NNS (r_pobj) Of_0\IN (r_prep) complained_16\VBD (l_prep) of_17\IN (l_pobj) pain_19\NN
D017693_D004414 NONE bicarbonate_6\NN (r_pobj) without_4\IN (r_prep) patients_3\NNS (r_pobj) Of_0\IN (r_prep) complained_16\VBD (l_advcl) complained_40\VBD (l_prep) of_41\IN (l_pobj) pain_43\NN
D017693_D004414 NONE bicarbonate_39\NN (r_dobj) received_37\VBD (r_relcl) men_31\NNS (r_pobj) of_28\IN (r_prep) 1_27\CD (r_nsubj) complained_40\VBD (r_advcl) complained_16\VBD (l_prep) of_17\IN (l_pobj) pain_19\NN
D017693_D004414 NONE bicarbonate_39\NN (r_dobj) received_37\VBD (r_relcl) men_31\NNS (r_pobj) of_28\IN (r_prep) 1_27\CD (r_nsubj) complained_40\VBD (l_prep) of_41\IN (l_pobj) pain_43\NN
11569530
C063968_D016171 NONE E4031_19\NNP (r_conj) cisapride_17\NN (r_conj) terodiline_15\NN (r_conj) terfenadine_13\NN (r_appos) investigated_11\VBN (l_nsubjpass) TDP_9\NNP
D020117_D016171 CID cisapride_17\NN (r_conj) terodiline_15\NN (r_conj) terfenadine_13\NN (r_appos) investigated_11\VBN (l_nsubjpass) TDP_9\NNP
D020117_D016171 CID cisapride_14\JJ (r_conj) terodiline_12\NN (r_conj) terfenadine_10\NN (r_appos) clinic_8\NN (r_pobj) in_6\IN (r_prep) shown_4\VBN (l_dobj) TDP_5\NNP
D016593_D016171 CID terfenadine_19\NN (r_appos) market_16\NN (r_pobj) from_14\IN (r_prep) withdrawal_10\NN (r_pobj) to_9\IN (r_prep) led_8\VBN (r_relcl) effect_5\NN (r_attr) is_1\VBZ (l_nsubj) TDP_0\NNP
D016593_D016171 CID terfenadine_13\NN (r_appos) investigated_11\VBN (l_nsubjpass) TDP_9\NNP
D016593_D016171 CID terfenadine_10\NN (r_appos) clinic_8\NN (r_pobj) in_6\IN (r_prep) shown_4\VBN (l_dobj) TDP_5\NNP
C010637_D016171 CID terodiline_21\NN (r_conj) terfenadine_19\NN (r_appos) market_16\NN (r_pobj) from_14\IN (r_prep) withdrawal_10\NN (r_pobj) to_9\IN (r_prep) led_8\VBN (r_relcl) effect_5\NN (r_attr) is_1\VBZ (l_nsubj) TDP_0\NNP
C010637_D016171 CID terodiline_15\NN (r_conj) terfenadine_13\NN (r_appos) investigated_11\VBN (l_nsubjpass) TDP_9\NNP
C010637_D016171 CID terodiline_12\NN (r_conj) terfenadine_10\NN (r_appos) clinic_8\NN (r_pobj) in_6\IN (r_prep) shown_4\VBN (l_dobj) TDP_5\NNP
6308277
D010433_D012640 CID pentylenetetrezol_30\NN (r_pobj) of_29\IN (r_prep) dose_28\NN (r_dobj) alter_25\VB (r_conj) modify_15\VB (l_dobj) seizures_17\NNS
D000082_D064420 NONE acetaminophen_5\NN (r_pobj) by_4\IN (r_prep) Reduction_0\NN (l_prep) in_1\IN (l_pobj) toxicity_3\NN
D000082_D064420 NONE acetaminophen_26\NN (r_pobj) of_25\IN (r_prep) presence_24\NN (r_nsubj) reduced_33\VBD (l_dobj) toxicity_36\NN
D002110_D012640 CID caffeine_23\NN (r_pobj) of_22\IN (r_prep) administration_21\NN (l_conj) onset_33\NN (l_prep) of_34\IN (l_pobj) convulsions_36\NNS
D002110_D012640 CID caffeine_23\NN (r_pobj) of_22\IN (r_prep) administration_21\NN (r_pobj) between_19\IN (r_prep) interval_18\NN (r_dobj) increased_16\VBD (l_conj) reduced_54\VBD (l_dobj) incidence_56\NN (l_prep) of_57\IN (l_pobj) seizures_59\NNS
D002110_D012640 CID caffeine_65\NN (r_pobj) of_64\IN (r_prep) presence_63\NN (r_pobj) in_61\IN (r_prep) produced_60\VBN (r_acl) seizures_59\NNS (r_pobj) of_57\IN (r_prep) incidence_56\NN (r_dobj) reduced_54\VBD (r_conj) increased_16\VBD (l_dobj) interval_18\NN (l_prep) between_19\IN (l_pobj) administration_21\NN (l_conj) onset_33\NN (l_prep) of_34\IN (l_pobj) convulsions_36\NNS
D002110_D012640 CID caffeine_65\NN (r_pobj) of_64\IN (r_prep) presence_63\NN (r_pobj) in_61\IN (r_prep) produced_60\VBN (r_acl) seizures_59\NNS
D002110_D012640 CID caffeine_12\NN (r_pobj) after_7\IN (r_prep) frequency_1\NN (l_prep) of_2\IN (l_pobj) seizures_6\NNS
D002110_D012640 CID caffeine_4\NN (r_pobj) of_3\IN (r_prep) absence_2\NN (r_pobj) In_0\IN (r_prep) modify_15\VB (l_dobj) seizures_17\NNS
D002110_D064420 NONE caffeine_2\NN (r_compound) toxicity_3\NN
D002110_D064420 NONE caffeine_11\NN (r_pobj) of_10\IN (r_prep) effects_9\NNS (r_dobj) augment_6\VB (r_xcomp) reported_4\VBN (r_advcl) focused_18\VBN (l_prep) on_19\IN (l_pobj) possibility_21\NN (l_acl) reduced_33\VBD (l_dobj) toxicity_36\NN
D002110_D064420 NONE caffeine_38\NN (r_pobj) of_37\IN (r_prep) toxicity_36\NN
D000082_D012640 NONE acetaminophen_11\NN (r_pobj) with_10\IN (r_prep) pretreatment_9\NN (r_nsubj) increased_16\VBD (l_dobj) interval_18\NN (l_prep) between_19\IN (l_pobj) administration_21\NN (l_conj) onset_33\NN (l_prep) of_34\IN (l_pobj) convulsions_36\NNS
D000082_D012640 NONE acetaminophen_11\NN (r_pobj) with_10\IN (r_prep) pretreatment_9\NN (r_nsubj) increased_16\VBD (l_conj) reduced_54\VBD (l_dobj) incidence_56\NN (l_prep) of_57\IN (l_pobj) seizures_59\NNS
D000082_D012640 NONE acetaminophen_49\NN (r_pobj) with_48\IN (r_prep) pretreatment_47\NN (r_conj) onset_33\NN (l_prep) of_34\IN (l_pobj) convulsions_36\NNS
D000082_D012640 NONE acetaminophen_49\NN (r_pobj) with_48\IN (r_prep) pretreatment_47\NN (r_conj) onset_33\NN (r_conj) administration_21\NN (r_pobj) between_19\IN (r_prep) interval_18\NN (r_dobj) increased_16\VBD (l_conj) reduced_54\VBD (l_dobj) incidence_56\NN (l_prep) of_57\IN (l_pobj) seizures_59\NNS
D000082_D012640 NONE acetaminophen_21\NN (r_pobj) by_20\IN (r_agent) reduced_14\VBN (l_nsubjpass) frequency_1\NN (l_prep) of_2\IN (l_pobj) seizures_6\NNS
D000082_D012640 NONE acetaminophen_6\FW (r_nsubj) modify_15\VB (l_dobj) seizures_17\NNS
16574712
D018817_D003072 CID MDMA_0\NN (r_compound) users_2\NNS (r_nsubj) show_3\VBP (l_dobj) impairments_9\NNS (l_acl) coupled_10\VBN (l_prep) with_11\IN (l_pobj) processes_17\NNS
D018817_D008569 NONE MDMA_12\NNP (r_pobj) of_11\IN (r_prep) users_10\NNS (r_pobj) in_9\IN (r_prep) reported_8\VBN (l_nsubjpass) deficits_5\NNS
D018817_D008569 NONE 3,4-methylenedioxymethamphetamine_14\CD (r_intj) MDMA_12\NNP (r_pobj) of_11\IN (r_prep) users_10\NNS (r_pobj) in_9\IN (r_prep) reported_8\VBN (l_nsubjpass) deficits_5\NNS
D018817_D008569 NONE ecstasy_16\NN (r_appos) MDMA_12\NNP (r_pobj) of_11\IN (r_prep) users_10\NNS (r_pobj) in_9\IN (r_prep) reported_8\VBN (l_nsubjpass) deficits_5\NNS
6773726
D005996_D003920 NONE nitroglycerin_3\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (r_nsubjpass) compared_12\VBN (l_prep) in_13\IN (l_pobj) subjects_16\NNS (l_appos) subjects_20\NNS (l_amod) diabetic_19\JJ
D005996_D003920 NONE nitroglycerin_3\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (r_nsubjpass) compared_12\VBN (l_prep) in_13\IN (l_pobj) subjects_16\NNS (l_appos) subjects_20\NNS (l_conj) subjects_28\NNS (l_amod) diabetic_27\JJ
D005996_D003920 NONE nitroglycerin_19\NN (r_pobj) after_18\IN (r_prep) decrease_13\NN (r_conj) increase_7\NN (r_pobj) of_5\IN (r_prep) course_4\NN (r_nsubj) were_20\VBD (l_acomp) similar_21\JJ (l_prep) in_22\IN (l_pobj) subjects_27\NNS (l_amod) normal_24\JJ (l_conj) diabetic_26\JJ
D005996_D003920 NONE nitroglycerin_19\NN (r_pobj) after_18\IN (r_prep) decrease_13\NN (r_conj) increase_7\NN (r_pobj) of_5\IN (r_prep) course_4\NN (r_nsubj) were_20\VBD (l_advcl) occurred_47\VBD (l_prep) in_48\IN (l_pobj) subjects_51\NNS (l_amod) diabetic_50\JJ
D005996_D009422 NONE nitroglycerin_3\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (r_nsubjpass) compared_12\VBN (l_prep) in_13\IN (l_pobj) subjects_16\NNS (l_appos) subjects_20\NNS (l_prep) without_21\IN (l_pobj) neuropathy_23\NN
D005996_D009422 NONE nitroglycerin_3\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (r_nsubjpass) compared_12\VBN (l_prep) in_13\IN (l_pobj) subjects_16\NNS (l_appos) subjects_20\NNS (l_conj) subjects_28\NNS (l_prep) with_29\IN (l_pobj) neuropathy_31\NN
D005996_D009422 NONE nitroglycerin_19\NN (r_pobj) after_18\IN (r_prep) decrease_13\NN (r_conj) increase_7\NN (r_pobj) of_5\IN (r_prep) course_4\NN (r_nsubj) were_20\VBD (l_acomp) similar_21\JJ (l_prep) in_22\IN (l_pobj) subjects_27\NNS (l_prep) without_28\IN (l_pobj) neuropathy_30\NN
D005996_D009422 NONE nitroglycerin_19\NN (r_pobj) after_18\IN (r_prep) decrease_13\NN (r_conj) increase_7\NN (r_pobj) of_5\IN (r_prep) course_4\NN (r_nsubj) were_20\VBD (l_advcl) occurred_47\VBD (l_prep) in_48\IN (l_pobj) subjects_51\NNS (l_prep) with_52\IN (l_pobj) neuropathy_54\NN
D005996_D007022 CID nitroglycerin_5\NN (r_pobj) by_4\IN (r_prep) hypotension_3\NN
D005996_D003929 NONE nitroglycerin_5\NN (l_prep) in_6\IN (l_pobj) neuropathy_9\NN
15130900
D003520_D001749 CID cyclophosphamide_12\NN (r_pobj) to_11\IN (r_prep) risks_8\NNS (r_appos) granulomatosis_6\NN (r_pobj) in_3\IN (r_prep) cancer_2\NN
D003520_D001749 CID cyclophosphamide_16\NN (r_pobj) to_15\IN (r_prep) relation_14\NN (r_conj) assess_3\VB (l_conj) characterise_5\VB (l_dobj) risk_7\NN (l_prep) of_8\IN (l_pobj) cancer_10\NN
D003520_D001749 CID cyclophosphamide_18\NN (l_conj) cancer_21\NN
D003520_D001749 CID cyclophosphamide_12\NN (r_pobj) in_11\IN (r_prep) increment_10\NN (r_pobj) for_6\IN (r_prep) doubled_5\VBD (l_nsubj) risk_1\NN (l_prep) of_2\IN (l_pobj) cancer_4\NN
D003520_D001749 CID cyclophosphamide_9\NN (r_pobj) between_8\IN (r_prep) relationship_7\NN (l_conj) risk_12\NN (l_prep) of_13\IN (l_pobj) cancer_15\NN
D003520_D014890 NONE cyclophosphamide_12\NN (r_pobj) to_11\IN (r_prep) risks_8\NNS (r_appos) granulomatosis_6\NN
D003520_D014890 NONE cyclophosphamide_16\NN (r_pobj) to_15\IN (r_prep) relation_14\NN (l_prep) in_18\IN (l_pobj) patients_19\NNS (l_prep) with_20\IN (l_pobj) granulomatosis_23\NN
D003520_D014890 NONE cyclophosphamide_9\NN (r_pobj) between_8\IN (r_prep) relationship_7\NN (l_conj) risk_12\NN (l_conj) risks_19\NNS (l_conj) possibility_28\NN (l_prep) of_29\IN (l_pobj) factors_31\NNS (l_acl) operating_32\VBG (l_prep) before_34\IN (l_pobj) granulomatosis_37\NN
150790
D007538_D001523 NONE isoniazid_22\NN (r_pobj) of_21\IN (r_prep) administration_20\NN (r_pobj) after_17\IN (r_prep) sleeping_15\VBG (r_conj) irritability_12\NN
D011736_D002653 NONE pyridoxine_1\JJ (r_advmod) dependent_3\JJ (r_amod) disorder_5\NN
D007538_D012893 NONE isoniazid_22\NN (r_pobj) of_21\IN (r_prep) administration_20\NN (r_pobj) after_17\IN (r_prep) sleeping_15\VBG (l_dobj) difficulties_16\NNS
D011736_D006948 NONE pyridoxine_3\NN (r_pobj) of_2\IN (r_prep) withdrawal_1\NN (r_nsubjpass) associated_5\VBN (l_prep) with_6\IN (l_pobj) return_7\NN (l_prep) of_8\IN (l_pobj) hyperkinesis_10\NN
D007538_D006948 CID isoniazid_22\NN (r_pobj) of_21\IN (r_prep) administration_20\NN (r_pobj) after_17\IN (r_prep) sleeping_15\VBG (r_conj) irritability_12\NN (r_conj) hyperkinesis_10\NN
D007538_D002653 CID isoniazid_8\NN (r_pobj) by_7\IN (r_agent) unmasked_6\VBD (r_acl) disorder_5\NN
D007538_D002653 CID isoniazid_22\NN (r_pobj) of_21\IN (r_prep) administration_20\NN (r_pobj) after_17\IN (r_prep) sleeping_15\VBG (r_conj) irritability_12\NN (r_conj) hyperkinesis_10\NN (r_pobj) with_9\IN (r_prep) had_5\VBD (l_dobj) deterioration_7\NN
3719553
D011241_D004342 NONE prednisone_3\NNP (r_conj) diphenhydramine_1\NN (r_nsubj) were_4\VBD (l_prep) in_6\IN (l_pcomp) preventing_7\VBG (l_dobj) recurrence_9\NN (l_prep) of_10\IN (l_pobj) reaction_13\NN
D005472_D007674 NONE 5-fluorouracil_11\CD (r_punct) reaction_2\NN (r_nsubj) occurred_12\VBD (l_prep) in_13\IN (l_pobj) patient_15\NN (l_prep) with_16\IN (l_pobj) carcinoma_18\NN (l_prep) of_19\IN (l_pobj) cavity_22\NN (l_conj) cirrhosis_24\NN (l_conj) function_32\NN
D005472_D005355 NONE 5-fluorouracil_11\CD (r_punct) reaction_2\NN (r_nsubj) occurred_12\VBD (l_prep) in_13\IN (l_pobj) patient_15\NN (l_prep) with_16\IN (l_pobj) carcinoma_18\NN (l_prep) of_19\IN (l_pobj) cavity_22\NN (l_conj) cirrhosis_24\NN
D005472_D000799 CID 5-fluorouracil_11\CD (r_punct) reaction_2\NN (l_acl) consisting_3\VBG (l_prep) of_4\IN (l_pobj) edema_6\NN
D005472_D009062 NONE 5-fluorouracil_11\CD (r_punct) reaction_2\NN (r_nsubj) occurred_12\VBD (l_prep) in_13\IN (l_pobj) patient_15\NN (l_prep) with_16\IN (l_pobj) carcinoma_18\NN (l_prep) of_19\IN (l_pobj) cavity_22\NN
D005472_D004342 NONE 5-fluorouracil_3\CD (r_punct) infusion_4\NN (r_pobj) to_2\IN (r_prep) reaction_1\NN
D005472_D004342 NONE 5-fluorouracil_11\CD (r_punct) reaction_2\NN
D002945_D005355 NONE cisplatin_27\NN (r_advmod) induced_29\VBN (r_amod) function_32\NN (r_conj) cirrhosis_24\NN
D002945_D009062 NONE cisplatin_27\NN (r_advmod) induced_29\VBN (r_amod) function_32\NN (r_conj) cirrhosis_24\NN (r_conj) cavity_22\NN
D002945_D004342 NONE cisplatin_27\NN (r_advmod) induced_29\VBN (r_amod) function_32\NN (r_conj) cirrhosis_24\NN (r_conj) cavity_22\NN (r_pobj) of_19\IN (r_prep) carcinoma_18\NN (r_pobj) with_16\IN (r_prep) patient_15\NN (r_pobj) in_13\IN (r_prep) occurred_12\VBD (l_nsubj) reaction_2\NN
D002945_D000799 NONE cisplatin_27\NN (r_advmod) induced_29\VBN (r_amod) function_32\NN (r_conj) cirrhosis_24\NN (r_conj) cavity_22\NN (r_pobj) of_19\IN (r_prep) carcinoma_18\NN (r_pobj) with_16\IN (r_prep) patient_15\NN (r_pobj) in_13\IN (r_prep) occurred_12\VBD (l_nsubj) reaction_2\NN (l_acl) consisting_3\VBG (l_prep) of_4\IN (l_pobj) edema_6\NN
D004155_D004342 NONE diphenhydramine_1\NN (r_nsubj) were_4\VBD (l_prep) in_6\IN (l_pcomp) preventing_7\VBG (l_dobj) recurrence_9\NN (l_prep) of_10\IN (l_pobj) reaction_13\NN
D002945_D007674 NONE cisplatin_27\NN (r_advmod) induced_29\VBN (r_amod) function_32\NN
12090760
D015215_D000740 CID azidothymidine_9\RB (r_advmod) induced_11\VBN (r_amod) anemia_12\NN
D015215_D000740 CID Azidothymidine_0\NNP (r_nsubjpass) reversed_8\VBN (l_nsubjpass) anemia_3\NN
D015215_D000740 CID AZT)-induced_2\VBN (r_compound) anemia_3\NN
15120741
D010862_D012640 CID pilocarpine_5\NN (r_compound) injection_6\NN (r_nsubj) causes_7\VBZ (l_dobj) SE_11\NNP (l_conj) development_16\NN (l_prep) of_17\IN (l_pobj) seizures_19\NNS
D001640_D013226 NONE bicuculline_5\NN (r_pobj) In_0\IN (r_prep) resulted_21\VBD (l_prep) in_22\IN (l_pobj) spike_26\NN (l_relcl) experience_41\VB (l_dobj) SE_42\NNP
D008274_D013226 NONE Mg(2+)-free_1\JJ (r_pobj) In_0\IN (r_prep) resulted_21\VBD (l_prep) in_22\IN (l_pobj) spike_26\NN (l_relcl) experience_41\VB (l_dobj) SE_42\NNP
D010862_D013226 CID pilocarpine_5\NN (r_compound) injection_6\NN (r_nsubj) causes_7\VBZ (l_dobj) SE_11\NNP (l_nmod) epilepticus_9\NN
D010862_D013226 CID pilocarpine_5\NN (r_compound) injection_6\NN (r_nsubj) causes_7\VBZ (l_dobj) SE_11\NNP
D010862_D013226 CID pilocarpine_34\NN (r_npadvmod) treated_36\VBN (r_amod) mice_37\NNS (r_conj) mice_32\NNS (r_pobj) from_30\IN (r_prep) cells_29\NNS (r_pobj) in_27\IN (r_prep) spike_26\NN (l_relcl) experience_41\VB (l_dobj) SE_42\NNP
D018698_D013226 NONE glutamate_37\NN (r_compound) receptor_38\NN (r_compound) antagonists_39\NNS (r_pobj) by_35\IN (r_agent) blocked_34\VBN (r_relcl) duration_30\NN (r_pobj) of_25\IN (r_prep) afterdischarges_24\NNS (r_conj) shifts_21\NNS (r_pobj) by_18\IN (r_prep) followed_11\VBD (r_advcl) resulted_6\VBD (l_prep) In_0\IN (l_pobj) survivors_2\NNS (l_compound) SE_1\NNP
D018698_D013226 NONE glutamate_1\NN (r_compound) photostimulation_2\NN (r_nsubj) resulted_15\VBD (l_prep) in_16\IN (l_pobj) responses_18\NNS (l_prep) of_19\IN (l_pobj) duration_24\NN (l_prep) in_25\IN (l_pobj) slices_26\NNS (l_prep) from_27\IN (l_pobj) survivors_29\NNS (l_compound) SE_28\NNP
14765563
D011803_D003128 CID quinine_7\NN (r_dobj) containing_6\VBG (r_acl) products_5\NNS (r_nsubj) produce_9\VB (l_dobj) status_18\NN (l_conj) seizures_20\NNS (l_conj) coma_23\NN
D011803_D012640 CID quinine_7\NN (r_dobj) containing_6\VBG (r_acl) products_5\NNS (r_nsubj) produce_9\VB (l_dobj) status_18\NN (l_conj) seizures_20\NNS
D011803_D002493 NONE quinine_7\NN (r_dobj) containing_6\VBG (r_acl) products_5\NNS (r_nsubj) produce_9\VB (l_dobj) complications_11\NNS
D011803_D020922 NONE quinine_23\NN (r_nsubj) is_24\VBZ (l_advcl) banned_8\VBD (l_dobj) use_10\NN (l_prep) for_11\IN (l_pobj) cramps_14\NNS
D011803_D003221 CID quinine_7\NN (r_dobj) containing_6\VBG (r_acl) products_5\NNS (r_nsubj) produce_9\VB (l_dobj) complications_11\NNS (l_prep) including_13\VBG (l_pobj) confusion_14\NN
10835440
D009553_D007022 CID Nimodipine_2\NNP (r_compound) Trial_6\NN (r_nsubj) found_10\VBD (l_dobj) correlation_12\NN (l_prep) between_13\IN (l_pobj) reduction_17\NN (l_prep) in_18\IN (l_pobj) pressure_20\NN
D009553_D007022 CID nimodipine_14\NN (r_npadvmod) induced_16\VBN (r_amod) reduction_17\NN (l_prep) in_18\IN (l_pobj) pressure_20\NN
D009553_D007022 CID Nimodipine_0\NNP (r_compound) treatment_1\NN (r_nsubj) resulted_2\VBD (l_prep) in_3\IN (l_pobj) reduction_7\NN (l_prep) in_8\IN (l_pobj) BP_10\NNP
D009553_D002544 NONE nimodipine_34\NN (r_parataxis) h_28\NN (r_appos) receive_19\VB (r_advcl) allocated_17\VBN (l_nsubjpass) METHODS_0\NNS (l_appos) Patients_2\NNS (l_prep) with_3\IN (l_pobj) diagnosis_6\NN (l_prep) of_7\IN (l_pobj) stroke_9\NN
D009553_D002544 NONE nimodipine_49\NN (r_conj) nimodipine_34\NN (r_parataxis) h_28\NN (r_appos) receive_19\VB (r_advcl) allocated_17\VBN (l_nsubjpass) METHODS_0\NNS (l_appos) Patients_2\NNS (l_prep) with_3\IN (l_pobj) diagnosis_6\NN (l_prep) of_7\IN (l_pobj) stroke_9\NN
D009553_D020521 NONE nimodipine_3\NN (r_pobj) of_1\IN (r_prep) Effect_0\NN (l_prep) after_9\IN (l_pobj) stroke_11\NN
D009553_D020521 NONE Nimodipine_2\NNP (r_compound) Trial_6\NN (l_compound) Stroke_5\NNP
D009553_D020521 NONE Nimodipine_2\NNP (r_compound) Trial_6\NN (r_nsubj) found_10\VBD (l_dobj) correlation_12\NN (l_prep) between_13\IN (l_pobj) reduction_17\NN (l_conj) outcome_27\NN (l_prep) in_28\IN (l_pobj) stroke_30\NN
D009553_D020521 NONE nimodipine_14\NN (r_npadvmod) induced_16\VBN (r_amod) reduction_17\NN (r_pobj) between_13\IN (r_prep) correlation_12\NN (r_dobj) found_10\VBD (l_nsubj) Trial_6\NN (l_compound) Stroke_5\NNP
D009553_D020521 NONE nimodipine_14\NN (r_npadvmod) induced_16\VBN (r_amod) reduction_17\NN (l_conj) outcome_27\NN (l_prep) in_28\IN (l_pobj) stroke_30\NN
D009553_D020521 NONE nimodipine_15\NN (r_pobj) of_11\IN (r_prep) administration_10\NN (r_pobj) after_7\IN (r_prep) worsening_6\VBG (l_prep) after_16\IN (l_pobj) stroke_18\NN
18464113
D006514_D006509 CID antigen_14\NN (r_nmod) patients_20\NNS (r_pobj) in_9\IN (r_prep) reactivation_8\NN (l_compound) virus_7\NN (l_compound) B_6\NNP
D006514_D006509 CID HBSAG_16\NNP (r_nmod) patients_20\NNS (r_pobj) in_9\IN (r_prep) reactivation_8\NN (l_compound) virus_7\NN (l_compound) B_6\NNP
D019259_D056486 NONE lamivudine_3\NN (r_compound) group_4\NN (r_pobj) In_0\IN (r_prep) observed_8\VBN (l_nsubjpass) hepatitis_6\NN
D006514_D009369 NONE antigen_14\NN (r_nmod) patients_20\NNS (l_compound) cancer_19\NN
D006514_D009369 NONE HBSAG_16\NNP (r_nmod) patients_20\NNS (l_compound) cancer_19\NN
D019259_D006509 NONE Lamivudine_0\NNP (l_prep) for_1\IN (l_pobj) prevention_3\NN (l_prep) of_4\IN (l_pobj) reactivation_8\NN (l_compound) virus_7\NN (l_compound) B_6\NNP
D019259_D006509 NONE lamivudine_20\NN (r_dobj) received_16\VBD (l_nsubj) patients_5\NNS (l_relcl) have_7\VBP (l_dobj) malignancies_11\NNS (l_prep) with_12\IN (l_pobj) infection_15\NN
D019259_D006509 NONE lamivudine_34\NN (r_dobj) receive_33\VB (r_relcl) group_29\NN (r_pobj) with_26\IN (r_prep) compared_25\VBN (r_prep) received_16\VBD (l_nsubj) patients_5\NNS (l_relcl) have_7\VBP (l_dobj) malignancies_11\NNS (l_prep) with_12\IN (l_pobj) infection_15\NN
D019259_D019337 NONE lamivudine_20\NN (r_dobj) received_16\VBD (l_nsubj) patients_5\NNS (l_relcl) have_7\VBP (l_dobj) malignancies_11\NNS
D019259_D019337 NONE lamivudine_34\NN (r_dobj) receive_33\VB (r_relcl) group_29\NN (r_pobj) with_26\IN (r_prep) compared_25\VBN (r_prep) received_16\VBD (l_nsubj) patients_5\NNS (l_relcl) have_7\VBP (l_dobj) malignancies_11\NNS
D019259_D009369 NONE Lamivudine_0\NNP (l_prep) for_1\IN (l_pobj) prevention_3\NN (l_prep) of_4\IN (l_pobj) reactivation_8\NN (l_prep) in_9\IN (l_pobj) patients_20\NNS (l_compound) cancer_19\NN
D019259_D009369 NONE lamivudine_20\NN (r_dobj) received_16\VBD (l_nsubj) patients_5\NNS (l_compound) cancer_4\NN
D019259_D009369 NONE lamivudine_34\NN (r_dobj) receive_33\VB (r_relcl) group_29\NN (r_pobj) with_26\IN (r_prep) compared_25\VBN (r_prep) received_16\VBD (l_nsubj) patients_5\NNS (l_compound) cancer_4\NN
D019259_D009369 NONE lamivudine_5\NN (r_nsubj) decreases_7\VBZ (l_dobj) incidence_9\NN (l_prep) of_10\IN (l_pobj) reactivation_12\NN (l_conj) morbidity_15\NN (l_prep) in_16\IN (l_pobj) patients_18\NNS (l_compound) cancer_17\NN
2924746
D005481_D015430 NONE HFDE_21\NNP (r_npadvmod) induced_23\VBN (r_amod) seizures_24\NNS (r_pobj) against_20\IN (r_prep) protective_19\JJ (r_acomp) was_17\VBD (l_conj) was_26\VBD (l_advcl) measured_30\VBN (l_agent) by_31\IN (l_pobj) gain_33\NN
D005481_D012640 CID ether_4\NN (r_pobj) by_2\IN (r_prep) induced_1\VBN (l_nsubj) Seizures_0\NNS
D005481_D012640 CID ether_4\NN (r_pobj) by_2\IN (r_prep) induced_1\VBN (l_conj) found_10\VBN (l_xcomp) be_12\VB (l_prep) than_21\IN (l_pobj) seizures_22\NNS
D005481_D012640 CID HFDE_6\NNP (r_appos) ether_4\NN (r_pobj) by_2\IN (r_prep) induced_1\VBN (l_nsubj) Seizures_0\NNS
D005481_D012640 CID HFDE_6\NNP (r_appos) ether_4\NN (r_pobj) by_2\IN (r_prep) induced_1\VBN (l_conj) found_10\VBN (l_xcomp) be_12\VB (l_prep) than_21\IN (l_pobj) seizures_22\NNS
D005481_D012640 CID HFDE_21\NNP (r_npadvmod) induced_23\VBN (r_amod) seizures_24\NNS
D002220_D015430 NONE CBZ_3\NNP (r_pobj) of_2\IN (r_prep) administration_1\NN (r_nsubj) was_17\VBD (l_conj) was_26\VBD (l_advcl) measured_30\VBN (l_agent) by_31\IN (l_pobj) gain_33\NN
D002220_D012640 NONE CBZ_20\NN (r_pobj) by_19\IN (r_prep) protection_18\NN (r_pobj) of_17\IN (r_prep) measure_16\NN (r_attr) be_12\VB (r_xcomp) found_10\VBN (r_conj) induced_1\VBN (l_nsubj) Seizures_0\NNS
D002220_D012640 NONE CBZ_20\NN (r_pobj) by_19\IN (r_prep) protection_18\NN (r_pobj) of_17\IN (r_prep) measure_16\NN (r_attr) be_12\VB (l_prep) than_21\IN (l_pobj) seizures_22\NNS
D002220_D012640 NONE CBZ_3\NNP (r_pobj) of_2\IN (r_prep) administration_1\NN (r_nsubj) was_17\VBD (l_acomp) protective_19\JJ (l_prep) against_20\IN (l_pobj) seizures_24\NNS
D005492_D064420 NONE folate_17\JJ (r_compound) concentrations_18\NNS (r_conj) plasma_14\NN (r_pobj) on_13\IN (r_prep) effect_12\NN (r_conj) toxicity_9\NN
D019946_D015430 NONE glycol_13\NN (r_appos) vehicle_10\NN (r_nsubjpass) found_22\VBN (l_xcomp) exhibit_24\VB (l_dobj) properties_26\NNS (l_prep) against_27\IN (l_pobj) seizures_29\NNS (l_conj) gain_33\NN
D019946_D012640 NONE glycol_13\NN (r_appos) vehicle_10\NN (r_nsubjpass) found_22\VBN (l_xcomp) exhibit_24\VB (l_dobj) properties_26\NNS (l_prep) against_27\IN (l_pobj) seizures_29\NNS
D002220_D064420 NONE carbamazepine_1\NN (r_compound) treatment_2\NN (l_appos) efficacy_7\NN (l_conj) toxicity_9\NN
2224762
C027260_D009369 NONE 4'-0-tetrahydropyranyladriamycin_10\NNP (r_dobj) bolus_9\NN (r_appos) Phase_1\NN (r_nsubjpass) done_15\VBN (l_prep) in_16\IN (l_pobj) patients_18\NNS (l_prep) in_19\IN (l_pobj) status_22\NN (l_prep) with_23\IN (l_pobj) tumors_25\NNS
C027260_D009369 NONE Pirarubicin_12\NNP (r_appos) 4'-0-tetrahydropyranyladriamycin_10\NNP (r_dobj) bolus_9\NN (r_appos) Phase_1\NN (r_nsubjpass) done_15\VBN (l_prep) in_16\IN (l_pobj) patients_18\NNS (l_prep) in_19\IN (l_pobj) status_22\NN (l_prep) with_23\IN (l_pobj) tumors_25\NNS
10721819
D004294_D001919 CID domperidone_26\NN (r_pobj) by_24\IN (r_agent) reduced_23\VBN (r_relcl) effect_19\NN (r_npadvmod) reversed_13\VBN (l_prep) to_14\IN (l_pobj) bradycardia_16\NNS
D001971_D007022 CID bromocriptine_5\NN (r_nsubj) induced_12\VBD (l_dobj) hypotension_14\NN
D001971_D007022 CID Bromocriptine_0\NNP (r_npadvmod) induced_2\VBN (r_amod) hypotension_3\NN
D007545_D007022 NONE isoproterenol_7\JJ (r_compound) pretreatment_8\NN (r_pobj) by_6\IN (r_prep) unaffected_5\JJ (r_acomp) was_4\VBD (l_nsubj) hypotension_3\NN
D004298_D013610 NONE dopamine_27\NN (r_compound) D2_28\NN (r_compound) receptors_29\NNS (r_pobj) at_25\IN (r_prep) bradycardia_21\NN (r_dobj) mask_19\VB (r_conj) predominate_16\VB (r_xcomp) appears_14\VBZ (l_nsubj) tachycardia_11\NN
D007545_D006332 CID Isoproterenol_0\JJ (r_compound) pretreatment_1\NN (r_nsubj) caused_5\VBD (l_dobj) hypertrophy_7\NN
D007545_D001919 CID isoproterenol_7\JJ (r_compound) pretreatment_8\NN (r_pobj) by_6\IN (r_prep) unaffected_5\JJ (r_acomp) was_4\VBD (l_advcl) reversed_13\VBN (l_prep) to_14\IN (l_pobj) bradycardia_16\NNS
D007545_D001919 CID isoproterenol_5\JJ (r_compound) pretreatment_6\NN (r_nsubj) abolished_9\VBD (l_conj) reversed_11\VBD (l_prep) to_16\IN (l_pobj) bradycardia_17\NNP
D001971_D013610 CID bromocriptine_9\NN (r_npadvmod) induced_11\VBN (r_amod) tachycardia_12\NN
D001971_D013610 CID bromocriptine_5\NN (r_npadvmod) induced_7\VBN (r_amod) tachycardia_8\NN
D001971_D013610 CID bromocriptine_13\NN (r_npadvmod) induced_15\VBN (r_amod) tachycardia_16\NN
D001971_D013610 CID bromocriptine_5\NN (r_nsubj) induced_12\VBD (l_dobj) hypotension_14\NN (l_conj) tachycardia_16\NN
D001971_D013610 CID Bromocriptine_0\NNP (r_npadvmod) induced_2\VBN (r_amod) hypotension_3\NN (r_nsubj) was_4\VBD (l_advcl) reversed_13\VBN (l_nsubjpass) tachycardia_11\NN
D001971_D013610 CID bromocriptine_12\NN (r_npadvmod) induced_14\VBN (r_amod) tachycardia_15\NN
D001971_D013610 CID bromocriptine_13\NN (r_pobj) of_12\IN (r_prep) tachycardia_11\NN
D001971_D001919 NONE Bromocriptine_0\NNP (r_npadvmod) induced_2\VBN (r_amod) hypotension_3\NN (r_nsubj) was_4\VBD (l_advcl) reversed_13\VBN (l_prep) to_14\IN (l_pobj) bradycardia_16\NNS
D001971_D001919 NONE bromocriptine_12\NN (r_npadvmod) induced_14\VBN (r_amod) tachycardia_15\NN (r_dobj) reversed_11\VBD (l_prep) to_16\IN (l_pobj) bradycardia_17\NNP
D001971_D001919 NONE bromocriptine_13\NN (r_pobj) of_12\IN (r_prep) tachycardia_11\NN (r_nsubj) appears_14\VBZ (l_xcomp) predominate_16\VB (l_conj) mask_19\VB (l_dobj) bradycardia_21\NN
D004294_D007022 NONE domperidone_26\NN (r_pobj) by_24\IN (r_agent) reduced_23\VBN (r_relcl) effect_19\NN (r_npadvmod) reversed_13\VBN (r_advcl) was_4\VBD (l_nsubj) hypotension_3\NN
D004298_D001919 NONE dopamine_27\NN (r_compound) D2_28\NN (r_compound) receptors_29\NNS (r_pobj) at_25\IN (r_prep) bradycardia_21\NN
D007545_D013610 NONE isoproterenol_7\NN (l_prep) on_8\IN (l_pobj) tachycardia_12\NN
D007545_D013610 NONE isoproterenol_10\NN (r_pobj) with_9\IN (r_prep) pretreatment_8\NN (r_nsubj) abolish_12\VB (l_dobj) tachycardia_16\NN
D007545_D013610 NONE isoproterenol_7\JJ (r_compound) pretreatment_8\NN (r_pobj) by_6\IN (r_prep) unaffected_5\JJ (r_acomp) was_4\VBD (l_advcl) reversed_13\VBN (l_nsubjpass) tachycardia_11\NN
D007545_D013610 NONE isoproterenol_5\JJ (r_compound) pretreatment_6\NN (r_nsubj) abolished_9\VBD (l_conj) reversed_11\VBD (l_dobj) tachycardia_15\NN
D004294_D013610 NONE domperidone_26\NN (r_pobj) by_24\IN (r_agent) reduced_23\VBN (r_relcl) effect_19\NN (r_npadvmod) reversed_13\VBN (l_nsubjpass) tachycardia_11\NN
18754075
D019386_D005923 NONE alendronate_10\JJ (r_nmod) administration_12\NN (l_prep) in_13\IN (l_pobj) patient_15\NN (l_prep) with_16\IN (l_pobj) glomerulosclerosis_19\NN
D019386_D011507 CID alendronate_10\JJ (r_nmod) administration_12\NN (r_pobj) after_6\IN (r_prep) proteinuria_1\NN
D013256_D009404 NONE steroid_19\NN (r_compound) therapy_20\NN (r_pobj) to_18\IN (r_prep) responding_16\VBG (l_nsubj) man_5\NN (l_prep) with_6\IN (l_pobj) syndrome_8\NN
D004164_D011507 NONE bisphosphonate_8\NN (r_nmod) administration_12\NN (r_pobj) after_6\IN (r_prep) proteinuria_1\NN
D004164_D011507 NONE bisphosphonates_11\NNS (r_nsubj) aggravate_13\VB (l_dobj) proteinuria_14\NN
D019386_D058186 CID alendronate_10\JJ (r_nmod) administration_12\NN (r_pobj) after_6\IN (r_prep) proteinuria_1\NN (l_conj) failure_5\NN
D019386_D058186 CID sodium_9\NN (r_nmod) administration_11\NN (r_nsubj) increased_19\VBD (l_prep) with_25\IN (l_pobj) failure_28\NN
D004164_D058186 NONE bisphosphonate_8\NN (r_nmod) administration_12\NN (r_pobj) after_6\IN (r_prep) proteinuria_1\NN (l_conj) failure_5\NN
D004164_D058186 NONE bisphosphonate_6\NN (r_pobj) of_3\IN (r_prep) days_2\NNS (r_pobj) Within_0\IN (r_prep) increased_19\VBD (l_prep) with_25\IN (l_pobj) failure_28\NN
D004164_D058186 NONE bisphosphonates_11\NNS (r_nsubj) aggravate_13\VB (l_dobj) proteinuria_14\NN (l_conj) failure_18\NN
D013256_D005923 NONE steroid_19\NN (r_compound) therapy_20\NN (r_pobj) to_18\IN (r_prep) responding_16\VBG (l_nsubj) man_5\NN (l_amod) due_9\IN (l_pobj) glomerulosclerosis_13\NN
D004164_D005923 NONE bisphosphonate_8\NN (r_nmod) administration_12\NN (l_prep) in_13\IN (l_pobj) patient_15\NN (l_prep) with_16\IN (l_pobj) glomerulosclerosis_19\NN
6747681
D002330_D005910 NONE BCNU_3\NNP (r_compound) chemotherapy_4\NN (l_prep) for_5\IN (l_pobj) treatment_6\NN (l_prep) of_7\IN (l_pobj) gliomas_9\NNS
D002330_D005910 NONE BCNU_7\NNP (r_nmod) 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN (r_pobj) of_6\IN (r_prep) clearance_5\NN (r_pobj) Because_0\IN (r_prep) provide_17\VB (l_dobj) advantage_20\NN (l_prep) over_21\IN (l_pobj) administration_23\NN (l_prep) for_24\IN (l_pobj) treatment_26\NN (l_prep) of_27\IN (l_pobj) gliomas_29\NNS
D002330_D005910 NONE 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN (r_pobj) of_6\IN (r_prep) clearance_5\NN (r_pobj) Because_0\IN (r_prep) provide_17\VB (l_dobj) advantage_20\NN (l_prep) over_21\IN (l_pobj) administration_23\NN (l_prep) for_24\IN (l_pobj) treatment_26\NN (l_prep) of_27\IN (l_pobj) gliomas_29\NNS
D000431_D014786 NONE ethanol_11\NN (r_compound) diluent_12\NN (r_pobj) of_9\IN (r_prep) concentration_8\NN (r_nsubjpass) lowered_14\VBN (r_advcl) decreased_5\VBD (l_nsubj) frequency_1\NN (l_prep) of_2\IN (l_pobj) loss_4\NN
D002330_D001254 NONE BCNU_29\NNP (r_compound) therapy_30\NN (r_pobj) of_25\IN (r_prep) courses_24\NNS (r_dobj) received_20\VBD (l_nsubj) patients_3\NNS (l_prep) to_8\IN (l_pobj) astrocytomas_10\NN
2522601
D002220_D051437 CID carbamazepine_2\NN (r_pobj) to_1\IN (r_prep) Hypersensitivity_0\NN (l_acl) presenting_3\VBG (l_prep) with_4\IN (l_pobj) reaction_7\NN (l_conj) failure_15\NN
D002220_D051437 CID carbamazepine_8\NN (r_pobj) to_7\IN (r_prep) hypersensitivity_6\NN (r_nsubj) presented_9\VBN (r_relcl) patient_3\NN (l_conj) reaction_17\NN (l_conj) eosinophilia_19\NN (l_conj) hyponatremia_21\NN (l_conj) failure_25\NN
D002220_D004802 NONE carbamazepine_2\NN (r_pobj) to_1\IN (r_prep) Hypersensitivity_0\NN (l_acl) presenting_3\VBG (l_prep) with_4\IN (l_pobj) reaction_7\NN (l_conj) eosinophilia_9\NN
D002220_D004802 NONE carbamazepine_8\NN (r_pobj) to_7\IN (r_prep) hypersensitivity_6\NN (r_nsubj) presented_9\VBN (r_relcl) patient_3\NN (l_conj) reaction_17\NN (l_conj) eosinophilia_19\NN
D002220_D004342 CID carbamazepine_2\NN (r_pobj) to_1\IN (r_prep) Hypersensitivity_0\NN
D002220_D004342 CID carbamazepine_8\NN (r_pobj) to_7\IN (r_prep) hypersensitivity_6\NN
D002220_D007955 CID carbamazepine_2\NN (r_pobj) to_1\IN (r_prep) Hypersensitivity_0\NN (l_acl) presenting_3\VBG (l_prep) with_4\IN (l_pobj) reaction_7\NN
D002220_D007955 CID carbamazepine_8\NN (r_pobj) to_7\IN (r_prep) hypersensitivity_6\NN (r_nsubj) presented_9\VBN (r_relcl) patient_3\NN (l_conj) reaction_17\NN
D002220_D007010 CID carbamazepine_8\NN (r_pobj) to_7\IN (r_prep) hypersensitivity_6\NN (r_nsubj) presented_9\VBN (r_relcl) patient_3\NN (l_conj) reaction_17\NN (l_conj) eosinophilia_19\NN (l_conj) hyponatremia_21\NN
D002220_D003873 CID carbamazepine_2\NN (r_pobj) to_1\IN (r_prep) Hypersensitivity_0\NN (l_acl) presenting_3\VBG (l_prep) with_4\IN (l_pobj) reaction_7\NN (l_conj) eosinophilia_9\NN (l_conj) erythroderma_11\NN
D002220_D003873 CID carbamazepine_8\NN (r_pobj) to_7\IN (r_prep) hypersensitivity_6\NN (r_nsubj) presented_9\VBN (l_prep) with_10\IN (l_pobj) erythroderma_12\NN
11426838
C050232_D064420 NONE tolylguanidine_22\NN (r_nmod) DTG_24\NNP (r_appos) antagonists_9\NNS (r_pobj) by_6\IN (r_agent) provided_5\VBN (r_acl) protection_4\NN (r_pobj) to_2\IN (r_prep) contrast_1\NN (r_pobj) In_0\IN (r_prep) worsened_37\VBD (l_dobj) toxicity_40\NN
C050232_D064420 NONE DTG_24\NNP (r_appos) antagonists_9\NNS (r_pobj) by_6\IN (r_agent) provided_5\VBN (r_acl) protection_4\NN (r_pobj) to_2\IN (r_prep) contrast_1\NN (r_pobj) In_0\IN (r_prep) worsened_37\VBD (l_dobj) toxicity_40\NN
D003042_D064420 NONE cocaine_42\NN (r_pobj) of_41\IN (r_prep) toxicity_40\NN
C093337_D012640 NONE BD1063_12\NNP (r_conj) BD1018_10\NN (r_pobj) with_9\IN (r_punct) attenuated_17\VBD (r_amod) convulsions_21\NNS
D009838_D012640 NONE oligodeoxynucleotide_23\NN (r_appos) receptors_19\NNS (r_pobj) of_17\IN (r_prep) antagonism_16\NN (r_dobj) involved_15\VBD (r_acl) ligands_14\NNS (r_pobj) of_11\IN (r_prep) effects_10\NNS (r_nsubjpass) shown_29\VBN (l_xcomp) attenuate_32\VB (l_dobj) effects_38\NNS (l_amod) convulsive_34\JJ
-1_D012640 NONE BD1018_10\NN (r_pobj) with_9\IN (r_punct) attenuated_17\VBD (r_amod) convulsions_21\NNS
-1_D012640 NONE LR132_15\NNS (r_conj) BD1063_12\NNP (r_conj) BD1018_10\NN (r_pobj) with_9\IN (r_punct) attenuated_17\VBD (r_amod) convulsions_21\NNS
D003042_D012640 CID cocaine_18\NN (r_npadvmod) induced_20\VBN (r_amod) convulsions_21\NNS
D003042_D012640 CID cocaine_9\NN (r_compound) effects_10\NNS (r_nsubjpass) shown_29\VBN (l_xcomp) attenuate_32\VB (l_dobj) effects_38\NNS (l_amod) convulsive_34\JJ
D003042_D012640 CID cocaine_40\NN (r_pobj) of_39\IN (r_prep) effects_38\NNS (l_amod) convulsive_34\JJ
-1_D064420 NONE BD1031_32\NN (r_conj) DTG_24\NNP (r_appos) antagonists_9\NNS (r_pobj) by_6\IN (r_agent) provided_5\VBN (r_acl) protection_4\NN (r_pobj) to_2\IN (r_prep) contrast_1\NN (r_pobj) In_0\IN (r_prep) worsened_37\VBD (l_dobj) toxicity_40\NN
-1_D064420 NONE 3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane_34\NN (r_appos) BD1031_32\NN (r_conj) DTG_24\NNP (r_appos) antagonists_9\NNS (r_pobj) by_6\IN (r_agent) provided_5\VBN (r_acl) protection_4\NN (r_pobj) to_2\IN (r_prep) contrast_1\NN (r_pobj) In_0\IN (r_prep) worsened_37\VBD (l_dobj) toxicity_40\NN
19957053
D004809_D002534 NONE ephedrine_3\JJ (r_conj) Phenylephrine_0\NNP (r_nsubj) reduces_4\VBZ (l_dobj) oxygenation_7\NN
D004809_D007022 NONE ephedrine_3\JJ (r_conj) Phenylephrine_0\NNP (r_nsubj) reduces_4\VBZ (l_dobj) oxygenation_7\NN (l_prep) following_8\VBG (l_dobj) hypotension_12\NN
D004809_D007022 NONE ephedrine_7\JJ (r_conj) phenylephrine_5\NN (r_pobj) of_4\IN (r_prep) effect_3\NN (r_dobj) describe_1\VBP (l_prep) following_16\VBG (l_dobj) hypotension_20\NN
D004809_D007022 NONE ephedrine_18\JJ (r_nsubj) maintains_19\VBZ (r_advcl) has_10\VBZ (l_nsubj) utilization_1\NN (l_acl) correct_5\VB (l_dobj) hypotension_6\NN
D010656_D007022 NONE Phenylephrine_0\NNP (r_nsubj) reduces_4\VBZ (l_dobj) oxygenation_7\NN (l_prep) following_8\VBG (l_dobj) hypotension_12\NN
D010656_D007022 NONE phenylephrine_5\NN (r_pobj) of_4\IN (r_prep) effect_3\NN (r_dobj) describe_1\VBP (l_prep) following_16\VBG (l_dobj) hypotension_20\NN
D010656_D007022 NONE phenylephrine_3\NN (r_pobj) of_2\IN (r_prep) utilization_1\NN (l_acl) correct_5\VB (l_dobj) hypotension_6\NN
D010656_D002534 CID Phenylephrine_0\NNP (r_nsubj) reduces_4\VBZ (l_dobj) oxygenation_7\NN
12684739
D004298_D019966 NONE dopamine_47\NN (r_appos) accumbens_43\NNS (r_oprd) explored_26\VBD (l_prep) Given_0\VBN (l_pobj) success_3\NN (l_prep) for_4\IN (l_pcomp) treating_5\VBG (l_dobj) abuse_7\NN
D004298_D019966 NONE DA_49\NNP (r_appos) dopamine_47\NN (r_appos) accumbens_43\NNS (r_oprd) explored_26\VBD (l_prep) Given_0\VBN (l_pobj) success_3\NN (l_prep) for_4\IN (l_pcomp) treating_5\VBG (l_dobj) abuse_7\NN
D003042_D005128 NONE cocaine_37\NN (r_npadvmod) induced_39\VBN (r_amod) increases_40\NNS (r_pobj) on_36\IN (r_prep) GVG_35\NNP (r_pobj) of_29\IN (r_prep) effects_28\NNS (r_dobj) explored_26\VBD (l_prep) Given_0\VBN (l_pobj) success_3\NN (l_prep) for_4\IN (l_pcomp) treating_5\VBG (l_dobj) abuse_7\NN (l_conj) risk_11\NN (l_prep) of_12\IN (l_pobj) defects_15\NNS
D003042_D005128 NONE cocaine_37\NN (r_npadvmod) induced_39\VBN (r_amod) increases_40\NNS (r_pobj) on_36\IN (r_prep) GVG_35\NNP (r_pobj) of_29\IN (r_prep) effects_28\NNS (r_dobj) explored_26\VBD (l_prep) Given_0\VBN (l_pobj) success_3\NN (l_prep) for_4\IN (l_pcomp) treating_5\VBG (l_dobj) abuse_7\NN (l_conj) risk_11\NN (l_prep) of_12\IN (l_pobj) defects_15\NNS (l_appos) VFD_17\NNP
D004298_D005128 NONE dopamine_47\NN (r_appos) accumbens_43\NNS (r_oprd) explored_26\VBD (l_prep) Given_0\VBN (l_pobj) success_3\NN (l_prep) for_4\IN (l_pcomp) treating_5\VBG (l_dobj) abuse_7\NN (l_conj) risk_11\NN (l_prep) of_12\IN (l_pobj) defects_15\NNS
D004298_D005128 NONE dopamine_47\NN (r_appos) accumbens_43\NNS (r_oprd) explored_26\VBD (l_prep) Given_0\VBN (l_pobj) success_3\NN (l_prep) for_4\IN (l_pcomp) treating_5\VBG (l_dobj) abuse_7\NN (l_conj) risk_11\NN (l_prep) of_12\IN (l_pobj) defects_15\NNS (l_appos) VFD_17\NNP
D004298_D005128 NONE DA_49\NNP (r_appos) dopamine_47\NN (r_appos) accumbens_43\NNS (r_oprd) explored_26\VBD (l_prep) Given_0\VBN (l_pobj) success_3\NN (l_prep) for_4\IN (l_pcomp) treating_5\VBG (l_dobj) abuse_7\NN (l_conj) risk_11\NN (l_prep) of_12\IN (l_pobj) defects_15\NNS
D004298_D005128 NONE DA_49\NNP (r_appos) dopamine_47\NN (r_appos) accumbens_43\NNS (r_oprd) explored_26\VBD (l_prep) Given_0\VBN (l_pobj) success_3\NN (l_prep) for_4\IN (l_pcomp) treating_5\VBG (l_dobj) abuse_7\NN (l_conj) risk_11\NN (l_prep) of_12\IN (l_pobj) defects_15\NNS (l_appos) VFD_17\NNP
D020888_D005128 CID GVG_35\NNP (r_pobj) of_29\IN (r_prep) effects_28\NNS (r_dobj) explored_26\VBD (l_prep) Given_0\VBN (l_pobj) success_3\NN (l_prep) for_4\IN (l_pcomp) treating_5\VBG (l_dobj) abuse_7\NN (l_conj) risk_11\NN (l_prep) of_12\IN (l_pobj) defects_15\NNS
D020888_D005128 CID GVG_35\NNP (r_pobj) of_29\IN (r_prep) effects_28\NNS (r_dobj) explored_26\VBD (l_prep) Given_0\VBN (l_pobj) success_3\NN (l_prep) for_4\IN (l_pcomp) treating_5\VBG (l_dobj) abuse_7\NN (l_conj) risk_11\NN (l_prep) of_12\IN (l_pobj) defects_15\NNS (l_appos) VFD_17\NNP
D020888_D019966 NONE GVG_35\NNP (r_pobj) of_29\IN (r_prep) effects_28\NNS (r_dobj) explored_26\VBD (l_prep) Given_0\VBN (l_pobj) success_3\NN (l_prep) for_4\IN (l_pcomp) treating_5\VBG (l_dobj) abuse_7\NN
D003042_D019966 NONE cocaine_37\NN (r_npadvmod) induced_39\VBN (r_amod) increases_40\NNS (r_pobj) on_36\IN (r_prep) GVG_35\NNP (r_pobj) of_29\IN (r_prep) effects_28\NNS (r_dobj) explored_26\VBD (l_prep) Given_0\VBN (l_pobj) success_3\NN (l_prep) for_4\IN (l_pcomp) treating_5\VBG (l_dobj) abuse_7\NN
17919553
C106791_D064420 NONE telithromycin_15\NNS (r_nsubj) was_16\VBD (l_prep) Based_0\VBN (l_prep) on_1\IN (l_pobj) score_3\NN (l_prep) on_6\IN (l_pobj) scale_13\NN (l_compound) probability_12\NN (l_compound) reaction_11\NN
C106791_D056486 CID telithromycin_6\NNS (r_relcl) exposure_4\NN (r_pobj) after_3\IN (r_prep) attack_2\NN (l_compound) hepatitis_1\NNP
C106791_D056486 CID telithromycin_19\NNS (r_compound) usage_20\NN (r_pobj) after_18\IN (r_prep) occurred_17\VBD (l_ccomp) suffered_3\VBN (l_dobj) episode_6\NN (l_prep) of_7\IN (l_pobj) hepatitis_10\NN
C106791_D056486 CID telithromycin_15\NNS (r_nsubj) was_16\VBD (l_attr) cause_19\NN (l_prep) of_20\IN (l_pobj) hepatitis_22\NN
C106791_D056486 CID telithromycin_15\NNS (r_nsubj) was_16\VBD (l_conj) suggested_30\VBD (l_dobj) hepatitis_35\NN
C106791_D056486 CID telithromycin_21\NNS (r_dobj) prescribed_20\VBD (r_relcl) physician_18\NN (r_pobj) to_15\IN (r_prep) communicated_14\VBN (r_advcl) avoided_7\VBN (l_nsubjpass) Recurrence_0\NN (l_prep) of_1\IN (l_pobj) attack_3\NN (l_compound) hepatitis_2\NN
C106791_D056486 CID telithromycin_14\NNS (r_pobj) of_13\IN (r_prep) administration_12\NN (r_pobj) with_10\IN (r_prep) associated_9\VBN (r_acl) case_4\NN (l_prep) of_5\IN (l_pobj) hepatitis_7\NN
7248170
D010634_D005355 NONE Phenobarbitone_0\NNP (r_npadvmod) induced_2\VBN (r_amod) enlargement_3\NN (l_appos) relationship_12\NN (l_prep) to_13\TO (l_pobj) cirrhosis_18\NN
D010634_D008103 CID phenobarbitone_60\NN (r_npadvmod) primed_62\VBN (r_amod) rat_63\NN (r_pobj) in_58\IN (r_prep) given_56\VBN (l_nsubj) ascites_20\VBZ (l_nsubj) yield_1\NN (l_prep) of_2\IN (l_pobj) cirrhosis_4\NN (l_prep) of_5\IN (l_pobj) liver_7\NN
D010634_D008103 CID phenobarbitone_88\NN (r_npadvmod) induced_90\VBN (r_amod) enlargement_91\NN (r_pobj) of_86\IN (r_prep) peak_85\NN (r_pobj) at_83\IN (r_prep) giving_73\VBG (r_pcomp) by_72\IN (r_prep) increased_65\VBN (r_conj) given_56\VBN (l_nsubj) ascites_20\VBZ (l_nsubj) yield_1\NN (l_prep) of_2\IN (l_pobj) cirrhosis_4\NN (l_prep) of_5\IN (l_pobj) liver_7\NN
D002251_D013163 NONE tetrachloride_55\NN (r_advmod) given_56\VBN (l_nsubj) ascites_20\VBZ (l_conj) albumin_27\NN (l_conj) splenomegaly_35\JJ
D002251_D013163 NONE tetrachloride_82\NN (r_advmod) calibrating_77\VBG (r_dative) giving_73\VBG (r_pcomp) by_72\IN (r_prep) increased_65\VBN (r_conj) given_56\VBN (l_nsubj) ascites_20\VBZ (l_conj) albumin_27\NN (l_conj) splenomegaly_35\JJ
D010634_D001201 NONE phenobarbitone_60\NN (r_npadvmod) primed_62\VBN (r_amod) rat_63\NN (r_pobj) in_58\IN (r_prep) given_56\VBN (l_nsubj) ascites_20\VBZ
D010634_D001201 NONE phenobarbitone_88\NN (r_npadvmod) induced_90\VBN (r_amod) enlargement_91\NN (r_pobj) of_86\IN (r_prep) peak_85\NN (r_pobj) at_83\IN (r_prep) giving_73\VBG (r_pcomp) by_72\IN (r_prep) increased_65\VBN (r_conj) given_56\VBN (l_nsubj) ascites_20\VBZ
D002251_D008103 CID tetrachloride_55\NN (r_advmod) given_56\VBN (l_nsubj) ascites_20\VBZ (l_nsubj) yield_1\NN (l_prep) of_2\IN (l_pobj) cirrhosis_4\NN (l_prep) of_5\IN (l_pobj) liver_7\NN
D002251_D008103 CID tetrachloride_82\NN (r_advmod) calibrating_77\VBG (r_dative) giving_73\VBG (r_pcomp) by_72\IN (r_prep) increased_65\VBN (r_conj) given_56\VBN (l_nsubj) ascites_20\VBZ (l_nsubj) yield_1\NN (l_prep) of_2\IN (l_pobj) cirrhosis_4\NN (l_prep) of_5\IN (l_pobj) liver_7\NN
D010634_D006529 CID Phenobarbitone_0\NNP (r_npadvmod) induced_2\VBN (r_amod) enlargement_3\NN (l_prep) of_4\IN (l_pobj) liver_6\NN
D010634_D006529 CID phenobarbitone_60\NN (r_npadvmod) primed_62\VBN (r_amod) rat_63\NN (r_pobj) in_58\IN (r_prep) given_56\VBN (l_conj) increased_65\VBN (l_prep) by_72\IN (l_pcomp) giving_73\VBG (l_prep) at_83\IN (l_pobj) peak_85\NN (l_prep) of_86\IN (l_pobj) enlargement_91\NN (l_prep) of_92\IN (l_pobj) liver_94\NN
D010634_D006529 CID phenobarbitone_88\NN (r_npadvmod) induced_90\VBN (r_amod) enlargement_91\NN (l_prep) of_92\IN (l_pobj) liver_94\NN
D002251_D006529 NONE tetrachloride_15\NN (r_advmod) induced_17\VBN (r_amod) cirrhosis_18\NN (r_pobj) to_13\TO (r_prep) relationship_12\NN (r_appos) enlargement_3\NN (l_prep) of_4\IN (l_pobj) liver_6\NN
D002251_D006529 NONE tetrachloride_55\NN (r_advmod) given_56\VBN (l_conj) increased_65\VBN (l_prep) by_72\IN (l_pcomp) giving_73\VBG (l_prep) at_83\IN (l_pobj) peak_85\NN (l_prep) of_86\IN (l_pobj) enlargement_91\NN (l_prep) of_92\IN (l_pobj) liver_94\NN
D002251_D006529 NONE tetrachloride_82\NN (r_advmod) calibrating_77\VBG (r_dative) giving_73\VBG (l_prep) at_83\IN (l_pobj) peak_85\NN (l_prep) of_86\IN (l_pobj) enlargement_91\NN (l_prep) of_92\IN (l_pobj) liver_94\NN
D010634_D001284 NONE phenobarbitone_60\NN (r_npadvmod) primed_62\VBN (r_amod) rat_63\NN (r_pobj) in_58\IN (r_prep) given_56\VBN (l_nsubj) ascites_20\VBZ (l_conj) albumin_27\NN (l_conj) splenomegaly_35\JJ (l_conj) atrophy_44\NN
D010634_D001284 NONE phenobarbitone_88\NN (r_npadvmod) induced_90\VBN (r_amod) enlargement_91\NN (r_pobj) of_86\IN (r_prep) peak_85\NN (r_pobj) at_83\IN (r_prep) giving_73\VBG (r_pcomp) by_72\IN (r_prep) increased_65\VBN (r_conj) given_56\VBN (l_nsubj) ascites_20\VBZ (l_conj) albumin_27\NN (l_conj) splenomegaly_35\JJ (l_conj) atrophy_44\NN
D002251_D001201 NONE tetrachloride_55\NN (r_advmod) given_56\VBN (l_nsubj) ascites_20\VBZ
D002251_D001201 NONE tetrachloride_82\NN (r_advmod) calibrating_77\VBG (r_dative) giving_73\VBG (r_pcomp) by_72\IN (r_prep) increased_65\VBN (r_conj) given_56\VBN (l_nsubj) ascites_20\VBZ
D010634_D013163 NONE phenobarbitone_60\NN (r_npadvmod) primed_62\VBN (r_amod) rat_63\NN (r_pobj) in_58\IN (r_prep) given_56\VBN (l_nsubj) ascites_20\VBZ (l_conj) albumin_27\NN (l_conj) splenomegaly_35\JJ
D010634_D013163 NONE phenobarbitone_88\NN (r_npadvmod) induced_90\VBN (r_amod) enlargement_91\NN (r_pobj) of_86\IN (r_prep) peak_85\NN (r_pobj) at_83\IN (r_prep) giving_73\VBG (r_pcomp) by_72\IN (r_prep) increased_65\VBN (r_conj) given_56\VBN (l_nsubj) ascites_20\VBZ (l_conj) albumin_27\NN (l_conj) splenomegaly_35\JJ
D002251_D005355 NONE tetrachloride_15\NN (r_advmod) induced_17\VBN (r_amod) cirrhosis_18\NN
D002251_D001284 NONE tetrachloride_55\NN (r_advmod) given_56\VBN (l_nsubj) ascites_20\VBZ (l_conj) albumin_27\NN (l_conj) splenomegaly_35\JJ (l_conj) atrophy_44\NN
D002251_D001284 NONE tetrachloride_82\NN (r_advmod) calibrating_77\VBG (r_dative) giving_73\VBG (r_pcomp) by_72\IN (r_prep) increased_65\VBN (r_conj) given_56\VBN (l_nsubj) ascites_20\VBZ (l_conj) albumin_27\NN (l_conj) splenomegaly_35\JJ (l_conj) atrophy_44\NN
17242861
D010862_D012640 NONE pilocarpine_4\NN (r_npadvmod) induced_6\VBN (r_amod) seizures_7\NNS
D010862_D012640 NONE pilocarpine_4\NN (r_npadvmod) induced_6\VBN (r_amod) seizures_7\NNS (r_pobj) to_3\IN (r_prep) susceptibility_2\NN (r_pobj) for_1\IN (r_prep) QTLs_0\NNS (r_nsubjpass) reported_19\VBN (l_conj) used_27\VBN (l_xcomp) localize_29\VB (l_dobj) genes_32\NNS (l_compound) susceptibility_31\NN (l_compound) seizure_30\NN
D010862_D012640 NONE pilocarpine_9\NN (r_npadvmod) induced_11\VBN (r_amod) seizures_12\NNS
D010862_D012640 NONE pilocarpine_23\NN (r_npadvmod) induced_25\VBN (r_amod) seizures_26\NNS
D010862_D004833 CID pilocarpine_4\NN (r_npadvmod) induced_6\VBN (r_amod) seizures_7\NNS (l_appos) model_10\NN (l_prep) of_11\IN (l_pobj) epilepsy_14\NN
15278670
D004737_D012640 NONE enflurane_12\NN (r_conj) sevoflurane_10\NN (r_pobj) between_9\IN (r_prep) threshold_8\NN (l_amod) convulsive_7\JJ
D004737_D012640 NONE enflurane_14\NN (r_conj) sevoflurane_12\NN (r_pobj) of_11\IN (r_prep) concentrations_10\NNS (r_nsubjpass) administered_16\VBN (l_conj) decreased_23\VBD (l_nsubj) pressure_20\NN (l_prep) at_21\IN (l_pobj) convulsions_22\NNS
D004737_D012640 NONE enflurane_37\NN (r_conj) %_33\NN (r_pobj) in_31\IN (r_conj) decreased_23\VBD (l_nsubj) pressure_20\NN (l_prep) at_21\IN (l_pobj) convulsions_22\NNS
D008012_D003866 NONE lidocaine_10\JJ (r_compound) toxicity_11\NN (r_pobj) of_9\IN (r_prep) effect_8\NN (r_dobj) reduces_5\VBZ (l_conj) carries_13\VBZ (l_prep) due_16\IN (l_pcomp) to_17\IN (l_pobj) depression_19\NN
C009250_D064420 NONE sevoflurane_4\NN (r_nsubj) reduces_5\VBZ (l_dobj) effect_8\NN (l_prep) of_9\IN (l_pobj) toxicity_11\NN
C009250_D003866 NONE sevoflurane_4\NN (r_nsubj) reduces_5\VBZ (l_conj) carries_13\VBZ (l_prep) due_16\IN (l_pcomp) to_17\IN (l_pobj) depression_19\NN
D008012_D012640 CID lidocaine_5\NN (r_npadvmod) induced_7\VBN (r_amod) convulsions_8\NNS
D008012_D012640 CID lidocaine_16\NN (r_compound) infusion_17\NN (r_pobj) with_15\IN (r_prep) was_8\VBD (l_nsubj) threshold_2\NN (l_amod) convulsive_1\JJ
D008012_D012640 CID lidocaine_10\JJ (r_compound) toxicity_11\NN (r_pobj) of_9\IN (r_prep) effect_8\NN (l_amod) convulsive_7\JJ
C009250_D012640 NONE sevoflurane_3\NN (r_pobj) of_2\IN (r_prep) effects_1\NNS (l_prep) on_4\IN (l_pobj) convulsions_8\NNS
C009250_D012640 NONE sevoflurane_3\NN (l_prep) on_4\IN (l_pobj) convulsions_8\NNS
C009250_D012640 NONE sevoflurane_40\NN (r_pobj) of_39\IN (r_prep) concentration_38\NN (r_nsubj) was_41\VBD (r_relcl) l(-1_31\NN (r_pobj) to_26\IN (r_prep) increasing_24\VBG (r_advcl) was_8\VBD (l_nsubj) threshold_2\NN (l_amod) convulsive_1\JJ
C009250_D012640 NONE sevoflurane_10\NN (r_pobj) between_9\IN (r_prep) threshold_8\NN (l_amod) convulsive_7\JJ
C009250_D012640 NONE sevoflurane_12\NN (r_pobj) of_11\IN (r_prep) concentrations_10\NNS (r_nsubjpass) administered_16\VBN (l_conj) decreased_23\VBD (l_nsubj) pressure_20\NN (l_prep) at_21\IN (l_pobj) convulsions_22\NNS
C009250_D012640 NONE sevoflurane_28\NN (r_pobj) in_25\IN (r_prep) decreased_23\VBD (l_nsubj) pressure_20\NN (l_prep) at_21\IN (l_pobj) convulsions_22\NNS
C009250_D012640 NONE sevoflurane_4\NN (r_nsubj) reduces_5\VBZ (l_dobj) effect_8\NN (l_amod) convulsive_7\JJ
D001030_D012640 NONE Apamin_0\NNP (r_nsubj) had_5\VBD (l_dobj) tendency_7\NN (l_acl) decrease_9\VB (l_dobj) threshold_12\NN (l_amod) convulsive_11\JJ
D008012_D064420 NONE lidocaine_10\JJ (r_compound) toxicity_11\NN
3856631
D001663_D052016 NONE bilirubin_10\NN (r_amod) elevations_11\NNS (r_conj) transaminase_8\NN (l_appos) neutropenia_13\NN (l_conj) mucositis_16\NN
D008727_D054198 NONE methotrexate_18\NNP (r_compound) regimen_19\NN (r_pobj) with_12\IN (r_prep) treated_11\VBN (l_nsubjpass) children_1\NNS (l_prep) with_2\IN (l_pobj) leukemia_5\NN
D008727_D054198 NONE methotrexate_28\NNP (r_compound) concentrations_29\NNS (r_dobj) maintain_26\VB (r_conj) achieve_24\VB (r_xcomp) designed_22\VBN (r_relcl) regimen_19\NN (r_pobj) with_12\IN (r_prep) treated_11\VBN (l_nsubjpass) children_1\NNS (l_prep) with_2\IN (l_pobj) leukemia_5\NN
D008727_D054198 NONE methotrexate_4\NN (r_nsubj) is_5\VBZ (l_attr) treatment_8\NN (l_prep) for_9\IN (l_pobj) induction_11\NN (l_prep) after_14\IN (l_pobj) relapse_16\NN (l_prep) in_17\IN (l_pobj) leukemia_20\NN
D001663_D064420 NONE bilirubin_10\NN (r_amod) elevations_11\NNS (r_conj) transaminase_8\NN (r_attr) were_5\VBD (l_nsubj) toxicities_3\NNS
D008727_D002493 NONE methotrexate_18\NNP (r_compound) regimen_19\NN (r_pobj) with_12\IN (r_prep) treated_11\VBN (l_nsubjpass) children_1\NNS (l_relcl) developed_7\VBD (l_dobj) disease_9\NN
D008727_D002493 NONE methotrexate_28\NNP (r_compound) concentrations_29\NNS (r_dobj) maintain_26\VB (r_conj) achieve_24\VB (r_xcomp) designed_22\VBN (r_relcl) regimen_19\NN (r_pobj) with_12\IN (r_prep) treated_11\VBN (l_nsubjpass) children_1\NNS (l_relcl) developed_7\VBD (l_dobj) disease_9\NN
D001663_D009503 NONE bilirubin_10\NN (r_amod) elevations_11\NNS (r_conj) transaminase_8\NN (l_appos) neutropenia_13\NN
D008727_D008577 NONE methotrexate_10\NNP (r_pobj) with_5\IN (r_prep) leukemia_4\NN
15957009
D014236_D008569 NONE metrifonate_15\NN (r_conj) Ro4368554_2\NNP (r_nsubj) reversed_24\VBD (l_dobj) deficits_26\NNS
D012701_D008569 NONE 5-HT(6_45\CD (r_compound) antagonists_48\NNS (r_conj) involved_31\VBN (r_ccomp) suggesting_25\VBG (r_advcl) reversed_16\VBD (l_dobj) cholinergic_18\JJ (l_conj) deficit_23\NN
D012601_D008569 CID scopolamine_29\NN (r_pobj) by_28\IN (r_agent) induced_27\VBN (r_acl) deficits_26\NNS
C507242_D008569 NONE Ro4368554_5\NN (r_nsubj) restores_6\VBZ (l_prep) in_9\IN (l_pobj) models_13\NNS (l_prep) of_14\IN (l_pobj) deficiency_16\NN
C507242_D008569 NONE Ro4368554_2\NNP (r_nsubj) reversed_24\VBD (l_dobj) deficits_26\NNS
C507242_D008569 NONE Ro4368554_4\NN (r_nsubj) improve_7\VB (r_advcl) reversed_16\VBD (l_dobj) cholinergic_18\JJ (l_conj) deficit_23\NN
C507242_D008569 NONE Ro4368554_39\NN (r_pobj) by_38\IN (r_prep) facilitation_34\NN (r_pobj) in_32\IN (r_prep) involved_31\VBN (r_ccomp) suggesting_25\VBG (r_advcl) reversed_16\VBD (l_dobj) cholinergic_18\JJ (l_conj) deficit_23\NN
D014364_D008569 NONE TRP_31\NNP (r_compound) depletion_32\NN (r_conj) scopolamine_29\NN (r_pobj) by_28\IN (r_agent) induced_27\VBN (r_acl) deficits_26\NNS
15188772
D004837_D009202 NONE epinephrine_15\NN (r_pobj) of_14\IN (r_prep) mg_13\NN (r_nsubj) developed_16\VBN (l_dobj) markers_44\NNS (l_prep) of_45\IN (l_pobj) necrosis_47\NN
D004837_D017682 CID epinephrine_15\NN (r_pobj) of_14\IN (r_prep) mg_13\NN (r_nsubj) developed_16\VBN (l_dobj) markers_44\NNS (l_amod) stunning_18\JJ
D004837_D062787 NONE epinephrine_12\NN (r_amod) overdose_13\NN
D004837_D018487 NONE epinephrine_12\NN (r_amod) overdose_13\NN (r_pobj) due_8\IN (r_prep) dysfunction_7\NN
D004837_D018487 NONE epinephrine_15\NN (r_pobj) of_14\IN (r_prep) mg_13\NN (r_nsubj) developed_16\VBN (l_dobj) markers_44\NNS (l_amod) stunning_18\JJ (l_relcl) characterized_21\VBN (l_conj) left_32\VBD (l_dobj) dysfunction_37\NN
D002395_D009202 NONE Catecholamine_0\NN (r_npadvmod) induced_2\VBN (r_amod) cardiomyopathy_3\NN
D002395_D009202 NONE catecholamines_10\NNS (r_pobj) of_8\IN (r_prep) excess_7\NN (r_pobj) due_4\IN (r_prep) cardiomyopathy_3\NN
17615423
C413408_D012206 CID atazanavir_16\NNS (r_conj) amiodarone_13\NN (r_conj) simvastatin_11\NN (r_pobj) of_10\IN (r_prep) use_9\NN (r_pobj) to_7\IN (r_prep) secondary_6\JJ (r_amod) failure_5\NN (r_conj) rhabdomyolysis_1\NN
C413408_D012206 CID atazanavir_14\NNS (l_acl) resulting_15\VBG (l_prep) in_16\IN (l_pobj) rhabdomyolysis_17\NN
D019821_D015658 NONE Simvastatin_0\NNP (r_nmod) medications_11\NNS (l_compound) virus_10\NN
C413408_D058186 CID atazanavir_16\NNS (r_conj) amiodarone_13\NN (r_conj) simvastatin_11\NN (r_pobj) of_10\IN (r_prep) use_9\NN (r_pobj) to_7\IN (r_prep) secondary_6\JJ (r_amod) failure_5\NN
C413408_D058186 CID atazanavir_14\NNS (l_acl) resulting_15\VBG (l_prep) in_16\IN (l_pobj) rhabdomyolysis_17\NN (l_conj) failure_21\NN
D000638_D012206 CID amiodarone_13\NN (r_conj) simvastatin_11\NN (r_pobj) of_10\IN (r_prep) use_9\NN (r_pobj) to_7\IN (r_prep) secondary_6\JJ (r_amod) failure_5\NN (r_conj) rhabdomyolysis_1\NN
D000638_D012206 CID amiodarone_11\NN (l_conj) atazanavir_14\NNS (l_acl) resulting_15\VBG (l_prep) in_16\IN (l_pobj) rhabdomyolysis_17\NN
D000638_D058186 CID amiodarone_13\NN (r_conj) simvastatin_11\NN (r_pobj) of_10\IN (r_prep) use_9\NN (r_pobj) to_7\IN (r_prep) secondary_6\JJ (r_amod) failure_5\NN
D000638_D058186 CID amiodarone_11\NN (l_conj) atazanavir_14\NNS (l_acl) resulting_15\VBG (l_prep) in_16\IN (l_pobj) rhabdomyolysis_17\NN (l_conj) failure_21\NN
D000638_D015658 NONE amiodarone_2\NN (r_conj) Simvastatin_0\NNP (r_nmod) medications_11\NNS (l_compound) virus_10\NN
D019821_D058186 CID simvastatin_11\NN (r_pobj) of_10\IN (r_prep) use_9\NN (r_pobj) to_7\IN (r_prep) secondary_6\JJ (r_amod) failure_5\NN
D019821_D058186 CID simvastatin_9\NN (l_conj) amiodarone_11\NN (l_conj) atazanavir_14\NNS (l_acl) resulting_15\VBG (l_prep) in_16\IN (l_pobj) rhabdomyolysis_17\NN (l_conj) failure_21\NN
D019821_D012206 CID simvastatin_11\NN (r_pobj) of_10\IN (r_prep) use_9\NN (r_pobj) to_7\IN (r_prep) secondary_6\JJ (r_amod) failure_5\NN (r_conj) rhabdomyolysis_1\NN
D019821_D012206 CID simvastatin_9\NN (l_conj) amiodarone_11\NN (l_conj) atazanavir_14\NNS (l_acl) resulting_15\VBG (l_prep) in_16\IN (l_pobj) rhabdomyolysis_17\NN
D019821_D012206 CID simvastatin_14\NN (r_amod) metabolism_15\NN (r_dobj) inhibit_13\VBP (r_relcl) drugs_11\NNS (r_pobj) of_9\IN (r_prep) presence_8\NN (r_pobj) in_6\IN (r_prep) increased_5\VBN (l_nsubjpass) risk_1\NN (l_prep) of_2\IN (l_pobj) rhabdomyolysis_3\NN
12584269
D016559_D007674 CID FK506_14\NNP (r_nsubjpass) tolerated_19\VBN (r_advcl) demonstrated_3\VBD (l_dobj) effect_7\NN (l_amod) nephrotoxic_6\JJ
D020123_D005355 NONE SRL_3\NNP (r_compound) combination_4\NN (r_nsubj) showed_5\VBD (l_dobj) degree_10\NN (l_prep) of_11\IN (l_pobj) fibrosis_12\NN
D016572_D007674 CID CsA_9\NNP (r_pobj) of_8\IN (r_prep) effect_7\NN (l_amod) nephrotoxic_6\JJ
D020123_D007674 CID SRL_5\NN (r_nsubj) seems_6\VBZ (r_conj) are_1\VBP (l_acomp) nephrotoxic_2\JJ
D020123_D007674 CID SRL_5\NN (r_nsubj) seems_6\VBZ (l_xcomp) act_8\VB (l_advcl) displaying_10\VBG (l_dobj) effects_14\NNS (l_amod) nephrotoxic_13\JJ
D020123_D007674 CID SRL_7\NN (r_nsubjpass) combined_9\VBN (l_prep) with_10\IN (l_pobj) indications_14\NNS (l_prep) of_15\IN (l_pobj) effect_19\NN (l_amod) nephrotoxic_18\JJ
D020123_D007674 CID SRL_11\NNP (r_conj) CsA_9\NNP (r_pobj) of_8\IN (r_prep) effect_7\NN (l_amod) nephrotoxic_6\JJ
D020123_D007674 CID SRL_16\NNP (r_conj) FK506_14\NNP (r_nsubjpass) tolerated_19\VBN (r_advcl) demonstrated_3\VBD (l_dobj) effect_7\NN (l_amod) nephrotoxic_6\JJ
D016559_D005355 NONE FK506_1\NNP (r_nmod) combination_4\NN (r_nsubj) showed_5\VBD (l_dobj) degree_10\NN (l_prep) of_11\IN (l_pobj) fibrosis_12\NN
14976857
D011405_D054092 NONE propafenone_26\NN (r_compound) overdose_27\NN (r_pobj) by_24\IN (r_agent) precipitated_23\VBN (r_conj) occurred_9\VBD (l_nsubj) shunt_1\NN (l_prep) via_4\IN (l_pobj) ovale_8\NN
D011405_D004437 NONE propafenone_9\NN (r_compound) overdose_10\NN (l_prep) in_11\IN (l_pobj) woman_14\NN (l_prep) with_15\IN (l_pobj) anomaly_18\NN
D011405_-1 NONE propafenone_9\NN (r_compound) overdose_10\NN (r_pobj) by_8\IN (r_agent) induced_7\VBN (r_acl) syndrome_6\NN
D011405_D062787 NONE propafenone_9\NN (r_compound) overdose_10\NN
D011405_D062787 NONE propafenone_26\NN (r_compound) overdose_27\NN
11166519
D003042_D012640 CID cocaine_1\NN (r_npadvmod) induced_3\VBN (r_amod) seizures_4\NNS
D003042_D012640 CID cocaine_22\NN (r_pobj) of_21\IN (r_prep) injection_20\NN (r_pobj) by_17\IN (r_agent) induced_16\VBN (r_acl) seizures_15\NNS
D003042_D012640 CID cocaine_14\NN (r_npadvmod) induced_16\VBN (r_amod) seizures_17\NNS
6209318
D008801_D014202 CID mexiletine_16\NN (r_amod) group_17\NN (r_pobj) in_14\IN (r_prep) frequent_13\JJ (r_acomp) were_11\VBD (l_nsubj) effects_3\NNS (l_appos) tremor_6\JJ
D008801_D012817 CID mexiletine_16\NN (r_amod) group_17\NN (r_pobj) in_14\IN (r_prep) frequent_13\JJ (r_acomp) were_11\VBD (l_nsubj) effects_3\NNS (l_appos) tremor_6\JJ (l_conj) problems_9\NNS
D008801_D009203 NONE mexiletine_9\NN (r_pobj) of_8\IN (r_prep) form_7\NN (r_pobj) of_3\IN (r_prep) effects_2\NNS (r_nsubjpass) evaluated_16\VBN (l_prep) in_17\IN (l_pobj) trial_23\NN (l_prep) in_24\IN (l_pobj) patients_26\NNS (l_prep) with_27\IN (l_pobj) infarction_31\NN
D008801_D009203 NONE Perlongets_13\NNP (r_pobj) of_8\IN (r_prep) form_7\NN (r_pobj) of_3\IN (r_prep) effects_2\NNS (r_nsubjpass) evaluated_16\VBN (l_prep) in_17\IN (l_pobj) trial_23\NN (l_prep) in_24\IN (l_pobj) patients_26\NNS (l_prep) with_27\IN (l_pobj) infarction_31\NN
D008801_D001145 NONE mexiletine_1\NN (r_nmod) trial_6\NN (l_appos) Report_9\NNP (l_prep) on_10\IN (l_pobj) arrhythmia_11\NN
D008801_D003643 NONE mexiletine_6\NN (r_amod) group_7\NN (r_pobj) in_4\IN (r_prep) deaths_3\NNS
20196116
D000995_D017114 CID Antituberculosis_0\NNP (r_nsubj) induced_3\VBN (l_dobj) failure_6\NN
D000995_D017114 CID Antituberculosis_0\NN (r_compound) therapy_1\NN (l_appos) failure_6\NN
D000995_D017114 CID Antituberculosis_0\NN (r_compound) therapy_1\NN (l_appos) failure_6\NN (l_appos) ALF_10\NNP
D000995_D017114 CID Antituberculosis_0\NN (r_compound) therapy_1\NN (r_nsubj) is_12\VBZ (l_attr) ALF_18\NNP
D001663_D001927 NONE bilirubin_11\NN (l_appos) time_21\NN (l_conj) encephalopathy_37\NN
20477932
D003042_D064420 NONE cocaine_6\NN (r_compound) toxicity_7\NN
D003042_D064420 NONE cocaine_24\NN (r_conj) brain_22\NN (r_nmod) behaviour_27\NN (r_pobj) in_20\IN (r_prep) status_19\NN (r_pobj) between_17\IN (r_prep) association_16\NN (r_conj) increase_10\NN (r_pobj) including_8\VBG (r_prep) toxicity_7\NN
C052342_D008569 NONE topiramate_22\NN (r_pobj) by_21\IN (r_prep) prevention_20\NN (r_conj) involvement_9\NN (r_appos) memory_2\NN (l_conj) learning_4\VBG (l_dobj) impairments_5\NNS
D003042_D008569 CID Cocaine_0\NN (r_nsubj) causes_1\VBZ (l_dobj) memory_2\NN (l_conj) learning_4\VBG (l_dobj) impairments_5\NNS
D003042_D007859 CID Cocaine_0\NN (r_nsubj) causes_1\VBZ (l_dobj) memory_2\NN (l_conj) learning_4\VBG (l_dobj) impairments_5\NNS
C052342_D007859 NONE topiramate_22\NN (r_pobj) by_21\IN (r_prep) prevention_20\NN (r_conj) involvement_9\NN (r_appos) memory_2\NN (l_conj) learning_4\VBG (l_dobj) impairments_5\NNS
D003042_D019970 NONE cocaine_43\NN (r_compound) administration_44\NN (r_pobj) of_42\IN (r_prep) model_41\NN (r_pobj) in_38\IN (r_prep) evaluated_37\VBN (l_nsubjpass) activity_2\NN (l_appos) stress_5\NN (l_conj) synthase_10\NN (l_conj) therapy_31\NN (l_prep) for_32\IN (l_pobj) addiction_34\NN
D009569_D019970 NONE oxide_9\NN (r_compound) synthase_10\NN (l_conj) therapy_31\NN (l_prep) for_32\IN (l_pobj) addiction_34\NN
C052342_D019970 NONE topiramate_26\NN (r_pobj) of_25\IN (r_prep) effect_24\NN (r_conj) learning_17\NN (r_conj) activity_14\NN (r_conj) synthase_10\NN (l_conj) therapy_31\NN (l_prep) for_32\IN (l_pobj) addiction_34\NN
7265370
C020743_D053040 NONE dyazide_3\RB (r_compound) therapy_4\NN (r_dobj) complicating_2\VBG (l_nsubj) nephrolithiasis_1\JJ
C020743_D053040 NONE triamterene_16\JJ (r_compound) therapy_17\NN (r_pobj) of_13\IN (r_prep) years_12\NNS (r_pobj) after_10\IN (r_prep) reported_6\VBN (l_nsubjpass) case_1\NN (l_prep) of_2\IN (l_pobj) nephrolithiasis_4\NN
D014223_D053040 CID Triamterene_0\JJ (r_compound) nephrolithiasis_1\JJ
D014223_D053040 CID triamterene_3\JJ (r_compound) nephrolithiasis_4\NN
D014223_D053040 CID triamterene_2\JJ (r_compound) nephrolithiasis_3\NN
D014223_D006973 NONE triamterene_3\JJ (r_compound) nephrolithiasis_4\NN (r_pobj) of_2\IN (r_prep) case_1\NN (r_nsubjpass) reported_6\VBN (l_prep) after_10\IN (l_pobj) years_12\NNS (l_prep) for_18\IN (l_pobj) hypertension_19\NN
C020743_D006973 NONE triamterene_16\JJ (r_compound) therapy_17\NN (r_pobj) of_13\IN (r_prep) years_12\NNS (l_prep) for_18\IN (l_pobj) hypertension_19\NN
424937
D008750_D056486 CID methyldopa_6\NN (r_pobj) by_5\IN (r_agent) induced_4\VBN (l_nsubj) Patterns_0\NNS (l_prep) of_1\IN (l_pobj) injury_3\NN
D008750_D056486 CID methyldopa_22\NN (r_npadvmod) induced_24\VBN (r_amod) hepatitis_25\NN
D008750_D056486 CID methyldopa_14\NN (r_pobj) between_13\IN (r_prep) relationship_12\NN (r_nsubjpass) proved_19\VBN (l_prep) with_20\IN (l_pobj) recurrence_22\NN (l_prep) of_23\IN (l_pobj) hepatitis_24\NN
D008750_D017114 NONE methyldopa_22\NN (r_npadvmod) induced_24\VBN (r_amod) hepatitis_25\NN (r_pobj) of_21\IN (r_prep) episode_20\NN (r_pobj) after_17\IN (r_prep) recommenced_14\VBN (r_advcl) developed_6\VBD (l_dobj) hepatitis_8\NN
D008750_D017093 NONE methyldopa_17\NN (r_dobj) taking_16\VBG (r_relcl) another_11\DT (r_nsubj) showed_22\VBD (r_conj) presented_5\VBN (l_prep) in_6\IN (l_pobj) failure_8\NN
D008750_D008107 NONE methyldopa_7\NN (r_pobj) to_6\IN (r_prep) related_5\VBN (r_acl) disease_4\NN
D008750_D008107 NONE methyldopa_14\NN (l_conj) dysfunction_17\NN
20470218
D008727_D056784 NONE methotrexate_32\NN (r_compound) toxicity_33\NN (r_conj) syndrome_6\NN (l_compound) leukoencephalopathy_5\JJ
D008727_D020521 NONE methotrexate_32\NN (r_compound) toxicity_33\NN (r_conj) syndrome_6\NN (l_conj) stroke_13\NN
D008727_D064420 NONE methotrexate_32\NN (r_compound) toxicity_33\NN
D008727_D004833 NONE methotrexate_32\NN (r_compound) toxicity_33\NN (r_conj) syndrome_6\NN (l_conj) stroke_13\NN (l_conj) epilepsy_22\NN
D008727_D007177 NONE methotrexate_32\NN (r_compound) toxicity_33\NN (l_conj) syndrome_40\NN (l_prep) of_41\IN (l_pobj) secretion_45\NN
15572383
D004317_D011507 CID adriamycin_10\NNS (r_pobj) by_9\IN (r_agent) induced_8\VBN (l_nsubjpass) proteinuria_6\NN
D004317_D011507 CID adriamycin_3\NNS (l_pobj) proteinuria_7\NN
D004317_D011507 CID adriamycin_12\NNS (r_advcl) correlated_4\VBD (l_prep) with_5\IN (l_pobj) rise_8\NN (l_prep) in_9\IN (l_pobj) proteinuria_10\NN
D004317_D009404 NONE adriamycin_3\NNS (l_pobj) proteinuria_7\NN (l_amod) nephrotic_5\JJ
D004317_D005923 NONE adriamycin_3\NNS (l_pobj) proteinuria_7\NN (l_conj) damage_11\NN (l_conj) glomerulosclerosis_15\NN
D004317_D007674 NONE adriamycin_12\NNS (r_advmod) induced_14\VBN (r_amod) damage_16\NN
D004317_D007674 NONE adriamycin_23\NNS (r_pobj) of_22\IN (r_prep) injection_21\NN (r_pobj) by_18\IN (r_agent) induced_17\VBN (r_acl) severity_13\NN (l_prep) of_14\IN (l_pobj) damage_16\NN
D004317_D007674 NONE adriamycin_3\NNS (l_pobj) proteinuria_7\NN (l_conj) damage_11\NN
D004317_D007674 NONE adriamycin_10\NNS (r_advmod) induced_12\VBN (r_amod) damage_14\NN
7582165
D000305_D004342 NONE corticosteroids_5\NNS (r_pobj) to_4\IN (r_prep) reactions_3\NNS
D010248_D004342 NONE paramethasone_3\NN (r_pobj) from_2\IN (r_prep) different_1\JJ (r_amod) Corticosteroids_0\NNS (r_nsubj) produced_5\VBD (l_dobj) reactions_7\NNS (l_compound) hypersensitivity_6\NN
D010248_D004342 NONE paramethasone_16\NN (r_pobj) by_15\IN (r_agent) caused_14\VBN (r_acl) allergy_13\NN
18208574
D006493_D013927 CID heparin_12\NN (r_npadvmod) induced_14\VBN (r_amod) thrombocytopenia_15\NN (r_pobj) with_11\IN (r_prep) patients_10\NNS (r_pobj) in_9\IN (r_prep) thrombosis_8\NN
D006493_D013927 CID heparin_12\NN (r_npadvmod) induced_14\VBN (r_amod) thrombocytopenia_15\NN (l_appos) assay_20\NN (l_prep) with_21\IN (l_pobj) thrombosis_22\NN
D006493_D013927 CID heparin_33\JJ (r_compound) concentration_34\NN (r_pobj) of_30\IN (r_prep) characteristics_29\NNS (r_dobj) utilizes_26\VBZ (l_advcl) correlate_1\VB (l_dobj) density_3\NN (l_prep) of_7\IN (l_pobj) thrombocytopenia_15\NN (l_appos) assay_20\NN (l_prep) with_21\IN (l_pobj) thrombosis_22\NN
D006493_D013921 CID heparin_12\NN (r_npadvmod) induced_14\VBN (r_amod) thrombocytopenia_15\NN
D006493_D013921 CID heparin_12\NN (r_npadvmod) induced_14\VBN (r_amod) thrombocytopenia_15\NN (l_appos) assay_20\NN (l_nmod) HIT_17\NN
D006493_D013921 CID heparin_33\JJ (r_compound) concentration_34\NN (r_pobj) of_30\IN (r_prep) characteristics_29\NNS (r_dobj) utilizes_26\VBZ (l_advcl) correlate_1\VB (l_dobj) density_3\NN (l_prep) of_7\IN (l_pobj) thrombocytopenia_15\NN
D006493_D013921 CID heparin_33\JJ (r_compound) concentration_34\NN (r_pobj) of_30\IN (r_prep) characteristics_29\NNS (r_dobj) utilizes_26\VBZ (l_advcl) correlate_1\VB (l_dobj) density_3\NN (l_prep) of_7\IN (l_pobj) thrombocytopenia_15\NN (l_appos) assay_20\NN (l_nmod) HIT_17\NN
D006493_D013921 CID heparin_21\NN (r_pobj) to_20\IN (r_prep) exposure_19\NN (r_pobj) after_18\IN (r_prep) Patients_0\NNS (l_prep) with_1\IN (l_pobj) decrease_6\NN (l_conj) thrombocytopenia_11\NNP
D006493_D013921 CID heparin_48\NN (r_pobj) of_47\IN (r_prep) concentration_46\NN (r_pobj) with_44\IN (r_prep) inhibition_43\NN (r_dobj) had_24\VBD (r_relcl) heparin_21\NN (r_pobj) to_20\IN (r_prep) exposure_19\NN (r_pobj) after_18\IN (r_prep) Patients_0\NNS (l_prep) with_1\IN (l_pobj) decrease_6\NN (l_conj) thrombocytopenia_11\NNP
19884587
D009582_D008850 CID Nitrofurantoins_0\NNS (r_nsubjpass) associated_2\VBN (l_prep) with_3\IN (l_pobj) anophthalmia_4\NN (l_conj) microphthalmos_6\NNS
D009582_D002971 CID Nitrofurantoins_0\NNS (r_nsubjpass) associated_2\VBN (l_appos) AOR_8\NNP (l_appos) AOR_26\NNP (l_conj) lip_58\NN
D009582_D002972 CID Nitrofurantoins_0\NNS (r_nsubjpass) associated_2\VBN (l_appos) AOR_8\NNP (l_appos) AOR_26\NNP (l_conj) lip_58\NN (l_prep) with_59\IN (l_pobj) palate_61\NN
D004917_D000014 NONE erythromycins_4\NNS (r_conj) penicillins_2\NNS (r_nsubjpass) associated_18\VBN (l_prep) with_19\IN (l_pobj) defects_22\NNS
D009582_D000014 CID nitrofurantoins_2\NNS (r_conj) Sulfonamides_0\NNS (r_nsubjpass) associated_4\VBN (l_prep) with_5\IN (l_pobj) defects_8\NNS
D013449_D000014 CID Sulfonamides_0\NNS (r_nsubjpass) associated_4\VBN (l_prep) with_5\IN (l_pobj) defects_8\NNS
D009582_D018636 CID Nitrofurantoins_0\NNS (r_nsubjpass) associated_2\VBN (l_appos) AOR_8\NNP (l_appos) syndrome_24\NN
D010406_D000014 NONE penicillins_2\NNS (r_nsubjpass) associated_18\VBN (l_prep) with_19\IN (l_pobj) defects_22\NNS
D009582_D006344 CID Nitrofurantoins_0\NNS (r_nsubjpass) associated_2\VBN (l_appos) AOR_8\NNP (l_appos) AOR_26\NNP (l_appos) defects_41\NNS
D009582_D000853 CID Nitrofurantoins_0\NNS (r_nsubjpass) associated_2\VBN (l_prep) with_3\IN (l_pobj) anophthalmia_4\NN
D013449_D018636 CID Sulfonamides_0\NNS (r_nsubjpass) associated_2\VBN (r_ccomp) interval_17\NN (l_appos) syndrome_30\NN
D013449_D000757 CID Sulfonamides_0\NNS (r_nsubjpass) associated_2\VBN (l_prep) with_3\IN (l_pobj) AOR_9\NNP (l_amod) anencephaly_4\NNS
D002511_D000014 NONE cephalosporins_7\NNS (r_conj) erythromycins_4\NNS (r_conj) penicillins_2\NNS (r_nsubjpass) associated_18\VBN (l_prep) with_19\IN (l_pobj) defects_22\NNS
17343925
D012906_D034381 CID smoking_3\NN (r_pobj) of_2\IN (r_prep) influence_1\NN (r_nsubjpass) estimated_13\VBN (l_advcl) associated_20\VBN (l_prep) with_21\IN (l_pcomp) hearing_22\VBG (l_dobj) loss_23\NN
D012906_D034381 CID smoking_16\NN (r_nsubjpass) associated_20\VBN (l_prep) with_21\IN (l_pcomp) hearing_22\VBG (l_dobj) loss_23\NN
8387218
D016049_D018149 CID didanosine_24\NN (r_dobj) ceasing_23\VBG (r_pcomp) on_22\IN (r_prep) returned_19\VBN (r_conj) require_16\VB (r_conj) developed_2\VBD (l_dobj) curves_5\VBZ
D015215_D015658 NONE zidovudine_17\NNP (r_pobj) to_16\IN (r_prep) intolerant_15\JJ (r_amod) individuals_14\NNS (l_amod) positive_13\JJ
D015215_D015658 NONE AZT_19\NNP (r_appos) individuals_14\NNS (l_amod) positive_13\JJ
D015215_D064420 NONE zidovudine_17\NNP (r_pobj) to_16\IN (r_prep) intolerant_15\JJ (r_amod) individuals_14\NNS (r_pobj) in_9\IN (r_prep) didanosine_5\NN (r_pobj) of_4\IN (r_prep) use_1\NN (l_conj) toxicity_3\NN
D015215_D064420 NONE AZT_19\NNP (r_appos) individuals_14\NNS (r_pobj) in_9\IN (r_prep) didanosine_5\NN (r_pobj) of_4\IN (r_prep) use_1\NN (l_conj) toxicity_3\NN
D016049_D003920 NONE didanosine_24\NN (r_dobj) ceasing_23\VBG (r_pcomp) on_22\IN (r_prep) returned_19\VBN (r_conj) require_16\VB (r_conj) developed_2\VBD (l_dobj) curves_5\VBZ (l_amod) characteristic_6\JJ (l_prep) of_7\IN (l_pobj) diabetes_8\NNS
D016049_D064420 NONE didanosine_5\NN (r_pobj) of_4\IN (r_prep) use_1\NN (l_conj) toxicity_3\NN
D016049_D064420 NONE ddI_7\NN (r_appos) didanosine_5\NN (r_pobj) of_4\IN (r_prep) use_1\NN (l_conj) toxicity_3\NN
D016049_D015658 NONE didanosine_5\NN (l_prep) in_9\IN (l_pobj) individuals_14\NNS (l_amod) positive_13\JJ
D016049_D015658 NONE ddI_7\NN (r_appos) didanosine_5\NN (l_prep) in_9\IN (l_pobj) individuals_14\NNS (l_amod) positive_13\JJ
1639466
D004656_D006973 NONE enalapril_33\NN (r_npadvmod) treated_35\VBN (r_amod) 8)_39\CD (r_appos) controls_27\NNS (r_appos) groups_23\NNS (r_pobj) to_21\IN (r_prep) assigned_20\VBN (l_prep) after_2\IN (l_pobj) clipping_3\VBG (l_prep) of_4\IN (l_pobj) artery_7\NN (l_appos) rats_10\NNS (l_amod) hypertensive_9\JJ
D004656_D006973 NONE enalapril_33\NN (r_npadvmod) treated_35\VBN (r_amod) 8)_39\CD (r_appos) controls_27\NNS (l_amod) hypertensive_26\JJ
D004656_D006973 NONE enalapril_25\NN (r_npadvmod) treated_27\VBN (r_amod) group_28\NN (r_pobj) in_23\IN (r_prep) lower_22\JJR (l_prep) compared_37\VBN (l_prep) with_38\IN (l_pobj) controls_41\NNS (l_amod) hypertensive_40\JJ
D002118_D000419 NONE calcium_8\NN (r_compound) channel_9\NN (l_appos) nitrendipine_11\NN (l_conj) angiotensin_14\NN (l_acl) converting_15\VBG (l_prep) on_19\IN (l_pobj) pressure_21\NN (l_conj) albuminuria_23\NN
D004656_D005921 NONE enalapril_14\JJ (r_compound) treatment_15\NN (r_pobj) after_13\IN (r_prep) change_12\VB (l_nsubj) excretion_7\NN (l_conj) glomerulosclerosis_9\NN
D009568_D005921 NONE nitrendipine_9\NN (r_npadvmod) treated_11\VBN (r_amod) group_12\NN (r_pobj) in_7\IN (r_prep) increased_6\VBN (l_nsubjpass) index_3\NN (l_compound) glomerulosclerosis_2\NN
D009568_D000419 CID nitrendipine_11\NN (l_conj) angiotensin_14\NN (l_acl) converting_15\VBG (l_prep) on_19\IN (l_pobj) pressure_21\NN (l_conj) albuminuria_23\NN
D009568_D000419 CID nitrendipine_5\NN (r_npadvmod) treated_7\VBN (r_amod) albuminuria_9\NN
D009568_D006978 NONE nitrendipine_7\NN (l_prep) on_8\IN (l_pobj) nephrosclerosis_9\NN (l_prep) in_10\IN (l_pobj) rats_11\NNS (l_prep) with_12\IN (l_pobj) hypertension_14\NN
D009568_D006978 NONE nitrendipine_11\NN (r_appos) channel_9\NN (r_pobj) with_6\IN (r_prep) treatment_5\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (r_nsubjpass) studied_35\VBN (l_prep) in_36\IN (l_pobj) rats_37\NNS (l_prep) with_38\IN (l_pobj) kidney_41\NN (l_appos) hypertension_46\NN
D000809_D000419 NONE angiotensin_14\NN (l_acl) converting_15\VBG (l_prep) on_19\IN (l_pobj) pressure_21\NN (l_conj) albuminuria_23\NN
D009568_D009400 CID nitrendipine_7\NN (l_prep) on_8\IN (l_pobj) nephrosclerosis_9\NN
D002118_D009400 NONE calcium_4\NN (r_compound) channel_5\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (l_appos) nitrendipine_7\NN (l_prep) on_8\IN (l_pobj) nephrosclerosis_9\NN
D002118_D006978 NONE calcium_4\NN (r_compound) channel_5\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (l_appos) nitrendipine_7\NN (l_prep) on_8\IN (l_pobj) nephrosclerosis_9\NN (l_prep) in_10\IN (l_pobj) rats_11\NNS (l_prep) with_12\IN (l_pobj) hypertension_14\NN
D002118_D006978 NONE calcium_8\NN (r_compound) channel_9\NN (r_pobj) with_6\IN (r_prep) treatment_5\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (r_nsubjpass) studied_35\VBN (l_prep) in_36\IN (l_pobj) rats_37\NNS (l_prep) with_38\IN (l_pobj) kidney_41\NN (l_appos) hypertension_46\NN
D004656_D000419 NONE enalapril_18\NN (r_dobj) converting_15\VBG (l_prep) on_19\IN (l_pobj) pressure_21\NN (l_conj) albuminuria_23\NN
D004656_D006978 NONE enalapril_18\NN (r_dobj) converting_15\VBG (r_acl) angiotensin_14\NN (r_conj) nitrendipine_11\NN (r_appos) channel_9\NN (r_pobj) with_6\IN (r_prep) treatment_5\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (r_nsubjpass) studied_35\VBN (l_prep) in_36\IN (l_pobj) rats_37\NNS (l_prep) with_38\IN (l_pobj) kidney_41\NN (l_appos) hypertension_46\NN
D009568_D006973 NONE nitrendipine_42\NN (r_advmod) treated_44\VBN (r_conj) 8)_39\CD (r_appos) controls_27\NNS (r_appos) groups_23\NNS (r_pobj) to_21\IN (r_prep) assigned_20\VBN (l_prep) after_2\IN (l_pobj) clipping_3\VBG (l_prep) of_4\IN (l_pobj) artery_7\NN (l_appos) rats_10\NNS (l_amod) hypertensive_9\JJ
D009568_D006973 NONE nitrendipine_42\NN (r_advmod) treated_44\VBN (r_conj) 8)_39\CD (r_appos) controls_27\NNS (l_amod) hypertensive_26\JJ
D009568_D006973 NONE nitrendipine_5\NN (r_npadvmod) treated_7\VBN (r_amod) albuminuria_9\NN (r_pobj) in_3\IN (r_prep) increased_10\VBD (l_prep) compared_20\VBN (l_prep) with_21\IN (l_pobj) hr_26\NN (l_prep) in_27\IN (l_pobj) controls_30\NNS (l_amod) hypertensive_29\JJ
D009568_D006973 NONE nitrendipine_9\NN (r_npadvmod) treated_11\VBN (r_amod) group_12\NN (r_pobj) in_7\IN (r_prep) increased_6\VBN (l_prep) compared_13\VBN (l_prep) with_14\IN (l_pobj) controls_17\NNS (l_amod) hypertensive_16\JJ
D009568_D006973 NONE nitrendipine_9\NN (r_npadvmod) treated_11\VBN (r_amod) group_12\NN (r_pobj) in_7\IN (r_prep) was_5\VBD (l_conj) lower_22\JJR (l_prep) compared_37\VBN (l_prep) with_38\IN (l_pobj) controls_41\NNS (l_amod) hypertensive_40\JJ
D000809_D006978 NONE angiotensin_14\NN (r_conj) nitrendipine_11\NN (r_appos) channel_9\NN (r_pobj) with_6\IN (r_prep) treatment_5\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (r_nsubjpass) studied_35\VBN (l_prep) in_36\IN (l_pobj) rats_37\NNS (l_prep) with_38\IN (l_pobj) kidney_41\NN (l_appos) hypertension_46\NN
16858720
D014859_D006470 NONE warfarin_1\JJ (r_compound) drug_3\NN (r_compound) interaction_4\NN (r_nsubj) contributed_7\VBN (l_prep) to_8\IN (l_pobj) haemorrhage_10\NN
D014859_D006470 NONE warfarin_1\JJ (r_compound) drug_3\NN (r_compound) interaction_4\NN (r_nsubj) contributed_7\VBN (l_conj) considered_34\VBN (l_nsubjpass) complication_32\NN (l_amod) bleeding_31\VBG
D014859_D006470 NONE warfarin_19\JJ (r_compound) patients_20\NNS (r_pobj) of_17\IN (r_prep) %_15\NN (r_pobj) in_11\IN (r_prep) contributed_7\VBN (l_prep) to_8\IN (l_pobj) haemorrhage_10\NN
D014859_D006470 NONE warfarin_19\JJ (r_compound) patients_20\NNS (r_pobj) of_17\IN (r_prep) %_15\NN (r_pobj) in_11\IN (r_prep) contributed_7\VBN (l_conj) considered_34\VBN (l_nsubjpass) complication_32\NN (l_amod) bleeding_31\VBG
D014859_D002543 CID warfarin_4\NN (r_pobj) by_3\IN (r_agent) induced_2\VBN (r_acl) haemorrhage_1\NN
D014859_D002543 CID warfarin_9\RB (r_npadvmod) induced_11\VBN (r_amod) haemorrhages_13\NNS
D014859_D002543 CID warfarin_16\JJ (r_pobj) due_14\IN (r_prep) evaluate_1\VB (l_dobj) frequency_3\NN (l_prep) of_8\IN (l_pobj) haemorrhages_13\NNS
D014859_D002543 CID warfarin_18\JJ (r_compound) drug_20\NN (r_compound) interactions_21\NNS (r_conj) warfarin_16\JJ (r_pobj) due_14\IN (r_prep) evaluate_1\VB (l_dobj) frequency_3\NN (l_prep) of_8\IN (l_pobj) haemorrhages_13\NNS
D014859_D002543 CID warfarin_8\JJ (r_nmod) interactions_13\NNS (r_nsubj) caused_16\VBN (l_dobj) haemorrhage_19\NN
D014859_D002543 CID warfarin_10\JJ (r_compound) drug_12\NN (r_conj) warfarin_8\JJ (r_nmod) interactions_13\NNS (r_nsubj) caused_16\VBN (l_dobj) haemorrhage_19\NN
D014859_D002543 CID warfarin_17\JJ (r_compound) treatment_18\NN (r_pobj) to_16\IN (r_prep) related_15\VBN (r_amod) as_14\IN (r_prep) assessed_13\VBN (l_prep) Among_0\IN (l_pobj) patients_2\NNS (l_prep) with_3\IN (l_pobj) haemorrhage_5\NN
D014859_D002543 CID Warfarin_0\NNP (r_npadvmod) induced_2\VBN (r_amod) haemorrhages_4\NNS
D014859_D002543 CID warfarin_4\RB (r_npadvmod) related_6\VBN (r_amod) haemorrhages_8\NNS
D014859_D002543 CID warfarin_26\NN (r_pobj) with_25\IN (r_prep) interact_24\VB (r_xcomp) known_22\VBN (r_acl) drugs_21\NNS (r_dobj) prescribing_20\VBG (r_advcl) taken_18\VBN (r_advcl) prevented_12\VBN (l_nsubjpass) proportion_2\NN (l_prep) of_3\IN (l_pobj) haemorrhages_8\NNS
3173179
D002216_D006973 NONE captopril_13\NN (r_pobj) of_12\IN (r_prep) introduction_11\NN (l_conj) withdrawal_16\NN (l_prep) in_19\IN (l_pobj) woman_23\NN (l_prep) with_24\IN (l_pobj) hypertension_26\NN
D002216_D009203 NONE captopril_13\NN (r_pobj) of_12\IN (r_prep) introduction_11\NN (r_pobj) with_9\IN (r_prep) coincided_8\VBD (l_nsubj) infarction_7\NN
D014700_D009203 CID Verapamil_0\NNP (r_compound) withdrawal_1\NN (l_prep) as_2\IN (l_pobj) cause_5\NN (l_prep) of_6\IN (l_pobj) infarction_8\NN
D014700_D009203 CID verapamil_18\NN (r_pobj) of_17\IN (r_prep) withdrawal_16\NN (r_conj) introduction_11\NN (r_pobj) with_9\IN (r_prep) coincided_8\VBD (l_nsubj) infarction_7\NN
D014700_D006973 NONE Verapamil_0\NNP (r_compound) withdrawal_1\NN (l_prep) as_2\IN (l_pobj) cause_5\NN (l_prep) of_6\IN (l_pobj) infarction_8\NN (l_prep) in_9\IN (l_pobj) woman_12\NN (l_amod) hypertensive_11\JJ
D014700_D006973 NONE verapamil_18\NN (r_pobj) of_17\IN (r_prep) withdrawal_16\NN (l_prep) in_19\IN (l_pobj) woman_23\NN (l_prep) with_24\IN (l_pobj) hypertension_26\NN
12202650
D002211_D063806 NONE Capsaicin_0\NN (r_npadvmod) induced_2\VBN (r_amod) pain_4\NN
D002211_D010146 CID Capsaicin_0\NNS (r_nsubjpass) injected_7\VBN (l_advcl) induce_13\VB (l_dobj) pain_14\NN
1833784
D015647_D006948 NONE 38393_17\CD (r_nummod) SKF_16\NNP (r_appos) agonist_15\NN (r_nsubj) had_18\VBD (r_advcl) Pretreatment_0\NN (l_prep) with_1\IN (l_pobj) agonist_4\NN (l_appos) hyperactivity_10\NN
-1_D006948 NONE PHNO_5\NNP (r_npadvmod) enhanced_6\VBN (r_amod) hyperactivity_10\NN
C534628_D006948 NONE 23390_12\CD (r_nummod) SCH_11\NNP (r_appos) antagonist_10\NN (r_pobj) by_6\IN (r_agent) blocked_5\VBN (l_nsubjpass) hyperactivity_3\NN
D004298_D006948 NONE dopamine_8\NN (r_conj) D1_5\NN (r_nmod) receptors_9\NNS (r_pobj) of_4\IN (r_prep) involvement_3\NN (l_prep) in_10\IN (l_pcomp) mediating_11\VBG (l_dobj) hyperactivity_15\NN
D009538_D006948 CID nicotine_12\NN (r_npadvmod) induced_14\VBN (r_amod) hyperactivity_15\NN
D009538_D006948 CID Nicotine_0\NNP (r_nsubj) caused_5\VBD (l_dobj) increase_8\NN (l_prep) in_9\IN (l_pobj) activity_11\NN
D009538_D006948 CID Nicotine_0\NN (r_npadvmod) induced_2\VBN (r_amod) hyperactivity_3\NN
D009538_D006948 CID nicotine_7\NN (r_npadvmod) induced_9\VBN (r_amod) hyperactivity_10\NN
D009538_D006948 CID nicotine_5\NN (r_compound) injection_6\NN (r_nsubj) induces_7\VBZ (l_dobj) hyperactivity_10\NN
D020891_D006948 NONE raclopride_18\NN (l_ccomp) blocked_5\VBN (l_nsubjpass) hyperactivity_3\NN
D005476_D006948 NONE fluphenazine_23\NN (r_conj) raclopride_18\NN (l_ccomp) blocked_5\VBN (l_nsubjpass) hyperactivity_3\NN
3371379
D014700_D020258 CID Verapamil_0\NNP (r_npadvmod) induced_2\VBN (l_dobj) neurotoxicity_4\NN
D014700_D020258 CID verapamil_11\NN (r_pobj) with_10\IN (r_prep) treatment_9\NN (r_pobj) after_7\IN (r_prep) signs_3\NNS (l_prep) of_4\IN (l_pobj) neurotoxicity_6\NN
D002118_D020258 NONE calcium_19\NN (r_compound) entry_20\NN (r_compound) blocker_21\NN (r_pobj) of_17\IN (r_prep) discontinuation_16\NN (r_pobj) after_15\IN (r_prep) recovery_14\NN (r_dobj) showed_12\VBD (l_nsubj) patients_1\NNS (l_prep) with_2\IN (l_pobj) signs_3\NNS (l_prep) of_4\IN (l_pobj) neurotoxicity_6\NN
D002220_D020258 CID carbamazepine_3\NN (r_compound) neurotoxicity_4\NN
D002220_D020258 CID carbamazepine_5\JJ (r_compound) neurotoxicity_6\NN
20080419
D010862_D004827 CID pilocarpine_24\NN (r_pobj) by_23\IN (r_agent) induced_22\VBN (r_acl) model_19\NN (l_prep) of_20\IN (l_pobj) epilepsy_21\NN
16938416
C032109_D050197 NONE esters_38\NNS (r_appos) therapy_33\NN (l_conj) atherosclerosis_42\NN
D004967_D050197 NONE estrogen_30\NN (r_compound) testosterone_32\NN (r_compound) therapy_33\NN (l_conj) atherosclerosis_42\NN
D013739_D050197 CID testosterone_3\NN (r_nsubjpass) associated_5\VBN (l_prep) with_6\IN (l_pobj) atherosclerosis_7\NN
D013739_D050197 CID testosterone_32\NN (r_compound) therapy_33\NN (l_conj) atherosclerosis_42\NN
D013739_D050197 CID testosterone_7\NN (r_compound) therapy_8\NN (r_nsubj) affect_11\VB (l_dobj) atherosclerosis_12\NN
D002784_D003920 NONE cholesterol_9\NN (r_compound) level_10\NN (r_conj) diabetes_7\NNS
D000431_D003920 NONE alcohol_17\NN (r_compound) use_18\NN (r_conj) pressure_14\NN (r_conj) level_10\NN (r_conj) diabetes_7\NNS
17612891
D003024_D012559 NONE clozapine_16\NN (r_pobj) of_15\IN (r_prep) commencement_14\NN (r_pobj) after_13\IN (r_prep) developed_7\VBD (l_nsubj) male_4\NN (l_prep) with_5\IN (l_pobj) schizophrenia_6\NN
D003024_D009205 CID clozapine_4\NN (r_pobj) with_3\IN (r_prep) associated_2\VBN (r_acl) myocarditis_1\NN
D003024_D009205 CID clozapine_10\NN (r_pobj) of_9\IN (r_prep) commencement_8\NN (r_pobj) with_6\IN (r_prep) associated_5\VBN (r_acl) case_1\NN (l_prep) of_2\IN (l_pobj) myocarditis_4\NN
D003024_D009205 CID clozapine_16\NN (r_pobj) of_15\IN (r_prep) commencement_14\NN (r_pobj) after_13\IN (r_prep) developed_7\VBD (l_dobj) onset_10\NN (l_prep) of_11\IN (l_pobj) myocarditis_12\NN
D003024_D009205 CID clozapine_11\NN (r_pobj) of_10\IN (r_prep) use_9\NN (r_pobj) with_7\IN (r_prep) associated_6\VBN (r_acl) complication_5\NN (r_attr) is_1\VBZ (l_nsubj) Myocarditis_0\NNP
D003024_D011618 NONE clozapine_2\NN (r_pobj) Considering_0\VBG (r_csubj) remains_3\VBZ (l_attr) standard_6\NN (l_prep) in_7\IN (l_pobj) treatment_8\NN (l_prep) of_9\IN (l_pobj) psychosis_11\NN
12716030
D006493_D006470 NONE heparin_7\VBN (r_nsubj) enhanced_8\VBD (l_dobj) volume_11\NN (l_prep) over_13\IN (l_pobj) that_14\DT (l_acl) seen_15\VBN (l_prep) in_16\IN (l_pobj) control_17\NN (l_dobj) animals_19\NNS (l_conj) bleeding_22\NN
D006493_D002543 NONE heparin_7\VBN (r_nsubj) enhanced_8\VBD (l_prep) In_0\IN (l_pobj) induction_2\NN (l_compound) ICH_1\NNP
D006493_D002543 NONE heparin_7\VBN (r_nsubj) enhanced_8\VBD (l_dobj) volume_11\NN (l_prep) over_13\IN (l_pobj) that_14\DT (l_acl) seen_15\VBN (l_prep) in_16\IN (l_pobj) control_17\NN (l_dobj) animals_19\NNS (l_compound) ICH_18\NNP
D006493_D006406 CID heparin_7\VBN (r_nsubj) enhanced_8\VBD (l_dobj) volume_11\NN (l_compound) hematoma_10\NN
16274958
D017255_D055154 CID acitretin_3\NN (r_conj) dysphonia_1\NN
D017255_D055154 CID acitretin_15\NN (r_pobj) by_14\IN (r_agent) treated_13\VBN (r_advcl) report_1\VBP (l_dobj) case_3\NN (l_prep) of_4\IN (l_pobj) woman_6\NN (l_acl) complaining_7\VBG (l_prep) of_8\IN (l_pobj) dysphonia_9\NN
D017255_D055154 CID acitretin_10\NN (r_advmod) induced_12\VBN (r_amod) dysphonia_13\NN
19631624
D002188_D007859 NONE cannabis_12\NN (r_compound) users_13\NNS (r_pobj) in_11\IN (r_prep) hypoactivity_10\NN (r_conj) hyperactivity_7\NN (r_appos) Deficits_0\NNS (l_prep) in_1\IN (l_pobj) learning_2\NN (l_conj) memory_4\NN
D018817_D008569 CID ecstasy_5\NN (r_compound) users_6\NNS (r_pobj) in_4\IN (r_prep) deficits_3\NNS
D018817_D008569 CID ecstasy_6\NN (r_compound) users_7\NNS (r_nsubj) display_8\VBP (l_dobj) impairments_9\NNS (l_prep) in_10\IN (l_pobj) performance_14\NN (l_nmod) learning_11\NN (l_conj) memory_13\NN
D002188_D006948 NONE cannabis_12\NN (r_compound) users_13\NNS (r_pobj) in_11\IN (r_prep) hypoactivity_10\NN (r_conj) hyperactivity_7\NN
D018817_D020258 NONE ecstasy_1\NN (r_npadvmod) specific_3\JJ (r_amod) effects_4\NNS (r_nsubjpass) related_7\VBN (l_prep) to_8\IN (l_pobj) vulnerability_10\NN (l_prep) to_16\IN (l_pobj) effects_19\NNS (l_amod) neurotoxic_18\JJ
D018817_D020258 NONE ecstasy_21\NN (r_pobj) of_20\IN (r_prep) effects_19\NNS (l_amod) neurotoxic_18\JJ
D018817_D006948 NONE ecstasy_13\NN (r_npadvmod) specific_15\JJ (r_amod) hyperactivity_16\NN
D002188_D008569 NONE cannabis_12\NN (r_compound) users_13\NNS (r_pobj) in_11\IN (r_prep) hypoactivity_10\NN (r_conj) hyperactivity_7\NN (r_appos) Deficits_0\NNS (l_prep) in_1\IN (l_pobj) learning_2\NN (l_conj) memory_4\NN
D018817_D007859 CID ecstasy_5\NN (r_compound) users_6\NNS (r_pobj) in_4\IN (r_prep) deficits_3\NNS
D018817_D007859 CID ecstasy_6\NN (r_compound) users_7\NNS (r_nsubj) display_8\VBP (l_dobj) impairments_9\NNS (l_prep) in_10\IN (l_pobj) performance_14\NN (l_nmod) learning_11\NN (l_conj) memory_13\NN
1732369
D004317_D009202 CID Doxorubicin_0\NNP (r_nsubj) is_1\VBZ (l_attr) agent_6\NN (l_acl) known_7\VBN (l_xcomp) cause_9\VB (l_dobj) cardiomyopathy_13\NN
D004280_D006331 NONE dobutamine_21\NN (r_compound) infusion_22\NN (r_dobj) using_20\VBG (r_xcomp) performed_19\VBN (l_advcl) develop_1\VB (l_dobj) test_7\NN (l_prep) for_8\IN (l_pobj) damage_10\NN
D004317_D009369 NONE doxorubicin_13\NN (r_npadvmod) treated_15\VBN (r_amod) survivors_19\NNS (l_prep) of_20\IN (l_pobj) cancer_22\NN
D004317_D009369 NONE doxorubicin_13\NN (r_pobj) due_11\IN (r_amod) damage_10\NN (r_pobj) for_8\IN (r_prep) test_7\NN (r_dobj) develop_1\VB (r_advcl) performed_19\VBN (l_xcomp) using_20\VBG (l_xcomp) differentiate_24\VB (l_dobj) survivors_29\NNS (l_prep) of_30\IN (l_pobj) cancer_32\NN
D004317_D009369 NONE doxorubicin_35\NN (r_pobj) with_34\IN (r_prep) treated_33\VBN (r_acl) survivors_29\NNS (l_prep) of_30\IN (l_pobj) cancer_32\NN
D004317_D006331 NONE doxorubicin_13\NN (r_pobj) due_11\IN (r_amod) damage_10\NN
D004317_D006331 NONE doxorubicin_35\NN (r_pobj) with_34\IN (r_prep) treated_33\VBN (r_acl) survivors_29\NNS (r_dobj) differentiate_24\VB (r_xcomp) using_20\VBG (r_xcomp) performed_19\VBN (l_advcl) develop_1\VB (l_dobj) test_7\NN (l_prep) for_8\IN (l_pobj) damage_10\NN
D004280_D009369 NONE Dobutamine_0\NNP (r_nsubj) stress_1\VBP (l_appos) indicator_6\NN (l_prep) of_7\IN (l_pobj) function_10\NN (l_prep) in_11\IN (l_pobj) survivors_19\NNS (l_prep) of_20\IN (l_pobj) cancer_22\NN
D004280_D009369 NONE dobutamine_21\NN (r_compound) infusion_22\NN (r_dobj) using_20\VBG (l_xcomp) differentiate_24\VB (l_dobj) survivors_29\NNS (l_prep) of_30\IN (l_pobj) cancer_32\NN
3629586
D002511_D006402 NONE cephalosporin_15\JJ (r_amod) hematotoxicity_16\NN
D002511_D006402 NONE Cephalosporin_0\JJ (r_amod) antibiotics_1\NNS (r_nsubj) cause_2\VBP (l_dobj) variety_4\NN (l_prep) of_5\IN (l_pobj) disturbances_7\NNS
D002511_D006402 NONE cephalosporin_4\NN (r_pobj) with_2\IN (r_prep) rechallenge_1\VB (r_pobj) Upon_0\IN (r_prep) reproduced_10\VBN (l_nsubjpass) syndrome_8\NN
D002511_D006402 NONE cephalosporin_20\NN (r_advmod) induced_22\VBN (r_amod) dyscrasias_24\NNS (r_pobj) to_18\IN (r_prep) similar_17\JJ (r_amod) hematotoxicity_16\NN
D002511_D006402 NONE cephalosporin_20\NN (r_advmod) induced_22\VBN (r_amod) dyscrasias_24\NNS
D015790_D009503 CID cefonicid_10\NN (r_pobj) of_9\IN (r_prep) administration_8\NN (r_nsubj) caused_16\VBD (l_dobj) incidence_21\NN (l_prep) of_22\IN (l_pobj) anemia_23\NN (l_conj) neutropenia_25\NN
C021341_D064420 NONE cefazedone_12\NN (r_conj) cefonicid_10\NN (r_pobj) of_9\IN (r_prep) administration_8\NN (r_nsubj) caused_16\VBD (l_prep) In_0\IN (l_pobj) studies_4\NNS (l_compound) toxicity_3\NN
D015790_D013921 CID cefonicid_10\NN (r_pobj) of_9\IN (r_prep) administration_8\NN (r_nsubj) caused_16\VBD (l_ccomp) thrombocytopenia_28\NN
C021341_D006402 NONE cefazedone_6\NN (r_conj) cefonicid_4\NN (r_pobj) of_3\IN (r_prep) effects_2\NNS (l_appos) model_13\NN (l_prep) of_14\IN (l_pobj) hematotoxicity_16\NN
C021341_D006402 NONE cefazedone_29\NN (r_conj) cefonicid_23\NN (r_dobj) receiving_18\VBG (r_acl) dogs_17\NNS (r_pobj) of_16\IN (r_prep) %_15\NN (r_pobj) in_12\IN (r_prep) occurred_11\VBD (r_conj) was_3\VBD (l_attr) compromising_6\NN (l_prep) of_7\IN (l_pobj) cytopenias_9\NNS
C021341_D006402 NONE cefazedone)-treated_20\VBN (r_amod) dogs_21\NNS (r_nsubj) showed_22\VBD (l_ccomp) reproduced_10\VBN (l_nsubjpass) syndrome_8\NN
C021341_D006402 NONE cefazedone_11\NN (r_conj) cefonicid_9\NN (r_pobj) of_8\IN (r_prep) doses_7\NNS (r_pobj) of_5\IN (r_prep) administration_4\NN (r_nsubj) induce_15\VB (l_dobj) hematotoxicity_16\NN
C021341_D006402 NONE cefazedone_11\NN (r_conj) cefonicid_9\NN (r_pobj) of_8\IN (r_prep) doses_7\NNS (r_pobj) of_5\IN (r_prep) administration_4\NN (r_nsubj) induce_15\VB (l_dobj) hematotoxicity_16\NN (l_amod) similar_17\JJ (l_prep) to_18\IN (l_pobj) dyscrasias_24\NNS
D015790_D064420 NONE cefonicid_10\NN (r_pobj) of_9\IN (r_prep) administration_8\NN (r_nsubj) caused_16\VBD (l_prep) In_0\IN (l_pobj) studies_4\NNS (l_compound) toxicity_3\NN
C021341_D009503 CID cefazedone_12\NN (r_conj) cefonicid_10\NN (r_pobj) of_9\IN (r_prep) administration_8\NN (r_nsubj) caused_16\VBD (l_dobj) incidence_21\NN (l_prep) of_22\IN (l_pobj) anemia_23\NN (l_conj) neutropenia_25\NN
C021341_D013921 CID cefazedone_12\NN (r_conj) cefonicid_10\NN (r_pobj) of_9\IN (r_prep) administration_8\NN (r_nsubj) caused_16\VBD (l_ccomp) thrombocytopenia_28\NN
D015790_D006402 NONE cefonicid_4\NN (r_pobj) of_3\IN (r_prep) effects_2\NNS (l_appos) model_13\NN (l_prep) of_14\IN (l_pobj) hematotoxicity_16\NN
D015790_D006402 NONE cefonicid_23\NN (r_dobj) receiving_18\VBG (r_acl) dogs_17\NNS (r_pobj) of_16\IN (r_prep) %_15\NN (r_pobj) in_12\IN (r_prep) occurred_11\VBD (r_conj) was_3\VBD (l_attr) compromising_6\NN (l_prep) of_7\IN (l_pobj) cytopenias_9\NNS
D015790_D006402 NONE cefonicid_16\NN (r_amod) dogs_21\NNS (r_nsubj) showed_22\VBD (l_ccomp) reproduced_10\VBN (l_nsubjpass) syndrome_8\NN
D015790_D006402 NONE cefonicid_9\NN (r_pobj) of_8\IN (r_prep) doses_7\NNS (r_pobj) of_5\IN (r_prep) administration_4\NN (r_nsubj) induce_15\VB (l_dobj) hematotoxicity_16\NN
D015790_D006402 NONE cefonicid_9\NN (r_pobj) of_8\IN (r_prep) doses_7\NNS (r_pobj) of_5\IN (r_prep) administration_4\NN (r_nsubj) induce_15\VB (l_dobj) hematotoxicity_16\NN (l_amod) similar_17\JJ (l_prep) to_18\IN (l_pobj) dyscrasias_24\NNS
D015790_D000740 CID cefonicid_10\NN (r_pobj) of_9\IN (r_prep) administration_8\NN (r_nsubj) caused_16\VBD (l_dobj) incidence_21\NN (l_prep) of_22\IN (l_pobj) anemia_23\NN
D015790_D000740 CID cefonicid_23\NN (r_dobj) receiving_18\VBG (r_acl) dogs_17\NNS (r_pobj) of_16\IN (r_prep) %_15\NN (r_pobj) in_12\IN (r_prep) occurred_11\VBD (r_conj) was_3\VBD (l_nsubj) anemia_2\NN
C021341_D000740 CID cefazedone_12\NN (r_conj) cefonicid_10\NN (r_pobj) of_9\IN (r_prep) administration_8\NN (r_nsubj) caused_16\VBD (l_dobj) incidence_21\NN (l_prep) of_22\IN (l_pobj) anemia_23\NN
C021341_D000740 CID cefazedone_29\NN (r_conj) cefonicid_23\NN (r_dobj) receiving_18\VBG (r_acl) dogs_17\NNS (r_pobj) of_16\IN (r_prep) %_15\NN (r_pobj) in_12\IN (r_prep) occurred_11\VBD (r_conj) was_3\VBD (l_nsubj) anemia_2\NN
14698717
D010672_D004827 NONE phenytoin_10\JJ (r_compound) treatment_11\NN (l_prep) in_12\IN (l_pobj) patients_15\NNS (l_amod) epileptic_14\JJ
D010672_D011605 NONE phenytoin_6\NN (r_pobj) with_5\IN (r_prep) treatment_4\NN (r_pobj) due_2\IN (r_amod) psychosis_1\NN
D010672_D011605 NONE phenytoin_10\JJ (r_compound) treatment_11\NN (r_dobj) following_9\VBG (r_acl) psychosis_8\NN
D010672_D011605 NONE phenytoin_10\JJ (r_compound) treatment_11\NN (r_pobj) following_9\VBG (r_prep) occur_8\VBP (r_relcl) symptoms_6\NNS
D010672_D012640 NONE phenytoin_10\JJ (r_compound) treatment_11\NN (r_pobj) following_9\VBG (r_prep) occur_8\VBP (r_relcl) symptoms_6\NNS (r_nsubj) be_17\VB (l_attr) result_20\NN (l_amod) unrelated_24\JJ (l_prep) to_25\IN (l_pobj) seizures_26\NNS
D010672_D014277 NONE phenytoin_10\JJ (r_compound) treatment_11\NN (l_prep) for_12\IN (l_pobj) neuralgia_14\NN
17931375
D006493_D003288 CID heparin_10\JJ (r_compound) injection_11\NN (l_prep) on_12\IN (l_pobj) bruising_13\VBG
D006493_D003288 CID heparin_24\NN (r_pobj) of_23\IN (r_prep) injection_22\NN (r_pobj) of_19\IN (r_prep) administration_18\NN (r_pobj) following_16\VBG (r_prep) effect_8\NN (l_prep) of_9\IN (l_pobj) duration_11\NN (l_prep) on_12\IN (l_pobj) bruising_13\VBG
D006493_D003288 CID heparin_13\NN (r_pobj) of_12\IN (r_prep) injection_11\NN (r_pobj) following_8\VBG (r_prep) prevent_4\VB (l_dobj) bruising_5\NN
D006493_D003288 CID heparin_13\NN (r_pobj) of_12\IN (r_prep) injection_11\NN (r_pobj) following_8\VBG (r_prep) prevent_4\VB (r_acl) methods_2\NNS (r_nsubjpass) studied_17\VBN (r_advcl) documented_35\JJ (l_nsubjpass) effect_22\NN (l_prep) of_23\IN (l_pobj) duration_25\NN (l_prep) on_26\IN (l_pobj) occurrence_28\NN (l_prep) of_29\IN (l_pobj) bruising_30\VBG
D006493_D003288 CID heparin_6\NN (r_pobj) on_4\IN (r_prep) bruising_3\NN
D006493_D003288 CID heparin_18\NN (r_pobj) of_17\IN (r_prep) administration_16\NN (r_pobj) following_13\VBG (r_prep) had_6\VBD (l_dobj) effect_8\NN (l_prep) on_9\IN (l_pobj) bruising_10\VBG
D006493_D010146 CID heparin_10\JJ (r_compound) injection_11\NN (l_prep) on_12\IN (l_pobj) bruising_13\VBG (l_conj) pain_15\NN
D006493_D010146 CID heparin_24\NN (r_pobj) of_23\IN (r_prep) injection_22\NN (r_pobj) of_19\IN (r_prep) administration_18\NN (r_pobj) following_16\VBG (r_prep) effect_8\NN (l_prep) of_9\IN (l_pobj) duration_11\NN (l_prep) on_12\IN (l_pobj) bruising_13\VBG (l_conj) pain_15\NN
D006493_D010146 CID heparin_13\NN (r_pobj) of_12\IN (r_prep) injection_11\NN (r_pobj) following_8\VBG (r_prep) prevent_4\VB (l_dobj) bruising_5\NN (l_conj) pain_7\NN
D006493_D010146 CID heparin_13\NN (r_pobj) of_12\IN (r_prep) injection_11\NN (r_pobj) following_8\VBG (r_prep) prevent_4\VB (r_acl) methods_2\NNS (r_nsubjpass) studied_17\VBN (r_advcl) documented_35\JJ (l_nsubjpass) effect_22\NN (l_prep) of_23\IN (l_pobj) duration_25\NN (l_prep) on_26\IN (l_pobj) occurrence_28\NN (l_prep) of_29\IN (l_pobj) bruising_30\VBG (l_conj) pain_32\NN
D006493_D010146 CID heparin_18\NN (r_pobj) of_17\IN (r_prep) administration_16\NN (r_pobj) following_13\VBG (r_prep) had_6\VBD (l_dobj) effect_8\NN (l_prep) on_9\IN (l_pobj) bruising_10\VBG (l_conj) pain_12\NN
2696505
D009599_D006973 NONE nitroprusside_31\NN (r_pobj) of_30\IN (r_prep) discontinuation_29\NN (r_pobj) after_28\IN (r_prep) observed_24\VBN (l_nsubjpass) hypertension_22\NN
D009599_D007022 CID nitroprusside_6\RB (l_prep) for_7\IN (l_pobj) hypotension_9\NN
D009599_D007022 CID nitroprusside_10\RB (r_advmod) induced_12\VBN (r_amod) hypotension_13\NN (r_conj) hypotension_8\NN
D009599_D007022 CID nitroprusside_10\RB (r_advmod) induced_12\VBN (r_amod) hypotension_13\NN
D009599_D016534 CID nitroprusside_31\NN (r_pobj) of_30\IN (r_prep) discontinuation_29\NN (r_pobj) after_28\IN (r_prep) observed_24\VBN (l_ccomp) associated_3\VBN (l_advcl) increase_13\NN (l_prep) in_14\IN (l_pobj) rate_16\NN (l_conj) output_19\NN
D007741_D007022 CID labetalol_4\NN (l_conj) nitroprusside_6\RB (l_prep) for_7\IN (l_pobj) hypotension_9\NN
D007741_D007022 CID labetalol_5\RB (r_npadvmod) induced_7\VBN (r_amod) hypotension_8\NN
D007741_D007022 CID labetalol_5\RB (r_npadvmod) induced_7\VBN (r_amod) hypotension_8\NN (l_conj) hypotension_13\NN
10579464
D003024_D002375 CID clozapine_2\NN (r_conj) NRA0160_0\NNP (r_nsubj) induced_4\VBN (l_dobj) catalepsy_5\NN
D008694_D006948 CID methamphetamine_8\NN (r_pobj) by_7\IN (r_agent) induced_6\VBN (r_acl) hyperactivity_5\NN
D008694_D006948 CID MAP_10\NNP (r_appos) methamphetamine_8\NN (r_pobj) by_7\IN (r_agent) induced_6\VBN (r_acl) hyperactivity_5\NN
C121249_D006948 NONE NRA0160_0\NNP (r_nsubj) antagonized_3\VBN (l_dobj) hyperactivity_5\NN
D003024_D006948 NONE clozapine_2\NN (r_conj) NRA0160_0\NNP (r_nsubj) antagonized_3\VBN (l_dobj) hyperactivity_5\NN
C121249_D002375 CID NRA0160_0\NNP (r_nsubj) induced_4\VBN (l_dobj) catalepsy_5\NN
19356307
C032208_D003704 NONE alcohol_13\NN (r_pobj) of_5\IN (r_prep) effects_4\NNS (l_compound) dementia_3\NN
D012601_D008569 CID scopolamine_12\NN (r_pobj) by_11\IN (r_agent) impaired_10\VBN
D012601_D008569 CID scopolamine_12\NN (r_pobj) by_11\IN (r_agent) impaired_10\VBN (r_amod) memory_9\NN (r_dobj) improve_8\VB (r_acl) ability_6\NN (r_dobj) showed_4\VBD (r_ccomp) relieved_20\VBD (l_dobj) deficit_22\NN (l_prep) of_23\IN (l_pobj) memory_25\NN
C032208_D008569 NONE alcohol_19\NN (r_nsubj) relieved_20\VBD (l_ccomp) showed_4\VBD (l_dobj) ability_6\NN (l_acl) improve_8\VB (l_dobj) memory_9\NN (l_amod) impaired_10\VBN
C032208_D008569 NONE alcohol_19\NN (r_nsubj) relieved_20\VBD (l_dobj) deficit_22\NN (l_prep) of_23\IN (l_pobj) memory_25\NN
D012601_D003704 NONE scopolamine_9\NN (r_pobj) by_8\IN (r_agent) induced_7\VBN (l_nsubj) Components_0\NNS (l_prep) of_1\IN (l_pobj) dementia_6\NN
C008281_D003704 NONE limonene_8\NN (r_nmod) alcohol_13\NN (r_pobj) of_5\IN (r_prep) effects_4\NNS (l_compound) dementia_3\NN
2273650
D012601_D000647 CID scopolamine_3\NN (r_pobj) by_2\IN (r_agent) produced_1\VBN (r_acl) Amnesia_0\NNP
D012601_D000647 CID scopolamine_5\NN (r_nsubj) reversed_7\VBD (l_dobj) amnesia_12\NN
D012601_D000647 CID scopolamine_5\NN (r_nsubj) reversed_7\VBD (l_conj) failed_23\VBD (l_xcomp) reverse_25\VB (l_dobj) amnesia_30\NN
D012601_D000647 CID scopolamine_9\NN (r_npadvmod) induced_11\VBN (r_amod) amnesia_12\NN
D012601_D000647 CID scopolamine_9\NN (r_npadvmod) induced_11\VBN (r_amod) amnesia_12\NN (r_dobj) reversed_7\VBD (l_conj) failed_23\VBD (l_xcomp) reverse_25\VB (l_dobj) amnesia_30\NN
D009270_D000647 NONE naloxone_37\NN (r_dobj) administered_36\VBN (r_acl) retrieval_32\NN (r_dobj) facilitated_29\VBD (r_conj) reversed_7\VBN (l_nsubjpass) Amnesia_0\NNP
D009020_D000647 NONE morphine_9\NN (r_pobj) by_8\IN (r_agent) reversed_7\VBN (l_nsubjpass) Amnesia_0\NNP
D009020_D000647 NONE morphine_27\NN (r_nsubj) facilitated_29\VBD (r_conj) reversed_7\VBN (l_nsubjpass) Amnesia_0\NNP
D003513_D000647 CID cycloheximide_5\NN (r_conj) scopolamine_3\NN (r_pobj) by_2\IN (r_agent) produced_1\VBN (r_acl) Amnesia_0\NNP
D003513_D000647 CID cycloheximide_22\NN (r_nsubj) failed_23\VBD (r_conj) reversed_7\VBD (l_dobj) amnesia_12\NN
D003513_D000647 CID cycloheximide_22\NN (r_nsubj) failed_23\VBD (l_xcomp) reverse_25\VB (l_dobj) amnesia_30\NN
D003513_D000647 CID cycloheximide_27\RB (r_advmod) induced_29\VBN (r_amod) amnesia_30\NN (r_dobj) reverse_25\VB (r_xcomp) failed_23\VBD (r_conj) reversed_7\VBD (l_dobj) amnesia_12\NN
D003513_D000647 CID cycloheximide_27\RB (r_advmod) induced_29\VBN (r_amod) amnesia_30\NN
18217897
D013792_D009369 NONE Thalidomide_0\NNP (r_nsubj) limited_2\VBN (l_prep) in_7\IN (l_pobj) lymphomas_15\NNS (l_appos) trial_20\NN (l_prep) of_21\IN (l_pobj) Cancer_23\NNP
D013792_D008228 NONE Thalidomide_0\NNP (r_nsubj) limited_2\VBN (l_prep) in_7\IN (l_pobj) lymphomas_15\NNS
D013792_D009101 NONE Thalidomide_0\NNP (r_nsubj) is_1\VBZ (l_attr) agent_4\NN (l_prep) with_5\IN (l_pobj) activity_7\NN (l_prep) in_8\IN (l_pobj) myeloma_10\NN
C467567_D008223 NONE lenalidomide_31\NN (r_appos) agent_29\NN (r_pobj) with_24\IN (r_prep) reported_23\VBN (r_acl) level_22\NN (r_pobj) with_18\IN (r_prep) contrast_17\NN (r_conj) demonstrate_4\VB (l_dobj) rate_8\NN (l_prep) in_13\IN (l_pobj) lymphomas_15\NNS
D013792_D008223 NONE Thalidomide_0\NNP (r_nsubj) is_1\VBZ (l_attr) agent_4\NN (l_prep) with_5\IN (l_pobj) activity_7\NN (l_prep) in_8\IN (l_pobj) myeloma_10\NN (l_conj) lymphoma_14\NN (l_conj) lymphoma_17\NN
D013792_D008223 NONE thalidomide_16\NN (r_dobj) received_15\VBD (l_nsubj) patients_8\NNS (l_prep) with_9\IN (l_pobj) lymphomas_14\NNS
D013792_D008223 NONE thalidomide_12\NN (r_pobj) to_9\IN (r_prep) rate_8\NN (l_prep) in_13\IN (l_pobj) lymphomas_15\NNS
D013792_D007938 NONE Thalidomide_0\NNP (r_nsubj) limited_2\VBN (l_prep) in_7\IN (l_pobj) lymphomas_15\NNS (l_appos) trial_20\NN (l_prep) of_21\IN (l_pobj) Cancer_23\NNP (l_conj) B._27\NNP (l_compound) Leukemia_25\NNP
D013792_D020522 NONE Thalidomide_0\NNP (r_nsubj) is_1\VBZ (l_attr) agent_4\NN (l_prep) with_5\IN (l_pobj) activity_7\NN (l_prep) in_8\IN (l_pobj) myeloma_10\NN (l_conj) lymphoma_14\NN
3070035
D002216_D051437 NONE captopril_2\NN (r_npadvmod) induced_4\VBN (r_amod) insufficiency_6\NN
D002216_D051437 NONE captopril_4\NN (r_npadvmod) induced_6\VBN (r_amod) failure_8\NN
D002216_D058186 CID captopril_27\NN (r_pobj) with_26\IN (r_prep) treatment_25\NN (r_pobj) following_24\VBG (r_prep) deterioration_20\NN (l_prep) of_21\IN (l_pobj) function_23\NN
D002216_D006978 NONE captopril_2\NN (r_npadvmod) induced_4\VBN (r_amod) insufficiency_6\NN (r_pobj) of_1\IN (r_prep) Reversibility_0\NN (l_prep) after_7\IN (l_pobj) use_9\NN (l_prep) in_10\IN (l_pobj) case_13\NN (l_prep) of_14\IN (l_pobj) hypertension_16\NN
D002216_D006973 NONE captopril_27\NN (r_pobj) with_26\IN (r_prep) treatment_25\NN (r_pobj) following_24\VBG (r_prep) deterioration_20\NN (r_dobj) developed_18\VBD (r_relcl) kidney_15\NN (r_pobj) to_12\IN (r_prep) artery_11\NN (r_pobj) with_7\IN (r_prep) hypertension_6\NN
1987816
D008094_D011141 CID Lithium_0\NN (r_npadvmod) induced_2\VBN (r_amod) polyuria_3\NN
4008111
D000638_D012848 CID Amiodarone_0\NN (r_npadvmod) induced_2\VBN (r_amod) block_4\NN
D000638_D012848 CID amiodarone_7\NN (r_compound) administration_8\NN (r_pobj) due_4\JJ (r_prep) observed_1\VBD (l_dobj) block_3\NN
D000638_D012848 CID amiodarone_5\NN (r_pobj) of_4\IN (r_prep) dosage_3\NN (r_pobj) in_1\IN (r_prep) Reduction_0\NN (r_nsubj) resulted_6\VBD (l_prep) in_7\IN (l_pobj) disappearance_9\NN (l_prep) of_10\IN (l_pobj) block_13\NN
D000638_D013617 NONE amiodarone_7\NN (r_compound) administration_8\NN (r_pobj) due_4\JJ (r_prep) observed_1\VBD (l_dobj) syndrome_24\NN (l_conj) tachycardia_27\NN
D000638_D009202 NONE amiodarone_7\NN (r_compound) administration_8\NN (l_prep) in_9\IN (l_pobj) boy_14\NN (l_prep) with_15\IN (l_pobj) cardiomyopathy_17\NN
D000638_D012804 NONE amiodarone_5\NN (r_pobj) of_4\IN (r_prep) dosage_3\NN (r_pobj) in_1\IN (r_prep) Reduction_0\NN (r_nsubj) resulted_6\VBD (l_prep) in_7\IN (l_pobj) disappearance_9\NN (l_conj) persistence_16\NN (l_prep) of_17\IN (l_pobj) bradycardia_20\NNP
D000638_D014927 NONE amiodarone_7\NN (r_compound) administration_8\NN (r_pobj) due_4\JJ (r_prep) observed_1\VBD (l_dobj) syndrome_24\NN
3425586
D003622_D000743 CID Dapsone_0\NN (r_npadvmod) associated_2\VBN (r_amod) anemia_6\NN
D003622_D000743 CID dapsone_23\NN (r_pobj) of_22\IN (r_prep) dose_21\NN (r_dobj) taking_19\VBG (r_advcl) developed_12\VBD (l_dobj) anemia_17\NN
D003622_D000743 CID dapsone_21\NN (r_nsubj) cause_24\VB (l_dobj) anemia_26\NN
D003622_D007918 NONE dapsone_23\NN (r_pobj) of_22\IN (r_prep) dose_21\NN (r_dobj) taking_19\VBG (r_advcl) developed_12\VBD (l_nsubj) woman_2\NN (l_conj) leprosy_11\NN
D003622_D006461 NONE dapsone_23\NN (r_pobj) of_22\IN (r_prep) dose_21\NN (l_acl) associated_32\VBN (l_prep) with_33\IN (l_pobj) hemolysis_35\NN
15338796
D000420_D008173 NONE salbutamol_19\NN (r_pobj) of_18\IN (r_prep) doses_17\NNS (r_pobj) of_15\IN (r_prep) administration_14\NN (r_pobj) after_13\IN (r_prep) disease_12\NN
D000420_D014202 CID salbutamol_4\NN (r_pobj) of_3\IN (r_prep) effects_2\NNS (l_compound) Tremor_0\NNP
D000420_D014202 CID salbutamol_6\NN (r_pobj) of_5\IN (r_prep) effects_4\NNS (l_compound) tremor_2\JJ
D000420_D014202 CID salbutamol_19\NN (r_pobj) of_18\IN (r_prep) doses_17\NNS (r_pobj) of_15\IN (r_prep) administration_14\NN (r_pobj) after_13\IN (r_prep) disease_12\NN (r_pobj) with_9\IN (r_prep) patients_8\NNS (r_pobj) in_6\IN (r_prep) assessed_4\VBD (l_dobj) tremor_5\NN
D000420_D014202 CID Salbutamol_0\NNP (r_nsubj) increased_2\VBD (l_dobj) severity_4\NN (l_compound) tremor_3\NN
3358181
D012312_D014693 CID ritodrine_6\JJ (r_compound) therapy_7\NN (r_pobj) after_5\IN (r_prep) section_4\NN (r_pobj) during_2\IN (r_prep) tachyarrhythmias_1\NNS
D010656_D007022 NONE phenylephrine_22\NN (l_relcl) treat_24\VB (l_dobj) patients_26\NNS (l_amod) hypotensive_25\JJ
D012312_D002318 NONE ritodrine_15\NN (r_pobj) of_14\IN (r_prep) infusion_13\NN (r_pobj) of_11\IN (r_prep) cessation_10\NN (r_pobj) after_9\IN (r_prep) complications_7\NNS
D010656_D013610 NONE phenylephrine_22\NN (l_relcl) treat_24\VB (l_prep) with_27\IN (l_pobj) tachycardia_28\NNS
D012312_D007752 NONE ritodrine_6\RB (l_prep) for_7\IN (l_pobj) labor_9\NN
D012312_D007752 NONE ritodrine_19\NN (r_pobj) of_18\IN (r_prep) effects_17\NNS (r_pobj) between_13\IN (r_prep) interactions_12\NNS (r_dobj) risk_11\VB (l_nsubj) patients_4\NNS (l_acl) receiving_5\VBG (l_dobj) ritodrine_6\RB (l_prep) for_7\IN (l_pobj) labor_9\NN
19581773
D012254_D004172 NONE ribavirin_21\RB (r_conj) alpha-2b_19\CD (r_conj) IFN_17\NNP (r_appos) interferon_15\NN (r_pobj) of_13\IN (r_prep) administration_12\NN (r_pobj) of_11\IN (r_prep) weeks_10\NNS (r_pobj) after_8\IN (r_prep) diplopia_7\NN
D012254_D019698 NONE ribavirin_8\JJ (r_conj) interferon_6\NN (r_nmod) treatment_9\NN (l_prep) for_10\IN (l_pobj) C._13\NNP
D012254_D019698 NONE ribavirin_21\RB (r_conj) alpha-2b_19\CD (r_conj) IFN_17\NNP (r_appos) interferon_15\NN (r_pobj) of_13\IN (r_prep) administration_12\NN (r_pobj) of_11\IN (r_prep) weeks_10\NNS (r_pobj) after_8\IN (r_prep) diplopia_7\NN (l_prep) for_22\IN (l_pobj) C_25\NNP
D012254_D019698 NONE ribavirin_21\RB (r_conj) alpha-2b_19\CD (r_conj) IFN_17\NNP (r_appos) interferon_15\NN (r_pobj) of_13\IN (r_prep) administration_12\NN (r_pobj) of_11\IN (r_prep) weeks_10\NNS (r_pobj) after_8\IN (r_prep) diplopia_7\NN (l_prep) for_22\IN (l_pobj) C_25\NNP (l_appos) CHC_27\NNP
D012254_D019698 NONE ribavirin_12\RB (r_conj) alpha-2b_10\CD (l_prep) for_13\IN (l_pobj) CHC_14\NNP
C417083_D004172 NONE alpha-2b_19\CD (r_conj) IFN_17\NNP (r_appos) interferon_15\NN (r_pobj) of_13\IN (r_prep) administration_12\NN (r_pobj) of_11\IN (r_prep) weeks_10\NNS (r_pobj) after_8\IN (r_prep) diplopia_7\NN
C417083_D009157 CID interferon_6\NN (r_nmod) treatment_9\NN (r_pobj) during_4\IN (r_prep) Development_0\NN (l_prep) of_1\IN (l_pobj) myasthenia_3\NN
C417083_D009157 CID alpha-2b_10\CD (r_pobj) of_7\IN (r_prep) therapy_6\NN (r_pobj) with_4\IN (r_prep) associated_3\VBN (r_acl) myasthenia_2\NN
C417083_D009157 CID IFN_35\NNP (r_compound) therapy_36\NN (r_pobj) of_34\IN (r_prep) complications_33\NNS (r_pobj) of_29\IN (r_prep) review_28\NN (r_pobj) with_26\IN (r_prep) present_23\VBP (l_ccomp) reported_18\VBN (l_nsubjpass) myasthenia_2\NN
C417083_D019698 NONE interferon_6\NN (r_nmod) treatment_9\NN (l_prep) for_10\IN (l_pobj) C._13\NNP
C417083_D019698 NONE alpha-2b_19\CD (r_conj) IFN_17\NNP (r_appos) interferon_15\NN (r_pobj) of_13\IN (r_prep) administration_12\NN (r_pobj) of_11\IN (r_prep) weeks_10\NNS (r_pobj) after_8\IN (r_prep) diplopia_7\NN (l_prep) for_22\IN (l_pobj) C_25\NNP
C417083_D019698 NONE alpha-2b_19\CD (r_conj) IFN_17\NNP (r_appos) interferon_15\NN (r_pobj) of_13\IN (r_prep) administration_12\NN (r_pobj) of_11\IN (r_prep) weeks_10\NNS (r_pobj) after_8\IN (r_prep) diplopia_7\NN (l_prep) for_22\IN (l_pobj) C_25\NNP (l_appos) CHC_27\NNP
C417083_D019698 NONE alpha-2b_10\CD (l_prep) for_13\IN (l_pobj) CHC_14\NNP
C417083_D019698 NONE IFN_35\NNP (r_compound) therapy_36\NN (r_pobj) of_34\IN (r_prep) complications_33\NNS (r_pobj) of_29\IN (r_prep) review_28\NN (r_pobj) with_26\IN (r_prep) present_23\VBP (l_ccomp) reported_18\VBN (l_nsubjpass) myasthenia_2\NN (l_acl) associated_3\VBN (l_prep) with_4\IN (l_pobj) therapy_6\NN (l_prep) of_7\IN (l_pobj) alpha-2b_10\CD (l_prep) for_13\IN (l_pobj) CHC_14\NNP
D012254_D009157 CID ribavirin_8\JJ (r_conj) interferon_6\NN (r_nmod) treatment_9\NN (r_pobj) during_4\IN (r_prep) Development_0\NN (l_prep) of_1\IN (l_pobj) myasthenia_3\NN
D012254_D009157 CID ribavirin_12\RB (r_conj) alpha-2b_10\CD (r_pobj) of_7\IN (r_prep) therapy_6\NN (r_pobj) with_4\IN (r_prep) associated_3\VBN (r_acl) myasthenia_2\NN
9088814
D000527_D007022 CID E1-induced_5\JJ (r_amod) hypotension_6\NN
D000527_D007022 CID E1_5\NN (l_appos) hypotension_8\NN
D000527_D007022 CID PGE1)-induced_7\JJ (r_amod) hypotension_8\NN
D000527_D007022 CID PGE1_10\NNP (r_pobj) with_9\IN (r_prep) induced_8\VBN (l_nsubjpass) hypotension_1\NN
D000527_D007022 CID PGE1-induced_13\JJ (r_amod) hypotension_14\NN
D003911_D020141 NONE dextran_23\NN (r_amod) solution_24\NN (r_pobj) of_22\IN (r_prep) amount_21\NN (r_pobj) with_18\IN (r_prep) replacing_16\VBG (r_conj) withdrawing_9\VBG (r_pcomp) by_8\IN (r_prep) produced_7\VBN (l_nsubjpass) Haemodilution_0\NN
D001663_D007022 NONE bilirubin_68\NN (r_conj) LDH_65\NNP (r_conj) SGPT_63\NNP (r_appos) SGOT_61\NNP (r_nsubj) showed_69\VBD (r_conj) showed_23\VBD (l_prep) after_42\IN (l_pobj) start_44\NN (l_prep) of_45\IN (l_pobj) hypotension_46\NN
D000527_D008107 CID PGE1-induced_13\JJ (r_amod) hypotension_14\NN (r_pobj) of_12\IN (r_prep) min_11\NN (r_pobj) of_7\IN (r_prep) combination_6\NN (r_nsubj) cause_19\VB (l_dobj) impairment_20\NN (l_prep) of_21\IN (l_pobj) function_23\NN
D000527_D020141 NONE E1-induced_5\JJ (r_amod) hypotension_6\NN (l_conj) haemodilution_8\NN
D000527_D020141 NONE E1_5\NN (l_appos) hypotension_8\NN (l_conj) haemodilution_10\NN
D000527_D020141 NONE PGE1)-induced_7\JJ (r_amod) hypotension_8\NN (l_conj) haemodilution_10\NN
D000527_D020141 NONE PGE1-induced_13\JJ (r_amod) hypotension_14\NN (l_conj) haemodilution_17\NN
18726058
D010208_D003389 NONE papaverine_13\NN (r_pobj) with_11\IN (r_prep) cases_10\NNS (r_pobj) in_7\IN (r_prep) described_6\VBN (l_nsubjpass) dysfunction_3\NN
D010208_D003389 NONE papaverine_8\NN (r_pobj) from_7\IN (r_prep) deficits_6\NNS
D010208_D020301 NONE hydrochloride_1\NN (r_nsubj) is_2\VBZ (l_attr) vasodilator_7\NN (l_acl) used_8\VBD (l_xcomp) manage_10\VB (l_dobj) vasospasm_11\NN
D010208_D020301 NONE papaverine_18\NN (r_dobj) received_16\VBD (l_prep) for_19\IN (l_pobj) vasospasm_20\NN
D010208_D020301 NONE papaverine_1\NN (r_nsubjpass) used_3\VBN (l_prep) as_4\IN (l_pobj) action_8\NN (l_acl) manage_10\VB (l_dobj) vasospasm_11\NN
D010208_D020301 NONE papaverine_1\NN (l_prep) for_2\IN (l_pobj) treatment_4\NN (l_prep) of_5\IN (l_pobj) vasospasm_6\NN
17639754
D064704_D006470 CID levofloxacin_20\JJ (r_conj) warfarin_18\NN (r_pobj) between_17\IN (r_prep) interaction_16\NN (r_pobj) of_14\IN (r_prep) result_13\NN (r_attr) be_11\VB (r_xcomp) appear_9\VBP (r_relcl) complications_7\NNS (l_compound) bleeding_6\NN
D014859_D006470 CID warfarin_18\NN (r_pobj) between_17\IN (r_prep) interaction_16\NN (r_pobj) of_14\IN (r_prep) result_13\NN (r_attr) be_11\VB (r_xcomp) appear_9\VBP (r_relcl) complications_7\NNS (l_compound) bleeding_6\NN
19473225
D000596_D010523 NONE acid_24\NN (r_compound) glutamine_25\NN (r_conj) glutamate_18\NN (r_nsubjpass) claimed_27\VBN (r_advcl) is_3\VBZ (l_nsubj) neuropathy_2\NN
D000596_D020258 NONE acid_24\NN (r_compound) glutamine_25\NN (r_conj) glutamate_18\NN (r_nsubjpass) claimed_27\VBN (l_xcomp) ameliorate_29\VB (l_dobj) neurotoxicity_31\NN
D018698_D010523 NONE glutamate_3\NN (r_compound) supplementation_4\NN (r_nsubj) failed_5\VBD (l_xcomp) protect_7\VB (l_prep) against_8\IN (l_pobj) neurotoxicity_10\NN
D018698_D010523 NONE glutamate_18\NN (r_nsubjpass) claimed_27\VBN (r_advcl) is_3\VBZ (l_nsubj) neuropathy_2\NN
D018698_D010523 NONE glutamine_25\NN (r_conj) glutamate_18\NN (r_nsubjpass) claimed_27\VBN (r_advcl) is_3\VBZ (l_nsubj) neuropathy_2\NN
D018698_D010523 NONE glutamate_9\NN (r_compound) supplementation_10\NN (l_prep) for_11\IN (l_pcomp) preventing_12\VBG (l_dobj) neuropathy_17\NN
D018698_D010523 NONE glutamate_8\NN (r_compound) supplementation_9\NN (r_nsubj) fails_14\VBZ (l_xcomp) protect_16\VB (l_prep) against_17\IN (l_pobj) neurotoxicity_19\NN
D018698_D020258 NONE glutamate_18\NN (r_nsubjpass) claimed_27\VBN (l_xcomp) ameliorate_29\VB (l_dobj) neurotoxicity_31\NN
D018698_D020258 NONE glutamine_25\NN (r_conj) glutamate_18\NN (r_nsubjpass) claimed_27\VBN (l_xcomp) ameliorate_29\VB (l_dobj) neurotoxicity_31\NN
D018698_D010051 NONE glutamate_26\NN (r_pobj) by_25\IN (r_agent) supplemented_24\VBN (l_ccomp) were_6\VBD (l_nsubj) patients_5\NNS (l_compound) cancer_4\NN
D017239_D010051 NONE PAC_16\NNP (r_npadvmod) containing_18\VBG (r_amod) regimen_19\NN (r_pobj) of_13\IN (r_prep) cycles_12\NNS (r_pobj) following_10\VBG (r_prep) analysis_9\NN (r_pobj) for_8\IN (r_prep) available_7\JJ (r_acomp) were_6\VBD (l_nsubj) patients_5\NNS (l_compound) cancer_4\NN
D017239_D020258 NONE paclitaxel_12\NN (r_pobj) with_11\IN (r_prep) chemotherapy_10\NN (r_pobj) for_9\IN (r_prep) factor_8\NN (r_attr) is_3\VBZ (l_advcl) claimed_27\VBN (l_xcomp) ameliorate_29\VB (l_dobj) neurotoxicity_31\NN
D017239_D020258 NONE PAC_14\NNP (r_appos) chemotherapy_10\NN (r_pobj) for_9\IN (r_prep) factor_8\NN (r_attr) is_3\VBZ (l_advcl) claimed_27\VBN (l_xcomp) ameliorate_29\VB (l_dobj) neurotoxicity_31\NN
D017239_D020258 NONE PAC_30\NNP (r_compound) neurotoxicity_31\NN
D017239_D010523 CID paclitaxel_12\NN (r_pobj) of_11\IN (r_prep) neurotoxicity_10\NN
D017239_D010523 CID paclitaxel_12\NN (r_pobj) with_11\IN (r_prep) chemotherapy_10\NN (r_pobj) for_9\IN (r_prep) factor_8\NN (r_attr) is_3\VBZ (l_nsubj) neuropathy_2\NN
D017239_D010523 CID PAC_14\NNP (r_appos) chemotherapy_10\NN (r_pobj) for_9\IN (r_prep) factor_8\NN (r_attr) is_3\VBZ (l_nsubj) neuropathy_2\NN
D017239_D010523 CID PAC_30\NNP (r_compound) neurotoxicity_31\NN (r_dobj) ameliorate_29\VB (r_xcomp) claimed_27\VBN (r_advcl) is_3\VBZ (l_nsubj) neuropathy_2\NN
D017239_D010523 CID PAC_13\NNP (r_npadvmod) induced_15\VBN (r_amod) neuropathy_17\NN
D017239_D010523 CID PAC_21\NNP (r_pobj) of_20\IN (r_prep) neurotoxicity_19\NN
435349
D013390_D005207 CID Suxamethonium_0\JJ (r_compound) rate_2\NN (l_conj) observed_4\JJ (l_dobj) fasciculations_5\NNS
D013390_D013746 NONE Sch_20\NNP (r_nsubjpass) exceeded_24\VBN (r_advcl) was_7\VBD (l_attr) response_10\NN (l_prep) to_11\IN (l_pobj) stimulation_13\NN (l_compound) tetanic_12\JJ
3827439
D000666_D058186 CID amphotericin_6\JJ (r_pobj) from_5\IN (r_prep) failure_4\NN
D000666_D058186 CID B_18\NNP (r_pobj) of_16\IN (r_prep) administration_15\NN (r_dobj) following_13\VBG (r_acl) failure_11\NN
D000666_D058186 CID amphotericin_3\JJ (r_advmod) propose_1\VBP (l_conj) activate_15\VB (l_advcl) contributing_20\VBG (l_prep) to_21\IN (l_pobj) failure_24\NN
D000666_D005355 NONE B_18\NNP (r_pobj) of_16\IN (r_prep) administration_15\NN (r_dobj) following_13\VBG (r_acl) failure_11\NN (r_dobj) developed_8\VBD (l_nsubj) patient_1\NN (l_prep) with_2\IN (l_pobj) cirrhosis_4\NN
D000666_D013174 NONE B_18\NNP (r_pobj) of_16\IN (r_prep) administration_15\NN (r_dobj) following_13\VBG (r_acl) failure_11\NN (r_dobj) developed_8\VBD (l_nsubj) patient_1\NN (l_conj) disseminated_6\VBN (l_dobj) sporotrichosis_7\NN
20667451
D003474_D003072 NONE Curcumin_0\NN (r_nsubj) ameliorates_1\VBZ (l_dobj) dysfunction_3\NN
D003474_D003072 NONE curcumin_14\NN (r_compound) administration_15\NN (r_pobj) of_12\IN (r_prep) effect_11\NN (l_prep) on_16\IN (l_pobj) impairment_23\NN
D003474_D003072 NONE curcumin_1\NN (r_compound) administration_2\NN (r_nsubj) prevented_3\VBD (l_dobj) impairment_6\NN
D003474_D003072 NONE curcumin_4\NN (r_nsubj) has_5\VBZ (l_dobj) effect_7\NN (l_prep) in_8\IN (l_pcomp) mitigating_9\VBG (l_dobj) deterioration_11\NN (l_prep) of_12\IN (l_pobj) functions_14\NNS
D003474_D003072 NONE curcumin_4\NN (r_nsubjpass) considered_7\VBN (l_advcl) phenobarbitone_16\NN (l_prep) in_20\IN (l_pcomp) preventing_21\VBG (l_dobj) impairment_23\NN
D002220_D003072 CID carbamazepine_10\NN (r_conj) phenobarbitone_8\NN (r_pobj) in_7\IN (r_prep) damage_6\NN (r_conj) dysfunction_3\NN
D002220_D003072 CID carbamazepine_6\NN (r_conj) phenobarbitone_4\NN (r_conj) drugs_2\NNS (r_nsubj) are_7\VBP (l_acomp) known_9\JJ (l_xcomp) cause_11\VB (l_dobj) impairment_13\NN
D002220_D003072 CID carbamazepine_19\NN (r_npadvmod) induced_21\VBN (r_conj) phenobarbitone-_17\JJ (r_nmod) impairment_23\NN
D002220_D003072 CID carbamazepine_5\NN (r_conj) phenobarbitone_3\NN (r_pobj) of_2\IN (r_prep) administration_1\NN (r_nsubj) caused_8\VBD (l_dobj) impairment_11\NN (l_prep) of_12\IN (l_pobj) learning_13\NN (l_conj) memory_15\NN
D002220_D003072 CID carbamazepine_24\NN (r_conj) phenobarbitone_22\NN (r_pobj) with_21\IN (r_prep) treated_20\VBN (r_acl) rats_19\NNS (r_pobj) in_18\IN (r_prep) damage_17\NN (r_conj) functions_14\NNS
D002220_D003072 CID carbamazepine_18\NN (r_compound) therapy_19\NN (r_conj) phenobarbitone_16\NN (l_prep) in_20\IN (l_pcomp) preventing_21\VBG (l_dobj) impairment_23\NN
D010634_D003072 CID phenobarbitone_8\NN (r_pobj) in_7\IN (r_prep) damage_6\NN (r_conj) dysfunction_3\NN
D010634_D003072 CID phenobarbitone_4\NN (r_conj) drugs_2\NNS (r_nsubj) are_7\VBP (l_acomp) known_9\JJ (l_xcomp) cause_11\VB (l_dobj) impairment_13\NN
D010634_D003072 CID phenobarbitone-_17\JJ (r_nmod) impairment_23\NN
D010634_D003072 CID phenobarbitone_3\NN (r_pobj) of_2\IN (r_prep) administration_1\NN (r_nsubj) caused_8\VBD (l_dobj) impairment_11\NN (l_prep) of_12\IN (l_pobj) learning_13\NN (l_conj) memory_15\NN
D010634_D003072 CID phenobarbitone_22\NN (r_pobj) with_21\IN (r_prep) treated_20\VBN (r_acl) rats_19\NNS (r_pobj) in_18\IN (r_prep) damage_17\NN (r_conj) functions_14\NNS
D010634_D003072 CID phenobarbitone_16\NN (l_prep) in_20\IN (l_pcomp) preventing_21\VBG (l_dobj) impairment_23\NN
12907309
C121465_D005334 NONE MPEP_3\NNP (r_pobj) of_2\IN (r_prep) action_1\NN (r_nsubjpass) associated_17\VBN (l_prep) with_18\IN (l_pobj) decrease_20\NN (l_prep) in_21\IN (l_pobj) outflow_23\NN (l_conj) inhibition_25\NN (l_prep) of_26\IN (l_pobj) hyperthermia_27\NN
C121465_D005334 NONE MPEP_3\NNP (r_pobj) by_2\IN (r_agent) rendered_1\VBN (r_acl) Neuroprotection_0\NNP (r_nsubjpass) associated_6\VBN (l_conj) with_29\IN (l_pobj) decrease_31\NN (l_prep) in_32\IN (l_pobj) hyperthermia_33\NN
C121465_D020258 NONE MPEP_3\NNP (r_pobj) of_2\IN (r_prep) action_1\NN (l_prep) in_10\IN (l_pobj) neurotoxicity_15\NN
D008694_D020258 NONE methamphetamine_11\NN (r_npadvmod) induced_13\VBN (r_amod) neurotoxicity_15\NN
D008694_D064420 NONE methamphetamine_18\NN (r_npadvmod) induced_20\VBN (r_amod) toxicity_21\NN
C121465_D064420 NONE MPEP_12\NNP (r_pobj) by_11\IN (r_prep) blockade_8\NN (r_nsubj) protect_14\VB (l_dobj) neurones_16\NNS (l_prep) against_17\IN (l_pobj) toxicity_21\NN
D004298_D005334 NONE dopamine_22\NN (r_compound) outflow_23\NN (l_conj) inhibition_25\NN (l_prep) of_26\IN (l_pobj) hyperthermia_27\NN
D004298_D005334 NONE dopamine_15\NN (r_compound) efflux_16\NN (r_pobj) of_10\IN (r_prep) reduction_9\NN (r_pobj) with_7\IN (r_prep) associated_6\VBN (l_conj) with_29\IN (l_pobj) decrease_31\NN (l_prep) in_32\IN (l_pobj) hyperthermia_33\NN
D004298_D020258 NONE dopamine_22\NN (r_compound) outflow_23\NN (r_pobj) in_21\IN (r_prep) decrease_20\NN (r_pobj) with_18\IN (r_prep) associated_17\VBN (l_nsubjpass) action_1\NN (l_prep) in_10\IN (l_pobj) neurotoxicity_15\NN
D008694_D005334 CID methamphetamine_11\NN (r_npadvmod) induced_13\VBN (r_amod) neurotoxicity_15\NN (r_pobj) in_10\IN (r_prep) action_1\NN (r_nsubjpass) associated_17\VBN (l_prep) with_18\IN (l_pobj) decrease_20\NN (l_prep) in_21\IN (l_pobj) outflow_23\NN (l_conj) inhibition_25\NN (l_prep) of_26\IN (l_pobj) hyperthermia_27\NN
D008694_D005334 CID methamphetamine_12\NN (r_npadvmod) induced_14\VBN (r_amod) efflux_16\NN (r_pobj) of_10\IN (r_prep) reduction_9\NN (r_pobj) with_7\IN (r_prep) associated_6\VBN (l_conj) with_29\IN (l_pobj) decrease_31\NN (l_prep) in_32\IN (l_pobj) hyperthermia_33\NN
11391224
D003042_D006974 NONE cocaine_23\NN (r_npadvmod) related_25\VBN (r_amod) failure_28\NN (r_conj) glomerulonephritis_20\NN (r_conj) nephritis_17\NN (r_conj) nephritis_12\NN (r_dobj) lupus_11\NN (r_conj) included_2\VBD (l_dobj) cases_3\NNS (l_prep) of_4\IN (l_pobj) hypertension_6\NN
D003042_D058186 CID cocaine_23\NN (r_npadvmod) related_25\VBN (r_amod) failure_28\NN
D003042_D011695 NONE cocaine_23\NN (r_npadvmod) related_25\VBN (r_amod) failure_28\NN (r_conj) glomerulonephritis_20\NN (r_conj) nephritis_17\NN
D003042_D008181 NONE cocaine_23\NN (r_npadvmod) related_25\VBN (r_amod) failure_28\NN (r_conj) glomerulonephritis_20\NN (r_conj) nephritis_17\NN (r_conj) nephritis_12\NN
D003042_D005921 NONE cocaine_23\NN (r_npadvmod) related_25\VBN (r_amod) failure_28\NN (r_conj) glomerulonephritis_20\NN
D003042_D057049 NONE cocaine_23\NN (r_npadvmod) related_25\VBN (r_amod) failure_28\NN (r_conj) glomerulonephritis_20\NN (r_conj) nephritis_17\NN (r_conj) nephritis_12\NN (r_dobj) lupus_11\NN (l_nsubj) microangiopathy_9\NN
14596845
D013395_D006948 CID sucrose_6\NN (r_dobj) experienced_4\VBN (r_relcl) animals_1\NNS (r_nsubj) were_9\VBD (l_acomp) hyperactive_10\JJ
D013395_D006948 CID sucrose_25\NN (r_appos) groups_19\NNS (r_pobj) with_16\IN (r_prep) compared_15\VBN (r_prep) were_9\VBD (l_acomp) hyperactive_10\JJ
D013395_D006948 CID sucrose_50\NN (r_conj) amphetamine_44\NN (r_pobj) with_43\IN (r_prep) chow_42\NN (r_appos) groups_19\NNS (r_pobj) with_16\IN (r_prep) compared_15\VBN (r_prep) were_9\VBD (l_acomp) hyperactive_10\JJ
D000661_D006948 CID amphetamine_15\NN (r_pobj) of_14\IN (r_prep) dose_13\NN (r_pobj) to_10\IN (r_prep) sensitization_9\NN
D000661_D006948 CID amphetamine_24\NN (r_pobj) of_23\IN (r_prep) dose_22\NN (r_pobj) to_19\IN (r_prep) show_14\VB (l_dobj) sensitization_18\NN
D000661_D006948 CID amphetamine_14\NN (r_pobj) to_13\IN (r_prep) response_12\NN (r_pobj) in_11\IN (r_prep) were_9\VBD (l_acomp) hyperactive_10\JJ
D000661_D006948 CID amphetamine_30\NN (r_compound) injection_31\NN (r_pobj) by_29\IN (r_agent) followed_28\VBN (r_acl) sucrose_25\NN (r_appos) groups_19\NNS (r_pobj) with_16\IN (r_prep) compared_15\VBN (r_prep) were_9\VBD (l_acomp) hyperactive_10\JJ
D000661_D006948 CID amphetamine_37\NN (r_compound) injection_38\NN (r_pobj) by_36\IN (r_agent) followed_35\VBN (r_acl) chow_34\NN (r_appos) groups_19\NNS (r_pobj) with_16\IN (r_prep) compared_15\VBN (r_prep) were_9\VBD (l_acomp) hyperactive_10\JJ
D000661_D006948 CID amphetamine_44\NN (r_pobj) with_43\IN (r_prep) chow_42\NN (r_appos) groups_19\NNS (r_pobj) with_16\IN (r_prep) compared_15\VBN (r_prep) were_9\VBD (l_acomp) hyperactive_10\JJ
D000661_D019966 NONE amphetamine_15\NN (r_pobj) of_14\IN (r_prep) dose_13\NN (r_pobj) to_10\IN (r_prep) sensitization_9\NN (r_dobj) causes_5\VBZ (l_nsubj) diet_1\NN (l_acl) promoting_2\VBG (l_dobj) dependency_4\NN
19445921
C066201_D009203 NONE A_5\NN (l_prep) on_6\IN (l_pobj) infarction_11\NN
C066201_D009203 NONE A_13\NN (r_pobj) of_10\IN (r_prep) potential_9\NN (l_prep) on_14\IN (l_pobj) infarction_19\NN
C066201_D009203 NONE A_9\DT (r_appos) salvianolic_7\JJ (r_nsubj) has_13\VBZ (l_dobj) effect_17\NN (l_prep) against_18\IN (l_pobj) infarction_23\NN
D000244_D012131 NONE ADP_13\NNP (r_nmod) O_15\NNP (r_conj) ratio_11\NN (r_pobj) by_7\IN (r_agent) characterized_6\VBN (r_acl) dysfunction_5\NN
D007545_D009203 CID isoproterenol_7\NN (r_npadvmod) induced_9\VBN (r_amod) infarction_11\NN
D007545_D009203 CID isoproterenol_15\NN (r_npadvmod) induced_17\VBN (r_amod) infarction_19\NN
D007545_D009203 CID isoproterenol_19\NN (r_npadvmod) induced_21\VBN (r_amod) infarction_23\NN
D007545_D012131 NONE isoproterenol_19\NN (r_npadvmod) treated_21\VBN (r_amod) rats_22\NNS (r_pobj) in_18\IN (r_prep) observed_17\VBN (l_nsubjpass) dysfunction_5\NN
C066201_D006331 NONE A_4\NN (r_appos) Administration_0\NN (l_conj) dysfunction_17\NN
D007545_D006331 NONE isoproterenol_13\NN (r_npadvmod) induced_15\VBN (r_amod) dysfunction_17\NN
D007545_D009202 NONE isoproterenol_13\NN (r_npadvmod) induced_15\VBN (r_amod) dysfunction_17\NN (l_conj) injury_20\NN
D007545_D009202 NONE isoproterenol_8\NN (r_npadvmod) induced_10\VBN (r_amod) damage_12\NN
C066201_D009202 NONE A_4\NN (r_appos) Administration_0\NN (l_conj) dysfunction_17\NN (l_conj) injury_20\NN
C066201_D009202 NONE A_6\NN (r_pobj) of_3\IN (r_prep) role_2\NN (l_prep) against_7\IN (l_pobj) damage_12\NN
7930386
D002997_D012893 CID Clomipramine_0\NNP (r_npadvmod) induced_2\VBN (r_amod) disturbance_4\NN
D002997_D012893 CID clomipramine_15\NN (r_compound) administration_16\NN (r_pobj) by_14\IN (r_agent) induced_13\VBN (r_conj) examine_6\VB (l_dobj) role_8\NN (l_prep) of_9\IN (l_pobj) disturbance_11\NN
9587734
D013390_D006947 CID suxamethonium_21\NN (r_pobj) of_20\IN (r_prep) use_19\NN (r_pobj) following_17\VBG (r_prep) case_5\NN (l_prep) of_6\IN (l_pobj) arrest_8\NN (l_conj) death_11\NN (l_prep) as_12\IN (l_pobj) result_14\NN (l_prep) of_15\IN (l_pobj) hyperkalaemia_16\NN
D013390_D006947 CID suxamethonium_35\NN (r_pobj) of_34\IN (r_prep) administration_33\NN (r_pobj) following_31\VBG (r_prep) signs_15\NNS (l_prep) of_16\IN (l_conj) of_21\IN (l_pobj) any_22\DT (l_prep) of_23\IN (l_pobj) conditions_28\NNS (l_prep) for_29\IN (l_pobj) hyperkalaemia_30\NN
D013390_D001919 CID suxamethonium_5\NN (l_appos) arrest_10\NN (l_amod) bradycardia_7\NN
D013390_D004342 CID suxamethonium_11\NN (r_pobj) to_10\IN (r_prep) hypersensitivity_9\NN
D013390_D003643 NONE Suxamethonium_0\NN (r_npadvmod) induced_2\VBN (r_amod) arrest_4\NN (l_conj) death_6\NN
D013390_D003643 NONE suxamethonium_21\NN (r_pobj) of_20\IN (r_prep) use_19\NN (r_pobj) following_17\VBG (r_prep) case_5\NN (l_prep) of_6\IN (l_pobj) arrest_8\NN (l_conj) death_11\NN
D013390_D003643 NONE suxamethonium_11\NN (r_pobj) to_10\IN (r_prep) hypersensitivity_9\NN (r_pobj) by_8\IN (r_agent) caused_7\VBN (l_nsubjpass) death_5\NN
D013390_D006323 CID Suxamethonium_0\NN (r_npadvmod) induced_2\VBN (r_amod) arrest_4\NN
D013390_D006323 CID suxamethonium_21\NN (r_pobj) of_20\IN (r_prep) use_19\NN (r_pobj) following_17\VBG (r_prep) case_5\NN (l_prep) of_6\IN (l_pobj) arrest_8\NN
D013390_D006323 CID suxamethonium_5\NN (l_appos) arrest_10\NN
11752354
D004967_D009203 NONE estrogen_38\NN (r_pobj) of_37\IN (r_prep) dose_36\NN (r_dep) identified_64\VBD (l_conj) enrolled_66\VBD (l_dobj) women_68\NNS (l_relcl) had_77\VBN (l_dobj) infarction_81\NN
D004967_D009203 NONE estrogen_38\NN (r_pobj) of_37\IN (r_prep) dose_36\NN (r_dep) identified_64\VBD (l_conj) enrolled_66\VBD (l_dobj) women_68\NNS (l_relcl) had_77\VBN (l_dobj) infarction_81\NN (l_prep) between_82\IN (l_pobj) 1990_83\CD (l_conj) women_89\NNS (l_relcl) had_93\VBN (l_dobj) infarction_96\NN
D017135_D009203 NONE desogestrel_19\NN (r_appos) generation_15\NN (r_nmod) contraceptives_33\NNS (r_pobj) in_12\IN (r_prep) included_11\VBN (r_acl) type_8\NN (r_pobj) to_6\IN (r_prep) according_5\VBG (r_prep) investigated_1\VBD (l_conj) identified_64\VBD (l_conj) enrolled_66\VBD (l_dobj) women_68\NNS (l_relcl) had_77\VBN (l_dobj) infarction_81\NN
D017135_D009203 NONE desogestrel_19\NN (r_appos) generation_15\NN (r_nmod) contraceptives_33\NNS (r_pobj) in_12\IN (r_prep) included_11\VBN (r_acl) type_8\NN (r_pobj) to_6\IN (r_prep) according_5\VBG (r_prep) investigated_1\VBD (l_conj) identified_64\VBD (l_conj) enrolled_66\VBD (l_dobj) women_68\NNS (l_relcl) had_77\VBN (l_dobj) infarction_81\NN (l_prep) between_82\IN (l_pobj) 1990_83\CD (l_conj) women_89\NNS (l_relcl) had_93\VBN (l_dobj) infarction_96\NN
D003276_D009203 CID contraceptives_1\NNS (l_conj) risk_4\NN (l_prep) of_5\IN (l_pobj) infarction_7\NN
D003276_D009203 CID contraceptives_7\NNS (r_pobj) of_5\IN (r_prep) use_4\NN (l_conj) risk_10\NN (l_prep) of_11\IN (l_pobj) infarction_13\NN
D003276_D009203 CID contraceptives_33\NNS (r_pobj) in_12\IN (r_prep) included_11\VBN (r_acl) type_8\NN (r_pobj) to_6\IN (r_prep) according_5\VBG (r_prep) investigated_1\VBD (l_conj) identified_64\VBD (l_conj) enrolled_66\VBD (l_dobj) women_68\NNS (l_relcl) had_77\VBN (l_dobj) infarction_81\NN
D003276_D009203 CID contraceptives_33\NNS (r_pobj) in_12\IN (r_prep) included_11\VBN (r_acl) type_8\NN (r_pobj) to_6\IN (r_prep) according_5\VBG (r_prep) investigated_1\VBD (l_conj) identified_64\VBD (l_conj) enrolled_66\VBD (l_dobj) women_68\NNS (l_relcl) had_77\VBN (l_dobj) infarction_81\NN (l_prep) between_82\IN (l_pobj) 1990_83\CD (l_conj) women_89\NNS (l_relcl) had_93\VBN (l_dobj) infarction_96\NN
D003276_D009203 CID contraceptive_39\NN (r_pobj) of_36\IN (r_prep) type_35\NN (r_dobj) used_33\VBD (r_relcl) women_31\NNS (r_pobj) among_30\IN (r_prep) infarction_29\NN
D003276_D009203 CID contraceptives_5\NNS (r_dobj) used_3\VBD (r_relcl) women_1\NNS (r_pobj) Among_0\IN (r_prep) was_10\VBD (r_ccomp) increased_53\VBN (l_nsubjpass) risk_48\NN (l_prep) of_49\IN (l_pobj) infarction_51\NN
D003276_D009203 CID contraceptives_62\NNS (r_dobj) used_57\VBD (r_relcl) women_55\NNS (r_pobj) among_54\IN (r_prep) increased_53\VBN (l_nsubjpass) risk_48\NN (l_prep) of_49\IN (l_pobj) infarction_51\NN
D003276_D009203 CID contraceptives_12\NNS (r_dobj) used_10\VBD (r_relcl) women_8\NNS (r_pobj) among_7\IN (r_prep) similar_6\JJ (r_acomp) was_5\VBD (l_nsubj) risk_1\NN (l_prep) of_2\IN (l_pobj) infarction_4\NN
C033273_D009203 NONE gestodene_21\NN (r_conj) desogestrel_19\NN (r_appos) generation_15\NN (r_nmod) contraceptives_33\NNS (r_pobj) in_12\IN (r_prep) included_11\VBN (r_acl) type_8\NN (r_pobj) to_6\IN (r_prep) according_5\VBG (r_prep) investigated_1\VBD (l_conj) identified_64\VBD (l_conj) enrolled_66\VBD (l_dobj) women_68\NNS (l_relcl) had_77\VBN (l_dobj) infarction_81\NN
C033273_D009203 NONE gestodene_21\NN (r_conj) desogestrel_19\NN (r_appos) generation_15\NN (r_nmod) contraceptives_33\NNS (r_pobj) in_12\IN (r_prep) included_11\VBN (r_acl) type_8\NN (r_pobj) to_6\IN (r_prep) according_5\VBG (r_prep) investigated_1\VBD (l_conj) identified_64\VBD (l_conj) enrolled_66\VBD (l_dobj) women_68\NNS (l_relcl) had_77\VBN (l_dobj) infarction_81\NN (l_prep) between_82\IN (l_pobj) 1990_83\CD (l_conj) women_89\NNS (l_relcl) had_93\VBN (l_dobj) infarction_96\NN
D011372_D009203 NONE progestagen_10\NN (r_pobj) of_9\IN (r_prep) type_8\NN (r_pobj) to_6\IN (r_prep) according_5\VBG (r_prep) investigated_1\VBD (l_conj) identified_64\VBD (l_conj) enrolled_66\VBD (l_dobj) women_68\NNS (l_relcl) had_77\VBN (l_dobj) infarction_81\NN
D011372_D009203 NONE progestagen_10\NN (r_pobj) of_9\IN (r_prep) type_8\NN (r_pobj) to_6\IN (r_prep) according_5\VBG (r_prep) investigated_1\VBD (l_conj) identified_64\VBD (l_conj) enrolled_66\VBD (l_dobj) women_68\NNS (l_relcl) had_77\VBN (l_dobj) infarction_81\NN (l_prep) between_82\IN (l_pobj) 1990_83\CD (l_conj) women_89\NNS (l_relcl) had_93\VBN (l_dobj) infarction_96\NN
D016912_D009203 NONE levonorgestrel_30\JJ (r_conj) desogestrel_19\NN (r_appos) generation_15\NN (r_nmod) contraceptives_33\NNS (r_pobj) in_12\IN (r_prep) included_11\VBN (r_acl) type_8\NN (r_pobj) to_6\IN (r_prep) according_5\VBG (r_prep) investigated_1\VBD (l_conj) identified_64\VBD (l_conj) enrolled_66\VBD (l_dobj) women_68\NNS (l_relcl) had_77\VBN (l_dobj) infarction_81\NN
D016912_D009203 NONE levonorgestrel_30\JJ (r_conj) desogestrel_19\NN (r_appos) generation_15\NN (r_nmod) contraceptives_33\NNS (r_pobj) in_12\IN (r_prep) included_11\VBN (r_acl) type_8\NN (r_pobj) to_6\IN (r_prep) according_5\VBG (r_prep) investigated_1\VBD (l_conj) identified_64\VBD (l_conj) enrolled_66\VBD (l_dobj) women_68\NNS (l_relcl) had_77\VBN (l_dobj) infarction_81\NN (l_prep) between_82\IN (l_pobj) 1990_83\CD (l_conj) women_89\NNS (l_relcl) had_93\VBN (l_dobj) infarction_96\NN
7444978
D013307_D004409 CID streptomycin_48\NNS (r_pobj) to_47\IN (r_prep) sensitive_46\JJ (r_acomp) is_44\VBZ (r_ccomp) indicating_40\VBG (r_advcl) occurred_23\VBD (l_ccomp) occurred_4\VBD (l_nsubj) movements_1\NNS
D013307_D004409 CID streptomycin_48\NNS (l_prep) than_49\IN (l_pobj) site_51\NN (l_amod) responsible_57\JJ (l_prep) for_58\IN (l_pobj) dyskinesias_60\NNS
D013307_D003638 CID streptomycin_48\NNS (r_pobj) to_47\IN (r_prep) sensitive_46\JJ (r_acomp) is_44\VBZ (r_ccomp) indicating_40\VBG (r_advcl) occurred_23\VBD (l_ccomp) occurred_4\VBD (l_nsubj) movements_1\NNS (l_conj) deafness_3\NN
D013307_D020258 NONE streptomycin_11\NNS (r_pobj) of_10\IN (r_prep) effects_9\NNS (l_amod) neurotoxic_8\JJ
18544179
D005283_D009325 NONE fentanyl_1\NN (r_dobj) Omitting_0\VBG (r_csubj) reduces_2\VBZ (l_dobj) nausea_3\NN
D005283_D009325 NONE fentanyl_2\NN (r_pobj) of_1\IN (r_prep) Omission_0\NN (r_nsubj) reduce_5\VB (l_conj) reduce_17\VB (l_conj) moderate_23\JJ (l_prep) to_24\TO (l_pobj) nausea_26\NN
D005283_D009325 NONE fentanyl_37\NN (r_nmod) dexamethasone_41\NN (r_pobj) with_36\IN (r_prep) %_35\NN (r_conj) %_32\NN (r_pobj) from_30\IN (r_prep) discharge_29\NN (r_pobj) to_28\IN (r_prep) prior_27\RB (r_advmod) reduce_17\VB (l_conj) moderate_23\JJ (l_prep) to_24\TO (l_pobj) nausea_26\NN
D005283_D009325 NONE fentanyl_39\NN (r_compound) dexamethasone_41\NN (r_pobj) with_36\IN (r_prep) %_35\NN (r_conj) %_32\NN (r_pobj) from_30\IN (r_prep) discharge_29\NN (r_pobj) to_28\IN (r_prep) prior_27\RB (r_advmod) reduce_17\VB (l_conj) moderate_23\JJ (l_prep) to_24\TO (l_pobj) nausea_26\NN
D005283_D009325 NONE fentanyl_3\NN (r_compound) groups_4\NNS (r_dobj) Combining_0\VBG (r_csubj) revealed_5\VBD (l_advcl) reducing_15\VBG (l_dobj) nausea_17\NN (l_conj) vomiting_19\NN (l_conj) nausea_21\NN
D005283_D009325 NONE fentanyl_3\NN (r_compound) groups_4\NNS (r_dobj) Combining_0\VBG (r_csubj) revealed_5\VBD (l_advcl) decreased_57\VBN (l_nsubjpass) nausea_50\NN
C009250_D007022 NONE sevoflurane_9\NN (r_npadvmod) sparing_11\VBG (r_amod) effect_12\NN (r_dobj) had_7\VBD (l_conj) depression_16\NN (l_conj) hypotension_18\NN
C009250_D010146 NONE sevoflurane_12\NN (r_pobj) after_11\IN (r_prep) reduces_2\VBZ (l_prep) without_7\IN (l_pcomp) increasing_8\VBG (l_dobj) pain_9\NN
C009250_D010146 NONE sevoflurane_23\NN (r_compound) anaesthesia_24\NN (r_pobj) after_22\IN (r_prep) h_21\NN (r_pobj) in_17\IN (r_prep) examined_5\VBD (l_dobj) incidence_7\NN (l_prep) of_10\IN (l_pobj) nausea_12\NN (l_conj) vomiting_14\NN (l_conj) pain_16\NN
D003907_D014839 NONE dexamethasone_41\NN (r_pobj) with_36\IN (r_prep) %_35\NN (r_conj) %_32\NN (r_pobj) from_30\IN (r_prep) discharge_29\NN (r_pobj) to_28\IN (r_prep) prior_27\RB (r_advmod) reduce_17\VB (l_dobj) incidence_19\NN (l_prep) of_20\IN (l_pobj) vomiting_21\NN
C009250_D001919 NONE sevoflurane_9\NN (r_npadvmod) sparing_11\VBG (r_amod) effect_12\NN (r_dobj) had_7\VBD (l_conj) depression_16\NN (l_conj) hypotension_18\NN (l_conj) bradycardia_20\NN
C009250_D020250 NONE sevoflurane_9\NN (r_pobj) with_8\IN (r_prep) advantages_1\NNS (r_pobj) Despite_0\IN (r_prep) occurs_15\VBZ (l_nsubj) nausea_12\NN (l_conj) vomiting_14\NN
C009250_D020250 NONE sevoflurane_23\NN (r_compound) anaesthesia_24\NN (r_pobj) after_22\IN (r_prep) h_21\NN (r_pobj) in_17\IN (r_prep) examined_5\VBD (l_dobj) incidence_7\NN (l_prep) of_10\IN (l_pobj) nausea_12\NN (l_conj) vomiting_14\NN
C009250_D020250 NONE sevoflurane_31\NN (r_relcl) supplement_29\NN (r_attr) be_23\VB (r_xcomp) appears_21\VBZ (l_advcl) exacerbated_2\VBD (l_dobj) nausea_4\NN (l_conj) vomiting_6\VBG
C009250_D010149 NONE sevoflurane_31\NN (r_relcl) supplement_29\NN (r_attr) be_23\VB (r_xcomp) appears_21\VBZ (l_advcl) exacerbated_2\VBD (l_dobj) nausea_4\NN (l_conj) vomiting_6\VBG (l_prep) without_7\IN (l_pobj) improvement_9\NN (l_prep) in_10\IN (l_pobj) pain_12\NN
C009250_D014839 NONE sevoflurane_12\NN (r_pobj) after_11\IN (r_prep) reduces_2\VBZ (l_dobj) nausea_3\NN (l_conj) vomiting_5\NN
C009250_D009325 NONE sevoflurane_12\NN (r_pobj) after_11\IN (r_prep) reduces_2\VBZ (l_dobj) nausea_3\NN
D003907_D009325 NONE dexamethasone_41\NN (r_pobj) with_36\IN (r_prep) %_35\NN (r_conj) %_32\NN (r_pobj) from_30\IN (r_prep) discharge_29\NN (r_pobj) to_28\IN (r_prep) prior_27\RB (r_advmod) reduce_17\VB (l_conj) moderate_23\JJ (l_prep) to_24\TO (l_pobj) nausea_26\NN
D003907_D020250 NONE dexamethasone_41\NN (r_pobj) with_36\IN (r_prep) %_35\NN (r_conj) %_32\NN (r_pobj) from_30\IN (r_prep) discharge_29\NN (r_pobj) to_28\IN (r_prep) prior_27\RB (r_advmod) reduce_17\VB (r_conj) reduce_5\VB (l_dobj) incidence_8\NN (l_prep) of_9\IN (l_pobj) nausea_11\NN (l_conj) vomiting_13\NN
D003907_D020250 NONE Dexamethasone_0\NNP (r_nsubj) had_1\VBD (l_dobj) effect_4\NN (l_prep) on_5\IN (l_pobj) incidence_7\NN (l_prep) of_10\IN (l_pobj) nausea_12\NN (l_conj) vomiting_14\NN
D005283_D014839 NONE fentanyl_1\NN (r_dobj) Omitting_0\VBG (r_csubj) reduces_2\VBZ (l_dobj) nausea_3\NN (l_conj) vomiting_5\NN
D005283_D014839 NONE fentanyl_2\NN (r_pobj) of_1\IN (r_prep) Omission_0\NN (r_nsubj) reduce_5\VB (l_conj) reduce_17\VB (l_dobj) incidence_19\NN (l_prep) of_20\IN (l_pobj) vomiting_21\NN
D005283_D014839 NONE fentanyl_37\NN (r_nmod) dexamethasone_41\NN (r_pobj) with_36\IN (r_prep) %_35\NN (r_conj) %_32\NN (r_pobj) from_30\IN (r_prep) discharge_29\NN (r_pobj) to_28\IN (r_prep) prior_27\RB (r_advmod) reduce_17\VB (l_dobj) incidence_19\NN (l_prep) of_20\IN (l_pobj) vomiting_21\NN
D005283_D014839 NONE fentanyl_39\NN (r_compound) dexamethasone_41\NN (r_pobj) with_36\IN (r_prep) %_35\NN (r_conj) %_32\NN (r_pobj) from_30\IN (r_prep) discharge_29\NN (r_pobj) to_28\IN (r_prep) prior_27\RB (r_advmod) reduce_17\VB (l_dobj) incidence_19\NN (l_prep) of_20\IN (l_pobj) vomiting_21\NN
D005283_D012131 CID Fentanyl_0\NNP (r_nsubj) reduce_2\VB (l_conj) had_7\VBD (l_conj) depression_16\NN
D005283_D020250 CID fentanyl_2\NN (r_pobj) of_1\IN (r_prep) Omission_0\NN (r_nsubj) reduce_5\VB (l_dobj) incidence_8\NN (l_prep) of_9\IN (l_pobj) nausea_11\NN (l_conj) vomiting_13\NN
D005283_D020250 CID fentanyl_37\NN (r_nmod) dexamethasone_41\NN (r_pobj) with_36\IN (r_prep) %_35\NN (r_conj) %_32\NN (r_pobj) from_30\IN (r_prep) discharge_29\NN (r_pobj) to_28\IN (r_prep) prior_27\RB (r_advmod) reduce_17\VB (r_conj) reduce_5\VB (l_dobj) incidence_8\NN (l_prep) of_9\IN (l_pobj) nausea_11\NN (l_conj) vomiting_13\NN
D005283_D020250 CID fentanyl_39\NN (r_compound) dexamethasone_41\NN (r_pobj) with_36\IN (r_prep) %_35\NN (r_conj) %_32\NN (r_pobj) from_30\IN (r_prep) discharge_29\NN (r_pobj) to_28\IN (r_prep) prior_27\RB (r_advmod) reduce_17\VB (r_conj) reduce_5\VB (l_dobj) incidence_8\NN (l_prep) of_9\IN (l_pobj) nausea_11\NN (l_conj) vomiting_13\NN
D005283_D020250 CID fentanyl_3\NN (r_compound) groups_4\NNS (r_dobj) Combining_0\VBG (r_csubj) revealed_5\VBD (l_advcl) reducing_15\VBG (l_dobj) nausea_17\NN (l_conj) vomiting_19\NN
D005283_D020250 CID fentanyl_1\NN (r_nsubj) exacerbated_2\VBD (l_dobj) nausea_4\NN (l_conj) vomiting_6\VBG
D005283_D001919 CID Fentanyl_0\NNP (r_nsubj) reduce_2\VB (l_conj) had_7\VBD (l_conj) depression_16\NN (l_conj) hypotension_18\NN (l_conj) bradycardia_20\NN
D005283_D010146 NONE fentanyl_1\NN (r_dobj) Omitting_0\VBG (r_csubj) reduces_2\VBZ (l_prep) without_7\IN (l_pcomp) increasing_8\VBG (l_dobj) pain_9\NN
D005283_D010146 NONE fentanyl_11\NN (r_pobj) of_10\IN (r_prep) omission_9\NN (r_pobj) by_7\IN (r_prep) unaffected_6\JJ (r_acomp) were_5\VBD (l_nsubj) severity_1\NN (l_compound) Pain_0\NN
D005283_D010149 NONE fentanyl_1\NN (r_nsubj) exacerbated_2\VBD (l_dobj) nausea_4\NN (l_conj) vomiting_6\VBG (l_prep) without_7\IN (l_pobj) improvement_9\NN (l_prep) in_10\IN (l_pobj) pain_12\NN
D005283_D007022 CID Fentanyl_0\NNP (r_nsubj) reduce_2\VB (l_conj) had_7\VBD (l_conj) depression_16\NN (l_conj) hypotension_18\NN
C009250_D012131 NONE sevoflurane_9\NN (r_npadvmod) sparing_11\VBG (r_amod) effect_12\NN (r_dobj) had_7\VBD (l_conj) depression_16\NN
17241784
D019821_D009135 CID statin_12\NN (r_compound) therapy_13\NN (r_pobj) with_11\IN (r_prep) associated_10\VBD (r_acl) myopathy_1\NNS
D019821_D009135 CID Statins_0\NNS (r_nsubj) cause_2\VB (l_ccomp) myopathy_5\NN
D019821_D009135 CID statins_9\NNS (r_nsubj) induce_11\VB (l_dobj) myopathy_13\NN
D019821_D009135 CID statins_4\NNS (r_nsubj) initiate_6\VB (l_dobj) myopathy_11\NN
D019821_D009135 CID statins_13\NNS (r_pobj) by_12\IN (r_prep) induction_11\NN (r_dobj) involve_9\VB (r_conj) is_5\VBZ (l_nsubj) mechanism_1\NN (l_prep) of_2\IN (l_pobj) myopathy_4\NN
D019821_-1 NONE Statins_0\NNS (r_nsubj) cause_2\VB (l_ccomp) myopathy_5\NN (l_conj) hyperCKaemia_7\NN
19308880
D014635_D003221 CID acid_10\NN (r_pobj) with_8\IN (r_prep) reaction_7\NN (r_appos) Confusion_0\NN
D014635_D003221 CID acid_10\NN (r_pobj) with_8\IN (r_prep) observed_7\VBD (r_acl) reaction_5\NN (r_attr) is_1\VBZ (l_nsubj) Confusion_0\NN
D014635_D003221 CID acid_17\NN (r_pobj) with_15\IN (r_prep) reported_12\VBN (r_acl) confusion_11\NN
D014635_D003221 CID acid_9\NN (r_pobj) with_7\IN (r_prep) reported_6\VBN (l_nsubjpass) cases_2\NNS (l_prep) of_3\IN (l_pobj) confusion_4\NN
D014635_D003221 CID acid_10\NN (r_compound) exposure_11\NN (r_pobj) following_8\VBG (r_prep) weeks_7\NNS (r_pobj) during_3\IN (r_prep) occurred_2\VBD (l_nsubj) Confusion_0\NN
D014635_D003221 CID acid_7\NN (r_pobj) with_5\IN (r_prep) confusion_4\NN
18182964
D003000_D006970 NONE clonidine_4\NN (r_pobj) on_3\IN (r_prep) was_1\VBD (l_nsubj) Drowsiness_0\NN
D003000_D006970 NONE clonidine_2\NN (r_dobj) prescribing_1\VBG (r_acl) Physicians_0\NNS (r_nsubj) monitor_4\VB (l_conj) advise_8\VB (l_dobj) patients_9\NNS (l_prep) about_10\IN (l_pobj) likelihood_13\NN (l_prep) of_14\IN (l_pobj) drowsiness_16\NN
D003000_D001919 CID clonidine_10\NN (r_pobj) with_9\IN (r_prep) treated_8\VBN (r_acl) subjects_7\NNS (r_pobj) in_6\IN (r_prep) incidents_3\NNS (l_prep) of_4\IN (l_pobj) bradycardia_5\NN
D003000_D001919 CID clonidine_17\NN (r_pobj) with_16\IN (r_prep) treated_15\VBN (r_acl) those_13\DT (r_pobj) with_12\IN (r_prep) compared_11\VBN (r_prep) treated_8\VBN (r_acl) subjects_7\NNS (r_pobj) in_6\IN (r_prep) incidents_3\NNS (l_prep) of_4\IN (l_pobj) bradycardia_5\NN
D003000_D001919 CID clonidine_2\NN (r_dobj) prescribing_1\VBG (r_acl) Physicians_0\NNS (r_nsubj) monitor_4\VB (l_prep) for_5\IN (l_pobj) bradycardia_6\NN
D008774_D001289 NONE methylphenidate_12\NN (l_prep) with_15\IN (l_pobj) disorder_21\NN
D008774_D001289 NONE methylphenidate_12\NN (l_prep) with_15\IN (l_pobj) disorder_21\NN (l_appos) ADHD_23\NNP
D008774_D001289 NONE methylphenidate_25\NN (r_conj) clonidine_18\NN (r_xcomp) assigned_16\VBN (l_nsubjpass) children_11\NNS (l_prep) with_12\IN (l_pobj) ADHD_13\NNP
D008774_D001289 NONE methylphenidate_34\NN (r_conj) clonidine_32\NN (r_conj) methylphenidate_25\NN (r_conj) clonidine_18\NN (r_xcomp) assigned_16\VBN (l_nsubjpass) children_11\NNS (l_prep) with_12\IN (l_pobj) ADHD_13\NNP
D008774_D001289 NONE methylphenidate_6\NN (r_pobj) with_5\IN (r_conj) used_2\VBN (r_acl) Clonidine_0\NNP (r_nsubj) appears_8\VBZ (l_conj) tolerated_12\VBN (l_prep) in_13\IN (l_pobj) ADHD_15\NNP
D003000_D001289 NONE Clonidine_0\NNP (l_prep) for_1\IN (l_pobj) disorder_7\NN
D003000_D001289 NONE clonidine_7\NN (r_pobj) of_6\IN (r_prep) safety_3\NN (r_dobj) examine_1\VB (r_csubj) used_8\VBN (l_conj) with_11\IN (l_pobj) methylphenidate_12\NN (l_prep) with_15\IN (l_pobj) disorder_21\NN
D003000_D001289 NONE clonidine_7\NN (r_pobj) of_6\IN (r_prep) safety_3\NN (r_dobj) examine_1\VB (r_csubj) used_8\VBN (l_conj) with_11\IN (l_pobj) methylphenidate_12\NN (l_prep) with_15\IN (l_pobj) disorder_21\NN (l_appos) ADHD_23\NNP
D003000_D001289 NONE clonidine_18\NN (r_xcomp) assigned_16\VBN (l_nsubjpass) children_11\NNS (l_prep) with_12\IN (l_pobj) ADHD_13\NNP
D003000_D001289 NONE clonidine_32\NN (r_conj) methylphenidate_25\NN (r_conj) clonidine_18\NN (r_xcomp) assigned_16\VBN (l_nsubjpass) children_11\NNS (l_prep) with_12\IN (l_pobj) ADHD_13\NNP
D003000_D001289 NONE Clonidine_0\NNP (r_nsubj) appears_8\VBZ (l_conj) tolerated_12\VBN (l_prep) in_13\IN (l_pobj) ADHD_15\NNP
20528871
C104457_D006402 CID AraG_8\NNP (r_pobj) than_7\IN (r_prep) combination_6\NN (r_pobj) for_4\IN (r_prep) greater_3\JJR (r_acomp) was_2\VBD (l_nsubj) toxicity_1\NN
D005047_D015458 NONE etoposide_5\RB (r_conj) nelarabine_3\NN (l_prep) in_9\IN (l_pobj) leukaemia_18\NN (l_conj) lymphoma_20\NN
D005047_D015458 NONE etoposide_14\NN (r_pobj) of_13\IN (r_prep) d_12\SYM (r_pobj) with_10\IN (r_prep) AraG_8\NNP (r_appos) nelarabine_6\JJ (r_pobj) of_5\IN (r_prep) d_4\SYM (r_pobj) of_2\IN (r_prep) combination_1\NN (r_nsubjpass) used_28\VBN (l_prep) in_32\IN (l_pobj) children_34\NNS (l_prep) with_35\IN (l_pobj) leukaemia_42\NN (l_conj) lymphoma_44\NN
D005047_D015458 NONE VP_16\NNP (r_appos) d_12\SYM (r_pobj) with_10\IN (r_prep) AraG_8\NNP (r_appos) nelarabine_6\JJ (r_pobj) of_5\IN (r_prep) d_4\SYM (r_pobj) of_2\IN (r_prep) combination_1\NN (r_nsubjpass) used_28\VBN (l_prep) in_32\IN (l_pobj) children_34\NNS (l_prep) with_35\IN (l_pobj) leukaemia_42\NN (l_conj) lymphoma_44\NN
D005047_D016399 NONE etoposide_5\RB (r_conj) nelarabine_3\NN (l_prep) in_9\IN (l_pobj) leukaemia_18\NN (l_conj) lymphoma_20\NN
D005047_D016399 NONE etoposide_14\NN (r_pobj) of_13\IN (r_prep) d_12\SYM (r_pobj) with_10\IN (r_prep) AraG_8\NNP (r_appos) nelarabine_6\JJ (r_pobj) of_5\IN (r_prep) d_4\SYM (r_pobj) of_2\IN (r_prep) combination_1\NN (r_nsubjpass) used_28\VBN (l_prep) in_32\IN (l_pobj) children_34\NNS (l_prep) with_35\IN (l_pobj) leukaemia_42\NN (l_conj) lymphoma_44\NN
D005047_D016399 NONE VP_16\NNP (r_appos) d_12\SYM (r_pobj) with_10\IN (r_prep) AraG_8\NNP (r_appos) nelarabine_6\JJ (r_pobj) of_5\IN (r_prep) d_4\SYM (r_pobj) of_2\IN (r_prep) combination_1\NN (r_nsubjpass) used_28\VBN (l_prep) in_32\IN (l_pobj) children_34\NNS (l_prep) with_35\IN (l_pobj) leukaemia_42\NN (l_conj) lymphoma_44\NN
C104457_D015458 NONE nelarabine_3\NN (l_prep) in_9\IN (l_pobj) leukaemia_18\NN (l_conj) lymphoma_20\NN
C104457_D015458 NONE nelarabine_6\JJ (r_pobj) of_5\IN (r_prep) d_4\SYM (r_pobj) of_2\IN (r_prep) combination_1\NN (r_nsubjpass) used_28\VBN (l_prep) in_32\IN (l_pobj) children_34\NNS (l_prep) with_35\IN (l_pobj) leukaemia_42\NN (l_conj) lymphoma_44\NN
C104457_D015458 NONE AraG_8\NNP (r_appos) nelarabine_6\JJ (r_pobj) of_5\IN (r_prep) d_4\SYM (r_pobj) of_2\IN (r_prep) combination_1\NN (r_nsubjpass) used_28\VBN (l_prep) in_32\IN (l_pobj) children_34\NNS (l_prep) with_35\IN (l_pobj) leukaemia_42\NN (l_conj) lymphoma_44\NN
D003520_D015458 NONE cyclophosphamide_8\NN (r_conj) etoposide_5\RB (r_conj) nelarabine_3\NN (l_prep) in_9\IN (l_pobj) leukaemia_18\NN (l_conj) lymphoma_20\NN
D003520_D015458 NONE cyclophosphamide_19\NN (r_conj) VP_16\NNP (r_appos) d_12\SYM (r_pobj) with_10\IN (r_prep) AraG_8\NNP (r_appos) nelarabine_6\JJ (r_pobj) of_5\IN (r_prep) d_4\SYM (r_pobj) of_2\IN (r_prep) combination_1\NN (r_nsubjpass) used_28\VBN (l_prep) in_32\IN (l_pobj) children_34\NNS (l_prep) with_35\IN (l_pobj) leukaemia_42\NN (l_conj) lymphoma_44\NN
D003520_D015458 NONE CPM_21\NNP (r_appos) VP_16\NNP (r_appos) d_12\SYM (r_pobj) with_10\IN (r_prep) AraG_8\NNP (r_appos) nelarabine_6\JJ (r_pobj) of_5\IN (r_prep) d_4\SYM (r_pobj) of_2\IN (r_prep) combination_1\NN (r_nsubjpass) used_28\VBN (l_prep) in_32\IN (l_pobj) children_34\NNS (l_prep) with_35\IN (l_pobj) leukaemia_42\NN (l_conj) lymphoma_44\NN
C104457_D016399 NONE nelarabine_3\NN (l_prep) in_9\IN (l_pobj) leukaemia_18\NN (l_conj) lymphoma_20\NN
C104457_D016399 NONE nelarabine_6\JJ (r_pobj) of_5\IN (r_prep) d_4\SYM (r_pobj) of_2\IN (r_prep) combination_1\NN (r_nsubjpass) used_28\VBN (l_prep) in_32\IN (l_pobj) children_34\NNS (l_prep) with_35\IN (l_pobj) leukaemia_42\NN (l_conj) lymphoma_44\NN
C104457_D016399 NONE AraG_8\NNP (r_appos) nelarabine_6\JJ (r_pobj) of_5\IN (r_prep) d_4\SYM (r_pobj) of_2\IN (r_prep) combination_1\NN (r_nsubjpass) used_28\VBN (l_prep) in_32\IN (l_pobj) children_34\NNS (l_prep) with_35\IN (l_pobj) leukaemia_42\NN (l_conj) lymphoma_44\NN
D003520_D016399 NONE cyclophosphamide_8\NN (r_conj) etoposide_5\RB (r_conj) nelarabine_3\NN (l_prep) in_9\IN (l_pobj) leukaemia_18\NN (l_conj) lymphoma_20\NN
D003520_D016399 NONE cyclophosphamide_19\NN (r_conj) VP_16\NNP (r_appos) d_12\SYM (r_pobj) with_10\IN (r_prep) AraG_8\NNP (r_appos) nelarabine_6\JJ (r_pobj) of_5\IN (r_prep) d_4\SYM (r_pobj) of_2\IN (r_prep) combination_1\NN (r_nsubjpass) used_28\VBN (l_prep) in_32\IN (l_pobj) children_34\NNS (l_prep) with_35\IN (l_pobj) leukaemia_42\NN (l_conj) lymphoma_44\NN
D003520_D016399 NONE CPM_21\NNP (r_appos) VP_16\NNP (r_appos) d_12\SYM (r_pobj) with_10\IN (r_prep) AraG_8\NNP (r_appos) nelarabine_6\JJ (r_pobj) of_5\IN (r_prep) d_4\SYM (r_pobj) of_2\IN (r_prep) combination_1\NN (r_nsubjpass) used_28\VBN (l_prep) in_32\IN (l_pobj) children_34\NNS (l_prep) with_35\IN (l_pobj) leukaemia_42\NN (l_conj) lymphoma_44\NN
D005047_D009422 NONE etoposide_14\NN (r_pobj) with_13\IN (r_prep) synchrony_12\NN (r_pobj) in_11\IN (r_prep) therapy_10\NN (r_pobj) as_8\IN (r_prep) giving_6\VBG (r_pcomp) of_5\IN (r_prep) safety_4\NN (r_dobj) supports_2\VBZ (l_advcl) monitored_24\VBN (l_nsubjpass) toxicity_20\NN
D003520_D009422 NONE cyclophosphamide_16\NN (r_conj) etoposide_14\NN (r_pobj) with_13\IN (r_prep) synchrony_12\NN (r_pobj) in_11\IN (r_prep) therapy_10\NN (r_pobj) as_8\IN (r_prep) giving_6\VBG (r_pcomp) of_5\IN (r_prep) safety_4\NN (r_dobj) supports_2\VBZ (l_advcl) monitored_24\VBN (l_nsubjpass) toxicity_20\NN
C104457_D009422 CID AraG_8\NNP (r_pobj) to_6\IN (r_prep) attributable_5\JJ (r_amod) effects_4\NNS (r_nsubj) included_9\VBD (l_dobj) neuropathy_17\NN
C104457_D009422 CID AraG_7\NN (r_dobj) giving_6\VBG (r_pcomp) of_5\IN (r_prep) safety_4\NN (r_dobj) supports_2\VBZ (l_advcl) monitored_24\VBN (l_nsubjpass) toxicity_20\NN
C104457_D059352 CID AraG_8\NNP (r_pobj) to_6\IN (r_prep) attributable_5\JJ (r_amod) effects_4\NNS (r_nsubj) included_9\VBD (l_dobj) neuropathy_17\NN (l_conj) pain_20\NN
10704919
D017665_D006461 NONE hydroxyl_32\NN (r_dobj) inactivated_30\VBN (r_parataxis) prevented_6\VBN (l_nsubjpass) effect_2\NN (l_amod) hemolytic_1\JJ
D017665_D006461 NONE hydroxyl_32\NN (r_dobj) inactivated_30\VBN (r_parataxis) prevented_6\VBN (l_advcl) indicating_34\VBG (l_ccomp) related_42\VBN (l_nsubjpass) hemolysis_39\NN
D013629_D006461 CID tamoxifen_6\NN (r_pobj) by_5\IN (r_agent) induced_4\VBN (l_nsubj) Hemolysis_0\NNP
D013629_D006461 CID TAM_0\NNP (r_nsubj) induces_1\VBZ (l_dobj) hemolysis_2\NN
D013629_D006461 CID TAM_13\NNP (r_nsubj) induces_14\VBZ (r_conj) is_4\VBZ (l_nsubj) extension_1\NN (l_prep) of_2\IN (l_pobj) hemolysis_3\NN
D013629_D006461 CID TAM_13\NNP (r_nsubj) induces_14\VBZ (l_dobj) hemolysis_16\NN
D013629_D006461 CID TAM_4\NNP (r_pobj) of_3\IN (r_prep) effect_2\NN (l_amod) hemolytic_1\JJ
D013629_D006461 CID TAM_4\NNP (r_pobj) of_3\IN (r_prep) effect_2\NN (r_nsubjpass) prevented_6\VBN (l_advcl) indicating_34\VBG (l_ccomp) related_42\VBN (l_nsubjpass) hemolysis_39\NN
D013629_D006461 CID TAM_36\NNP (r_npadvmod) induced_38\VBN (r_amod) hemolysis_39\NN (r_nsubjpass) related_42\VBN (r_ccomp) indicating_34\VBG (r_advcl) prevented_6\VBN (l_nsubjpass) effect_2\NN (l_amod) hemolytic_1\JJ
D013629_D006461 CID TAM_36\NNP (r_npadvmod) induced_38\VBN (r_amod) hemolysis_39\NN
D013629_D006461 CID TAM_17\NNP (r_npadvmod) induced_19\VBN (r_amod) hemolysis_20\NN
D013629_D006461 CID TAM_3\NNP (r_pobj) by_2\IN (r_agent) caused_1\VBN (r_acl) Hemolysis_0\NNP
D013629_D006461 CID TAM_3\NNP (r_pobj) by_2\IN (r_agent) caused_1\VBN (r_acl) Hemolysis_0\NNP (r_nsubjpass) preceded_6\VBN (l_prep) excluding_18\VBG (l_pobj) mechanism_24\NN (l_prep) of_25\IN (l_pobj) hemolysis_26\NN
D013629_D006461 CID TAM_15\NNP (r_compound) incorporation_16\NN (r_pobj) to_12\IN (r_prep) related_11\VBN (l_nsubjpass) protection_5\NN (l_prep) from_6\IN (l_pobj) hemolysis_7\NN
D013629_D006461 CID TAM_2\NNP (r_npadvmod) induced_4\VBN (r_amod) results_6\NNS (l_compound) hemolysis_5\NN
D013629_D001943 NONE Tamoxifen_0\NNP (r_nsubj) induces_18\VBZ (l_nsubj) drug_7\NN (l_acl) prescribed_10\VBN (l_prep) in_11\IN (l_pobj) chemotherapy_13\NN (l_prep) of_14\IN (l_pobj) cancer_16\NN
D013629_D001943 NONE TAM_2\NNP (r_appos) Tamoxifen_0\NNP (r_nsubj) induces_18\VBZ (l_nsubj) drug_7\NN (l_acl) prescribed_10\VBN (l_prep) in_11\IN (l_pobj) chemotherapy_13\NN (l_prep) of_14\IN (l_pobj) cancer_16\NN
D011188_D006461 NONE K(+_11\NNP (r_pobj) of_10\IN (r_prep) leakage_9\NN (r_pobj) by_7\IN (r_agent) preceded_6\VBN (l_nsubjpass) Hemolysis_0\NNP
D011188_D006461 NONE K(+_11\NNP (r_pobj) of_10\IN (r_prep) leakage_9\NN (r_pobj) by_7\IN (r_agent) preceded_6\VBN (l_prep) excluding_18\VBG (l_pobj) mechanism_24\NN (l_prep) of_25\IN (l_pobj) hemolysis_26\NN
D013629_D000743 CID Tamoxifen_0\NNP (r_nsubj) induces_18\VBZ (l_dobj) changes_19\NNS (l_prep) in_20\IN (l_pobj) shape_23\NN (l_prep) of_24\IN (l_pobj) erythrocytes_25\NNS (l_conj) anemia_28\NN
D013629_D000743 CID TAM_2\NNP (r_appos) Tamoxifen_0\NNP (r_nsubj) induces_18\VBZ (l_dobj) changes_19\NNS (l_prep) in_20\IN (l_pobj) shape_23\NN (l_prep) of_24\IN (l_pobj) erythrocytes_25\NNS (l_conj) anemia_28\NN
D013629_D000743 CID TAM_6\NNP (r_pobj) of_5\IN (r_prep) effects_4\NNS (r_dobj) evaluates_2\VBZ (l_advcl) attempting_12\VBG (l_xcomp) identify_14\VB (l_dobj) mechanisms_17\NNS (l_prep) on_18\IN (l_pobj) anemia_23\NN
D013629_D000743 CID TAM_19\NNP (r_npadvmod) induced_21\VBN (r_amod) anemia_23\NN
D013629_D000743 CID TAM_13\NNP (r_pobj) by_12\IN (r_agent) promoted_11\VBN (r_acl) stability_10\NN (r_dobj) decreased_8\VBD (l_conj) resulting_15\VBG (l_prep) in_16\IN (l_pobj) anemia_18\NN
D010100_D006461 NONE oxygen_7\NN (r_compound) consumption_8\NN (r_pobj) of_6\IN (r_prep) absence_5\NN (r_pobj) by_4\IN (r_agent) evidenced_3\VBN (l_conj) determined_13\VBN (l_prep) in_14\IN (l_pobj) parallel_15\NN (l_prep) with_16\IN (l_pobj) hemolysis_20\NN
D024502_D006461 NONE tocopherol_13\NN (r_pobj) of_10\IN (r_prep) concentrations_9\NNS (r_pobj) by_7\IN (r_agent) prevented_6\VBN (l_nsubjpass) effect_2\NN (l_amod) hemolytic_1\JJ
D024502_D006461 NONE tocopherol_13\NN (r_pobj) of_10\IN (r_prep) concentrations_9\NNS (r_pobj) by_7\IN (r_agent) prevented_6\VBN (l_advcl) indicating_34\VBG (l_ccomp) related_42\VBN (l_nsubjpass) hemolysis_39\NN
D024502_D006461 NONE T_17\NNP (r_appos) tocopherol_13\NN (r_pobj) of_10\IN (r_prep) concentrations_9\NNS (r_pobj) by_7\IN (r_agent) prevented_6\VBN (l_nsubjpass) effect_2\NN (l_amod) hemolytic_1\JJ
D024502_D006461 NONE T_17\NNP (r_appos) tocopherol_13\NN (r_pobj) of_10\IN (r_prep) concentrations_9\NNS (r_pobj) by_7\IN (r_agent) prevented_6\VBN (l_advcl) indicating_34\VBG (l_ccomp) related_42\VBN (l_nsubjpass) hemolysis_39\NN
D024502_D006461 NONE acetate_23\NN (r_conj) concentrations_9\NNS (r_pobj) by_7\IN (r_agent) prevented_6\VBN (l_nsubjpass) effect_2\NN (l_amod) hemolytic_1\JJ
D024502_D006461 NONE acetate_23\NN (r_conj) concentrations_9\NNS (r_pobj) by_7\IN (r_agent) prevented_6\VBN (l_advcl) indicating_34\VBG (l_ccomp) related_42\VBN (l_nsubjpass) hemolysis_39\NN
D024502_D006461 NONE TAc_27\NNS (r_appos) acetate_23\NN (r_conj) concentrations_9\NNS (r_pobj) by_7\IN (r_agent) prevented_6\VBN (l_nsubjpass) effect_2\NN (l_amod) hemolytic_1\JJ
D024502_D006461 NONE TAc_27\NNS (r_appos) acetate_23\NN (r_conj) concentrations_9\NNS (r_pobj) by_7\IN (r_agent) prevented_6\VBN (l_advcl) indicating_34\VBG (l_ccomp) related_42\VBN (l_nsubjpass) hemolysis_39\NN
D024505_D006461 NONE tocopherols_9\NNS (r_pobj) by_8\IN (r_prep) protection_5\NN (l_prep) from_6\IN (l_pobj) hemolysis_7\NN
10683478
D001058_D006948 CID apomorphine_5\NN (r_npadvmod) induced_7\VBN (r_amod) hyperactivity_8\NN
D004298_D007035 NONE dopamine_28\NN (r_relcl) changes_26\NNS (r_dobj) produce_24\VB (r_conj) induce_19\VB (l_dobj) hypothermia_20\NN
D001058_D007035 CID Apomorphine_0\NNP (r_nsubjpass) selected_8\VBN (l_dobj) ability_17\NN (l_acl) induce_19\VB (l_dobj) hypothermia_20\NN
D001058_D007035 CID apomorphine_11\NN (l_prep) as_13\IN (l_pobj) hypothermia_17\NN
D018491_D007035 NONE agonist_5\NN (r_appos) Apomorphine_0\NNP (r_nsubjpass) selected_8\VBN (l_dobj) ability_17\NN (l_acl) induce_19\VB (l_dobj) hypothermia_20\NN
12041669
D000961_D000741 NONE globulin_1\NN (l_prep) in_2\IN (l_pobj) treatment_4\NN (l_prep) of_5\IN (l_pobj) anemia_12\NN
D000961_D000741 NONE globulin_5\NN (r_compound) therapy_6\NN (r_dobj) received_3\VBD (l_prep) for_7\IN (l_pobj) anemia_9\NN
D000961_D000741 NONE globulin_3\NN (r_dobj) Use_0\NN (r_nsubj) be_5\VB (l_attr) treatment_8\NN (l_prep) of_9\IN (l_pobj) anemia_16\NN
D010396_D000741 CID penicillamine_8\NN (r_npadvmod) induced_10\VBN (r_amod) anemia_12\NN
D010396_D000741 CID penicillamine_14\NN (r_compound) therapy_15\NN (r_nsubjpass) described_17\VBN (l_nsubjpass) patient_1\NN (l_relcl) received_3\VBD (l_prep) for_7\IN (l_pobj) anemia_9\NN
D010396_D000741 CID penicillamine_12\NN (r_npadvmod) induced_14\VBN (r_amod) anemia_16\NN
12536034
D020888_D004832 CID vigabatrin_15\NN (r_conj) carbamazepine_13\NN (r_pobj) of_12\IN (r_prep) administration_11\NN (r_pobj) after_10\IN (r_prep) present_2\VBP (l_dobj) patients_4\NNS (l_prep) with_5\IN (l_pobj) epilepsy_9\NN
D005680_D004832 NONE acid_4\NN (r_npadvmod) transmitted_6\VBN (r_amod) circuitry_8\NN (r_compound) accounts_9\VBZ (l_prep) for_10\IN (l_pobj) part_13\NN (l_prep) of_14\IN (l_pobj) neurophysiology_17\NN (l_prep) of_18\IN (l_pobj) epilepsy_21\NN
D002220_D004832 CID carbamazepine_13\NN (r_pobj) of_12\IN (r_prep) administration_11\NN (r_pobj) after_10\IN (r_prep) present_2\VBP (l_dobj) patients_4\NNS (l_prep) with_5\IN (l_pobj) epilepsy_9\NN
10365197
D003042_D019970 NONE cocaine_1\NN (r_npadvmod) dependent_3\JJ (r_amod) outpatients_4\NNS (l_prep) with_5\IN (l_pobj) disorder_10\NN (l_appos) CIMD_12\NNP
D003042_D019970 NONE cocaine_6\NN (r_npadvmod) induced_8\VBN (r_amod) disorder_10\NN (l_appos) CIMD_12\NNP
D003042_D001523 NONE Cocaine_0\NN (r_npadvmod) induced_2\VBN (r_amod) disorder_4\NN (l_appos) rates_7\NNS (l_conj) symptoms_10\NNS (l_amod) psychiatric_9\JJ
D003042_D001523 NONE cocaine_14\NN (r_npadvmod) dependent_16\JJ (r_amod) sample_17\NN (r_pobj) in_11\IN (r_prep) rates_7\NNS (l_conj) symptoms_10\NNS (l_amod) psychiatric_9\JJ
D003042_D001523 NONE cocaine_1\NN (r_npadvmod) dependent_3\JJ (r_amod) outpatients_4\NNS (r_nsubjpass) compared_24\VBN (l_prep) on_25\IN (l_pobj) measures_26\NNS (l_prep) of_27\IN (l_pobj) symptoms_29\NNS (l_amod) psychiatric_28\JJ
D003042_D001523 NONE cocaine_6\NN (r_npadvmod) induced_8\VBN (r_amod) disorder_10\NN (r_pobj) with_5\IN (r_prep) outpatients_4\NNS (r_nsubjpass) compared_24\VBN (l_prep) on_25\IN (l_pobj) measures_26\NNS (l_prep) of_27\IN (l_pobj) symptoms_29\NNS (l_amod) psychiatric_28\JJ
D003042_D019964 CID Cocaine_0\NN (r_npadvmod) induced_2\VBN (r_amod) disorder_4\NN
D003042_D019964 CID cocaine_14\NN (r_npadvmod) dependent_16\JJ (r_amod) sample_17\NN (r_pobj) in_11\IN (r_prep) rates_7\NNS (r_appos) disorder_4\NN
D003042_D019964 CID cocaine_1\NN (r_npadvmod) dependent_3\JJ (r_amod) outpatients_4\NNS (l_prep) with_5\IN (l_pobj) disorder_10\NN
D003042_D019964 CID cocaine_1\NN (r_npadvmod) dependent_3\JJ (r_amod) outpatients_4\NNS (l_conj) disorders_17\NNS
D003042_D019964 CID cocaine_1\NN (r_npadvmod) dependent_3\JJ (r_amod) outpatients_4\NNS (l_conj) disorders_17\NNS (l_conj) disorder_22\NN
D003042_D019964 CID cocaine_6\NN (r_npadvmod) induced_8\VBN (r_amod) disorder_10\NN
D003042_D019964 CID cocaine_6\NN (r_npadvmod) induced_8\VBN (r_amod) disorder_10\NN (r_pobj) with_5\IN (r_prep) outpatients_4\NNS (l_conj) disorders_17\NNS
D003042_D019964 CID cocaine_6\NN (r_npadvmod) induced_8\VBN (r_amod) disorder_10\NN (r_pobj) with_5\IN (r_prep) outpatients_4\NNS (l_conj) disorders_17\NNS (l_conj) disorder_22\NN
16160878
D014579_D001919 NONE II_8\NNP (r_pobj) of_5\IN (r_prep) injection_4\NN (r_nsubj) causes_9\NNS (l_dobj) hypertension_10\NN (l_conj) bradycardia_12\NN
D003345_D010409 NONE corticosterone_35\NN (r_compound) level_36\NN (r_conj) had_12\VBD (l_dobj) erection_25\NN
D014579_D006973 NONE II_8\NNP (r_pobj) of_5\IN (r_prep) injection_4\NN (r_nsubj) causes_9\NNS (l_dobj) hypertension_10\NN
D001058_D010409 CID apomorphine_21\NN (r_npadvmod) induced_23\VBN (r_amod) erection_25\NN
D014579_D001523 NONE II_6\NNP (r_nsubjpass) involved_9\VBN (l_prep) in_10\IN (l_pobj) aspects_12\NNS (l_prep) of_13\IN (l_pobj) disorders_15\NNS
D014579_D010409 NONE II_11\NNP (r_pobj) of_8\IN (r_prep) administration_7\NN (r_nsubj) had_12\VBD (l_dobj) erection_25\NN
2385256
D008274_D009157 CID magnesium_6\NN (r_compound) administration_7\NN (r_pobj) after_5\IN (r_prep) weakness_4\NN (r_pobj) as_3\IN (r_prep) presenting_2\VBG (r_acl) gravis_1\NN
D008274_D009157 CID magnesium_3\NN (r_compound) administration_4\NN (r_pobj) after_2\IN (r_prep) paralysis_1\NN (r_nsubjpass) described_7\VBN (l_prep) in_8\IN (l_pobj) patients_9\NNS (l_prep) with_10\IN (l_pobj) gravis_13\NN
D008274_D009468 NONE magnesium_17\NN (r_compound) administration_18\NN (r_pobj) after_15\IN (r_prep) became_12\VBD (r_relcl) disease_10\NN
D008274_D011782 NONE magnesium_17\NN (r_compound) administration_18\NN (r_pobj) after_15\IN (r_prep) became_12\VBD (l_acomp) quadriplegic_14\JJ
D008274_D010243 NONE magnesium_3\NN (r_compound) administration_4\NN (r_pobj) after_2\IN (r_prep) paralysis_1\NN
D008274_D020511 NONE magnesium_10\NN (r_pobj) of_9\IN (r_prep) effects_8\NNS (r_pobj) to_5\IN (r_prep) sensitive_4\JJ (r_acomp) are_2\VBP (r_relcl) Patients_0\NNS (r_nsubjpass) suspected_13\VBN (l_prep) of_14\IN (l_pcomp) having_15\VBG (l_dobj) disorder_18\NN (l_prep) of_19\IN (l_pobj) transmission_21\NN
D008274_D011225 NONE magnesium_17\NN (r_compound) administration_18\NN (l_prep) for_19\IN (l_pobj) preeclampsia_20\NN
3076126
D009525_D009135 CID niacin_35\NN (r_conj) gemfibrozil_33\NN (r_conj) cyclosporin_31\NN (r_pobj) with_30\IN (r_prep) treated_29\VBN (r_acl) patients_27\NNS (r_pobj) in_26\IN (r_prep) reported_21\VBN (r_conj) associated_2\VBN (r_acl) Myopathy_0\NNP
D015248_D009135 CID gemfibrozil_33\NN (r_conj) cyclosporin_31\NN (r_pobj) with_30\IN (r_prep) treated_29\VBN (r_acl) patients_27\NNS (r_pobj) in_26\IN (r_prep) reported_21\VBN (r_conj) associated_2\VBN (r_acl) Myopathy_0\NNP
D009525_D009212 NONE niacin_35\NN (r_conj) gemfibrozil_33\NN (r_conj) cyclosporin_31\NN (r_pobj) with_30\IN (r_prep) treated_29\VBN (r_acl) patients_27\NNS (r_pobj) in_26\IN (r_prep) reported_21\VBN (r_conj) associated_2\VBN (l_prep) in_3\IN (l_pobj) cases_5\NNS (l_prep) with_6\IN (l_pobj) myoglobinuria_7\NNS
D016572_D009212 NONE cyclosporin_31\NN (r_pobj) with_30\IN (r_prep) treated_29\VBN (r_acl) patients_27\NNS (r_pobj) in_26\IN (r_prep) reported_21\VBN (r_conj) associated_2\VBN (l_prep) in_3\IN (l_pobj) cases_5\NNS (l_prep) with_6\IN (l_pobj) myoglobinuria_7\NNS
D008148_D009135 NONE lovastatin_23\NN (r_pobj) with_22\IN (r_prep) reported_21\VBN (r_conj) associated_2\VBN (r_acl) Myopathy_0\NNP
D009525_D051437 NONE niacin_35\NN (r_conj) gemfibrozil_33\NN (r_conj) cyclosporin_31\NN (r_pobj) with_30\IN (r_prep) treated_29\VBN (r_acl) patients_27\NNS (r_pobj) in_26\IN (r_prep) reported_21\VBN (l_prep) in_10\IN (l_pobj) cases_12\NNS (l_prep) with_13\IN (l_pobj) failure_16\NN
D008148_D051437 CID lovastatin_23\NN (r_pobj) with_22\IN (r_prep) reported_21\VBN (l_prep) in_10\IN (l_pobj) cases_12\NNS (l_prep) with_13\IN (l_pobj) failure_16\NN
D008148_D009212 CID lovastatin_23\NN (r_pobj) with_22\IN (r_prep) reported_21\VBN (r_conj) associated_2\VBN (l_prep) in_3\IN (l_pobj) cases_5\NNS (l_prep) with_6\IN (l_pobj) myoglobinuria_7\NNS
D015248_D051437 NONE gemfibrozil_33\NN (r_conj) cyclosporin_31\NN (r_pobj) with_30\IN (r_prep) treated_29\VBN (r_acl) patients_27\NNS (r_pobj) in_26\IN (r_prep) reported_21\VBN (l_prep) in_10\IN (l_pobj) cases_12\NNS (l_prep) with_13\IN (l_pobj) failure_16\NN
D016572_D009135 CID cyclosporin_31\NN (r_pobj) with_30\IN (r_prep) treated_29\VBN (r_acl) patients_27\NNS (r_pobj) in_26\IN (r_prep) reported_21\VBN (r_conj) associated_2\VBN (r_acl) Myopathy_0\NNP
D016572_D051437 NONE cyclosporin_31\NN (r_pobj) with_30\IN (r_prep) treated_29\VBN (r_acl) patients_27\NNS (r_pobj) in_26\IN (r_prep) reported_21\VBN (l_prep) in_10\IN (l_pobj) cases_12\NNS (l_prep) with_13\IN (l_pobj) failure_16\NN
D015248_D009212 NONE gemfibrozil_33\NN (r_conj) cyclosporin_31\NN (r_pobj) with_30\IN (r_prep) treated_29\VBN (r_acl) patients_27\NNS (r_pobj) in_26\IN (r_prep) reported_21\VBN (r_conj) associated_2\VBN (l_prep) in_3\IN (l_pobj) cases_5\NNS (l_prep) with_6\IN (l_pobj) myoglobinuria_7\NNS
1592014
D003042_D020521 NONE cocaine_8\NN (r_pobj) of_7\IN (r_prep) t1/2_5\NN (r_appos) life_3\NN (r_nsubj) is_9\VBZ (l_conj) occur_29\VB (l_nsubj) some_14\DT (l_prep) of_15\IN (l_pobj) consequences_17\NNS (l_prep) of_18\IN (l_pobj) use_20\NN (l_prep) as_23\IN (l_pobj) seizures_24\NNS (l_conj) strokes_26\NNS
C005618_D012640 CID benzoylecgonine_6\NN (r_pobj) by_2\IN (r_agent) induced_1\VBN (l_nsubj) Seizures_0\NNS
C005618_D012640 CID benzoylecgonine_11\NN (r_appos) metabolite_7\NN (r_pobj) of_4\IN (r_prep) potential_3\NN (r_dobj) evaluated_1\VBD (l_advcl) cause_17\VB (l_dobj) seizures_18\NNS
C005618_D012640 CID BE_13\VB (r_appos) metabolite_7\NN (r_pobj) of_4\IN (r_prep) potential_3\NN (r_dobj) evaluated_1\VBD (l_advcl) cause_17\VB (l_dobj) seizures_18\NNS
C005618_D012640 CID BE_0\VB (r_advmod) Induced_2\VBN (r_amod) seizures_3\NNS
C005618_D012640 CID BE_23\NNP (r_pobj) by_22\IN (r_agent) induced_21\VBN (r_acl) those_20\DT (r_nsubj) were_24\VBD (l_advcl) characterized_7\VBN (l_nsubjpass) seizures_4\NNS
C005618_D012640 CID BE_0\VB (r_advmod) Injected_2\VBN (r_amod) rats_3\NNS (l_relcl) have_7\VB (l_dobj) seizures_8\NNS
C005618_D012640 CID BE_0\VB (r_advmod) Injected_2\VBN (r_amod) rats_3\NNS (r_nsubj) had_9\VBD (l_prep) without_19\IN (l_pobj) seizures_20\NNS
C005618_D012640 CID BE_5\VB (r_advmod) induced_7\VBN (r_conj) cocaine-_3\NN (r_nmod) seizures_8\NNS
C005618_D012640 CID BE_5\VB (r_advmod) induced_7\VBN (r_conj) cocaine-_3\NN (r_nmod) seizures_8\NNS (r_nsubj) differ_9\VBP (r_relcl) finding_1\NN (r_nsubj) suggests_13\VBZ (l_dobj) mechanism_17\NN (l_prep) for_18\IN (l_pobj) seizures_22\NNS
C005618_D012640 CID BE_32\VB (r_conj) emphasizes_24\VBZ (r_conj) suggests_13\VBZ (l_nsubj) finding_1\NN (l_relcl) differ_9\VBP (l_nsubj) seizures_8\NNS
C005618_D012640 CID BE_32\VB (r_conj) emphasizes_24\VBZ (r_conj) suggests_13\VBZ (l_dobj) mechanism_17\NN (l_prep) for_18\IN (l_pobj) seizures_22\NNS
D003042_D003643 NONE cocaine_1\NN (r_npadvmod) induced_3\VBN (r_amod) seizures_4\NNS (r_nsubjpass) characterized_7\VBN (l_conj) resulted_16\VBD (l_prep) in_17\IN (l_pobj) death_18\NN
D003042_D003643 NONE cocaine_1\NN (r_npadvmod) induced_3\VBN (r_amod) seizures_4\NNS (r_nsubjpass) characterized_7\VBN (r_advcl) were_24\VBD (l_conj) resulted_36\VBD (l_prep) in_37\IN (l_pobj) death_38\NN
C005618_D003643 NONE BE_23\NNP (r_pobj) by_22\IN (r_agent) induced_21\VBN (r_acl) those_20\DT (r_nsubj) were_24\VBD (l_advcl) characterized_7\VBN (l_conj) resulted_16\VBD (l_prep) in_17\IN (l_pobj) death_18\NN
C005618_D003643 NONE BE_23\NNP (r_pobj) by_22\IN (r_agent) induced_21\VBN (r_acl) those_20\DT (r_nsubj) were_24\VBD (l_conj) resulted_36\VBD (l_prep) in_37\IN (l_pobj) death_38\NN
D003042_D012640 CID cocaine_4\NN (r_compound) metabolite_5\NN (r_amod) benzoylecgonine_6\NN (r_pobj) by_2\IN (r_agent) induced_1\VBN (l_nsubj) Seizures_0\NNS
D003042_D012640 CID cocaine_8\NN (r_pobj) of_7\IN (r_prep) t1/2_5\NN (r_appos) life_3\NN (r_nsubj) is_9\VBZ (l_conj) occur_29\VB (l_nsubj) some_14\DT (l_prep) of_15\IN (l_pobj) consequences_17\NNS (l_prep) of_18\IN (l_pobj) use_20\NN (l_prep) as_23\IN (l_pobj) seizures_24\NNS
D003042_D012640 CID cocaine_9\NN (r_pobj) of_8\IN (r_prep) metabolite_7\NN (r_pobj) of_4\IN (r_prep) potential_3\NN (r_dobj) evaluated_1\VBD (l_advcl) cause_17\VB (l_dobj) seizures_18\NNS
D003042_D012640 CID cocaine_19\NN (r_pobj) of_18\IN (r_prep) amounts_17\NNS (r_pobj) by_15\IN (r_agent) induced_14\VBN (r_acl) those_13\DT (r_pobj) than_12\IN (r_prep) latencies_11\NNS (r_dobj) had_8\VBD (r_conj) occurred_4\VBD (l_nsubj) seizures_3\NNS
D003042_D012640 CID cocaine_1\NN (r_npadvmod) induced_3\VBN (r_amod) seizures_4\NNS
D003042_D012640 CID cocaine_15\NN (r_npadvmod) injected_17\VBN (r_amod) animals_18\NNS (r_pobj) than_14\IN (r_prep) activity_13\NN (r_dobj) had_9\VBD (l_nsubj) rats_3\NNS (l_relcl) have_7\VB (l_dobj) seizures_8\NNS
D003042_D012640 CID cocaine_15\NN (r_npadvmod) injected_17\VBN (r_amod) animals_18\NNS (r_pobj) than_14\IN (r_prep) activity_13\NN (r_dobj) had_9\VBD (l_prep) without_19\IN (l_pobj) seizures_20\NNS
D003042_D012640 CID cocaine-_3\NN (r_nmod) seizures_8\NNS
D003042_D012640 CID cocaine-_3\NN (r_nmod) seizures_8\NNS (r_nsubj) differ_9\VBP (r_relcl) finding_1\NN (r_nsubj) suggests_13\VBZ (l_dobj) mechanism_17\NN (l_prep) for_18\IN (l_pobj) seizures_22\NNS
D003042_D012640 CID cocaine_19\NN (r_npadvmod) induced_21\VBN (r_amod) seizures_22\NNS (r_pobj) for_18\IN (r_prep) mechanism_17\NN (r_dobj) suggests_13\VBZ (l_nsubj) finding_1\NN (l_relcl) differ_9\VBP (l_nsubj) seizures_8\NNS
D003042_D012640 CID cocaine_19\NN (r_npadvmod) induced_21\VBN (r_amod) seizures_22\NNS
D003042_D012640 CID cocaine_29\NN (r_compound) metabolite_30\NN (r_pobj) of_27\IN (r_prep) importance_26\NN (r_dobj) emphasizes_24\VBZ (r_conj) suggests_13\VBZ (l_nsubj) finding_1\NN (l_relcl) differ_9\VBP (l_nsubj) seizures_8\NNS
D003042_D012640 CID cocaine_29\NN (r_compound) metabolite_30\NN (r_pobj) of_27\IN (r_prep) importance_26\NN (r_dobj) emphasizes_24\VBZ (r_conj) suggests_13\VBZ (l_dobj) mechanism_17\NN (l_prep) for_18\IN (l_pobj) seizures_22\NNS
1867351
D015767_D008288 NONE mefloquine_10\NN (r_pobj) with_9\IN (r_prep) treatment_8\NN (r_conj) prophylaxis_6\NN (l_compound) malaria_5\NN
21029050
D013390_D001049 CID succinylcholine_9\NN (r_pobj) after_8\IN (r_prep) mutations_2\NNS (l_prep) in_3\IN (l_pobj) patients_4\NNS (l_prep) with_5\IN (l_pobj) apnea_7\NN
D013390_D001049 CID succinylcholine_11\NN (r_pobj) of_10\IN (r_prep) action_9\NN (r_pobj) of_8\IN (r_prep) duration_7\NN (r_pobj) with_4\IN (r_prep) patients_3\NNS (r_pobj) of_1\IN (r_prep) eleven_0\CD (r_nsubj) had_12\VBD (l_advcl) indicating_17\VBG (l_ccomp) is_20\VBZ (l_attr) reason_23\NN (l_prep) for_24\IN (l_pobj) period_27\NN (l_prep) of_28\IN (l_pobj) apnea_29\NN
322550
D009599_D007022 CID nitroprusside_8\RB (r_advmod) induced_10\VBN (r_amod) hypotension_11\NN
D009599_D007022 CID nitroprusside_1\JJ (r_amod) infusion_2\NN (r_nsubj) produced_3\VBD (l_dobj) decrease_6\NN (l_prep) in_7\IN (l_pobj) pressure_10\NN
D009599_D007022 CID Nitroprusside_0\NNP (r_nsubj) caused_1\VBD (l_dobj) decreases_3\NNS (l_prep) in_4\IN (l_pobj) pressure_7\NN
D009599_D007022 NONE nitroprusside_1\JJ (r_amod) levels_4\NNS (r_pobj) During_0\IN (r_prep) alter_10\VB (l_conj) produce_31\VBP (l_dobj) decreases_33\NNS (l_prep) in_34\IN (l_pobj) pressure_37\NN (l_conj) output_40\NN
D014867_D002303 NONE H2O_22\NNP (r_punct) levels_16\NNS (r_conj) alter_10\VB (l_conj) produce_31\VBP (l_dobj) decreases_33\NNS (l_prep) in_34\IN (l_pobj) pressure_37\NN (l_conj) output_40\NN
D014867_D007022 NONE H2O_22\NNP (r_punct) levels_16\NNS (r_conj) alter_10\VB (l_conj) produce_31\VBP (l_dobj) decreases_33\NNS (l_prep) in_34\IN (l_pobj) pressure_37\NN (l_conj) output_40\NN
D009599_D002303 NONE nitroprusside_1\JJ (r_amod) infusion_2\NN (r_nsubj) produced_3\VBD (l_conj) increased_13\VBN (l_conj) decreased_17\VBD (l_dobj) output_19\NN
D009599_D002303 NONE nitroprusside_1\JJ (r_amod) levels_4\NNS (r_pobj) During_0\IN (r_prep) alter_10\VB (l_conj) produce_31\VBP (l_dobj) decreases_33\NNS (l_prep) in_34\IN (l_pobj) pressure_37\NN (l_conj) output_40\NN
3031535
D006220_D002375 CID haloperidol_28\NN (r_pobj) by_27\IN (r_agent) induced_26\VBN (r_advcl) are_22\VBP (r_advcl) have_6\VBP (l_dobj) role_9\NN (l_prep) in_10\IN (l_pobj) manifestation_12\NN (l_prep) of_13\IN (l_pobj) catalepsy_14\NN
D006220_D002375 CID haloperidol_28\NN (r_pobj) by_27\IN (r_agent) induced_26\VBN (r_advcl) are_22\VBP (l_prep) in_24\IN (l_pobj) catalepsy_25\NN
D013759_D002375 CID 9-tetrahydrocannabinol_7\NN (r_pobj) by_5\IN (r_agent) induced_4\VBN (l_nsubj) involvement_1\NN (l_prep) in_2\IN (l_pobj) catalepsy_3\NN
D013759_D002375 CID THC_17\NNP (r_pobj) by_16\IN (r_agent) induced_15\VBN (r_acl) manifestation_12\NN (l_prep) of_13\IN (l_pobj) catalepsy_14\NN
D013759_D002375 CID THC_17\NNP (r_pobj) by_16\IN (r_agent) induced_15\VBN (r_acl) manifestation_12\NN (r_pobj) in_10\IN (r_prep) role_9\NN (r_dobj) have_6\VBP (l_advcl) are_22\VBP (l_prep) in_24\IN (l_pobj) catalepsy_25\NN
9284778
D017402_D008107 NONE chlorofluorocarbons_14\NNS (r_pobj) of_13\IN (r_prep) substitutes_12\NNS (r_pobj) as_8\IN (r_prep) used_7\VBN (r_acl) hydrochlorofluorocarbons_6\NNS (r_pobj) by_5\IN (r_agent) caused_4\VBN (r_acl) Epidemic_0\NN (l_prep) of_1\IN (l_pobj) disease_3\NN
D006221_D056486 NONE 1-bromo-1-chloro-2,2,2-trifluoroethane_9\CD (r_pobj) as_8\IN (r_prep) way_7\NN (r_pobj) in_4\IN (r_prep) metabolised_3\VBN (l_advcl) form_14\VB (l_dobj) intermediates_18\NNS (l_relcl) implicated_23\VBN (l_prep) in_24\IN (l_pobj) hepatotoxicity_26\NN
D006221_D056486 NONE halothane_11\NN (r_appos) 1-bromo-1-chloro-2,2,2-trifluoroethane_9\CD (r_pobj) as_8\IN (r_prep) way_7\NN (r_pobj) in_4\IN (r_prep) metabolised_3\VBN (l_advcl) form_14\VB (l_dobj) intermediates_18\NNS (l_relcl) implicated_23\VBN (l_prep) in_24\IN (l_pobj) hepatotoxicity_26\NN
D006221_D056486 NONE halothane_28\NN (r_pobj) of_27\IN (r_prep) hepatotoxicity_26\NN
C072959_D008107 CID 1-chloro-1,2,2,2-tetrafluoroethane_27\NN (r_conj) HCFC_23\NNP (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD (r_pobj) of_20\IN (r_prep) mixture_19\NN (r_pobj) to_17\IN (r_prep) exposure_16\NN (r_dobj) repeated_14\VBN (r_relcl) workers_10\NNS (r_pobj) in_7\IN (r_prep) epidemic_3\NN (l_prep) of_4\IN (l_pobj) disease_6\NN
C072959_D008107 CID 124_30\CD (r_nummod) HCFC_29\NNP (r_appos) HCFC_23\NNP (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD (r_pobj) of_20\IN (r_prep) mixture_19\NN (r_pobj) to_17\IN (r_prep) exposure_16\NN (r_dobj) repeated_14\VBN (r_relcl) workers_10\NNS (r_pobj) in_7\IN (r_prep) epidemic_3\NN (l_prep) of_4\IN (l_pobj) disease_6\NN
C072959_D008107 CID 124_8\CD (r_conj) HCFCs_5\NNS (r_nsubj) result_10\VB (l_prep) in_11\IN (l_pobj) disease_14\NN
D014269_D056486 NONE trifluoroacetyl_16\NNS (r_compound) halide_17\NN (r_compound) intermediates_18\NNS (l_relcl) implicated_23\VBN (l_prep) in_24\IN (l_pobj) hepatotoxicity_26\NN
D014269_D056486 NONE trifluoroacetyl_17\NN (r_npadvmod) altered_19\VBN (r_amod) proteins_21\NNS (r_nsubjpass) involved_23\VBN (r_ccomp) suggest_15\VBP (l_advcl) known_11\VBN (l_nsubjpass) mechanism_3\NN (l_prep) of_4\IN (l_pobj) hepatotoxicity_5\NN
C067411_D056486 NONE 124_9\CD (r_conj) HCFCs_6\NNS (r_pobj) to_5\IN (r_prep) exposure_1\NN (r_nsubj) result_11\VB (l_prep) in_12\IN (l_pobj) injury_15\NN
C072959_D056486 NONE 124_9\CD (r_conj) HCFCs_6\NNS (r_pobj) to_5\IN (r_prep) exposure_1\NN (r_nsubj) result_11\VB (l_prep) in_12\IN (l_pobj) injury_15\NN
-1_D008107 NONE hydrochlorofluorocarbons_6\NNS (r_pobj) by_5\IN (r_agent) caused_4\VBN (r_acl) Epidemic_0\NN (l_prep) of_1\IN (l_pobj) disease_3\NN
D010126_D008107 NONE ozone_9\NN (r_npadvmod) sparing_11\VBG (r_amod) substitutes_12\NNS (r_pobj) as_8\IN (r_prep) used_7\VBN (r_acl) hydrochlorofluorocarbons_6\NNS (r_pobj) by_5\IN (r_agent) caused_4\VBN (r_acl) Epidemic_0\NN (l_prep) of_1\IN (l_pobj) disease_3\NN
C067411_D008107 CID 1,1-dichloro-2,2,2-trifluoroethane_21\CD (r_pobj) of_20\IN (r_prep) mixture_19\NN (r_pobj) to_17\IN (r_prep) exposure_16\NN (r_dobj) repeated_14\VBN (r_relcl) workers_10\NNS (r_pobj) in_7\IN (r_prep) epidemic_3\NN (l_prep) of_4\IN (l_pobj) disease_6\NN
C067411_D008107 CID 123_24\CD (r_nummod) HCFC_23\NNP (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD (r_pobj) of_20\IN (r_prep) mixture_19\NN (r_pobj) to_17\IN (r_prep) exposure_16\NN (r_dobj) repeated_14\VBN (r_relcl) workers_10\NNS (r_pobj) in_7\IN (r_prep) epidemic_3\NN (l_prep) of_4\IN (l_pobj) disease_6\NN
C067411_D008107 CID 124_8\CD (r_conj) HCFCs_5\NNS (r_nsubj) result_10\VB (l_prep) in_11\IN (l_pobj) disease_14\NN
8752018
D008094_D001714 NONE Lithium_0\NN (r_nsubj) remains_1\VBZ (l_attr) treatment_6\NN (l_prep) for_7\IN (l_pobj) treatment_12\NN (l_prep) of_13\IN (l_pobj) disorder_15\NN
D008094_D001714 NONE lithium_10\NN (r_pobj) from_9\IN (r_prep) switching_6\VBG (l_dobj) patients_8\NNS (l_amod) bipolar_7\JJ
D008094_D001714 NONE lithium_8\NN (r_pobj) of_7\IN (r_prep) substitution_6\NN (r_nsubj) was_18\VBD (l_acomp) helpful_20\JJ (l_prep) in_21\IN (l_pcomp) reducing_22\VBG (l_dobj) cognitive_24\JJ (l_acl) attributed_31\VBN (l_prep) to_32\IN (l_pobj) lithium_33\NN (l_prep) in_34\IN (l_pobj) patients_37\NNS (l_amod) bipolar_36\JJ
D008094_D001714 NONE lithium_33\NN (l_prep) in_34\IN (l_pobj) patients_37\NNS (l_amod) bipolar_36\JJ
D008094_D001714 NONE lithium_12\NN (l_prep) in_13\IN (l_pobj) patients_15\NNS (l_amod) bipolar_14\JJ
D008094_D011141 NONE lithium_15\NN (r_pobj) of_14\IN (r_prep) effects_13\NNS (l_prep) as_18\IN (l_pobj) polyuria_19\NN
D008094_D011141 NONE lithium_25\NN (r_compound) effects_27\NNS (r_nsubj) remain_40\VBP (l_advcl) written_4\VBN (l_prep) about_5\IN (l_pobj) management_7\NN (l_prep) of_8\IN (l_pobj) effects_13\NNS (l_prep) as_18\IN (l_pobj) polyuria_19\NN
D014635_D003072 NONE sodium_13\NN (r_dobj) divalproex_12\NN (r_advcl) reduced_7\VBN (r_acl) deficits_6\NNS
D014635_D003072 NONE sodium_13\NN (r_dobj) divalproex_12\NN (l_xcomp) alleviate_15\VB (l_dobj) impairments_20\NNS
D014635_D003072 NONE sodium_17\NN (r_pobj) with_15\IN (r_prep) substitution_6\NN (r_nsubj) was_18\VBD (l_acomp) helpful_20\JJ (l_prep) in_21\IN (l_pcomp) reducing_22\VBG (l_dobj) cognitive_24\JJ (l_conj) motivational_26\JJ (l_conj) deficits_30\NNS
D014635_D003072 NONE sodium_6\NN (r_nsubj) was_7\VBD (l_attr) alternative_10\NN (l_prep) to_11\IN (l_pobj) lithium_12\NN (l_prep) in_13\IN (l_pobj) patients_15\NNS (l_acl) experiencing_16\VBG (l_dobj) deficits_18\NNS
D014635_D003072 NONE sodium_6\NN (r_nsubj) was_7\VBD (l_attr) alternative_10\NN (l_prep) to_11\IN (l_pobj) lithium_12\NN (l_prep) in_13\IN (l_pobj) patients_15\NNS (l_acl) experiencing_16\VBG (l_dobj) deficits_18\NNS (l_conj) loss_20\NN (l_prep) of_21\IN (l_pobj) creativity_22\NN
D014635_D003072 NONE sodium_6\NN (r_nsubj) was_7\VBD (l_attr) alternative_10\NN (l_prep) to_11\IN (l_pobj) lithium_12\NN (l_prep) in_13\IN (l_pobj) patients_15\NNS (l_acl) experiencing_16\VBG (l_dobj) deficits_18\NNS (l_conj) loss_20\NN (l_prep) of_21\IN (l_pobj) creativity_22\NN (l_conj) impairments_26\NNS
D014635_D001714 NONE sodium_13\NN (r_dobj) divalproex_12\NN (r_advcl) switching_6\VBG (l_dobj) patients_8\NNS (l_amod) bipolar_7\JJ
D014635_D001714 NONE sodium_17\NN (r_pobj) with_15\IN (r_prep) substitution_6\NN (r_nsubj) was_18\VBD (l_acomp) helpful_20\JJ (l_prep) in_21\IN (l_pcomp) reducing_22\VBG (l_dobj) cognitive_24\JJ (l_acl) attributed_31\VBN (l_prep) to_32\IN (l_pobj) lithium_33\NN (l_prep) in_34\IN (l_pobj) patients_37\NNS (l_amod) bipolar_36\JJ
D014635_D001714 NONE sodium_6\NN (r_nsubj) was_7\VBD (l_attr) alternative_10\NN (l_prep) to_11\IN (l_pobj) lithium_12\NN (l_prep) in_13\IN (l_pobj) patients_15\NNS (l_amod) bipolar_14\JJ
D008094_D003072 CID Lithium_0\NN (r_npadvmod) associated_2\VBN (r_amod) deficits_6\NNS
D008094_D003072 CID lithium_15\NN (r_pobj) of_14\IN (r_prep) effects_13\NNS (r_pobj) of_8\IN (r_prep) management_7\NN (r_pobj) about_5\IN (r_prep) written_4\VBN (r_advcl) remain_40\VBP (l_nsubj) effects_27\NNS (l_prep) as_29\IN (l_pobj) deficits_31\NNS
D008094_D003072 CID lithium_15\NN (r_pobj) of_14\IN (r_prep) effects_13\NNS (r_pobj) of_8\IN (r_prep) management_7\NN (r_pobj) about_5\IN (r_prep) written_4\VBN (r_advcl) remain_40\VBP (l_nsubj) effects_27\NNS (l_prep) as_29\IN (l_pobj) deficits_31\NNS (l_conj) loss_33\NN (l_prep) of_34\IN (l_pobj) creativity_35\NN
D008094_D003072 CID lithium_15\NN (r_pobj) of_14\IN (r_prep) effects_13\NNS (r_pobj) of_8\IN (r_prep) management_7\NN (r_pobj) about_5\IN (r_prep) written_4\VBN (r_advcl) remain_40\VBP (l_nsubj) effects_27\NNS (l_prep) as_29\IN (l_pobj) deficits_31\NNS (l_conj) loss_33\NN (l_conj) impairments_39\NNS
D008094_D003072 CID lithium_25\NN (r_compound) effects_27\NNS (l_prep) as_29\IN (l_pobj) deficits_31\NNS
D008094_D003072 CID lithium_25\NN (r_compound) effects_27\NNS (l_prep) as_29\IN (l_pobj) deficits_31\NNS (l_conj) loss_33\NN (l_prep) of_34\IN (l_pobj) creativity_35\NN
D008094_D003072 CID lithium_25\NN (r_compound) effects_27\NNS (l_prep) as_29\IN (l_pobj) deficits_31\NNS (l_conj) loss_33\NN (l_conj) impairments_39\NNS
D008094_D003072 CID lithium_10\NN (r_pobj) from_9\IN (r_prep) switching_6\VBG (l_advcl) divalproex_12\NN (l_xcomp) alleviate_15\VB (l_dobj) impairments_20\NNS
D008094_D003072 CID lithium_8\NN (r_pobj) of_7\IN (r_prep) substitution_6\NN (r_nsubj) was_18\VBD (l_acomp) helpful_20\JJ (l_prep) in_21\IN (l_pcomp) reducing_22\VBG (l_dobj) cognitive_24\JJ (l_conj) motivational_26\JJ (l_conj) deficits_30\NNS
D008094_D003072 CID lithium_33\NN (r_pobj) to_32\IN (r_prep) attributed_31\VBN (r_acl) cognitive_24\JJ (l_conj) motivational_26\JJ (l_conj) deficits_30\NNS
D008094_D003072 CID lithium_12\NN (l_prep) in_13\IN (l_pobj) patients_15\NNS (l_acl) experiencing_16\VBG (l_dobj) deficits_18\NNS
D008094_D003072 CID lithium_12\NN (l_prep) in_13\IN (l_pobj) patients_15\NNS (l_acl) experiencing_16\VBG (l_dobj) deficits_18\NNS (l_conj) loss_20\NN (l_prep) of_21\IN (l_pobj) creativity_22\NN
D008094_D003072 CID lithium_12\NN (l_prep) in_13\IN (l_pobj) patients_15\NNS (l_acl) experiencing_16\VBG (l_dobj) deficits_18\NNS (l_conj) loss_20\NN (l_prep) of_21\IN (l_pobj) creativity_22\NN (l_conj) impairments_26\NNS
D008094_D014202 NONE lithium_15\NN (r_pobj) of_14\IN (r_prep) effects_13\NNS (l_prep) as_18\IN (l_pobj) polyuria_19\NN (l_conj) tremor_21\NN
D008094_D014202 NONE lithium_25\NN (r_compound) effects_27\NNS (r_nsubj) remain_40\VBP (l_advcl) written_4\VBN (l_prep) about_5\IN (l_pobj) management_7\NN (l_prep) of_8\IN (l_pobj) effects_13\NNS (l_prep) as_18\IN (l_pobj) polyuria_19\NN (l_conj) tremor_21\NN
7516729
D014700_D001919 CID verapamil_6\NN (r_pobj) by_5\IN (r_agent) induced_4\VBN (r_acl) bradycardia_3\NNS
6727060
D008787_D005767 NONE metoclopramide_23\RB (r_dobj) took_22\VBD (l_prep) for_24\IN (l_pobj) disorder_26\NN
D008787_D004409 CID metoclopramide_7\NN (r_pobj) by_6\IN (r_agent) caused_5\VBN (r_acl) dyskinesia_4\JJ
D008787_D004409 CID metoclopramide_23\RB (r_dobj) took_22\VBD (r_advcl) appeared_3\VBD (l_nsubj) movements_2\NNS
D008787_D004409 CID metoclopramide_2\JJ (r_compound) administration_3\NN (r_nsubjpass) discontinued_5\VBN (r_advcl) improved_11\VBD (l_nsubj) movements_9\NNS
983936
D006854_D009202 NONE hydrocortisone_8\NN (l_prep) on_9\IN (l_pobj) injury_14\NN
D001241_D009202 NONE acid_3\NN (l_conj) dipyridamole_5\NN (l_conj) hydrocortisone_8\NN (l_prep) on_9\IN (l_pobj) injury_14\NN
D004837_D009203 NONE epinephrine_9\NN (r_amod) infusion_10\NN (r_appos) injury_7\NN (r_dobj) producing_4\VBG (r_pcomp) for_3\IN (r_prep) model_2\NN (r_nsubjpass) developed_14\VBN (l_advcl) study_16\VB (l_dobj) effects_19\NNS (l_prep) of_20\IN (l_pobj) agents_21\NNS (l_relcl) alter_26\VB (l_dobj) evolution_28\NN (l_prep) of_29\IN (l_pobj) infarction_32\NN
D004837_D009202 CID epinephrine_10\NN (r_npadvmod) induced_12\VBN (r_amod) injury_14\NN
D004837_D009202 CID epinephrine_9\NN (r_amod) infusion_10\NN (r_appos) injury_7\NN
D004176_D009202 NONE dipyridamole_5\NN (l_conj) hydrocortisone_8\NN (l_prep) on_9\IN (l_pobj) injury_14\NN
11431197
D011899_D009395 CID Ranitidine_0\NNP (r_npadvmod) induced_2\VBN (r_amod) nephritis_5\NN
D011899_D009395 CID ranitidine_5\NN (r_npadvmod) induced_7\VBN (r_amod) nephritis_10\NN
12757899
D012834_D013226 NONE silver_3\NN (r_npadvmod) stained_5\VBN (r_amod) CA3_6\NN (r_pobj) of_2\IN (r_prep) extent_1\NN (r_nsubjpass) evaluated_12\VBN (l_prep) after_15\IN (l_pobj) SE_16\NNP
D008094_D013226 CID lithium_17\NN (r_compound) pilocarpine_19\NN (r_npadvmod) induced_21\VBN (r_amod) SE_22\NNP
D004958_D001930 NONE Estradiol_0\NN (r_nsubj) reduces_1\VBZ (l_dobj) injury_6\NN
D004958_D013226 NONE estradiol_7\NN (r_pobj) of_4\IN (r_prep) effects_3\NNS (l_conj) rats_14\NNS (l_acl) subjected_15\VBN (l_prep) to_16\IN (l_pobj) SE_22\NNP
D007608_D013226 NONE acid_10\NN (r_npadvmod) induced_12\VBN (r_amod) status_13\NN (l_appos) SE_16\NNP (l_amod) epilepticus_14\NN
D007608_D013226 NONE acid_10\NN (r_npadvmod) induced_12\VBN (r_amod) status_13\NN (l_appos) SE_16\NNP
D004958_D012640 NONE Estradiol_0\NN (r_nsubj) reduces_1\VBZ (l_dobj) injury_6\NN (l_amod) induced_4\VBN (l_npadvmod) seizure_2\NN
D004958_D012640 NONE estradiol_7\NN (r_pobj) of_6\IN (r_prep) effects_5\NNS (l_prep) on_8\IN (l_pobj) threshold_10\NN (l_compound) seizure_9\NN
D007608_D001930 NONE acid_10\NN (r_npadvmod) induced_12\VBN (r_amod) status_13\NN (r_pobj) by_8\IN (r_agent) induced_7\VBN (r_advcl) protect_1\VBP (l_dobj) rats_3\NNS (l_prep) from_4\IN (l_pobj) injury_6\NN
D010862_D013226 CID pilocarpine_19\NN (r_npadvmod) induced_21\VBN (r_amod) SE_22\NNP
8073369
D009538_D002543 CID nicotine_30\NN (r_nmod) chicks_34\NNS (r_pobj) in_28\IN (r_prep) occurred_27\VBD (l_nsubj) hemorrhage_26\NN
C007112_D001176 CID coniine_2\NN (r_nsubj) failed_4\VBN (l_xcomp) produce_6\VB (l_dobj) arthrogryposis_7\NN
C007112_D001176 CID coniine_15\RB (r_npadvmod) induced_17\VBN (r_amod) arthrogryposis_18\NN
D009538_D009140 NONE nicotine_7\NN (r_compound) sulfate_8\NN (r_conj) coniine_5\NN (r_pobj) by_3\IN (r_agent) caused_2\VBN (r_acl) deformations_1\NNS
D009538_D009140 NONE nicotine_7\NN (r_compound) sulfate_8\NN (r_conj) coniine_5\NN (r_pobj) by_3\IN (r_agent) caused_2\VBN (r_acl) deformations_1\NNS (r_nsubj) were_9\VBD (l_attr) flexion_11\NN (l_prep) of_14\IN (l_pobj) toes_18\NNS
C007112_D009140 NONE coniine_5\NN (r_pobj) by_3\IN (r_agent) caused_2\VBN (r_acl) deformations_1\NNS
C007112_D009140 NONE coniine_5\NN (r_pobj) by_3\IN (r_agent) caused_2\VBN (r_acl) deformations_1\NNS (r_nsubj) were_9\VBD (l_attr) flexion_11\NN (l_prep) of_14\IN (l_pobj) toes_18\NNS
15863244
D010894_D006345 NONE piroxicam_23\NN (r_nmod) inhibitor_31\NN (r_pobj) to_22\IN (r_prep) exposed_21\VBN (r_acl) fetuses_20\NNS (r_pobj) for_18\IN (r_prep) performed_17\VBN (l_nsubjpass) analysis_3\NN (l_prep) for_4\IN (l_pobj) defects_15\NNS
D010894_D009139 CID piroxicam_24\NN (r_pobj) of_23\IN (r_prep) dose_22\NN (r_pobj) with_19\IN (r_prep) treated_18\VBN (r_acl) rats_17\NNS (r_pobj) in_16\IN (r_prep) found_15\VBN (l_nsubjpass) toxicity_1\NN (l_appos) retardation_5\NN (l_conj) increase_8\NN (l_prep) of_9\IN (l_pobj) variations_13\NNS
D010894_D064420 NONE piroxicam_19\NN (r_compound) study_20\NN (r_conj) DFU_17\NNP (r_appos) inhibitors_11\NNS (r_pobj) of_4\IN (r_prep) toxicity_3\NN
D010894_D064420 NONE piroxicam_17\NN (r_pobj) of_11\IN (r_prep) toxicity_10\NN
D010894_D064420 NONE piroxicam_24\NN (r_pobj) of_23\IN (r_prep) dose_22\NN (r_pobj) with_19\IN (r_prep) treated_18\VBN (r_acl) rats_17\NNS (r_pobj) in_16\IN (r_prep) found_15\VBN (l_nsubjpass) toxicity_1\NN
C106876_D064420 NONE DFU_17\NNP (r_appos) inhibitors_11\NNS (r_pobj) of_4\IN (r_prep) toxicity_3\NN
C106876_D064420 NONE DFU_22\NNP (r_conj) toxicity_10\NN
C106876_D064420 NONE phenyl-2(5H)-furanon_26\XX (l_ccomp) was_5\VBD (l_xcomp) evaluate_7\VB (l_dobj) toxicity_10\NN
C106876_D064420 NONE DFU_10\NNP (r_nmod) toxicity_12\NN
D010894_D009436 NONE piroxicam_23\NN (r_nmod) inhibitor_31\NN (r_pobj) to_22\IN (r_prep) exposed_21\VBN (r_acl) fetuses_20\NNS (r_pobj) for_18\IN (r_prep) performed_17\VBN (l_nsubjpass) analysis_3\NN (l_prep) for_4\IN (l_pobj) defects_15\NNS
D010894_D005317 CID piroxicam_24\NN (r_pobj) of_23\IN (r_prep) dose_22\NN (r_pobj) with_19\IN (r_prep) treated_18\VBN (r_acl) rats_17\NNS (r_pobj) in_16\IN (r_prep) found_15\VBN (l_nsubjpass) toxicity_1\NN (l_appos) retardation_5\NN
9495837
D012601_D000647 CID scopolamine_18\NN (r_pobj) by_17\IN (r_agent) induced_16\VBN (r_acl) amnesia_15\NN
D004025_D000647 CID dicyclomine_26\NN (r_conj) kg-1_22\NNP (r_appos) scopolamine_18\NN (r_pobj) by_17\IN (r_agent) induced_16\VBN (r_acl) amnesia_15\NN
D000109_D000647 NONE acetylcholine_73\NN (r_amod) levels_75\NNS (r_pobj) in_72\IN (r_prep) increase_71\NN (r_pobj) through_69\IN (r_prep) /-)-PG-9_68\NFP (r_punct) shown_44\VBN (l_dobj) ratio_48\NN (l_relcl) be_53\VB (l_acomp) responsible_54\JJ (l_prep) for_55\IN (l_pobj) antinociception_57\NN (l_conj) effect_63\NN (l_amod) amnesic_62\JJ
C087567_D000647 NONE /-)-PG-9_2\. (r_nsubj) was_11\VBD (l_acomp) able_12\JJ (l_xcomp) prevent_14\VB (l_dobj) amnesia_15\NN
C087567_D000647 NONE /-)-PG-9_5\NFP (r_conj) of_2\IN (r_prep) profiles_1\NNS (r_nsubj) shown_44\VBN (l_dobj) ratio_48\NN (l_relcl) be_53\VB (l_acomp) responsible_54\JJ (l_prep) for_55\IN (l_pobj) antinociception_57\NN (l_conj) effect_63\NN (l_amod) amnesic_62\JJ
C087567_D000647 NONE /-)-PG-9_68\NFP (r_punct) shown_44\VBN (l_dobj) ratio_48\NN (l_relcl) be_53\VB (l_acomp) responsible_54\JJ (l_prep) for_55\IN (l_pobj) antinociception_57\NN (l_conj) effect_63\NN (l_amod) amnesic_62\JJ
11875660
D001374_D009436 NONE 5-azacytidine_6\NN (r_pobj) by_5\IN (r_agent) induced_4\VBN (r_acl) exencephaly_3\NNS
17532790
D001971_D010300 NONE bromocriptine_36\NN (r_conj) DOPA_34\NNP (r_appos) changes_8\NNS (l_acl) occurring_9\VBG (l_prep) at_10\IN (l_pobj) level_13\NN (l_acl) obtained_17\VBN (l_prep) from_18\IN (l_pobj) model_25\NN (l_prep) of_26\IN (l_pobj) PD_27\NNP
D007980_D004409 CID DOPA_12\NNP (r_npadvmod) induced_14\VBN (r_amod) dyskinesia_15\NN
D007980_D004409 CID DOPA_2\NNP (r_npadvmod) induced_4\VBN (r_amod) dyskinesia_5\NN
D007980_D004409 CID DOPA_2\NNP (r_npadvmod) induced_4\VBN (r_amod) dyskinesia_5\NN (l_appos) LID_7\NNP
D007980_D004409 CID DOPA_31\NNP (r_pobj) with_28\IN (r_prep) treatment_27\NN (r_pobj) after_24\IN (r_prep) arise_15\VBP (r_relcl) complications_13\NNS (r_pobj) among_10\IN (r_prep) is_9\VBZ (l_nsubj) dyskinesia_5\NN
D007980_D004409 CID DOPA_31\NNP (r_pobj) with_28\IN (r_prep) treatment_27\NN (r_pobj) after_24\IN (r_prep) arise_15\VBP (r_relcl) complications_13\NNS (r_pobj) among_10\IN (r_prep) is_9\VBZ (l_nsubj) dyskinesia_5\NN (l_appos) LID_7\NNP
D007980_D004409 CID DOPA_5\NNP (r_pobj) with_2\IN (r_prep) treated_1\VBD (l_conj) allocated_7\VBN (l_prep) to_8\IN (l_pobj) groups_10\NNS (l_acl) based_11\VBN (l_prep) on_12\IN (l_pobj) presence_14\NN (l_conj) absence_16\NN (l_prep) of_17\IN (l_pobj) LID_18\NNP
D016627_D010300 NONE 6-hydroxydopamine_21\CD (r_compound) lesion_23\NN (r_compound) rat_24\NN (r_compound) model_25\NN (l_prep) of_26\IN (l_pobj) PD_27\NNP
D007980_D010300 NONE DOPA_2\NNP (r_npadvmod) induced_4\VBN (r_amod) dyskinesia_5\NN (r_nsubj) is_9\VBZ (l_prep) among_10\IN (l_pobj) complications_13\NNS (l_relcl) arise_15\VBP (l_prep) in_16\IN (l_pobj) patients_23\NNS (l_nmod) disease_19\NN
D007980_D010300 NONE DOPA_2\NNP (r_npadvmod) induced_4\VBN (r_amod) dyskinesia_5\NN (r_nsubj) is_9\VBZ (l_prep) among_10\IN (l_pobj) complications_13\NNS (l_relcl) arise_15\VBP (l_prep) in_16\IN (l_pobj) patients_23\NNS (l_nmod) PD_21\NNP
D007980_D010300 NONE DOPA_31\NNP (r_pobj) with_28\IN (r_prep) treatment_27\NN (r_pobj) after_24\IN (r_prep) arise_15\VBP (l_prep) in_16\IN (l_pobj) patients_23\NNS (l_nmod) disease_19\NN
D007980_D010300 NONE DOPA_31\NNP (r_pobj) with_28\IN (r_prep) treatment_27\NN (r_pobj) after_24\IN (r_prep) arise_15\VBP (l_prep) in_16\IN (l_pobj) patients_23\NNS (l_nmod) PD_21\NNP
D007980_D010300 NONE DOPA_34\NNP (r_appos) changes_8\NNS (l_acl) occurring_9\VBG (l_prep) at_10\IN (l_pobj) level_13\NN (l_acl) obtained_17\VBN (l_prep) from_18\IN (l_pobj) model_25\NN (l_prep) of_26\IN (l_pobj) PD_27\NNP
11198499
C023754_D007022 CID tizanidine_5\NN (r_pobj) of_4\IN (r_prep) initiation_3\NN (r_dobj) following_1\VBG (r_acl) Hypotension_0\NN
C023754_D007022 CID tizanidine_29\NN (r_pobj) of_28\IN (r_prep) addition_27\NN (r_pobj) following_25\VBG (r_prep) developed_23\VBD (l_dobj) hypotension_24\NN
D017706_D006973 NONE lisinopril_11\NN (r_pobj) with_10\IN (r_prep) treated_9\VBN (r_acl) boy_7\NN (r_dobj) present_2\VBP (l_advcl) control_20\VB (l_dobj) hypertension_21\NN
D000809_D009128 NONE angiotensin_14\NN (r_appos) lisinopril_11\NN (r_pobj) with_10\IN (r_prep) treated_9\VBN (r_acl) boy_7\NN (r_dobj) present_2\VBP (l_advcl) control_20\VB (l_dobj) hypertension_21\NN (l_relcl) developed_23\VBD (l_prep) following_25\VBG (l_pobj) addition_27\NN (l_prep) for_35\IN (l_pobj) treatment_37\NN (l_prep) of_38\IN (l_pobj) spasticity_39\NN
C023754_D006973 NONE tizanidine_5\NN (r_pobj) of_4\IN (r_prep) initiation_3\NN (l_prep) in_6\IN (l_pobj) patient_8\NN (l_acl) treated_9\VBN (l_prep) with_10\IN (l_pobj) angiotensin_12\NN (l_acl) converting_13\VBG (l_prep) for_16\IN (l_pobj) hypertension_18\NN
C023754_D006973 NONE tizanidine_29\NN (r_pobj) of_28\IN (r_prep) addition_27\NN (r_pobj) following_25\VBG (r_prep) developed_23\VBD (r_relcl) hypertension_21\NN
C023754_D006973 NONE tizanidine_4\NN (r_pobj) of_3\IN (r_prep) interaction_2\NN (r_nsubjpass) kept_11\VBN (l_advcl) prescribing_15\VBG (l_xcomp) treat_18\VB (l_dobj) hypertension_20\NN
D000809_D006973 NONE angiotensin_12\NN (l_acl) converting_13\VBG (l_prep) for_16\IN (l_pobj) hypertension_18\NN
D000809_D006973 NONE angiotensin_14\NN (r_appos) lisinopril_11\NN (r_pobj) with_10\IN (r_prep) treated_9\VBN (r_acl) boy_7\NN (r_dobj) present_2\VBP (l_advcl) control_20\VB (l_dobj) hypertension_21\NN
C023754_D009128 NONE tizanidine_29\NN (r_pobj) of_28\IN (r_prep) addition_27\NN (l_prep) for_35\IN (l_pobj) treatment_37\NN (l_prep) of_38\IN (l_pobj) spasticity_39\NN
C023754_D009128 NONE tizanidine_4\NN (r_pobj) of_3\IN (r_prep) interaction_2\NN (r_nsubjpass) kept_11\VBN (l_advcl) prescribing_15\VBG (l_xcomp) treat_18\VB (l_dobj) hypertension_20\NN (l_conj) spasticity_22\NN
D017706_D009128 NONE lisinopril_11\NN (r_pobj) with_10\IN (r_prep) treated_9\VBN (r_acl) boy_7\NN (r_dobj) present_2\VBP (l_advcl) control_20\VB (l_dobj) hypertension_21\NN (l_relcl) developed_23\VBD (l_prep) following_25\VBG (l_pobj) addition_27\NN (l_prep) for_35\IN (l_pobj) treatment_37\NN (l_prep) of_38\IN (l_pobj) spasticity_39\NN
D000809_D007022 NONE angiotensin_12\NN (r_pobj) with_10\IN (r_prep) treated_9\VBN (r_acl) patient_8\NN (r_pobj) in_6\IN (r_prep) initiation_3\NN (r_dobj) following_1\VBG (r_acl) Hypotension_0\NN
D000809_D007022 NONE angiotensin_4\NN (r_pobj) with_3\IN (r_prep) treated_2\VBN (r_csubj) have_9\VB (l_dobj) ability_12\NN (l_acl) respond_14\VB (l_prep) to_15\IN (l_pobj) hypotension_16\NN
D000809_D007022 NONE angiotensin_14\NN (r_appos) lisinopril_11\NN (r_pobj) with_10\IN (r_prep) treated_9\VBN (r_acl) boy_7\NN (r_dobj) present_2\VBP (l_advcl) control_20\VB (l_dobj) hypertension_21\NN (l_relcl) developed_23\VBD (l_dobj) hypotension_24\NN
D017706_D007022 CID lisinopril_11\NN (r_pobj) with_10\IN (r_prep) treated_9\VBN (r_acl) boy_7\NN (r_dobj) present_2\VBP (l_advcl) control_20\VB (l_dobj) hypertension_21\NN (l_relcl) developed_23\VBD (l_dobj) hypotension_24\NN
8423889
D000928_D009069 NONE antidepressant_20\JJ (r_amod) fluoxetine_21\NN (r_pobj) to_18\IN (r_prep) exposure_17\NN (r_pobj) after_16\IN (r_prep) amount_4\NN (l_prep) of_5\IN (l_pobj) disability_7\NN
D004298_D010300 NONE dopamine_6\NN (r_npadvmod) antagonistic_8\JJ (r_amod) capacity_9\NN (l_prep) in_12\IN (l_pobj) patients_16\NNS (l_compound) disease_15\NN
D005473_D009069 CID fluoxetine_5\NN (r_amod) medication_6\NN (r_pobj) after_4\IN (r_prep) Increase_0\NNP (l_prep) of_1\IN (l_pobj) disability_3\NN
D005473_D009069 CID fluoxetine_21\NN (r_pobj) to_18\IN (r_prep) exposure_17\NN (r_pobj) after_16\IN (r_prep) amount_4\NN (l_prep) of_5\IN (l_pobj) disability_7\NN
D005473_D010300 NONE fluoxetine_21\NN (r_pobj) to_18\IN (r_prep) exposure_17\NN (r_pobj) after_16\IN (r_prep) amount_4\NN (l_prep) in_8\IN (l_pobj) patients_10\NNS (l_prep) with_11\IN (l_pobj) disease_15\NN
D005473_D010300 NONE fluoxetine_11\NN (r_pobj) of_10\IN (r_prep) capacity_9\NN (l_prep) in_12\IN (l_pobj) patients_16\NNS (l_compound) disease_15\NN
D000928_D010300 NONE antidepressant_20\JJ (r_amod) fluoxetine_21\NN (r_pobj) to_18\IN (r_prep) exposure_17\NN (r_pobj) after_16\IN (r_prep) amount_4\NN (l_prep) in_8\IN (l_pobj) patients_10\NNS (l_prep) with_11\IN (l_pobj) disease_15\NN
1420741
D016572_D003424 NONE cyclosporin_16\NN (r_pobj) to_15\IN (r_prep) similar_14\JJ (r_amod) properties_13\NNS (r_pobj) with_11\IN (r_prep) antibiotic_10\NN (r_appos) Treatment_0\NN (l_prep) of_1\IN (l_pobj) disease_4\NN
D005672_D015212 NONE acid_13\NN (r_pobj) of_11\IN (r_prep) use_10\NN (l_prep) at_14\IN (l_pobj) level_17\NN (l_prep) in_18\IN (l_pobj) disease_21\NN
D005672_D003424 NONE acid_7\NN (r_pobj) with_5\IN (r_prep) disease_4\NN
D005672_D003424 NONE acid_28\NN (r_compound) treatment_29\NN (r_pobj) of_26\IN (r_prep) tolerability_25\NN (r_conj) pharmacodynamics_23\NNS (r_dobj) estimate_21\VB (r_advcl) undertaken_19\VBN (l_prep) Because_0\IN (l_pobj) need_3\NN (l_prep) for_4\IN (l_pobj) development_6\NN (l_prep) of_7\IN (l_pobj) treatments_9\NNS (l_prep) for_10\IN (l_pobj) disease_13\NN
D005672_D003424 NONE acid_9\NN (r_nsubj) be_11\VB (l_prep) in_14\IN (l_pobj) patients_21\NNS (l_compound) disease_20\NN
18703024
D006220_D002375 CID haloperidol_3\NN (r_npadvmod) induced_5\VBN (r_amod) catalepsy_6\NN
D016291_D002375 NONE MK-801-induced_8\JJ (r_compound) locomotion_9\NN (r_conj) catalepsy_6\NN
11679859
D011346_D017109 CID prochlorperazine_3\NN (r_pobj) of_2\IN (r_prep) administration_1\NN (r_nsubj) affect_12\VB (l_dobj) incidence_14\NN (l_prep) of_15\IN (l_pobj) akathisia_16\NN
D011346_D017109 CID prochlorperazine_12\NN (r_pobj) of_10\IN (r_prep) administration_9\NN (r_pobj) after_8\IN (r_prep) akathisia_7\NN
D011346_D017109 CID prochlorperazine_10\NN (r_nsubjpass) administered_12\VBN (r_advcl) reduction_3\NN (l_prep) in_4\IN (l_pobj) incidence_6\NN (l_prep) of_7\IN (l_pobj) akathisia_8\NN
D011346_D014839 NONE prochlorperazine_8\NN (l_prep) for_9\IN (l_pobj) headache_10\NN (l_conj) nausea_12\NN (l_conj) vomiting_15\NN
D011346_D009325 NONE prochlorperazine_8\NN (l_prep) for_9\IN (l_pobj) headache_10\NN (l_conj) nausea_12\NN
D011346_D009325 NONE prochlorperazine_3\NN (r_pobj) of_2\IN (r_prep) efficacy_1\NN (l_prep) in_4\IN (l_pobj) treatment_6\NN (l_prep) of_7\IN (l_pobj) headache_8\NN (l_conj) nausea_10\NN
D011346_D006261 NONE prochlorperazine_8\NN (l_prep) for_9\IN (l_pobj) headache_10\NN
D011346_D006261 NONE prochlorperazine_3\NN (r_pobj) of_2\IN (r_prep) efficacy_1\NN (l_prep) in_4\IN (l_pobj) treatment_6\NN (l_prep) of_7\IN (l_pobj) headache_8\NN
3828020
D010665_D002544 CID phenylpropanolamine_8\NN (r_pobj) of_7\IN (r_prep) dose_6\NN (r_pobj) with_2\IN (r_prep) infarction_1\NN
D010665_D002544 CID PPA_20\NNP (r_pobj) of_19\IN (r_prep) dose_18\NN (r_dobj) taking_14\VBG (r_pcomp) after_13\IN (r_prep) suffered_9\VBD (l_dobj) infarction_12\NN
2396046
D010634_D006528 NONE phenobarbital_35\NN (r_dobj) containing_34\VBG (r_acl) diet_33\NN (r_dobj) fed_30\VBD (r_conj) fed_10\VBD (l_nsubj) nodules_3\NNS (l_conj) carcinomas_6\NNS
D010634_D006528 NONE phenobarbital_35\NN (r_dobj) containing_34\VBG (r_acl) diet_33\NN (r_dobj) fed_30\VBD (r_conj) fed_10\VBD (l_advcl) developed_26\VBN (l_nsubj) nodule_21\NN (l_conj) carcinoma_25\NN
D010634_D006528 NONE phenobarbital_39\RB (r_npadvmod) containing_41\VBG (r_amod) diet_45\NN (r_dobj) fed_37\VBD (r_conj) was_9\VBD (l_nsubj) incidence_1\NN (l_prep) of_2\IN (l_conj) of_6\IN (l_pobj) carcinomas_8\NNS
D002794_D006528 CID choline_13\NN (r_npadvmod) supplemented_15\VBN (r_amod) diet_16\NN (r_dobj) fed_10\VBD (l_nsubj) nodules_3\NNS (l_conj) carcinomas_6\NNS
D002794_D006528 CID choline_13\NN (r_npadvmod) supplemented_15\VBN (r_amod) diet_16\NN (r_dobj) fed_10\VBD (l_advcl) developed_26\VBN (l_nsubj) nodule_21\NN (l_conj) carcinoma_25\NN
D002794_D006528 CID choline_23\NN (r_npadvmod) devoid_25\JJ (r_amod) diet_26\NN (r_dobj) fed_20\VBD (r_conj) was_9\VBD (l_nsubj) incidence_1\NN (l_prep) of_2\IN (l_conj) of_6\IN (l_pobj) carcinomas_8\NNS
D002794_D006528 CID choline_42\NN (r_npadvmod) devoid_44\JJ (r_amod) diet_45\NN (r_dobj) fed_37\VBD (r_conj) was_9\VBD (l_nsubj) incidence_1\NN (l_prep) of_2\IN (l_conj) of_6\IN (l_pobj) carcinomas_8\NNS
9698967
D008619_D019954 NONE mepivacaine_43\NN (r_amod) mg_45\NN (r_pobj) with_42\IN (r_prep) block_41\NN (r_pobj) of_39\IN (r_prep) performance_38\NN (r_pobj) after_37\IN (r_prep) min_36\NN (r_appos) group_28\NN (r_appos) observed_21\VBN (l_nsubjpass) increase_1\NN (l_acl) accompanied_6\VBN (l_agent) by_7\IN (l_pobj) fibrillation_9\NN (l_conj) agitation_11\NN (l_conj) shouts_14\NNS
D004837_D004387 NONE adrenaline_47\NN (r_dobj) containing_46\VBG (r_pcomp) with_42\IN (r_prep) block_41\NN (r_pobj) of_39\IN (r_prep) performance_38\NN (r_pobj) after_37\IN (r_prep) min_36\NN (r_appos) group_28\NN (l_prep) for_51\IN (l_pobj) correction_52\NN (l_prep) of_53\IN (l_pobj) contracture_56\NN
D008619_D004387 NONE mepivacaine_43\NN (r_amod) mg_45\NN (r_pobj) with_42\IN (r_prep) block_41\NN (r_pobj) of_39\IN (r_prep) performance_38\NN (r_pobj) after_37\IN (r_prep) min_36\NN (r_appos) group_28\NN (l_prep) for_51\IN (l_pobj) correction_52\NN (l_prep) of_53\IN (l_pobj) contracture_56\NN
D008619_D011595 NONE mepivacaine_43\NN (r_amod) mg_45\NN (r_pobj) with_42\IN (r_prep) block_41\NN (r_pobj) of_39\IN (r_prep) performance_38\NN (r_pobj) after_37\IN (r_prep) min_36\NN (r_appos) group_28\NN (r_appos) observed_21\VBN (l_nsubjpass) increase_1\NN (l_acl) accompanied_6\VBN (l_agent) by_7\IN (l_pobj) fibrillation_9\NN (l_conj) agitation_11\NN
D008619_D006973 CID mepivacaine_43\NN (r_amod) mg_45\NN (r_pobj) with_42\IN (r_prep) block_41\NN (r_pobj) of_39\IN (r_prep) performance_38\NN (r_pobj) after_37\IN (r_prep) min_36\NN (r_appos) group_28\NN (r_appos) observed_21\VBN (l_nsubjpass) increase_1\NN (l_prep) in_2\IN (l_pobj) pressure_4\NN
D004837_D014474 NONE adrenaline_47\NN (r_dobj) containing_46\VBG (r_pcomp) with_42\IN (r_prep) block_41\NN (r_pobj) of_39\IN (r_prep) performance_38\NN (r_pobj) after_37\IN (r_prep) min_36\NN (r_appos) group_28\NN (r_appos) observed_21\VBN (l_nsubjpass) increase_1\NN (l_acl) accompanied_6\VBN (l_agent) by_7\IN (l_pobj) fibrillation_9\NN (l_conj) agitation_11\NN (l_conj) shouts_14\NNS (l_prep) of_17\IN (l_pobj) consciousness_18\NN
D004837_D019954 NONE adrenaline_47\NN (r_dobj) containing_46\VBG (r_pcomp) with_42\IN (r_prep) block_41\NN (r_pobj) of_39\IN (r_prep) performance_38\NN (r_pobj) after_37\IN (r_prep) min_36\NN (r_appos) group_28\NN (r_appos) observed_21\VBN (l_nsubjpass) increase_1\NN (l_acl) accompanied_6\VBN (l_agent) by_7\IN (l_pobj) fibrillation_9\NN (l_conj) agitation_11\NN (l_conj) shouts_14\NNS
D008619_D001281 CID mepivacaine_43\NN (r_amod) mg_45\NN (r_pobj) with_42\IN (r_prep) block_41\NN (r_pobj) of_39\IN (r_prep) performance_38\NN (r_pobj) after_37\IN (r_prep) min_36\NN (r_appos) group_28\NN (r_appos) observed_21\VBN (l_nsubjpass) increase_1\NN (l_acl) accompanied_6\VBN (l_agent) by_7\IN (l_pobj) fibrillation_9\NN
D008619_D014474 NONE mepivacaine_43\NN (r_amod) mg_45\NN (r_pobj) with_42\IN (r_prep) block_41\NN (r_pobj) of_39\IN (r_prep) performance_38\NN (r_pobj) after_37\IN (r_prep) min_36\NN (r_appos) group_28\NN (r_appos) observed_21\VBN (l_nsubjpass) increase_1\NN (l_acl) accompanied_6\VBN (l_agent) by_7\IN (l_pobj) fibrillation_9\NN (l_conj) agitation_11\NN (l_conj) shouts_14\NNS (l_prep) of_17\IN (l_pobj) consciousness_18\NN
D004837_D006973 CID adrenaline_47\NN (r_dobj) containing_46\VBG (r_pcomp) with_42\IN (r_prep) block_41\NN (r_pobj) of_39\IN (r_prep) performance_38\NN (r_pobj) after_37\IN (r_prep) min_36\NN (r_appos) group_28\NN (r_appos) observed_21\VBN (l_nsubjpass) increase_1\NN (l_prep) in_2\IN (l_pobj) pressure_4\NN
D004837_D011595 NONE adrenaline_47\NN (r_dobj) containing_46\VBG (r_pcomp) with_42\IN (r_prep) block_41\NN (r_pobj) of_39\IN (r_prep) performance_38\NN (r_pobj) after_37\IN (r_prep) min_36\NN (r_appos) group_28\NN (r_appos) observed_21\VBN (l_nsubjpass) increase_1\NN (l_acl) accompanied_6\VBN (l_agent) by_7\IN (l_pobj) fibrillation_9\NN (l_conj) agitation_11\NN
D004837_D001281 CID adrenaline_47\NN (r_dobj) containing_46\VBG (r_pcomp) with_42\IN (r_prep) block_41\NN (r_pobj) of_39\IN (r_prep) performance_38\NN (r_pobj) after_37\IN (r_prep) min_36\NN (r_appos) group_28\NN (r_appos) observed_21\VBN (l_nsubjpass) increase_1\NN (l_acl) accompanied_6\VBN (l_agent) by_7\IN (l_pobj) fibrillation_9\NN
1616457
D010424_D000647 CID pentobarbital_7\NN (r_pobj) by_6\IN (r_agent) caused_5\VBN (r_acl) amnesia_4\NN
D010424_D000647 CID pentobarbital_15\NN (r_nmod) ip_20\NNP (r_pobj) by_14\IN (r_agent) produced_13\VBN (r_acl) amnesia_12\NN
12589964
D004317_D009202 CID doxorubicin_14\NN (r_npadvmod) induced_16\VBN (r_amod) rats_18\NNS (r_pobj) in_13\IN (r_prep) damage_12\NN
D004317_D009202 CID doxorubicin_14\NN (r_npadvmod) induced_16\VBN (r_amod) rats_18\NNS (l_amod) cardiomyopathy_17\NN
D004317_D009202 CID doxorubicin_20\NN (r_pobj) of_19\IN (r_prep) model_18\NN (r_pobj) in_15\IN (r_prep) damage_14\NN
D004317_D009202 CID doxorubicin_20\NN (r_pobj) of_19\IN (r_prep) model_18\NN (l_appos) cardiomyopathy_23\NN
D004317_D009202 CID DOX)-induced_22\VBN (r_amod) cardiomyopathy_23\NN (r_appos) model_18\NN (r_pobj) in_15\IN (r_prep) damage_14\NN
D004317_D009202 CID DOX)-induced_22\VBN (r_amod) cardiomyopathy_23\NN
D004317_D009202 CID DOX_6\NNP (r_pobj) after_5\IN (r_prep) markers_1\NNS (r_pobj) Among_0\IN (r_prep) showed_11\VBD (l_dobj) ability_14\NN (l_acl) detect_16\VB (l_dobj) damage_18\NN
D004317_D066126 NONE DOX_13\NNP (r_pobj) after_12\IN (r_prep) amount_7\NN (r_pobj) between_5\IN (r_prep) discrepancy_4\NN (r_attr) was_2\VBD (r_advcl) is_33\VBZ (l_acomp) likely_34\JJ (l_ccomp) indicates_41\VBZ (l_conj) be_55\VB (l_attr) marker_58\NN (l_prep) for_59\IN (l_pobj) prediction_61\NN (l_prep) of_62\IN (l_pobj) cardiotoxicity_65\NN
D004317_D066126 NONE DOX_40\NNP (r_nsubj) indicates_41\VBZ (l_conj) be_55\VB (l_attr) marker_58\NN (l_prep) for_59\IN (l_pobj) prediction_61\NN (l_prep) of_62\IN (l_pobj) cardiotoxicity_65\NN
D004317_D005355 NONE DOX_8\NNP (r_pobj) given_7\VBN (r_prep) rats_6\NNS (r_pobj) from_4\IN (r_prep) hearts_3\NNS (r_pobj) of_2\IN (r_prep) evaluation_1\NN (r_nsubj) revealed_9\VBD (l_dobj) degrees_12\NNS (l_prep) of_13\IN (l_pobj) fibrosis_17\NN
D004317_D064420 NONE DOX_3\NNP (r_compound) rats_4\NNS (r_pobj) of_1\IN (r_prep) Eighteen_0\CD (r_nsubj) died_5\VBD (l_prep) of_7\IN (l_pobj) toxicity_9\NN
D004317_D006331 NONE doxorubicin_20\NN (r_pobj) of_19\IN (r_prep) model_18\NN (r_pobj) in_15\IN (r_prep) damage_14\NN (r_pobj) of_12\IN (r_prep) diagnosis_11\NN (r_pobj) for_9\IN (r_prep) investigated_1\VBD (l_conj) examined_27\VBD (l_dobj) relationship_29\NN (l_prep) with_35\IN (l_pobj) development_37\NN (l_prep) of_38\IN (l_pobj) disorders_40\NNS
D004317_D006331 NONE DOX)-induced_22\VBN (r_amod) cardiomyopathy_23\NN (r_appos) model_18\NN (r_pobj) in_15\IN (r_prep) damage_14\NN (r_pobj) of_12\IN (r_prep) diagnosis_11\NN (r_pobj) for_9\IN (r_prep) investigated_1\VBD (l_conj) examined_27\VBD (l_dobj) relationship_29\NN (l_prep) with_35\IN (l_pobj) development_37\NN (l_prep) of_38\IN (l_pobj) disorders_40\NNS
D004317_D017202 NONE DOX_6\NNP (r_pobj) after_5\IN (r_prep) markers_1\NNS (l_prep) of_2\IN (l_pobj) injury_4\NN
11379838
D000928_D001714 CID Antidepressant_0\NNP (r_npadvmod) induced_2\VBN (r_amod) mania_3\NN
D000928_D001714 CID Antidepressant_0\NNP (r_npadvmod) induced_2\VBN (r_amod) mania_3\NN (l_prep) in_4\IN (l_pobj) patients_6\NNS (l_amod) bipolar_5\JJ
D000928_D001714 CID antidepressants_10\NNS (r_pobj) with_9\IN (r_prep) associated_8\VBN (r_acl) mania_7\NN
D000928_D001714 CID antidepressants_10\NNS (r_pobj) with_9\IN (r_prep) associated_8\VBN (r_acl) mania_7\NN (r_pobj) to_6\IN (r_prep) switching_5\VBG (r_pcomp) of_4\IN (r_prep) risks_3\NNS (r_pobj) about_1\IN (r_prep) Concerns_0\NNS (r_nsubj) continue_11\VBP (l_xcomp) interfere_13\VB (l_prep) with_14\IN (l_pobj) establishment_16\NN (l_prep) of_17\IN (l_pobj) paradigm_21\NN (l_prep) for_22\IN (l_pobj) depression_24\NN
D000928_D001714 CID antidepressant_43\NN (r_amod) therapy_44\NN (r_pobj) of_42\IN (r_prep) type_41\NN (r_appos) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (r_pobj) with_10\IN (r_prep) compared_9\VBN (l_nsubjpass) Patients_0\NNS (l_relcl) experienced_2\VBD (l_dobj) switch_7\NN (l_amod) manic_4\JJ
D000928_D001714 CID antidepressant_43\NN (r_amod) therapy_44\NN (r_pobj) of_42\IN (r_prep) type_41\NN (r_appos) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (r_pobj) with_10\IN (r_prep) compared_9\VBN (l_nsubjpass) Patients_0\NNS (l_relcl) experienced_2\VBD (l_dobj) switch_7\NN (l_amod) manic_4\JJ (l_conj) hypomanic_6\JJ
D000928_D001714 CID antidepressant_43\NN (r_amod) therapy_44\NN (r_pobj) of_42\IN (r_prep) type_41\NN (r_appos) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (l_relcl) did_13\VBD (l_prep) on_15\IN (l_pobj) variables_17\NNS (l_prep) including_18\VBG (l_pobj) age_19\NN (l_conj) sex_21\NN (l_conj) diagnosis_23\NN (l_appos) IV_27\NNP (l_appos) I_29\PRP
D000928_D001714 CID antidepressant_43\NN (r_amod) therapy_44\NN (r_pobj) of_42\IN (r_prep) type_41\NN (r_appos) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (l_relcl) did_13\VBD (l_prep) on_15\IN (l_pobj) variables_17\NNS (l_prep) including_18\VBG (l_pobj) age_19\NN (l_conj) sex_21\NN (l_conj) diagnosis_23\NN (l_appos) IV_27\NNP (l_appos) I_29\PRP (l_prep) vs._30\IN (l_pobj) II_32\NNP
D000928_D001714 CID antidepressant_43\NN (r_amod) therapy_44\NN (r_pobj) of_42\IN (r_prep) type_41\NN (r_appos) episodes_39\NNS (l_amod) manic_38\JJ
D000928_D001714 CID antidepressant_50\NN (r_amod) drugs_51\NNS (r_pobj) vs._49\IN (r_prep) therapy_48\NN (r_dobj) used_45\VBN (r_acl) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (r_pobj) with_10\IN (r_prep) compared_9\VBN (l_nsubjpass) Patients_0\NNS (l_relcl) experienced_2\VBD (l_dobj) switch_7\NN (l_amod) manic_4\JJ
D000928_D001714 CID antidepressant_50\NN (r_amod) drugs_51\NNS (r_pobj) vs._49\IN (r_prep) therapy_48\NN (r_dobj) used_45\VBN (r_acl) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (r_pobj) with_10\IN (r_prep) compared_9\VBN (l_nsubjpass) Patients_0\NNS (l_relcl) experienced_2\VBD (l_dobj) switch_7\NN (l_amod) manic_4\JJ (l_conj) hypomanic_6\JJ
D000928_D001714 CID antidepressant_50\NN (r_amod) drugs_51\NNS (r_pobj) vs._49\IN (r_prep) therapy_48\NN (r_dobj) used_45\VBN (r_acl) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (l_relcl) did_13\VBD (l_prep) on_15\IN (l_pobj) variables_17\NNS (l_prep) including_18\VBG (l_pobj) age_19\NN (l_conj) sex_21\NN (l_conj) diagnosis_23\NN (l_appos) IV_27\NNP (l_appos) I_29\PRP
D000928_D001714 CID antidepressant_50\NN (r_amod) drugs_51\NNS (r_pobj) vs._49\IN (r_prep) therapy_48\NN (r_dobj) used_45\VBN (r_acl) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (l_relcl) did_13\VBD (l_prep) on_15\IN (l_pobj) variables_17\NNS (l_prep) including_18\VBG (l_pobj) age_19\NN (l_conj) sex_21\NN (l_conj) diagnosis_23\NN (l_appos) IV_27\NNP (l_appos) I_29\PRP (l_prep) vs._30\IN (l_pobj) II_32\NNP
D000928_D001714 CID antidepressant_50\NN (r_amod) drugs_51\NNS (r_pobj) vs._49\IN (r_prep) therapy_48\NN (r_dobj) used_45\VBN (r_acl) episodes_39\NNS (l_amod) manic_38\JJ
D008094_D001714 NONE lithium_73\NN (r_appos) stabilizers_71\NNS (r_pobj) of_69\IN (r_prep) type_68\NN (r_conj) use_66\NN (r_conj) inhibitors_60\NNS (r_appos) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (r_pobj) with_10\IN (r_prep) compared_9\VBN (l_nsubjpass) Patients_0\NNS (l_relcl) experienced_2\VBD (l_dobj) switch_7\NN (l_amod) manic_4\JJ
D008094_D001714 NONE lithium_73\NN (r_appos) stabilizers_71\NNS (r_pobj) of_69\IN (r_prep) type_68\NN (r_conj) use_66\NN (r_conj) inhibitors_60\NNS (r_appos) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (r_pobj) with_10\IN (r_prep) compared_9\VBN (l_nsubjpass) Patients_0\NNS (l_relcl) experienced_2\VBD (l_dobj) switch_7\NN (l_amod) manic_4\JJ (l_conj) hypomanic_6\JJ
D008094_D001714 NONE lithium_73\NN (r_appos) stabilizers_71\NNS (r_pobj) of_69\IN (r_prep) type_68\NN (r_conj) use_66\NN (r_conj) inhibitors_60\NNS (r_appos) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (l_relcl) did_13\VBD (l_prep) on_15\IN (l_pobj) variables_17\NNS (l_prep) including_18\VBG (l_pobj) age_19\NN (l_conj) sex_21\NN (l_conj) diagnosis_23\NN (l_appos) IV_27\NNP (l_appos) I_29\PRP
D008094_D001714 NONE lithium_73\NN (r_appos) stabilizers_71\NNS (r_pobj) of_69\IN (r_prep) type_68\NN (r_conj) use_66\NN (r_conj) inhibitors_60\NNS (r_appos) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (l_relcl) did_13\VBD (l_prep) on_15\IN (l_pobj) variables_17\NNS (l_prep) including_18\VBG (l_pobj) age_19\NN (l_conj) sex_21\NN (l_conj) diagnosis_23\NN (l_appos) IV_27\NNP (l_appos) I_29\PRP (l_prep) vs._30\IN (l_pobj) II_32\NNP
D008094_D001714 NONE lithium_73\NN (r_appos) stabilizers_71\NNS (r_pobj) of_69\IN (r_prep) type_68\NN (r_conj) use_66\NN (r_conj) inhibitors_60\NNS (r_appos) episodes_39\NNS (l_amod) manic_38\JJ
D017367_D001714 CID inhibitors_60\NNS (r_appos) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (r_pobj) with_10\IN (r_prep) compared_9\VBN (l_nsubjpass) Patients_0\NNS (l_relcl) experienced_2\VBD (l_dobj) switch_7\NN (l_amod) manic_4\JJ
D017367_D001714 CID inhibitors_60\NNS (r_appos) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (r_pobj) with_10\IN (r_prep) compared_9\VBN (l_nsubjpass) Patients_0\NNS (l_relcl) experienced_2\VBD (l_dobj) switch_7\NN (l_amod) manic_4\JJ (l_conj) hypomanic_6\JJ
D017367_D001714 CID inhibitors_60\NNS (r_appos) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (l_relcl) did_13\VBD (l_prep) on_15\IN (l_pobj) variables_17\NNS (l_prep) including_18\VBG (l_pobj) age_19\NN (l_conj) sex_21\NN (l_conj) diagnosis_23\NN (l_appos) IV_27\NNP (l_appos) I_29\PRP
D017367_D001714 CID inhibitors_60\NNS (r_appos) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (l_relcl) did_13\VBD (l_prep) on_15\IN (l_pobj) variables_17\NNS (l_prep) including_18\VBG (l_pobj) age_19\NN (l_conj) sex_21\NN (l_conj) diagnosis_23\NN (l_appos) IV_27\NNP (l_appos) I_29\PRP (l_prep) vs._30\IN (l_pobj) II_32\NNP
D017367_D001714 CID inhibitors_60\NNS (r_appos) episodes_39\NNS (l_amod) manic_38\JJ
D017367_D001714 CID SSRIs_62\NNPS (r_appos) inhibitors_60\NNS (r_appos) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (r_pobj) with_10\IN (r_prep) compared_9\VBN (l_nsubjpass) Patients_0\NNS (l_relcl) experienced_2\VBD (l_dobj) switch_7\NN (l_amod) manic_4\JJ
D017367_D001714 CID SSRIs_62\NNPS (r_appos) inhibitors_60\NNS (r_appos) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (r_pobj) with_10\IN (r_prep) compared_9\VBN (l_nsubjpass) Patients_0\NNS (l_relcl) experienced_2\VBD (l_dobj) switch_7\NN (l_amod) manic_4\JJ (l_conj) hypomanic_6\JJ
D017367_D001714 CID SSRIs_62\NNPS (r_appos) inhibitors_60\NNS (r_appos) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (l_relcl) did_13\VBD (l_prep) on_15\IN (l_pobj) variables_17\NNS (l_prep) including_18\VBG (l_pobj) age_19\NN (l_conj) sex_21\NN (l_conj) diagnosis_23\NN (l_appos) IV_27\NNP (l_appos) I_29\PRP
D017367_D001714 CID SSRIs_62\NNPS (r_appos) inhibitors_60\NNS (r_appos) episodes_39\NNS (r_pobj) of_36\IN (r_prep) number_35\NN (r_appos) those_11\DT (l_relcl) did_13\VBD (l_prep) on_15\IN (l_pobj) variables_17\NNS (l_prep) including_18\VBG (l_pobj) age_19\NN (l_conj) sex_21\NN (l_conj) diagnosis_23\NN (l_appos) IV_27\NNP (l_appos) I_29\PRP (l_prep) vs._30\IN (l_pobj) II_32\NNP
D017367_D001714 CID SSRIs_62\NNPS (r_appos) inhibitors_60\NNS (r_appos) episodes_39\NNS (l_amod) manic_38\JJ
D017367_D001714 CID SSRIs_29\NNS (r_pobj) with_28\IN (r_prep) treated_27\VBN (r_acl) patients_26\NNS (r_pobj) of_25\IN (r_prep) subgroup_24\NN (r_pobj) of_22\IN (r_prep) %_21\NN (r_pobj) in_19\IN (r_prep) experienced_42\JJ (r_parataxis) patients_11\NNS (r_pobj) of_9\IN (r_prep) %_8\NN (r_pobj) in_6\IN (r_prep) occurred_5\VBD (l_nsubj) Switches_0\NNS (l_prep) to_1\IN (l_pobj) hypomania_2\NN
D017367_D001714 CID SSRIs_29\NNS (r_pobj) with_28\IN (r_prep) treated_27\VBN (r_acl) patients_26\NNS (r_pobj) of_25\IN (r_prep) subgroup_24\NN (r_pobj) of_22\IN (r_prep) %_21\NN (r_pobj) in_19\IN (r_prep) experienced_42\JJ (r_parataxis) patients_11\NNS (r_pobj) of_9\IN (r_prep) %_8\NN (r_pobj) in_6\IN (r_prep) occurred_5\VBD (l_nsubj) Switches_0\NNS (l_prep) to_1\IN (l_pobj) hypomania_2\NN (l_conj) mania_4\NN
D017367_D001714 CID SSRIs_29\NNS (r_pobj) with_28\IN (r_prep) treated_27\VBN (r_acl) patients_26\NNS (r_pobj) of_25\IN (r_prep) subgroup_24\NN (r_pobj) of_22\IN (r_prep) %_21\NN (r_pobj) in_19\IN (r_prep) experienced_42\JJ (l_dobj) episodes_44\NNS (l_amod) manic_43\JJ
D017367_D001714 CID SSRIs_29\NNS (r_pobj) with_28\IN (r_prep) treated_27\VBN (r_acl) patients_26\NNS (r_pobj) of_25\IN (r_prep) subgroup_24\NN (r_pobj) of_22\IN (r_prep) %_21\NN (r_pobj) in_19\IN (r_prep) experienced_42\JJ (r_parataxis) patients_11\NNS (r_pobj) of_9\IN (r_prep) %_8\NN (r_pobj) in_6\IN (r_prep) occurred_5\VBD (l_npadvmod) episodes_56\NNS (l_amod) hypomanic_55\JJ
11206082
D005680_D012640 NONE GABA(A_24\NNP (r_nmod) ligands_27\NNS (r_pobj) of_22\IN (r_prep) effects_21\NNS (r_pobj) to_18\IN (r_prep) sensitive_17\JJ (r_acomp) are_14\VBP (l_nsubj) lines_2\NNS (l_acl) selected_3\VBN (l_prep) for_4\IN (l_pobj) sensitivities_6\NNS (l_prep) to_7\IN (l_pobj) seizures_13\NNS
D005680_D012640 NONE GABA(A_44\NNP (r_nmod) site_48\NN (r_pobj) of_42\IN (r_prep) agonist_41\NN (r_appos) carboline-3-carboxylate_32\NN (r_pobj) of_28\IN (r_prep) injection_27\NN (r_pobj) by_23\IN (r_agent) induced_22\VBN (r_acl) seizures_21\NNS
D001569_D012640 NONE benzodiazepine_47\NN (r_amod) site_48\NN (r_pobj) of_42\IN (r_prep) agonist_41\NN (r_appos) carboline-3-carboxylate_32\NN (r_pobj) of_28\IN (r_prep) injection_27\NN (r_pobj) by_23\IN (r_agent) induced_22\VBN (r_acl) seizures_21\NNS
C036150_D012640 CID carboline_10\NN (r_npadvmod) induced_12\VBN (r_amod) seizures_13\NNS
C036150_D012640 CID carboline-3-carboxylate_32\NN (r_pobj) of_28\IN (r_prep) injection_27\NN (r_pobj) by_23\IN (r_agent) induced_22\VBN (r_acl) seizures_21\NNS
C036150_D012640 CID CCM_36\NNP (r_appos) carboline-3-carboxylate_32\NN (r_pobj) of_28\IN (r_prep) injection_27\NN (r_pobj) by_23\IN (r_agent) induced_22\VBN (r_acl) seizures_21\NNS
D010852_D012640 CID picrotoxin-_25\NN (r_amod) seizures_30\NNS
D010433_D012640 CID pentylenetetrazol_27\NN (r_npadvmod) induced_29\VBN (r_conj) picrotoxin-_25\NN (r_amod) seizures_30\NNS
D003975_D012640 NONE diazepam_2\NN (r_npadvmod) induced_4\VBN (r_amod) anxiolysis_5\NN (r_dobj) measured_1\VBD (l_dobj) sedation_17\NN (l_prep) by_18\IN (l_pcomp) recording_19\VBG (l_dobj) states_22\NNS (l_conj) seizures_30\NNS
D003975_D012640 NONE diazepam_14\NN (r_npadvmod) induced_16\VBN (r_amod) sedation_17\NN (l_prep) by_18\IN (l_pcomp) recording_19\VBG (l_dobj) states_22\NNS (l_conj) seizures_30\NNS
18951540
D007980_D004409 CID levodopa_5\NN (r_npadvmod) induced_7\VBN (r_amod) dyskinesias_8\NNS
D007980_D010300 NONE levodopa_5\NN (r_npadvmod) induced_7\VBN (r_amod) dyskinesias_8\NNS (l_prep) in_9\IN (l_pobj) disease_12\NN
17879945
D019438_D050197 CID ritonavir_5\VBZ (r_compound) treatment_6\NN (r_nsubj) increases_7\VBZ (l_dobj) formation_10\NN (l_compound) lesion_9\NN
4027862
D003891_D003693 CID Desipramine_0\NN (r_npadvmod) induced_2\VBN (r_amod) delirium_3\NN
D003891_D003693 CID Desipramine_7\NNP (r_nsubj) developed_8\VBD (l_dobj) delirium_10\NN
7862923
D002220_D019965 NONE Carbamazepine_0\NNP (r_nsubjpass) switched_2\VBN (l_prep) among_8\IN (l_pobj) patients_19\NNS (l_amod) psychotic_18\JJ
D002220_D012559 NONE Carbamazepine_0\NNP (r_nsubjpass) switched_2\VBN (l_prep) among_8\IN (l_pobj) patients_19\NNS (l_amod) schizophrenic_15\JJ
D003024_D019965 NONE clozapine_26\NN (r_conj) chlorpromazine_24\NN (r_conj) haloperidol_22\NN (r_dobj) using_20\VBG (r_acl) patients_19\NNS (l_amod) psychotic_18\JJ
D002746_D012559 NONE chlorpromazine_24\NN (r_conj) haloperidol_22\NN (r_dobj) using_20\VBG (r_acl) patients_19\NNS (l_amod) schizophrenic_15\JJ
C036006_D012559 NONE oxcarbazepine_7\NN (r_pobj) to_3\IN (r_prep) switched_2\VBN (l_prep) among_8\IN (l_pobj) patients_19\NNS (l_amod) schizophrenic_15\JJ
D006220_D019965 NONE haloperidol_22\NN (r_dobj) using_20\VBG (r_acl) patients_19\NNS (l_amod) psychotic_18\JJ
D002746_D019965 NONE chlorpromazine_24\NN (r_conj) haloperidol_22\NN (r_dobj) using_20\VBG (r_acl) patients_19\NNS (l_amod) psychotic_18\JJ
C036006_D019965 NONE oxcarbazepine_7\NN (r_pobj) to_3\IN (r_prep) switched_2\VBN (l_prep) among_8\IN (l_pobj) patients_19\NNS (l_amod) psychotic_18\JJ
D003024_D012559 NONE clozapine_26\NN (r_conj) chlorpromazine_24\NN (r_conj) haloperidol_22\NN (r_dobj) using_20\VBG (r_acl) patients_19\NNS (l_amod) schizophrenic_15\JJ
D006220_D012559 NONE haloperidol_22\NN (r_dobj) using_20\VBG (r_acl) patients_19\NNS (l_amod) schizophrenic_15\JJ
18221780
D016202_D010146 NONE NMDA_3\NNP (r_compound) enhancement_5\NN (r_pobj) in_2\IN (r_prep) differences_1\NNS (l_prep) in_9\IN (l_pobj) model_12\NN (l_prep) of_13\IN (l_pobj) pain_15\NN
D016202_D010146 NONE NMDA_9\NNP (r_compound) antagonists_10\NNS (r_pobj) between_8\IN (r_prep) interaction_7\NN (l_prep) in_13\IN (l_pobj) model_17\NN (l_compound) pain_16\NN
D002211_D059787 NONE capsaicin_11\NN (r_compound) model_12\NN (r_pobj) in_9\IN (r_prep) differences_1\NNS (l_appos) comparisons_17\NNS (l_prep) to_18\IN (l_pobj) models_20\NNS (l_prep) of_21\IN (l_pobj) pain_23\NN
D009020_D059787 NONE morphine_7\NN (r_compound) antihyperalgesia_8\NN (r_pobj) of_6\IN (r_prep) enhancement_5\NN (r_pobj) in_2\IN (r_prep) differences_1\NNS (l_appos) comparisons_17\NNS (l_prep) to_18\IN (l_pobj) models_20\NNS (l_prep) of_21\IN (l_pobj) pain_23\NN
D009020_D059787 NONE morphine_21\NN (r_pobj) of_20\IN (r_prep) effects_19\NNS (r_dobj) enhance_16\VBP (l_prep) In_0\IN (l_pobj) models_3\NNS (l_compound) pain_2\NN
D009020_D059787 NONE morphine_2\NN (r_compound) antinociception_3\NN (r_pobj) of_1\IN (r_prep) Enhancement_0\NN (r_nsubjpass) seen_7\VBN (l_prep) in_8\IN (l_pobj) males_10\NNS (l_prep) in_13\IN (l_pobj) models_17\NNS (l_compound) pain_16\NN
D009020_D059787 NONE morphine_12\NN (r_conj) antagonists_10\NNS (r_pobj) between_8\IN (r_prep) interaction_7\NN (l_prep) in_13\IN (l_pobj) model_17\NN (l_relcl) distinguished_21\VBN (l_prep) from_22\IN (l_pobj) those_23\DT (l_acl) observed_24\VBN (l_prep) in_25\IN (l_pobj) models_28\NNS (l_compound) pain_27\NN
D003915_D059787 NONE dextromethorphan_5\NNP (r_pobj) by_4\IN (r_prep) Enhancement_0\NN (r_nsubjpass) seen_7\VBN (l_prep) in_8\IN (l_pobj) males_10\NNS (l_prep) in_13\IN (l_pobj) models_17\NNS (l_compound) pain_16\NN
D002211_D010146 NONE capsaicin_11\NN (r_compound) model_12\NN (l_prep) of_13\IN (l_pobj) pain_15\NN
D002211_D006930 CID capsaicin_11\NN (r_pobj) of_10\IN (r_prep) administration_9\NN (r_pobj) by_8\IN (r_agent) induced_7\VBN (l_nsubjpass) hyperalgesia_5\NN
D016202_D059787 NONE NMDA_3\NNP (r_compound) enhancement_5\NN (r_pobj) in_2\IN (r_prep) differences_1\NNS (l_appos) comparisons_17\NNS (l_prep) to_18\IN (l_pobj) models_20\NNS (l_prep) of_21\IN (l_pobj) pain_23\NN
D016202_D059787 NONE aspartate_11\NNP (r_nmod) antagonists_15\NNS (r_nsubj) enhance_16\VBP (l_prep) In_0\IN (l_pobj) models_3\NNS (l_compound) pain_2\NN
D016202_D059787 NONE NMDA_13\NNP (r_nmod) antagonists_15\NNS (r_nsubj) enhance_16\VBP (l_prep) In_0\IN (l_pobj) models_3\NNS (l_compound) pain_2\NN
D016202_D059787 NONE NMDA_9\NNP (r_compound) antagonists_10\NNS (r_pobj) between_8\IN (r_prep) interaction_7\NN (l_prep) in_13\IN (l_pobj) model_17\NN (l_relcl) distinguished_21\VBN (l_prep) from_22\IN (l_pobj) those_23\DT (l_acl) observed_24\VBN (l_prep) in_25\IN (l_pobj) models_28\NNS (l_compound) pain_27\NN
D009020_D010146 NONE morphine_7\NN (r_compound) antihyperalgesia_8\NN (r_pobj) of_6\IN (r_prep) enhancement_5\NN (r_pobj) in_2\IN (r_prep) differences_1\NNS (l_prep) in_9\IN (l_pobj) model_12\NN (l_prep) of_13\IN (l_pobj) pain_15\NN
D009020_D010146 NONE morphine_12\NN (r_conj) antagonists_10\NNS (r_pobj) between_8\IN (r_prep) interaction_7\NN (l_prep) in_13\IN (l_pobj) model_17\NN (l_compound) pain_16\NN
17261653
D003000_D001919 CID Clonidine_0\NNP (r_npadvmod) induced_2\VBN (l_dobj) bradycardia_3\NN
7858459
C007744_D020258 NONE fluorocitrate_16\NN (r_conj) fluoroacetate_14\NN (r_pobj) by_13\IN (r_prep) blockade_12\NN (r_pobj) to_8\IN (r_prep) due_7\JJ (r_acomp) be_6\VB (l_nsubj) pathogenesis_1\NN (l_prep) of_2\IN (l_pobj) neurotoxicity_4\NN
D002955_D020258 NONE acid_2\NN (r_nsubj) was_3\VBD (r_advcl) suspected_21\VBN (l_nsubjpass) neurotoxicity_12\NN
D005472_D009369 NONE 5-fluorouracil_3\CD (r_punct) folinic_5\JJ (r_amod) therapy_8\NN (r_nsubj) become_11\VBN (l_attr) regimen_14\NN (l_prep) for_15\IN (l_pobj) cancers_17\NNS
D005472_D003128 CID 5-fluorouracil_35\CD (r_punct) of_34\IN (r_prep) dose_29\NN (r_nmod) infusion_39\NN (r_pobj) during_26\IN (r_prep) lasting_21\VBG (r_advcl) lapsed_15\VBD (l_prep) into_16\IN (l_pobj) coma_19\NN
D005472_D003221 CID 5-fluorouracil_10\CD (r_punct) of_9\IN (r_prep) infusion_8\NN (r_pobj) by_3\IN (r_agent) induced_2\VBN (l_nsubj) confusion_1\NN
D005472_D003221 CID 5-fluorouracil_35\CD (r_punct) of_34\IN (r_prep) dose_29\NN (r_nmod) infusion_39\NN (r_pobj) during_26\IN (r_prep) lasting_21\VBG (r_advcl) lapsed_15\VBD (r_conj) developed_1\VBD (l_dobj) symptoms_4\NNS (l_prep) of_5\IN (l_pobj) confusion_7\NN
D005472_D003221 CID 5-fluorouracil_35\CD (r_punct) of_34\IN (r_prep) dose_29\NN (r_nmod) infusion_39\NN (r_pobj) during_26\IN (r_prep) lasting_21\VBG (r_advcl) lapsed_15\VBD (r_conj) developed_1\VBD (l_dobj) symptoms_4\NNS (l_prep) of_5\IN (l_pobj) confusion_7\NN (l_conj) disorientation_9\NN
D002955_D009369 NONE acid_6\NN (r_compound) infusion_7\NN (r_compound) therapy_8\NN (r_nsubj) become_11\VBN (l_attr) regimen_14\NN (l_prep) for_15\IN (l_pobj) cancers_17\NNS
D002955_D003128 CID acid_38\NN (r_compound) infusion_39\NN (r_pobj) during_26\IN (r_prep) lasting_21\VBG (r_advcl) lapsed_15\VBD (l_prep) into_16\IN (l_pobj) coma_19\NN
D005463_D020258 NONE fluoroacetate_14\NN (r_pobj) by_13\IN (r_prep) blockade_12\NN (r_pobj) to_8\IN (r_prep) due_7\JJ (r_acomp) be_6\VB (l_nsubj) pathogenesis_1\NN (l_prep) of_2\IN (l_pobj) neurotoxicity_4\NN
D013831_D020258 NONE thiamine_18\NN (r_compound) deficiency_19\NN (r_conj) blockade_12\NN (r_pobj) to_8\IN (r_prep) due_7\JJ (r_acomp) be_6\VB (l_nsubj) pathogenesis_1\NN (l_prep) of_2\IN (l_pobj) neurotoxicity_4\NN
D005472_D020258 NONE 5-fluorouracil_18\CD (r_punct) suspected_21\VBN (l_nsubjpass) neurotoxicity_12\NN
D005472_D020258 NONE 5-fluorouracil_3\CD (r_punct) neurotoxicity_4\NN
D002945_D013274 NONE cisplatinum_11\NN (l_appos) hours_24\NNS (l_conj) acid_28\NN (l_prep) for_29\IN (l_pobj) adenocarcinoma_33\NN
D002955_D001523 NONE acid_38\NN (r_compound) infusion_39\NN (r_pobj) during_26\IN (r_prep) lasting_21\VBG (r_advcl) lapsed_15\VBD (r_conj) developed_1\VBD (l_dobj) symptoms_4\NNS (l_prep) of_5\IN (l_pobj) confusion_7\NN (l_conj) disorientation_9\NN (l_conj) irritability_11\NN
D002955_D003221 CID acid_13\NN (r_conj) infusion_8\NN (r_pobj) by_3\IN (r_agent) induced_2\VBN (l_nsubj) confusion_1\NN
D002955_D003221 CID acid_38\NN (r_compound) infusion_39\NN (r_pobj) during_26\IN (r_prep) lasting_21\VBG (r_advcl) lapsed_15\VBD (r_conj) developed_1\VBD (l_dobj) symptoms_4\NNS (l_prep) of_5\IN (l_pobj) confusion_7\NN
D002955_D003221 CID acid_38\NN (r_compound) infusion_39\NN (r_pobj) during_26\IN (r_prep) lasting_21\VBG (r_advcl) lapsed_15\VBD (r_conj) developed_1\VBD (l_dobj) symptoms_4\NNS (l_prep) of_5\IN (l_pobj) confusion_7\NN (l_conj) disorientation_9\NN
D005047_D013274 NONE etoposide_13\NN (r_conj) cisplatinum_11\NN (l_appos) hours_24\NNS (l_conj) acid_28\NN (l_prep) for_29\IN (l_pobj) adenocarcinoma_33\NN
D002955_D013274 NONE acid_28\NN (l_prep) for_29\IN (l_pobj) adenocarcinoma_33\NN
C007419_D020258 NONE dihydrouracil_22\VBN (r_compound) dehydrogenase_23\NN (r_compound) deficiency_24\NN (r_conj) deficiency_19\NN (r_conj) blockade_12\NN (r_pobj) to_8\IN (r_prep) due_7\JJ (r_acomp) be_6\VB (l_nsubj) pathogenesis_1\NN (l_prep) of_2\IN (l_pobj) neurotoxicity_4\NN
D005472_D013274 NONE 5-fluorouracil_18\CD (r_punct) m2/24_23\NN (r_compound) hours_24\NNS (l_conj) acid_28\NN (l_prep) for_29\IN (l_pobj) adenocarcinoma_33\NN
D005472_D001523 NONE 5-fluorouracil_35\CD (r_punct) of_34\IN (r_prep) dose_29\NN (r_nmod) infusion_39\NN (r_pobj) during_26\IN (r_prep) lasting_21\VBG (r_advcl) lapsed_15\VBD (r_conj) developed_1\VBD (l_dobj) symptoms_4\NNS (l_prep) of_5\IN (l_pobj) confusion_7\NN (l_conj) disorientation_9\NN (l_conj) irritability_11\NN
2234245
D003676_D064420 NONE desferrioxamine_10\NN (r_pobj) of_9\IN (r_prep) doses_8\NNS (r_dobj) receiving_5\VBG (r_acl) patients_4\NNS (r_pobj) in_3\IN (r_prep) appeared_2\VBD (l_nsubj) toxicity_1\NN
D003676_D014786 NONE desferrioxamine_8\NN (r_dobj) receiving_7\VBG (r_acl) patients_6\NNS (r_pobj) in_4\IN (r_prep) toxicity_3\NN
D003676_D014786 NONE desferrioxamine_10\NN (r_dobj) receiving_9\VBG (r_acl) patients_8\NNS (r_pobj) During_0\IN (r_prep) monitored_25\VBN (l_prep) for_26\IN (l_pobj) detection_27\NN (l_prep) of_28\IN (l_pobj) toxicity_30\NN
D003676_D014786 NONE desferrioxamine_15\NN (r_dobj) receiving_14\VBG (r_acl) patients_13\NNS (r_pobj) in_11\IN (r_prep) complication_10\NN (r_attr) is_6\VBZ (l_nsubj) toxicity_5\NN
D003676_D034381 NONE Desferrioxamine_0\NNP (r_compound) withdrawal_1\NN (r_nsubj) resulted_2\VBD (l_conj) reversal_22\NN (l_prep) of_23\IN (l_pcomp) hearing_24\NN (l_dobj) loss_25\NN
D003676_D006311 NONE desferrioxamine_8\NN (r_dobj) receiving_7\VBG (r_acl) patients_6\NNS (r_pobj) in_4\IN (r_prep) toxicity_3\NN
D003676_D006311 NONE desferrioxamine_10\NN (r_dobj) receiving_9\VBG (r_acl) patients_8\NNS (r_pobj) During_0\IN (r_prep) monitored_25\VBN (l_prep) for_26\IN (l_pobj) detection_27\NN (l_prep) of_28\IN (l_pobj) toxicity_30\NN
D003676_D006311 NONE desferrioxamine_15\NN (r_dobj) receiving_14\VBG (r_acl) patients_13\NNS (r_pobj) in_11\IN (r_prep) complication_10\NN (r_attr) is_6\VBZ (l_nsubj) toxicity_5\NN
-1_D064420 NONE aluminium_19\NN (r_conj) ferritin_17\NN (r_nmod) levels_21\NNS (r_pobj) of_16\IN (r_prep) normalization_15\NN (r_pobj) with_13\IN (r_prep) coincided_12\VBD (r_conj) appeared_2\VBD (l_nsubj) toxicity_1\NN
17437408
D010862_D012640 CID pilocarpine_11\NN (r_npadvmod) induced_13\VBN (r_amod) seizures_14\NNS
18020536
D001569_D004244 CID BZDs_4\NNP (r_nmod) RDs_6\NNS (r_pobj) of_3\IN (r_prep) use_2\NN (r_nsubjpass) associated_8\VBN (l_prep) with_9\IN (l_pobj) dizziness_10\NN
D001569_D005221 CID BZDs_4\NNP (r_nmod) RDs_6\NNS (r_pobj) of_3\IN (r_prep) use_2\NN (r_nsubjpass) associated_8\VBN (l_npadvmod) inability_12\NN (l_acl) sleep_14\VB (l_prep) after_15\IN (l_pcomp) awaking_16\VBG (l_prep) at_17\IN (l_pobj) night_18\NN (l_conj) tiredness_20\NN
D001569_D003866 CID BZDs_4\NNP (r_nmod) RDs_6\NNS (r_pobj) of_3\IN (r_prep) use_2\NN (r_nsubjpass) associated_8\VBN (l_npadvmod) inability_12\NN (l_acl) sleep_14\VB (l_prep) after_15\IN (l_conj) with_31\IN (l_pobj) symptoms_34\NNS
D001569_D007319 CID BZDs_4\NNP (r_nmod) RDs_6\NNS (r_pobj) of_3\IN (r_prep) use_2\NN (r_nsubjpass) associated_8\VBN (l_npadvmod) inability_12\NN (l_acl) sleep_14\VB
9625142
D001663_D000744 NONE bilirubin_21\NN (r_pobj) in_19\IN (r_prep) increase_18\NN (l_conj) decrease_24\NN (l_prep) in_25\IN (l_pobj) concentration_27\NN (l_acl) caused_28\VBN (l_agent) by_29\IN (l_pobj) anemia_33\NN
D047090_D000744 NONE lactam_11\NN (r_compound) antibiotic_12\NN (r_dobj) withholding_8\VBG (r_pcomp) after_7\IN (r_prep) returned_4\VBD (r_advcl) was_15\VBD (l_attr) increase_18\NN (l_conj) decrease_24\NN (l_prep) in_25\IN (l_pobj) concentration_27\NN (l_acl) caused_28\VBN (l_agent) by_29\IN (l_pobj) anemia_33\NN
D002443_D000744 CID ceftriaxone_11\NN (r_pobj) by_10\IN (r_prep) induced_9\VBN (l_nsubj) hepatitis_1\NNP (l_appos) anemia_5\NN
D002443_-1 NONE ceftriaxone_11\NN (r_pobj) by_10\IN (r_prep) induced_9\VBN (l_nsubj) hepatitis_1\NNP (l_appos) anemia_5\NN (l_conj) erythroblastocytopenia_8\NN
D002443_D056486 CID ceftriaxone_11\NN (r_pobj) by_10\IN (r_prep) induced_9\VBN (l_nsubj) hepatitis_1\NNP
D002443_D056486 CID ceftriaxone_12\NN (r_dobj) ingesting_10\VBG (r_pcomp) after_9\IN (r_prep) developed_5\VBD (l_dobj) hepatitis_7\NN
D001663_-1 NONE bilirubin_21\NN (r_pobj) in_19\IN (r_prep) increase_18\NN (l_conj) decrease_24\NN (l_prep) in_25\IN (l_pobj) concentration_27\NN (l_acl) caused_28\VBN (l_agent) by_29\IN (l_pobj) anemia_33\NN (l_conj) erythroblastocytopenia_35\NN
D047090_-1 NONE lactam_11\NN (r_compound) antibiotic_12\NN (r_dobj) withholding_8\VBG (r_pcomp) after_7\IN (r_prep) returned_4\VBD (r_advcl) was_15\VBD (l_attr) increase_18\NN (l_conj) decrease_24\NN (l_prep) in_25\IN (l_pobj) concentration_27\NN (l_acl) caused_28\VBN (l_agent) by_29\IN (l_pobj) anemia_33\NN (l_conj) erythroblastocytopenia_35\NN
16403073
D007654_D016171 CID Ketoconazole_0\NNP (r_nsubj) induced_1\VBD (l_dobj) pointes_4\FW
D007654_D016171 CID ketoconazole_24\RB (r_dobj) taking_23\VBG (r_pcomp) after_22\IN (r_prep) torsades_16\NNS (l_dobj) pointes_18\FW
D007654_D016171 CID ketoconazole_24\RB (r_dobj) taking_23\VBG (r_pcomp) after_22\IN (r_prep) torsades_16\NNS (l_dobj) pointes_18\FW (l_appos) TdP_20\NN
D007654_D016171 CID ketoconazole_13\RB (r_nsubj) prolong_16\VB (l_conj) induce_20\VB (l_dobj) TdP._21\NN
D007654_D008133 CID ketoconazole_24\RB (r_dobj) taking_23\VBG (r_pcomp) after_22\IN (r_prep) torsades_16\NNS (r_conj) developed_9\VBD (l_dobj) interval_14\NN
D007654_D008133 CID ketoconazole_5\JJ (r_nsubjpass) administered_7\VBN (l_prep) to_8\IN (l_pobj) patients_9\NNS (l_prep) with_10\IN (l_pobj) factors_12\NNS (l_prep) for_13\IN (l_pobj) syndrome_17\NN
D007654_D009181 NONE ketoconazole_24\RB (r_dobj) taking_23\VBG (l_prep) for_25\IN (l_pobj) treatment_26\NN (l_prep) of_27\IN (l_pobj) infection_29\NN
D007654_D003324 NONE ketoconazole_24\RB (r_dobj) taking_23\VBG (r_pcomp) after_22\IN (r_prep) torsades_16\NNS (r_conj) developed_9\VBD (r_relcl) woman_3\NN (l_prep) with_4\IN (l_pobj) disease_7\NN
3341566
D009599_D007022 CID nitroprusside_10\RB (r_advmod) induced_12\VBN (r_amod) hypotension_13\NN
D009599_D007022 CID SNP_21\NNP (r_compound) group_22\NN (r_pobj) in_19\IN (r_prep) that_18\DT (r_pobj) with_17\IN (r_prep) compared_16\VBN (r_prep) higher_15\RBR (r_acomp) was_8\VBD (l_prep) During_0\IN (l_pobj) hypotension_4\NN
D009599_D007022 CID SNP_7\NNP (r_compound) groups_8\NNS (r_pobj) in_3\IN (r_prep) Hg_2\NNP (l_prep) during_12\IN (l_pobj) hypotension_13\NN
D009599_D006470 NONE nitroprusside_10\RB (r_advmod) induced_12\VBN (r_amod) hypotension_13\NN (r_pobj) during_8\IN (r_prep) than_7\IN (r_prep) is_3\VBZ (l_prep) during_5\IN (l_pobj) hemorrhage_6\NN
D009599_D006470 NONE nitroprusside_28\NN (r_advcl) decreased_4\VBN (l_prep) for_9\IN (l_pobj) minutes_11\NNS (l_prep) by_13\IN (l_pobj) hemorrhage_14\NN
D009599_D006470 NONE nitroprusside_28\NN (r_advcl) decreased_4\VBN (l_prep) for_9\IN (l_pobj) minutes_11\NNS (l_prep) by_13\IN (l_pobj) hemorrhage_14\NN (l_appos) HEM_16\NNP
D009599_D006470 NONE SNP_30\NNP (r_dep) n_32\CC (r_npadvmod) nitroprusside_28\NN (r_advcl) decreased_4\VBN (l_prep) for_9\IN (l_pobj) minutes_11\NNS (l_prep) by_13\IN (l_pobj) hemorrhage_14\NN
D009599_D006470 NONE SNP_30\NNP (r_dep) n_32\CC (r_npadvmod) nitroprusside_28\NN (r_advcl) decreased_4\VBN (l_prep) for_9\IN (l_pobj) minutes_11\NNS (l_prep) by_13\IN (l_pobj) hemorrhage_14\NN (l_appos) HEM_16\NNP
D009599_D006470 NONE SNP_21\NNP (r_compound) group_22\NN (r_pobj) in_19\IN (r_prep) that_18\DT (r_pobj) with_17\IN (r_prep) compared_16\VBN (r_prep) higher_15\RBR (r_acomp) was_8\VBD (l_prep) During_0\IN (l_pobj) hypotension_4\NN (l_amod) induced_3\VBN (l_npadvmod) HEM_1\NNP
D009599_D006470 NONE SNP_17\NNP (r_compound) group_18\NN (r_pobj) in_15\IN (r_prep) Hg_14\NNP (r_appos) mm_13\NN (r_pobj) with_9\IN (r_prep) compared_8\VBN (r_prep) Hg_2\NNP (l_prep) in_3\IN (l_pobj) group_6\NN (l_compound) HEM_5\NNP
D009599_D006470 NONE SNP_7\NNP (r_compound) groups_8\NNS (l_nmod) HEM_5\NNP
15009014
D001285_D006940 NONE atropine_16\NN (r_pobj) by_10\IN (r_agent) abolished_9\VBN (l_nsubjpass) increases_2\NNS (l_prep) in_3\IN (l_pobj) flow_6\NN
D002211_D006940 CID Capsaicin_0\NNS (r_nsubj) applied_7\VBN (l_conj) induced_13\VBN (l_dobj) increases_14\NNS (l_prep) in_15\IN (l_pobj) flow_20\NN
19058010
D007545_D009203 CID isoproterenol_9\JJ (r_pobj) in_8\IN (r_prep) combination_7\NN (r_pobj) of_1\IN (r_prep) Effect_0\NN (r_nsubj) induced_10\VBN (l_dobj) infarction_12\NN
D007545_D009203 CID isoproterenol_37\NN (r_pobj) in_36\IN (r_prep) bound_34\VBN (r_acl) effects_9\NNS (r_dobj) investigate_6\VB (r_xcomp) aimed_4\VBN (l_parataxis) ISO)-induced_39\VBN (l_dobj) infarction_41\NN
D007545_D009203 CID ISO)-induced_39\VBN (l_dobj) infarction_41\NN
D007545_D009203 CID ISO_14\NN (r_pobj) during_13\IN (r_prep) effect_6\NN (r_dobj) indicate_2\VBP (l_ccomp) induced_15\VBN (l_dobj) infarction_17\NN
D010936_D009203 NONE tea_3\NN (r_nmod) combination_7\NN (r_pobj) of_1\IN (r_prep) Effect_0\NN (r_nsubj) induced_10\VBN (l_dobj) infarction_12\NN
D010936_D009203 NONE tea_12\NN (r_pobj) of_10\IN (r_prep) effects_9\NNS (r_dobj) investigate_6\VB (r_xcomp) aimed_4\VBN (l_parataxis) ISO)-induced_39\VBN (l_dobj) infarction_41\NN
D010936_D009203 NONE tea_9\NN (r_pobj) of_7\IN (r_prep) effect_6\NN (r_dobj) indicate_2\VBP (l_ccomp) induced_15\VBN (l_dobj) infarction_17\NN
D014810_D009203 NONE E_6\NN (r_conj) tea_3\NN (r_nmod) combination_7\NN (r_pobj) of_1\IN (r_prep) Effect_0\NN (r_nsubj) induced_10\VBN (l_dobj) infarction_12\NN
D014810_D009203 NONE E_15\NN (r_conj) tea_12\NN (r_pobj) of_10\IN (r_prep) effects_9\NNS (r_dobj) investigate_6\VB (r_xcomp) aimed_4\VBN (l_parataxis) ISO)-induced_39\VBN (l_dobj) infarction_41\NN
D014810_D009203 NONE E_12\NN (r_conj) tea_9\NN (r_pobj) of_7\IN (r_prep) effect_6\NN (r_dobj) indicate_2\VBP (l_ccomp) induced_15\VBN (l_dobj) infarction_17\NN
2096243
C017367_D019965 CID Carmofur_0\NN (r_npadvmod) induced_2\VBN (r_amod) disorders_5\NNS
C017367_D019965 CID carmofur_19\NN (r_npadvmod) induced_21\VBN (r_amod) leukoencephalopathy_22\NN (r_pobj) of_18\IN (r_prep) onset_17\NN (r_pobj) after_15\IN (r_prep) period_14\NN (r_pobj) in_11\IN (r_prep) female_10\NN (r_pobj) in_5\IN (r_prep) observed_4\VBN (l_nsubjpass) disorder_2\NN
C017367_D056784 CID carmofur_19\NN (r_npadvmod) induced_21\VBN (r_amod) leukoencephalopathy_22\NN
C017367_D056784 CID carmofur_2\NN (r_npadvmod) induced_4\VBN (r_amod) leukoencephalopathy_5\JJ
C017367_D010554 NONE carmofur_2\NN (r_npadvmod) induced_4\VBN (r_amod) leukoencephalopathy_5\JJ (r_nsubj) result_8\VB (l_prep) in_9\IN (l_pobj) syndrome_12\NN
3676049
D007530_D007022 CID isoflurane_6\RB (r_npadvmod) induced_8\VBN (r_amod) hypotension_9\NN
D007530_D007022 CID isoflurane_12\RB (r_npadvmod) induced_14\VBN (r_amod) hypotension_15\NN
D007530_D007022 CID isoflurane_19\NN (r_pobj) of_18\IN (r_prep) dose_17\NN (r_dobj) increasing_15\VBG (r_pcomp) by_14\IN (r_prep) induced_13\VBN (l_nsubjpass) hypotension_1\NN
D008628_D007022 NONE Hg_11\NNP (r_pobj) of_6\IN (r_prep) MAP_5\NNP (r_pobj) to_2\IN (r_prep) hypotension_1\NN
D014978_D013345 NONE xenon-133_24\. (r_punct) measured_4\VBN (l_prep) after_9\IN (l_pobj) haemorrhage_12\NN
D010100_D007022 NONE oxygen_8\NN (r_pobj) for_7\IN (r_prep) rate_6\NN (r_conj) flow_2\NN (r_nsubjpass) measured_10\VBN (l_prep) during_11\IN (l_pobj) hypotension_15\NN
D007530_D002532 NONE isoflurane_6\RB (r_npadvmod) induced_8\VBN (r_amod) hypotension_9\NN (l_prep) in_10\IN (l_pobj) patients_11\NNS (l_acl) subjected_12\VBN (l_prep) for_15\IN (l_pobj) aneurysms_17\NNS
D007530_D002532 NONE isoflurane_12\RB (r_npadvmod) induced_14\VBN (r_amod) hypotension_15\NN (l_prep) in_16\IN (l_pobj) patients_18\NNS (l_acl) subjected_19\VBN (l_prep) to_20\IN (l_pobj) craniotomy_21\NN (l_prep) for_22\IN (l_pobj) clipping_23\NN (l_prep) of_24\IN (l_pobj) aneurysm_27\NN
D007530_D000783 NONE isoflurane_7\JJ (r_amod) concentration_8\NN (r_nsubjpass) reduced_10\VBN (l_prep) After_0\IN (l_pobj) clipping_2\NN (l_prep) of_3\IN (l_pobj) aneurysm_5\NN
D010100_D002532 NONE oxygen_8\NN (r_pobj) for_7\IN (r_prep) rate_6\NN (r_conj) flow_2\NN (r_nsubjpass) measured_10\VBN (l_prep) during_11\IN (l_pobj) hypotension_15\NN (l_prep) in_16\IN (l_pobj) patients_18\NNS (l_acl) subjected_19\VBN (l_prep) to_20\IN (l_pobj) craniotomy_21\NN (l_prep) for_22\IN (l_pobj) clipping_23\NN (l_prep) of_24\IN (l_pobj) aneurysm_27\NN
10706004
D011188_D003866 NONE K)-ATPase_28\NNP (r_pobj) of_23\IN (r_prep) properties_22\NNS (r_pobj) of_19\IN (r_prep) consequence_18\NN (r_pobj) as_16\IN (r_prep) accompanied_9\VBN (l_agent) by_10\IN (l_pobj) Na+-extrusion_12\NN (l_amod) depressed_11\JJ
D009569_D003866 NONE NO_2\JJ (r_compound) synthase_4\NN (r_pobj) of_1\IN (r_prep) Inhibition_0\NN (r_nsubj) induced_5\VBD (l_dobj) hypertension_8\NN (l_acl) accompanied_9\VBN (l_agent) by_10\IN (l_pobj) Na+-extrusion_12\NN (l_amod) depressed_11\JJ
D019331_D006973 NONE ester_49\NN (r_appos) kg_40\NNS (r_pobj) with_36\IN (r_prep) inhibition_35\NN (r_pobj) by_31\IN (r_prep) rats_30\NNS (r_pobj) in_29\IN (r_prep) induced_28\VBN (r_advcl) studied_14\VBD (l_dobj) response_16\NN (l_prep) of_17\IN (l_pobj) K)-ATPase_22\NNP (l_prep) to_23\IN (l_pobj) hypertension_27\NN
D019331_D006973 NONE NAME_53\NNP (r_appos) ester_49\NN (r_appos) kg_40\NNS (r_pobj) with_36\IN (r_prep) inhibition_35\NN (r_pobj) by_31\IN (r_prep) rats_30\NNS (r_pobj) in_29\IN (r_prep) induced_28\VBN (r_advcl) studied_14\VBD (l_dobj) response_16\NN (l_prep) of_17\IN (l_pobj) K)-ATPase_22\NNP (l_prep) to_23\IN (l_pobj) hypertension_27\NN
D012964_D003866 NONE Na+-extrusion_12\NN (l_amod) depressed_11\JJ
D012964_D003866 NONE Na+-binding_21\NN (r_compound) properties_22\NNS (r_pobj) of_19\IN (r_prep) consequence_18\NN (r_pobj) as_16\IN (r_prep) accompanied_9\VBN (l_agent) by_10\IN (l_pobj) Na+-extrusion_12\NN (l_amod) depressed_11\JJ
D012964_D003866 NONE Na_26\UH (r_nmod) K)-ATPase_28\NNP (r_pobj) of_23\IN (r_prep) properties_22\NNS (r_pobj) of_19\IN (r_prep) consequence_18\NN (r_pobj) as_16\IN (r_prep) accompanied_9\VBN (l_agent) by_10\IN (l_pobj) Na+-extrusion_12\NN (l_amod) depressed_11\JJ
D009569_D006973 CID oxide_17\NN (r_npadvmod) deficient_18\JJ (r_amod) hypertension_19\NN
D009569_D006973 CID NO_2\DT (r_det) synthesis_3\NN (r_pobj) of_1\IN (r_prep) Inhibition_0\NN (r_nsubj) induces_4\VBZ (l_dobj) hypertension_6\NN
D009569_D006973 CID NO_24\JJ (r_npadvmod) deficient_26\JJ (r_amod) hypertension_27\NN
D009569_D006973 CID NO_32\JJ (r_compound) synthase_34\NN (r_compound) inhibition_35\NN (r_pobj) by_31\IN (r_prep) rats_30\NNS (r_pobj) in_29\IN (r_prep) induced_28\VBN (r_advcl) studied_14\VBD (l_dobj) response_16\NN (l_prep) of_17\IN (l_pobj) K)-ATPase_22\NNP (l_prep) to_23\IN (l_pobj) hypertension_27\NN
D009569_D006973 CID NO_2\JJ (r_compound) synthase_4\NN (r_pobj) of_1\IN (r_prep) Inhibition_0\NN (r_nsubj) induced_5\VBD (l_dobj) hypertension_8\NN
D000255_D006973 NONE ATP_4\NNP (r_conj) sodium_2\NN (r_nmod) affinities_5\NNS (r_pobj) of_1\IN (r_prep) Changes_0\NNS (l_prep) during_13\IN (l_conj) after_15\IN (l_pobj) hypertension_19\NN
D000255_D006973 NONE ATP_20\NNP (r_npadvmod) binding_22\VBG (r_amod) site_23\NN (r_pobj) of_18\IN (r_prep) affinity_17\NN (r_pobj) due_14\IN (r_prep) increased_12\VBD (r_parataxis) activity_6\NN (l_prep) After_0\IN (l_pobj) recovery_1\NN (l_prep) from_2\IN (l_pobj) hypertension_3\NN
D000255_D006973 NONE ATP_33\NNP (r_pobj) for_32\IN (r_prep) value_31\NN (r_pobj) from_27\IN (r_prep) revealed_26\VBN (r_advcl) activity_6\NN (l_prep) After_0\IN (l_pobj) recovery_1\NN (l_prep) from_2\IN (l_pobj) hypertension_3\NN
D012964_D006973 NONE sodium_2\NN (r_nmod) affinities_5\NNS (r_pobj) of_1\IN (r_prep) Changes_0\NNS (l_prep) during_13\IN (l_conj) after_15\IN (l_pobj) hypertension_19\NN
D012964_D006973 NONE Na_10\UH (r_nmod) K)-ATPase_12\NNP (r_pobj) of_6\IN (r_prep) affinities_5\NNS (r_pobj) of_1\IN (r_prep) Changes_0\NNS (l_prep) during_13\IN (l_conj) after_15\IN (l_pobj) hypertension_19\NN
D012964_D006973 NONE sodium_9\NN (r_compound) level_10\NN (r_pobj) of_7\IN (r_prep) elevation_6\NN (r_nsubjpass) documented_12\VBN (l_prep) In_0\IN (l_pobj) models_2\NNS (l_prep) of_3\IN (l_pobj) hypertension_4\NN
D012964_D006973 NONE Na+_11\NNP (r_pobj) of_10\IN (r_prep) transport_9\NN (r_pobj) in_7\IN (r_prep) disturbances_6\NNS (r_pobj) of_5\IN (r_prep) basis_4\NN (r_dobj) assess_1\VB (r_advcl) studied_14\VBD (l_dobj) response_16\NN (l_prep) of_17\IN (l_pobj) K)-ATPase_22\NNP (l_prep) to_23\IN (l_pobj) hypertension_27\NN
D012964_D006973 NONE Na_20\UH (r_nmod) K)-ATPase_22\NNP (l_prep) to_23\IN (l_pobj) hypertension_27\NN
D012964_D006973 NONE Na_9\NNP (r_npadvmod) increased_12\VBD (r_parataxis) activity_6\NN (l_prep) After_0\IN (l_pobj) recovery_1\NN (l_prep) from_2\IN (l_pobj) hypertension_3\NN
D012964_D006973 NONE Na+-extrusion_12\NN (r_pobj) by_10\IN (r_agent) accompanied_9\VBN (r_acl) hypertension_8\NN
D012964_D006973 NONE Na+-binding_21\NN (r_compound) properties_22\NNS (r_pobj) of_19\IN (r_prep) consequence_18\NN (r_pobj) as_16\IN (r_prep) accompanied_9\VBN (r_acl) hypertension_8\NN
D012964_D006973 NONE Na_26\UH (r_nmod) K)-ATPase_28\NNP (r_pobj) of_23\IN (r_prep) properties_22\NNS (r_pobj) of_19\IN (r_prep) consequence_18\NN (r_pobj) as_16\IN (r_prep) accompanied_9\VBN (r_acl) hypertension_8\NN
D011188_D006973 NONE K)-ATPase_12\NNP (r_pobj) of_6\IN (r_prep) affinities_5\NNS (r_pobj) of_1\IN (r_prep) Changes_0\NNS (l_prep) during_13\IN (l_conj) after_15\IN (l_pobj) hypertension_19\NN
D011188_D006973 NONE K)-ATPase_22\NNP (l_prep) to_23\IN (l_pobj) hypertension_27\NN
D011188_D006973 NONE K)-ATPase_11\NNP (r_nsubj) increased_12\VBD (r_parataxis) activity_6\NN (l_prep) After_0\IN (l_pobj) recovery_1\NN (l_prep) from_2\IN (l_pobj) hypertension_3\NN
D011188_D006973 NONE K)-ATPase_28\NNP (r_pobj) of_23\IN (r_prep) properties_22\NNS (r_pobj) of_19\IN (r_prep) consequence_18\NN (r_pobj) as_16\IN (r_prep) accompanied_9\VBN (r_acl) hypertension_8\NN
10737864
D003000_D001919 CID clonidine_14\NN (r_pobj) given_12\VBN (r_prep) induces_15\VBZ (l_dobj) withdrawal_17\NN (l_conj) bradycardia_19\NNP
D003000_D001919 CID clonidine_24\NN (r_poss) effects_27\NNS (r_nsubj) mirror_35\VB (r_ccomp) hypothesized_22\VBD (l_ccomp) exhibits_5\VBZ (l_conj) induces_15\VBZ (l_dobj) withdrawal_17\NN (l_conj) bradycardia_19\NNP
D003000_D001919 CID clonidine_19\NN (r_npadvmod) induced_21\VBN (r_amod) bradycardia_22\NN
12617329
D014508_D007674 NONE urea_10\NN (r_conj) creatinine_8\NN (r_pobj) of_7\IN (r_prep) concentrations_6\NNS (r_dobj) measuring_4\VBG (r_pcomp) by_3\IN (r_prep) assessed_2\VBN (l_nsubjpass) Nephrotoxicity_0\NN
D006170_D007674 NONE Arabic_6\JJ (r_pobj) with_4\IN (r_prep) treatment_3\NN (l_prep) on_7\IN (l_pobj) nephrotoxicity_9\NN
D006170_D007674 NONE Arabic_14\JJ (r_pobj) with_12\IN (r_prep) rats_11\NNS (r_pobj) of_10\IN (r_prep) treatment_9\NN (l_prep) on_15\IN (l_pobj) failure_18\NN (l_acl) induced_19\VBN (l_agent) by_20\IN (l_pobj) nephrotoxicity_25\NN
D006170_D007674 NONE Arabic_6\JJ (r_amod) treatment_7\NN (r_nsubj) induced_9\VBN (l_dobj) amelioration_12\NN (l_prep) of_13\IN (l_pobj) some_14\DT (l_prep) of_15\IN (l_pobj) indices_20\NNS (l_prep) of_21\IN (l_pobj) nephrotoxicity_23\NN
D005839_D007683 NONE GM_1\NNP (r_npadvmod) induced_3\VBN (r_amod) necrosis_6\NN
D005839_D007683 NONE GM_16\NNP (r_dobj) given_15\VBN (r_acl) rats_14\NNS (r_pobj) in_13\IN (r_prep) severe_12\JJ (r_acomp) be_9\VB (r_xcomp) appeared_7\VBD (l_nsubj) necrosis_6\NN
D005839_D007683 NONE GM_25\NNP (r_pobj) given_24\VBN (r_acl) those_23\DT (r_pobj) in_22\IN (r_prep) than_21\IN (r_prep) given_15\VBN (r_acl) rats_14\NNS (r_pobj) in_13\IN (r_prep) severe_12\JJ (r_acomp) be_9\VB (r_xcomp) appeared_7\VBD (l_nsubj) necrosis_6\NN
D005839_D007674 NONE gentamicin_8\NN (r_amod) nephrotoxicity_9\NN
D005839_D007674 NONE gentamicin_21\NN (r_nmod) nephrotoxicity_25\NN
D005839_D007674 NONE GM_23\NNP (r_nmod) nephrotoxicity_25\NN
D005839_D007674 NONE GM_22\NNP (r_compound) nephrotoxicity_23\NN
D006170_D058186 CID Arabic_14\JJ (r_pobj) with_12\IN (r_prep) rats_11\NNS (r_pobj) of_10\IN (r_prep) treatment_9\NN (l_prep) on_15\IN (l_pobj) failure_18\NN
D005839_D058186 CID gentamicin_21\NN (r_nmod) nephrotoxicity_25\NN (r_pobj) by_20\IN (r_agent) induced_19\VBN (r_acl) failure_18\NN
D005839_D058186 CID GM_23\NNP (r_nmod) nephrotoxicity_25\NN (r_pobj) by_20\IN (r_agent) induced_19\VBN (r_acl) failure_18\NN
D006170_D007683 NONE Arabic_20\JJ (r_pobj) with_18\IN (r_prep) given_15\VBN (r_acl) rats_14\NNS (r_pobj) in_13\IN (r_prep) severe_12\JJ (r_acomp) be_9\VB (r_xcomp) appeared_7\VBD (l_nsubj) necrosis_6\NN
D003404_D007674 NONE creatinine_8\NN (r_pobj) of_7\IN (r_prep) concentrations_6\NNS (r_dobj) measuring_4\VBG (r_pcomp) by_3\IN (r_prep) assessed_2\VBN (l_nsubjpass) Nephrotoxicity_0\NN
D005978_D007674 NONE glutathione_16\NN (r_conj) measuring_4\VBG (r_pcomp) by_3\IN (r_prep) assessed_2\VBN (l_nsubjpass) Nephrotoxicity_0\NN
D005978_D007674 NONE GSH_18\NNP (r_appos) glutathione_16\NN (r_conj) measuring_4\VBG (r_pcomp) by_3\IN (r_prep) assessed_2\VBN (l_nsubjpass) Nephrotoxicity_0\NN
6466532
D006024_D001919 NONE glycopyrrolate_3\NN (l_prep) in_6\IN (l_pobj) prevention_8\NN (l_prep) of_9\IN (l_pobj) bradycardia_10\NN
D006024_D001919 NONE glycopyrrolate_5\NN (r_pobj) of_4\IN (r_prep) administration_3\NN (r_pobj) of_2\IN (r_prep) effectiveness_1\NN (l_acl) prevent_27\VB (l_dobj) arrhythmia_28\NN (l_conj) bradycardia_30\NNP
D001285_D001919 NONE atropine_5\NN (r_conj) glycopyrrolate_3\NN (l_prep) in_6\IN (l_pobj) prevention_8\NN (l_prep) of_9\IN (l_pobj) bradycardia_10\NN
D001285_D001919 NONE atropine_12\NN (r_conj) kg-1_10\NNS (r_dobj) glycopyrrolate_5\NN (r_pobj) of_4\IN (r_prep) administration_3\NN (r_pobj) of_2\IN (r_prep) effectiveness_1\NN (l_acl) prevent_27\VB (l_dobj) arrhythmia_28\NN (l_conj) bradycardia_30\NNP
D013390_D001145 NONE suxamethonium_17\NN (r_pobj) of_16\IN (r_prep) doses_15\NNS (r_pobj) following_13\VBG (r_prep) bradycardia_10\NN (l_conj) arrhythmias_12\NNS
D013390_D001145 NONE suxamethonium_35\NN (r_pobj) of_34\IN (r_prep) doses_33\NNS (r_pobj) following_31\VBG (r_prep) prevent_27\VB (l_dobj) arrhythmia_28\NN
D013390_D001919 CID suxamethonium_17\NN (r_pobj) of_16\IN (r_prep) doses_15\NNS (r_pobj) following_13\VBG (r_prep) bradycardia_10\NN
D013390_D001919 CID suxamethonium_35\NN (r_pobj) of_34\IN (r_prep) doses_33\NNS (r_pobj) following_31\VBG (r_prep) prevent_27\VB (l_dobj) arrhythmia_28\NN (l_conj) bradycardia_30\NNP
D001285_D001145 NONE atropine_5\NN (r_conj) glycopyrrolate_3\NN (l_prep) in_6\IN (l_pobj) prevention_8\NN (l_prep) of_9\IN (l_pobj) bradycardia_10\NN (l_conj) arrhythmias_12\NNS
D001285_D001145 NONE atropine_12\NN (r_conj) kg-1_10\NNS (r_dobj) glycopyrrolate_5\NN (r_pobj) of_4\IN (r_prep) administration_3\NN (r_pobj) of_2\IN (r_prep) effectiveness_1\NN (l_acl) prevent_27\VB (l_dobj) arrhythmia_28\NN
D006024_D001145 NONE glycopyrrolate_3\NN (l_prep) in_6\IN (l_pobj) prevention_8\NN (l_prep) of_9\IN (l_pobj) bradycardia_10\NN (l_conj) arrhythmias_12\NNS
D006024_D001145 NONE glycopyrrolate_5\NN (r_pobj) of_4\IN (r_prep) administration_3\NN (r_pobj) of_2\IN (r_prep) effectiveness_1\NN (l_acl) prevent_27\VB (l_dobj) arrhythmia_28\NN
9199746
D014640_D013290 NONE vancomycin_14\NNP (l_prep) for_15\IN (l_pobj) endophthalmitis_20\NN
D000583_D064420 NONE amikacin_4\RB (l_nsubj) toxicity_1\NN
D000617_D009877 NONE aminoglycosides_2\NNS (r_nsubj) improved_5\VBN (l_dobj) prognosis_7\NN (l_prep) in_8\IN (l_pobj) endophthalmitis_9\NN
D019793_D013684 NONE fluorescein_1\NN (r_amod) angiography_2\NN (r_nsubj) confirmed_3\VBD (l_dobj) closure_6\NN (l_conj) telangiectasis_8\NN
D000583_D013290 NONE amikacin_6\JJ (r_prep) presumed_5\VBN (l_prep) following_9\VBG (l_pobj) treatment_10\NN (l_prep) with_11\IN (l_pobj) amikacin_12\JJ (l_conj) vancomycin_14\NNP (l_prep) for_15\IN (l_pobj) endophthalmitis_20\NN
D000583_D013290 NONE amikacin_12\JJ (l_conj) vancomycin_14\NNP (l_prep) for_15\IN (l_pobj) endophthalmitis_20\NN
D000617_D007238 NONE aminoglycosides_2\NNS (r_nsubj) improved_5\VBN (r_advcl) impair_14\VB (l_nsubj) infarction_12\NN
D000583_D012164 CID amikacin_6\JJ (l_pobj) toxicity_8\NN
D000583_D012164 CID amikacin_12\JJ (r_pobj) with_11\IN (r_prep) treatment_10\NN (r_pobj) following_9\VBG (r_prep) presumed_5\VBN (l_prep) amikacin_6\JJ (l_pobj) toxicity_8\NN
D014640_D012164 NONE vancomycin_14\NNP (r_conj) amikacin_12\JJ (r_pobj) with_11\IN (r_prep) treatment_10\NN (r_pobj) following_9\VBG (r_prep) presumed_5\VBN (l_prep) amikacin_6\JJ (l_pobj) toxicity_8\NN
17175308
D020123_D007674 NONE SRL_13\NNP (r_pobj) with_12\IN (r_prep) treated_11\VBN (l_prep) due_18\IN (l_pobj) nephropathy_22\NN (l_advmod) CAN_24\VB
D020123_D011507 CID sirolimus_4\VB (r_pobj) to_3\TO (r_prep) conversion_2\NN (r_pobj) after_1\IN (r_prep) Proteinuria_0\NNP
D020123_D011507 CID sirolimus_11\NN (r_compound) therapy_12\NN (r_pobj) of_10\IN (r_prep) consequence_9\NN (r_pobj) as_7\IN (r_prep) reported_6\VBN (l_nsubjpass) proteinuria_3\NN
D020123_D011507 CID SRL_18\NN (r_compound) conversion_19\NN (r_pobj) after_17\IN (r_prep) displayed_14\VBD (l_dobj) proteinuria_16\NN
D020123_D011507 CID SRL_8\NN (r_pobj) of_7\IN (r_prep) use_6\NN (r_pobj) after_4\IN (r_prep) was_2\VBD (l_nsubj) proteinuria_1\NN
D020123_D051436 NONE SRL_13\NNP (r_pobj) with_12\IN (r_prep) treated_11\VBN (l_prep) due_18\IN (l_pobj) nephropathy_22\NN
3750012
D010396_D001172 NONE penicillamine_4\NN (l_conj) therapy_7\NN (l_prep) for_8\IN (l_pobj) arthritis_10\NN
D010396_D001172 NONE penicillamine_16\NN (l_conj) therapy_19\NN (l_prep) for_20\IN (l_pobj) arthritis_22\NN
D002738_D001172 NONE chloroquine_6\NN (r_amod) therapy_7\NN (l_prep) for_8\IN (l_pobj) arthritis_10\NN
D002738_D001172 NONE chloroquine_18\NN (r_compound) therapy_19\NN (l_prep) for_20\IN (l_pobj) arthritis_22\NN
D002738_D009157 CID chloroquine_6\NN (r_amod) therapy_7\NN (r_conj) penicillamine_4\NN (r_pobj) by_3\IN (r_agent) caused_2\VBN (r_acl) gravis_1\NN
D002738_D009157 CID chloroquine_18\NN (r_compound) therapy_19\NN (r_conj) penicillamine_16\NN (r_pobj) after_15\IN (r_prep) had_7\VBD (l_dobj) gravis_14\NN
D010396_D009157 CID penicillamine_4\NN (r_pobj) by_3\IN (r_agent) caused_2\VBN (r_acl) gravis_1\NN
D010396_D009157 CID penicillamine_16\NN (r_pobj) after_15\IN (r_prep) had_7\VBD (l_dobj) gravis_14\NN
18186898
D019259_D009135 CID lamivudine_24\NN (r_pobj) by_23\IN (r_agent) augmented_22\VBN (r_conj) triggered_18\VBN (r_relcl) dysfunction_15\NN (r_pobj) from_13\IN (r_prep) resulted_12\VBN (l_nsubj) dysfunction_7\NN (l_conj) myopathy_9\NNS
D016559_D000138 NONE tacrolimus_1\NN (r_nsubjpass) suspected_3\VBN (l_xcomp) be_5\VB (l_attr) cause_7\NN (l_prep) of_8\IN (l_pobj) acidosis_14\NN
D016559_D000138 NONE tacrolimus_1\NN (r_nsubjpass) suspected_3\VBN (l_conj) replaced_17\VBN (l_agent) by_18\IN (l_pobj) sirolimus_19\NN (l_conj) acidosis_21\NN
D020123_D000138 NONE sirolimus_19\NN (r_pobj) by_18\IN (r_agent) replaced_17\VBN (r_conj) suspected_3\VBN (l_xcomp) be_5\VB (l_attr) cause_7\NN (l_prep) of_8\IN (l_pobj) acidosis_14\NN
D020123_D000138 NONE sirolimus_19\NN (l_conj) acidosis_21\NN
D019259_D005198 CID lamivudine_24\NN (r_pobj) by_23\IN (r_agent) augmented_22\VBN (r_conj) triggered_18\VBN (r_relcl) dysfunction_15\NN (r_pobj) from_13\IN (r_prep) resulted_12\VBN (l_nsubj) dysfunction_7\NN
D016559_D009135 CID tacrolimus_20\NN (r_pobj) by_19\IN (r_agent) triggered_18\VBN (r_relcl) dysfunction_15\NN (r_pobj) from_13\IN (r_prep) resulted_12\VBN (l_nsubj) dysfunction_7\NN (l_conj) myopathy_9\NNS
D019259_D028361 NONE lamivudine_24\NN (r_pobj) by_23\IN (r_agent) augmented_22\VBN (r_conj) triggered_18\VBN (r_relcl) dysfunction_15\NN
D016559_D028361 NONE tacrolimus_20\NN (r_pobj) by_19\IN (r_agent) triggered_18\VBN (r_relcl) dysfunction_15\NN
D016559_D005198 CID tacrolimus_20\NN (r_pobj) by_19\IN (r_agent) triggered_18\VBN (r_relcl) dysfunction_15\NN (r_pobj) from_13\IN (r_prep) resulted_12\VBN (l_nsubj) dysfunction_7\NN
D019259_D006509 NONE Lamivudine_0\NNP (r_nsubjpass) added_2\VBN (l_prep) because_3\IN (l_pobj) infection_9\NN
12084448
D007069_D009207 CID ifosfamide_27\NN (r_pobj) of_26\IN (r_prep) infusion_25\NN (r_pobj) after_23\IN (r_prep) disabling_14\VBG (l_dobj) myoclonus_16\NN
D007069_D009207 CID ifosfamide_12\JJ (r_pobj) of_11\IN (r_prep) infusion_10\NN (r_pobj) during_9\IN (r_prep) presence_6\NN (r_nsubj) suggest_31\VBP (l_ccomp) associated_36\VBN (l_nsubjpass) myoclonus_34\NN
D007069_D009207 CID IFX_41\NNP (r_pobj) of_40\IN (r_prep) use_39\NN (r_pobj) with_37\IN (r_prep) associated_36\VBN (l_nsubjpass) myoclonus_34\NN
D007069_D001927 CID Ifosfamide_0\NNP (r_compound) encephalopathy_1\NN
D007069_D010954 NONE ifosfamide_27\NN (r_pobj) of_26\IN (r_prep) infusion_25\NN (l_prep) for_28\IN (l_pobj) plasmacytoma_29\NN
D007069_D020820 NONE Ifosfamide_0\NNP (r_compound) encephalopathy_1\NN (l_acl) presenting_2\VBG (l_prep) with_3\IN (l_pobj) asterixis_4\NNS
D007069_D020820 NONE ifosfamide_3\NN (r_pobj) of_2\IN (r_prep) administration_1\NN (r_nsubjpass) discontinued_5\VBN (l_conj) resolved_12\VBD (l_nsubj) asterixis_11\NNS
D007069_D020820 NONE ifosfamide_12\JJ (r_pobj) of_11\IN (r_prep) infusion_10\NN (r_pobj) during_9\IN (r_prep) presence_6\NN (l_prep) of_7\IN (l_pobj) asterixis_8\NNS
D007069_D020820 NONE IFX_41\NNP (r_pobj) of_40\IN (r_prep) use_39\NN (r_pobj) with_37\IN (r_prep) associated_36\VBN (r_ccomp) suggest_31\VBP (l_nsubj) presence_6\NN (l_prep) of_7\IN (l_pobj) asterixis_8\NNS
15458908
D020849_D005705 NONE Raloxifene_0\NNP (r_nsubj) increase_3\VB (l_dep) disease_20\NN
D020849_D005705 NONE Raloxifene_0\NNP (r_nsubjpass) associated_2\VBN (l_conj) was_13\VBD (l_attr) risk_16\NN (l_prep) for_17\IN (l_pobj) cataracts_18\NNS (l_conj) disease_21\NN
D020849_D054556 CID raloxifene_11\NN (r_nsubjpass) associated_13\VBN (l_prep) with_14\IN (l_pobj) risk_17\NN (l_prep) for_18\IN (l_pobj) thromboembolism_20\NN
D020849_D054556 CID Raloxifene_0\NNP (r_nsubjpass) associated_2\VBN (l_prep) with_3\IN (l_pobj) risk_6\NN (l_prep) for_7\IN (l_pobj) thromboembolism_9\NN
D020849_D004714 NONE Raloxifene_0\NNP (r_nsubj) increase_3\VB (l_dep) disease_20\NN (l_appos) CI_27\NNP (l_appos) hyperplasia_34\NN
D020849_D004714 NONE Raloxifene_0\NNP (r_nsubjpass) associated_2\VBN (l_conj) was_13\VBD (l_attr) risk_16\NN (l_prep) for_17\IN (l_pobj) cataracts_18\NNS (l_conj) disease_21\NN (l_conj) hyperplasia_24\NN
D020849_D002386 NONE Raloxifene_0\NNP (r_nsubj) increase_3\VB (l_dobj) risk_4\NN (l_prep) for_5\IN (l_pobj) cataracts_6\NNS
D020849_D002386 NONE Raloxifene_0\NNP (r_nsubjpass) associated_2\VBN (l_conj) was_13\VBD (l_attr) risk_16\NN (l_prep) for_17\IN (l_pobj) cataracts_18\NNS
D020849_D010024 NONE Raloxifene_4\NNP (r_compound) Evaluation_5\NNP (r_pobj) of_3\IN (r_prep) Outcomes_2\NNPS (r_nsubj) enrolled_17\VBD (l_prep) with_21\IN (l_pobj) osteoporosis_22\NN
D020849_D016889 NONE Raloxifene_0\NNP (r_nsubj) increase_3\VB (l_dep) disease_20\NN (l_appos) CI_27\NNP (l_appos) hyperplasia_34\NN (l_appos) %_40\NN (l_conj) cancer_49\NN
D020849_D016889 NONE Raloxifene_0\NNP (r_nsubjpass) associated_2\VBN (l_conj) was_13\VBD (l_attr) risk_16\NN (l_prep) for_17\IN (l_pobj) cataracts_18\NNS (l_conj) disease_21\NN (l_conj) hyperplasia_24\NN (l_conj) cancer_28\NN
17491223
D017256_D017202 NONE Sestamibi_46\NNP (r_nmod) emission_50\NN (r_dobj) using_43\VBG (r_conj) detecting_36\VBG (l_dobj) ischemia_41\NN
D004280_D017202 CID dobutamine_14\NN (r_npadvmod) induced_16\VBN (r_amod) ischemia_18\NN
D004280_D017202 CID dobutamine_8\NN (r_npadvmod) induced_10\VBN (r_amod) ischemia_12\NN
D004280_D017202 CID dobutamine_37\NN (r_npadvmod) induced_39\VBN (r_amod) ischemia_41\NN
D017256_D007511 NONE Sestamibi_46\NNP (r_nmod) emission_50\NN (r_dobj) using_43\VBG (r_conj) detecting_36\VBG (r_pcomp) for_35\IN (r_prep) assess_3\VB (l_conj) computed_51\VBD (l_advcl) assess_60\VB (l_dobj) presence_62\NN (l_prep) of_65\IN (l_pobj) ischemia_66\NN
D004280_D007511 NONE dobutamine_37\NN (r_npadvmod) induced_39\VBN (r_amod) ischemia_41\NN (r_dobj) detecting_36\VBG (r_pcomp) for_35\IN (r_prep) assess_3\VB (l_conj) computed_51\VBD (l_advcl) assess_60\VB (l_dobj) presence_62\NN (l_prep) of_65\IN (l_pobj) ischemia_66\NN
10091617
D012642_D010300 NONE Selegiline_0\NNP (r_advmod) induced_2\VBN (l_dobj) hypotension_4\NN (l_prep) in_5\IN (l_pobj) disease_8\NN
D012642_D010300 NONE selegiline_30\NN (r_dobj) receive_27\VB (r_xcomp) randomized_25\VBN (r_acl) mortality_15\NN (r_dobj) found_12\VBD (l_nsubj) trial_11\NN (l_nmod) Group_7\NNP (l_compound) Disease_5\NNP
D012642_D010300 NONE selegiline_30\NN (r_dobj) receive_27\VB (r_xcomp) randomized_25\VBN (r_acl) mortality_15\NN (l_prep) in_16\IN (l_pobj) patients_17\NNS (l_prep) with_18\IN (l_pobj) disease_21\NN
D012642_D010300 NONE selegiline_30\NN (r_dobj) receive_27\VB (r_xcomp) randomized_25\VBN (r_acl) mortality_15\NN (l_prep) in_16\IN (l_pobj) patients_17\NNS (l_prep) with_18\IN (l_pobj) disease_21\NN (l_appos) PD_23\NNP
D012642_D010300 NONE selegiline_17\RB (r_dobj) receiving_16\VBG (r_acl) patients_15\NNS (l_compound) PD_14\NNP
D012642_D010300 NONE selegiline_18\NN (r_pobj) on_17\IN (r_prep) marked_10\VBN (l_prep) in_11\IN (l_pobj) patients_16\NNS (l_compound) PD_15\NNP
D007980_D007024 NONE dopa_11\NNP (r_conj) therapy_5\NN (r_nsubjpass) associated_13\VBN (l_prep) with_14\IN (l_pobj) hypotension_18\NN
D007980_D007024 NONE dopa_13\NNP (r_pobj) with_10\IN (r_prep) combination_9\NN (r_pobj) in_8\IN (r_prep) selegiline_7\NN (r_nsubjpass) associated_15\VBN (l_prep) with_16\IN (l_pobj) hypotension_19\NN
D012642_D007024 CID Selegiline_0\NNP (r_advmod) induced_2\VBN (l_dobj) hypotension_4\NN
D012642_D007024 CID selegiline_7\NN (r_pobj) with_6\IN (r_prep) therapy_5\NN (r_nsubjpass) associated_13\VBN (l_prep) with_14\IN (l_pobj) hypotension_18\NN
D012642_D007024 CID selegiline_25\NN (r_pobj) of_24\IN (r_prep) withdrawal_23\NN (r_pobj) by_22\IN (r_agent) abolished_21\VBN (r_relcl) hypotension_18\NN
D012642_D007024 CID selegiline_29\NN (r_dobj) stopping_28\VBG (l_prep) in_30\IN (l_pobj) expectation_32\NN (l_acl) shed_36\VB (l_prep) on_38\IN (l_pobj) mechanisms_40\NNS (l_relcl) causes_45\VBZ (l_dobj) hypotension_47\NN
D012642_D007024 CID selegiline_18\NN (r_pobj) on_17\IN (r_prep) marked_10\VBN (r_relcl) hypotension_7\NN
D012642_D007024 CID selegiline_9\NN (r_pobj) of_8\IN (r_prep) withdrawal_7\NN (r_pobj) after_6\IN (r_prep) ameliorated_3\VBN (l_nsubjpass) hypotension_1\NN
D012642_D007024 CID selegiline_1\NN (r_dobj) Stopping_0\VBG (r_csubj) reduced_4\VBD (l_dobj) pressures_11\NNS
D012642_D007024 CID selegiline_7\NN (r_nsubjpass) associated_15\VBN (l_prep) with_16\IN (l_pobj) hypotension_19\NN
D007980_D010300 NONE dopa_36\NN (r_nsubj) compared_37\VBN (r_conj) found_12\VBD (l_nsubj) trial_11\NN (l_nmod) Group_7\NNP (l_compound) Disease_5\NNP
D007980_D010300 NONE dopa_36\NN (r_nsubj) compared_37\VBN (r_conj) found_12\VBD (l_dobj) mortality_15\NN (l_prep) in_16\IN (l_pobj) patients_17\NNS (l_prep) with_18\IN (l_pobj) disease_21\NN
D007980_D010300 NONE dopa_36\NN (r_nsubj) compared_37\VBN (r_conj) found_12\VBD (l_dobj) mortality_15\NN (l_prep) in_16\IN (l_pobj) patients_17\NNS (l_prep) with_18\IN (l_pobj) disease_21\NN (l_appos) PD_23\NNP
D007980_D010300 NONE dopa_43\NN (r_dobj) taking_40\VBG (r_acl) those_39\DT (r_pobj) with_38\IN (r_prep) compared_37\VBN (r_conj) found_12\VBD (l_nsubj) trial_11\NN (l_nmod) Group_7\NNP (l_compound) Disease_5\NNP
D007980_D010300 NONE dopa_43\NN (r_dobj) taking_40\VBG (r_acl) those_39\DT (r_pobj) with_38\IN (r_prep) compared_37\VBN (r_conj) found_12\VBD (l_dobj) mortality_15\NN (l_prep) in_16\IN (l_pobj) patients_17\NNS (l_prep) with_18\IN (l_pobj) disease_21\NN
D007980_D010300 NONE dopa_43\NN (r_dobj) taking_40\VBG (r_acl) those_39\DT (r_pobj) with_38\IN (r_prep) compared_37\VBN (r_conj) found_12\VBD (l_dobj) mortality_15\NN (l_prep) in_16\IN (l_pobj) patients_17\NNS (l_prep) with_18\IN (l_pobj) disease_21\NN (l_appos) PD_23\NNP
2951327
D005996_D007022 CID nitroglycerin_103\NN (r_conj) hydralazine_101\NN (r_pobj) by_100\IN (r_agent) induced_99\VBN (r_acl) hypotension_98\NN
D009638_D007022 NONE norepinephrine_76\NN (r_amod) rate_78\NN (r_pobj) of_74\IN (r_prep) augmentation_73\NN (r_conj) tachycardia_70\NN (r_conj) +/-_45\NN (r_appos) was_29\VBD (l_conj) observed_90\VBN (l_advcl) is_93\VBZ (l_prep) in_94\IN (l_pobj) contrast_95\NN (l_prep) to_96\IN (l_pobj) hypotension_98\NN
D005996_D013610 NONE nitroglycerin_103\NN (r_conj) hydralazine_101\NN (r_pobj) by_100\IN (r_agent) induced_99\VBN (r_acl) hypotension_98\NN (r_pobj) to_96\IN (r_prep) contrast_95\NN (r_pobj) in_94\IN (r_prep) is_93\VBZ (r_advcl) observed_90\VBN (r_conj) was_29\VBD (l_appos) +/-_45\NN (l_conj) tachycardia_70\NN
D006830_D013610 NONE hydralazine_101\NN (r_pobj) by_100\IN (r_agent) induced_99\VBN (r_acl) hypotension_98\NN (r_pobj) to_96\IN (r_prep) contrast_95\NN (r_pobj) in_94\IN (r_prep) is_93\VBZ (r_advcl) observed_90\VBN (r_conj) was_29\VBD (l_appos) +/-_45\NN (l_conj) tachycardia_70\NN
D009638_D013610 NONE norepinephrine_76\NN (r_amod) rate_78\NN (r_pobj) of_74\IN (r_prep) augmentation_73\NN (r_conj) tachycardia_70\NN
D006830_D007022 CID hydralazine_101\NN (r_pobj) by_100\IN (r_agent) induced_99\VBN (r_acl) hypotension_98\NN
19657887
D000431_D004417 CID alcohol_9\NN (r_pobj) of_8\IN (r_prep) ingestion_7\NN (r_pobj) after_5\IN (r_prep) hour_4\NN (r_pobj) In_0\IN (r_prep) developed_12\VBD (l_dobj) malaise_13\NN (l_prep) with_14\IN (l_pobj) flushing_15\NN (l_prep) of_16\IN (l_pobj) face_18\NN (l_conj) tachycardia_20\NN (l_conj) dyspnea_23\NN
D000431_D013610 CID alcohol_9\NN (r_pobj) of_8\IN (r_prep) ingestion_7\NN (r_pobj) after_5\IN (r_prep) hour_4\NN (r_pobj) In_0\IN (r_prep) developed_12\VBD (l_dobj) malaise_13\NN (l_prep) with_14\IN (l_pobj) flushing_15\NN (l_prep) of_16\IN (l_pobj) face_18\NN (l_conj) tachycardia_20\NN
D000431_D005483 CID alcohol_9\NN (r_pobj) of_8\IN (r_prep) ingestion_7\NN (r_pobj) after_5\IN (r_prep) hour_4\NN (r_pobj) In_0\IN (r_prep) developed_12\VBD (l_dobj) malaise_13\NN (l_prep) with_14\IN (l_pobj) flushing_15\NN (l_prep) of_16\IN (l_pobj) face_18\NN
D004221_D013610 NONE disulfiram_7\NN (r_npadvmod) like_9\JJ (r_amod) syndrome_10\NN (l_prep) with_11\IN (l_pcomp) flushing_12\NN (l_conj) tachycardia_14\NN
D004221_D005483 NONE disulfiram_7\NN (r_npadvmod) like_9\JJ (r_amod) syndrome_10\NN (l_prep) with_11\IN (l_pcomp) flushing_12\NN
D004221_D007022 NONE disulfiram_7\NN (r_npadvmod) like_9\JJ (r_amod) syndrome_10\NN (l_prep) with_11\IN (l_pcomp) flushing_12\NN (l_conj) tachycardia_14\NN (l_conj) hypotension_18\NN
2071257
D012601_D000647 NONE scopolamine_13\NN (r_pobj) by_12\IN (r_agent) caused_11\VBN (r_acl) amnesia_10\NN
D005997_D008569 NONE glycerylphosphorylcholine_15\NN (r_pobj) of_10\IN (r_prep) effects_9\NNS (l_prep) on_23\IN (l_pobj) impairment_25\NN
D005997_D008569 NONE GFC_21\NNP (r_appos) glycerylphosphorylcholine_15\NN (r_pobj) of_10\IN (r_prep) effects_9\NNS (l_prep) on_23\IN (l_pobj) impairment_25\NN
D012601_D008569 CID scopolamine_28\NN (r_pobj) by_27\IN (r_agent) induced_26\VBN (r_acl) impairment_25\NN
D012601_D008569 CID scopolamine_20\NN (r_pobj) by_19\IN (r_agent) induced_18\VBN (r_acl) impairment_13\NN (l_prep) of_14\IN (l_pobj) attention_15\NN (l_conj) memory_17\NN
D005997_D000647 NONE phosphorylcholine_8\NN (r_pobj) of_1\IN (r_prep) Effect_0\NN (l_prep) on_9\IN (l_pobj) amnesia_10\NN
2375138
D008874_D006323 CID midazolam_2\RB (r_npadvmod) associated_4\VBN (r_amod) arrest_6\NN
D008874_D006323 CID midazolam_17\NN (r_pobj) of_16\IN (r_prep) administration_15\NN (r_pobj) with_13\IN (r_prep) associated_12\VBN (r_acl) case_6\NN (l_prep) of_7\IN (l_pobj) arrest_9\NN
D008874_D003643 NONE midazolam_2\RB (r_npadvmod) associated_4\VBN (r_amod) arrest_6\NN (l_conj) death_8\NN
D008874_D003643 NONE midazolam_17\NN (r_pobj) of_16\IN (r_prep) administration_15\NN (r_pobj) with_13\IN (r_prep) associated_12\VBN (r_acl) case_6\NN (l_prep) of_7\IN (l_pobj) arrest_9\NN (l_conj) death_11\NN
1436384
C070935_D020258 NONE LY274614_13\NNP (r_pobj) by_12\IN (r_prep) rodents_11\NNS (r_pobj) in_10\IN (r_prep) neurons_9\NNS (r_pobj) toward_6\IN (r_prep) neurotoxicity_5\NN
C070935_D020258 NONE LY274614_23\NNP (r_nsubj) is_24\VBZ (r_conj) involves_18\VBZ (l_nsubj) effect_8\NN (l_amod) neurotoxic_7\JJ
D000661_D020258 CID amphetamine_2\NN (r_npadvmod) induced_4\VBN (r_amod) neurotoxicity_5\NN
D000661_D020258 CID amphetamine_10\NN (r_nmod) compounds_13\NNS (r_pobj) of_9\IN (r_prep) effect_8\NN (l_amod) neurotoxic_7\JJ
D000596_D020258 NONE acid_18\NN (r_compound) antagonist_19\NN (r_appos) LY274614_13\NNP (r_pobj) by_12\IN (r_prep) rodents_11\NNS (r_pobj) in_10\IN (r_prep) neurons_9\NNS (r_pobj) toward_6\IN (r_prep) neurotoxicity_5\NN
D004298_D020258 NONE dopamine_8\NN (r_compound) neurons_9\NNS (r_pobj) toward_6\IN (r_prep) neurotoxicity_5\NN
D004298_D020258 NONE dopamine_16\NN (r_compound) neurons_17\NNS (r_pobj) toward_14\IN (r_prep) compounds_13\NNS (r_pobj) of_9\IN (r_prep) effect_8\NN (l_amod) neurotoxic_7\JJ
D016202_D020258 NONE NMDA_19\NNP (r_compound) receptors_20\NNS (r_dobj) involves_18\VBZ (l_nsubj) effect_8\NN (l_amod) neurotoxic_7\JJ
D016202_D020258 NONE NMDA_26\NNP (r_compound) antagonist_28\NN (r_attr) is_24\VBZ (r_conj) involves_18\VBZ (l_nsubj) effect_8\NN (l_amod) neurotoxic_7\JJ
12443032
D003042_D002637 CID Cocaine_0\NN (r_nsubj) related_1\VBN (l_dobj) pain_3\NN
D003042_D002637 CID cocaine_6\NN (r_pobj) of_5\IN (r_prep) tendency_4\NN (l_acl) produce_8\VB (l_dobj) pain_10\NN
D003042_D002637 CID cocaine_6\NN (r_pobj) of_5\IN (r_prep) tendency_4\NN (r_nsubj) ought_11\MD (l_xcomp) be_13\VB (l_advcl) faced_22\VBN (l_prep) with_23\IN (l_pobj) victim_26\NN (l_prep) of_27\IN (l_pobj) pain_29\NN
D003042_D002637 CID cocaine_7\NN (r_compound) use_8\NN (r_pobj) to_6\IN (r_prep) related_5\VBN (r_acl) mechanism_1\NN (l_prep) of_2\IN (l_pobj) pain_4\NN
11135224
D017239_D002289 NONE Paclitaxel_0\NNP (l_conj) cisplatin_2\NN (l_conj) chemotherapy_7\NN (l_prep) within_8\IN (l_pobj) approach_12\NN (l_prep) in_13\IN (l_pobj) carcinoma_18\NN
D017239_D002289 NONE paclitaxel_18\NN (r_pobj) of_16\IN (r_prep) toxicity_15\NN (r_conj) rate_12\NN (r_conj) feasibility_9\NN (r_dobj) determine_7\VB (l_xcomp) treat_26\VB (l_dobj) NSCLC_28\NN
D017239_D002289 NONE paclitaxel_30\NN (r_pobj) of_29\IN (r_prep) combination_28\NN (r_pobj) with_26\IN (r_prep) treated_25\VBN (l_nsubjpass) patients_7\NNS (l_prep) with_8\IN (l_pobj) NSCLC_11\NNP
D017239_D002289 NONE paclitaxel_3\NN (r_pobj) of_2\IN (r_prep) combination_1\NN (r_nsubjpass) tolerated_11\VBN (l_conj) shows_13\VBZ (l_prep) in_16\IN (l_pobj) NSCLC_18\NNP
C056507_D064420 NONE gemcitabine_23\NN (r_compound) combination_24\NN (r_conj) paclitaxel_18\NN (r_pobj) of_16\IN (r_prep) toxicity_15\NN
D002945_D002289 NONE cisplatin_2\NN (l_conj) chemotherapy_7\NN (l_prep) within_8\IN (l_pobj) approach_12\NN (l_prep) in_13\IN (l_pobj) carcinoma_18\NN
D002945_D002289 NONE Cisplatin_0\NN (r_npadvmod) based_2\VBN (r_amod) combinations_4\NNS (r_nsubj) improve_5\VBP (l_dobj) quality_6\NN (l_prep) in_11\IN (l_pobj) carcinoma_16\NN
D002945_D002289 NONE Cisplatin_0\NN (r_npadvmod) based_2\VBN (r_amod) combinations_4\NNS (r_nsubj) improve_5\VBP (l_dobj) quality_6\NN (l_prep) in_11\IN (l_pobj) carcinoma_16\NN (l_appos) NSCLC_18\NNP
D002945_D002289 NONE cisplatin_20\NN (r_conj) paclitaxel_18\NN (r_pobj) of_16\IN (r_prep) toxicity_15\NN (r_conj) rate_12\NN (r_conj) feasibility_9\NN (r_dobj) determine_7\VB (l_xcomp) treat_26\VB (l_dobj) NSCLC_28\NN
D002945_D002289 NONE cisplatin_47\NN (r_conj) treated_25\VBN (l_nsubjpass) patients_7\NNS (l_prep) with_8\IN (l_pobj) NSCLC_11\NNP
D002945_D002289 NONE cisplatin_5\NN (r_conj) paclitaxel_3\NN (r_pobj) of_2\IN (r_prep) combination_1\NN (r_nsubjpass) tolerated_11\VBN (l_conj) shows_13\VBZ (l_prep) in_16\IN (l_pobj) NSCLC_18\NNP
D017239_D064420 NONE paclitaxel_18\NN (r_pobj) of_16\IN (r_prep) toxicity_15\NN
D002945_D064420 NONE cisplatin_20\NN (r_conj) paclitaxel_18\NN (r_pobj) of_16\IN (r_prep) toxicity_15\NN
C056507_D002289 NONE gemcitabine_5\NN (r_compound) combination_6\NN (r_compound) chemotherapy_7\NN (l_prep) within_8\IN (l_pobj) approach_12\NN (l_prep) in_13\IN (l_pobj) carcinoma_18\NN
C056507_D002289 NONE gemcitabine_23\NN (r_compound) combination_24\NN (r_conj) paclitaxel_18\NN (r_pobj) of_16\IN (r_prep) toxicity_15\NN (r_conj) rate_12\NN (r_conj) feasibility_9\NN (r_dobj) determine_7\VB (l_xcomp) treat_26\VB (l_dobj) NSCLC_28\NN
C056507_D002289 NONE gemcitabine_65\NN (r_conj) treated_25\VBN (l_nsubjpass) patients_7\NNS (l_prep) with_8\IN (l_pobj) NSCLC_11\NNP
C056507_D002289 NONE gemcitabine_8\NN (r_conj) combination_1\NN (r_nsubjpass) tolerated_11\VBN (l_conj) shows_13\VBZ (l_prep) in_16\IN (l_pobj) NSCLC_18\NNP
3403780
D000082_D017093 NONE Paracetamol_0\NN (r_npadvmod) associated_2\VBN (r_amod) coma_3\NN (l_appos) acidosis_6\NN (l_conj) failure_11\NN
D000082_D003128 NONE Paracetamol_0\NN (r_npadvmod) associated_2\VBN (r_amod) coma_3\NN
D000082_D058186 CID paracetamol_13\JJ (r_compound) ingestion_14\NN (r_pobj) following_12\VBG (r_prep) failure_8\NN (l_conj) failure_11\NN
D000082_D058186 NONE Paracetamol_0\NN (r_npadvmod) associated_2\VBN (r_amod) coma_3\NN (l_appos) acidosis_6\NN (l_conj) failure_11\NN
D000082_D000138 CID Paracetamol_0\NN (r_npadvmod) associated_2\VBN (r_amod) coma_3\NN (l_appos) acidosis_6\NN
D000082_D000138 CID paracetamol_13\JJ (r_compound) ingestion_14\NN (r_pobj) following_12\VBG (r_prep) failure_8\NN (r_nsubjpass) presented_16\VBN (l_nsubjpass) case_1\NN (l_prep) of_2\IN (l_pobj) acidosis_4\NN
D000082_D017114 CID paracetamol_13\JJ (r_compound) ingestion_14\NN (r_pobj) following_12\VBG (r_prep) failure_8\NN (l_conj) failure_11\NN
2632720
D006854_D006973 NONE cortisol_8\NN (r_compound) levels_9\NNS (r_nsubjpass) achieved_12\VBN (l_conj) demonstrated_22\VBD (l_dobj) hypertension_23\NN
D007654_D003480 NONE ketoconazole_16\JJ (r_pobj) with_15\IN (r_prep) basis_14\NN (r_pobj) on_9\IN (r_prep) treated_8\VBN (l_nsubj) patients_3\NNS (l_prep) with_4\IN (l_pobj) syndrome_7\NN
D007654_D006973 CID ketoconazole_7\JJ (r_compound) treatment_8\NN (r_pobj) of_5\IN (r_prep) complication_4\NN (r_pobj) as_2\IN (r_prep) hypertension_1\NN
D007654_D006973 CID ketoconazole_16\JJ (r_pobj) with_15\IN (r_prep) basis_14\NN (r_pobj) on_9\IN (r_prep) treated_8\VBN (l_advcl) developed_17\VBN (l_dobj) hypertension_19\NN
D007654_D006973 CID ketoconazole_14\JJ (r_compound) therapy_15\NN (r_dobj) following_13\VBG (r_prep) achieved_12\VBN (l_conj) demonstrated_22\VBD (l_dobj) hypertension_23\NN
D007654_D006973 CID ketoconazole_12\NN (r_pobj) of_11\IN (r_prep) doses_10\NNS (r_pobj) with_8\IN (r_prep) treatment_7\NN (r_nsubj) induce_14\VB (l_dobj) blockade_16\NN (l_acl) leading_17\VBG (l_prep) to_18\IN (l_pobj) hypertension_22\NN
17042910
C065179_D006973 NONE atorvastatin_5\NN (r_pobj) of_4\IN (r_prep) effects_3\NNS (l_prep) in_6\IN (l_pobj) hypertension_10\NN
C065179_D006973 NONE Atorvastatin_0\NNP (r_nsubj) possesses_4\VBZ (l_dobj) properties_6\NNS (l_relcl) reported_10\VBN (l_xcomp) improve_12\VB (l_prep) through_15\IN (l_pobj) availability_17\NN (l_prep) of_18\IN (l_pobj) production_23\NN (l_prep) in_24\IN (l_pobj) forms_26\NNS (l_prep) of_27\IN (l_pobj) hypertension_28\NN
C065179_D006973 NONE Ato_2\NNP (r_appos) Atorvastatin_0\NNP (r_nsubj) possesses_4\VBZ (l_dobj) properties_6\NNS (l_relcl) reported_10\VBN (l_xcomp) improve_12\VB (l_prep) through_15\IN (l_pobj) availability_17\NN (l_prep) of_18\IN (l_pobj) production_23\NN (l_prep) in_24\IN (l_pobj) forms_26\NNS (l_prep) of_27\IN (l_pobj) hypertension_28\NN
D013481_D006973 NONE superoxide_19\NN (r_advmod) increased_18\VBN (r_conj) characterized_5\VBN (l_nsubjpass) hypertension_3\NN
D013481_D006973 NONE O2-_21\NNPS (r_nmod) production_23\NN (r_appos) Dexamethasone_0\NNP (l_parataxis) characterized_5\VBN (l_nsubjpass) hypertension_3\NN
D013481_D006973 NONE O2-_22\JJ (r_compound) production_23\NN (l_prep) in_24\IN (l_pobj) forms_26\NNS (l_prep) of_27\IN (l_pobj) hypertension_28\NN
D003907_D006973 CID dexamethasone_7\NN (r_npadvmod) induced_9\VBN (r_amod) hypertension_10\NN
D003907_D006973 CID Dexamethasone_0\NNP (l_parataxis) characterized_5\VBN (l_nsubjpass) hypertension_3\NN
D003907_D006973 CID Dex)-induced_2\JJ (r_amod) hypertension_3\NN
D009569_D006973 NONE oxide_12\NN (r_nmod) deficiency_16\NN (r_pobj) with_10\IN (r_prep) associated_9\VBN (r_acl) dysfunction_8\NN (r_pobj) by_6\IN (r_agent) characterized_5\VBN (l_nsubjpass) hypertension_3\NN
D009569_D006973 NONE NO_14\NNP (r_intj) deficiency_16\NN (r_pobj) with_10\IN (r_prep) associated_9\VBN (r_acl) dysfunction_8\NN (r_pobj) by_6\IN (r_agent) characterized_5\VBN (l_nsubjpass) hypertension_3\NN
D009569_D006973 NONE NO_19\DT (r_amod) production_23\NN (l_prep) in_24\IN (l_pobj) forms_26\NNS (l_prep) of_27\IN (l_pobj) hypertension_28\NN
3780846
D006220_D009127 CID haloperidol_7\NN (r_nsubjpass) used_14\VBN (l_prep) in_15\IN (l_pobj) order_16\NN (l_acl) block_18\VB (l_conj) estimate_24\VB (l_dobj) degree_27\NN (l_prep) of_28\IN (l_pobj) tolerance_30\NN (l_prep) to_31\IN (l_pobj) rigidity_33\NN
D006220_D009127 CID Haloperidol_0\NNP (r_nsubj) enhanced_1\VBD (l_dobj) rigidity_3\NN
D009020_D009127 CID morphine_14\NN (r_pobj) by_13\IN (r_agent) produced_12\VBN (r_acl) rigidity_11\NN
D009020_D009127 CID morphine_10\NN (r_pobj) by_9\IN (r_agent) produced_8\VBN (r_acl) rigidity_7\NN
D009020_D009127 CID morphine_9\NN (r_pobj) of_8\IN (r_prep) dose_7\NN (r_dobj) given_4\VBN (r_csubj) showed_15\VBD (l_dobj) rigidity_18\NN
D009020_D009127 CID morphine_6\NN (r_pobj) with_5\IN (r_prep) treated_1\VBD (l_conj) showed_27\VBD (l_dobj) rigidity_29\NN
D009020_D009127 CID morphine_35\NN (r_pobj) of_34\IN (r_prep) dose_33\NN (r_pobj) after_30\IN (r_prep) showed_27\VBD (l_dobj) rigidity_29\NN
D009020_D009127 CID morphine_16\NN (r_pobj) of_15\IN (r_prep) action_14\NN (r_pobj) to_12\IN (r_prep) due_11\JJ (r_acomp) be_10\VB (r_xcomp) assumed_8\VBN (r_relcl) rigidity_4\NN
D009020_D018476 CID morphine_6\NN (r_pobj) with_5\IN (r_prep) treated_1\VBD (l_conj) showed_27\VBD (l_prep) after_30\IN (l_pobj) dose_33\NN (l_relcl) was_37\VBD (l_conj) were_46\VBD (l_acomp) akinetic_47\JJ
D009020_D018476 CID morphine_35\NN (r_pobj) of_34\IN (r_prep) dose_33\NN (l_relcl) was_37\VBD (l_conj) were_46\VBD (l_acomp) akinetic_47\JJ
3693336
D014229_D003866 NONE Triazolam_0\NNP (r_npadvmod) induced_2\VBN (l_dobj) episodes_4\NNS (l_prep) in_8\IN (l_pobj) patient_11\NN (l_amod) depressed_10\JJ
D014229_D003866 NONE triazolam_3\NN (r_pobj) of_2\IN (r_prep) doses_1\NNS (r_nsubj) induced_5\VBD (l_dobj) episodes_7\NNS (l_prep) in_10\IN (l_pobj) woman_14\NN (l_amod) depressed_12\JJ
D014229_D001714 CID Triazolam_0\NNP (r_npadvmod) induced_2\VBN (l_dobj) episodes_4\NNS (l_prep) of_5\IN (l_pobj) mania_7\NN
D014229_D001714 CID triazolam_3\NN (r_pobj) of_2\IN (r_prep) doses_1\NNS (r_nsubj) induced_5\VBD (l_dobj) episodes_7\NNS (l_prep) of_8\IN (l_pobj) mania_9\NN
D014229_D001714 CID triazolam_10\NN (r_pobj) of_9\IN (r_prep) action_8\NN (r_pobj) of_7\IN (r_prep) duration_6\NN (r_pobj) with_4\IN (r_prep) coincident_3\JJ (r_acomp) was_2\VBD (l_nsubj) excitement_1\NN (l_amod) Manic_0\JJ
12523465
C022189_D006212 CID zonisamide_4\NN (r_pobj) with_3\IN (r_prep) associated_2\VBN (r_acl) hallucinations_1\NNS
C022189_D006212 CID zonisamide_29\NN (r_amod) treatment_30\NN (r_pobj) after_28\IN (r_prep) altered_25\VBD (r_conj) experienced_20\VBD (r_relcl) patients_18\NNS (r_dobj) describe_16\VBP (l_advcl) reported_6\VBN (l_nsubjpass) hallucinations_2\NNS
C022189_D006212 CID zonisamide_29\NN (r_amod) treatment_30\NN (r_pobj) after_28\IN (r_prep) altered_25\VBD (r_conj) experienced_20\VBD (l_dobj) hallucinations_23\NNS
C022189_D012640 NONE Zonisamide_0\NNP (r_nsubj) is_1\VBZ (l_attr) drug_7\NN (l_acl) used_8\VBN (l_xcomp) treat_10\VB (l_dobj) types_12\NNS (l_prep) of_13\IN (l_pobj) seizures_14\NNS
15649445
D012110_D004409 CID reserpine_1\NN (r_nsubj) change_6\VBP (l_conj) elicit_12\VBP (l_dobj) dyskinesia_14\NN
D012110_D004409 CID Reserpine-_0\NNP (l_conj) dyskinesia_6\NN
D012110_D004409 CID Reserpine-_0\NNP (r_nsubj) are_7\VBP (l_attr) models_10\NNS (l_prep) of_11\IN (l_pobj) dyskinesia_13\JJ
D012110_D004409 CID Reserpine-_0\NNP (r_nsubj) are_7\VBP (l_attr) models_10\NNS (l_prep) of_11\IN (l_pobj) dyskinesia_13\JJ (l_appos) TD_15\NN
D012110_D004409 CID reserpine_12\NN (r_pobj) by_10\IN (r_prep) induced_7\VBD (l_dobj) dyskinesia_9\NN
D018698_D004409 NONE glutamate_9\NN (r_compound) uptake_10\NN (r_dobj) change_6\VBP (l_conj) elicit_12\VBP (l_dobj) dyskinesia_14\NN
D018698_D004409 NONE glutamate_5\NN (r_compound) uptake_6\NN (r_pobj) in_4\IN (r_prep) decrease_3\NN (r_nsubj) correlates_7\VBZ (l_prep) with_9\IN (l_pobj) increase_11\NN (l_prep) in_12\IN (l_pobj) incidence_14\NN (l_prep) of_15\IN (l_pobj) diskinesia_17\NN
D006220_D004409 CID haloperidol_4\NN (r_compound) change_6\VBP (l_conj) elicit_12\VBP (l_dobj) dyskinesia_14\NN
D006220_D004409 CID haloperidol_2\NN (r_npadvmod) induced_4\VBN (r_amod) dyskinesia_6\NN
D006220_D004409 CID haloperidol_2\NN (r_npadvmod) induced_4\VBN (r_amod) dyskinesia_6\NN (r_conj) Reserpine-_0\NNP (r_nsubj) are_7\VBP (l_attr) models_10\NNS (l_prep) of_11\IN (l_pobj) dyskinesia_13\JJ
D006220_D004409 CID haloperidol_2\NN (r_npadvmod) induced_4\VBN (r_amod) dyskinesia_6\NN (r_conj) Reserpine-_0\NNP (r_nsubj) are_7\VBP (l_attr) models_10\NNS (l_prep) of_11\IN (l_pobj) dyskinesia_13\JJ (l_appos) TD_15\NN
D006220_D004409 CID haloperidol_15\NN (r_compound) administration_16\NN (r_conj) reserpine_12\NN (r_pobj) by_10\IN (r_prep) induced_7\VBD (l_dobj) dyskinesia_9\NN
18631865
D020123_D051436 NONE rapamycin_16\NNS (r_nmod) inhibitors_20\NNS (r_pobj) of_15\IN (r_prep) target_14\NN (r_pobj) to_12\IN (r_prep) conversion_8\NN (l_prep) in_25\IN (l_pobj) recipients_28\NNS (l_prep) with_29\IN (l_pobj) nephropathy_32\NN
D020123_D051436 NONE sirolimus_23\NN (r_appos) inhibitors_20\NNS (r_pobj) of_15\IN (r_prep) target_14\NN (r_pobj) to_12\IN (r_prep) conversion_8\NN (l_prep) in_25\IN (l_pobj) recipients_28\NNS (l_prep) with_29\IN (l_pobj) nephropathy_32\NN
D020123_D011507 CID sirolimus_5\NN (r_pobj) to_4\IN (r_prep) due_3\JJ (r_acomp) was_2\VBD (l_nsubj) proteinuria_1\NN
D020123_D011507 CID sirolimus_5\NN (r_pobj) to_4\IN (r_prep) due_3\JJ (r_acomp) was_2\VBD (r_csubj) remained_14\VBD (l_advcl) observed_22\VBN (l_nsubjpass) proteinuria_19\NN
D020123_D011507 CID sirolimus_24\NN (r_compound) therapy_25\NN (r_pobj) during_23\IN (r_prep) observed_22\VBN (r_advcl) remained_14\VBD (l_csubj) was_2\VBD (l_nsubj) proteinuria_1\NN
D020123_D011507 CID sirolimus_24\NN (r_compound) therapy_25\NN (r_pobj) during_23\IN (r_prep) observed_22\VBN (l_nsubjpass) proteinuria_19\NN
D020123_D011507 CID sirolimus_34\NN (r_nmod) novo_36\NNP (r_dobj) received_33\VBD (r_relcl) patients_31\NNS (r_pobj) in_30\IN (r_conj) in_26\IN (r_prep) observed_22\VBN (r_advcl) remained_14\VBD (l_csubj) was_2\VBD (l_nsubj) proteinuria_1\NN
D020123_D011507 CID sirolimus_34\NN (r_nmod) novo_36\NNP (r_dobj) received_33\VBD (r_relcl) patients_31\NNS (r_pobj) in_30\IN (r_conj) in_26\IN (r_prep) observed_22\VBN (l_nsubjpass) proteinuria_19\NN
1085609
D007538_D012640 CID isoniazid_6\NN (r_amod) therapy_7\NN (r_pobj) due_4\IN (r_amod) convulsions_3\NNS
D007538_D012640 CID isoniazid_6\NN (r_pobj) on_5\IN (r_prep) infant_4\NN (r_nsubjpass) admitted_18\VBN (l_prep) after_19\IN (l_pobj) days_21\NNS (l_prep) of_22\IN (l_pobj) fits_24\NNS
D007538_D012640 CID isoniazid_19\NN (r_relcl) aetiology_13\NN (r_dobj) suggesting_11\VBG (r_advcl) ceased_2\VBD (l_nsubj) fits_1\NNS
D011736_D012640 NONE pyridoxine_1\NN (r_nmod) convulsions_3\NNS
D011736_D012640 NONE pyridoxine_9\NN (r_dobj) administering_7\VBG (r_pcomp) of_6\IN (r_prep) hours_5\NNS (r_pobj) within_3\IN (r_prep) ceased_2\VBD (l_nsubj) fits_1\NNS
D011736_D012640 NONE pyridoxine_15\JJ (r_compound) deficiency_16\NN (r_pobj) of_14\IN (r_prep) aetiology_13\NN (r_dobj) suggesting_11\VBG (r_advcl) ceased_2\VBD (l_nsubj) fits_1\NNS
D007538_D014376 NONE isoniazid_6\NN (r_pobj) on_5\IN (r_prep) infant_4\NN (l_prep) because_13\IN (l_pobj) tuberculosis_16\NN
891050
D004176_D001002 NONE dipyridamole_6\NN (r_conj) heparin_4\JJ (r_pobj) with_3\IN (r_prep) treated_2\VBN (l_conj) rose_20\VBD (l_conj) stopped_37\VBN (l_prep) after_28\IN (l_pobj) onset_30\NN (l_prep) of_31\IN (l_pobj) anuria_32\NN
D003276_D006463 CID contraceptives_17\NNS (r_dobj) taking_15\VBG (r_acl) woman_14\NN (r_pobj) in_12\IN (r_prep) syndrome_8\NN
D003276_D006463 CID contraceptives_17\NNS (r_dobj) taking_15\VBG (r_acl) woman_14\NN (r_pobj) in_12\IN (r_prep) syndrome_8\NN (l_appos) HUS_10\NNP
D006493_D001002 NONE heparin_4\JJ (r_pobj) with_3\IN (r_prep) treated_2\VBN (l_conj) rose_20\VBD (l_conj) stopped_37\VBN (l_prep) after_28\IN (l_pobj) onset_30\NN (l_prep) of_31\IN (l_pobj) anuria_32\NN
7199841
C004616_D010243 CID CE_11\NN (r_nmod) %_15\NN (r_pobj) of_8\IN (r_prep) injection_7\NN (r_dobj) received_5\VBD (r_relcl) animals_3\NNS (r_pobj) Of_0\IN (r_prep) paralysis_21\NN
D002045_D010243 NONE bupivacaine_6\NN (r_dobj) received_5\VBD (r_relcl) animals_3\NNS (r_pobj) of_1\IN (r_prep) None_0\NN (r_nsubj) titrated_14\VBN (l_prep) to_15\IN (l_pobj) paralysis_23\NN
C004616_D013118 CID CE_12\NNP (r_dobj) received_9\VBD (r_relcl) animals_7\NNS (r_pobj) of_5\IN (r_prep) cords_4\NNS (r_pobj) Of_0\IN (r_prep) 13_14\CD (r_nsubj) showed_15\VBD (l_dobj) necrosis_17\NN
11256525
D000588_D001002 NONE amine_26\NN (r_conj) furosemide_24\NN (r_nmod) infusion_27\NN (r_pobj) despite_20\IN (r_prep) lasted_17\VBD (r_relcl) anuria_14\NN
D019808_D006331 NONE losartan_5\NN (l_compound) dysfunction_4\NN
D000809_D012078 NONE angiotensin_24\NN (r_compound) system_25\NN (r_pobj) of_20\IN (r_prep) activation_19\NN (r_pobj) in_16\IN (r_prep) resulted_15\VBD (l_nsubj) stenosis_6\NN
D019808_D001002 CID losartan_4\NN (r_amod) administration_5\NN (r_dobj) following_3\VBG (r_prep) anuria_2\NN
D019808_D001002 CID losartan_27\NN (r_amod) administration_28\NN (r_pobj) after_26\IN (r_prep) developed_20\VBD (l_dobj) episodes_22\NNS (l_prep) of_23\IN (l_pobj) anuria_25\NN
D019808_D001002 CID losartan_9\NN (r_pobj) of_8\IN (r_prep) mg_7\NN (r_pobj) of_5\IN (r_prep) dose_4\NN (r_nsubj) resulted_10\VBD (l_prep) in_11\IN (l_pobj) anuria_14\NN
D019808_D001002 CID losartan_7\NN (r_nsubjpass) prescribed_9\VBN (l_conj) developed_22\VBD (l_dobj) episode_25\NN (l_prep) of_26\IN (l_pobj) anuria_28\NN
D019808_D014652 NONE losartan_12\NN (r_nsubj) cause_14\VB (l_dobj) complications_17\NNS (l_prep) in_18\IN (l_pobj) patients_19\NNS (l_prep) with_20\IN (l_pobj) disease_22\NN
D005665_D001002 NONE furosemide_24\NN (r_nmod) infusion_27\NN (r_pobj) despite_20\IN (r_prep) lasted_17\VBD (r_relcl) anuria_14\NN
D019808_D051436 NONE losartan_27\NN (r_amod) administration_28\NN (r_pobj) after_26\IN (r_prep) developed_20\VBD (r_relcl) kidney_14\NN (l_conj) insufficiency_18\NN
D000809_D006333 NONE angiotensin_24\NN (r_compound) system_25\NN (r_pobj) of_20\IN (r_prep) activation_19\NN (r_pobj) in_16\IN (r_prep) resulted_15\VBD (l_nsubj) stenosis_6\NN (l_acl) combined_7\VBN (l_prep) with_8\IN (l_pobj) failure_10\NN
D000804_D014652 NONE II_9\NNP (r_compound) antagonist_11\NN (r_compound) losartan_12\NN (r_nsubj) cause_14\VB (l_dobj) complications_17\NNS (l_prep) in_18\IN (l_pobj) patients_19\NNS (l_prep) with_20\IN (l_pobj) disease_22\NN
D019808_D006973 NONE losartan_27\NN (r_amod) administration_28\NN (r_pobj) after_26\IN (r_prep) developed_20\VBD (r_relcl) kidney_14\NN (r_pobj) with_11\IN (r_prep) man_10\NN (l_amod) hypertensive_9\JJ
3412544
D010615_D014516 NONE phenacetin_22\JJ (r_pobj) of_20\IN (r_prep) consumption_19\NN (r_pobj) with_18\IN (r_prep) associated_17\VBN (r_acl) pelvis_12\NN (l_conj) ureter_14\NN (l_conj) bladder_16\NN
D010615_D014516 NONE phenacetin_13\NN (r_pobj) of_12\IN (r_prep) consumption_11\NN (l_relcl) increased_17\VBD (l_conj) for_30\IN (l_pobj) cancer_32\NN
D010615_D007680 CID phenacetin_13\NN (r_pobj) of_12\IN (r_prep) consumption_11\NN (l_relcl) increased_17\VBD (l_dobj) risk_19\NN (l_prep) for_20\IN (l_pobj) cancer_21\NN (l_prep) of_22\IN (l_pobj) pelvis_25\NN (l_conj) bladder_27\NN
D010615_D007680 NONE phenacetin_22\JJ (r_pobj) of_20\IN (r_prep) consumption_19\NN (r_pobj) with_18\IN (r_prep) associated_17\VBN (r_acl) pelvis_12\NN (l_conj) ureter_14\NN (l_conj) bladder_16\NN
D000082_D007681 NONE paracetamol_1\JJ (r_nsubj) cause_2\VB (l_dobj) cancer_4\NN (l_conj) necrosis_8\NN
D000082_D007681 NONE paracetamol_24\NNP (r_conj) phenacetin_22\JJ (r_pobj) of_20\IN (r_prep) consumption_19\NN (r_pobj) with_18\IN (r_prep) associated_17\VBN (r_acl) pelvis_12\NN (r_pobj) of_9\IN (r_prep) necrosis_6\NN
D000082_D007681 NONE paracetamol_12\JJ (r_compound) consumption_13\NN (r_pobj) from_11\IN (r_prep) risk_10\NN (l_prep) for_14\IN (l_pobj) necrosis_17\NN
D000082_D001749 NONE paracetamol_24\NNP (r_conj) phenacetin_22\JJ (r_pobj) of_20\IN (r_prep) consumption_19\NN (r_pobj) with_18\IN (r_prep) associated_17\VBN (r_acl) pelvis_12\NN (l_conj) ureter_14\NN (l_conj) bladder_16\NN
D000082_D014516 NONE paracetamol_24\NNP (r_conj) phenacetin_22\JJ (r_pobj) of_20\IN (r_prep) consumption_19\NN (r_pobj) with_18\IN (r_prep) associated_17\VBN (r_acl) pelvis_12\NN (l_conj) ureter_14\NN (l_conj) bladder_16\NN
D000082_D014516 NONE paracetamol_12\JJ (r_compound) consumption_13\NN (r_pobj) from_11\IN (r_prep) risk_10\NN (r_dobj) substantiate_7\VB (r_xcomp) unable_5\JJ (r_acomp) were_4\VBD (l_advcl) was_25\VBD (l_attr) suggestion_27\NN (l_prep) of_28\IN (l_pobj) association_30\NN (l_prep) with_31\IN (l_pobj) cancer_32\NN (l_prep) of_33\IN (l_pobj) ureter_35\NN
D000082_D014523 NONE paracetamol_1\JJ (r_nsubj) cause_2\VB (l_dobj) cancer_4\NN
D000082_D007680 NONE paracetamol_24\NNP (r_conj) phenacetin_22\JJ (r_pobj) of_20\IN (r_prep) consumption_19\NN (r_pobj) with_18\IN (r_prep) associated_17\VBN (r_acl) pelvis_12\NN (l_conj) ureter_14\NN (l_conj) bladder_16\NN
D000082_D009369 NONE paracetamol_12\JJ (r_compound) consumption_13\NN (r_pobj) from_11\IN (r_prep) risk_10\NN (l_conj) any_19\DT (l_prep) of_20\IN (l_pobj) cancers_22\NNS
D010615_D007681 CID phenacetin_22\JJ (r_pobj) of_20\IN (r_prep) consumption_19\NN (r_pobj) with_18\IN (r_prep) associated_17\VBN (r_acl) pelvis_12\NN (r_pobj) of_9\IN (r_prep) necrosis_6\NN
D010615_D007681 CID phenacetin_13\NN (r_pobj) of_12\IN (r_prep) consumption_11\NN (r_pobj) by_10\IN (r_agent) increased_7\VBN (l_nsubjpass) risk_1\NN (l_prep) of_2\IN (l_pobj) necrosis_5\NN
D010615_D001749 CID phenacetin_13\NN (r_pobj) of_12\IN (r_prep) consumption_11\NN (l_relcl) increased_17\VBD (l_dobj) risk_19\NN (l_prep) for_20\IN (l_pobj) cancer_21\NN (l_prep) of_22\IN (l_pobj) pelvis_25\NN (l_conj) bladder_27\NN
D010615_D001749 NONE phenacetin_22\JJ (r_pobj) of_20\IN (r_prep) consumption_19\NN (r_pobj) with_18\IN (r_prep) associated_17\VBN (r_acl) pelvis_12\NN (l_conj) ureter_14\NN (l_conj) bladder_16\NN
9862868
D004997_D002780 CID estradiol_9\NNP (r_nmod) treatment_13\NN (r_nmod) cholestasis_16\NN (r_dobj) used_1\VBD (l_dobj) models_3\NNS (l_prep) of_4\IN (l_pobj) cholestasis_6\NN
D004997_D002780 CID EE_11\NNP (r_nmod) treatment_13\NN (r_nmod) cholestasis_16\NN (r_dobj) used_1\VBD (l_dobj) models_3\NNS (l_prep) of_4\IN (l_pobj) cholestasis_6\NN
D004997_D001651 NONE estradiol_9\NNP (r_nmod) treatment_13\NN (r_nmod) cholestasis_16\NN
D004997_D001651 NONE EE_11\NNP (r_nmod) treatment_13\NN (r_nmod) cholestasis_16\NN
2008831
D008755_D000787 NONE methylergonovine_6\NN (r_pobj) of_5\IN (r_prep) administration_4\NN (r_pobj) of_2\IN (r_prep) effects_1\NNS (r_nsubjpass) studied_8\VBN (l_prep) without_25\IN (l_pobj) angina_26\NN (l_appos) pectoris_27\NN
D008755_D013035 NONE methylergonovine_19\NN (r_pobj) of_18\IN (r_prep) dose_17\NN (r_pobj) of_13\IN (r_prep) injection_12\NN (r_dobj) use_9\VBP (r_relcl) tests_6\NNS (l_compound) spasm_4\NN
D008755_D000788 NONE methylergonovine_6\NN (r_pobj) of_5\IN (r_prep) administration_4\NN (l_prep) in_7\IN (l_pobj) patients_8\NNS (l_prep) with_9\IN (l_conj) without_11\IN (l_pobj) angina_13\NN
D008755_D000788 NONE methylergonovine_6\NN (r_pobj) of_5\IN (r_prep) administration_4\NN (r_pobj) of_2\IN (r_prep) effects_1\NNS (r_nsubjpass) studied_8\VBN (l_prep) in_9\IN (l_pobj) patients_11\NNS (l_prep) with_12\IN (l_pobj) angina_14\NN
D008755_D000788 NONE methylergonovine_19\NN (r_pobj) of_18\IN (r_prep) dose_17\NN (r_pobj) of_13\IN (r_prep) injection_12\NN (r_dobj) use_9\VBP (r_relcl) tests_6\NNS (r_nsubj) have_21\VBP (l_dobj) sensitivity_24\NN (l_prep) in_25\IN (l_pobj) angina_27\NN
D008755_D002637 NONE methylergonovine_6\NN (r_pobj) of_5\IN (r_prep) administration_4\NN (r_pobj) of_2\IN (r_prep) effects_1\NNS (r_nsubjpass) studied_8\VBN (l_prep) in_9\IN (l_pobj) patients_11\NNS (l_prep) with_12\IN (l_pobj) angina_14\NN (l_conj) patients_17\NNS (l_prep) with_18\IN (l_pobj) pain_21\NN
17020434
D001241_D020521 NONE aspirin_24\NN (r_nsubj) reduces_26\VBZ (r_conj) reduces_13\VBZ (l_dobj) risk_15\NN (l_prep) of_16\IN (l_pobj) stroke_17\NN
D001241_D020521 NONE aspirin_12\NN (l_prep) in_13\IN (l_pcomp) preventing_14\VBG (l_dobj) strokes_15\NNS
D014812_D004617 NONE K_16\NNP (r_compound) drugs_18\NNS (r_pobj) as_14\IN (r_prep) efficient_13\JJ (l_prep) in_19\IN (l_pobj) prevention_21\NN (l_prep) of_22\IN (l_pobj) events_24\NNS
C081309_D004617 NONE Irbesartan_10\NNP (r_pobj) with_9\IN (r_prep) Trial_8\NN (r_nsubj) demonstrated_19\VBN (l_ccomp) is_22\VBZ (l_acomp) superior_23\JJ (l_xcomp) platelet_25\NN (l_prep) in_32\IN (l_pobj) events_37\NNS
C479958_D001281 NONE Idraparinux_0\NNP (r_nsubjpass) evaluated_9\VBN (l_prep) in_10\IN (l_pobj) patients_11\NNS (l_prep) with_12\IN (l_pobj) fibrillation_14\NN
D000809_D001281 NONE Angiotensin_0\NN (r_npadvmod) converting_2\VBG (r_amod) inhibitors_4\NNS (r_nsubj) hold_12\VBP (l_dobj) promise_13\NN (l_prep) in_14\IN (l_pobj) fibrillation_16\NN
D000804_D020257 NONE II_7\CD (r_nummod) drugs_11\NNS (r_conj) inhibitors_4\NNS (r_nsubj) hold_12\VBP (l_dobj) promise_13\NN (l_prep) in_14\IN (l_pobj) fibrillation_16\NN (l_prep) through_17\IN (l_pobj) remodelling_19\NN
D014859_D004617 NONE warfarin_21\NN (r_nsubj) is_22\VBZ (l_acomp) superior_23\JJ (l_xcomp) platelet_25\NN (l_prep) in_32\IN (l_pobj) events_37\NNS
C426686_D004617 NONE Ximelagatran_0\NN (r_nsubjpass) found_9\VBN (l_xcomp) be_11\VB (l_acomp) efficient_13\JJ (l_prep) in_19\IN (l_pobj) prevention_21\NN (l_prep) of_22\IN (l_pobj) events_24\NNS
D000804_D001281 NONE II_7\CD (r_nummod) drugs_11\NNS (r_conj) inhibitors_4\NNS (r_nsubj) hold_12\VBP (l_dobj) promise_13\NN (l_prep) in_14\IN (l_pobj) fibrillation_16\NN
D014859_D001281 NONE warfarin_21\NN (r_nsubj) is_22\VBZ (r_ccomp) demonstrated_19\VBN (l_nsubj) Trial_8\NN (l_compound) Clopidogrel_7\NNP (l_compound) Fibrillation_6\NNP
C055162_D004617 NONE Clopidogrel_7\NNP (r_compound) Trial_8\NN (r_nsubj) demonstrated_19\VBN (l_ccomp) is_22\VBZ (l_acomp) superior_23\JJ (l_xcomp) platelet_25\NN (l_prep) in_32\IN (l_pobj) events_37\NNS
C055162_D004617 NONE clopidogrel_28\JJ (r_dobj) platelet_25\NN (l_prep) in_32\IN (l_pobj) events_37\NNS
D001241_D001281 NONE aspirin_30\NN (r_conj) clopidogrel_28\JJ (r_dobj) platelet_25\NN (r_xcomp) superior_23\JJ (r_acomp) is_22\VBZ (r_ccomp) demonstrated_19\VBN (l_nsubj) Trial_8\NN (l_compound) Clopidogrel_7\NNP (l_compound) Fibrillation_6\NNP
D014812_D056486 NONE K_16\NNP (r_compound) drugs_18\NNS (r_pobj) as_14\IN (r_prep) efficient_13\JJ (r_acomp) be_11\VB (r_xcomp) found_9\VBN (l_conj) withdrawn_30\VBN (l_prep) because_31\IN (l_pobj) tests_36\NNS (l_compound) function_35\NN
C426686_D056486 CID Ximelagatran_0\NN (r_nsubjpass) found_9\VBN (l_conj) withdrawn_30\VBN (l_prep) because_31\IN (l_pobj) tests_36\NNS (l_compound) function_35\NN
C055162_D001281 NONE Clopidogrel_7\NNP (l_compound) Fibrillation_6\NNP
C055162_D001281 NONE clopidogrel_28\JJ (r_dobj) platelet_25\NN (r_xcomp) superior_23\JJ (r_acomp) is_22\VBZ (r_ccomp) demonstrated_19\VBN (l_nsubj) Trial_8\NN (l_compound) Clopidogrel_7\NNP (l_compound) Fibrillation_6\NNP
C081309_D001281 NONE Irbesartan_10\NNP (r_pobj) with_9\IN (r_prep) Trial_8\NN (l_compound) Clopidogrel_7\NNP (l_compound) Fibrillation_6\NNP
D000809_D020257 NONE Angiotensin_0\NN (r_npadvmod) converting_2\VBG (r_amod) inhibitors_4\NNS (r_nsubj) hold_12\VBP (l_dobj) promise_13\NN (l_prep) in_14\IN (l_pobj) fibrillation_16\NN (l_prep) through_17\IN (l_pobj) remodelling_19\NN
D001241_D004617 NONE aspirin_30\NN (r_conj) clopidogrel_28\JJ (r_dobj) platelet_25\NN (l_prep) in_32\IN (l_pobj) events_37\NNS
D014859_D020521 NONE warfarin_12\NN (r_nsubj) reduces_13\VBZ (l_dobj) risk_15\NN (l_prep) of_16\IN (l_pobj) stroke_17\NN
D014859_D020521 NONE warfarin_8\VB (r_nsubj) is_9\VBZ (l_acomp) superior_10\JJ (l_prep) to_11\IN (l_pobj) aspirin_12\NN (l_prep) in_13\IN (l_pcomp) preventing_14\VBG (l_dobj) strokes_15\NNS
11745184
D004999_D001943 NONE WR-2721_7\NNP (r_nmod) amifostine_9\NN (r_pobj) of_4\IN (r_prep) trial_3\NN (l_prep) for_11\IN (l_pobj) carcinoma_14\NN
D004999_D001943 NONE amifostine_9\NN (r_pobj) of_4\IN (r_prep) trial_3\NN (l_prep) for_11\IN (l_pobj) carcinoma_14\NN
D004999_D001943 NONE amifostine_10\NN (r_conj) cisplatin_8\NN (r_pobj) of_7\IN (r_prep) combination_6\NN (r_pobj) of_4\IN (r_prep) study_3\NN (r_nsubjpass) conducted_12\VBN (l_prep) in_13\IN (l_pobj) patients_14\NNS (l_prep) with_15\IN (l_pobj) carcinoma_19\NN
D002945_D020258 NONE cisplatin_10\NN (r_pobj) with_9\IN (r_prep) observed_8\VBN (r_advcl) limited_31\VBN (l_nsubj) toxicities_16\NNS (l_acl) associated_17\VBN (l_prep) with_18\IN (l_pcomp) cisplatin_19\NN (l_preconj) nephrotoxicity_23\NN (l_conj) ototoxicity_25\NN (l_conj) neurotoxicity_28\NN
D002945_D020258 NONE cisplatin_19\NN (l_preconj) nephrotoxicity_23\NN (l_conj) ototoxicity_25\NN (l_conj) neurotoxicity_28\NN
D002945_D001943 NONE cisplatin_5\NN (r_nmod) amifostine_9\NN (r_pobj) of_4\IN (r_prep) trial_3\NN (l_prep) for_11\IN (l_pobj) carcinoma_14\NN
D002945_D001943 NONE Cisplatin_0\NNP (r_nsubj) has_1\VBZ (l_advcl) used_6\VBN (l_prep) as_7\IN (l_pobj) treatment_13\NN (l_prep) of_14\IN (l_pobj) carcinoma_17\NN
D002945_D001943 NONE cisplatin_10\NN (r_pobj) with_9\IN (r_prep) observed_8\VBN (r_advcl) limited_31\VBN (l_dobj) use_33\NN (l_prep) as_34\IN (l_pobj) treatment_36\NN (l_prep) for_37\IN (l_pobj) carcinoma_39\NN
D002945_D001943 NONE cisplatin_19\NN (r_pcomp) with_18\IN (r_prep) associated_17\VBN (r_acl) toxicities_16\NNS (r_nsubj) limited_31\VBN (l_dobj) use_33\NN (l_prep) as_34\IN (l_pobj) treatment_36\NN (l_prep) for_37\IN (l_pobj) carcinoma_39\NN
D002945_D001943 NONE cisplatin_8\NN (r_pobj) of_7\IN (r_prep) combination_6\NN (r_pobj) of_4\IN (r_prep) study_3\NN (r_nsubjpass) conducted_12\VBN (l_prep) in_13\IN (l_pobj) patients_14\NNS (l_prep) with_15\IN (l_pobj) carcinoma_19\NN
D002945_D006311 CID cisplatin_10\NN (r_pobj) with_9\IN (r_prep) observed_8\VBN (r_advcl) limited_31\VBN (l_nsubj) toxicities_16\NNS (l_acl) associated_17\VBN (l_prep) with_18\IN (l_pcomp) cisplatin_19\NN (l_preconj) nephrotoxicity_23\NN (l_conj) ototoxicity_25\NN
D002945_D006311 CID cisplatin_19\NN (l_preconj) nephrotoxicity_23\NN (l_conj) ototoxicity_25\NN
D002945_D006311 CID cisplatin_3\NN (r_pobj) of_2\IN (r_prep) trials_1\NNS (r_nsubj) suggested_7\VBD (l_ccomp) reduced_24\VBN (l_nsubjpass) incidence_10\NN (l_prep) of_13\IN (l_pobj) nephrotoxicity_17\NN (l_conj) ototoxicity_19\NN
D002945_D006311 CID cisplatin_14\NN (r_advmod) induced_16\VBN (r_amod) nephrotoxicity_17\NN (l_conj) ototoxicity_19\NN
D004999_D006311 NONE amifostine_5\NN (r_conj) cisplatin_3\NN (r_pobj) of_2\IN (r_prep) trials_1\NNS (r_nsubj) suggested_7\VBD (l_ccomp) reduced_24\VBN (l_nsubjpass) incidence_10\NN (l_prep) of_13\IN (l_pobj) nephrotoxicity_17\NN (l_conj) ototoxicity_19\NN
D004999_D009369 NONE amifostine_18\NN (r_pobj) of_17\IN (r_prep) addition_16\NN (r_pobj) with_14\IN (r_prep) observed_13\VBN (l_nsubjpass) effect_5\NN (l_amod) protective_4\JJ (l_npadvmod) tumor_2\NN
D004999_D064420 NONE amifostine_18\NN (r_pobj) of_17\IN (r_prep) addition_16\NN (r_pobj) with_14\IN (r_prep) observed_13\VBN (l_nsubjpass) effect_5\NN (l_conj) reduced_7\VBN (l_dobj) toxicity_8\NN
D002945_D064420 NONE cisplatin_10\NN (r_pobj) with_9\IN (r_prep) observed_8\VBN (r_advcl) limited_31\VBN (l_nsubj) toxicities_16\NNS
D002945_D064420 NONE cisplatin_19\NN (r_pcomp) with_18\IN (r_prep) associated_17\VBN (r_acl) toxicities_16\NNS
D002945_D064420 NONE cisplatin_20\VB (r_acl) amifostine_18\NN (r_pobj) of_17\IN (r_prep) addition_16\NN (r_pobj) with_14\IN (r_prep) observed_13\VBN (l_nsubjpass) effect_5\NN (l_conj) reduced_7\VBN (l_dobj) toxicity_8\NN
D002945_D009422 CID cisplatin_3\NN (r_pobj) of_2\IN (r_prep) trials_1\NNS (r_nsubj) suggested_7\VBD (l_ccomp) reduced_24\VBN (l_nsubjpass) incidence_10\NN (l_prep) of_13\IN (l_pobj) nephrotoxicity_17\NN (l_conj) ototoxicity_19\NN (l_conj) neuropathy_22\NN
D002945_D009422 CID cisplatin_14\NN (r_advmod) induced_16\VBN (r_amod) nephrotoxicity_17\NN (l_conj) ototoxicity_19\NN (l_conj) neuropathy_22\NN
D004999_D007674 NONE amifostine_5\NN (r_conj) cisplatin_3\NN (r_pobj) of_2\IN (r_prep) trials_1\NNS (r_nsubj) suggested_7\VBD (l_ccomp) reduced_24\VBN (l_nsubjpass) incidence_10\NN (l_prep) of_13\IN (l_pobj) nephrotoxicity_17\NN
D004999_D009422 NONE amifostine_5\NN (r_conj) cisplatin_3\NN (r_pobj) of_2\IN (r_prep) trials_1\NNS (r_nsubj) suggested_7\VBD (l_ccomp) reduced_24\VBN (l_nsubjpass) incidence_10\NN (l_prep) of_13\IN (l_pobj) nephrotoxicity_17\NN (l_conj) ototoxicity_19\NN (l_conj) neuropathy_22\NN
D002945_D007674 CID cisplatin_10\NN (r_pobj) with_9\IN (r_prep) observed_8\VBN (r_advcl) limited_31\VBN (l_nsubj) toxicities_16\NNS (l_acl) associated_17\VBN (l_prep) with_18\IN (l_pcomp) cisplatin_19\NN (l_preconj) nephrotoxicity_23\NN
D002945_D007674 CID cisplatin_19\NN (l_preconj) nephrotoxicity_23\NN
D002945_D007674 CID cisplatin_3\NN (r_pobj) of_2\IN (r_prep) trials_1\NNS (r_nsubj) suggested_7\VBD (l_ccomp) reduced_24\VBN (l_nsubjpass) incidence_10\NN (l_prep) of_13\IN (l_pobj) nephrotoxicity_17\NN
D002945_D007674 CID cisplatin_14\NN (r_advmod) induced_16\VBN (r_amod) nephrotoxicity_17\NN
D002945_D009369 NONE cisplatin_20\VB (r_acl) amifostine_18\NN (r_pobj) of_17\IN (r_prep) addition_16\NN (r_pobj) with_14\IN (r_prep) observed_13\VBN (l_nsubjpass) effect_5\NN (l_amod) protective_4\JJ (l_npadvmod) tumor_2\NN
8410052
D010862_D002544 CID pilocarpine_10\NN (r_npadvmod) induced_12\VBN (r_amod) status_13\NN (r_pobj) by_8\IN (r_agent) evoked_7\VBN (l_nsubjpass) Infarcts_0\NNS (l_prep) in_1\IN (l_pobj) reticulata_5\NNS
D010862_D013226 CID pilocarpine_10\NN (r_npadvmod) induced_12\VBN (r_amod) status_13\NN (r_pobj) by_8\IN (r_agent) evoked_7\VBN (l_advmod) epilepticus_14\NN
D019344_D001480 NONE lactate_10\NN (r_pobj) of_9\IN (r_prep) infusion_8\NN (r_pobj) by_7\IN (r_agent) produced_6\VBN (l_nsubjpass) injury_1\NN (l_prep) in_2\IN (l_pobj) cortex_4\NN
14657095
D000666_D006333 CID B_20\NNP (r_pobj) with_18\IN (r_prep) developed_5\VBD (l_dobj) failure_12\NN
D000666_D006333 CID AmB_22\NNP (r_appos) B_20\NNP (r_pobj) with_18\IN (r_prep) developed_5\VBD (l_dobj) failure_12\NN
D000666_D006333 CID AmB._12\NN (r_pobj) for_11\IN (r_prep) substituted_10\VBN (r_advcl) resolved_6\VBD (r_acl) abnormalities_2\NNS (l_conj) failure_5\NN
D000666_D064420 NONE AmB._12\NN (r_pobj) of_11\IN (r_prep) toxicity_10\NN
C101425_D006333 NONE posaconazole_8\NN (r_nsubjpass) substituted_10\VBN (r_advcl) resolved_6\VBD (r_acl) abnormalities_2\NNS (l_conj) failure_5\NN
D000666_D003047 NONE B_20\NNP (r_pobj) with_18\IN (r_prep) developed_5\VBD (l_prep) for_24\IN (l_pobj) coccidioidomycosis_26\NN
D000666_D003047 NONE AmB_22\NNP (r_appos) B_20\NNP (r_pobj) with_18\IN (r_prep) developed_5\VBD (l_prep) for_24\IN (l_pobj) coccidioidomycosis_26\NN
D000666_D002311 CID B_6\NNP (r_compound) therapy_7\NN (r_pobj) to_4\IN (r_prep) related_3\VBN (r_acl) cardiomyopathy_2\NN
D000666_D002311 CID B_20\NNP (r_pobj) with_18\IN (r_prep) developed_5\VBD (l_dobj) failure_12\NN (l_amod) cardiomyopathy_7\NN
D000666_D002311 CID AmB_22\NNP (r_appos) B_20\NNP (r_pobj) with_18\IN (r_prep) developed_5\VBD (l_dobj) failure_12\NN (l_amod) cardiomyopathy_7\NN
2334618
D009020_D013610 NONE morphine_26\NN (r_compound) infusion_27\NN (r_compound) group_28\NN (r_pobj) in_24\IN (r_prep) beats_17\NNS (r_conj) tachyarrhythmias_7\NNS
D009020_D018879 CID morphine_26\NN (r_compound) infusion_27\NN (r_compound) group_28\NN (r_pobj) in_24\IN (r_prep) beats_17\NNS
D002045_D001049 NONE bupivacaine_34\NN (r_pobj) of_31\IN (r_prep) infusion_30\NN (r_dobj) receiving_26\VBG (r_acl) patients_25\NNS (r_conj) patients_10\NNS (r_pobj) between_8\IN (r_prep) compared_7\VBN (l_nsubjpass) incidence_1\NN (l_prep) of_2\IN (l_pobj) apnoea_5\NN
D009020_D001049 NONE morphine_17\NN (r_pobj) of_16\IN (r_prep) infusion_15\NN (r_dobj) receiving_11\VBG (r_acl) patients_10\NNS (r_pobj) between_8\IN (r_prep) compared_7\VBN (l_nsubjpass) incidence_1\NN (l_prep) of_2\IN (l_pobj) apnoea_5\NN
D009020_D020181 CID morphine_25\NN (r_compound) infusion_26\NN (r_dobj) had_23\VBD (r_relcl) patients_21\NNS (r_pobj) in_20\IN (r_prep) occurred_17\VBD (l_nsubj) obstructive_1\JJ (l_appos) P_3\NN (l_conj) apnoea_10\NN
D009020_D020182 CID morphine_25\NN (r_compound) infusion_26\NN (r_dobj) had_23\VBD (r_relcl) patients_21\NNS (r_pobj) in_20\IN (r_prep) occurred_17\VBD (l_nsubj) obstructive_1\JJ (l_appos) P_3\NN (l_conj) apnoea_10\NN
8437969
D002927_D007938 NONE cimetidine_27\NN (r_dobj) receiving_23\VBG (r_advcl) recurrent_14\JJ (r_appos) man_4\NN (l_prep) with_5\IN (l_pobj) leukemia_6\NN
D002927_D001145 NONE cimetidine_6\NN (r_compound) administration_7\NN (r_pobj) to_5\IN (r_prep) related_4\VBN (l_nsubjpass) arrhythmias_1\NNS
D011899_D001145 NONE ranitidine_18\NN (r_compound) treatment_19\NN (r_pobj) during_17\IN (r_prep) recur_16\VB (r_conj) disappeared_9\VBD (l_ccomp) related_4\VBN (l_nsubjpass) arrhythmias_1\NNS
D002927_D054138 CID cimetidine_7\NN (r_pobj) with_3\IN (r_prep) associated_2\VBN (r_acl) arrest_1\NN
D002927_D054138 CID cimetidine_27\NN (r_dobj) receiving_23\VBG (r_advcl) recurrent_14\JJ (l_appos) episodes_17\NNS (l_prep) of_18\IN (l_pobj) arrest_21\NN
D002927_D054138 CID cimetidine_14\NN (r_pobj) with_10\IN (r_prep) associated_9\VBN (r_acl) case_5\NN (l_prep) of_6\IN (l_pobj) arrest_8\NN
D002927_D001919 CID cimetidine_7\NN (r_pobj) of_6\IN (r_prep) infusions_5\NNS (r_pobj) of_2\IN (r_prep) administration_1\NN (r_nsubjpass) associated_10\VBN (l_prep) with_11\IN (l_pobj) development_13\NN (l_prep) of_14\IN (l_pobj) bradyarrhythmias_15\NNS
D002927_D006331 NONE cimetidine_27\NN (r_dobj) receiving_23\VBG (r_advcl) recurrent_14\JJ (r_appos) man_4\NN (l_conj) history_9\NN (l_prep) of_10\IN (l_pobj) disease_12\NN
2870085
C047847_D002637 NONE flestolol_6\NN (r_compound) infusion_7\NN (r_nsubjpass) found_9\VBN (l_xcomp) be_11\VB (l_acomp) safe_12\JJ (l_conj) effective_14\JJ (l_prep) in_15\IN (l_pcomp) controlling_16\VBG (l_dobj) pain_18\NN
C047847_D013610 NONE Flestolol_0\NNP (r_nsubj) produced_1\VBD (l_dobj) attenuation_6\NN (l_prep) of_7\IN (l_pobj) tachycardia_11\NN
D007545_D013610 CID isoproterenol_8\NN (r_npadvmod) induced_10\VBN (r_amod) tachycardia_11\NN
C047847_D013617 NONE Flestolol_0\NNP (r_nsubj) reduced_2\VBD (l_prep) in_5\IN (l_pobj) patients_6\NNS (l_prep) with_7\IN (l_pobj) tachyarrhythmia_9\NN
C047847_D000789 NONE flestolol_6\NN (r_compound) infusion_7\NN (r_nsubjpass) found_9\VBN (l_prep) In_0\IN (l_pobj) patients_1\NNS (l_prep) with_2\IN (l_pobj) angina_4\NN
7053303
D002927_D003704 CID cimetidine_10\NN (r_pobj) due_8\IN (r_amod) case_4\NN (l_prep) of_5\IN (l_pobj) dementia_6\NN
D002927_D003704 CID cimetidine_40\JJ (r_compound) levels_41\NNS (r_dobj) had_39\VBD (r_relcl) disease_37\NN (r_pobj) without_33\IN (r_prep) patients_32\NNS (r_pobj) of_30\IN (r_prep) group_29\NN (r_pobj) in_27\IN (r_prep) cimetidine_10\NN (r_pobj) due_8\IN (r_amod) case_4\NN (l_prep) of_5\IN (l_pobj) dementia_6\NN
D002927_D003704 CID cimetidine_3\NN (r_compound) levels_4\NNS (r_nsubj) induce_9\VB (l_dobj) dementia_10\NN
D002927_D008107 NONE cimetidine_10\NN (l_prep) in_27\IN (l_pobj) group_29\NN (l_prep) of_30\IN (l_pobj) patients_32\NNS (l_prep) without_33\IN (l_pobj) disease_37\NN
D002927_D008107 NONE cimetidine_40\JJ (r_compound) levels_41\NNS (r_dobj) had_39\VBD (r_relcl) disease_37\NN
D002927_D007674 NONE cimetidine_10\NN (l_prep) in_27\IN (l_pobj) group_29\NN (l_prep) of_30\IN (l_pobj) patients_32\NNS (l_prep) without_33\IN (l_pobj) disease_37\NN
D002927_D007674 NONE cimetidine_40\JJ (r_compound) levels_41\NNS (r_dobj) had_39\VBD (r_relcl) disease_37\NN
12921865
D005680_D012640 NONE acid_21\NN (l_appos) receptor_26\NN (l_prep) against_27\IN (l_pobj) increase_29\NN (l_prep) in_30\IN (l_pobj) sensitivity_31\NN (l_prep) to_32\IN (l_pobj) effects_35\NNS (l_prep) of_36\IN (l_pobj) cocaine_37\NN (l_acl) engendered_38\VBN (l_agent) by_39\IN (l_pobj) administration_42\NN (l_appos) kindling_45\NN (l_compound) seizure_44\NN
D005680_D012640 NONE GABA(A_23\NNP (r_appos) acid_21\NN (l_appos) receptor_26\NN (l_prep) against_27\IN (l_pobj) increase_29\NN (l_prep) in_30\IN (l_pobj) sensitivity_31\NN (l_prep) to_32\IN (l_pobj) effects_35\NNS (l_prep) of_36\IN (l_pobj) cocaine_37\NN (l_acl) engendered_38\VBN (l_agent) by_39\IN (l_pobj) administration_42\NN (l_appos) kindling_45\NN (l_compound) seizure_44\NN
D005680_D012640 NONE GABA(A_4\NN (r_nmod) modulators_6\NNS (r_pobj) of_1\IN (r_prep) All_0\DT (r_nsubj) suppressed_7\VBD (l_dobj) expression_9\NN (l_prep) of_10\IN (l_pobj) seizures_12\NNS
D013256_D001523 NONE steroids_1\NNS (r_nsubj) demonstrate_2\VBP (l_dobj) actions_4\NNS (l_relcl) have_6\VBP (l_dobj) relevance_7\NN (l_prep) for_8\IN (l_pobj) host_10\NN (l_prep) of_11\IN (l_pobj) disorders_15\NNS
D011280_D012640 NONE Allopregnanolone_0\NN (r_nsubjpass) tested_34\VBN (l_prep) for_35\IN (l_pobj) ability_37\NN (l_acl) suppress_39\VB (l_dobj) expression_41\NN (l_appos) effect_44\NN (l_conj) development_47\NN (l_prep) of_52\IN (l_pobj) seizures_56\NNS
D011280_D012640 NONE pregnan-20-one_6\NNP (r_advmod) 3alpha_2\CD (r_appos) Allopregnanolone_0\NN (r_nsubjpass) tested_34\VBN (l_prep) for_35\IN (l_pobj) ability_37\NN (l_acl) suppress_39\VB (l_dobj) expression_41\NN (l_appos) effect_44\NN (l_conj) development_47\NN (l_prep) of_52\IN (l_pobj) seizures_56\NNS
D011280_D012640 NONE pregnanolone_9\NN (r_appos) Allopregnanolone_0\NN (r_nsubjpass) tested_34\VBN (l_prep) for_35\IN (l_pobj) ability_37\NN (l_acl) suppress_39\VB (l_dobj) expression_41\NN (l_appos) effect_44\NN (l_conj) development_47\NN (l_prep) of_52\IN (l_pobj) seizures_56\NNS
D011280_D012640 NONE pregnan-20-one_15\NNP (r_parataxis) pregnanolone_9\NN (r_appos) Allopregnanolone_0\NN (r_nsubjpass) tested_34\VBN (l_prep) for_35\IN (l_pobj) ability_37\NN (l_acl) suppress_39\VB (l_dobj) expression_41\NN (l_appos) effect_44\NN (l_conj) development_47\NN (l_prep) of_52\IN (l_pobj) seizures_56\NNS
D011280_D012640 NONE allopregnanolone_24\NN (r_pobj) of_23\IN (r_prep) derivative_22\NN (r_appos) ganaxolone_18\NN (r_conj) pregnanolone_9\NN (r_appos) Allopregnanolone_0\NN (r_nsubjpass) tested_34\VBN (l_prep) for_35\IN (l_pobj) ability_37\NN (l_acl) suppress_39\VB (l_dobj) expression_41\NN (l_appos) effect_44\NN (l_conj) development_47\NN (l_prep) of_52\IN (l_pobj) seizures_56\NNS
D011280_D012640 NONE allopregnanolone_16\NN (r_nsubj) inhibited_19\VBD (r_advcl) suppressed_7\VBD (l_dobj) expression_9\NN (l_prep) of_10\IN (l_pobj) seizures_12\NNS
C105051_D012640 NONE ganaxolone_18\NN (r_conj) pregnanolone_9\NN (r_appos) Allopregnanolone_0\NN (r_nsubjpass) tested_34\VBN (l_prep) for_35\IN (l_pobj) ability_37\NN (l_acl) suppress_39\VB (l_dobj) expression_41\NN (l_appos) effect_44\NN (l_conj) development_47\NN (l_prep) of_52\IN (l_pobj) seizures_56\NNS
C105051_D012640 NONE pregnan-20-one_31\NNP (r_appos) 3alpha_25\CD (r_appos) allopregnanolone_24\NN (r_pobj) of_23\IN (r_prep) derivative_22\NN (r_appos) ganaxolone_18\NN (r_conj) pregnanolone_9\NN (r_appos) Allopregnanolone_0\NN (r_nsubjpass) tested_34\VBN (l_prep) for_35\IN (l_pobj) ability_37\NN (l_acl) suppress_39\VB (l_dobj) expression_41\NN (l_appos) effect_44\NN (l_conj) development_47\NN (l_prep) of_52\IN (l_pobj) seizures_56\NNS
C105051_D012640 NONE ganaxolone_18\NN (r_conj) allopregnanolone_16\NN (r_nsubj) inhibited_19\VBD (r_advcl) suppressed_7\VBD (l_dobj) expression_9\NN (l_prep) of_10\IN (l_pobj) seizures_12\NNS
D013256_D009422 NONE steroids_1\NNS (r_nsubj) demonstrate_2\VBP (l_dobj) actions_4\NNS (l_relcl) have_6\VBP (l_dobj) relevance_7\NN (l_prep) for_8\IN (l_pobj) host_10\NN (l_prep) of_11\IN (l_pobj) disorders_15\NNS
D013256_D012640 NONE steroids_4\NNS (l_prep) against_5\IN (l_pobj) seizures_9\NNS
D013256_D012640 NONE steroid_13\NN (l_relcl) modulate_16\VBP (l_dobj) acid_21\NN (l_appos) receptor_26\NN (l_prep) against_27\IN (l_pobj) increase_29\NN (l_prep) in_30\IN (l_pobj) sensitivity_31\NN (l_prep) to_32\IN (l_pobj) effects_35\NNS (l_prep) of_36\IN (l_pobj) cocaine_37\NN (l_acl) engendered_38\VBN (l_agent) by_39\IN (l_pobj) administration_42\NN (l_appos) kindling_45\NN (l_compound) seizure_44\NN
D003042_D012640 CID cocaine_6\NN (r_compound) seizures_9\NNS
D003042_D012640 CID cocaine_37\NN (l_acl) engendered_38\VBN (l_agent) by_39\IN (l_pobj) administration_42\NN (l_appos) kindling_45\NN (l_compound) seizure_44\NN
D003042_D012640 CID cocaine_41\NN (r_compound) administration_42\NN (l_appos) kindling_45\NN (l_compound) seizure_44\NN
D003042_D012640 CID cocaine_53\NN (r_npadvmod) kindled_55\VBN (r_amod) seizures_56\NNS
D003042_D012640 CID cocaine_10\NN (r_pobj) of_7\IN (r_prep) administration_6\NN (r_pobj) by_4\IN (r_agent) induced_3\VBN (l_csubjpass) Kindled_0\VBN (l_dobj) seizures_1\NNS
16904497
D014221_D011128 NONE triamcinolone_16\NN (r_pobj) of_15\IN (r_prep) injection_14\NN (r_pobj) by_12\IN (r_agent) caused_11\VBN (r_acl) report_5\NN (l_prep) of_6\IN (l_pobj) syndrome_9\NN
D002045_D011128 CID bupivacaine_18\NN (r_conj) triamcinolone_16\NN (r_pobj) of_15\IN (r_prep) injection_14\NN (r_pobj) by_12\IN (r_agent) caused_11\VBN (r_acl) report_5\NN (l_prep) of_6\IN (l_pobj) syndrome_9\NN
D013256_D010146 NONE steroid_16\NN (r_compound) injection_17\NN (r_pobj) for_14\IN (r_prep) scheduled_13\VBN (l_nsubjpass) woman_4\NN (l_prep) with_5\IN (l_pobj) pain_11\NN
D013256_D011128 NONE steroid_5\NN (r_compound) injection_6\NN (r_pobj) after_3\IN (r_prep) syndrome_2\NN
D013256_D009422 NONE steroid_10\NN (r_compound) injections_11\NNS (r_pobj) after_8\IN (r_prep) vigilance_4\NN (l_prep) for_5\IN (l_pobj) deterioration_7\NN
D013256_D011843 NONE steroid_11\NN (r_compound) injections_12\NNS (r_conj) therapy_8\NN (r_attr) are_6\VBP (l_nsubj) methods_2\NNS (l_prep) of_3\IN (l_pobj) radiculopathy_5\NN
D013256_D017116 NONE steroid_16\NN (r_compound) injection_17\NN (r_pobj) for_14\IN (r_prep) scheduled_13\VBN (l_nsubjpass) woman_4\NN (l_prep) with_5\IN (l_pobj) pain_11\NN
12596116
D015282_D000860 NONE Octreotide_0\NNP (r_npadvmod) induced_2\VBN (l_dobj) hypoxemia_3\NN
D015282_D006976 CID Octreotide_0\NNP (r_npadvmod) induced_2\VBN (l_dobj) hypoxemia_3\NN (l_conj) hypertension_6\NN
D015282_D006976 CID octreotide_10\NN (r_advmod) developed_2\VBD (l_nsubj) hypertension_1\NN
D015282_D005402 NONE octreotide_10\NN (r_advmod) developed_2\VBD (l_advcl) enhance_13\VB (l_dobj) resolution_14\NN (l_prep) of_15\IN (l_pobj) fistula_17\NN
16337777
D010862_D004833 CID pilocarpine_49\NN (r_amod) model_50\NN (l_prep) of_51\IN (l_pobj) epilepsy_54\NN
D010862_D013226 NONE pilocarpine_49\NN (r_amod) model_50\NN (r_pobj) of_47\IN (r_prep) phase_46\NN (r_pobj) in_43\IN (r_prep) provoke_18\VB (r_xcomp) sufficient_16\JJ (r_acomp) be_15\VB (l_nsubj) generation_8\NN (l_prep) during_11\IN (l_pobj) epilepticus_13\NN
D010862_D004827 NONE pilocarpine_12\NN (r_pobj) by_11\IN (r_agent) induced_10\VBN (r_acl) model_7\NN (l_prep) of_8\IN (l_pobj) epilepsy_9\NN
18503483
D016559_D020968 CID tacrolimus_2\NN (r_npadvmod) associated_4\VBN (r_amod) neuritis_6\NN
C107135_D020968 NONE everolimus_10\NN (r_pobj) to_9\TO (r_prep) conversion_8\NN (r_pobj) after_7\IN (r_prep) Recovery_0\NN (l_prep) of_1\IN (l_pobj) neuritis_6\NN
11334364
D000082_D066126 NONE acetaminophen_13\RB (r_advmod) induced_15\VBN (r_amod) nephrotoxicity_16\NN (l_conj) toxicity_22\NN (l_conj) cardiotoxicity_27\NN
D000082_D066126 NONE acetaminophen_16\RB (r_advmod) prevent_15\VB (l_dobj) toxicity_25\NN (l_conj) doxorubicin_28\NN (l_dobj) cardiotoxicity_31\NN
D000082_D066126 NONE AAP)-induced_18\VBN (r_compound) nephrotoxicity_19\NN (r_nmod) toxicity_25\NN (l_conj) doxorubicin_28\NN (l_dobj) cardiotoxicity_31\NN
D000638_D066126 NONE amiodarone_18\NN (r_npadvmod) induced_20\VBN (r_amod) toxicity_22\NN (l_conj) cardiotoxicity_27\NN
D000638_D066126 NONE amiodarone_21\NN (r_appos) nephrotoxicity_19\NN (r_nmod) toxicity_25\NN (l_conj) doxorubicin_28\NN (l_dobj) cardiotoxicity_31\NN
D000638_D066126 NONE AMI)-induced_23\JJ (r_amod) toxicity_25\NN (l_conj) doxorubicin_28\NN (l_dobj) cardiotoxicity_31\NN
D000638_D007674 NONE amiodarone_18\NN (r_npadvmod) induced_20\VBN (r_amod) toxicity_22\NN (r_conj) nephrotoxicity_16\NN
D000638_D007674 NONE amiodarone_21\NN (r_appos) nephrotoxicity_19\NN
D000638_D007674 NONE AMI)-induced_23\JJ (r_amod) toxicity_25\NN (l_nmod) nephrotoxicity_19\NN
C511402_D009336 NONE extract_35\NN (r_pobj) by_28\IN (r_prep) cardiotoxicity_27\NN (r_conj) toxicity_22\NN (r_conj) nephrotoxicity_16\NN (r_pobj) during_12\IN (r_prep) deaths_11\NNS (l_amod) apoptotic_7\JJ (l_conj) necrotic_9\JJ
C511402_D009336 NONE GSPE_31\NNP (r_pobj) by_30\IN (r_agent) blocked_29\VBN (r_relcl) necrosis_20\NN
C511402_D008171 NONE extract_35\NN (r_pobj) by_28\IN (r_prep) cardiotoxicity_27\NN (r_conj) toxicity_22\NN
C511402_D008171 NONE extract_10\NN (r_pobj) of_5\IN (r_prep) ability_4\NN (l_acl) prevent_15\VB (l_dobj) toxicity_25\NN
C511402_D008171 NONE GSPE_12\NNP (r_appos) extract_10\NN (r_pobj) of_5\IN (r_prep) ability_4\NN (l_acl) prevent_15\VB (l_dobj) toxicity_25\NN
D000082_D007674 CID acetaminophen_13\RB (r_advmod) induced_15\VBN (r_amod) nephrotoxicity_16\NN
D000082_D007674 CID acetaminophen_16\RB (r_advmod) prevent_15\VB (l_dobj) toxicity_25\NN (l_nmod) nephrotoxicity_19\NN
D000082_D007674 CID AAP)-induced_18\VBN (r_compound) nephrotoxicity_19\NN
D000638_D009336 CID amiodarone_18\NN (r_npadvmod) induced_20\VBN (r_amod) toxicity_22\NN (r_conj) nephrotoxicity_16\NN (r_pobj) during_12\IN (r_prep) deaths_11\NNS (l_amod) apoptotic_7\JJ (l_conj) necrotic_9\JJ
D000638_D009336 CID AMI_11\NNP (r_conj) AAP_9\NNP (r_appos) drugs_4\NNS (r_nsubj) induced_14\VBD (l_prep) in_17\IN (l_pobj) addition_18\NN (l_prep) to_19\IN (l_pobj) necrosis_20\NN
C511402_D017695 NONE GSPE_30\NNP (r_compound) preexposure_31\NN (r_pobj) of_29\IN (r_prep) absence_28\NN (r_pobj) in_26\IN (r_prep) variety_17\NN (r_pobj) with_15\IN (r_prep) damage_14\NN
D000638_D008171 CID amiodarone_18\NN (r_npadvmod) induced_20\VBN (r_amod) toxicity_22\NN
D000638_D008171 CID amiodarone_21\NN (r_appos) nephrotoxicity_19\NN (r_nmod) toxicity_25\NN
D000638_D008171 CID AMI)-induced_23\JJ (r_amod) toxicity_25\NN
D004317_D007674 NONE doxorubicin_24\NN (r_npadvmod) induced_26\VBN (r_amod) cardiotoxicity_27\NN (r_conj) toxicity_22\NN (r_conj) nephrotoxicity_16\NN
D004317_D007674 NONE doxorubicin_28\NN (r_conj) toxicity_25\NN (l_nmod) nephrotoxicity_19\NN
D004317_D007674 NONE DOX)-induced_30\JJ (r_amod) cardiotoxicity_31\NN (r_dobj) doxorubicin_28\NN (r_conj) toxicity_25\NN (l_nmod) nephrotoxicity_19\NN
D000082_D009336 CID acetaminophen_13\RB (r_advmod) induced_15\VBN (r_amod) nephrotoxicity_16\NN (r_pobj) during_12\IN (r_prep) deaths_11\NNS (l_amod) apoptotic_7\JJ (l_conj) necrotic_9\JJ
D000082_D009336 CID AAP_9\NNP (r_appos) drugs_4\NNS (r_nsubj) induced_14\VBD (l_prep) in_17\IN (l_pobj) addition_18\NN (l_prep) to_19\IN (l_pobj) necrosis_20\NN
C511402_D007674 NONE extract_35\NN (r_pobj) by_28\IN (r_prep) cardiotoxicity_27\NN (r_conj) toxicity_22\NN (r_conj) nephrotoxicity_16\NN
C511402_D007674 NONE extract_10\NN (r_pobj) of_5\IN (r_prep) ability_4\NN (l_acl) prevent_15\VB (l_dobj) toxicity_25\NN (l_nmod) nephrotoxicity_19\NN
C511402_D007674 NONE GSPE_12\NNP (r_appos) extract_10\NN (r_pobj) of_5\IN (r_prep) ability_4\NN (l_acl) prevent_15\VB (l_dobj) toxicity_25\NN (l_nmod) nephrotoxicity_19\NN
D004317_D008171 NONE doxorubicin_24\NN (r_npadvmod) induced_26\VBN (r_amod) cardiotoxicity_27\NN (r_conj) toxicity_22\NN
D004317_D008171 NONE doxorubicin_28\NN (r_conj) toxicity_25\NN
D004317_D008171 NONE DOX)-induced_30\JJ (r_amod) cardiotoxicity_31\NN (r_dobj) doxorubicin_28\NN (r_conj) toxicity_25\NN
D000082_D008171 NONE acetaminophen_13\RB (r_advmod) induced_15\VBN (r_amod) nephrotoxicity_16\NN (l_conj) toxicity_22\NN
D000082_D008171 NONE acetaminophen_16\RB (r_advmod) prevent_15\VB (l_dobj) toxicity_25\NN
D000082_D008171 NONE AAP)-induced_18\VBN (r_compound) nephrotoxicity_19\NN (r_nmod) toxicity_25\NN
D004317_D009336 CID doxorubicin_24\NN (r_npadvmod) induced_26\VBN (r_amod) cardiotoxicity_27\NN (r_conj) toxicity_22\NN (r_conj) nephrotoxicity_16\NN (r_pobj) during_12\IN (r_prep) deaths_11\NNS (l_amod) apoptotic_7\JJ (l_conj) necrotic_9\JJ
D004317_D009336 CID DOX_13\NNP (r_conj) AMI_11\NNP (r_conj) AAP_9\NNP (r_appos) drugs_4\NNS (r_nsubj) induced_14\VBD (l_prep) in_17\IN (l_pobj) addition_18\NN (l_prep) to_19\IN (l_pobj) necrosis_20\NN
C511402_D066126 NONE extract_35\NN (r_pobj) by_28\IN (r_prep) cardiotoxicity_27\NN
C511402_D066126 NONE extract_10\NN (r_pobj) of_5\IN (r_prep) ability_4\NN (l_acl) prevent_15\VB (l_dobj) toxicity_25\NN (l_conj) doxorubicin_28\NN (l_dobj) cardiotoxicity_31\NN
C511402_D066126 NONE GSPE_12\NNP (r_appos) extract_10\NN (r_pobj) of_5\IN (r_prep) ability_4\NN (l_acl) prevent_15\VB (l_dobj) toxicity_25\NN (l_conj) doxorubicin_28\NN (l_dobj) cardiotoxicity_31\NN
D004317_D066126 CID doxorubicin_24\NN (r_npadvmod) induced_26\VBN (r_amod) cardiotoxicity_27\NN
D004317_D066126 CID doxorubicin_28\NN (l_dobj) cardiotoxicity_31\NN
D004317_D066126 CID DOX)-induced_30\JJ (r_amod) cardiotoxicity_31\NN
19346865
D008795_D007239 NONE metronidazole_4\NN (r_dobj) taking_3\VBG (l_advcl) treat_23\VB (l_dobj) infection_25\NN
D008795_D001927 CID metronidazole_5\NN (r_npadvmod) induced_7\VBN (r_amod) encephalopathy_8\NN (r_pobj) in_4\IN (r_prep) lesion_3\NN
D008795_D001927 CID metronidazole_5\NN (r_npadvmod) induced_7\VBN (r_amod) encephalopathy_8\NN
D008795_D001927 CID metronidazole_9\NN (r_npadvmod) induced_11\VBN (r_amod) encephalopathy_12\NN (r_pobj) in_8\IN (r_prep) lesions_7\NNS
D008795_D001927 CID metronidazole_9\NN (r_npadvmod) induced_11\VBN (r_amod) encephalopathy_12\NN
D008795_D001927 CID metronidazole_20\NN (r_npadvmod) induced_22\VBN (r_amod) encephalopathy_23\NN
D008795_D001927 CID metronidazole_11\NN (r_npadvmod) induced_13\VBN (r_amod) encephalopathy_14\NN (r_pobj) for_10\IN (r_prep) characteristic_9\NN (r_pobj) as_7\IN (r_prep) considered_6\VBN (l_nsubjpass) lesions_3\NNS
D008795_D001927 CID metronidazole_11\NN (r_npadvmod) induced_13\VBN (r_amod) encephalopathy_14\NN
3970039
D003520_D002277 CID Cyclophosphamide_0\NNP (r_compound) therapy_1\NN (r_nsubj) increases_2\VBZ (l_dobj) risk_4\NN (l_prep) of_5\IN (l_pobj) carcinoma_6\NN (l_prep) of_7\IN (l_pobj) bladder_9\NN
D000477_D015470 CID agents_4\NNS (r_pobj) with_2\IN (r_prep) treated_1\VBN (r_csubj) have_5\VBP (l_dobj) risk_8\NN (l_prep) of_9\IN (l_pobj) development_10\NN (l_prep) of_11\IN (l_pobj) leukemia_14\NN
D000477_D015470 CID agents_19\NNS (r_nsubjpass) associated_23\VBN (r_conj) have_5\VBP (l_dobj) risk_8\NN (l_prep) of_9\IN (l_pobj) development_10\NN (l_prep) of_11\IN (l_pobj) leukemia_14\NN
D000477_D009369 NONE agents_31\NNS (r_appos) drugs_27\NNS (r_pobj) of_25\IN (r_prep) use_24\NN (r_nsubjpass) reserved_41\VBN (r_conj) collected_14\VBN (l_nsubjpass) Data_0\NNS (l_prep) on_1\IN (l_pobj) risk_5\NN (l_prep) of_6\IN (l_pobj) malignancy_7\NN
D003520_D001172 NONE cyclophosphamide_17\NN (r_conj) azathioprine_15\NN (r_pobj) with_14\IN (r_prep) treated_13\VBN (r_acl) studies_7\NNS (l_prep) of_8\IN (l_pobj) patients_9\NNS (l_prep) with_10\IN (l_pobj) arthritis_12\NN
D000477_D001172 NONE agents_31\NNS (r_appos) drugs_27\NNS (r_pobj) of_25\IN (r_prep) use_24\NN (r_nsubjpass) reserved_41\VBN (r_conj) collected_14\VBN (l_nsubjpass) Data_0\NNS (l_prep) on_1\IN (l_pobj) risk_5\NN (l_prep) of_6\IN (l_pobj) malignancy_7\NN (l_prep) in_8\IN (l_pobj) arthritis_10\NN
D000477_D001172 NONE agents_31\NNS (r_appos) drugs_27\NNS (r_pobj) of_25\IN (r_prep) use_24\NN (l_prep) in_33\IN (l_pobj) treatment_35\NN (l_prep) of_36\IN (l_pobj) arthritis_38\NN
D003520_D009369 NONE cyclophosphamide_17\NN (r_conj) azathioprine_15\NN (r_pobj) with_14\IN (r_prep) treated_13\VBN (r_acl) studies_7\NNS (r_attr) been_2\VBN (l_conj) increased_29\VBN (l_nsubjpass) incidence_20\NN (l_prep) of_21\IN (l_pobj) most_22\JJS (l_prep) of_23\IN (l_pobj) cancers_26\NNS
D003520_D001749 CID Cyclophosphamide_0\NNP (r_compound) therapy_1\NN (r_nsubj) increases_2\VBZ (l_dobj) risk_4\NN (l_prep) of_5\IN (l_pobj) carcinoma_6\NN (l_prep) of_7\IN (l_pobj) bladder_9\NN
D000477_D008228 CID agents_4\NNS (r_pobj) with_2\IN (r_prep) treated_1\VBN (r_csubj) have_5\VBP (l_conj) associated_23\VBN (l_prep) with_24\IN (l_pobj) development_26\NN (l_prep) of_27\IN (l_pobj) lymphoma_32\NN
D000477_D008228 CID agents_19\NNS (r_nsubjpass) associated_23\VBN (l_prep) with_24\IN (l_pobj) development_26\NN (l_prep) of_27\IN (l_pobj) lymphoma_32\NN
D001379_D009369 NONE azathioprine_15\NN (r_pobj) with_14\IN (r_prep) treated_13\VBN (r_acl) studies_7\NNS (r_attr) been_2\VBN (l_conj) increased_29\VBN (l_nsubjpass) incidence_20\NN (l_prep) of_21\IN (l_pobj) most_22\JJS (l_prep) of_23\IN (l_pobj) cancers_26\NNS
D001379_D001172 NONE azathioprine_15\NN (r_pobj) with_14\IN (r_prep) treated_13\VBN (r_acl) studies_7\NNS (l_prep) of_8\IN (l_pobj) patients_9\NNS (l_prep) with_10\IN (l_pobj) arthritis_12\NN
D001379_D008228 CID azathioprine_21\NN (r_conj) agents_19\NNS (r_nsubjpass) associated_23\VBN (l_prep) with_24\IN (l_pobj) development_26\NN (l_prep) of_27\IN (l_pobj) lymphoma_32\NN
D001379_D015470 NONE azathioprine_21\NN (r_conj) agents_19\NNS (r_nsubjpass) associated_23\VBN (r_conj) have_5\VBP (l_dobj) risk_8\NN (l_prep) of_9\IN (l_pobj) development_10\NN (l_prep) of_11\IN (l_pobj) leukemia_14\NN
2266990
D008454_D001068 CID mazindol_4\NN (r_pobj) to_3\IN (r_prep) attributable_2\JJ (r_amod) effects_1\NNS (r_nsubj) included_5\VBN (l_dobj) appetite_7\NN
D008454_D001068 CID mazindol_35\NN (r_amod) dosage_36\NN (r_nsubjpass) reduced_38\VBN (l_ccomp) included_5\VBN (l_dobj) appetite_7\NN
D008454_D020388 NONE mazindol_7\NN (l_prep) in_8\IN (l_pobj) dystrophy_10\NN
D008454_D020388 NONE mazindol_7\NN (r_pobj) of_6\IN (r_prep) trial_5\NN (r_dobj) conducted_1\VBD (l_prep) in_16\IN (l_pobj) boys_18\NNS (l_prep) with_19\IN (l_pobj) dystrophy_21\NN
D008454_D020388 NONE Mazindol_0\JJ (r_compound) doses_1\NNS (r_nsubj) slow_3\VBP (l_dobj) progression_5\NN (l_prep) of_6\IN (l_pobj) weakness_7\NN (l_prep) in_8\IN (l_pobj) dystrophy_10\NN
D008454_D014987 CID mazindol_4\NN (r_pobj) to_3\IN (r_prep) attributable_2\JJ (r_amod) effects_1\NNS (r_nsubj) included_5\VBN (l_dobj) appetite_7\NN (l_appos) mouth_14\NN
D008454_D014987 CID mazindol_35\NN (r_amod) dosage_36\NN (r_nsubjpass) reduced_38\VBN (l_ccomp) included_5\VBN (l_dobj) appetite_7\NN (l_appos) mouth_14\NN
D008454_D018908 NONE Mazindol_0\JJ (r_compound) doses_1\NNS (r_nsubj) slow_3\VBP (l_dobj) progression_5\NN (l_prep) of_6\IN (l_pobj) weakness_7\NN
D008454_D012817 CID mazindol_4\NN (r_pobj) to_3\IN (r_prep) attributable_2\JJ (r_amod) effects_1\NNS (r_nsubj) included_5\VBN (l_dobj) appetite_7\NN (l_appos) change_21\NN (l_conj) symptoms_29\NNS
D008454_D012817 CID mazindol_35\NN (r_amod) dosage_36\NN (r_nsubjpass) reduced_38\VBN (l_ccomp) included_5\VBN (l_dobj) appetite_7\NN (l_appos) change_21\NN (l_conj) symptoms_29\NNS
6861444
D009638_D006973 CID noradrenaline_3\NN (r_pobj) of_2\IN (r_prep) infusion_1\NN (r_nsubj) caused_4\VBD (l_dobj) hypertension_5\NN
D009638_D006973 CID noradrenaline_8\NN (r_amod) infusion_9\NN (r_pobj) after_5\IN (r_prep) hypertension_4\NN
D009638_D006973 CID noradrenaline_18\NN (r_dobj) circulating_17\VBG (r_pcomp) of_16\IN (r_prep) levels_15\NNS (r_pobj) by_12\IN (r_agent) produced_11\VBN (l_nsubjpass) hypertension_4\NN
137340
D010830_D006948 NONE physostigmine_12\NN (r_pobj) by_11\IN (r_agent) attenuated_10\VBN (r_conj) potentiated_6\VBN (l_nsubjpass) hyperactivity_4\NN
D012701_D006948 NONE serotonin_22\NN (r_compound) depletor_23\NN (r_nsubj) caused_25\VBD (l_dobj) change_28\NN (l_prep) in_29\IN (l_pobj) hyperactivity_31\NN
D009388_D006948 NONE neostigmine_6\NN (r_conj) methscopolamine_4\NN (r_nsubj) had_18\VBD (l_dobj) effect_20\NN (l_prep) on_21\IN (l_pobj) hyperactivity_23\NN
D012601_D006948 CID scopolamine_8\NN (r_pobj) by_7\IN (r_agent) potentiated_6\VBN (l_nsubjpass) hyperactivity_4\NN
D010134_D006948 NONE chlorophenylalamine_9\NN (r_pobj) with_6\IN (r_prep) pretreatment_5\NN (r_nsubj) caused_25\VBD (l_dobj) change_28\NN (l_prep) in_29\IN (l_pobj) hyperactivity_31\NN
D019832_D006948 NONE methscopolamine_4\NN (r_nsubj) had_18\VBD (l_dobj) effect_20\NN (l_prep) on_21\IN (l_pobj) hyperactivity_23\NN
D009020_D006948 CID morphine_5\NN (r_npadvmod) induced_7\VBN (r_amod) increase_8\NN (l_prep) in_9\IN (l_pobj) activity_11\NN
D009020_D006948 CID morphine_7\NN (r_npadvmod) induced_9\VBN (r_amod) increase_10\NN (l_prep) in_11\IN (l_pobj) activity_13\NN
D009020_D006948 CID morphine_7\NN (r_compound) HC1_9\NNP (r_pobj) of_6\IN (r_prep) mg/kg_5\NN (r_pobj) of_3\IN (r_prep) administration_2\NN (r_nsubj) produced_10\VBD (l_dobj) increase_13\NN (l_prep) in_14\IN (l_pobj) activity_16\NN
D009020_D006948 CID morphine_1\NN (r_npadvmod) induced_3\VBN (r_amod) hyperactivity_4\NN
D009020_D006948 CID morphine_26\NN (r_pobj) by_25\IN (r_agent) produced_24\VBN (r_acl) hyperactivity_23\NN
227508
D008750_D007022 CID methyldopa_8\NN (r_pobj) of_3\IN (r_prep) effect_2\NN (l_amod) hypotensive_1\JJ
D003000_D006973 NONE clonidine_17\NN (r_pobj) by_15\IN (r_agent) produced_14\VBN (r_acl) pressure_10\NN (r_pobj) in_8\IN (r_prep) decrease_7\NN (r_dobj) rats_5\NNS (l_amod) hypertensive_4\JJ
D003000_D006973 NONE clonidine_7\NN (r_preconj) In_0\IN (l_pobj) membranes_2\NNS (l_prep) from_3\IN (l_pobj) rats_6\NNS (l_amod) hypertensive_5\JJ
D003000_D006973 NONE clonidine_42\NN (r_npadvmod) suppressible_44\NN (r_amod) binding_45\NN (r_dobj) influence_41\VB (r_conj) influence_18\VB (l_prep) In_0\IN (l_pobj) membranes_2\NNS (l_prep) from_3\IN (l_pobj) rats_6\NNS (l_amod) hypertensive_5\JJ
-1_D006973 NONE nalozone_31\NN (r_pobj) by_30\IN (r_agent) reversed_29\VBN (r_conj) inhibited_27\VBN (r_conj) rats_5\NNS (l_amod) hypertensive_4\JJ
-1_D006973 NONE 3H]-naloxone_23\CD (r_pobj) of_21\IN (r_prep) binding_20\NN (r_dobj) influence_18\VB (l_prep) In_0\IN (l_pobj) membranes_2\NNS (l_prep) from_3\IN (l_pobj) rats_6\NNS (l_amod) hypertensive_5\JJ
-1_D006973 NONE 3H]-dihydroergocryptine_48\CD (r_nummod) nM_51\NNP (r_pobj) of_46\IN (r_prep) binding_45\NN (r_dobj) influence_41\VB (r_conj) influence_18\VB (l_prep) In_0\IN (l_pobj) membranes_2\NNS (l_prep) from_3\IN (l_pobj) rats_6\NNS (l_amod) hypertensive_5\JJ
D009270_D006973 NONE naloxone_30\NN (r_nsubj) influence_41\VB (r_conj) influence_18\VB (l_prep) In_0\IN (l_pobj) membranes_2\NNS (l_prep) from_3\IN (l_pobj) rats_6\NNS (l_amod) hypertensive_5\JJ
D009270_D007022 NONE naloxone_14\NN (r_pobj) by_13\IN (r_agent) reversed_12\VBN (l_nsubjpass) effect_2\NN (l_amod) hypotensive_1\JJ
16680561
C476217_D006261 CID cinacalcet_15\NN (r_pobj) with_14\IN (r_prep) receiving_12\VBG (r_pcomp) than_10\IN (r_prep) alone_9\RB (r_amod) events_4\NNS (r_dobj) reported_2\VBD (r_ccomp) reported_35\VBN (l_nsubjpass) nausea_29\NN (l_conj) headache_31\NN
C476217_D006261 CID cinacalcet_43\NN (r_conj) desipramine_41\NN (r_pobj) with_39\IN (r_prep) treated_38\VBN (r_acl) patients_37\NNS (r_pobj) for_36\IN (r_prep) reported_35\VBN (l_nsubjpass) nausea_29\NN (l_conj) headache_31\NN
C476217_D009325 CID cinacalcet_15\NN (r_pobj) with_14\IN (r_prep) receiving_12\VBG (r_pcomp) than_10\IN (r_prep) alone_9\RB (r_amod) events_4\NNS (r_dobj) reported_2\VBD (r_ccomp) reported_35\VBN (l_nsubjpass) nausea_29\NN
C476217_D009325 CID cinacalcet_43\NN (r_conj) desipramine_41\NN (r_pobj) with_39\IN (r_prep) treated_38\VBN (r_acl) patients_37\NNS (r_pobj) for_36\IN (r_prep) reported_35\VBN (l_nsubjpass) nausea_29\NN
D003891_D006261 CID desipramine_8\NN (r_pobj) with_7\IN (r_prep) treatment_6\NN (r_dobj) following_5\VBG (r_acl) events_4\NNS (r_dobj) reported_2\VBD (r_ccomp) reported_35\VBN (l_nsubjpass) nausea_29\NN (l_conj) headache_31\NN
D003891_D006261 CID desipramine_13\NN (r_dobj) receiving_12\VBG (r_pcomp) than_10\IN (r_prep) alone_9\RB (r_amod) events_4\NNS (r_dobj) reported_2\VBD (r_ccomp) reported_35\VBN (l_nsubjpass) nausea_29\NN (l_conj) headache_31\NN
D003891_D006261 CID desipramine_41\NN (r_pobj) with_39\IN (r_prep) treated_38\VBN (r_acl) patients_37\NNS (r_pobj) for_36\IN (r_prep) reported_35\VBN (l_nsubjpass) nausea_29\NN (l_conj) headache_31\NN
D003891_D009325 CID desipramine_8\NN (r_pobj) with_7\IN (r_prep) treatment_6\NN (r_dobj) following_5\VBG (r_acl) events_4\NNS (r_dobj) reported_2\VBD (r_ccomp) reported_35\VBN (l_nsubjpass) nausea_29\NN
D003891_D009325 CID desipramine_13\NN (r_dobj) receiving_12\VBG (r_pcomp) than_10\IN (r_prep) alone_9\RB (r_amod) events_4\NNS (r_dobj) reported_2\VBD (r_ccomp) reported_35\VBN (l_nsubjpass) nausea_29\NN
D003891_D009325 CID desipramine_41\NN (r_pobj) with_39\IN (r_prep) treated_38\VBN (r_acl) patients_37\NNS (r_pobj) for_36\IN (r_prep) reported_35\VBN (l_nsubjpass) nausea_29\NN
7881871
D011692_D011507 CID aminonucleoside_12\NN (r_nmod) nephropathy_15\NN (r_pobj) of_9\IN (r_prep) pathogenesis_8\NN (r_pobj) in_6\IN (r_prep) implicated_5\VBN (l_prep) with_17\IN (l_pcomp) reducing_20\VBG (l_dobj) proteinuria_22\NN
D011692_D011507 CID PAN)-induced_14\JJ (r_amod) nephropathy_15\NN (r_pobj) of_9\IN (r_prep) pathogenesis_8\NN (r_pobj) in_6\IN (r_prep) implicated_5\VBN (l_prep) with_17\IN (l_pcomp) reducing_20\VBG (l_dobj) proteinuria_22\NN
D011692_D011507 CID PAN_14\NNP (r_compound) nephropathy_15\NN (r_pobj) in_13\IN (r_prep) injury_12\NN
D010100_D011507 NONE oxygen_1\NN (r_compound) species_2\NNS (r_nsubjpass) implicated_5\VBN (l_prep) with_17\IN (l_pcomp) reducing_20\VBG (l_dobj) proteinuria_22\NN
D010100_D007674 NONE oxygen_1\NN (r_compound) species_2\NNS (r_nsubjpass) implicated_5\VBN (l_prep) in_6\IN (l_pobj) pathogenesis_8\NN (l_prep) of_9\IN (l_pobj) nephropathy_15\NN
D011692_D007674 CID aminonucleoside_7\NN (r_advmod) induced_9\VBN (r_amod) nephropathy_10\NN
D011692_D007674 CID aminonucleoside_12\NN (r_nmod) nephropathy_15\NN
D011692_D007674 CID PAN)-induced_14\JJ (r_amod) nephropathy_15\NN
D011692_D007674 CID PAN_14\NNP (r_compound) nephropathy_15\NN
6666578
D010396_D001018 CID penicillamine_2\NN (r_compound) induced_4\VBN (l_advmod) angiopathy_5\NN
9249847
D014700_D013611 CID verapamil_7\NN (r_nmod) ablation_10\NN (r_pobj) after_6\IN (r_prep) induced_1\VBD (l_dobj) tachycardia_5\NN
D014700_D013611 CID verapamil_10\NN (r_nmod) block_14\NN (r_pobj) after_9\IN (r_prep) beats_8\NNS (r_pobj) by_5\IN (r_agent) caused_4\VBN (r_acl) QRS_0\UH (r_nsubj) established_22\VBD (l_dobj) attack_25\NN (l_compound) AVRT_24\NN
D014700_D002311 NONE verapamil_7\NN (r_nmod) ablation_10\NN (l_conj) cardiomyopathy_24\NN
D014700_D014927 NONE verapamil_7\NN (r_nmod) ablation_10\NN (l_prep) in_11\IN (l_pobj) patient_13\NN (l_prep) with_14\IN (l_pobj) syndrome_20\NN
3107448
D005905_D003924 NONE glyburide_18\NN (r_amod) therapy_19\NN (r_pobj) of_17\IN (r_prep) initiation_16\NN (r_pobj) after_15\IN (r_prep) developed_7\VBD (l_nsubj) patients_1\NNS (l_prep) with_2\IN (l_pobj) mellitus_6\NN
D005905_D056486 CID Glyburide_0\NN (r_npadvmod) induced_2\VBN (r_amod) hepatitis_3\NN
D005905_D056486 CID glyburide_1\NN (r_pobj) For_0\IN (r_prep) exist_15\VBP (l_nsubj) reports_12\NNS (l_prep) of_13\IN (l_pobj) hepatotoxicity_14\NN
D005905_D056486 CID glyburide_18\NN (r_amod) therapy_19\NN (r_pobj) of_17\IN (r_prep) initiation_16\NN (r_pobj) after_15\IN (r_prep) developed_7\VBD (l_dobj) syndrome_13\NN
D005905_D056486 CID Glyburide_0\NNP (r_nsubj) produce_2\VB (l_dobj) illness_8\NN
D013453_D056486 NONE sulfonylureas_14\NNS (r_pobj) with_13\IN (r_prep) reported_10\VBN (l_nsubjpass) hepatotoxicity_3\NN
D013453_D056486 NONE sulfonylurea_7\NN (r_nsubj) exist_15\VBP (l_nsubj) reports_12\NNS (l_prep) of_13\IN (l_pobj) hepatotoxicity_14\NN
6387529
D003975_D000379 NONE diazepam_3\NN (r_pobj) of_2\IN (r_prep) effects_1\NNS (l_conj) propranolol_5\NN (l_prep) in_6\IN (l_pobj) patients_7\NNS (l_prep) with_8\IN (l_pobj) disorder_10\NN (l_conj) agoraphobia_12\NNP
D003975_D000379 NONE diazepam_6\NN (r_pobj) of_5\IN (r_prep) doses_4\NNS (r_pobj) of_2\IN (r_prep) effects_1\NNS (r_nsubj) propranolol_27\NN (r_advcl) investigated_58\VBN (l_nsubjpass) dose_37\NN (l_prep) on_47\IN (l_pobj) performance_49\NN (l_prep) of_50\IN (l_pobj) patients_51\NNS (l_prep) with_52\IN (l_pobj) disorders_54\NNS (l_conj) agoraphobia_56\NNP
D011433_D000379 NONE propranolol_5\NN (l_prep) in_6\IN (l_pobj) patients_7\NNS (l_prep) with_8\IN (l_pobj) disorder_10\NN (l_conj) agoraphobia_12\NNP
D011433_D000379 NONE propranolol_27\NN (r_advcl) investigated_58\VBN (l_nsubjpass) dose_37\NN (l_prep) on_47\IN (l_pobj) performance_49\NN (l_prep) of_50\IN (l_pobj) patients_51\NNS (l_prep) with_52\IN (l_pobj) disorders_54\NNS (l_conj) agoraphobia_56\NNP
D003975_D008569 CID diazepam_12\NN (r_pobj) for_11\IN (r_prep) greater_10\JJR (r_acomp) was_9\VBD (r_conj) impaired_2\VBD (l_dobj) recall_5\NN
D003975_D016584 NONE diazepam_3\NN (r_pobj) of_2\IN (r_prep) effects_1\NNS (l_conj) propranolol_5\NN (l_prep) in_6\IN (l_pobj) patients_7\NNS (l_prep) with_8\IN (l_pobj) disorder_10\NN
D003975_D016584 NONE diazepam_6\NN (r_pobj) of_5\IN (r_prep) doses_4\NNS (r_pobj) of_2\IN (r_prep) effects_1\NNS (r_nsubj) propranolol_27\NN (r_advcl) investigated_58\VBN (l_nsubjpass) dose_37\NN (l_prep) on_47\IN (l_pobj) performance_49\NN (l_prep) of_50\IN (l_pobj) patients_51\NNS (l_prep) with_52\IN (l_pobj) disorders_54\NNS
D011433_D008569 CID propranolol_14\NN (r_advcl) diazepam_12\NN (r_pobj) for_11\IN (r_prep) greater_10\JJR (r_acomp) was_9\VBD (r_conj) impaired_2\VBD (l_dobj) recall_5\NN
D011433_D016584 NONE propranolol_5\NN (l_prep) in_6\IN (l_pobj) patients_7\NNS (l_prep) with_8\IN (l_pobj) disorder_10\NN
D011433_D016584 NONE propranolol_27\NN (r_advcl) investigated_58\VBN (l_nsubjpass) dose_37\NN (l_prep) on_47\IN (l_pobj) performance_49\NN (l_prep) of_50\IN (l_pobj) patients_51\NNS (l_prep) with_52\IN (l_pobj) disorders_54\NNS
18083142
D004298_D001008 NONE dopamine_9\NN (r_compound) knockout_13\NN (r_pobj) of_8\IN (r_prep) performance_7\NN (r_dobj) evaluated_5\VBD (l_advcl) examine_36\VB (l_dobj) contribution_38\NN (l_prep) of_39\IN (l_pobj) signaling_41\NN (l_prep) to_42\IN (l_pobj) anxiety_46\NN
D004298_D001008 NONE dopamine_17\NN (r_nmod) hydroxylase_20\NN (r_nmod) inhibitor_24\NN (r_appos) administration_12\NN (r_pobj) following_11\VBG (r_prep) attenuated_6\VBN (l_nsubjpass) anxiety_3\NN
D015016_D001008 NONE yohimbine_48\NN (r_appos) antagonist_47\NN (r_conj) prazosin_42\NN (r_nsubj) had_49\VBD (r_advcl) pretreatment_10\NN (l_prep) with_11\IN (l_pobj) antagonist_17\NN (l_acl) propranolol_18\NN (l_dobj) behavior_26\NN (l_amod) like_25\JJ (l_npadvmod) anxiety_23\NN
D011433_D001008 NONE propranolol_18\NN (l_dobj) behavior_26\NN (l_amod) like_25\JJ (l_npadvmod) anxiety_23\NN
D003042_D001008 CID cocaine_12\NN (r_npadvmod) induced_14\VBN (r_amod) anxiety_15\NN
D003042_D001008 CID cocaine_4\NN (r_poss) effects_7\NNS (r_nsubjpass) studied_10\VBN (r_advcl) paid_17\VBN (l_dative) to_18\IN (l_pobj) states_22\NNS (l_acl) induced_23\VBN (l_agent) by_24\IN (l_pobj) cocaine_25\NN (l_prep) as_28\IN (l_pobj) anxiety_29\NN
D003042_D001008 CID cocaine_25\NN (l_prep) as_28\IN (l_pobj) anxiety_29\NN
D003042_D001008 CID cocaine_43\NN (r_npadvmod) induced_45\VBN (r_amod) anxiety_46\NN
D003042_D001008 CID cocaine_4\NN (r_nsubj) increased_8\VBN (l_dobj) behavior_12\NN (l_amod) like_11\JJ (l_npadvmod) anxiety_9\NN
D003042_D001008 CID Cocaine_0\NN (r_npadvmod) induced_2\VBN (r_amod) anxiety_3\NN
D003042_D001008 CID cocaine_20\NN (r_npadvmod) induced_22\VBN (r_amod) behavior_26\NN (l_amod) like_25\JJ (l_npadvmod) anxiety_23\NN
D003042_D001008 CID cocaine_14\NN (r_npadvmod) induced_16\VBN (r_amod) anxiety_17\NN
D011224_D001008 NONE prazosin_42\NN (r_nsubj) had_49\VBD (r_advcl) pretreatment_10\NN (l_prep) with_11\IN (l_pobj) antagonist_17\NN (l_acl) propranolol_18\NN (l_dobj) behavior_26\NN (l_amod) like_25\JJ (l_npadvmod) anxiety_23\NN
D009638_D001008 NONE Norepinephrine_0\NN (r_compound) signaling_1\VBG (r_nsubj) is_7\VBZ (l_acomp) critical_8\JJ (l_prep) for_9\IN (l_pobj) expression_10\NN (l_prep) of_11\IN (l_pobj) anxiety_15\NN
D009638_D001008 NONE norepinephrine_22\NN (r_dobj) lack_21\VBP (r_relcl) mice_18\NNS (r_appos) knockout_13\NN (r_pobj) of_8\IN (r_prep) performance_7\NN (r_dobj) evaluated_5\VBD (l_advcl) examine_36\VB (l_dobj) contribution_38\NN (l_prep) of_39\IN (l_pobj) signaling_41\NN (l_prep) to_42\IN (l_pobj) anxiety_46\NN
D009638_D001008 NONE NE_24\NNP (r_appos) norepinephrine_22\NN (r_dobj) lack_21\VBP (r_relcl) mice_18\NNS (r_appos) knockout_13\NN (r_pobj) of_8\IN (r_prep) performance_7\NN (r_dobj) evaluated_5\VBD (l_advcl) examine_36\VB (l_dobj) contribution_38\NN (l_prep) of_39\IN (l_pobj) signaling_41\NN (l_prep) to_42\IN (l_pobj) anxiety_46\NN
D004221_D001008 NONE disulfiram_14\NN (r_pobj) of_13\IN (r_prep) administration_12\NN (r_pobj) following_11\VBG (r_prep) attenuated_6\VBN (l_nsubjpass) anxiety_3\NN
3173180
D008795_D006463 CID metronidazole_7\NN (r_pobj) with_6\IN (r_prep) treatment_5\NN (r_pobj) after_4\IN (r_prep) syndrome_3\NN
D008795_D006463 CID metronidazole_19\NN (r_pobj) with_18\IN (r_prep) treatment_17\NN (r_pobj) after_16\IN (r_prep) developed_10\VBD (l_dobj) syndrome_15\NN
D008795_D006463 CID metronidazole_4\NN (r_pobj) of_3\IN (r_prep) involvement_2\NN (l_prep) in_5\IN (l_pobj) aetiology_7\NN (l_prep) of_8\IN (l_pobj) syndrome_13\NN
D008795_D006463 CID metronidazole_4\NN (r_pobj) of_3\IN (r_prep) involvement_2\NN (r_nsubjpass) established_16\VBN (r_advcl) suggest_43\VBP (l_nsubj) action_20\NN (l_conj) evidence_33\NN (l_prep) of_34\IN (l_pobj) changes_36\NNS (l_prep) in_37\IN (l_pobj) syndrome_42\NN
D008795_D006463 CID metronidazole_4\NN (r_pobj) of_3\IN (r_prep) involvement_2\NN (r_nsubjpass) established_16\VBN (r_advcl) suggest_43\VBP (l_dobj) link_46\NN (l_prep) between_47\IN (l_pobj) treatment_49\NN (l_conj) cases_52\NNS (l_prep) of_53\IN (l_pobj) syndrome_58\NN
D008795_D006463 CID metronidazole_48\NN (r_amod) treatment_49\NN (r_pobj) between_47\IN (r_prep) link_46\NN (r_dobj) suggest_43\VBP (l_advcl) established_16\VBN (l_nsubjpass) involvement_2\NN (l_prep) in_5\IN (l_pobj) aetiology_7\NN (l_prep) of_8\IN (l_pobj) syndrome_13\NN
D008795_D006463 CID metronidazole_48\NN (r_amod) treatment_49\NN (r_pobj) between_47\IN (r_prep) link_46\NN (r_dobj) suggest_43\VBP (l_nsubj) action_20\NN (l_conj) evidence_33\NN (l_prep) of_34\IN (l_pobj) changes_36\NNS (l_prep) in_37\IN (l_pobj) syndrome_42\NN
D008795_D006463 CID metronidazole_48\NN (r_amod) treatment_49\NN (l_conj) cases_52\NNS (l_prep) of_53\IN (l_pobj) syndrome_58\NN
2578334
D001564_D011230 CID benzo[a]-pyrene_53\NN (r_appos) carcinogens_51\NNS (r_pobj) by_48\IN (r_agent) induced_47\VBN (r_acl) phase_43\NN (r_pobj) during_41\IN (r_prep) given_38\VBN (l_nsubjpass) 5-AzC_24\CD (l_advcl) test_1\VB (l_dobj) validity_3\NN (l_prep) of_4\IN (l_pobj) hypothesis_6\NN (l_acl) plays_11\VBZ (l_prep) in_15\IN (l_pobj) initiation_17\NN (l_prep) of_18\IN (l_pobj) process_20\NN
D008770_D011230 CID nitrosourea_65\NN (r_appos) carcinogens_51\NNS (r_pobj) by_48\IN (r_agent) induced_47\VBN (r_acl) phase_43\NN (r_pobj) during_41\IN (r_prep) given_38\VBN (l_nsubjpass) 5-AzC_24\CD (l_advcl) test_1\VB (l_dobj) validity_3\NN (l_prep) of_4\IN (l_pobj) hypothesis_6\NN (l_acl) plays_11\VBZ (l_prep) in_15\IN (l_pobj) initiation_17\NN (l_prep) of_18\IN (l_pobj) process_20\NN
D019813_D011230 CID 1,2-dimethylhydrazine_71\CD (r_conj) 60_67\CD (r_appos) nitrosourea_65\NN (r_appos) carcinogens_51\NNS (r_pobj) by_48\IN (r_agent) induced_47\VBN (r_acl) phase_43\NN (r_pobj) during_41\IN (r_prep) given_38\VBN (l_nsubjpass) 5-AzC_24\CD (l_advcl) test_1\VB (l_dobj) validity_3\NN (l_prep) of_4\IN (l_pobj) hypothesis_6\NN (l_acl) plays_11\VBZ (l_prep) in_15\IN (l_pobj) initiation_17\NN (l_prep) of_18\IN (l_pobj) process_20\NN
D019813_D011230 CID 1,2-DMH_73\NNP (r_appos) nitrosourea_65\NN (r_appos) carcinogens_51\NNS (r_pobj) by_48\IN (r_agent) induced_47\VBN (r_acl) phase_43\NN (r_pobj) during_41\IN (r_prep) given_38\VBN (l_nsubjpass) 5-AzC_24\CD (l_advcl) test_1\VB (l_dobj) validity_3\NN (l_prep) of_4\IN (l_pobj) hypothesis_6\NN (l_acl) plays_11\VBZ (l_prep) in_15\IN (l_pobj) initiation_17\NN (l_prep) of_18\IN (l_pobj) process_20\NN
D001374_D011230 CID 5-azacytidine_0\RB (r_nsubj) potentiates_1\VBZ (l_dobj) initiation_2\NN (l_acl) induced_3\VBN (l_agent) by_4\IN (l_pobj) carcinogens_5\NNS
D001374_D011230 CID 5-azacytidine_22\JJ (r_punct) 5-AzC_24\CD (l_advcl) test_1\VB (l_dobj) validity_3\NN (l_prep) of_4\IN (l_pobj) hypothesis_6\NN (l_acl) plays_11\VBZ (l_prep) in_15\IN (l_pobj) initiation_17\NN (l_prep) of_18\IN (l_pobj) process_20\NN
D001374_D011230 CID 5-AzC_24\CD (l_advcl) test_1\VB (l_dobj) validity_3\NN (l_prep) of_4\IN (l_pobj) hypothesis_6\NN (l_acl) plays_11\VBZ (l_prep) in_15\IN (l_pobj) initiation_17\NN (l_prep) of_18\IN (l_pobj) process_20\NN
8669433
D010615_D007676 CID phenacetin_16\NN (r_pobj) with_15\IN (r_prep) comparison_14\NN (r_appos) use_1\NN (l_prep) as_4\IN (l_pobj) factor_7\NN (l_prep) for_8\IN (l_pobj) failure_11\NN
D010615_D007676 CID phenacetin_14\NN (r_pobj) of_13\IN (r_prep) use_12\NN (r_nsubjpass) associated_16\VBN (l_prep) with_17\IN (l_pobj) development_19\NN (l_prep) of_20\IN (l_pobj) failure_23\NN
D010615_D007676 CID phenacetin_14\NN (r_pobj) of_13\IN (r_prep) use_12\NN (r_nsubjpass) associated_16\VBN (l_prep) with_17\IN (l_pobj) development_19\NN (l_prep) of_20\IN (l_pobj) failure_23\NN (l_conj) disease_29\NN
D010615_D007676 CID phenacetin_14\NN (r_pobj) of_13\IN (r_prep) use_12\NN (r_nsubjpass) associated_16\VBN (l_prep) with_17\IN (l_pobj) development_19\NN (l_prep) of_20\IN (l_pobj) failure_23\NN (l_conj) disease_29\NN (l_appos) ESRD_31\NNP
D010615_D007676 CID phenacetin_5\NN (r_nsubj) contribute_9\VB (l_prep) to_10\IN (l_pobj) burden_12\NN (l_prep) of_13\IN (l_pobj) ESRD_14\NNP
D000082_D007676 NONE acetaminophen_3\NN (r_pobj) of_2\IN (r_prep) use_1\NN (l_prep) as_4\IN (l_pobj) factor_7\NN (l_prep) for_8\IN (l_pobj) failure_11\NN
D000082_D007676 NONE acetaminophen_27\NN (r_pobj) of_26\IN (r_prep) use_25\NN (r_nsubjpass) associated_30\VBN (l_prep) with_31\IN (l_pobj) failure_34\NN
D000082_D007676 NONE acetaminophen_27\NN (r_pobj) of_26\IN (r_prep) use_25\NN (r_nsubjpass) associated_30\VBN (l_prep) with_31\IN (l_pobj) failure_34\NN (l_conj) ESRD_36\NNP
D000082_D007676 NONE acetaminophen_7\RB (r_conj) phenacetin_5\NN (r_nsubj) contribute_9\VB (l_prep) to_10\IN (l_pobj) burden_12\NN (l_prep) of_13\IN (l_pobj) ESRD_14\NNP
D000082_D007676 NONE acetaminophen_6\NN (r_pobj) of_5\IN (r_prep) use_4\NN (r_nsubj) increases_8\VBZ (l_dobj) risk_10\NN (l_prep) of_11\IN (l_pobj) ESRD_12\NNP
8741744
D009538_D009069 NONE nicotine_29\NN (r_pobj) by_28\IN (r_agent) caused_27\VBN (r_acl) hypoactivity_26\NN
D009538_D009069 NONE nicotine_48\NN (r_npadvmod) induced_50\VBN (r_amod) hyperactivity_51\NN (r_dobj) enhanced_39\VBD (r_advcl) blunted_14\VBD (l_dobj) hypoactivity_26\NN
D009538_D006948 CID nicotine_29\NN (r_pobj) by_28\IN (r_agent) caused_27\VBN (r_acl) hypoactivity_26\NN (r_dobj) blunted_14\VBD (l_advcl) enhanced_39\VBD (l_dobj) hyperactivity_51\NN
D009538_D006948 CID nicotine_48\NN (r_npadvmod) induced_50\VBN (r_amod) hyperactivity_51\NN
2894766
D012460_D002305 CID sulfasalazine_29\NN (r_compound) therapy_30\NN (r_dobj) receiving_25\VBG (r_relcl) man_21\NN (r_pobj) in_16\IN (r_prep) developed_15\VBN (r_acl) autoantibodies_14\NNS (r_conj) evidence_7\NN (l_prep) of_8\IN (l_pobj) tamponade_10\NN
D012460_D008180 CID Sulfasalazine_0\NNP (r_npadvmod) induced_2\VBN (r_amod) erythematosus_4\NN
D012460_D008180 CID sulfasalazine_7\RB (r_npadvmod) induced_9\VBN (r_amod) lupus_10\NN
D012460_D008180 CID sulfasalazine_3\NN (r_dobj) use_2\VBP (r_relcl) Physicians_0\NNS (r_nsubj) be_12\VB (l_acomp) aware_13\JJ (l_prep) of_14\IN (l_pobj) signs_16\NNS (l_prep) of_17\IN (l_pobj) syndrome_22\NN
D012460_D008180 CID sulfasalazine_18\NN (r_npadvmod) induced_20\VBN (r_amod) syndrome_22\NN
D012460_D012700 NONE sulfasalazine_7\RB (r_npadvmod) induced_9\VBN (r_amod) lupus_10\NN (l_relcl) manifested_13\VBD (l_prep) with_14\IN (l_pobj) serositis_15\NN
D012460_D003093 NONE sulfasalazine_29\NN (r_compound) therapy_30\NN (r_dobj) receiving_25\VBG (l_prep) for_31\IN (l_pobj) colitis_34\NN
D012460_D011014 CID sulfasalazine_29\NN (r_compound) therapy_30\NN (r_dobj) receiving_25\VBG (r_relcl) man_21\NN (r_pobj) in_16\IN (r_prep) developed_15\VBN (r_acl) autoantibodies_14\NNS (r_conj) evidence_7\NN (r_appos) effusions_4\NNS (l_dep) Pneumonitis_0\NNP
D012460_D010996 CID sulfasalazine_29\NN (r_compound) therapy_30\NN (r_dobj) receiving_25\VBG (r_relcl) man_21\NN (r_pobj) in_16\IN (r_prep) developed_15\VBN (r_acl) autoantibodies_14\NNS (r_conj) evidence_7\NN (r_appos) effusions_4\NNS
D012460_D015212 NONE sulfasalazine_3\NN (r_dobj) use_2\VBP (l_xcomp) treat_5\VB (l_dobj) patients_6\NNS (l_prep) with_7\IN (l_pobj) disease_10\NN
D012460_D015212 NONE sulfasalazine_18\NN (r_npadvmod) induced_20\VBN (r_amod) syndrome_22\NN (r_pobj) of_17\IN (r_prep) signs_16\NNS (r_pobj) of_14\IN (r_prep) aware_13\JJ (r_acomp) be_12\VB (l_nsubj) Physicians_0\NNS (l_relcl) use_2\VBP (l_xcomp) treat_5\VB (l_dobj) patients_6\NNS (l_prep) with_7\IN (l_pobj) disease_10\NN
19729346
D010098_D010146 NONE oxycodone_18\NN (r_pobj) of_14\IN (r_prep) dose_13\NN (r_pobj) of_9\IN (r_prep) effects_8\NNS (r_dobj) measured_2\VBD (l_dobj) adults_39\NNS (l_relcl) suffering_43\VBG (l_prep) from_44\IN (l_pobj) pain_49\NN
D010098_D059350 NONE oxycodone_30\NN (r_pobj) of_26\IN (r_prep) dose_25\NN (r_pobj) to_22\IN (r_prep) response_21\NN (r_pobj) in_20\IN (r_prep) changes_19\NNS (r_dobj) suffering_11\VBG (l_prep) from_12\IN (l_pobj) pain_14\NN
14513889
D007654_D009422 NONE Ketoconazole_0\NNP (r_npadvmod) induced_2\VBN (l_dobj) sequelae_4\NNS
20633755
D013390_D001049 CID Suxamethonium_0\NNS (r_nsubj) induced_1\VBD (l_dobj) apnea_3\NN
D013390_D001049 CID Suxamethonium_0\JJ (r_nsubj) causes_1\VBZ (l_dobj) apnea_3\NN
D009943_D001049 CID poisons_17\NNS (r_pobj) by_12\IN (r_agent) deactivated_11\VBN (r_relcl) patients_5\NNS (r_pobj) in_4\IN (r_prep) apnea_3\NN
D009943_D001049 CID compound_14\NN (r_pobj) by_12\IN (r_prep) attempt_11\NN (r_pobj) about_9\IN (r_prep) information_8\NN (r_nsubjpass) concealed_16\VBN (r_advcl) ensued_5\VBD (l_nsubj) apnea_1\NN
8319760
D000804_D009404 NONE II_43\NNP (r_compound) antagonist_45\NN (r_appos) inhibited_29\VBN (l_ccomp) induced_19\VBN (l_nsubj) appearance_1\NN (l_prep) of_2\IN (l_pobj) syndromes_4\NNS
D000804_D011507 NONE II_43\NNP (r_compound) antagonist_45\NN (r_appos) inhibited_29\VBN (l_ccomp) induced_19\VBN (l_nsubj) appearance_1\NN (l_prep) of_2\IN (l_pobj) syndromes_4\NNS (l_prep) as_6\IN (l_pobj) proteinuria_7\NN
D001806_D009404 NONE urea_17\NN (r_pobj) in_14\IN (r_prep) increase_13\NN (r_conj) hypercholesterolemia_11\NN (r_conj) hypoalbuminemia_9\NN (r_conj) proteinuria_7\NN (r_pobj) as_6\IN (r_prep) syndromes_4\NNS
D019808_D009401 NONE 753_1\CD (r_nummod) Dup_0\NN (r_nsubj) prevents_2\VBZ (l_dobj) development_4\NN (l_prep) of_5\IN (l_pobj) nephrosis_10\NN
D000804_D006937 NONE II_43\NNP (r_compound) antagonist_45\NN (r_appos) inhibited_29\VBN (l_ccomp) induced_19\VBN (l_nsubj) appearance_1\NN (l_prep) of_2\IN (l_pobj) syndromes_4\NNS (l_prep) as_6\IN (l_pobj) proteinuria_7\NN (l_conj) hypoalbuminemia_9\NN (l_conj) hypercholesterolemia_11\NN
D011692_D009401 NONE aminonucleoside_7\NN (r_advmod) induced_9\VBN (r_amod) nephrosis_10\NN
D011692_D009401 NONE aminonucleoside_17\NN (r_advmod) induced_19\VBN (r_amod) nephrosis_20\NN
D011692_D009404 CID aminonucleoside_26\NN (r_advmod) induced_19\VBN (l_nsubj) appearance_1\NN (l_prep) of_2\IN (l_pobj) syndromes_4\NNS
D019808_D006937 NONE 753_35\CD (r_nummod) Dup_34\NN (r_nmod) losartan_37\NN (r_pobj) of_33\IN (r_prep) administration_32\NN (r_pobj) by_30\IN (r_agent) inhibited_29\VBN (l_ccomp) induced_19\VBN (l_nsubj) appearance_1\NN (l_prep) of_2\IN (l_pobj) syndromes_4\NNS (l_prep) as_6\IN (l_pobj) proteinuria_7\NN (l_conj) hypoalbuminemia_9\NN (l_conj) hypercholesterolemia_11\NN
D019808_D006937 NONE losartan_37\NN (r_pobj) of_33\IN (r_prep) administration_32\NN (r_pobj) by_30\IN (r_agent) inhibited_29\VBN (l_ccomp) induced_19\VBN (l_nsubj) appearance_1\NN (l_prep) of_2\IN (l_pobj) syndromes_4\NNS (l_prep) as_6\IN (l_pobj) proteinuria_7\NN (l_conj) hypoalbuminemia_9\NN (l_conj) hypercholesterolemia_11\NN
D019808_D011507 NONE 753_35\CD (r_nummod) Dup_34\NN (r_nmod) losartan_37\NN (r_pobj) of_33\IN (r_prep) administration_32\NN (r_pobj) by_30\IN (r_agent) inhibited_29\VBN (l_ccomp) induced_19\VBN (l_nsubj) appearance_1\NN (l_prep) of_2\IN (l_pobj) syndromes_4\NNS (l_prep) as_6\IN (l_pobj) proteinuria_7\NN
D019808_D011507 NONE losartan_37\NN (r_pobj) of_33\IN (r_prep) administration_32\NN (r_pobj) by_30\IN (r_agent) inhibited_29\VBN (l_ccomp) induced_19\VBN (l_nsubj) appearance_1\NN (l_prep) of_2\IN (l_pobj) syndromes_4\NNS (l_prep) as_6\IN (l_pobj) proteinuria_7\NN
D011692_D006937 CID aminonucleoside_26\NN (r_advmod) induced_19\VBN (l_nsubj) appearance_1\NN (l_prep) of_2\IN (l_pobj) syndromes_4\NNS (l_prep) as_6\IN (l_pobj) proteinuria_7\NN (l_conj) hypoalbuminemia_9\NN (l_conj) hypercholesterolemia_11\NN
D019808_D034141 NONE 753_35\CD (r_nummod) Dup_34\NN (r_nmod) losartan_37\NN (r_pobj) of_33\IN (r_prep) administration_32\NN (r_pobj) by_30\IN (r_agent) inhibited_29\VBN (l_ccomp) induced_19\VBN (l_nsubj) appearance_1\NN (l_prep) of_2\IN (l_pobj) syndromes_4\NNS (l_prep) as_6\IN (l_pobj) proteinuria_7\NN (l_conj) hypoalbuminemia_9\NN
D019808_D034141 NONE losartan_37\NN (r_pobj) of_33\IN (r_prep) administration_32\NN (r_pobj) by_30\IN (r_agent) inhibited_29\VBN (l_ccomp) induced_19\VBN (l_nsubj) appearance_1\NN (l_prep) of_2\IN (l_pobj) syndromes_4\NNS (l_prep) as_6\IN (l_pobj) proteinuria_7\NN (l_conj) hypoalbuminemia_9\NN
D001806_D011507 NONE urea_17\NN (r_pobj) in_14\IN (r_prep) increase_13\NN (r_conj) hypercholesterolemia_11\NN (r_conj) hypoalbuminemia_9\NN (r_conj) proteinuria_7\NN
D000809_D009401 NONE angiotensin_10\NN (r_compound) system_11\NN (l_prep) in_12\IN (l_pobj) development_14\NN (l_prep) of_15\IN (l_pobj) nephrosis_20\NN
D001806_D034141 NONE urea_17\NN (r_pobj) in_14\IN (r_prep) increase_13\NN (r_conj) hypercholesterolemia_11\NN (r_conj) hypoalbuminemia_9\NN
D000804_D034141 NONE II_43\NNP (r_compound) antagonist_45\NN (r_appos) inhibited_29\VBN (l_ccomp) induced_19\VBN (l_nsubj) appearance_1\NN (l_prep) of_2\IN (l_pobj) syndromes_4\NNS (l_prep) as_6\IN (l_pobj) proteinuria_7\NN (l_conj) hypoalbuminemia_9\NN
D011692_D011507 CID aminonucleoside_26\NN (r_advmod) induced_19\VBN (l_nsubj) appearance_1\NN (l_prep) of_2\IN (l_pobj) syndromes_4\NNS (l_prep) as_6\IN (l_pobj) proteinuria_7\NN
D011692_D034141 CID aminonucleoside_26\NN (r_advmod) induced_19\VBN (l_nsubj) appearance_1\NN (l_prep) of_2\IN (l_pobj) syndromes_4\NNS (l_prep) as_6\IN (l_pobj) proteinuria_7\NN (l_conj) hypoalbuminemia_9\NN
D019808_D009404 NONE 753_35\CD (r_nummod) Dup_34\NN (r_nmod) losartan_37\NN (r_pobj) of_33\IN (r_prep) administration_32\NN (r_pobj) by_30\IN (r_agent) inhibited_29\VBN (l_ccomp) induced_19\VBN (l_nsubj) appearance_1\NN (l_prep) of_2\IN (l_pobj) syndromes_4\NNS
D019808_D009404 NONE losartan_37\NN (r_pobj) of_33\IN (r_prep) administration_32\NN (r_pobj) by_30\IN (r_agent) inhibited_29\VBN (l_ccomp) induced_19\VBN (l_nsubj) appearance_1\NN (l_prep) of_2\IN (l_pobj) syndromes_4\NNS
D001806_D006937 NONE urea_17\NN (r_pobj) in_14\IN (r_prep) increase_13\NN (r_conj) hypercholesterolemia_11\NN
11147747
D018490_D014549 CID antidepressants_1\NNS (l_conj) incontinence_4\NN
D018490_D014549 CID antidepressants_8\NNS (r_pobj) to_6\IN (r_prep) secondary_5\JJ (r_amod) incontinence_4\NN
D020280_D014549 CID sertraline_22\NN (r_conj) paroxetine_20\NN (r_pobj) to_14\IN (r_prep) developed_11\VBD (l_dobj) secondary_13\JJ (l_compound) incontinence_12\NN
C047426_D014549 CID venlafaxine_10\NN (r_dobj) taking_9\VBG (r_advcl) experienced_6\VBD (l_dobj) incontinence_7\NN
C047426_D014549 CID venlafaxine_35\NNP (r_pobj) on_34\IN (r_prep) developed_30\VBD (r_relcl) third_28\NN (r_conj) paroxetine_20\NN (r_pobj) to_14\IN (r_prep) developed_11\VBD (l_dobj) secondary_13\JJ (l_compound) incontinence_12\NN
D017374_D014549 CID paroxetine_20\NN (r_pobj) to_14\IN (r_prep) developed_11\VBD (l_dobj) secondary_13\JJ (l_compound) incontinence_12\NN
D016651_D014549 CID carbonate_12\NN (r_dobj) taking_10\VBG (r_relcl) cases_5\NNS (r_pobj) of_2\IN (r_prep) 2_1\CD (r_pobj) In_0\IN (r_prep) contributed_23\VBN (l_prep) to_24\IN (l_pobj) incontinence_26\NN
D012701_D014549 NONE serotonin_17\NN (r_compound) paroxetine_20\NN (r_pobj) to_14\IN (r_prep) developed_11\VBD (l_dobj) secondary_13\JJ (l_compound) incontinence_12\NN
20882060
D009496_D002375 NONE neurotensin_3\NN (l_prep) on_4\IN (l_pobj) catalepsy_9\NN
D009496_D002375 NONE neurotensin_3\NN (r_pobj) of_2\IN (r_prep) infusions_1\NNS (r_nsubj) reversed_8\VBD (l_dobj) catalepsy_13\NN
D006220_D002375 CID haloperidol_5\NN (r_npadvmod) induced_7\VBN (r_amod) catalepsy_9\NN
D006220_D002375 CID haloperidol_9\NN (r_npadvmod) induced_11\VBN (r_amod) catalepsy_13\NN
D006220_D010302 NONE haloperidol_12\NN (r_npadvmod) induced_14\VBN (r_amod) symptoms_16\NNS
D009496_D010302 NONE neurotensin_10\NN (l_prep) on_11\IN (l_pobj) symptoms_16\NNS
3496378
D014217_D056486 CID troleandomycin_3\NN (r_npadvmod) induced_5\VBN (r_amod) hepatitis_7\NN
D014217_D056486 CID troleandomycin_9\NN (r_npadvmod) induced_11\VBN (r_relcl) patient_6\NN (r_pobj) of_4\IN (r_prep) case_3\NN (r_dobj) report_1\VBP (l_ccomp) followed_14\VBN (l_nsubjpass) hepatitis_12\NN
D014217_D056486 CID troleandomycin_8\NN (r_npadvmod) induced_10\VBN (r_amod) hepatitis_12\NN
D014217_D002779 CID troleandomycin_3\NN (r_npadvmod) induced_5\VBN (r_amod) hepatitis_7\NN (r_pobj) after_2\IN (r_prep) cholestasis_1\NN
D014217_D002779 CID troleandomycin_9\NN (r_npadvmod) induced_11\VBN (r_relcl) patient_6\NN (r_pobj) of_4\IN (r_prep) case_3\NN (r_dobj) report_1\VBP (l_ccomp) followed_14\VBN (l_agent) by_15\IN (l_pobj) cholestasis_18\NN
D014217_D002779 CID troleandomycin_8\NN (r_npadvmod) induced_10\VBN (r_amod) hepatitis_12\NN (r_dobj) follow_7\VB (l_nsubj) cholestasis_5\NN
D014217_D007565 CID troleandomycin_5\NN (r_pobj) of_4\IN (r_prep) administration_3\NN (r_pobj) after_2\IN (r_prep) occurred_1\VBD (l_nsubj) Jaundice_0\NN
D014217_D004802 CID troleandomycin_5\NN (r_pobj) of_4\IN (r_prep) administration_3\NN (r_pobj) after_2\IN (r_prep) occurred_1\VBD (l_conj) associated_11\VBN (l_prep) with_12\IN (l_pobj) hypereosinophilia_13\NNS
16005948
D003042_D064420 NONE cocaine_3\NN (r_compound) toxicity_4\NN
-1_D064420 NONE GNC92H2_12\NNP (r_pobj) of_11\IN (r_prep) dose_10\NN (r_pobj) with_7\IN (r_prep) observed_6\VBN (l_nsubjpass) blockade_1\NN (l_prep) of_2\IN (l_pobj) toxicity_4\NN
-1_D003643 NONE GNC92H2_12\NNP (r_pobj) of_11\IN (r_prep) dose_10\NN (l_appos) seizures_28\NNS (l_prt) up_29\IN (l_prep) to_30\TO (l_pobj) %_32\NN (l_conj) death_34\NN
-1_D003643 NONE GNC92H2_2\NNP (r_nsubj) prevented_3\VBD (l_dobj) death_4\NN
D003042_D062787 NONE cocaine_4\NN (r_pobj) of_3\IN (r_prep) use_2\NN (r_nsubj) continues_5\VBZ (l_prep) in_6\IN (l_pobj) proportions_8\NNS (l_conj) treatment_10\NN (l_prep) for_11\IN (l_pobj) overdose_13\NN
D003042_D003643 NONE cocaine_3\NN (r_compound) toxicity_4\NN (r_pobj) of_2\IN (r_prep) blockade_1\NN (r_nsubjpass) observed_6\VBN (l_prep) with_7\IN (l_pobj) dose_10\NN (l_appos) seizures_28\NNS (l_prt) up_29\IN (l_prep) to_30\TO (l_pobj) %_32\NN (l_conj) death_34\NN
D003042_D003643 NONE cocaine_8\NN (r_compound) injection_9\NN (r_dobj) prevented_3\VBD (l_dobj) death_4\NN
-1_D062787 NONE GNC92H2_6\NNP (r_pobj) of_1\IN (r_prep) Evaluation_0\NN (l_prep) as_7\IN (l_pobj) immunotherapy_9\NN (l_prep) for_10\IN (l_pobj) overdose_12\NN
-1_D062787 NONE GNC92H2_7\NNP (r_pobj) of_3\IN (r_prep) potential_2\NN (r_nsubjpass) examined_9\VBN (l_advcl) using_10\VBG (l_dobj) model_12\NN (l_prep) of_13\IN (l_pobj) overdose_15\NN
-1_D062787 NONE GNC92H2_7\NNP (r_pobj) of_6\IN (r_prep) potential_5\NN (l_prep) as_8\IN (l_pobj) tool_11\NN (l_prep) against_12\IN (l_pobj) overdose_14\NN
-1_D012640 NONE GNC92H2_12\NNP (r_pobj) of_11\IN (r_prep) dose_10\NN (l_appos) seizures_28\NNS
D003042_D012640 CID cocaine_3\NN (r_compound) toxicity_4\NN (r_pobj) of_2\IN (r_prep) blockade_1\NN (r_nsubjpass) observed_6\VBN (l_prep) with_7\IN (l_pobj) dose_10\NN (l_appos) seizures_28\NNS
11897407
D007545_D009203 CID isoproterenol_6\NN (r_npadvmod) induced_8\VBN (r_amod) infarction_10\NN
D007545_D009203 CID isoproterenol_22\NN (r_npadvmod) induced_24\VBN (r_amod) infarction_27\NN
C067171_D009203 NONE glucarate_2\NN (l_prep) for_3\IN (l_pobj) detection_4\NN (l_prep) of_5\IN (l_pobj) infarction_10\NN
C067171_D009203 NONE glucarate_2\NN (r_nsubj) was_3\VBD (l_conj) used_14\VBN (l_xcomp) study_16\VB (l_dobj) biodistribution_18\NN (l_prep) in_19\IN (l_pobj) rats_20\NNS (l_prep) with_21\IN (l_pobj) infarction_27\NN
D005937_D007238 NONE acid_9\NN (r_pobj) on_7\IN (r_prep) based_6\VBN (r_acl) radiopharmaceutical_5\NN (l_amod) avid_4\JJ (l_npadvmod) infarct_2\NN
D007545_D007238 NONE isoproterenol_18\NN (r_pobj) with_17\IN (r_prep) obtained_16\VBN (r_conj) implies_7\VBZ (l_nsubj) model_2\NN (l_acl) used_3\VBN (l_xcomp) produce_5\VB (l_dobj) infarction_6\NN
D007545_D007238 NONE isoproterenol_12\JJ (r_compound) administration_13\NN (r_pobj) after_11\IN (r_prep) h_10\NN (r_npadvmod) developed_6\VBD (l_dobj) infarct_8\NN
567256
D004054_D000230 NONE diethylstilbestrol_25\NN (r_pobj) with_24\IN (r_prep) liver_23\NN
D004054_D008113 CID diethylstilbestrol_6\NN (r_pobj) with_5\IN (r_prep) associated_4\VBN (r_acl) liver_3\NN
D004054_D008113 CID diethylstilbestrol_25\NN (r_pobj) with_24\IN (r_prep) liver_23\NN (r_pobj) of_21\IN (r_prep) adenocarcinoma_20\NN (r_pobj) for_15\IN (r_prep) treated_14\VBN (r_relcl) man_10\NN (r_pobj) in_5\IN (r_prep) occurred_4\VBD (l_nsubj) Angiosarcoma_0\NNP (l_prep) of_1\IN (l_pobj) liver_3\NN
D004054_D008113 NONE diethylstilbestrol_25\NN (r_pobj) with_24\IN (r_prep) liver_23\NN
D004054_D006394 CID diethylstilbestrol_6\NN (r_pobj) with_5\IN (r_prep) associated_4\VBN (r_acl) liver_3\NN
D004054_D006394 CID diethylstilbestrol_25\NN (r_pobj) with_24\IN (r_prep) liver_23\NN (r_pobj) of_21\IN (r_prep) adenocarcinoma_20\NN (r_pobj) for_15\IN (r_prep) treated_14\VBN (r_relcl) man_10\NN (r_pobj) in_5\IN (r_prep) occurred_4\VBD (l_nsubj) Angiosarcoma_0\NNP (l_prep) of_1\IN (l_pobj) liver_3\NN
15515654
D003676_D034381 NONE DFO_5\NNP (r_poss) role_8\NN (l_prep) in_9\IN (l_pobj) development_11\NN (l_prep) of_12\IN (l_pobj) impairment_14\NN
D003676_D006311 NONE DFO_6\NNP (r_pobj) than_5\IN (r_prep) other_4\JJ (r_amod) factor_2\NN (l_compound) ototoxic_1\JJ
D003676_D006319 CID DFO_6\NNP (r_compound) reduction_7\NN (r_pobj) to_5\IN (r_prep) submitted_4\VBN (l_nsubjpass) Subjects_0\NNS (l_prep) with_1\IN (l_pobj) SNHL_2\NNP
18162529
D004967_D006966 NONE estrogen_20\NN (r_npadvmod) induced_22\VBN (r_amod) surge_24\NN (r_conj) secretion_17\NN (r_appos) parameters_9\NNS (r_dobj) inhibited_6\VBD (l_nsubj) hyperprolactinemia_5\NN
D013469_D006966 CID sulpiride_7\NN (r_pobj) by_3\IN (r_agent) induced_2\VBN (r_acl) hyperprolactinemia_1\NN
D012313_D006966 NONE acid_5\NN (r_compound) levels_6\NNS (l_conj) signaling_9\NN (l_conj) inhibition_13\NN (l_amod) hyperprolactinemic_12\JJ
D004298_D006966 NONE dopamine_5\NN (r_compound) antagonist_6\NN (r_compound) sulpiride_7\NN (r_pobj) by_3\IN (r_agent) induced_2\VBN (r_acl) hyperprolactinemia_1\NN
D013256_D006966 NONE steroid_14\NN (r_npadvmod) dependent_16\JJ (r_amod) manner_17\NN (r_pobj) in_12\IN (r_prep) inhibited_8\VBN (l_agent) by_9\IN (l_pobj) hyperprolactinemia_11\NN
D004958_D006966 NONE estradiol_22\NN (r_pobj) on_21\IN (r_prep) dependent_20\JJ (r_acomp) are_19\VBP (l_nsubj) levels_6\NNS (l_conj) signaling_9\NN (l_conj) inhibition_13\NN (l_amod) hyperprolactinemic_12\JJ
D004958_D006966 NONE estradiol_30\NN (r_pobj) of_29\IN (r_prep) levels_28\NNS (r_pobj) of_25\IN (r_prep) presence_24\NN (r_pobj) in_22\IN (r_conj) caused_8\VBD (l_nsubj) hyperprolactinemia_1\NN
11587867
D014750_-1 NONE vincristine_28\NN (r_pobj) to_27\IN (r_prep) exposed_26\VBN (r_acl) areas_25\NNS (r_pobj) in_24\IN (r_prep) transformation_23\NN
D014750_D054198 NONE vincristine_9\NN (r_compound) instillation_10\NN (l_prep) in_11\IN (l_pobj) girl_15\NN (l_prep) with_16\IN (l_pobj) leucemia_20\NN
D014750_D054198 NONE vincristine_9\NN (r_compound) instillation_10\NN (l_prep) in_11\IN (l_pobj) girl_15\NN (l_prep) with_16\IN (l_pobj) leucemia_20\NN (l_conj) man_25\NN (l_prep) with_26\IN (l_pobj) lymphoma_28\NN
D014750_D009410 CID vincristine_28\NN (r_pobj) to_27\IN (r_prep) exposed_26\VBN (r_acl) areas_25\NNS (r_pobj) in_24\IN (r_prep) transformation_23\NN (r_conj) degeneration_14\NN (l_prep) of_15\IN (l_pobj) myelin_16\NN (l_conj) axons_18\NNS
D014750_D003711 CID vincristine_28\NN (r_pobj) to_27\IN (r_prep) exposed_26\VBN (r_acl) areas_25\NNS (r_pobj) in_24\IN (r_prep) transformation_23\NN (r_conj) degeneration_14\NN (l_prep) of_15\IN (l_pobj) myelin_16\NN (l_conj) axons_18\NNS
D014750_D001927 NONE vincristin_6\NN (r_compound) administration_7\NN (r_pobj) due_2\IN (r_prep) myeloencephalopathy_1\NN
2312209
D007548_D009336 NONE dinitrate_22\NN (r_pobj) of_20\IN (r_prep) administration_19\NN (r_pobj) following_17\VBG (r_prep) suffered_8\VBD (l_nsubj) necrosis_7\NN
D007548_D009203 CID dinitrate_7\NN (r_pobj) of_5\IN (r_prep) administration_4\NN (r_dobj) following_2\VBG (r_prep) infarction_1\NN
D007548_D009203 CID dinitrate_22\NN (r_pobj) of_20\IN (r_prep) administration_19\NN (r_pobj) following_17\VBG (r_prep) suffered_8\VBD (l_dobj) infarction_12\NN
6229975
D013999_D007238 NONE timolol_17\NN (r_compound) group_18\NN (r_pobj) in_15\IN (r_prep) remained_13\VBD (r_conj) increased_7\VBD (l_punct) ,_4\, (l_punct) infarction_3\NN
D013999_D009203 NONE timolol_8\NN (r_compound) treatment_9\NN (l_prep) after_10\IN (l_pobj) infarction_12\NN
D013999_D009203 NONE timolol_6\NN (r_compound) treatment_7\NN (r_pobj) of_2\IN (r_prep) effect_1\NN (l_prep) after_11\IN (l_pobj) infarction_13\NN
D013999_D009203 NONE timolol_33\NN (r_conj) evaluated_15\VBN (l_nsubjpass) effect_1\NN (l_prep) after_11\IN (l_pobj) infarction_13\NN
D013999_D001919 NONE timolol_6\NN (r_npadvmod) induced_8\VBN (r_amod) bradycardia_9\NN
10901305
D007649_D004204 NONE ketamine_7\NN (l_prep) to_8\IN (l_pobj) manipulation_9\NN (l_prep) of_10\IN (l_pobj) fracture_12\NN (l_conj) dislocation_14\NN
D007649_D050723 NONE Ketamine_0\NN (l_dobj) sedation_1\NN (l_prep) for_2\IN (l_pobj) reduction_4\NN (l_prep) of_5\IN (l_pobj) fractures_8\NNS
D007649_D050723 NONE ketamine_14\NN (l_prep) for_15\IN (l_pobj) sedation_16\NN (l_prep) in_17\IN (l_pobj) treatment_19\NN (l_prep) of_20\IN (l_pobj) fractures_23\NNS
D007649_D050723 NONE ketamine_7\NN (l_prep) to_8\IN (l_pobj) manipulation_9\NN (l_prep) of_10\IN (l_pobj) fracture_12\NN
D007649_D050723 NONE Ketamine_0\NNP (r_nsubj) provided_7\VBD (l_dobj) sedation_9\NN (l_acl) facilitate_12\VB (l_dobj) reduction_14\NN (l_prep) of_15\IN (l_pobj) fractures_18\NNS
7988234
D017706_D000799 CID lisinopril_6\NN (r_compound) therapy_7\NN (r_pobj) to_5\IN (r_prep) history_1\NN (l_prep) of_2\IN (l_pobj) angioedema_3\NN
D008790_D000799 CID metoprolol_6\NN (r_pobj) of_5\IN (r_prep) administration_4\NN (r_dobj) following_1\VBG (r_prep) Angioedema_0\NNP
D008790_D000799 CID metoprolol_12\NN (r_nsubjpass) given_14\VBN (l_advcl) resulting_16\VBG (l_prep) in_17\IN (l_pobj) angioedema_19\NN
D013256_D000799 NONE steroids_7\NNS (r_pobj) with_5\IN (r_prep) resolved_2\VBD (l_nsubj) angioedema_1\NN
D004155_D000799 NONE diphenhydramine_9\NN (r_conj) steroids_7\NNS (r_pobj) with_5\IN (r_prep) resolved_2\VBD (l_nsubj) angioedema_1\NN
2054792
D004317_D009369 NONE adriamycin_2\NNS (r_pobj) of_1\IN (r_prep) Effect_0\NN (l_acl) combined_3\VBN (l_prep) on_8\IN (l_pobj) tumor_9\NN
D004317_D005334 NONE adriamycin_2\NNS (r_pobj) of_1\IN (r_prep) Effect_0\NN (l_acl) combined_3\VBN (l_prep) with_4\IN (l_pobj) hyperthermia_7\NN
D004317_D005334 NONE Adriamycin_3\NNP (r_npadvmod) mediated_5\VBN (r_amod) activity_7\NN (l_conj) toxicities_11\NNS (l_prep) by_12\IN (l_pobj) hyperthermia_15\NN
D004317_D005334 NONE Adriamycin_13\NNP (r_npadvmod) mediated_15\VBN (r_amod) activity_17\NN (r_dobj) enhanced_11\VBD (l_nsubj) hyperthermia_2\NN
D004317_D005334 NONE Adriamycin_7\NNP (r_npadvmod) mediated_9\VBN (r_amod) effect_11\NN (r_dobj) enhances_6\VBZ (l_nsubj) hyperthermia_5\NN
D004317_D064420 NONE Adriamycin_3\NNP (r_npadvmod) mediated_5\VBN (r_amod) activity_7\NN (l_conj) toxicities_11\NNS
D004317_D064420 NONE Adriamycin_7\NNP (r_npadvmod) mediated_9\VBN (r_amod) effect_11\NN (r_dobj) enhances_6\VBZ (r_advcl) increased_18\VBN (l_nsubjpass) toxicity_15\NN
20621845
D002122_D014652 NONE chloride_18\NN (l_appos) injury_22\NN
D002122_D014652 NONE CaCl(2))-induced_20\VBN (r_amod) injury_22\NN
D002122_D017545 CID CaCl2-induced_14\VBN (r_amod) aneurysm_17\NN
D002122_D017545 CID chloride_18\NN (r_pobj) by_16\IN (r_prep) establish_5\VB (l_dobj) model_8\NN (l_prep) of_9\IN (l_pobj) aneurysm_12\NN
D002122_D017545 CID chloride_18\NN (r_pobj) by_16\IN (r_prep) establish_5\VB (l_dobj) model_8\NN (l_prep) of_9\IN (l_pobj) aneurysm_12\NN (l_appos) TAA_14\NNP
D002122_D017545 CID chloride_18\NN (r_pobj) by_16\IN (r_prep) establish_5\VB (r_xcomp) designed_3\VBN (l_conj) metalloproteinases_39\NNS (l_conj) inhibitors_46\NNS (l_prep) in_50\IN (l_pobj) formation_52\NN (l_compound) TAA_51\NNP
D002122_D017545 CID CaCl(2))-induced_20\VBN (r_amod) injury_22\NN (r_appos) chloride_18\NN (r_pobj) by_16\IN (r_prep) establish_5\VB (l_dobj) model_8\NN (l_prep) of_9\IN (l_pobj) aneurysm_12\NN
D002122_D017545 CID CaCl(2))-induced_20\VBN (r_amod) injury_22\NN (r_appos) chloride_18\NN (r_pobj) by_16\IN (r_prep) establish_5\VB (l_dobj) model_8\NN (l_prep) of_9\IN (l_pobj) aneurysm_12\NN (l_appos) TAA_14\NNP
D002122_D017545 CID CaCl(2))-induced_20\VBN (r_amod) injury_22\NN (r_appos) chloride_18\NN (r_pobj) by_16\IN (r_prep) establish_5\VB (r_xcomp) designed_3\VBN (l_conj) metalloproteinases_39\NNS (l_conj) inhibitors_46\NNS (l_prep) in_50\IN (l_pobj) formation_52\NN (l_compound) TAA_51\NNP
D002122_D017545 CID )_9\-RRB- (r_punct) establishes_2\VBZ (l_dobj) model_5\NN (l_compound) TAA_4\NNP
1835291
D009241_D029424 NONE bromide_5\NN (r_pobj) of_3\IN (r_prep) effects_2\NNS (l_prep) in_8\IN (l_pobj) disease_12\NN
D009241_D029424 NONE bromide_9\NN (r_compound) aerosol_10\NN (r_pobj) of_7\IN (r_prep) dose_6\NN (r_pobj) of_3\IN (r_prep) effects_2\NNS (r_nsubjpass) compared_37\VBN (l_prep) in_38\IN (l_pobj) study_48\NN (l_prep) in_49\IN (l_pobj) patients_51\NNS (l_prep) with_52\IN (l_pobj) disease_58\NN
D009241_D029424 NONE ipratropium_4\NN (r_nsubj) is_5\VBZ (l_prep) in_13\IN (l_pobj) patients_14\NNS (l_prep) with_15\IN (l_pobj) obstruction_18\NN
D013806_D029424 NONE theophylline_7\NN (r_conj) bromide_5\NN (r_pobj) of_3\IN (r_prep) effects_2\NNS (l_prep) in_8\IN (l_pobj) disease_12\NN
D013806_D029424 NONE theophylline_19\NN (r_amod) tablets_20\NNS (r_conj) aerosol_10\NN (r_pobj) of_7\IN (r_prep) dose_6\NN (r_pobj) of_3\IN (r_prep) effects_2\NNS (r_nsubjpass) compared_37\VBN (l_prep) in_38\IN (l_pobj) study_48\NN (l_prep) in_49\IN (l_pobj) patients_51\NNS (l_prep) with_52\IN (l_pobj) disease_58\NN
D013806_D029424 NONE theophylline_12\NN (r_pobj) than_10\IN (r_prep) bronchodilator_9\NN (r_attr) is_5\VBZ (l_prep) in_13\IN (l_pobj) patients_14\NNS (l_prep) with_15\IN (l_pobj) obstruction_18\NN
D013806_D005767 CID theophylline_9\JJ (r_amod) use_10\NN (r_pobj) after_8\IN (r_prep) experienced_7\VBN (r_acl) those_6\DT (r_nsubj) involve_12\VB (l_dobj) systems_17\NNS
D013806_D002318 CID theophylline_9\JJ (r_amod) use_10\NN (r_pobj) after_8\IN (r_prep) experienced_7\VBN (r_acl) those_6\DT (r_nsubj) involve_12\VB (l_dobj) systems_17\NNS
347884
D006220_D019967 NONE haloperidol_6\NN (r_pobj) with_5\IN (r_prep) study_4\NN (r_pobj) In_0\IN (r_prep) found_11\VBN (l_xcomp) be_13\VB (l_acomp) effective_15\JJ (l_prep) in_16\IN (l_pobj) treatment_18\NN (l_prep) of_19\IN (l_pobj) syndromes_21\NNS (l_acl) belonging_22\VBG (l_prep) to_24\IN (l_pobj) group_27\NN
2445283
D012254_D000740 CID ribavirin_7\NN (r_nsubj) has_8\VBZ (l_conj) managed_31\VBN (l_nsubjpass) anemia_20\NN
D012254_D006478 NONE ribavirin_5\NN (r_pobj) of_4\IN (r_prep) effect_3\NN (r_conj) Tolerance_0\NN (l_prep) in_6\IN (l_pobj) patients_7\NNS (l_prep) with_8\IN (l_pobj) fever_11\NN
D012254_D006478 NONE ribavirin_5\NN (r_pobj) of_4\IN (r_prep) effect_3\NN (r_conj) Tolerance_0\NN (r_nsubjpass) studied_7\VBN (l_prep) in_8\IN (l_pobj) patients_10\NNS (l_prep) with_11\IN (l_pobj) fever_14\NN
D012254_D006478 NONE ribavirin_5\NN (r_pobj) of_4\IN (r_prep) effect_3\NN (r_conj) Tolerance_0\NN (r_nsubjpass) studied_7\VBN (l_prep) in_8\IN (l_pobj) patients_10\NNS (l_prep) with_11\IN (l_pobj) fever_14\NN (l_appos) AHF_16\NNP
D012254_D006478 NONE ribavirin_7\NN (r_nsubj) has_8\VBZ (l_dobj) effect_11\NN (l_prep) in_12\IN (l_pobj) cases_14\NNS (l_prep) of_15\IN (l_pobj) AHF_16\NNP
D012254_D006478 NONE ribavirin_5\RB (r_pobj) of_4\IN (r_prep) effect_3\NN (l_prep) during_6\IN (l_pobj) days_9\NNS (l_prep) of_10\IN (l_pobj) AHF_11\NNP
D012254_D014766 NONE ribavirin_2\RB (r_pobj) of_1\IN (r_prep) Administration_0\NN (r_nsubj) resulted_3\VBD (l_prep) in_4\IN (l_pobj) neutralization_6\NN (l_prep) of_7\IN (l_pobj) viremia_8\NN
17854040
D012964_D006509 NONE na_9\TO (r_aux) ve_10\VB (l_dobj) virus_13\NN (l_appos) patients_18\NNS (l_amod) infected_17\JJ
D012964_D006509 NONE na_9\TO (r_aux) ve_10\VB (l_dobj) virus_13\NN (l_appos) patients_18\NNS (l_prep) with_19\IN (l_conj) without_21\IN (l_pobj) implications_27\NNS (l_conj) patients_40\NNS (l_amod) infected_37\VBN
D012964_D006509 NONE na_21\NN (r_aux) ve_22\VB (r_acl) study_4\NN (l_acl) investigate_6\VB (l_dobj) virus_12\NN (l_compound) B_11\NN
D012964_D006509 NONE na_21\TO (r_aux) ve_22\VB (l_dobj) patients_29\NNS (l_amod) infected_28\VBN
D012964_D015658 NONE na_9\TO (r_aux) ve_10\VB (l_dobj) virus_13\NN (l_appos) patients_18\NNS (l_prep) with_19\IN (l_conj) without_21\IN (l_pobj) implications_27\NNS (l_punct) :_26\: (l_punct) infection_25\NN
D012964_D015658 NONE na_9\TO (r_aux) ve_10\VB (l_dobj) virus_13\NN (l_appos) patients_18\NNS (l_prep) with_19\IN (l_conj) without_21\IN (l_pobj) implications_27\NNS (l_conj) patients_40\NNS (l_amod) infected_37\VBN
D012964_D015658 NONE na_21\NN (r_aux) ve_22\VB (r_acl) study_4\NN (r_attr) was_1\VBD (l_punct) ._41\. (l_punct) in_37\IN (l_punct) infection_36\NN
D012964_D015658 NONE na_21\TO (r_aux) ve_22\VB (l_dobj) patients_29\NNS (l_amod) infected_28\VBN
D019259_D015658 NONE lamivudine_3\NN (r_compound) resistance_5\NN (r_pobj) with_2\IN (r_prep) associated_1\VBN (r_acl) Mutations_0\NNS (r_nsubj) ve_10\VB (l_dobj) virus_13\NN (l_appos) patients_18\NNS (l_prep) with_19\IN (l_conj) without_21\IN (l_pobj) implications_27\NNS (l_punct) :_26\: (l_punct) infection_25\NN
D019259_D015658 NONE lamivudine_3\NN (r_compound) resistance_5\NN (r_pobj) with_2\IN (r_prep) associated_1\VBN (r_acl) Mutations_0\NNS (r_nsubj) ve_10\VB (l_dobj) virus_13\NN (l_appos) patients_18\NNS (l_prep) with_19\IN (l_conj) without_21\IN (l_pobj) implications_27\NNS (l_conj) patients_40\NNS (l_amod) infected_37\VBN
D019259_D015658 NONE lamivudine_7\JJ (r_npadvmod) resistant_9\JJ (r_amod) virus_12\NN (r_dobj) investigate_6\VB (r_acl) study_4\NN (r_attr) was_1\VBD (l_punct) ._41\. (l_punct) in_37\IN (l_punct) infection_36\NN
D019259_D015658 NONE lamivudine_19\NN (r_compound) na_21\NN (r_aux) ve_22\VB (r_acl) study_4\NN (r_attr) was_1\VBD (l_punct) ._41\. (l_punct) in_37\IN (l_punct) infection_36\NN
D019259_D015658 NONE lamivudine_1\NN (r_npadvmod) resistant_3\JJ (r_amod) strains_4\NNS (r_nsubjpass) detected_6\VBN (l_conj) patients_28\NNS (l_amod) infected_27\VBN
D019259_D015658 NONE lamivudine_14\NN (r_npadvmod) resistant_16\JJ (r_amod) strains_17\NNS (l_prep) in_18\IN (l_pcomp) ve_22\VB (l_dobj) patients_29\NNS (l_amod) infected_28\VBN
D019259_D015658 NONE lamivudine_22\NN (r_npadvmod) containing_24\VBG (r_advcl) emergence_16\NN (r_pobj) in_14\IN (r_prep) result_13\VB (l_conj) applied_38\VBN (l_advcl) is_45\VBZ (l_acomp) likely_46\JJ (l_xcomp) have_48\VB (l_dobj) implications_50\NNS (l_prep) in_51\IN (l_pobj) management_53\NN (l_prep) of_54\IN (l_pobj) patients_61\NNS (l_amod) infected_60\VBN
D019259_D006509 NONE lamivudine_3\NN (r_compound) resistance_5\NN (r_pobj) with_2\IN (r_prep) associated_1\VBN (r_acl) Mutations_0\NNS (r_nsubj) ve_10\VB (l_dobj) virus_13\NN (l_appos) patients_18\NNS (l_amod) infected_17\JJ
D019259_D006509 NONE lamivudine_3\NN (r_compound) resistance_5\NN (r_pobj) with_2\IN (r_prep) associated_1\VBN (r_acl) Mutations_0\NNS (r_nsubj) ve_10\VB (l_dobj) virus_13\NN (l_appos) patients_18\NNS (l_prep) with_19\IN (l_conj) without_21\IN (l_pobj) implications_27\NNS (l_conj) patients_40\NNS (l_amod) infected_37\VBN
D019259_D006509 NONE lamivudine_7\JJ (r_npadvmod) resistant_9\JJ (r_amod) virus_12\NN (l_compound) B_11\NN
D019259_D006509 NONE lamivudine_19\NN (r_compound) na_21\NN (r_aux) ve_22\VB (r_acl) study_4\NN (l_acl) investigate_6\VB (l_dobj) virus_12\NN (l_compound) B_11\NN
D019259_D006509 NONE lamivudine_1\NN (r_npadvmod) resistant_3\JJ (r_amod) strains_4\NNS (r_nsubjpass) detected_6\VBN (l_prep) in_7\IN (l_pobj) patients_17\NNS (l_compound) B_16\NNP
D019259_D006509 NONE lamivudine_1\NN (r_npadvmod) resistant_3\JJ (r_amod) strains_4\NNS (r_nsubjpass) detected_6\VBN (l_conj) patients_28\NNS (l_amod) infected_27\VBN
D019259_D006509 NONE lamivudine_14\NN (r_npadvmod) resistant_16\JJ (r_amod) strains_17\NNS (l_prep) in_18\IN (l_pcomp) ve_22\VB (l_dobj) patients_29\NNS (l_amod) infected_28\VBN
D019259_D006509 NONE lamivudine_22\NN (r_npadvmod) containing_24\VBG (r_advcl) emergence_16\NN (r_pobj) in_14\IN (r_prep) result_13\VB (l_conj) applied_38\VBN (l_advcl) is_45\VBZ (l_acomp) likely_46\JJ (l_xcomp) have_48\VB (l_dobj) implications_50\NNS (l_prep) in_51\IN (l_pobj) management_53\NN (l_prep) of_54\IN (l_pobj) patients_61\NNS (l_amod) infected_60\VBN
7468724
D013726_D007752 NONE terbutaline_4\JJ (r_compound) treatment_5\NN (l_prep) for_6\IN (l_pobj) labor_8\NN
D013726_D007752 NONE terbutaline_11\NN (l_prep) for_12\IN (l_pobj) labor_14\NN
D013726_D002318 CID terbutaline_4\JJ (r_compound) treatment_5\NN (r_pobj) with_3\IN (r_prep) associated_2\VBN (r_acl) complications_1\NNS
D013726_D002318 CID terbutaline_11\NN (r_pobj) with_10\IN (r_prep) treated_9\VBN (r_acl) patients_8\NNS (r_pobj) in_4\IN (r_prep) occurred_3\VBD (l_nsubj) complications_2\NNS
7269015
D003520_D003556 NONE cyclophosphamide_13\NN (r_npadvmod) induced_15\VBN (r_conj) radiation_11\NN (r_nmod) cystitis_16\NN (r_conj) cystitis_8\NN
D003520_D003556 NONE cyclophosphamide_13\NN (r_npadvmod) induced_15\VBN (r_conj) radiation_11\NN (r_nmod) cystitis_16\NN
D002066_D006470 CID Busulfan_0\NNS (r_npadvmod) induced_2\VBN (r_amod) cystitis_4\NN
D002066_D006470 CID busulfan_4\NNS (r_npadvmod) induced_6\VBN (r_amod) cystitis_8\NN
D002066_D002277 NONE busulfan_7\NNS (r_pobj) of_6\IN (r_prep) tendency_5\NN (r_pobj) of_2\IN (r_prep) view_1\NN (r_pobj) In_0\IN (l_advcl) induce_9\VB (l_dobj) atypia_11\NN (l_conj) carcinoma_13\NN
D002066_D003556 CID Busulfan_0\NNS (r_npadvmod) induced_2\VBN (r_amod) cystitis_4\NN
D002066_D003556 CID busulfan_4\NNS (r_npadvmod) induced_6\VBN (r_amod) cystitis_8\NN
D002066_D003556 CID busulfan_7\NNS (r_amod) cystitis_8\NN
D002066_D003556 CID busulfan_7\NNS (r_amod) cystitis_8\NN (l_conj) cystitis_16\NN
15899738
D003401_D001281 CID creatine_5\NN (r_compound) supplementation_7\NN (r_pobj) with_4\IN (r_prep) associated_3\VBN (r_acl) fibrillation_2\NN
D003401_D001145 NONE creatine_5\NN (l_prep) to_6\IN (l_pobj) development_8\NN (l_prep) of_9\IN (l_pobj) arrhythmia_10\NN
12615818
D017373_D011085 NONE acetate_1\NN (r_nsubjpass) licensed_12\VBN (l_conj) is_26\VBZ (l_attr) option_30\NN (l_prep) for_31\IN (l_pobj) syndrome_34\NN
D017373_D011085 NONE acetate_1\NN (r_nsubjpass) licensed_12\VBN (l_conj) is_26\VBZ (l_attr) option_30\NN (l_prep) for_31\IN (l_pobj) syndrome_34\NN (l_appos) PCOS_36\NNP
D017373_D011085 NONE CPA_7\NNP (r_nmod) EE_9\NNP (r_appos) estradiol_5\NN (r_nsubjpass) licensed_12\VBN (l_conj) is_26\VBZ (l_attr) option_30\NN (l_prep) for_31\IN (l_pobj) syndrome_34\NN
D017373_D011085 NONE CPA_7\NNP (r_nmod) EE_9\NNP (r_appos) estradiol_5\NN (r_nsubjpass) licensed_12\VBN (l_conj) is_26\VBZ (l_attr) option_30\NN (l_prep) for_31\IN (l_pobj) syndrome_34\NN (l_appos) PCOS_36\NNP
D017373_D011085 NONE CPA_42\NNP (r_nmod) EE_44\NNP (r_pobj) with_41\IN (r_prep) associated_40\VBN (r_acl) VTE_39\NNP (r_pobj) of_38\IN (r_prep) risk_37\NN (r_dobj) estimate_35\VB (r_advcl) conducted_7\VBD (l_npadvmod) years_27\NNS (l_prep) with_28\IN (l_pobj) acne_29\NN (l_conj) hirsutism_31\NN (l_conj) PCOS_33\NNP
D017373_D011085 NONE CPA_13\NNP (r_nmod) EE_15\NNP (r_pobj) of_12\IN (r_prep) use_11\NN (l_prep) in_16\IN (l_pobj) women_17\NNS (l_prep) with_18\IN (l_pobj) acne_19\NN (l_conj) hirsutism_21\NN (l_conj) PCOS_23\NNP
D003276_D054556 NONE contraceptives_23\NNS (r_pobj) with_19\IN (r_prep) compared_18\VBN (r_prep) demonstrated_3\VBN (l_dobj) risk_6\NN (l_prep) of_7\IN (l_pobj) thromboembolism_9\NN
D003276_D054556 NONE contraceptives_23\NNS (r_pobj) with_19\IN (r_prep) compared_18\VBN (r_prep) demonstrated_3\VBN (l_dobj) risk_6\NN (l_prep) of_7\IN (l_pobj) thromboembolism_9\NN (l_appos) VTE_11\NNP
D004997_D006628 NONE estradiol_5\NN (r_nsubjpass) licensed_12\VBN (l_prep) for_16\IN (l_pobj) treatment_18\NN (l_prep) of_19\IN (l_pobj) women_20\NNS (l_prep) with_21\IN (l_pobj) acne_22\NN (l_conj) hirsutism_24\NN
D004997_D006628 NONE EE_9\NNP (r_appos) estradiol_5\NN (r_nsubjpass) licensed_12\VBN (l_prep) for_16\IN (l_pobj) treatment_18\NN (l_prep) of_19\IN (l_pobj) women_20\NNS (l_prep) with_21\IN (l_pobj) acne_22\NN (l_conj) hirsutism_24\NN
D004997_D006628 NONE EE_44\NNP (r_pobj) with_41\IN (r_prep) associated_40\VBN (r_acl) VTE_39\NNP (r_pobj) of_38\IN (r_prep) risk_37\NN (r_dobj) estimate_35\VB (r_advcl) conducted_7\VBD (l_npadvmod) years_27\NNS (l_prep) with_28\IN (l_pobj) acne_29\NN (l_conj) hirsutism_31\NN
D004997_D006628 NONE EE_15\NNP (r_pobj) of_12\IN (r_prep) use_11\NN (l_prep) in_16\IN (l_pobj) women_17\NNS (l_prep) with_18\IN (l_pobj) acne_19\NN (l_conj) hirsutism_21\NN
D017373_D000152 NONE acetate_1\NN (r_nsubjpass) licensed_12\VBN (l_prep) for_16\IN (l_pobj) treatment_18\NN (l_prep) of_19\IN (l_pobj) women_20\NNS (l_prep) with_21\IN (l_pobj) acne_22\NN
D017373_D000152 NONE CPA_7\NNP (r_nmod) EE_9\NNP (r_appos) estradiol_5\NN (r_nsubjpass) licensed_12\VBN (l_prep) for_16\IN (l_pobj) treatment_18\NN (l_prep) of_19\IN (l_pobj) women_20\NNS (l_prep) with_21\IN (l_pobj) acne_22\NN
D017373_D000152 NONE CPA_42\NNP (r_nmod) EE_44\NNP (r_pobj) with_41\IN (r_prep) associated_40\VBN (r_acl) VTE_39\NNP (r_pobj) of_38\IN (r_prep) risk_37\NN (r_dobj) estimate_35\VB (r_advcl) conducted_7\VBD (l_npadvmod) years_27\NNS (l_prep) with_28\IN (l_pobj) acne_29\NN
D017373_D000152 NONE CPA_13\NNP (r_nmod) EE_15\NNP (r_pobj) of_12\IN (r_prep) use_11\NN (l_prep) in_16\IN (l_pobj) women_17\NNS (l_prep) with_18\IN (l_pobj) acne_19\NN
D017373_D006628 NONE acetate_1\NN (r_nsubjpass) licensed_12\VBN (l_prep) for_16\IN (l_pobj) treatment_18\NN (l_prep) of_19\IN (l_pobj) women_20\NNS (l_prep) with_21\IN (l_pobj) acne_22\NN (l_conj) hirsutism_24\NN
D017373_D006628 NONE CPA_7\NNP (r_nmod) EE_9\NNP (r_appos) estradiol_5\NN (r_nsubjpass) licensed_12\VBN (l_prep) for_16\IN (l_pobj) treatment_18\NN (l_prep) of_19\IN (l_pobj) women_20\NNS (l_prep) with_21\IN (l_pobj) acne_22\NN (l_conj) hirsutism_24\NN
D017373_D006628 NONE CPA_42\NNP (r_nmod) EE_44\NNP (r_pobj) with_41\IN (r_prep) associated_40\VBN (r_acl) VTE_39\NNP (r_pobj) of_38\IN (r_prep) risk_37\NN (r_dobj) estimate_35\VB (r_advcl) conducted_7\VBD (l_npadvmod) years_27\NNS (l_prep) with_28\IN (l_pobj) acne_29\NN (l_conj) hirsutism_31\NN
D017373_D006628 NONE CPA_13\NNP (r_nmod) EE_15\NNP (r_pobj) of_12\IN (r_prep) use_11\NN (l_prep) in_16\IN (l_pobj) women_17\NNS (l_prep) with_18\IN (l_pobj) acne_19\NN (l_conj) hirsutism_21\NN
D004997_D054556 CID estradiol_14\NN (r_appos) risk_1\NN (l_prep) of_2\IN (l_pobj) thromboembolism_4\NN
D004997_D054556 CID EE_17\NNP (r_pobj) with_14\IN (r_prep) associated_13\VBN (r_acl) thromboembolism_9\NN
D004997_D054556 CID EE_17\NNP (r_pobj) with_14\IN (r_prep) associated_13\VBN (r_acl) thromboembolism_9\NN (l_appos) VTE_11\NNP
D004997_D054556 CID EE_44\NNP (r_pobj) with_41\IN (r_prep) associated_40\VBN (r_acl) VTE_39\NNP
D004997_D054556 CID EE_15\NNP (r_pobj) of_12\IN (r_prep) use_11\NN (r_pobj) with_9\IN (r_prep) associated_8\VBN (r_acl) risk_5\NN (l_prep) of_6\IN (l_pobj) VTE_7\NNP
D004997_D011085 NONE estradiol_5\NN (r_nsubjpass) licensed_12\VBN (l_conj) is_26\VBZ (l_attr) option_30\NN (l_prep) for_31\IN (l_pobj) syndrome_34\NN
D004997_D011085 NONE estradiol_5\NN (r_nsubjpass) licensed_12\VBN (l_conj) is_26\VBZ (l_attr) option_30\NN (l_prep) for_31\IN (l_pobj) syndrome_34\NN (l_appos) PCOS_36\NNP
D004997_D011085 NONE EE_9\NNP (r_appos) estradiol_5\NN (r_nsubjpass) licensed_12\VBN (l_conj) is_26\VBZ (l_attr) option_30\NN (l_prep) for_31\IN (l_pobj) syndrome_34\NN
D004997_D011085 NONE EE_9\NNP (r_appos) estradiol_5\NN (r_nsubjpass) licensed_12\VBN (l_conj) is_26\VBZ (l_attr) option_30\NN (l_prep) for_31\IN (l_pobj) syndrome_34\NN (l_appos) PCOS_36\NNP
D004997_D011085 NONE EE_44\NNP (r_pobj) with_41\IN (r_prep) associated_40\VBN (r_acl) VTE_39\NNP (r_pobj) of_38\IN (r_prep) risk_37\NN (r_dobj) estimate_35\VB (r_advcl) conducted_7\VBD (l_npadvmod) years_27\NNS (l_prep) with_28\IN (l_pobj) acne_29\NN (l_conj) hirsutism_31\NN (l_conj) PCOS_33\NNP
D004997_D011085 NONE EE_15\NNP (r_pobj) of_12\IN (r_prep) use_11\NN (l_prep) in_16\IN (l_pobj) women_17\NNS (l_prep) with_18\IN (l_pobj) acne_19\NN (l_conj) hirsutism_21\NN (l_conj) PCOS_23\NNP
D017373_D054556 CID acetate_9\NN (r_oprd) prescribed_7\VBD (r_acl) women_6\NNS (r_pobj) in_5\IN (r_prep) thromboembolism_4\NN
D017373_D054556 CID CPA_15\NNP (r_nmod) EE_17\NNP (r_pobj) with_14\IN (r_prep) associated_13\VBN (r_acl) thromboembolism_9\NN
D017373_D054556 CID CPA_15\NNP (r_nmod) EE_17\NNP (r_pobj) with_14\IN (r_prep) associated_13\VBN (r_acl) thromboembolism_9\NN (l_appos) VTE_11\NNP
D017373_D054556 CID CPA_42\NNP (r_nmod) EE_44\NNP (r_pobj) with_41\IN (r_prep) associated_40\VBN (r_acl) VTE_39\NNP
D017373_D054556 CID CPA_13\NNP (r_nmod) EE_15\NNP (r_pobj) of_12\IN (r_prep) use_11\NN (r_pobj) with_9\IN (r_prep) associated_8\VBN (r_acl) risk_5\NN (l_prep) of_6\IN (l_pobj) VTE_7\NNP
D004997_D000152 NONE estradiol_5\NN (r_nsubjpass) licensed_12\VBN (l_prep) for_16\IN (l_pobj) treatment_18\NN (l_prep) of_19\IN (l_pobj) women_20\NNS (l_prep) with_21\IN (l_pobj) acne_22\NN
D004997_D000152 NONE EE_9\NNP (r_appos) estradiol_5\NN (r_nsubjpass) licensed_12\VBN (l_prep) for_16\IN (l_pobj) treatment_18\NN (l_prep) of_19\IN (l_pobj) women_20\NNS (l_prep) with_21\IN (l_pobj) acne_22\NN
D004997_D000152 NONE EE_44\NNP (r_pobj) with_41\IN (r_prep) associated_40\VBN (r_acl) VTE_39\NNP (r_pobj) of_38\IN (r_prep) risk_37\NN (r_dobj) estimate_35\VB (r_advcl) conducted_7\VBD (l_npadvmod) years_27\NNS (l_prep) with_28\IN (l_pobj) acne_29\NN
D004997_D000152 NONE EE_15\NNP (r_pobj) of_12\IN (r_prep) use_11\NN (l_prep) in_16\IN (l_pobj) women_17\NNS (l_prep) with_18\IN (l_pobj) acne_19\NN
12483326
D002945_D009916 NONE cisplatin_11\NN (r_pcomp) than_10\IN (r_prep) effects_9\NNS (r_dobj) have_6\VB (r_xcomp) said_4\VBN (l_ccomp) known_20\JJ (l_auxpass) are_18\VBP (l_nsubj) toxicity_17\NN
D002945_D005128 NONE cisplatin_11\NN (r_pcomp) than_10\IN (r_prep) effects_9\NNS (r_dobj) have_6\VB (r_xcomp) said_4\VBN (l_ccomp) known_20\JJ (l_auxpass) are_18\VBP (l_nsubj) toxicity_17\NN
D016190_D005909 NONE carboplatin_9\NN (r_pobj) of_8\IN (r_prep) injection_7\NN (l_prep) for_10\IN (l_pobj) glioblastomas_12\NNS
D016190_D005909 NONE carboplatin_10\NN (r_pobj) of_9\IN (r_prep) injection_8\NN (l_prep) for_11\IN (l_pobj) glioblastomas_13\NNS
D016190_D005128 NONE carboplatin_9\NN (r_pobj) of_8\IN (r_prep) injection_7\NN (r_pobj) after_5\IN (r_prep) toxicity_4\NN
D016190_D005128 NONE carboplatin_2\NN (r_nsubjpass) said_4\VBN (l_ccomp) known_20\JJ (l_auxpass) are_18\VBP (l_nsubj) toxicity_17\NN
D016190_D005128 NONE carboplatin_16\NN (r_pobj) of_15\IN (r_prep) injection_14\NN (r_pobj) after_12\IN (r_prep) experienced_3\VBD (l_dobj) case_5\NN (l_prep) of_6\IN (l_pobj) toxicity_11\NN
D016190_D005128 NONE carboplatin_5\NN (r_pobj) of_4\IN (r_prep) injection_3\NN (r_dobj) performing_1\VBG (r_advcl) be_9\VB (l_acomp) aware_10\JJ (l_prep) of_11\IN (l_pobj) toxicity_16\NN
D016190_D009916 NONE carboplatin_9\NN (r_pobj) of_8\IN (r_prep) injection_7\NN (r_pobj) after_5\IN (r_prep) toxicity_4\NN
D016190_D009916 NONE carboplatin_2\NN (r_nsubjpass) said_4\VBN (l_ccomp) known_20\JJ (l_auxpass) are_18\VBP (l_nsubj) toxicity_17\NN
D016190_D009916 NONE carboplatin_16\NN (r_pobj) of_15\IN (r_prep) injection_14\NN (r_pobj) after_12\IN (r_prep) experienced_3\VBD (l_dobj) case_5\NN (l_prep) of_6\IN (l_pobj) toxicity_11\NN
D016190_D064420 NONE carboplatin_7\NN (r_amod) toxicity_8\NN
7292072
D003891_D017180 CID desipramine_4\JJ (r_amod) toxicity_5\NN (r_pobj) in_3\IN (r_prep) tachycardia_2\NN
D003891_D017180 CID desipramine_10\NN (r_amod) toxicity_11\NN (r_pobj) by_9\IN (r_agent) induced_8\VBN (r_acl) tachycardia_7\NN
D003891_D064420 NONE desipramine_4\JJ (r_amod) toxicity_5\NN
D003891_D064420 NONE desipramine_10\NN (r_amod) toxicity_11\NN
9401499
D013988_D000741 CID Ticlopidine_0\NNP (r_npadvmod) induced_2\VBN (r_amod) anemia_4\NN
D013988_D000741 CID ticlopidine_8\NN (r_npadvmod) induced_10\VBN (r_amod) anemia_12\NN
D013988_D000741 CID ticlopidine_2\NN (r_npadvmod) induced_4\VBN (r_amod) anemia_6\NN
D013988_D000380 CID ticlopidine_9\NN (r_pobj) of_8\IN (r_prep) initiation_7\NN (r_pobj) after_6\IN (r_prep) occurred_1\VBD (l_nsubj) Agranulocytosis_0\NN
9195768
D018170_D010292 CID sumatriptan_7\NN (r_pobj) of_5\IN (r_prep) use_4\NN (r_dobj) following_2\VBG (r_prep) sensations_1\NNS
17147461
D000804_D011507 NONE II_52\CD (r_compound) blockers_54\NNS (r_conj) inhibitors_49\NNS (r_pobj) of_44\IN (r_prep) use_43\NN (r_conj) monitoring_36\NN (l_prep) of_37\IN (l_pobj) proteinuria_38\NN
D000804_D011507 NONE II_52\CD (r_compound) blockers_54\NNS (r_conj) inhibitors_49\NNS (r_pobj) of_44\IN (r_prep) use_43\NN (r_conj) monitoring_36\NN (l_advcl) occurs_57\VBZ (l_nsubj) proteinuria_56\NN
D000809_D011507 NONE angiotensin_45\NN (r_npadvmod) converting_47\VBG (r_amod) inhibitors_49\NNS (r_pobj) of_44\IN (r_prep) use_43\NN (r_conj) monitoring_36\NN (l_prep) of_37\IN (l_pobj) proteinuria_38\NN
D000809_D011507 NONE angiotensin_45\NN (r_npadvmod) converting_47\VBG (r_amod) inhibitors_49\NNS (r_pobj) of_44\IN (r_prep) use_43\NN (r_conj) monitoring_36\NN (l_advcl) occurs_57\VBZ (l_nsubj) proteinuria_56\NN
D020123_D011507 CID Sirolimus_0\NNP (r_npadvmod) associated_2\VBN (r_amod) proteinuria_3\NN
D020123_D011507 CID sirolimus_11\NN (r_nsubjpass) associated_13\VBN (l_prep) with_14\IN (l_pobj) proteinuria_15\NN
D020123_D011507 CID sirolimus_3\NN (r_npadvmod) associated_5\VBN (r_amod) proteinuria_6\NN
D020123_D011507 CID sirolimus_21\NN (r_pobj) of_20\IN (r_prep) effects_19\NNS (r_pobj) of_16\IN (r_prep) knowledge_15\NN (r_pobj) by_14\IN (r_agent) minimised_13\VBN (l_dep) use_27\NN (l_appos) monitoring_36\NN (l_prep) of_37\IN (l_pobj) proteinuria_38\NN
D020123_D011507 CID sirolimus_21\NN (r_pobj) of_20\IN (r_prep) effects_19\NNS (r_pobj) of_16\IN (r_prep) knowledge_15\NN (r_pobj) by_14\IN (r_agent) minimised_13\VBN (l_dep) use_27\NN (l_appos) monitoring_36\NN (l_advcl) occurs_57\VBZ (l_nsubj) proteinuria_56\NN
D020123_D011507 CID sirolimus_29\NN (r_pobj) of_28\IN (r_prep) use_27\NN (l_appos) monitoring_36\NN (l_prep) of_37\IN (l_pobj) proteinuria_38\NN
D020123_D011507 CID sirolimus_29\NN (r_pobj) of_28\IN (r_prep) use_27\NN (l_appos) monitoring_36\NN (l_advcl) occurs_57\VBZ (l_nsubj) proteinuria_56\NN
D020123_D058186 NONE sirolimus_11\NN (r_nsubjpass) associated_13\VBN (l_prep) with_14\IN (l_pobj) proteinuria_15\NN (l_conj) dysfunction_19\NN
D020123_D058186 NONE sirolimus_6\NN (r_pobj) with_5\IN (r_prep) associated_4\VBN (r_acl) dysfunction_3\NN
D020123_D007674 CID Sirolimus_0\NNP (r_npadvmod) associated_2\VBN (r_amod) proteinuria_3\NN (l_conj) dysfunction_6\NN
D020123_D007674 CID Sirolimus_0\NNP (r_nsubj) represents_1\VBZ (l_dobj) advance_5\NN (l_prep) in_6\IN (l_pobj) prevention_8\NN (l_prep) of_9\IN (l_pobj) rejection_13\NN (l_conj) nephropathy_17\NN
D020123_D007674 CID sirolimus_1\NN (r_nsubj) share_4\VB (r_advcl) designated_18\VBN (l_oprd) drug_24\NN (l_amod) nephrotoxic_23\JJ
12464714
D004878_D006970 NONE ergotamine_19\NNP (r_nmod) caffeine_21\NN (r_conj) rizatriptan_17\NN (r_pobj) after_16\IN (r_prep) >_7\XX (r_appos) events_4\NNS (l_appos) nausea_34\NN (l_conj) somnolence_42\NN
D004878_D004244 NONE ergotamine_19\NNP (r_nmod) caffeine_21\NN (r_conj) rizatriptan_17\NN (r_pobj) after_16\IN (r_prep) >_7\XX (r_appos) events_4\NNS (r_nsubj) were_25\VBD (l_attr) dizziness_26\NN
D002110_D008881 NONE caffeine_13\NN (l_prep) in_14\IN (l_pobj) migraine_15\NN
D002110_D008881 NONE caffeine_22\NN (r_appos) ergotamine_18\NN (r_pobj) to_16\IN (r_prep) tablet_15\NN (r_amod) rizatriptan_12\JJ (r_pobj) for_10\IN (r_prep) preference_9\NN (r_dobj) assessed_7\VBD (l_prep) in_26\IN (l_pobj) patients_28\NNS (l_acl) treating_29\VBG (l_dobj) attack_33\NN (l_compound) migraine_32\JJ
C093622_D010146 NONE rizatriptan_12\NN (r_pobj) after_11\IN (r_prep) h_10\NN (r_npadvmod) were_6\VBD (l_acomp) free_8\JJ (l_npadvmod) pain_7\NN
C093622_D010146 NONE rizatriptan_31\JJ (r_nsubj) being_32\VBG (r_advcl) were_6\VBD (l_acomp) free_8\JJ (l_npadvmod) pain_7\NN
C093622_D010146 NONE rizatriptan_6\NN (r_dobj) taking_5\VBG (r_acl) patients_4\NNS (r_pobj) of_3\IN (r_prep) %_2\NN (r_nsubj) were_7\VBD (l_acomp) free_9\JJ (l_npadvmod) pain_8\NN
C093622_D004244 CID rizatriptan_17\NN (r_pobj) after_16\IN (r_prep) >_7\XX (r_appos) events_4\NNS (r_nsubj) were_25\VBD (l_attr) dizziness_26\NN
D002110_D012001 NONE caffeine_7\NN (l_prep) in_8\IN (l_pobj) proportions_10\NNS (l_prep) of_11\IN (l_pobj) patients_12\NNS (l_prep) with_13\IN (l_pobj) nausea_15\NN (l_conj) vomiting_17\VBG (l_conj) phonophobia_19\NNS
C093622_D012001 NONE Rizatriptan_0\NNP (r_nsubj) was_1\VBD (l_acomp) superior_3\JJ (l_prep) to_4\IN (l_pobj) caffeine_7\NN (l_prep) in_8\IN (l_pobj) proportions_10\NNS (l_prep) of_11\IN (l_pobj) patients_12\NNS (l_prep) with_13\IN (l_pobj) nausea_15\NN (l_conj) vomiting_17\VBG (l_conj) phonophobia_19\NNS
D002110_D014839 NONE caffeine_7\NN (l_prep) in_8\IN (l_pobj) proportions_10\NNS (l_prep) of_11\IN (l_pobj) patients_12\NNS (l_prep) with_13\IN (l_pobj) nausea_15\NN (l_conj) vomiting_17\VBG
D002110_D004244 NONE caffeine_21\NN (r_conj) rizatriptan_17\NN (r_pobj) after_16\IN (r_prep) >_7\XX (r_appos) events_4\NNS (r_nsubj) were_25\VBD (l_attr) dizziness_26\NN
D012701_D008881 NONE 5-HT(1B/1D_4\CD (r_nummod) receptor_6\NN (r_compound) agonist_7\NN (l_prep) with_8\IN (l_pobj) absorption_11\NN (l_conj) onset_14\NN (l_prep) in_17\IN (l_pobj) treatment_20\NN (l_prep) of_21\IN (l_pobj) migraine_22\NN
D004878_D014839 NONE ergotamine_5\NN (r_nmod) caffeine_7\NN (l_prep) in_8\IN (l_pobj) proportions_10\NNS (l_prep) of_11\IN (l_pobj) patients_12\NNS (l_prep) with_13\IN (l_pobj) nausea_15\NN (l_conj) vomiting_17\VBG
C093622_D006261 NONE rizatriptan_19\JJ (r_dobj) preferring_18\VBG (r_acl) patients_17\NNS (r_pobj) of_16\IN (r_prep) %_15\NN (r_pobj) by_13\IN (r_agent) cited_12\VBN (r_acl) reason_8\NN (r_attr) was_4\VBD (l_nsubj) relief_1\NN (l_prep) of_2\IN (l_pobj) headache_3\NN
D004878_D008881 NONE ergotamine_11\NN (r_nmod) caffeine_13\NN (l_prep) in_14\IN (l_pobj) migraine_15\NN
D004878_D008881 NONE ergotamine_18\NN (r_pobj) to_16\IN (r_prep) tablet_15\NN (r_amod) rizatriptan_12\JJ (r_pobj) for_10\IN (r_prep) preference_9\NN (r_dobj) assessed_7\VBD (l_prep) in_26\IN (l_pobj) patients_28\NNS (l_acl) treating_29\VBG (l_dobj) attack_33\NN (l_compound) migraine_32\JJ
C093622_D009325 CID Rizatriptan_0\NNP (r_nsubj) was_1\VBD (l_acomp) superior_3\JJ (l_prep) to_4\IN (l_pobj) caffeine_7\NN (l_prep) in_8\IN (l_pobj) proportions_10\NNS (l_prep) of_11\IN (l_pobj) patients_12\NNS (l_prep) with_13\IN (l_pobj) nausea_15\NN
C093622_D009325 CID rizatriptan_17\NN (r_pobj) after_16\IN (r_prep) >_7\XX (r_appos) events_4\NNS (l_appos) nausea_34\NN
C093622_D020795 NONE Rizatriptan_0\NNP (r_nsubj) was_1\VBD (l_acomp) superior_3\JJ (l_prep) to_4\IN (l_pobj) caffeine_7\NN (l_prep) in_8\IN (l_pobj) proportions_10\NNS (l_prep) of_11\IN (l_pobj) patients_12\NNS (l_prep) with_13\IN (l_pobj) nausea_15\NN (l_conj) vomiting_17\VBG (l_conj) phonophobia_19\NNS (l_conj) photophobia_21\NNS
D002110_D009325 NONE caffeine_7\NN (l_prep) in_8\IN (l_pobj) proportions_10\NNS (l_prep) of_11\IN (l_pobj) patients_12\NNS (l_prep) with_13\IN (l_pobj) nausea_15\NN
D002110_D009325 NONE caffeine_21\NN (r_conj) rizatriptan_17\NN (r_pobj) after_16\IN (r_prep) >_7\XX (r_appos) events_4\NNS (l_appos) nausea_34\NN
D004878_D012001 NONE ergotamine_5\NN (r_nmod) caffeine_7\NN (l_prep) in_8\IN (l_pobj) proportions_10\NNS (l_prep) of_11\IN (l_pobj) patients_12\NNS (l_prep) with_13\IN (l_pobj) nausea_15\NN (l_conj) vomiting_17\VBG (l_conj) phonophobia_19\NNS
D002110_D020795 NONE caffeine_7\NN (l_prep) in_8\IN (l_pobj) proportions_10\NNS (l_prep) of_11\IN (l_pobj) patients_12\NNS (l_prep) with_13\IN (l_pobj) nausea_15\NN (l_conj) vomiting_17\VBG (l_conj) phonophobia_19\NNS (l_conj) photophobia_21\NNS
D004878_D020795 NONE ergotamine_5\NN (r_nmod) caffeine_7\NN (l_prep) in_8\IN (l_pobj) proportions_10\NNS (l_prep) of_11\IN (l_pobj) patients_12\NNS (l_prep) with_13\IN (l_pobj) nausea_15\NN (l_conj) vomiting_17\VBG (l_conj) phonophobia_19\NNS (l_conj) photophobia_21\NNS
C093622_D006970 NONE rizatriptan_17\NN (r_pobj) after_16\IN (r_prep) >_7\XX (r_appos) events_4\NNS (l_appos) nausea_34\NN (l_conj) somnolence_42\NN
D004878_D009325 NONE ergotamine_5\NN (r_nmod) caffeine_7\NN (l_prep) in_8\IN (l_pobj) proportions_10\NNS (l_prep) of_11\IN (l_pobj) patients_12\NNS (l_prep) with_13\IN (l_pobj) nausea_15\NN
D004878_D009325 NONE ergotamine_19\NNP (r_nmod) caffeine_21\NN (r_conj) rizatriptan_17\NN (r_pobj) after_16\IN (r_prep) >_7\XX (r_appos) events_4\NNS (l_appos) nausea_34\NN
C093622_D014839 NONE Rizatriptan_0\NNP (r_nsubj) was_1\VBD (l_acomp) superior_3\JJ (l_prep) to_4\IN (l_pobj) caffeine_7\NN (l_prep) in_8\IN (l_pobj) proportions_10\NNS (l_prep) of_11\IN (l_pobj) patients_12\NNS (l_prep) with_13\IN (l_pobj) nausea_15\NN (l_conj) vomiting_17\VBG
D002110_D010146 NONE caffeine_22\NN (r_pobj) with_19\IN (r_prep) treated_18\VBN (r_acl) %_17\NN (r_pobj) with_15\IN (r_prep) compared_14\VBN (r_prep) were_6\VBD (l_acomp) free_8\JJ (l_npadvmod) pain_7\NN
D002110_D010146 NONE caffeine_35\NN (r_pobj) on_32\IN (r_prep) patients_31\NNS (r_pobj) of_30\IN (r_prep) %_29\NN (r_pobj) to_27\IN (r_prep) compared_26\VBN (r_prep) were_7\VBD (l_acomp) free_9\JJ (l_npadvmod) pain_8\NN
D002110_D006261 NONE caffeine_29\NN (r_dobj) preferred_26\VBD (r_relcl) patients_24\NNS (r_pobj) of_23\IN (r_prep) %_22\NN (r_conj) rizatriptan_19\JJ (r_dobj) preferring_18\VBG (r_acl) patients_17\NNS (r_pobj) of_16\IN (r_prep) %_15\NN (r_pobj) by_13\IN (r_agent) cited_12\VBN (r_acl) reason_8\NN (r_attr) was_4\VBD (l_nsubj) relief_1\NN (l_prep) of_2\IN (l_pobj) headache_3\NN
C093622_D008881 NONE rizatriptan_7\JJ (r_pobj) for_6\IN (r_prep) preference_5\NN (r_conj) efficacy_3\NN (r_pobj) of_2\IN (r_prep) comparison_1\NN (l_conj) caffeine_13\NN (l_prep) in_14\IN (l_pobj) migraine_15\NN
C093622_D008881 NONE Rizatriptan_0\NNP (r_nsubj) is_1\VBZ (l_attr) agonist_7\NN (l_prep) with_8\IN (l_pobj) absorption_11\NN (l_conj) onset_14\NN (l_prep) in_17\IN (l_pobj) treatment_20\NN (l_prep) of_21\IN (l_pobj) migraine_22\NN
C093622_D008881 NONE rizatriptan_12\JJ (r_pobj) for_10\IN (r_prep) preference_9\NN (r_dobj) assessed_7\VBD (l_prep) in_26\IN (l_pobj) patients_28\NNS (l_acl) treating_29\VBG (l_dobj) attack_33\NN (l_compound) migraine_32\JJ
D004878_D010146 NONE ergotamine_20\NN (r_nmod) caffeine_22\NN (r_pobj) with_19\IN (r_prep) treated_18\VBN (r_acl) %_17\NN (r_pobj) with_15\IN (r_prep) compared_14\VBN (r_prep) were_6\VBD (l_acomp) free_8\JJ (l_npadvmod) pain_7\NN
D004878_D010146 NONE ergotamine_33\NNP (r_nmod) caffeine_35\NN (r_pobj) on_32\IN (r_prep) patients_31\NNS (r_pobj) of_30\IN (r_prep) %_29\NN (r_pobj) to_27\IN (r_prep) compared_26\VBN (r_prep) were_7\VBD (l_acomp) free_9\JJ (l_npadvmod) pain_8\NN
D004878_D006261 NONE ergotamine_27\NN (r_nmod) caffeine_29\NN (r_dobj) preferred_26\VBD (r_relcl) patients_24\NNS (r_pobj) of_23\IN (r_prep) %_22\NN (r_conj) rizatriptan_19\JJ (r_dobj) preferring_18\VBG (r_acl) patients_17\NNS (r_pobj) of_16\IN (r_prep) %_15\NN (r_pobj) by_13\IN (r_agent) cited_12\VBN (r_acl) reason_8\NN (r_attr) was_4\VBD (l_nsubj) relief_1\NN (l_prep) of_2\IN (l_pobj) headache_3\NN
D002110_D006970 NONE caffeine_21\NN (r_conj) rizatriptan_17\NN (r_pobj) after_16\IN (r_prep) >_7\XX (r_appos) events_4\NNS (l_appos) nausea_34\NN (l_conj) somnolence_42\NN
18619688
D004317_D003643 NONE Adriamycin_0\NNP (r_advmod) induced_2\VBN (r_amod) death_5\NN
D004317_D003643 NONE adriamycin_17\NNS (r_pobj) by_16\IN (r_agent) induced_15\VBN (r_advcl) plays_3\VBZ (l_nsubj) death_2\NN
C025946_D006333 NONE 3-methyladenine_2\LS (r_appos) METHODS_0\NNS (r_nsubjpass) used_13\VBN (l_prep) in_14\IN (l_pobj) model_18\NN (l_compound) failure_17\NN
C025946_D006333 NONE 3MA_4\VBN (r_appos) 3-methyladenine_2\LS (r_appos) METHODS_0\NNS (r_nsubjpass) used_13\VBN (l_prep) in_14\IN (l_pobj) model_18\NN (l_compound) failure_17\NN
D004317_D006333 CID Adriamycin_0\NNP (r_advmod) induced_2\VBN (r_amod) death_5\NN (r_nsubj) plays_6\VBZ (l_prep) in_10\IN (l_pobj) model_13\NN (l_prep) of_14\IN (l_pobj) failure_16\NN
D004317_D006333 CID adriamycin_7\NNS (r_pobj) by_6\IN (r_agent) induced_5\VBN (r_acl) failure_4\NN
D004317_D006333 CID adriamycin_20\NNS (r_pobj) by_19\IN (r_agent) induced_18\VBN (r_acl) progression_14\NN (l_prep) of_15\IN (l_pobj) failure_17\NN
D004317_D006333 CID adriamycin_20\NNS (r_pobj) by_19\IN (r_agent) induced_18\VBN (r_acl) progression_14\NN (r_pobj) in_12\IN (r_prep) involved_11\VBN (r_ccomp) investigate_7\VB (l_advcl) develop_26\VB (l_dobj) strategy_30\NN (l_prep) for_31\IN (l_pobj) failure_33\NN
D004317_D006333 CID adriamycin_23\NNS (r_pobj) by_22\IN (r_agent) induced_21\VBN (r_acl) model_18\NN (l_compound) failure_17\NN
D004317_D006333 CID adriamycin_17\NNS (r_pobj) by_16\IN (r_agent) induced_15\VBN (r_advcl) plays_3\VBZ (l_prep) in_7\IN (l_pobj) pathogenesis_9\NN (l_prep) of_10\IN (l_pobj) failure_12\NN
D004317_D006333 CID adriamycin_13\NNS (r_pobj) by_12\IN (r_agent) caused_11\VBN (r_acl) failure_10\NN
11250767
D011441_D005921 CID propylthiouracil_13\NN (l_relcl) developed_25\VBD (l_nsubj) syndrome_17\NN (l_prep) of_18\IN (l_pobj) pericarditis_19\NN (l_conj) fever_21\NN (l_conj) glomerulonephritis_24\NN
D011441_D010493 CID Propylthiouracil_0\NNP (r_npadvmod) induced_2\VBN (r_amod) vasculitis_11\NN (l_prep) in_12\IN (l_pobj) conjunction_13\NN (l_prep) with_14\IN (l_pobj) pericarditis_15\NN
D011441_D010493 CID propylthiouracil_5\NN (r_npadvmod) induced_7\VBN (r_amod) vasculitis_8\NN (l_acl) manifesting_9\VBG (l_prep) with_10\IN (l_pobj) pericarditis_11\NN
D011441_D010493 CID propylthiouracil_13\NN (l_relcl) developed_25\VBD (l_nsubj) syndrome_17\NN (l_prep) of_18\IN (l_pobj) pericarditis_19\NN
D011441_D010493 CID uracil_20\NN (r_compound) therapy_21\NN (r_pobj) with_18\IN (r_prep) associated_17\VBN (r_acl) vasculitis_16\NN (r_pobj) in_9\IN (r_prep) reports_6\NNS (l_prep) of_7\IN (l_pobj) pericarditis_8\NN
D011441_D010493 CID uracil_14\NN (r_compound) therapy_15\NN (r_appos) propylthio-_13\VB (r_pobj) to_12\IN (r_prep) attributable_11\JJ (r_amod) manifestation_5\NN (r_attr) be_2\VB (l_nsubj) Pericarditis_0\NNP
D011441_D006980 NONE propylthiouracil_13\NN (r_pobj) with_12\IN (r_prep) treated_11\VBN (r_acl) report_5\NN (l_prep) of_6\IN (l_pobj) woman_8\NN (l_prep) with_9\IN (l_pobj) hyperthyroidism_10\NN
D011441_D014657 NONE Propylthiouracil_0\NNP (r_npadvmod) induced_2\VBN (r_amod) vasculitis_11\NN
D011441_D014657 NONE propylthiouracil_5\NN (r_npadvmod) induced_7\VBN (r_amod) vasculitis_8\NN
D011441_D014657 NONE uracil_20\NN (r_compound) therapy_21\NN (r_pobj) with_18\IN (r_prep) associated_17\VBN (r_acl) vasculitis_16\NN
D011441_D014657 NONE uracil_14\NN (r_compound) therapy_15\NN (r_appos) propylthio-_13\VB (r_pobj) to_12\IN (r_prep) attributable_11\JJ (r_amod) manifestation_5\NN (l_prep) of_6\IN (l_pobj) vasculitis_10\NN
D011441_D005334 CID propylthiouracil_13\NN (l_relcl) developed_25\VBD (l_nsubj) syndrome_17\NN (l_prep) of_18\IN (l_pobj) pericarditis_19\NN (l_conj) fever_21\NN
11706060
D019344_D000163 NONE lactate_8\NN (r_dobj) elevates_6\VBZ (l_prep) in_9\IN (l_pobj) mice_12\NNS (l_compound) AIDS_11\NNP
D019344_D000163 NONE lactate_18\NN (l_prep) in_22\IN (l_pobj) AIDS_23\NNP
D019344_D000163 NONE LA_20\NNP (r_appos) lactate_18\NN (l_prep) in_22\IN (l_pobj) AIDS_23\NNP
D019344_D000163 NONE LA_10\NNP (l_prep) in_11\IN (l_pobj) mice_14\NNS (l_compound) transgenic_13\JJ (l_compound) AIDS_12\NNP
D019259_D000163 NONE lamivudine_43\NN (r_pobj) of_40\IN (r_prep) combination_39\NN (r_pobj) with_36\IN (r_prep) treated_35\VBN (l_nsubjpass) mice_15\NNS (l_compound) AIDS_14\NNP
D019344_D009202 NONE lactate_8\NN (r_dobj) elevates_6\VBZ (r_conj) causes_3\VBZ (l_advmod) cardiomyopathy_4\NN
D019344_D009202 NONE lactate_18\NN (r_pobj) in_15\IN (r_conj) in_9\IN (l_pobj) CM_12\NNP (l_amod) cardiomyopathy_10\NN
D019344_D009202 NONE lactate_18\NN (r_pobj) in_15\IN (r_conj) in_9\IN (l_pobj) CM_12\NNP
D019344_D009202 NONE LA_20\NNP (r_appos) lactate_18\NN (r_pobj) in_15\IN (r_conj) in_9\IN (l_pobj) CM_12\NNP (l_amod) cardiomyopathy_10\NN
D019344_D009202 NONE LA_20\NNP (r_appos) lactate_18\NN (r_pobj) in_15\IN (r_conj) in_9\IN (l_pobj) CM_12\NNP
D019344_D009202 NONE LA_41\NNP (r_pobj) of_39\IN (r_prep) determination_38\NN (r_conj) underwent_7\VBD (l_dobj) echocardiography_8\RB (l_appos) quantitation_10\NN (l_prep) of_11\IN (l_pobj) abundance_12\NN (l_prep) of_13\IN (l_pobj) markers_15\NNS (l_prep) of_16\IN (l_pobj) CM_17\NNP
D019344_D009202 NONE LA_10\NNP (r_pobj) with_8\IN (r_prep) CM_7\NNP
D019344_D028361 NONE lactate_18\NN (r_pobj) in_15\IN (r_conj) in_9\IN (r_prep) implicated_8\VBN (l_prep) through_24\IN (l_pobj) mechanisms_25\NNS (l_prep) of_26\IN (l_pobj) dysfunction_28\NN
D019344_D028361 NONE LA_20\NNP (r_appos) lactate_18\NN (r_pobj) in_15\IN (r_conj) in_9\IN (r_prep) implicated_8\VBN (l_prep) through_24\IN (l_pobj) mechanisms_25\NNS (l_prep) of_26\IN (l_pobj) dysfunction_28\NN
D019469_D000163 NONE indinavir_46\NNS (r_conj) lamivudine_43\NN (r_pobj) of_40\IN (r_prep) combination_39\NN (r_pobj) with_36\IN (r_prep) treated_35\VBN (l_nsubjpass) mice_15\NNS (l_compound) AIDS_14\NNP
D002118_D009202 NONE calcium_30\NN (r_compound) ATPase_31\NNP (r_conj) encoding_21\VBG (r_parataxis) quantitation_10\NN (l_prep) of_11\IN (l_pobj) abundance_12\NN (l_prep) of_13\IN (l_pobj) markers_15\NNS (l_prep) of_16\IN (l_pobj) CM_17\NNP
D015215_D000163 NONE zidovudine_41\NN (r_nmod) lamivudine_43\NN (r_pobj) of_40\IN (r_prep) combination_39\NN (r_pobj) with_36\IN (r_prep) treated_35\VBN (l_nsubjpass) mice_15\NNS (l_compound) AIDS_14\NNP
9100294
D020748_D018376 CID 5967_14\CD (r_prep) 40_12\CD (r_nummod) Ro_11\NNP (r_appos) blocker_9\NN (r_nsubj) induced_16\VBD (l_dobj) alterations_18\NNS
D009543_D018376 CID nifedipine_29\NN (r_conj) verapamil_27\NN (r_pobj) for_26\IN (r_prep) significant_24\JJ (r_acomp) was_22\VBD (r_conj) observed_7\VBN (l_nsubjpass) incidence_2\NN (l_prep) of_3\IN (l_pobj) malformations_5\NNS
D002118_D018376 NONE calcium_7\NN (r_compound) channel_8\NN (r_compound) blockers_9\NNS (r_pobj) to_6\IN (r_prep) exposed_5\VBN (r_acl) alterations_1\NNS
D002118_D018376 NONE calcium_7\NN (r_compound) channel_8\NN (r_compound) blocker_9\NN (r_nsubj) induced_16\VBD (l_dobj) alterations_18\NNS
D002118_D018376 NONE calcium_10\NN (r_compound) channel_11\NN (r_compound) blockers_12\NNS (r_nsubj) induce_15\VBP (l_dobj) malformations_17\NNS
D002118_D018376 NONE calcium_7\NN (r_compound) channel_8\NN (r_compound) blockers_9\NNS (r_pobj) of_5\IN (r_prep) one_4\CD (r_dobj) administered_3\VBN (l_prep) during_10\IN (l_pobj) period_12\NN (l_prep) of_13\IN (l_pobj) morphogenesis_15\NN (l_conj) offspring_18\NN (l_acl) examined_19\VBD (l_prep) on_20\IN (l_pobj) day_21\NN (l_prep) of_23\IN (l_pobj) gestation_24\NN (l_prep) for_25\IN (l_pobj) malformations_27\NNS
D002118_D018376 NONE calcium_15\NN (r_compound) channel_16\NN (r_compound) blockers_17\NNS (r_pobj) of_12\IN (r_prep) each_11\DT (r_pobj) to_10\IN (r_prep) exposure_9\NN (r_pobj) after_8\IN (r_prep) observed_7\VBN (l_nsubjpass) incidence_2\NN (l_prep) of_3\IN (l_pobj) malformations_5\NNS
D014700_D018376 CID verapamil_27\NN (r_pobj) for_26\IN (r_prep) significant_24\JJ (r_acomp) was_22\VBD (r_conj) observed_7\VBN (l_nsubjpass) incidence_2\NN (l_prep) of_3\IN (l_pobj) malformations_5\NNS
16867021
C052075_D006948 NONE THP_6\NNP (r_nmod) time_16\NN (r_npadvmod) traveled_19\VBD (l_prep) On_0\IN (l_pobj) hyperactivity_4\NN
C052075_D006948 NONE THP_0\NNP (r_nsubj) exhibited_1\VBD (l_dobj) profile_6\NN (l_prep) by_7\IN (l_pcomp) potentiating_8\VBG (l_conj) reducing_14\VBG (l_dobj) hyperactivity_18\NN
C052075_D002375 CID thioperamide_13\JJ (r_conj) microg_9\NN (r_parataxis) methylhistamine_3\NN (r_nsubj) cause_27\VB (l_dobj) catalepsy_28\NN
C052075_D002375 CID THP_15\NNP (r_appos) thioperamide_13\JJ (r_conj) microg_9\NN (r_parataxis) methylhistamine_3\NN (r_nsubj) cause_27\VB (l_dobj) catalepsy_28\NN
C052075_D002375 CID THP_0\NNP (r_nsubj) exhibited_1\VBD (l_dobj) profile_6\NN (l_prep) by_7\IN (l_pcomp) potentiating_8\VBG (l_dobj) catalepsy_12\NN
D001058_D006948 NONE apomorphine_21\NN (r_dobj) reducing_20\VBG (r_conj) reducing_14\VBG (l_dobj) hyperactivity_18\NN
D000661_D006948 CID amphetamine_1\NN (r_npadvmod) induced_3\VBN (r_amod) hyperactivity_4\NN
D000661_D006948 CID amphetamine_15\NN (r_npadvmod) induced_17\VBN (r_amod) hyperactivity_18\NN
D006220_D006948 NONE haloperidol_9\NN (r_npadvmod) induced_11\VBN (r_amod) catalepsy_12\NN (r_dobj) potentiating_8\VBG (l_conj) reducing_14\VBG (l_dobj) hyperactivity_18\NN
D001058_D002375 NONE apomorphine_19\NN (r_npadvmod) induced_21\VBN (r_amod) behavior_23\NN (r_dobj) study_6\VB (l_dobj) effect_8\NN (l_prep) of_9\IN (l_pobj) ligands_12\NNS (l_prep) on_13\IN (l_pobj) catalepsy_17\NN
D001058_D002375 NONE apomorphine_12\NN (r_nsubjpass) used_26\VBN (r_advcl) induced_2\VBN (l_nsubjpass) Catalepsy_0\NNP
D001058_D002375 NONE apomorphine_21\NN (r_dobj) reducing_20\VBG (r_conj) reducing_14\VBG (r_conj) potentiating_8\VBG (l_dobj) catalepsy_12\NN
D006220_D002375 CID haloperidol_4\NN (r_pobj) by_3\IN (r_agent) induced_2\VBN (l_nsubjpass) Catalepsy_0\NNP
D006220_D002375 CID haloperidol_4\NN (r_pobj) to_3\IN (r_prep) prior_2\RB (r_advmod) resulted_5\VBD (l_prep) in_6\IN (l_pobj) increase_11\NN (l_prep) in_12\IN (l_pobj) catalepsy_14\NN
D006220_D002375 CID haloperidol_9\NN (r_npadvmod) induced_11\VBN (r_amod) catalepsy_12\NN
D000661_D002375 NONE amphetamine_25\NN (r_npadvmod) induced_27\VBN (r_amod) activities_29\NNS (r_conj) behavior_23\NN (r_dobj) study_6\VB (l_dobj) effect_8\NN (l_prep) of_9\IN (l_pobj) ligands_12\NNS (l_prep) on_13\IN (l_pobj) catalepsy_17\NN
D000661_D002375 NONE amphetamine_19\NN (r_conj) apomorphine_12\NN (r_nsubjpass) used_26\VBN (r_advcl) induced_2\VBN (l_nsubjpass) Catalepsy_0\NNP
D000661_D002375 NONE amphetamine_15\NN (r_npadvmod) induced_17\VBN (r_amod) hyperactivity_18\NN (r_dobj) reducing_14\VBG (r_conj) potentiating_8\VBG (l_dobj) catalepsy_12\NN
D006632_D002375 NONE histamine_10\NN (r_nmod) ligands_12\NNS (l_prep) on_13\IN (l_pobj) catalepsy_17\NN
C069357_D002375 NONE methylhistamine_3\NN (r_nsubj) cause_27\VB (l_dobj) catalepsy_28\NN
C069357_D002375 NONE RAMH_5\NNP (r_appos) methylhistamine_3\NN (r_nsubj) cause_27\VB (l_dobj) catalepsy_28\NN
19269743
D002211_D010146 CID capsaicin_9\NN (r_npadvmod) induced_11\VBN (r_amod) pain_12\NN
D002211_D010146 CID capsaicin_21\NN (r_pobj) of_20\IN (r_prep) doses_19\NNS (r_pobj) of_17\IN (r_prep) injections_16\NNS (r_dobj) received_14\VBD (l_prep) In_0\IN (l_pobj) order_1\NN (l_acl) address_3\VB (l_dobj) memory_8\NN (l_compound) pain_7\NN
D002211_D010146 CID capsaicin_11\NN (r_compound) doses_12\NNS (r_pobj) across_10\IN (r_prep) discriminate_5\VB (l_dobj) magnitude_7\NN (l_compound) pain_6\NN
84204
D002927_D008107 NONE cimetidine_19\FW (r_conj) dysfunction_8\NN
D002927_D003221 CID cimetidine_7\NN (r_npadvmod) associated_9\VBN (r_amod) confusion_11\NN
D002927_D003221 CID cimetidine_3\NN (r_npadvmod) associated_5\VBN (r_amod) confusion_7\NN
D002927_D051437 NONE cimetidine_19\FW (r_conj) dysfunction_8\NN
11027905
D016202_D009437 NONE aspartate_13\NNP (r_nmod) antagonists_17\NNS (r_nsubj) be_24\VB (l_acomp) effective_25\JJ (l_prep) in_26\IN (l_pcomp) improving_27\VBG (l_dobj) analgesia_29\NN (l_prep) in_30\IN (l_pobj) syndromes_33\NNS (l_prep) as_36\IN (l_pobj) pain_38\NN
D016202_D009437 NONE NMDA_15\NNP (r_nmod) antagonists_17\NNS (r_nsubj) be_24\VB (l_acomp) effective_25\JJ (l_prep) in_26\IN (l_pcomp) improving_27\VBG (l_dobj) analgesia_29\NN (l_prep) in_30\IN (l_pobj) syndromes_33\NNS (l_prep) as_36\IN (l_pobj) pain_38\NN
D016202_D010146 NONE aspartate_13\NNP (r_nmod) antagonists_17\NNS (r_nsubj) be_24\VB (l_acomp) effective_25\JJ (l_prep) in_26\IN (l_pcomp) improving_27\VBG (l_dobj) analgesia_29\NN (l_prep) in_30\IN (l_pobj) syndromes_33\NNS (l_compound) pain_32\NN
D016202_D010146 NONE NMDA_15\NNP (r_nmod) antagonists_17\NNS (r_nsubj) be_24\VB (l_acomp) effective_25\JJ (l_prep) in_26\IN (l_pcomp) improving_27\VBG (l_dobj) analgesia_29\NN (l_prep) in_30\IN (l_pobj) syndromes_33\NNS (l_compound) pain_32\NN
D007649_D009437 NONE ketamine_21\NN (r_pobj) as_20\IN (r_prep) antagonists_17\NNS (r_nsubj) be_24\VB (l_acomp) effective_25\JJ (l_prep) in_26\IN (l_pcomp) improving_27\VBG (l_dobj) analgesia_29\NN (l_prep) in_30\IN (l_pobj) syndromes_33\NNS (l_prep) as_36\IN (l_pobj) pain_38\NN
D007649_D009437 NONE Ketamine_0\NNP (r_nsubj) improve_2\VB (l_dobj) analgesia_4\NN (l_prep) in_5\IN (l_pobj) syndromes_8\NNS (l_prep) as_11\IN (l_pobj) pain_13\NN
D007649_D010146 NONE ketamine_21\NN (r_pobj) as_20\IN (r_prep) antagonists_17\NNS (r_nsubj) be_24\VB (l_acomp) effective_25\JJ (l_prep) in_26\IN (l_pcomp) improving_27\VBG (l_dobj) analgesia_29\NN (l_prep) in_30\IN (l_pobj) syndromes_33\NNS (l_compound) pain_32\NN
D007649_D010146 NONE ketamine_7\NN (r_pobj) of_6\IN (r_prep) doses_5\NNS (r_pobj) of_3\IN (r_prep) bolus_2\NN (r_nsubjpass) given_16\VBN (l_dative) to_17\IN (l_pobj) patients_20\NNS (l_relcl) was_23\VBD (l_nsubj) pain_22\NN
D007649_D010146 NONE Ketamine_0\NN (r_nsubj) reduced_8\VBD (l_dobj) intensity_11\NN (l_compound) pain_10\NN
D007649_D010146 NONE Ketamine_0\NNP (r_nsubj) improve_2\VB (l_dobj) analgesia_4\NN (l_prep) in_5\IN (l_pobj) syndromes_8\NNS (l_compound) pain_7\NN
D007649_D009369 NONE ketamine_4\NN (l_prep) in_5\IN (l_pobj) patients_7\NNS (l_compound) cancer_6\NN
D007649_D009369 NONE ketamine_7\NN (r_pobj) of_6\IN (r_prep) doses_5\NNS (r_pobj) of_3\IN (r_prep) bolus_2\NN (r_nsubjpass) given_16\VBN (l_dative) to_17\IN (l_pobj) patients_20\NNS (l_compound) cancer_19\NN
D009020_D009369 NONE morphine_9\NN (r_compound) therapy_10\NN (r_pobj) on_8\IN (r_prep) patients_7\NNS (l_compound) cancer_6\NN
D009020_D009369 NONE morphine_26\NN (r_pobj) by_25\IN (r_prep) unrelieved_24\JJ (r_acomp) was_23\VBD (r_relcl) patients_20\NNS (l_compound) cancer_19\NN
D009020_D009437 NONE morphine_3\NN (r_compound) analgesia_4\NN (l_prep) in_5\IN (l_pobj) syndromes_8\NNS (l_prep) as_11\IN (l_pobj) pain_13\NN
D009020_D010146 NONE morphine_4\NN (r_pobj) to_3\IN (r_prep) responsive_2\JJ (r_amod) Pain_0\NN
D009020_D010146 NONE morphine_26\NN (r_pobj) by_25\IN (r_prep) unrelieved_24\JJ (r_acomp) was_23\VBD (l_nsubj) pain_22\NN
D009020_D010146 NONE morphine_3\NN (r_compound) analgesia_4\NN (l_prep) in_5\IN (l_pobj) syndromes_8\NNS (l_compound) pain_7\NN
3409645
D008727_D007172 CID methotrexate_23\NNP (r_pobj) of_22\IN (r_prep) taking_21\NN (r_conj) was_1\VBD (l_nsubj) Impotence_0\NN
7234705
D011342_D008133 NONE procainamide_5\NN (r_nsubj) produce_7\VB (l_dobj) syndrome_14\NN
D011342_D018879 NONE procainamide_6\NN (r_nsubjpass) administered_8\VBN (l_prep) for_10\IN (l_pobj) treatment_11\NN (l_prep) of_12\IN (l_pobj) contractions_16\NNS
D011342_D017180 CID Procainamide_0\NNP (r_npadvmod) induced_2\VBN (l_dobj) tachycardia_5\NN
D011342_D017180 CID procainamide_3\RB (r_advmod) induced_5\VBN (r_amod) tachycardia_8\NNS
D011342_D017180 CID procainamide_17\NN (r_pobj) of_16\IN (r_prep) mg_15\IN (r_pobj) of_11\IN (r_prep) administration_10\NN (r_pobj) after_8\IN (r_prep) appeared_7\VBD (l_nsubj) tachycardia_6\NN
D011342_D017180 CID procainamide_17\NN (r_pobj) of_16\IN (r_prep) mg_15\IN (r_pobj) of_11\IN (r_prep) administration_10\NN (l_prep) for_18\IN (l_pobj) treatment_20\NN (l_prep) of_21\IN (l_pobj) tachycardia_24\NN
D011342_D017180 CID procainamide_16\NN (r_amod) therapy_17\NN (r_pobj) of_15\IN (r_prep) continuation_14\NN (r_pobj) despite_13\IN (r_prep) reoccur_24\VB (l_nsubj) tachycardia_21\NN
D011342_D017180 CID procainamide_5\NN (r_nsubj) produce_7\VB (l_prep) with_15\IN (l_pobj) tachycardia_18\NN
D011342_D001282 NONE procainamide_6\NN (r_nsubjpass) administered_8\VBN (l_prep) for_10\IN (l_pobj) treatment_11\NN (l_prep) of_12\IN (l_pobj) contractions_16\NNS (l_conj) flutter_19\NN
1549199
D007980_D011618 NONE levodopa_13\RB (r_npadvmod) induced_15\VBN (r_amod) psychosis_16\NN
D007980_D064420 NONE levodopa_9\NN (r_compound) therapy_10\NN (r_pobj) for_8\IN (r_prep) dose_7\NN (r_dobj) starting_6\NN (r_acl) correct_5\JJ (r_attr) is_2\VBZ (r_advcl) started_16\VBN (l_prep) following_27\VBG (l_pobj) rule_30\NN (l_relcl) attempt_33\VB (l_xcomp) titrate_35\VB (l_dobj) levodopa_38\NN (l_relcl) lead_49\VB (l_prep) to_50\IN (l_pobj) toxicity_51\NN
D007980_D064420 NONE levodopa_38\NN (l_relcl) lead_49\VB (l_prep) to_50\IN (l_pobj) toxicity_51\NN
D007980_D020447 CID levodopa_13\RB (r_npadvmod) induced_15\VBN (r_amod) psychosis_16\NN (l_conj) disturbances_19\NNS (l_conj) parasomnias_21\NNS
D002230_D064420 NONE carbidopa_36\NN (r_compound) levodopa_38\NN (l_relcl) lead_49\VB (l_prep) to_50\IN (l_pobj) toxicity_51\NN
D007980_D007024 CID levodopa_13\RB (r_npadvmod) induced_15\VBN (r_amod) psychosis_16\NN (r_conj) hypotension_11\NN
D007980_D012893 NONE levodopa_13\RB (r_npadvmod) induced_15\VBN (r_amod) psychosis_16\NN (l_conj) disturbances_19\NNS
D007980_D005767 CID levodopa_13\RB (r_npadvmod) induced_15\VBN (r_amod) psychosis_16\NN (r_conj) hypotension_11\NN (r_conj) disorders_8\NNS
18308784
C035054_D007859 NONE Rg1_1\NNP (r_nsubj) restores_2\VBZ (l_dobj) impairment_4\NN (l_prep) of_5\IN (l_pobj) learning_6\VBG
C035054_D007859 NONE Rg1_0\NNP (l_advcl) ameliorate_11\VB (l_dobj) impairment_14\NN
C035054_D007859 NONE Rg1_11\NN (r_pobj) of_10\IN (r_prep) effect_9\NN (l_prep) on_12\IN (l_pobj) impairment_14\NN
D009020_D007859 CID morphine_10\NN (r_compound) administration_11\NN (r_pobj) by_8\IN (r_agent) induced_7\VBN (r_acl) impairment_4\NN (l_prep) of_5\IN (l_pobj) learning_6\VBG
D009020_D007859 CID morphine_17\NN (r_compound) administration_18\NN (r_pobj) by_15\IN (r_prep) impairment_14\NN
D036145_D007859 NONE ginsenoside_4\NN (r_pobj) as_2\IN (r_prep) ameliorate_11\VB (l_dobj) impairment_14\NN
18768591
D004317_D034141 CID Doxorubicin_0\NNP (r_compound) treatment_1\NN (r_nsubj) resulted_2\VBD (l_conj) 15/44_21\CD (l_prep) of_22\IN (l_pobj) mice_25\NNS (l_acl) leading_26\VBG (l_prep) to_27\IN (l_pobj) syndrome_30\NN (l_prep) with_31\IN (l_pobj) ascites_32\NNS (l_conj) lipidemia_34\NN (l_conj) hypoalbuminemia_37\VB
D000450_D009404 NONE aldosterone_1\NN (r_compound) levels_2\NNS (r_nsubj) increased_3\VBD (l_prep) in_4\IN (l_pobj) mice_6\NNS (l_amod) nephrotic_5\JJ
D012964_D007674 NONE sodium_7\NN (r_compound) channel_8\NN (r_pobj) to_5\IN (r_prep) leads_4\VBZ (l_nsubj) nephropathy_3\NN
D000450_D005355 NONE aldosterone_1\NN (r_npadvmod) sensitive_3\JJ (r_amod) SGK1_10\NNP (r_nsubjpass) shown_13\VBN (l_xcomp) participate_15\VB (l_conj) mediate_23\VB (l_dobj) fibrosis_25\NN
D004317_D011507 CID Doxorubicin_0\NNP (r_compound) treatment_1\NN (r_nsubj) resulted_2\VBD (l_prep) in_3\IN (l_pobj) proteinuria_5\NN
D014508_D009404 NONE urea_8\NN (r_compound) concentrations_9\NNS (r_nsubj) increased_10\VBD (l_prep) During_0\IN (l_pobj) course_2\NN (l_prep) of_3\IN (l_pobj) syndrome_5\NN
D004317_D001201 CID Doxorubicin_0\NNP (r_compound) treatment_1\NN (r_nsubj) resulted_2\VBD (l_conj) 15/44_21\CD (l_prep) of_22\IN (l_pobj) mice_25\NNS (l_acl) leading_26\VBG (l_prep) to_27\IN (l_pobj) syndrome_30\NN (l_prep) with_31\IN (l_pobj) ascites_32\NNS
D004317_D009404 CID doxorubicin_8\NN (r_npadvmod) induced_10\VBN (r_amod) syndrome_12\NN
D004317_D009404 CID Doxorubicin_0\NNP (r_compound) treatment_1\NN (r_nsubj) resulted_2\VBD (l_conj) 15/44_21\CD (l_prep) of_22\IN (l_pobj) mice_25\NNS (l_acl) leading_26\VBG (l_prep) to_27\IN (l_pobj) syndrome_30\NN
D012964_D016055 NONE sodium_7\NN (r_compound) channel_8\NN (l_appos) retention_12\NN
D004317_D005355 NONE Doxorubicin_0\NNP (r_npadvmod) induced_2\VBN (r_amod) nephropathy_3\NN (r_nsubj) leads_4\VBZ (l_prep) to_5\IN (l_pobj) channel_8\NN (l_appos) retention_12\NN (l_conj) fibrosis_15\NN
D004317_D006949 CID Doxorubicin_0\NNP (r_compound) treatment_1\NN (r_nsubj) resulted_2\VBD (l_conj) 15/44_21\CD (l_prep) of_22\IN (l_pobj) mice_25\NNS (l_acl) leading_26\VBG (l_prep) to_27\IN (l_pobj) syndrome_30\NN (l_prep) with_31\IN (l_pobj) ascites_32\NNS (l_conj) lipidemia_34\NN
D004317_D007674 NONE Doxorubicin_0\NNP (r_npadvmod) induced_2\VBN (r_amod) nephropathy_3\NN
D004317_D016055 NONE Doxorubicin_0\NNP (r_npadvmod) induced_2\VBN (r_amod) nephropathy_3\NN (r_nsubj) leads_4\VBZ (l_prep) to_5\IN (l_pobj) channel_8\NN (l_appos) retention_12\NN
D012964_D005355 NONE sodium_7\NN (r_compound) channel_8\NN (l_appos) retention_12\NN (l_conj) fibrosis_15\NN
1967484
D013469_D004409 NONE sulpiride_11\NN (r_npadvmod) induced_13\VBN (l_dobj) dyskinesia_15\JJ
D013469_D010302 NONE sulpiride_11\NN (r_npadvmod) induced_13\VBN (l_dobj) dyskinesia_15\JJ (l_conj) parkinsonism_17\NN
D013469_D004421 CID Sulpiride_0\NNP (r_npadvmod) induced_2\VBN (l_dobj) dystonia_4\NN
D013469_D004421 CID sulpiride_17\NN (r_compound) therapy_18\NN (r_dobj) starting_16\VBG (r_pcomp) after_15\IN (r_prep) developed_8\VBD (l_dobj) dystonia_11\NN
D013469_D004421 CID sulpiride_8\NN (r_npadvmod) induced_10\VBN (r_amod) dystonia_12\NN
12707296
D006854_D006973 NONE cortisol_7\NN (r_npadvmod) induced_9\VBN (r_amod) hypertension_10\NN
D006854_D006973 NONE cortisol_12\NN (r_npadvmod) induced_14\VBN (r_amod) hypertension_15\NN
D006854_D006973 NONE cortisol_3\NN (r_npadvmod) induced_5\VBN (r_amod) increases_6\NNS (l_prep) in_7\IN (l_pobj) pressure_9\NN
D001120_D006973 NONE arginine_2\NN (r_compound) transport_3\NN (l_prep) with_6\IN (l_pobj) hypertension_10\NN
D001120_D006973 NONE arginine_4\NN (r_compound) nitric_6\NN (r_compound) system_8\NN (r_nsubjpass) implicated_10\VBN (l_prep) in_11\IN (l_pobj) hypertension_15\NN
D001120_D006973 NONE arginine_19\NN (r_compound) system_21\NN (r_pobj) in_15\IN (r_prep) abnormalities_14\NNS (r_pobj) with_13\IN (r_prep) associated_12\VBN (l_nsubjpass) increases_6\NNS (l_prep) in_7\IN (l_pobj) pressure_9\NN
D009569_D006973 NONE oxide_7\NN (r_compound) system_8\NN (r_nsubjpass) implicated_10\VBN (l_prep) in_11\IN (l_pobj) hypertension_15\NN
2440413
D005680_D012640 NONE GABA_24\NNP (r_compound) A_26\NNP (r_nmod) channel_31\NN (r_attr) be_22\VB (l_nsubj) site_7\NN (l_amod) responsible_8\JJ (l_prep) for_9\IN (l_pobj) decrease_11\NN (l_prep) in_12\IN (l_pobj) activity_14\NN (l_compound) seizure_13\NN
C034818_D012640 CID carboline-3-carboxylate_36\NNP (r_conj) acid_21\NN (r_pobj) to_19\IN (r_pcomp) due_18\IN (r_prep) activity_17\NN (r_nsubj) was_46\VBD (l_ccomp) decreased_12\VBN (l_nsubjpass) activity_1\NN (l_compound) Seizure_0\NN
C034818_D012640 CID carboline-3-carboxylate_36\NNP (r_conj) acid_21\NN (r_pobj) to_19\IN (r_pcomp) due_18\IN (r_prep) activity_17\NN (l_compound) seizure_16\NN
C034818_D012640 CID DMCM_38\NNP (r_appos) carboline-3-carboxylate_36\NNP (r_conj) acid_21\NN (r_pobj) to_19\IN (r_pcomp) due_18\IN (r_prep) activity_17\NN (r_nsubj) was_46\VBD (l_ccomp) decreased_12\VBN (l_nsubjpass) activity_1\NN (l_compound) Seizure_0\NN
C034818_D012640 CID DMCM_38\NNP (r_appos) carboline-3-carboxylate_36\NNP (r_conj) acid_21\NN (r_pobj) to_19\IN (r_pcomp) due_18\IN (r_prep) activity_17\NN (l_compound) seizure_16\NN
D001640_D012640 CID bicuculline_26\NN (r_conj) acid_21\NN (r_pobj) to_19\IN (r_pcomp) due_18\IN (r_prep) activity_17\NN (r_nsubj) was_46\VBD (l_ccomp) decreased_12\VBN (l_nsubjpass) activity_1\NN (l_compound) Seizure_0\NN
D001640_D012640 CID bicuculline_26\NN (r_conj) acid_21\NN (r_pobj) to_19\IN (r_pcomp) due_18\IN (r_prep) activity_17\NN (l_compound) seizure_16\NN
D001640_D012640 CID BCC_28\NNP (r_appos) acid_21\NN (r_pobj) to_19\IN (r_pcomp) due_18\IN (r_prep) activity_17\NN (r_nsubj) was_46\VBD (l_ccomp) decreased_12\VBN (l_nsubjpass) activity_1\NN (l_compound) Seizure_0\NN
D001640_D012640 CID BCC_28\NNP (r_appos) acid_21\NN (r_pobj) to_19\IN (r_pcomp) due_18\IN (r_prep) activity_17\NN (l_compound) seizure_16\NN
D013331_D012640 CID strychnine_42\NN (r_conj) carboline-3-carboxylate_36\NNP (r_conj) acid_21\NN (r_pobj) to_19\IN (r_pcomp) due_18\IN (r_prep) activity_17\NN (r_nsubj) was_46\VBD (l_ccomp) decreased_12\VBN (l_nsubjpass) activity_1\NN (l_compound) Seizure_0\NN
D013331_D012640 CID strychnine_42\NN (r_conj) carboline-3-carboxylate_36\NNP (r_conj) acid_21\NN (r_pobj) to_19\IN (r_pcomp) due_18\IN (r_prep) activity_17\NN (l_compound) seizure_16\NN
D013331_D012640 CID STR_44\NNP (r_appos) acid_21\NN (r_pobj) to_19\IN (r_pcomp) due_18\IN (r_prep) activity_17\NN (r_nsubj) was_46\VBD (l_ccomp) decreased_12\VBN (l_nsubjpass) activity_1\NN (l_compound) Seizure_0\NN
D013331_D012640 CID STR_44\NNP (r_appos) acid_21\NN (r_pobj) to_19\IN (r_pcomp) due_18\IN (r_prep) activity_17\NN (l_compound) seizure_16\NN
D015097_D012640 CID acid_21\NN (r_pobj) to_19\IN (r_pcomp) due_18\IN (r_prep) activity_17\NN (r_nsubj) was_46\VBD (l_ccomp) decreased_12\VBN (l_nsubjpass) activity_1\NN (l_compound) Seizure_0\NN
D015097_D012640 CID acid_21\NN (r_pobj) to_19\IN (r_pcomp) due_18\IN (r_prep) activity_17\NN (l_compound) seizure_16\NN
D015097_D012640 CID MPA_23\NNP (r_appos) acid_21\NN (r_pobj) to_19\IN (r_pcomp) due_18\IN (r_prep) activity_17\NN (r_nsubj) was_46\VBD (l_ccomp) decreased_12\VBN (l_nsubjpass) activity_1\NN (l_compound) Seizure_0\NN
D015097_D012640 CID MPA_23\NNP (r_appos) acid_21\NN (r_pobj) to_19\IN (r_pcomp) due_18\IN (r_prep) activity_17\NN (l_compound) seizure_16\NN
D010433_D012640 CID PTZ_27\NNP (r_pobj) to_24\TO (r_prep) decrease_21\VB (l_dobj) threshold_23\NN (l_compound) seizure_22\NN
D010433_D012640 CID PTZ_13\NNP (r_npadvmod) induced_15\VBN (r_amod) seizures_16\NNS
D010433_D012640 CID PTZ_4\NNP (r_pobj) due_2\IN (r_amod) activity_1\NN (l_compound) Seizure_0\NN
D010433_D012640 CID PTZ_4\NNP (r_pobj) due_2\IN (r_amod) activity_1\NN (r_nsubjpass) decreased_12\VBN (r_ccomp) was_46\VBD (l_nsubj) activity_17\NN (l_compound) seizure_16\NN
D010433_D012640 CID PTZ_14\NNP (r_pobj) by_13\IN (r_agent) induced_12\VBN (r_acl) activity_11\NN (l_compound) seizure_10\NN
D010433_D012640 CID PTZ_14\NNP (r_pobj) by_13\IN (r_agent) induced_12\VBN (r_acl) activity_11\NN (r_pobj) to_9\IN (r_prep) occur_8\VB (l_advcl) decreased_36\VBN (l_nsubjpass) response_26\NN (l_prep) to_27\IN (l_pobj) agents_34\NNS (l_amod) inducing_33\VBG (l_npadvmod) seizure_31\NN
D001556_D012640 NONE hexachlorocyclohexane_5\NN (r_pobj) of_2\IN (r_prep) effects_1\NNS (l_prep) on_9\IN (l_pobj) seizures_13\NNS
D001556_D012640 NONE lindane_7\NN (r_appos) hexachlorocyclohexane_5\NN (r_pobj) of_2\IN (r_prep) effects_1\NNS (l_prep) on_9\IN (l_pobj) seizures_13\NNS
D001556_D012640 NONE hexachlorocyclohexane_2\NN (r_nsubjpass) shown_19\VBN (l_xcomp) decrease_21\VB (l_dobj) threshold_23\NN (l_compound) seizure_22\NN
D001556_D012640 NONE HCH_6\NNP (r_appos) hexachlorocyclohexane_2\NN (r_nsubjpass) shown_19\VBN (l_xcomp) decrease_21\VB (l_dobj) threshold_23\NN (l_compound) seizure_22\NN
D001556_D012640 NONE lindane_15\NN (r_pobj) of_12\IN (r_prep) ingredient_11\NN (r_appos) hexachlorocyclohexane_2\NN (r_nsubjpass) shown_19\VBN (l_xcomp) decrease_21\VB (l_dobj) threshold_23\NN (l_compound) seizure_22\NN
D001556_D012640 NONE HCH_7\NNP (r_pobj) to_4\IN (r_prep) exposure_3\NN (r_pobj) after_2\IN (r_prep) h_1\NN (l_conj) increase_10\VB (l_prep) to_12\IN (l_pobj) seizures_16\NNS
D001556_D012640 NONE HCH_24\NNP (r_pobj) to_21\IN (r_prep) exposure_20\NN (r_pobj) after_19\IN (r_prep) h_18\NN (l_dep) h_1\NN (l_conj) increase_10\VB (l_prep) to_12\IN (l_pobj) seizures_16\NNS
D001556_D012640 NONE HCH_30\NNP (r_pobj) of_25\IN (r_prep) administration_24\NN (r_pobj) after_22\IN (r_prep) tested_15\VBN (l_nsubjpass) severity_5\NN (l_prep) of_6\IN (l_pobj) response_7\NN (l_prep) to_8\IN (l_pobj) agents_13\NNS (l_amod) inducing_12\VBG (l_npadvmod) seizure_10\NN
D001556_D012640 NONE HCH_8\NNP (r_pobj) of_5\IN (r_prep) administration_4\NN (r_pobj) after_2\IN (r_prep) increased_18\VBN (l_nsubjpass) activity_11\NN (l_prep) of_12\IN (l_pobj) agents_16\NNS (l_amod) inducing_15\VBG (l_npadvmod) seizure_13\NN
D001556_D012640 NONE HCH_31\NNP (r_appos) h_27\NN (r_dep) observed_36\VBN (l_advcl) increased_18\VBN (l_nsubjpass) activity_11\NN (l_prep) of_12\IN (l_pobj) agents_16\NNS (l_amod) inducing_15\VBG (l_npadvmod) seizure_13\NN
D001556_D012640 NONE HCH_22\NNP (r_pobj) after_19\IN (r_prep) h_18\NN (r_npadvmod) occur_8\VB (l_prep) to_9\IN (l_pobj) activity_11\NN (l_compound) seizure_10\NN
D001556_D012640 NONE HCH_22\NNP (r_pobj) after_19\IN (r_prep) h_18\NN (r_npadvmod) occur_8\VB (l_advcl) decreased_36\VBN (l_nsubjpass) response_26\NN (l_prep) to_27\IN (l_pobj) agents_34\NNS (l_amod) inducing_33\VBG (l_npadvmod) seizure_31\NN
D001556_D012640 NONE HCH_20\NNP (r_nsubj) be_22\VB (l_nsubj) site_7\NN (l_amod) responsible_8\JJ (l_prep) for_9\IN (l_pobj) decrease_11\NN (l_prep) in_12\IN (l_pobj) activity_14\NN (l_compound) seizure_13\NN
D010852_D012640 CID picrotoxin_6\NN (r_conj) PTZ_4\NNP (r_pobj) due_2\IN (r_amod) activity_1\NN (l_compound) Seizure_0\NN
D010852_D012640 CID picrotoxin_6\NN (r_conj) PTZ_4\NNP (r_pobj) due_2\IN (r_amod) activity_1\NN (r_nsubjpass) decreased_12\VBN (r_ccomp) was_46\VBD (l_nsubj) activity_17\NN (l_compound) seizure_16\NN
D010852_D012640 CID PTX_8\NNP (r_appos) PTZ_4\NNP (r_pobj) due_2\IN (r_amod) activity_1\NN (l_compound) Seizure_0\NN
D010852_D012640 CID PTX_8\NNP (r_appos) PTZ_4\NNP (r_pobj) due_2\IN (r_amod) activity_1\NN (r_nsubjpass) decreased_12\VBN (r_ccomp) was_46\VBD (l_nsubj) activity_17\NN (l_compound) seizure_16\NN
D010852_D012640 CID PTX_16\NNP (r_conj) PTZ_14\NNP (r_pobj) by_13\IN (r_agent) induced_12\VBN (r_acl) activity_11\NN (l_compound) seizure_10\NN
D010852_D012640 CID PTX_16\NNP (r_conj) PTZ_14\NNP (r_pobj) by_13\IN (r_agent) induced_12\VBN (r_acl) activity_11\NN (r_pobj) to_9\IN (r_prep) occur_8\VB (l_advcl) decreased_36\VBN (l_nsubjpass) response_26\NN (l_prep) to_27\IN (l_pobj) agents_34\NNS (l_amod) inducing_33\VBG (l_npadvmod) seizure_31\NN
1527456
D008012_D014012 NONE lignocaine_7\NN (r_pobj) of_6\IN (r_prep) instillation_5\NN (r_pobj) by_3\IN (r_prep) Treatment_0\NN (l_prep) of_1\IN (l_pobj) tinnitus_2\NN
D008012_D014012 NONE lidocaine_9\NN (r_appos) lignocaine_7\NN (r_pobj) of_6\IN (r_prep) instillation_5\NN (r_pobj) by_3\IN (r_prep) Treatment_0\NN (l_prep) of_1\IN (l_pobj) tinnitus_2\NN
D008012_D014012 NONE lignocaine_12\NN (r_pobj) of_11\IN (r_prep) instillation_10\NN (r_pobj) by_8\IN (r_prep) treating_6\VBG (l_dobj) IST_7\NNP
D008012_D014012 NONE lidocaine_14\NN (r_appos) lignocaine_12\NN (r_pobj) of_11\IN (r_prep) instillation_10\NN (r_pobj) by_8\IN (r_prep) treating_6\VBG (l_dobj) IST_7\NNP
2515254
D005996_D008881 CID nitroglycerin_11\NN (r_pobj) of_10\IN (r_prep) application_9\NN (r_dobj) received_4\VBD (l_nsubj) patients_3\NNS (l_compound) migraine_2\NN
D005996_D008881 CID nitroglycerin_7\NN (r_pobj) by_6\IN (r_agent) induced_5\VBN (l_nsubjpass) attacks_3\NNS (l_compound) migraine_2\NN
D005996_D008881 CID nitroglycerin_13\NN (r_pobj) with_11\IN (r_prep) attack_10\NN (r_dobj) developed_6\VBD (r_relcl) patients_3\NNS (l_compound) migraine_2\NN
D005996_D008881 CID nitroglycerin_7\NN (r_pobj) of_6\IN (r_prep) effect_5\NN (l_amod) inducing_4\VBG (l_npadvmod) migraine_2\NN
D005996_D008881 CID nitroglycerin_7\NN (r_pobj) of_6\IN (r_prep) effect_5\NN (r_nsubj) seems_8\VBZ (l_advcl) suggesting_21\VBG (l_ccomp) is_26\VBZ (l_prep) of_27\IN (l_pobj) importance_29\NN (l_prep) in_30\IN (l_pobj) development_32\NN (l_prep) of_33\IN (l_pobj) crisis_36\NN (l_compound) migraine_35\JJ
D005996_D010146 NONE nitroglycerin_7\NN (r_pobj) of_6\IN (r_prep) effect_5\NN (r_nsubj) seems_8\VBZ (l_xcomp) depend_10\VB (l_prep) on_11\IN (l_pobj) stimulation_13\NN (l_prep) of_14\IN (l_pobj) site_17\NN (l_prep) of_18\IN (l_pobj) pain_19\NN
20080983
D003042_D012893 CID cocaine_23\NN (r_compound) users_24\NNS (r_pobj) in_21\IN (r_prep) sleepiness_20\NN
D003042_D012893 CID cocaine_18\NN (r_compound) users_19\NNS (r_pobj) in_16\IN (r_prep) sleepiness_15\NN
C048833_D012893 NONE modafinil_15\NN (l_conj) sleepiness_20\NN
C048833_D012893 NONE Modafinil_0\NNP (r_nsubjpass) associated_2\VBN (l_advcl) measured_10\VBN (l_conj) decrease_22\NN (l_prep) in_23\IN (l_pobj) sleepiness_26\NN
C048833_D012893 NONE modafinil_3\NN (r_nsubj) promotes_4\VBZ (l_conj) normalizes_8\VBZ (l_conj) decreases_13\VBZ (l_dobj) sleepiness_15\NN
3125768
D015760_D009127 CID alfentanil_4\NN (r_npadvmod) induced_6\VBN (r_amod) rigidity_7\NN
D015760_D009127 CID alfentanil_8\NN (r_npadvmod) induced_10\VBN (r_amod) rigidity_11\NN
D015760_D009127 CID alfentanil_9\NN (r_advcl) prevented_7\VBN (l_nsubjpass) rigidity_4\NN
C032943_D009127 NONE metocurine_10\NN (r_pobj) with_9\IN (r_prep) abolished_8\VBN (l_nsubjpass) rigidity_6\NN
20698227
C473478_D006461 CID sunitinib_16\JJ (r_pobj) as_15\IN (r_prep) inhibitors_13\NNS (r_pobj) of_11\IN (r_prep) number_10\NN (r_nsubjpass) found_21\VBN (l_advcl) cause_23\VB (l_dobj) hemolysis_25\NN
D012254_D006461 NONE ribavirin_1\RB (r_nsubjpass) found_4\VBN (l_conj) found_21\VBN (l_advcl) cause_23\VB (l_dobj) hemolysis_25\NN
C471405_D006461 CID sorafenib_18\NNS (r_conj) sunitinib_16\JJ (r_pobj) as_15\IN (r_prep) inhibitors_13\NNS (r_pobj) of_11\IN (r_prep) number_10\NN (r_nsubjpass) found_21\VBN (l_advcl) cause_23\VB (l_dobj) hemolysis_25\NN
C100416_D019698 NONE 2a_14\CD (r_pobj) by_10\IN (r_agent) treated_9\VBN (l_csubjpass) infected_3\VBN (l_prep) with_4\IN (l_pobj) virus_7\NN
D012254_D019698 NONE ribavirin_16\RB (r_conj) 2a_14\CD (r_pobj) by_10\IN (r_agent) treated_9\VBN (l_csubjpass) infected_3\VBN (l_prep) with_4\IN (l_pobj) virus_7\NN
D012254_D019698 NONE ribavirin_16\RB (r_conj) markers_14\NNS (r_dobj) angiogenesis_12\NN (r_pobj) between_11\IN (r_prep) link_10\NN (r_dobj) investigating_8\VBG (r_acl) study_4\NN (r_attr) is_1\VBZ (l_advcl) induced_17\VBD (l_dobj) anemia_18\NN (l_prep) in_19\IN (l_pobj) patients_20\NNS (l_prep) with_21\IN (l_pobj) C_23\NNP
D012254_D000740 NONE ribavirin_16\RB (r_conj) markers_14\NNS (r_dobj) angiogenesis_12\NN (r_pobj) between_11\IN (r_prep) link_10\NN (r_dobj) investigating_8\VBG (r_acl) study_4\NN (r_attr) is_1\VBZ (l_advcl) induced_17\VBD (l_dobj) anemia_18\NN
D012254_D000743 NONE ribavirin_8\RB (r_pobj) for_7\IN (r_prep) treatment_6\NN (r_pobj) of_5\IN (r_prep) target_4\NN (l_acl) associated_9\VBN (l_dobj) anemia_11\NN
18261172
D000806_D007674 NONE ACEi_5\NNP (r_nmod) therapy_8\NN (r_pobj) with_4\IN (r_prep) used_3\VBN (l_conj) increased_15\VBD (l_dobj) dysfunction_17\NN
D020123_D011507 CID sirolimus_6\NN (r_npadvmod) based_8\VBN (r_amod) immunosuppression_9\NN (r_pobj) to_5\IN (r_prep) switch_4\NN (r_pobj) after_3\IN (r_prep) Development_0\NN (l_prep) of_1\IN (l_pobj) proteinuria_2\NN
D020123_D011507 CID sirolmus_7\NN (r_nsubj) lacks_11\VBZ (r_ccomp) reported_23\VBN (l_nsubjpass) proteinuria_17\NN
D020123_D011507 CID Srl_9\NNP (r_appos) sirolmus_7\NN (r_nsubj) lacks_11\VBZ (r_ccomp) reported_23\VBN (l_nsubjpass) proteinuria_17\NN
D020123_D011507 CID Srl_20\NNP (r_pobj) with_19\IN (r_prep) associated_18\VBN (r_acl) proteinuria_17\NN
D020123_D011507 CID Srl_10\NNP (r_pobj) with_9\IN (r_prep) associated_8\VBN (r_acl) incidence_5\NN (l_prep) of_6\IN (l_pobj) proteinuria_7\NN
D020123_D011507 CID Srl_12\NNP (r_pobj) to_11\IN (r_prep) switch_10\NN (r_pobj) after_9\IN (r_prep) develop_4\VB (l_nsubj) proteinuria_2\NN
D020123_D011507 CID Srl_0\NNP (r_nsubjpass) used_3\VBN (l_prep) with_4\IN (l_pobj) therapy_8\NN (l_acl) monitored_11\VBD (l_prep) for_12\IN (l_pobj) proteinuria_13\NN
D057911_D007674 NONE ARB_7\NNP (r_compound) therapy_8\NN (r_pobj) with_4\IN (r_prep) used_3\VBN (l_conj) increased_15\VBD (l_dobj) dysfunction_17\NN
D057911_D011507 NONE blocker_6\NN (r_nmod) therapy_10\NN (r_conj) inhibitor_1\NN (r_nsubj) reduced_11\VBN (l_dobj) development_13\NN (l_compound) proteinuria_12\NN
D057911_D011507 NONE ARB_8\NNP (r_nmod) therapy_10\NN (r_conj) inhibitor_1\NN (r_nsubj) reduced_11\VBN (l_dobj) development_13\NN (l_compound) proteinuria_12\NN
D057911_D011507 NONE ARB_7\NNP (r_compound) therapy_8\NN (l_acl) monitored_11\VBD (l_prep) for_12\IN (l_pobj) proteinuria_13\NN
D000806_D011507 NONE inhibitor_1\NN (r_nsubj) reduced_11\VBN (l_dobj) development_13\NN (l_compound) proteinuria_12\NN
D000806_D011507 NONE ACEi_5\NNP (r_nmod) therapy_8\NN (l_acl) monitored_11\VBD (l_prep) for_12\IN (l_pobj) proteinuria_13\NN
D020123_D007674 NONE sirolmus_7\NN (r_nsubj) lacks_11\VBZ (l_dobj) effects_13\NNS (l_amod) nephrotoxic_12\JJ
D020123_D007674 NONE Srl_9\NNP (r_appos) sirolmus_7\NN (r_nsubj) lacks_11\VBZ (l_dobj) effects_13\NNS (l_amod) nephrotoxic_12\JJ
D020123_D007674 NONE Srl_20\NNP (r_pobj) with_19\IN (r_prep) associated_18\VBN (r_acl) proteinuria_17\NN (r_nsubjpass) reported_23\VBN (l_ccomp) lacks_11\VBZ (l_dobj) effects_13\NNS (l_amod) nephrotoxic_12\JJ
D020123_D007674 NONE Srl_0\NNP (r_nsubjpass) used_3\VBN (l_conj) increased_15\VBD (l_dobj) dysfunction_17\NN
7834920
D007538_D014397 NONE isoniazid_9\NN (l_prep) for_10\IN (l_pobj) tuberculosis_12\NN
D012293_D005921 CID rifampin_6\NN (r_amod) therapy_7\NN (r_pobj) with_4\IN (r_prep) associated_3\VBN (r_acl) glomerulonephritis_2\NN
D012293_D005921 CID rifampin_17\NN (r_pobj) with_16\IN (r_prep) treated_15\VBN (r_acl) patient_14\NN (r_pobj) in_12\IN (r_prep) finding_6\NN (l_prep) of_7\IN (l_pobj) glomerulonephritis_11\NN
D012293_D005921 CID rifampin_20\NN (r_pobj) with_19\IN (r_prep) treated_18\VBN (r_acl) patient_17\NN (r_pobj) in_15\IN (r_prep) occurrence_5\NN (l_prep) of_6\IN (l_pobj) glomerulonephritis_9\NN
D012293_D005921 CID rifampin_20\NN (r_pobj) with_19\IN (r_prep) treated_18\VBN (r_acl) patient_17\NN (r_pobj) in_15\IN (r_prep) occurrence_5\NN (l_prep) of_6\IN (l_pobj) glomerulonephritis_9\NN (l_prep) with_10\IN (l_pobj) crescents_11\NNS (l_conj) glomerulonephritis_14\NN
D012293_D014397 NONE rifampin_6\NN (r_amod) therapy_7\NN (l_prep) for_8\IN (l_pobj) tuberculosis_10\NN
D012293_D014397 NONE rifampin_7\NN (r_pobj) of_6\IN (r_prep) regimen_5\NN (r_dobj) underwent_2\VBD (l_conj) isoniazid_9\NN (l_prep) for_10\IN (l_pobj) tuberculosis_12\NN
D007538_D051437 NONE isoniazid_9\NN (r_conj) underwent_2\VBD (l_conj) discovered_15\VBN (l_xcomp) developed_18\VBN (l_dobj) signs_19\NNS (l_prep) of_20\IN (l_pobj) failure_23\NN
D012293_D051437 CID rifampin_7\NN (r_pobj) of_6\IN (r_prep) regimen_5\NN (r_dobj) underwent_2\VBD (l_conj) discovered_15\VBN (l_xcomp) developed_18\VBN (l_dobj) signs_19\NNS (l_prep) of_20\IN (l_pobj) failure_23\NN
11928786
D016642_D062787 NONE Zyban_0\NNP (r_nsubj) caused_1\VBD (l_dobj) toxicity_6\NN (l_prep) in_7\IN (l_pobj) overdose_8\NN
D016642_D064420 NONE Bupropion_0\NNP (r_nmod) toxicity_4\NN
D016642_D064420 NONE Zyban_2\NNP (r_nmod) toxicity_4\NN
D000241_D012640 NONE adenosine_14\NN (r_pobj) with_13\IN (r_prep) treated_12\VBN (r_conj) treated_3\VBN (l_nsubjpass) seizures_1\NNS
D003975_D013610 NONE diazepam_5\NN (l_conj) tachycardia_9\NN
D016642_D002318 NONE Zyban_0\NNP (r_nsubj) caused_1\VBD (l_dobj) toxicity_6\NN
D016642_D020258 NONE Zyban_0\NNP (r_nsubj) caused_1\VBD (l_dobj) toxicity_6\NN
D000241_D013610 NONE adenosine_14\NN (r_pobj) with_13\IN (r_prep) treated_12\VBN (r_conj) treated_3\VBN (l_prep) with_4\IN (l_pobj) diazepam_5\NN (l_conj) tachycardia_9\NN
D003975_D012640 NONE diazepam_5\NN (r_pobj) with_4\IN (r_prep) treated_3\VBN (l_nsubjpass) seizures_1\NNS
3560095
D005480_D001171 NONE Flurbiprofen_0\NNP (l_prep) in_1\IN (l_pobj) treatment_3\NN (l_prep) of_4\IN (l_pobj) arthritis_7\NN
D005480_D001171 NONE flurbiprofen_13\JJ (r_pobj) with_12\IN (r_prep) treated_11\VBN (r_relcl) arthritis_7\NN
D005480_D001168 NONE flurbiprofen_13\JJ (r_pobj) with_12\IN (r_prep) treated_11\VBN (r_relcl) arthritis_7\NN (r_pobj) with_4\IN (r_prep) patients_3\NNS (r_nsubj) had_26\VBD (l_dobj) decreases_29\NNS (l_prep) in_32\IN (l_pobj) indices_35\NNS (l_compound) arthritis_34\NN
8701950
D001241_D000743 NONE aspirin_20\NN (r_conj) corticosteroids_18\NNS (r_conj) replacement_16\NN (r_appos) discontinuation_4\NN (r_nsubj) led_24\VBD (l_prep) to_25\IN (l_pobj) resolution_26\NN (l_prep) of_27\IN (l_pobj) MAHA_28\NNP
D016572_D000743 NONE A_19\NNP (l_appos) drug_28\NN (l_acl) known_30\VBN (l_xcomp) induce_32\VB (l_dobj) MAHA_33\NNP
D016572_D000743 NONE CyA_21\NN (r_appos) A_19\NNP (l_appos) drug_28\NN (l_acl) known_30\VBN (l_xcomp) induce_32\VB (l_dobj) MAHA_33\NNP
D016559_D000743 CID FK506_4\NNP (r_dobj) complicating_3\VBG (l_nsubj) anemia_2\NN
D016559_D000743 CID tacrolimus_6\NNP (r_nmod) therapy_8\NN (r_appos) FK506_4\NNP (r_dobj) complicating_3\VBG (l_nsubj) anemia_2\NN
D016559_D000743 CID FK506_17\NNP (r_nmod) therapy_21\NN (r_pobj) under_16\IN (r_prep) recipients_15\NNS (r_pobj) in_11\IN (r_prep) episodes_3\NNS (l_prep) of_4\IN (l_pobj) anemia_7\NN
D016559_D000743 CID FK506_17\NNP (r_nmod) therapy_21\NN (r_pobj) under_16\IN (r_prep) recipients_15\NNS (r_pobj) in_11\IN (r_prep) episodes_3\NNS (l_prep) of_4\IN (l_pobj) anemia_7\NN (l_appos) MAHA_9\NNP
D016559_D000743 CID tacrolimus_19\NNP (r_nmod) therapy_21\NN (r_pobj) under_16\IN (r_prep) recipients_15\NNS (r_pobj) in_11\IN (r_prep) episodes_3\NNS (l_prep) of_4\IN (l_pobj) anemia_7\NN
D016559_D000743 CID tacrolimus_19\NNP (r_nmod) therapy_21\NN (r_pobj) under_16\IN (r_prep) recipients_15\NNS (r_pobj) in_11\IN (r_prep) episodes_3\NNS (l_prep) of_4\IN (l_pobj) anemia_7\NN (l_appos) MAHA_9\NNP
D016559_D000743 CID FK506_6\NNP (r_pobj) of_5\IN (r_prep) discontinuation_4\NN (r_nsubj) led_24\VBD (l_prep) to_25\IN (l_pobj) resolution_26\NN (l_prep) of_27\IN (l_pobj) MAHA_28\NNP
D016559_D000743 CID FK506_6\NNP (r_pobj) of_5\IN (r_prep) reintroduction_4\NN (r_nsubj) led_7\VBD (l_prep) to_8\IN (l_pobj) recurrence_10\NN (l_prep) of_11\IN (l_pobj) MAHA_12\NNP
D016559_D000743 CID FK506-associated_0\VBN (r_amod) MAHA_1\NNP
D016559_D000743 CID FK506_9\NNP (r_nsubj) seem_12\VB (l_oprd) A_19\NNP (l_appos) drug_28\NN (l_acl) known_30\VBN (l_xcomp) induce_32\VB (l_dobj) MAHA_33\NNP
D000305_D000743 NONE corticosteroids_18\NNS (r_conj) replacement_16\NN (r_appos) discontinuation_4\NN (r_nsubj) led_24\VBD (l_prep) to_25\IN (l_pobj) resolution_26\NN (l_prep) of_27\IN (l_pobj) MAHA_28\NNP
D004176_D000743 NONE dipyridamole_23\NN (r_conj) aspirin_20\NN (r_conj) corticosteroids_18\NNS (r_conj) replacement_16\NN (r_appos) discontinuation_4\NN (r_nsubj) led_24\VBD (l_prep) to_25\IN (l_pobj) resolution_26\NN (l_prep) of_27\IN (l_pobj) MAHA_28\NNP
18809400
D008063_D010523 NONE acid_7\NN (r_nsubj) reduce_9\VB (l_dobj) risk_11\NN (l_prep) of_12\IN (l_pcomp) developing_13\VBG (l_dobj) toxicity_16\NN
D017239_D028361 NONE paclitaxel_7\NN (r_conj) cisplatin_5\NN (r_nsubj) cause_8\VBP (l_dobj) impairment_11\NN
D017239_D028361 NONE paclitaxel_11\NN (r_pobj) in_10\IN (r_prep) event_8\NN (r_attr) is_4\VBZ (l_nsubj) toxicity_3\NN
D002945_D020258 NONE cisplatin_13\NN (r_conj) in_10\IN (r_prep) event_8\NN (r_attr) is_4\VBZ (l_advcl) induced_14\VBN (l_dobj) neurotoxicity_15\NN
D017239_D020258 NONE paclitaxel_11\NN (r_pobj) in_10\IN (r_prep) event_8\NN (r_attr) is_4\VBZ (l_advcl) induced_14\VBN (l_dobj) neurotoxicity_15\NN
D008063_D001480 NONE acid_10\NN (r_pobj) of_6\IN (r_prep) efficacy_5\NN (l_prep) in_11\IN (l_pcomp) preventing_12\VBG (l_dobj) damage_14\NN
D008063_D001480 NONE acid_34\NN (r_conj) agents_29\NNS (r_pobj) to_27\IN (r_prep) exposure_26\NN (r_pobj) after_25\IN (r_prep) function_19\NN (r_conj) apoptosis_16\NN (r_conj) investigating_3\VBG (l_dobj) efficacy_5\NN (l_prep) in_11\IN (l_pcomp) preventing_12\VBG (l_dobj) damage_14\NN
D017239_D010523 CID paclitaxel_32\NN (r_pobj) to_31\IN (r_prep) neurons_30\NNS (r_appos) ganglion_25\NN (r_pobj) of_22\IN (r_prep) cultures_21\NNS (r_dobj) exposing_19\VBG (r_pcomp) by_18\IN (r_prep) mimic_13\VBP (r_relcl) model_5\NN (r_dobj) used_1\VBD (l_xcomp) induced_8\VBD (l_dobj) neuropathy_10\NN
D002945_D010523 CID cisplatin_34\NN (r_conj) paclitaxel_32\NN (r_pobj) to_31\IN (r_prep) neurons_30\NNS (r_appos) ganglion_25\NN (r_pobj) of_22\IN (r_prep) cultures_21\NNS (r_dobj) exposing_19\VBG (r_pcomp) by_18\IN (r_prep) mimic_13\VBP (r_relcl) model_5\NN (r_dobj) used_1\VBD (l_xcomp) induced_8\VBD (l_dobj) neuropathy_10\NN
D008063_D009410 NONE acid_7\NN (r_nsubj) is_8\VBZ (l_advcl) plays_18\VBZ (l_dobj) role_21\NN (l_prep) in_22\IN (l_pobj) cascade_25\NN
D008063_D009410 NONE acid_35\NN (r_pobj) of_31\IN (r_prep) effects_30\NNS (r_nsubj) depend_36\VBP (r_conj) plays_18\VBZ (l_dobj) role_21\NN (l_prep) in_22\IN (l_pobj) cascade_25\NN
D002945_D028361 NONE cisplatin_5\NN (r_nsubj) cause_8\VBP (l_dobj) impairment_11\NN
D002945_D028361 NONE cisplatin_13\NN (r_conj) in_10\IN (r_prep) event_8\NN (r_attr) is_4\VBZ (l_nsubj) toxicity_3\NN
D008063_D020258 NONE acid_3\NN (r_nsubj) prevents_4\VBZ (l_dobj) damage_6\NN (l_conj) neurotoxicity_8\NN
D008063_D020258 NONE acid_7\NN (r_nsubj) is_8\VBZ (l_advcl) induced_12\VBN (l_dobj) neurotoxicity_13\NN
D008063_D020258 NONE acid_35\NN (r_pobj) of_31\IN (r_prep) effects_30\NNS (r_nsubj) depend_36\VBP (r_conj) plays_18\VBZ (r_advcl) is_8\VBZ (l_advcl) induced_12\VBN (l_dobj) neurotoxicity_13\NN
D008063_D020258 NONE acid_3\NN (r_nsubj) exerts_4\VBZ (l_conj) induced_9\VBN (l_dobj) neurotoxicity_10\NN
D008063_D009422 NONE acid_3\NN (r_nsubj) prevents_4\VBZ (l_dobj) damage_6\NN (l_prep) in_9\IN (l_pobj) neuropathy_12\NN
D008063_D028361 NONE acid_3\NN (r_nsubj) prevents_4\VBZ (l_dobj) damage_6\NN
D008063_D028361 NONE acid_7\NN (r_nsubj) is_8\VBZ (l_advcl) plays_18\VBZ (l_nsubj) damage_17\NN
D008063_D028361 NONE acid_35\NN (r_pobj) of_31\IN (r_prep) effects_30\NNS (r_nsubj) depend_36\VBP (r_conj) plays_18\VBZ (l_nsubj) damage_17\NN
D008063_D028361 NONE acid_3\NN (r_nsubj) exerts_4\VBZ (r_ccomp) rescues_16\VBZ (l_dobj) toxicity_19\NN
11961407
D011692_D011507 CID PAN_21\NNP (r_compound) injection_22\NN (r_pobj) after_20\IN (r_prep) days_19\NNS (r_npadvmod) analyzed_2\VBN (l_advcl) include_26\VB (l_dobj) phase_30\NN (l_prep) of_31\IN (l_pobj) proteinuria_32\NN
D011692_D011507 CID PAN_21\NNP (r_compound) injection_22\NN (r_pobj) after_20\IN (r_prep) days_19\NNS (r_npadvmod) analyzed_2\VBN (l_advcl) include_26\VB (l_dobj) phase_30\NN (l_appos) days_39\NNS (l_conj) phase_47\NN (l_prep) of_48\IN (l_pobj) proteinuria_49\NN
D014443_D009401 NONE tyrosine_2\NN (r_compound) phosphatase_3\NN (l_prep) in_7\IN (l_pobj) nephrosis_10\NN
D011692_D005921 NONE PAN_21\NNP (r_compound) injection_22\NN (r_pobj) after_20\IN (r_prep) days_19\NNS (r_npadvmod) analyzed_2\VBN (l_advcl) include_26\VB (l_dobj) phase_30\NN (l_appos) days_39\NNS (l_conj) phase_47\NN (l_acl) associated_50\VBN (l_prep) with_51\IN (l_pobj) glomerulosclerosis_52\NN
D011692_D009401 CID PAN_9\NNP (r_compound) nephrosis_10\NN
D011692_D009401 CID aminonucleoside_1\JJ (r_amod) nephrosis_2\NN
D011692_D009401 CID aminonucleoside_11\NN (r_advmod) induced_4\VBN (l_nsubjpass) nephrosis_2\NN
D011692_D009401 CID PAN_13\NNP (r_appos) aminonucleoside_11\NN (r_advmod) induced_4\VBN (l_nsubjpass) nephrosis_2\NN
11581460
D005283_D009127 NONE fentanyl_5\NN (r_compound) administration_6\NN (r_pobj) of_4\IN (r_prep) effects_3\NNS (r_nsubj) include_7\VBP (l_dobj) rigidity_10\NN
D005283_D001745 CID fentanyl_22\NN (r_pobj) of_21\IN (r_prep) infusion_20\NN (r_pobj) of_18\IN (r_prep) result_17\NN (r_pobj) as_15\IN (r_prep) mimicking_13\VBG (r_acl) dilatation_12\NN (r_pobj) to_9\IN (r_prep) leading_8\VBG (r_acl) cases_3\NNS (l_prep) of_4\IN (l_pobj) retention_7\NN
D005283_D006869 NONE fentanyl_22\NN (r_pobj) of_21\IN (r_prep) infusion_20\NN (r_pobj) of_18\IN (r_prep) result_17\NN (r_pobj) as_15\IN (r_prep) mimicking_13\VBG (l_dobj) hydronephrosis_14\NN
D005283_D001919 CID fentanyl_5\NN (r_compound) administration_6\NN (r_pobj) of_4\IN (r_prep) effects_3\NNS (r_nsubj) include_7\VBP (l_dobj) rigidity_10\NN (l_conj) hypotension_12\NN (l_conj) depression_15\NN (l_conj) bradycardia_18\NN
D005283_D016055 CID fentanyl_12\NN (r_pobj) of_11\IN (r_prep) infusion_10\NN (r_pobj) of_7\IN (r_prep) result_6\NN (r_pobj) as_4\IN (r_prep) retention_1\NN (l_prep) of_2\IN (l_pobj) urine_3\NN
D005283_D007022 CID fentanyl_5\NN (r_compound) administration_6\NN (r_pobj) of_4\IN (r_prep) effects_3\NNS (r_nsubj) include_7\VBP (l_dobj) rigidity_10\NN (l_conj) hypotension_12\NN
D005283_D012131 CID fentanyl_5\NN (r_compound) administration_6\NN (r_pobj) of_4\IN (r_prep) effects_3\NNS (r_nsubj) include_7\VBP (l_dobj) rigidity_10\NN (l_conj) hypotension_12\NN (l_conj) depression_15\NN
2024540
D004656_D006333 NONE enalapril_11\NN (r_pobj) of_10\IN (r_prep) safety_9\NN (l_prep) in_14\IN (l_pobj) phase_18\NN (l_prep) of_19\IN (l_pobj) patients_20\NNS (l_prep) with_21\IN (l_pobj) failure_24\NN
D000806_D007022 CID inhibitors_10\NNS (r_appos) enzyme_6\NN (r_dobj) converting_5\VBG (l_prep) into_11\IN (l_pobj) treatment_14\NN (l_prep) of_15\IN (l_pobj) patients_16\NNS (l_prep) with_17\IN (l_pobj) failure_20\NN (l_conj) cases_22\NNS (l_prep) of_23\IN (l_pobj) hypotension_25\NN
D000806_D007022 CID inhibitor_7\NN (r_pobj) of_4\IN (r_prep) safety_3\NN (r_dobj) assess_1\VB (r_advcl) designed_19\VBN (l_prep) compared_21\VBD (l_pobj) incidence_23\NN (l_prep) of_26\IN (l_pobj) hypotension_28\NN
D000806_D006333 NONE inhibitors_10\NNS (r_appos) enzyme_6\NN (r_dobj) converting_5\VBG (l_prep) into_11\IN (l_pobj) treatment_14\NN (l_prep) of_15\IN (l_pobj) patients_16\NNS (l_prep) with_17\IN (l_pobj) failure_20\NN
D004656_D007022 NONE enalapril_8\NN (r_appos) inhibitor_7\NN (r_pobj) of_4\IN (r_prep) safety_3\NN (r_dobj) assess_1\VB (r_advcl) designed_19\VBN (l_prep) compared_21\VBD (l_pobj) incidence_23\NN (l_prep) of_26\IN (l_pobj) hypotension_28\NN
D004656_D007022 NONE enalapril_3\RB (r_dobj) received_2\VBD (r_relcl) Patients_0\NNS (r_nsubj) experienced_4\VBD (l_dobj) hypotension_11\NN
D011224_D007022 CID prazosin_14\NN (r_npadvmod) controlled_16\VBN (r_amod) trial_17\NN (r_nsubjpass) designed_19\VBN (l_prep) compared_21\VBD (l_pobj) incidence_23\NN (l_prep) of_26\IN (l_pobj) hypotension_28\NN
D011224_D007022 CID prazosin_21\NN (r_dobj) received_20\VBD (r_relcl) patients_18\NNS (r_pobj) than_16\IN (r_prep) hypotension_11\NN
D011224_D006333 NONE prazosin_13\NN (r_conj) enalapril_11\NN (r_pobj) of_10\IN (r_prep) safety_9\NN (l_prep) in_14\IN (l_pobj) phase_18\NN (l_prep) of_19\IN (l_pobj) patients_20\NNS (l_prep) with_21\IN (l_pobj) failure_24\NN
19300402
D001920_D003929 NONE Bradykinin_0\NN (r_compound) antagonists_2\NNS (r_nsubj) induced_12\VBD (l_dobj) hyperalgesia_13\NN (l_prep) in_14\IN (l_pobj) chemotherapy_15\NN (l_conj) model_20\NN (l_compound) rat_19\NN (l_compound) neuropathy_18\NN
D013311_D006930 CID streptozotocin_11\NNS (r_conj) antagonists_2\NNS (r_nsubj) induced_12\VBD (l_dobj) hyperalgesia_13\NN
D013311_D006930 CID streptozotocin_1\JJ (r_npadvmod) induced_3\VBN (r_amod) hyperalgesia_4\NN
D013311_D006930 CID streptozotocin_1\JJ (r_npadvmod) induced_3\VBN (r_amod) hyperalgesia_4\NN (r_pobj) In_0\IN (r_prep) participates_9\VBZ (l_advcl) induced_20\VBN (l_dobj) hyperalgesia_21\NN
D014750_D006930 CID vincristine_9\NN (r_pobj) in_8\IN (r_prep) antagonists_2\NNS (r_nsubj) induced_12\VBD (l_dobj) hyperalgesia_13\NN
D014750_D006930 CID vincristine_26\NN (r_pobj) by_25\IN (r_agent) produced_24\VBN (r_acl) hyperalgesia_23\NN
D014750_D006930 CID vincristine_18\NN (r_pobj) in_17\IN (r_prep) induced_20\VBN (r_advcl) participates_9\VBZ (l_prep) In_0\IN (l_pobj) hyperalgesia_4\NN
D014750_D006930 CID vincristine_18\NN (r_pobj) in_17\IN (r_prep) induced_20\VBN (l_dobj) hyperalgesia_21\NN
D001920_D009437 NONE bradykinin_8\NN (r_pobj) of_7\IN (r_prep) doses_6\NNS (r_pobj) of_4\IN (r_prep) administration_3\NN (r_nsubj) be_16\VB (l_acomp) effective_17\JJ (l_prep) in_18\IN (l_pobj) alleviation_19\NN (l_prep) of_20\IN (l_pobj) pain_22\NN
D013311_D003929 CID streptozotocin_11\NNS (r_conj) antagonists_2\NNS (r_nsubj) induced_12\VBD (l_dobj) hyperalgesia_13\NN (l_prep) in_14\IN (l_pobj) chemotherapy_15\NN (l_conj) model_20\NN (l_compound) rat_19\NN (l_compound) neuropathy_18\NN
D009569_D003929 NONE oxide_5\NN (r_compound) synthase_6\NN (r_compound) inhibitors_7\NNS (r_conj) antagonists_2\NNS (r_nsubj) induced_12\VBD (l_dobj) hyperalgesia_13\NN (l_prep) in_14\IN (l_pobj) chemotherapy_15\NN (l_conj) model_20\NN (l_compound) rat_19\NN (l_compound) neuropathy_18\NN
D014750_D003929 NONE vincristine_9\NN (r_pobj) in_8\IN (r_prep) antagonists_2\NNS (r_nsubj) induced_12\VBD (l_dobj) hyperalgesia_13\NN (l_prep) in_14\IN (l_pobj) chemotherapy_15\NN (l_conj) model_20\NN (l_compound) rat_19\NN (l_compound) neuropathy_18\NN
D001920_D006930 NONE Bradykinin_0\NN (r_compound) antagonists_2\NNS (r_nsubj) induced_12\VBD (l_dobj) hyperalgesia_13\NN
D001920_D006930 NONE bradykinin_9\NN (r_compound) receptors_10\NNS (r_pobj) of_8\IN (r_prep) inhibition_7\NN (r_nsubj) reduces_21\VBZ (l_dobj) hyperalgesia_23\NN
D001920_D006930 NONE bradykinin_19\NN (r_conj) activation_15\NN (r_conj) synthase_10\NN (r_pobj) of_7\IN (r_prep) products_6\NNS (r_nsubjpass) involved_21\VBN (l_prep) in_22\IN (l_pobj) hyperalgesia_23\NN
D001920_D006930 NONE bradykinin_14\NN (r_pobj) of_13\IN (r_prep) activity_12\NN (r_pobj) in_10\IN (r_prep) participates_9\VBZ (l_prep) In_0\IN (l_pobj) hyperalgesia_4\NN
D001920_D006930 NONE bradykinin_14\NN (r_pobj) of_13\IN (r_prep) activity_12\NN (r_pobj) in_10\IN (r_prep) participates_9\VBZ (l_advcl) induced_20\VBN (l_dobj) hyperalgesia_21\NN
D001920_D006930 NONE bradykinin_22\NN (r_nsubj) seemed_23\VBD (r_conj) participates_9\VBZ (l_prep) In_0\IN (l_pobj) hyperalgesia_4\NN
D001920_D006930 NONE bradykinin_22\NN (r_nsubj) seemed_23\VBD (r_conj) participates_9\VBZ (l_advcl) induced_20\VBN (l_dobj) hyperalgesia_21\NN
D009569_D009437 NONE NO_12\DT (r_det) inhibitors_14\NNS (r_conj) antagonists_10\NNS (r_dobj) bradykinin_8\NN (r_pobj) of_7\IN (r_prep) doses_6\NNS (r_pobj) of_4\IN (r_prep) administration_3\NN (r_nsubj) be_16\VB (l_acomp) effective_17\JJ (l_prep) in_18\IN (l_pobj) alleviation_19\NN (l_prep) of_20\IN (l_pobj) pain_22\NN
D009569_D006930 NONE oxide_5\NN (r_compound) synthase_6\NN (r_compound) inhibitors_7\NNS (r_conj) antagonists_2\NNS (r_nsubj) induced_12\VBD (l_dobj) hyperalgesia_13\NN
D009569_D006930 NONE NO_13\DT (r_det) synthase_14\NN (r_conj) inhibition_7\NN (r_nsubj) reduces_21\VBZ (l_dobj) hyperalgesia_23\NN
D009569_D006930 NONE NO_18\DT (r_det) activity_20\NN (r_nsubj) reduces_21\VBZ (l_dobj) hyperalgesia_23\NN
D009569_D006930 NONE NO_9\DT (r_compound) synthase_10\NN (r_pobj) of_7\IN (r_prep) products_6\NNS (r_nsubjpass) involved_21\VBN (l_prep) in_22\IN (l_pobj) hyperalgesia_23\NN
D009569_D006930 NONE NO_13\DT (r_det) activation_15\NN (r_conj) synthase_10\NN (r_pobj) of_7\IN (r_prep) products_6\NNS (r_nsubjpass) involved_21\VBN (l_prep) in_22\IN (l_pobj) hyperalgesia_23\NN
D009569_D006930 NONE NO_7\DT (r_compound) synthase_8\NN (r_nsubj) participates_9\VBZ (l_prep) In_0\IN (l_pobj) hyperalgesia_4\NN
D009569_D006930 NONE NO_7\DT (r_compound) synthase_8\NN (r_nsubj) participates_9\VBZ (l_advcl) induced_20\VBN (l_dobj) hyperalgesia_21\NN
D009569_D006930 NONE NO_27\DT (r_det) pathway_29\NN (r_dobj) activate_25\VB (r_xcomp) seemed_23\VBD (r_conj) participates_9\VBZ (l_prep) In_0\IN (l_pobj) hyperalgesia_4\NN
D009569_D006930 NONE NO_27\DT (r_det) pathway_29\NN (r_dobj) activate_25\VB (r_xcomp) seemed_23\VBD (r_conj) participates_9\VBZ (l_advcl) induced_20\VBN (l_dobj) hyperalgesia_21\NN
11642480
D015283_D003865 NONE citalopram_8\NN (r_pobj) with_7\IN (r_prep) treatment_6\NN (l_prep) by_9\IN (l_pobj) boy_14\NN (l_prep) with_15\IN (l_pobj) depression_17\NN
D015283_D003866 NONE citalopram_7\NN (r_pobj) on_6\IN (r_prep) adolescent_5\NN (l_amod) depressed_4\JJ
D015283_D004409 CID citalopram_7\NN (r_pobj) on_6\IN (r_prep) adolescent_5\NN (r_pobj) in_2\IN (r_prep) twitching_1\VBG
D015283_D004409 CID citalopram_8\NN (r_pobj) with_7\IN (r_prep) treatment_6\NN (l_prep) by_9\IN (l_pobj) boy_14\NN (l_prep) with_15\IN (l_pobj) depression_17\NN (l_relcl) exhibited_19\VBD (l_dobj) twitching_21\NN
15859940
D016572_D057049 CID cyclosporine_18\NN (r_pobj) to_17\IN (r_prep) secondary_15\JJ (r_amod) related_13\VBN (r_acomp) was_11\VBD (l_nsubj) cause_7\NN (l_prep) of_8\IN (l_pobj) microangiopathy_10\NN
D016572_D064420 NONE cyclosporine_7\NN (r_nmod) toxicity_11\NN
D016559_D064420 NONE tacrolimus_9\NN (r_conj) cyclosporine_7\NN (r_nmod) toxicity_11\NN
8595686
D013874_D010146 NONE Thiopentone_0\NN (r_compound) pretreatment_1\NN (l_prep) for_2\IN (l_pobj) pain_5\NN
D013874_D010146 NONE thiopentone_17\NN (r_nsubj) reduces_19\VBZ (r_advcl) reduces_4\VBZ (l_dobj) incidence_6\NN (l_prep) of_9\IN (l_pobj) pain_12\NN
D015742_D010146 CID propofol_3\JJ (r_amod) pain_5\NN
D015742_D010146 CID propofol_10\JJ (r_amod) pain_12\NN
D008012_D010146 NONE lidocaine_3\NN (r_nsubj) reduces_4\VBZ (l_dobj) incidence_6\NN (l_prep) of_9\IN (l_pobj) pain_12\NN
11263551
D016572_-1 NONE cyclosporine_18\NN (r_pobj) of_17\IN (r_prep) effect_16\NN (r_attr) is_10\VBZ (l_nsubj) Syndrome_6\NNP (l_appos) CIPS_8\NNP
D016559_-1 NONE tacrolimus_20\NN (r_conj) cyclosporine_18\NN (r_pobj) of_17\IN (r_prep) effect_16\NN (r_attr) is_10\VBZ (l_nsubj) Syndrome_6\NNP (l_appos) CIPS_8\NNP
D016559_D010146 CID tacrolimus_5\VB (r_compound) trough_6\NN (r_compound) levels_7\NNS (r_pobj) of_2\IN (r_prep) reduction_1\NN (r_nsubj) led_15\VBD (l_prep) to_16\IN (l_pobj) relief_17\NN (l_prep) of_18\IN (l_pobj) pain_19\NN
D016559_D010146 CID tacrolimus_20\NN (r_conj) cyclosporine_18\NN (r_pobj) of_17\IN (r_prep) effect_16\NN (r_attr) is_10\VBZ (l_nsubj) Syndrome_6\NNP (l_compound) Pain_5\NNP
D016572_D010146 CID cyclosporine-_3\NN (r_nmod) levels_7\NNS (r_pobj) of_2\IN (r_prep) reduction_1\NN (r_nsubj) led_15\VBD (l_prep) to_16\IN (l_pobj) relief_17\NN (l_prep) of_18\IN (l_pobj) pain_19\NN
D016572_D010146 CID cyclosporine_18\NN (r_pobj) of_17\IN (r_prep) effect_16\NN (r_attr) is_10\VBZ (l_nsubj) Syndrome_6\NNP (l_compound) Pain_5\NNP
D002118_D010146 NONE calcium_12\NN (r_compound) channel_13\NN (r_compound) blockers_14\NNS (r_pobj) of_11\IN (r_prep) administration_10\NN (r_conj) reduction_1\NN (r_nsubj) led_15\VBD (l_prep) to_16\IN (l_pobj) relief_17\NN (l_prep) of_18\IN (l_pobj) pain_19\NN
2572625
C013295_D056486 NONE thienodiazepine_27\NN (r_amod) derivative_28\NN (r_appos) patient_6\NN (l_relcl) developed_8\VBD (l_dobj) hepatitis_10\NN
C013295_D047508 NONE thienodiazepine_27\NN (r_amod) derivative_28\NN (r_appos) patient_6\NN (l_relcl) developed_8\VBD (l_prep) with_11\IN (l_pobj) necrosis_14\NN
C084599_D056486 CID Clotiazepam_0\NNP (r_npadvmod) induced_2\VBN (r_amod) hepatitis_4\NN
C084599_D056486 CID clotiazepam_24\NN (r_pobj) of_23\IN (r_prep) administration_22\NN (r_pobj) of_21\IN (r_prep) onset_20\NN (r_pobj) after_18\IN (r_prep) developed_8\VBD (l_dobj) hepatitis_10\NN
C084599_D056486 CID clotiazepam_9\NN (r_xcomp) related_7\VBN (r_acl) administration_1\NN (r_nsubj) interfere_13\VB (l_conj) induce_19\VB (l_dobj) relapse_21\NN (l_prep) of_22\IN (l_pobj) hepatitis_23\NN
C084599_D056486 CID clotiazepam_4\NN (r_nsubj) induce_6\VB (l_dobj) hepatitis_8\NN
C084599_D056486 CID clotiazepam_4\NN (r_nsubj) induce_6\VB (l_conj) suggests_10\VBZ (l_ccomp) is_13\VBZ (l_attr) hepatotoxicity_16\NN
C084599_D056486 CID clotiazepam_18\NN (r_pobj) between_17\IN (r_prep) hepatotoxicity_16\NN (r_attr) is_13\VBZ (r_ccomp) suggests_10\VBZ (r_conj) induce_6\VB (l_dobj) hepatitis_8\NN
C084599_D056486 CID clotiazepam_18\NN (r_pobj) between_17\IN (r_prep) hepatotoxicity_16\NN
C084599_D047508 NONE clotiazepam_24\NN (r_pobj) of_23\IN (r_prep) administration_22\NN (r_pobj) of_21\IN (r_prep) onset_20\NN (r_pobj) after_18\IN (r_prep) developed_8\VBD (l_prep) with_11\IN (l_pobj) necrosis_14\NN
D001569_D056486 NONE benzodiazepines_4\NNS (r_pobj) of_2\IN (r_prep) administration_1\NN (r_nsubj) interfere_13\VB (l_conj) induce_19\VB (l_dobj) relapse_21\NN (l_prep) of_22\IN (l_pobj) hepatitis_23\NN
D001569_D056486 NONE benzodiazepines_21\NNS (r_conj) clotiazepam_18\NN (r_pobj) between_17\IN (r_prep) hepatotoxicity_16\NN (r_attr) is_13\VBZ (r_ccomp) suggests_10\VBZ (r_conj) induce_6\VB (l_dobj) hepatitis_8\NN
D001569_D056486 NONE benzodiazepines_21\NNS (r_conj) clotiazepam_18\NN (r_pobj) between_17\IN (r_prep) hepatotoxicity_16\NN
10406016
C007789_D007249 NONE Fucoidan_0\NNP (r_npadvmod) treated_2\VBN (r_amod) rats_3\NNS (r_nsubj) exhibited_4\VBD (l_conj) had_13\VBD (l_conj) tended_18\VBD (l_xcomp) have_20\VB (l_dobj) inflammation_22\NN
C007789_D020141 CID Fucoidan_0\NNP (r_npadvmod) treated_2\VBN (r_amod) rats_3\NNS (r_nsubj) exhibited_4\VBD (l_dobj) evidence_5\NN (l_prep) of_6\IN (l_pobj) clotting_9\NN
C007789_D020141 CID Fucoidan_0\NNP (r_npadvmod) treated_2\VBN (r_amod) rats_3\NNS (r_nsubj) exhibited_4\VBD (l_dobj) evidence_5\NN (l_prep) of_6\IN (l_pobj) clotting_9\NN (l_conj) hemodilution_11\NN
C007789_D001925 NONE fucoidan_5\RB (l_relcl) reported_10\VBN (l_xcomp) reduce_12\VB (l_dobj) damage_15\NN
C007789_D002543 NONE fucoidan_2\JJ (r_compound) treatment_3\NN (l_prep) on_4\IN (l_pobj) hemorrhage_9\NN
C007789_D002543 NONE fucoidan_5\RB (r_dobj) tested_1\VBD (l_prep) in_17\IN (l_pobj) model_20\NN (l_prep) of_21\IN (l_pobj) hemorrhage_23\NN
C007789_D006406 NONE Fucoidan_0\NNP (r_npadvmod) treated_2\VBN (r_amod) rats_3\NNS (r_nsubj) exhibited_4\VBD (l_conj) had_13\VBD (l_dobj) hematomas_15\NNS
C007789_D006406 NONE Fucoidan_0\NNP (r_npadvmod) treated_2\VBN (r_amod) rats_3\NNS (r_nsubj) exhibited_4\VBD (l_conj) had_13\VBD (l_conj) tended_18\VBD (l_xcomp) have_20\VB (l_dobj) inflammation_22\NN (l_prep) in_23\IN (l_pobj) vicinity_25\NN (l_prep) of_26\IN (l_pobj) hematoma_28\NN
12820454
D016729_D000740 CID acetate_6\NN (r_dobj) received_2\VBD (l_conj) evaluated_32\VBN (l_prep) for_33\IN (l_pobj) anemia_34\NN
D016729_D000740 CID A_10\NNP (r_appos) acetate_6\NN (r_dobj) received_2\VBD (l_conj) evaluated_32\VBN (l_prep) for_33\IN (l_pobj) anemia_34\NN
D005485_D000740 CID flutamide_23\NN (r_nmod) tid_25\NN (r_conj) days_19\NNS (r_appos) acetate_6\NN (r_dobj) received_2\VBD (l_conj) evaluated_32\VBN (l_prep) for_33\IN (l_pobj) anemia_34\NN
2476560
D001556_D012532 NONE lindane_12\NN (r_dobj) consider_11\VBP (l_ccomp) initiated_5\VBN (l_nsubjpass) Treatment_0\NN (l_prep) for_1\IN (l_pobj) scabies_2\NNS
D001556_D012532 NONE hexachloride_16\NN (r_appos) lindane_12\NN (r_dobj) consider_11\VBP (l_ccomp) initiated_5\VBN (l_nsubjpass) Treatment_0\NN (l_prep) for_1\IN (l_pobj) scabies_2\NNS
D001556_D000741 CID lindane_4\NN (r_dobj) accumulating_2\VBG (r_csubj) be_6\VB (l_conj) associated_16\VBN (l_prep) with_17\IN (l_pobj) anaemia_19\NN
D001556_D002493 CID lindane_4\NN (r_dobj) accumulating_2\VBG (r_csubj) be_6\VB (l_acomp) toxic_7\JJ (l_prep) to_8\IN (l_pobj) system_12\NN
3560096
D011188_D006947 NONE potassium_8\NN (r_dobj) effect_6\NN (r_xcomp) known_4\VBN (r_acl) medications_3\NNS (r_nsubjpass) given_11\VBN (r_advcl) is_18\VBZ (l_acomp) suggestive_19\JJ (l_prep) of_20\IN (l_pobj) relationship_27\NN (l_prep) between_28\IN (l_pobj) sulindac_29\NN (l_conj) hyperkalemia_31\NN
D007213_D006947 CID indomethacin_17\NN (r_pobj) as_16\IN (r_prep) NSAID_13\NNP (r_appos) agents_11\NNS (r_pobj) of_8\IN (r_prep) complication_7\NN (r_pobj) as_5\IN (r_prep) recognized_4\VBN (l_nsubjpass) Hyperkalemia_0\NNP
D013467_D006947 CID sulindac_3\NN (r_compound) therapy_4\NN (r_pobj) with_2\IN (r_prep) associated_1\VBN (r_acl) Hyperkalemia_0\NNP
D013467_D006947 CID sulindac_22\NN (r_compound) administration_23\NN (r_pobj) of_21\IN (r_prep) days_20\NNS (r_pobj) within_16\IN (r_prep) developed_15\VBD (l_nsubj) hyperkalemia_6\VBD
D013467_D006947 CID sulindac_29\NN (l_conj) hyperkalemia_31\NN
1009330
D011206_D003556 CID iodine_10\NN (r_conj) colistin_6\NN (r_nmod) irrigations_11\NNS (r_pobj) of_3\IN (r_prep) percentage_2\NN (r_nsubjpass) associated_13\VBN (l_prep) with_14\IN (l_pobj) cystitis_16\NN
C004658_D003556 NONE choloroaniline_10\NN (r_appos) product_7\NN (r_nsubj) is_11\VBZ (l_attr) factor_15\NN (l_prep) in_16\IN (l_pobj) cystitis_22\NN
C010882_D003556 CID digluconate_19\NN (r_npadvmod) associated_20\VBN (r_amod) cystitis_22\NN
D003091_D003556 CID colistin_6\NN (r_nmod) irrigations_11\NNS (r_pobj) of_3\IN (r_prep) percentage_2\NN (r_nsubjpass) associated_13\VBN (l_prep) with_14\IN (l_pobj) cystitis_16\NN
C005253_D003556 NONE Picloxydine_0\NNP (r_compound) irrigations_1\NNS (r_nsubj) appeared_2\VBD (l_xcomp) have_4\VB (l_dobj) incidence_7\NN (l_prep) of_8\IN (l_pobj) cystitis_10\NN
D007612_D003556 CID kanamycin_4\NN (r_compound) colistin_6\NN (r_nmod) irrigations_11\NNS (r_pobj) of_3\IN (r_prep) percentage_2\NN (r_nsubjpass) associated_13\VBN (l_prep) with_14\IN (l_pobj) cystitis_16\NN
19387625
D002211_D006930 CID capsaicin_7\NN (r_npadvmod) induced_9\VBN (r_amod) hyperalgesia_11\NN
D002211_D006930 CID capsaicin_16\NN (r_npadvmod) induced_18\VBN (r_amod) hyperalgesia_20\NN
D002211_D006930 CID capsaicin_20\NN (r_npadvmod) untreated_22\VBN (r_amod) condition_25\NN (r_pobj) of_19\IN (r_prep) that_18\DT (r_pobj) to_17\IN (r_prep) similar_16\JJ (r_acomp) is_14\VBZ (l_nsubj) magnitude_7\NN (l_prep) of_8\IN (l_pobj) modulation_10\NN (l_prep) in_11\IN (l_pobj) hyperalgesia_13\NN
D002211_D006930 CID capsaicin_7\NN (r_compound) treatment_8\NN (r_pobj) between_6\IN (r_prep) interaction_5\NN (r_dobj) showing_3\VBG (r_csubj) suggest_12\VBP (l_ccomp) affect_22\VB (l_nsubj) hyperalgesia_18\NN
D002211_D006930 CID capsaicin_14\NN (r_npadvmod) induced_16\VBN (r_amod) hyperalgesia_18\NN
D002211_D010146 NONE capsaicin_7\NN (r_npadvmod) induced_9\VBN (r_amod) hyperalgesia_11\NN (r_pobj) in_6\IN (r_prep) intensity_5\NN (l_compound) pain_4\NN
D002211_D010146 NONE capsaicin_16\NN (r_npadvmod) induced_18\VBN (r_amod) hyperalgesia_20\NN (r_pobj) in_15\IN (r_prep) attention_14\NN (r_pobj) by_13\IN (r_agent) affected_12\VBN (l_nsubjpass) ratings_10\NNS (l_compound) intensity_9\NN (l_compound) pain_8\NN
D002211_D010146 NONE capsaicin_7\NN (r_compound) treatment_8\NN (r_pobj) between_6\IN (r_prep) interaction_5\NN (r_dobj) showing_3\VBG (r_csubj) suggest_12\VBP (l_ccomp) affect_22\VB (l_dobj) pain_24\NN
D002211_D010146 NONE capsaicin_14\NN (r_npadvmod) induced_16\VBN (r_amod) hyperalgesia_18\NN (r_nsubj) affect_22\VB (l_dobj) pain_24\NN
18821488
C068820_D064420 NONE hexyloxy)-6-methoxy-4-methylquinoline_16\NNP (r_nmod) WR242511_18\NNP (r_pobj) of_6\IN (r_prep) administration_5\NN (r_pobj) following_4\VBG (r_prep) Toxicity_0\NN
C068820_D064420 NONE WR242511_18\NNP (r_pobj) of_6\IN (r_prep) administration_5\NN (r_pobj) following_4\VBG (r_prep) Toxicity_0\NN
C068820_D064420 NONE WR242511_4\NNP (r_nsubjpass) pursued_8\VBN (l_advcl) dissociated_27\VBN (l_prep) from_28\IN (l_pobj) those_29\DT (l_acl) producing_30\VBG (l_dobj) toxicity_32\NN
C068820_D011041 NONE WR242511_4\NNP (r_nsubjpass) pursued_8\VBN (l_prep) as_9\IN (l_pobj) pretreatment_11\NN (l_prep) for_12\IN (l_pobj) poisoning_14\NN
C068820_D006456 CID WR242511_11\NNP (r_pobj) of_10\IN (r_prep) postinjection_9\NN (r_dobj) noted_5\VBN (l_nsubjpass) hemoglobinuria_3\NN
C080436_D064420 NONE 8-aminoquinoline_8\JJ (r_compound) 8-[(4-amino_9\CD (r_compound) l_11\NN (r_compound) methylbutyl)amino]-_13\NN (r_punct) WR242511_18\NNP (r_pobj) of_6\IN (r_prep) administration_5\NN (r_pobj) following_4\VBG (r_prep) Toxicity_0\NN
C068820_D008708 NONE WR242511_4\NNP (l_relcl) produced_7\VBD (l_dobj) methemoglobinemia_9\NN
3782049
D008972_D058186 CID molindone_18\NN (r_compound) administration_19\NN (r_pobj) following_17\VBG (r_prep) rhabdomyolysis_11\NN (l_conj) failure_16\NN
D008972_D012206 CID molindone_6\NN (r_compound) administration_7\NN (r_pobj) following_5\VBG (r_prep) rhabdomyolysis_4\NN
D008972_D012206 CID molindone_18\NN (r_compound) administration_19\NN (r_pobj) following_17\VBG (r_prep) rhabdomyolysis_11\NN
D008972_D012559 NONE molindone_18\NN (r_compound) administration_19\NN (r_pobj) following_17\VBG (r_prep) rhabdomyolysis_11\NN (r_dobj) illustrate_9\VB (r_xcomp) reported_7\VBN (l_nsubjpass) case_1\NN (l_prep) of_2\IN (l_pobj) patient_5\NN (l_amod) schizophrenic_4\JJ
8690168
D006497_D003928 NONE sulphate_3\NN (r_npadvmod) associated_5\VBN (r_amod) sites_7\NNS (l_prep) in_8\IN (l_pobj) membrane_12\NN (l_prep) of_13\IN (l_pobj) rats_14\NNS (l_prep) with_15\IN (l_pobj) nephropathy_20\NN
D013311_D003928 CID streptozotocin_16\NNS (r_npadvmod) induced_18\VBN (r_amod) nephropathy_20\NN
C015445_D003920 NONE blue_38\JJ (r_dobj) employing_33\VBG (r_advcl) studied_12\VBN (l_prep) after_17\IN (l_pobj) induction_18\NN (l_prep) of_19\IN (l_pobj) diabetes_20\NNS
D013311_D003920 NONE streptozotocin_22\NNS (r_pobj) by_21\IN (r_prep) induction_18\NN (l_prep) of_19\IN (l_pobj) diabetes_20\NNS
D013311_D003920 NONE streptozotocin_4\JJ (r_amod) diabetic_6\JJ
D006497_D003920 NONE sulphate_1\NN (r_npadvmod) associated_3\VBN (r_amod) sites_5\NNS (r_nsubjpass) studied_12\VBN (l_prep) after_17\IN (l_pobj) induction_18\NN (l_prep) of_19\IN (l_pobj) diabetes_20\NNS
D006497_D003920 NONE sulphate_18\NN (r_compound) charge_19\NN (r_compound) density_22\NN (r_nsubjpass) found_24\VBN (l_prep) in_3\IN (l_pobj) rats_7\NNS (l_amod) diabetic_6\JJ
1468485
D015237_D006470 NONE alpha_14\NN (r_pobj) of_11\IN (r_prep) saline_8\NN (r_pobj) with_6\IN (r_prep) irrigation_5\NN (r_pobj) including_3\VBG (r_prep) treatment_1\NN (r_nsubj) failed_16\VBD (l_xcomp) control_19\VB (l_dobj) hemorrhage_20\NN
D003520_D006470 CID cyclophosphamide_7\NN (r_npadvmod) induced_9\VBN (r_amod) cystitis_11\NN
D003520_D006470 CID cyclophosphamide_10\NN (r_compound) therapy_11\NN (r_pobj) due_8\IN (r_prep) report_1\VBP (l_dobj) case_3\NN (l_prep) of_4\IN (l_pobj) cystitis_7\NN
D003520_D006470 CID cyclophosphamide_16\NN (r_pobj) of_15\IN (r_prep) treatment_14\NN (r_pobj) in_12\IN (r_prep) alternative_11\NN (r_dobj) offer_8\VB (l_dobj) cystitis_20\NN
D010100_D006470 NONE oxygen_1\NN (r_compound) therapy_2\NN (l_prep) for_3\IN (l_pobj) control_4\NN (l_prep) of_5\IN (l_pobj) cystitis_11\NN
D010100_D003556 NONE oxygen_1\NN (r_compound) therapy_2\NN (l_prep) for_3\IN (l_pobj) control_4\NN (l_prep) of_5\IN (l_pobj) cystitis_11\NN
D003520_D003556 CID cyclophosphamide_7\NN (r_npadvmod) induced_9\VBN (r_amod) cystitis_11\NN
D003520_D003556 CID cyclophosphamide_10\NN (r_compound) therapy_11\NN (r_pobj) due_8\IN (r_prep) report_1\VBP (l_dobj) case_3\NN (l_prep) of_4\IN (l_pobj) cystitis_7\NN
D003520_D003556 CID cyclophosphamide_16\NN (r_pobj) of_15\IN (r_prep) treatment_14\NN (r_pobj) in_12\IN (r_prep) alternative_11\NN (r_dobj) offer_8\VB (l_dobj) cystitis_20\NN
D003520_D014890 NONE cyclophosphamide_10\NN (r_compound) therapy_11\NN (l_prep) for_12\IN (l_pobj) granulomatosis_15\NN
88336
D002719_D013375 NONE chlormethiazole_6\NN (r_pobj) of_5\IN (r_prep) doses_4\NNS (r_dobj) received_2\VBD (l_prep) for_7\IN (l_pobj) symptoms_10\NNS
D002719_D003128 CID chlormethiazole_10\NN (r_compound) intoxication_11\NN (r_pobj) with_9\IN (r_prep) those_8\DT (r_pobj) of_7\IN (r_prep) two_6\CD (r_conj) overdose_4\NN (r_pobj) with_2\IN (r_prep) patient_1\NN (r_nsubj) conformed_12\VBD (l_prep) to_13\IN (l_pobj) criteria_15\NNS (l_prep) of_16\IN (l_pobj) coma_19\NN
D009567_D013375 NONE nitrazepam_19\NN (r_pobj) of_18\IN (r_prep) overdose_17\NN (r_dobj) took_14\VBD (r_conj) received_2\VBD (l_prep) for_7\IN (l_pobj) symptoms_10\NNS
D000431_D062787 NONE alcohol_8\NN (r_compound) withdrawal_9\NN (r_compound) symptoms_10\NNS (r_pobj) for_7\IN (r_prep) received_2\VBD (l_conj) took_14\VBD (l_dobj) overdose_17\NN
D000431_D013375 NONE alcohol_8\NN (r_compound) withdrawal_9\NN (r_compound) symptoms_10\NNS
D009567_D003128 CID nitrazepam_3\JJ (r_amod) overdose_4\NN (r_pobj) with_2\IN (r_prep) patient_1\NN (r_nsubj) conformed_12\VBD (l_prep) to_13\IN (l_pobj) criteria_15\NNS (l_prep) of_16\IN (l_pobj) coma_19\NN
D002719_D062787 NONE chlormethiazole_6\NN (r_pobj) of_5\IN (r_prep) doses_4\NNS (r_dobj) received_2\VBD (l_conj) took_14\VBD (l_dobj) overdose_17\NN
D002719_D062787 NONE chlormethiazole_10\NN (r_compound) intoxication_11\NN (r_pobj) with_9\IN (r_prep) those_8\DT (r_pobj) of_7\IN (r_prep) two_6\CD (r_conj) overdose_4\NN
D009567_D062787 CID nitrazepam_19\NN (r_pobj) of_18\IN (r_prep) overdose_17\NN
D009567_D062787 CID nitrazepam_3\JJ (r_amod) overdose_4\NN
9334596
D013739_D020018 CID testosterone_5\NN (r_pobj) for_4\IN (r_prep) screened_3\VBN (l_conj) screened_9\VBN (l_prep) on_12\IN (l_pobj) basis_14\NN (l_prep) of_15\IN (l_pobj) desire_18\NN
D013739_D020018 CID testosterone_22\NN (r_conj) gynecomastia_20\NN (r_conj) desire_18\NN
D013739_D020018 CID testosterone_1\NN (r_dobj) Determining_0\VBG (l_prep) in_3\IN (l_pobj) cases_4\NNS (l_prep) of_5\IN (l_pobj) desire_8\NN
D013739_D020018 CID testosterone_23\NN (r_pobj) with_21\IN (r_prep) cases_20\NNS (r_pobj) of_18\IN (r_prep) %_17\NN (r_dobj) missed_15\VBN (l_csubj) Determining_0\VBG (l_prep) in_3\IN (l_pobj) cases_4\NNS (l_prep) of_5\IN (l_pobj) desire_8\NN
D013739_D020018 CID testosterone_8\NN (r_nsubjpass) determined_10\VBN (l_prep) in_12\IN (l_pobj) cases_13\NNS (l_prep) of_14\IN (l_pobj) desire_17\NN
D013739_D020018 CID testosterone_14\NN (r_conj) gynecomastia_12\NN (r_conj) desire_10\NN
D013739_D007027 NONE testosterone_5\NN (r_compound) levels_6\NNS (r_pobj) of_1\IN (r_prep) Most_0\JJS (r_nsubj) seemed_7\VBD (l_xcomp) result_9\VB (l_prep) from_10\IN (l_pobj) dysfunction_13\NN
D001971_D006966 NONE bromocriptine_13\NN (l_prep) for_14\IN (l_pobj) hyperprolactinemia_15\NN
D013739_D006177 NONE testosterone_5\NN (r_pobj) for_4\IN (r_prep) screened_3\VBN (l_conj) screened_9\VBN (l_prep) on_12\IN (l_pobj) basis_14\NN (l_prep) of_15\IN (l_pobj) desire_18\NN (l_conj) gynecomastia_20\NN
D013739_D006177 NONE testosterone_22\NN (r_conj) gynecomastia_20\NN
D013739_D006177 NONE testosterone_14\NN (r_conj) gynecomastia_12\NN
D013739_D010911 NONE testosterone_6\NN (r_compound) determination_7\NN (r_pobj) after_5\IN (r_prep) discovered_4\VBN (l_nsubjpass) tumors_2\NNS
C004648_D007006 NONE heptylate_5\NN (l_conj) gonadotropin_9\NN (l_prep) for_10\IN (l_pobj) hypogonadism_11\NN
C004648_D006966 NONE heptylate_5\NN (l_conj) gonadotropin_9\NN (l_prep) for_10\IN (l_pobj) hypogonadism_11\NN (l_conj) bromocriptine_13\NN (l_prep) for_14\IN (l_pobj) hyperprolactinemia_15\NN
D001971_D007006 NONE bromocriptine_13\NN (r_conj) hypogonadism_11\NN
D013739_D007172 NONE testosterone_6\NN (r_pobj) of_4\IN (r_prep) results_3\NNS (l_prep) in_10\IN (l_pobj) patients_12\NNS (l_acl) referred_13\VBD (l_prep) because_14\IN (l_pobj) dysfunction_17\NN
D013739_D007172 NONE testosterone_5\NN (r_compound) levels_6\NNS (r_pobj) of_1\IN (r_prep) Most_0\JJS (r_nsubj) seemed_7\VBD (l_xcomp) result_9\VB (l_prep) because_14\IN (l_conj) have_24\VB (l_dobj) role_28\NN (l_prep) in_29\IN (l_pobj) dysfunction_31\NN
D013739_D007172 NONE testosterone_6\NN (r_pobj) of_4\IN (r_prep) effects_3\NNS (l_prep) in_10\IN (l_pobj) dysfunction_12\NN
1919871
D000082_D007681 CID paracetamol_22\JJ (r_conj) aspirin_20\NN (r_pobj) with_19\IN (r_prep) treatment_18\NN (r_pobj) during_13\IN (r_prep) developed_12\VBN (r_acl) ability_11\NN (r_conj) necrosis_2\NN
D000082_D007681 CID paracetamol_22\JJ (r_conj) aspirin_20\NN (r_pobj) with_19\IN (r_prep) treatment_18\NN (r_pobj) during_13\IN (r_prep) developed_12\VBN (r_acl) ability_11\NN (r_conj) necrosis_2\NN (l_appos) RPN_4\NNP
D001241_D007681 CID aspirin_20\NN (r_pobj) with_19\IN (r_prep) treatment_18\NN (r_pobj) during_13\IN (r_prep) developed_12\VBN (r_acl) ability_11\NN (r_conj) necrosis_2\NN
D001241_D007681 CID aspirin_20\NN (r_pobj) with_19\IN (r_prep) treatment_18\NN (r_pobj) during_13\IN (r_prep) developed_12\VBN (r_acl) ability_11\NN (r_conj) necrosis_2\NN (l_appos) RPN_4\NNP
8955532
D003911_D006973 NONE dextran_15\NN (r_pobj) of_11\IN (r_prep) clearance_10\NN (l_prep) before_16\IN (l_conj) during_18\IN (l_pobj) hypertension_23\NN
D001920_D006973 NONE bradykinin_4\NN (l_prep) in_7\IN (l_pobj) disruption_8\NN (l_prep) during_15\IN (l_pobj) hypertension_17\NN
D001920_D006973 NONE bradykinin_15\NN (r_pobj) of_14\IN (r_prep) release_13\NN (r_pobj) of_10\IN (r_prep) role_9\NN (r_dobj) determine_7\VB (l_xcomp) activate_17\VB (l_prep) in_20\IN (l_pobj) disruption_21\NN (l_prep) during_28\IN (l_pobj) hypertension_30\NN
D001920_D006973 NONE bradykinin_23\NN (r_pobj) of_22\IN (r_prep) release_21\NN (r_pobj) to_17\IN (r_prep) related_16\VBN (l_auxpass) is_14\VBZ (l_nsubj) disruption_4\NN (l_prep) during_11\IN (l_pobj) hypertension_13\NN
D010656_D006973 CID phenylephrine_19\NN (r_npadvmod) induced_21\VBN (r_amod) hypertension_23\NN
C065679_D006973 NONE Hoe-140_30\NNP (r_conj) vehicle_28\NN (r_pobj) with_27\IN (r_prep) treated_26\VBN (r_acl) rats_25\NNS (r_pobj) in_24\IN (r_prep) hypertension_23\NN
19037603
D019259_D012216 NONE lamivudine_3\NN (r_pobj) of_2\IN (r_prep) use_1\NN (l_prep) with_4\IN (l_pobj) therapy_7\NN (l_prep) for_8\IN (l_pobj) disorders_10\NNS
D019259_D012216 NONE lamivudine_18\NN (r_pobj) of_17\IN (r_prep) administration_16\NN (r_pobj) of_13\IN (r_prep) effectiveness_12\NN (r_pobj) concerning_10\VBG (r_prep) report_7\VB (r_xcomp) was_5\VBD (l_attr) patients_30\NNS (l_prep) with_31\IN (l_pobj) disease_33\NN
D019259_D012216 NONE lamivudine_23\JJ (r_compound) therapies_24\NNS (r_pobj) on_18\IN (r_prep) were_17\VBD (r_relcl) diseases_14\NNS
D006514_D012216 NONE antigen_24\NN (r_pobj) in_19\IN (r_prep) administration_16\NN (r_pobj) of_13\IN (r_prep) effectiveness_12\NN (r_pobj) concerning_10\VBG (r_prep) report_7\VB (r_xcomp) was_5\VBD (l_attr) patients_30\NNS (l_prep) with_31\IN (l_pobj) disease_33\NN
D006514_D012216 NONE Ag_27\NNP (r_appos) antigen_24\NN (r_pobj) in_19\IN (r_prep) administration_16\NN (r_pobj) of_13\IN (r_prep) effectiveness_12\NN (r_pobj) concerning_10\VBG (r_prep) report_7\VB (r_xcomp) was_5\VBD (l_attr) patients_30\NNS (l_prep) with_31\IN (l_pobj) disease_33\NN
D006514_D012216 NONE Ag_9\NNP (r_nmod) patients_11\NNS (l_prep) with_12\IN (l_pobj) diseases_14\NNS
809711
D005996_D007022 CID Nitroglycerin_0\NNP (r_nsubjpass) shown_3\VBN (r_ccomp) potentiated_17\VBN (l_agent) by_21\IN (l_pobj) agents_22\NNS (l_relcl) reverse_24\VBP (l_dobj) hypotension_28\NN
D005996_D007022 CID nitroglycerin_25\NN (r_npadvmod) induced_27\VBN (r_amod) hypotension_28\NN
D005996_D009203 NONE nitroglycerin_9\NN (r_pobj) of_7\IN (r_prep) effects_6\NNS (l_prep) in_10\IN (l_pobj) patients_11\NNS (l_prep) with_12\IN (l_pobj) infarction_15\NN
D005996_D009203 NONE Nitroglycerin_0\NNP (r_nsubjpass) shown_3\VBN (l_xcomp) reduce_5\VB (l_prep) during_10\IN (l_pobj) infarction_13\NN
D005996_D009203 NONE nitroglycerin_25\NN (r_npadvmod) induced_27\VBN (r_amod) hypotension_28\NN (r_dobj) reverse_24\VBP (r_relcl) agents_22\NNS (r_pobj) by_21\IN (r_agent) potentiated_17\VBN (l_ccomp) shown_3\VBN (l_xcomp) reduce_5\VB (l_prep) during_10\IN (l_pobj) infarction_13\NN
D005996_D009203 NONE nitroglycerin_9\NN (r_dobj) received_7\VBD (l_nsubj) patients_1\NNS (l_prep) with_2\IN (l_pobj) infarctions_6\NNS
D005996_D009203 NONE nitroglycerin_8\NN (r_pobj) to_7\IN (r_prep) phenylephrine_6\NN (r_pobj) of_5\IN (r_prep) addition_4\NN (r_nsubj) is_9\VBZ (l_acomp) beneficial_11\JJ (l_prep) in_12\IN (l_pobj) treatment_14\NN (l_prep) of_15\IN (l_pobj) patients_16\NNS (l_prep) with_17\IN (l_pobj) infarction_20\NN
D010656_D009203 NONE phenylephrine_2\NN (l_prep) of_3\IN (l_pobj) effects_6\NNS (l_prep) in_10\IN (l_pobj) patients_11\NNS (l_prep) with_12\IN (l_pobj) infarction_15\NN
D010656_D009203 NONE phenylephrine_6\NN (r_pobj) of_5\IN (r_prep) addition_4\NN (r_nsubj) is_9\VBZ (l_acomp) beneficial_11\JJ (l_prep) in_12\IN (l_pobj) treatment_14\NN (l_prep) of_15\IN (l_pobj) patients_16\NNS (l_prep) with_17\IN (l_pobj) infarction_20\NN
17600377
C524754_D009410 NONE coumarate_17\NN (r_nsubj) is_18\VBZ (l_attr) candidate_22\NN (l_relcl) characterized_29\VBN (l_agent) by_30\IN (l_pobj) death_34\NN
D012601_D003072 CID scopolamine_17\NN (r_npadvmod) injected_19\VBN (r_amod) rats_20\NNS (r_pobj) in_16\IN (r_prep) decline_15\NN
C544092_D003072 NONE beta_24\NN (r_pobj) in_22\IN (r_conj) in_16\IN (r_prep) decline_15\NN
C544092_D003072 NONE 42)-infused_34\VBN (r_amod) rats_35\NNS (r_dobj) beta_31\NN (r_advcl) found_5\VBN (l_xcomp) attenuate_7\VB (l_dobj) deficits_9\NNS
C524754_D003704 NONE coumarate_7\NN (r_appos) compound_2\NN (r_nsubj) attenuates_9\VBZ (l_conj) shows_13\VBZ (l_dobj) effects_15\NNS (l_prep) in_16\IN (l_amod) vitro_17\FW (l_conj) in_19\IN (l_pobj) models_22\NNS (l_compound) dementia_21\NN
C524754_D003072 NONE coumarate_7\NN (r_appos) compound_2\NN (r_nsubj) attenuates_9\VBZ (l_dobj) deficits_11\NNS
C524754_D003072 NONE coumarate_11\NN (r_nsubj) improve_13\VB (l_dobj) decline_15\NN
C524754_D003072 NONE coumarate_3\NN (r_nsubjpass) found_5\VBN (l_xcomp) attenuate_7\VB (l_dobj) deficits_9\NNS
C524754_D003072 NONE coumarate_17\NN (r_nsubj) is_18\VBZ (l_attr) candidate_22\NN (l_relcl) characterized_29\VBN (l_agent) by_30\IN (l_pobj) death_34\NN (l_conj) decline_37\NN (l_prep) of_38\IN (l_pobj) function_40\NN
C524754_D000544 NONE coumarate_17\NN (r_nsubj) is_18\VBZ (l_attr) candidate_22\NN (l_prep) against_23\IN (l_pobj) disease_26\NN
10526274
C056507_D064420 NONE GEM_1\NNP (r_nsubj) obtain_4\VB (l_prep) with_17\IN (l_pobj) toxicity_19\NN
C056507_D064420 NONE GEM_12\NNP (r_pobj) of_11\IN (r_prep) combination_10\NN (r_pobj) of_8\IN (r_prep) efficacy_5\NN (l_conj) toxicity_7\NN
C030852_D064420 NONE VNB_14\NNP (r_conj) GEM_12\NNP (r_pobj) of_11\IN (r_prep) combination_10\NN (r_pobj) of_8\IN (r_prep) efficacy_5\NN (l_conj) toxicity_7\NN
D002945_D064420 NONE cisplatin_28\NN (r_dobj) receiving_27\VBG (r_pcomp) to_26\IN (r_prep) contraindication_25\NN (r_pobj) with_23\IN (r_prep) those_22\DT (r_conj) NSCLC_20\NNP (r_pobj) with_18\IN (r_prep) patients_17\NNS (r_pobj) in_15\IN (r_prep) combination_10\NN (r_pobj) of_8\IN (r_prep) efficacy_5\NN (l_conj) toxicity_7\NN
D002945_D002289 NONE cisplatin_20\NN (r_dobj) receive_19\VB (r_relcl) years_11\NNS (r_npadvmod) age_9\NN (l_nsubj) Gemcitabine_0\NNP (l_conj) vinorelbine_2\NN (l_prep) in_3\IN (l_pobj) patients_8\NNS (l_compound) carcinoma_7\NN
D002945_D002289 NONE cisplatin_28\NN (r_dobj) receiving_27\VBG (r_pcomp) to_26\IN (r_prep) contraindication_25\NN (r_pobj) with_23\IN (r_prep) those_22\DT (r_conj) NSCLC_20\NNP
D002945_D002289 NONE cisplatin_33\NN (r_dobj) receiving_32\VBG (r_pcomp) to_31\IN (r_prep) contraindication_30\NN (r_dobj) had_28\VBD (r_conj) were_21\VBD (r_conj) /=_16\NFP (r_punct) included_8\VBN (l_nsubjpass) patients_3\NNS (l_prep) with_4\IN (l_pobj) NSCLC_6\NNP
C030852_D002289 NONE vinorelbine_2\NN (l_prep) in_3\IN (l_pobj) patients_8\NNS (l_compound) carcinoma_7\NN
C030852_D002289 NONE VNB_14\NNP (r_conj) GEM_12\NNP (r_pobj) of_11\IN (r_prep) combination_10\NN (l_prep) in_15\IN (l_pobj) patients_17\NNS (l_prep) with_18\IN (l_pobj) NSCLC_20\NNP
C056507_D002289 NONE Gemcitabine_0\NNP (l_conj) vinorelbine_2\NN (l_prep) in_3\IN (l_pobj) patients_8\NNS (l_compound) carcinoma_7\NN
C056507_D002289 NONE GEM_12\NNP (r_pobj) of_11\IN (r_prep) combination_10\NN (l_prep) in_15\IN (l_pobj) patients_17\NNS (l_prep) with_18\IN (l_pobj) NSCLC_20\NNP
6692345
D005200_D063646 NONE FANFT_16\NNP (r_compound) carcinogenesis_17\NN
D005200_D063646 NONE FANFT_30\NNP (r_pobj) on_29\IN (r_prep) effect_28\NN (r_nsubj) is_34\VBZ (r_conj) involved_14\VBN (l_prep) in_15\IN (l_pobj) carcinogenesis_17\NN
D001241_D063646 NONE aspirin_26\NN (r_poss) effect_28\NN (r_nsubj) is_34\VBZ (r_conj) involved_14\VBN (l_prep) in_15\IN (l_pobj) carcinogenesis_17\NN
D005200_D013274 CID N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP (r_pobj) with_6\IN (r_prep) aspirin_5\NN (r_pobj) of_4\IN (r_prep) administration_3\NN (r_nsubj) resulted_13\VBD (l_prep) in_14\IN (l_pobj) incidence_17\NN (l_conj) induction_27\NN (l_prep) of_28\IN (l_pobj) tumors_30\NNS
D005200_D013274 CID FANFT_9\NNP (r_appos) N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP (r_pobj) with_6\IN (r_prep) aspirin_5\NN (r_pobj) of_4\IN (r_prep) administration_3\NN (r_nsubj) resulted_13\VBD (l_prep) in_14\IN (l_pobj) incidence_17\NN (l_conj) induction_27\NN (l_prep) of_28\IN (l_pobj) tumors_30\NNS
D005200_D013274 CID FANFT_19\NNP (r_npadvmod) induced_21\VBN (r_amod) carcinomas_23\NNS (r_pobj) of_18\IN (r_prep) incidence_17\NN (l_conj) induction_27\NN (l_prep) of_28\IN (l_pobj) tumors_30\NNS
D001241_D001749 NONE aspirin_5\NN (r_pobj) of_4\IN (r_prep) administration_3\NN (r_nsubj) resulted_13\VBD (l_prep) in_14\IN (l_pobj) incidence_17\NN (l_prep) of_18\IN (l_pobj) carcinomas_23\NNS
D001241_D013274 NONE aspirin_5\NN (r_pobj) of_4\IN (r_prep) administration_3\NN (r_nsubj) resulted_13\VBD (l_prep) in_14\IN (l_pobj) incidence_17\NN (l_conj) induction_27\NN (l_prep) of_28\IN (l_pobj) tumors_30\NNS
D005200_D001749 CID N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP (r_pobj) with_6\IN (r_prep) aspirin_5\NN (r_pobj) of_4\IN (r_prep) administration_3\NN (r_nsubj) resulted_13\VBD (l_prep) in_14\IN (l_pobj) incidence_17\NN (l_prep) of_18\IN (l_pobj) carcinomas_23\NNS
D005200_D001749 CID FANFT_9\NNP (r_appos) N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP (r_pobj) with_6\IN (r_prep) aspirin_5\NN (r_pobj) of_4\IN (r_prep) administration_3\NN (r_nsubj) resulted_13\VBD (l_prep) in_14\IN (l_pobj) incidence_17\NN (l_prep) of_18\IN (l_pobj) carcinomas_23\NNS
D005200_D001749 CID FANFT_19\NNP (r_npadvmod) induced_21\VBN (r_amod) carcinomas_23\NNS
2950248
D004176_D017202 NONE Dipyridamole_0\NNP (r_npadvmod) induced_2\VBN (r_amod) ischemia_4\NN
D004176_D017202 NONE dipyridamole_16\NN (r_compound) therapy_17\NN (r_pobj) of_14\IN (r_prep) effect_13\NN (r_pobj) as_10\IN (r_prep) reported_9\VBN (l_advcl) demonstrated_27\VBN (l_nsubjpass) ischemia_24\NN
D004176_D017202 NONE dipyridamole_20\NN (r_dep) induced_22\VBN (r_amod) ischemia_24\NN
D004176_D003324 NONE dipyridamole_16\NN (r_compound) therapy_17\NN (r_pobj) of_14\IN (r_prep) effect_13\NN (r_pobj) as_10\IN (r_prep) reported_9\VBN (l_advcl) demonstrated_27\VBN (l_xcomp) occur_29\VB (l_prep) with_34\IN (l_pobj) disease_37\NN
D004176_D003324 NONE dipyridamole_20\NN (r_dep) induced_22\VBN (r_amod) ischemia_24\NN (r_nsubjpass) demonstrated_27\VBN (l_xcomp) occur_29\VB (l_prep) with_34\IN (l_pobj) disease_37\NN
D004176_D007511 NONE dipyridamole_23\NN (r_npadvmod) induced_25\VBN (r_amod) ischemia_26\NN
D004176_D000787 CID dipyridamole_10\NN (r_pobj) of_8\IN (r_prep) administration_7\NN (r_pobj) after_6\IN (r_prep) occurred_5\VBD (l_nsubj) Angina_0\NNP
18791946
D002939_D015746 CID ciprofloxacin_16\NNS (r_pobj) of_14\IN (r_prep) administration_13\NN (r_pobj) after_11\IN (r_prep) reported_5\VBN (l_prep) with_6\IN (l_pobj) pain_8\NN
D002939_D000743 CID ciprofloxacin_7\NNS (r_pobj) with_6\IN (r_prep) associated_5\VBN (r_acl) thrombocytopenia_1\JJ (l_conj) anaemia_4\NN
D002939_D000743 CID ciprofloxacin_5\NNS (r_nsubj) precipitate_7\VB (l_dobj) thrombocytopenia_11\JJ (l_conj) anaemia_14\NN
D002939_D013921 CID ciprofloxacin_7\NNS (r_pobj) with_6\IN (r_prep) associated_5\VBN (r_acl) thrombocytopenia_1\JJ
D002939_D013921 CID ciprofloxacin_5\NNS (r_nsubj) precipitate_7\VB (l_dobj) thrombocytopenia_11\JJ
D002939_D014552 NONE ciprofloxacin_16\NNS (r_pobj) of_14\IN (r_prep) administration_13\NN (l_prep) for_17\IN (l_pobj) suspect_19\NN (l_prep) of_20\IN (l_pobj) infection_23\NN
D002939_D007565 CID ciprofloxacin_16\NNS (r_pobj) of_14\IN (r_prep) administration_13\NN (r_pobj) after_11\IN (r_prep) reported_5\VBN (l_prep) with_6\IN (l_pobj) pain_8\NN (l_conj) jaundice_10\NN
17344566
D013974_D007037 NONE thyroxine_7\NN (l_compound) taking_6\VBG (l_nsubj) male_5\NN (l_amod) hypothyroid_4\JJ
D013974_D009135 NONE thyroxine_7\NN (r_nsubj) presented_10\VBD (l_prep) with_11\IN (l_pobj) syndrome_15\NN (l_conj) myonecrosis_17\NN
D019821_D009135 NONE Simvastatin_0\NNP (r_npadvmod) induced_2\VBN (r_amod) syndrome_6\NN (l_conj) myonecrosis_8\NN
D019821_D009135 NONE simvastatin_9\NN (r_conj) thyroxine_7\NN (r_nsubj) presented_10\VBD (l_prep) with_11\IN (l_pobj) syndrome_15\NN (l_conj) myonecrosis_17\NN
D019821_D007037 NONE Simvastatin_0\NNP (r_npadvmod) induced_2\VBN (r_amod) syndrome_6\NN (l_acl) associated_9\VBN (l_prep) with_10\IN (l_pobj) hypothyroidism_11\NN
D019821_D007037 NONE simvastatin_9\NN (r_conj) thyroxine_7\NN (l_compound) taking_6\VBG (l_nsubj) male_5\NN (l_amod) hypothyroid_4\JJ
D019821_D003161 CID Simvastatin_0\NNP (r_npadvmod) induced_2\VBN (r_amod) syndrome_6\NN
D019821_D003161 CID simvastatin_9\NN (r_conj) thyroxine_7\NN (r_nsubj) presented_10\VBD (l_prep) with_11\IN (l_pobj) syndrome_15\NN
D013974_D003161 NONE thyroxine_7\NN (r_nsubj) presented_10\VBD (l_prep) with_11\IN (l_pobj) syndrome_15\NN
